Textbook Of Functional Medicine 2010 [Hardcover ed.] 0977371379, 9780977371372

Citation preview

Textbook of Functional Medicine

Institute for Functional Medicine 2010 The Global Leader in Functional Medicine Education

David S. Jones, MD Editor in Chief

Institute for Functional Medicine Gig Harbor, WA 2010

)2

(c 0

01

David S. Jones, MD, Editor in Chief Sheila Quinn, Managing Editor

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Copyright ©2005, 2006, 2007, 2008, 2009, 2010 The Institute for Functional Medicine 4411 Pt. Fosdick Dr NW, Ste 305 P. O. Box 1697 Gig Harbor, WA 98335 800-228-0622 www.functionalmedicine.org

All rights reserved. No part of this book may be reproduced, stored, or transmitted in any form by any means, including electronic, mechanical, photocopying, or otherwise, without prior written permission of the copyright owner. Permissions may be sought by contacting The Institute for Functional Medicine in writing at the above address. Printing history: First printing, November 2005 Second printing, July 2006 Third printing, September 2010

ed

e

in

ic

Disclaimer Health care is a complex and constantly evolving field. No publication can be assumed to encompass the full scope of information that an individual practitioner brings to his or her practice and, therefore, this book is not intended to be used as a clinical manual recommending specific treatments for individual patients. It is intended for use as an educational tool, to broaden the knowledge and perspective of the practitioner. It is the responsibility of the healthcare practitioner to make his or her own determination of the usefulness and applicability of any information contained herein. Neither the publisher, the editors, authors, nor reviewers assume any liability for any injury and/or damage to persons or property arising from the use of information to be found in this publication.

ISBN-13: 978-0-9773713-7-2

Production Team Editorial and project assistance: Allison Templet, Virginia Kolano, Sherrie Torgerson, Stephanie Roberts Design: D.K. Luraas Graphics: Lynn Siefken Indexing: Marilyn Anderson Printing: Colorgraphics/Cenveo

Contributing Authors, Reviewers, and Editors Contributing Authors Barb Schiltz, MS, RD Virginia Shapiro, DC Michael Stone, MD, MS Nancy Sudak, MD Thomas Sult, MD John M. Tatum, MD Alex Vasquez, DC, ND David Wickes, DC Catherine Willner, MD

)2

(c

B. Jayne Alexander, DO Bruce N. Ames, PhD Sidney MacDonald Baker, MD Peter Bennett, ND Jeffrey S. Bland, PhD John Cline, BSc, MD Daniel Cosgrove, MD Walter J. Crinnion, ND Gary Darland, PhD Joel M. Evans, MD William J. Evans, PhD William B. Ferril, MD Kara N. Fitzgerald, ND Leo Galland, MD Michael D. Gershon, MD Patrick Hanaway, MD Bethany Hays, MD Robert J. Hedaya, MD Mark C. Houston, MD Mark A. Hyman, MD Mary James, ND David S. Jones, MD Joseph J. Lamb, MD Robert H. Lerman, MD, PhD Edward Leyton, MD Peter Libby, MD DeAnn Liska, PhD Jay Lombard, MD Dan Lukaczer, ND Michael D. Lumpkin, PhD Michael Lyon, MD Woody R. McGinnis, MD Carolyn McMakin, MA, DC David Musnick, MD Joseph E. Pizzorno Jr., ND Lara Pizzorno, MA Div, MA Lit, LMT James O. Prochaska, PhD Janice M. Prochaska, MSW, PhD Sheila Quinn, BS Robert Rountree, MD

0

01

Author biographical sketches are available in the Appendix.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Reviewers

e

in

ic

ed

Mark Bostrom, DO, ND David Buscher, MD Oscar Umahro Cadogan Sharon Dennis, DO Jeanne Drisko, MD Ilia Elenkov, MD, PhD Marilyn Gage, MD David Haase, MD Aviad Haramati, PhD Tori Hudson, ND Trent Nichols, MD Adam Perlman, MD, MPH David Perlmutter, MD Paul Reilly, ND David Riley, MD Pamela Smith, MD, MPH R. W. Watkins, MD

Editors David S. Jones, MD, Editor in Chief Sheila Quinn, BS, Managing Editor The Institute for Functional Medicine appreciates the vision, dedication, and outstanding contributions of the abovenamed individuals, without whom this book would not have been possible.

i

Acknowledgements The Institute for Functional Medicine gratefully acknowledges the generosity of the following individuals and organizations, whose donations supported the development of this book. The Allegheny Foundation Francis Maes, DC

The Park Foundation Alan Velasquez

Alpha Plus AB

Sharon Dennis, DO

Joseph Lamb, MD, PC

Jean & Scott Rigden, MD

Anonymous

Marilyn Gage, MD

Seung J. Lee, PhD

Sarah Ryterband, MD

Arlington Family Practice

Bethany Hays, MD

Frank Lipman, MD

Tamara Sachs, MD

Center for Healthy Living & Longevity

Ted Hull

Vincent Marinkovich, MD

Karyn Shanks, MD

Thomas Morledge, MD

Thomas Sult, MD

Richard Combs, MD

Sandra Hyland, RPT & Glenn Hyland, MD

(c

Coco Kelapa Newton, MPH, RD, CCN

Heidi Wittels, MD

Felecia Dawson, MD

Sedona Center for Complementary Medicine James Seeba, OMD, LAc Herbert Slavin, MD John Slizeski, DC, PC Leonard Smith, MD Pamela Smith, MD Len Sperry, MD Ann Stanger, MD Mary Stock, RPh, CCN Michael Stone, MD, MS David L. Sulkosky, DDS Paige Thibodeau Valori Treloar, MD Charles Tucker, DDS Kevin T. Wand, DO Elizabeth Wanek, MD Alan Weiner, DO Annemarie S. Welch, MD Ronald Williams, DDS Victoria M. Wood, RD Gerald Wyker, MD Conradine Zarndt Gary Zimmerman, DC

)2

Soram Singh Khalsa, MD Stuart Ferraris, DDS Marjorie Fisher John Flaxel, MD Jay Foster, PhD, CCN Bruce Gollub, MD Nellie Grose, MD, MPH Martha Grout, MD David Haase, MD Rolf Habersang, MD Michael Hall Laurie Hofmann Bruce Homstead, MS Brian Chungi Hong, MD Dominique Hort, DC, CCN, ND Craig Jordan, DC Jeffrey Kauffman, MD Christine M. Keenan, RN Judith Knapp, BS, RD, LDN Jacob Kornberg, MD Paul Le Por, DO Leonard Leo, DC, DCN, DHerb Kam Wah Leung, MD Sandra T.K. Leung, DC Diana Little, MD Alan Mackenzie, DDS

Craig Mackey, DC Sandra Magin, OMD, LAc Carolyn McMakin, DC Joseph Meese, BSPh Christina Minger, EdD, LPC Margaret Mitchell, MD C.B. Moore, MD Maureen & Jerold Morantz, DC Jane Murray, MD Rebecca Murray, ARNP, MSN, FNP Loretta Naylor Thomas O’Bryan, DC Tyler Parham, DC, DACBN Penelope Potter, MD Kathleen M. Power, DC Mitchell Pozega Andrea Cole Raub, DO Dalinda Reese, MD Linda Rodriguez, NC, CPT, CNC Nancy Russell, MD, ABHM J. Michael Ryan, MD Naina Sachdev, MD Kristina Sargent, DC

Lester Adler, MD Anne Allison, RN Richard Bahr, MD Thomas Barnard, MD John Bender, ND Deborah Bernstein, MD Dan Beskind, MD John Biggs, BSC, RNCP Barbara Bradley, DC David Brubaker John Cline, MD Beverly Copeland, MD Creative Health Institute Ruth DeBusk, PhD, RD John Decosmo, III, DO Jeanne Drisko, MD Maria Engel

Andreas Fikioris Christy Fritz Marianne Genetti Thomas Giammatteo, DC Leland Green, MD Steven Green, DDS Curt Hamilton, CCN Anne Hines, MD Stephen Inkeles, MD Dolores Kent, NC Nat Kirkland, Jr, MD Arlyn LaBair, MD Robert Lee, DO Pierrette Lefebvre, MD Sanford Levy, MD Bobbi Lewis, MS, RD Rosalba Lopez, PhD

Frank Melograna, MD, PC Memphis Star Health Services Devin Mikles, MD Thomas Miller, DC Phillip Mosbaugh, MD Jeffrey Mueller, MD James Mumma, DC Kathy Mumma, DC Richard Ng, MD Edward Noa, DC Mark Olsen, MD Margaret Peterson, MD Gerald Phillips, MD Kim Piller Patricia Power, NUTR Renovare Clinic, PA Donald Riemer, MD

0

01

Mel Alter, LPh, CCN Gerald Andreoli, DC Thomas Archie, Jr, MD Sidney Baker, MD James Bean, MD Michael Bernui, DO Carol Beveridge, PhM, RNCP Lucie Blouin, ND Catherine Bock, ND J. Alexander Bralley, PhD Graham Broughton, PhD Gaetan Brouillard, MD Julie & Michael Bryant, DC Donald Buehler, MD Louis Cady, MD Phil Cappellano Center for Nutrition & Therapy Stephen Chiarello, MD Margaret Christensen, MD Andrea Cohen, MD COREhealth Karen Coshow, ND Lester Ducote, Jr, MD Anthony Edwards, MD Lance Farber, DC, CCN

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All ii

Michael Rothman, MD Elizabeth Schultz, DO Susan Solomon, MD Leslie Stewart, DC Nancy Sudak, MD John Thomson, PhD, DA Martin Towbin, MD Ruth Leyse Wallace, PhD Woodrow Weiss, MD Janelle White, MD Katherine Worden, DO, PC Kathy Wurster, DC Kristofer Young, DC Allen Zak, DC

Preface the past two decades: How are the body’s physiological systems linked together? And how is their function influenced by both environment and genetics? The recognition that these two questions are inextricably linked to each other has become much clearer with the discovery that the human genome contains far fewer genes than expected and that much of our biological uniqueness is related to the “non-coding” region of the genome—the region that controls systems of gene expression.4 In essence, we have learned that our complex phenotype cannot be adequately understood by exploring one gene at a time (although that exploration is a vital part of building our knowledge). Systems of genetic expression give rise to our biological complexity and they need to be understood from an integrated perspective. Health care is an enterprise focused on the alleviation of human suffering caused by disease and dysfunction. Disease has its start as a functional impairment (a dysfunction) that, left untreated, becomes a diagnosable disease that later can become the cause of death. Each disease has a past, a present, and a future tied to the progressive loss of function and vitality. James Fries in his landmark article on aging, morbidity, and natural death termed this the “loss of organ reserve.”5 This functional systems biology approach to understanding the origin of disease is now being encouraged by the National Institutes of Health under the new program, NIH Roadmap, as a route to accelerate medical discoveries that will improve health.6 “In this set of NIH Roadmap initiatives, researchers will focus on the development of new technologies to accelerate discovery and facilitate comprehensive study of biological pathways and networks.” It is presently driving research in immunology, neurology, cardiology, endocrinology, and radiology. Three characteristics define the systems biology approach to medicine: emergence, robustness, and modularity.7 Emergence represents the specific characteristics that are displayed in a complex system that are not demonstrated by its individual parts and cannot be predicted

)2

(c

Clinicians who focus on the management of complex, chronic disease have not chosen an easy path. This book describes an approach to improving patient outcomes across a wide range of chronic health conditions through careful analysis of common underlying pathways that interact to produce disease and dysfunction or health and vitality. Outstanding content has been contributed by experts from diverse disciplines that traditionally do not integrate their knowledge within a single text. The approach to disease management and health promotion described herein represents the evolution of the functional medicine model over the past fifteen years through the voices of its leaders. Functional medicine reflects a systems biology approach to health care: a comprehensive analysis of the manner in which all components of the human biological system interact functionally with the environment over time.1 Over the past century, biology and medicine have focused heavily upon understanding the physiology and biochemistry of individual organs, cells, and molecules. Traditionally, researchers and clinicians have explored one component of various biological systems at a time.2 In clinical practice, this process usually leads to the differential diagnosis. In drug discovery, it helps us understand how individual compounds interact with a specific drug target in human physiology. From these investigations has emerged an exceptional knowledge base. We are now poised to comprehend the common underlying pathways of health and disease as never before. We can acknowledge that most diseases are rarely the result of a single physiological problem localized to a single organ.3 Rather, most chronic disease results from the complex interactions of multiple organ systems and multiple physiological and biochemical pathways with environmental influences and genetic predispositions. This knowledge demands a new clinical approach to prevention and treatment. Two challenging questions that have stimulated the development of functional medicine have emerged over

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All iii

Textbook of Functional Medicine

tional medicine clinicians, as developed from scientific progress in the field of psychoneuroimmunology.11 In looking back at the history of medicine in the 20th century, the origin of this concept of function can be credited to a large degree to the work of Dr. Hans Selye.12 His pioneering work related to the functional endocrinology of what he termed “stress” and its relationship to chronic diseases as diverse as peptic ulcer, hypertension, and heart disease created a new medical model for disease arising out of dysfunction, rather than from infectious organisms or inborn errors of metabolism. He put a physiological mechanism behind the concept that “it is more important to know what kind of person has the disease, than what disease the person has.”13 Voices from all aspects of our society are merging into a unified call for a new model to address chronic health conditions. A 2005 article in The New England Journal of Medicine pointed out that children being born today may be the first generation in the history of the United States with a lower life expectancy than their parents.14 This prediction comes at a time when the United States spends twice as much per capita for health as any other country, but is 37th in the world in terms of health outcomes. Another 2005 NEJM study reported that Medicare is in great danger from the increasing prevalence of age-related chronic diseases, which it does not have the resources to address.15 The former chairman of Intel Corporation, Dr. Andrew Grove, recently commented in the Journal of the American Medical Association that innovation in medicine is slow and that a new model is needed to address the serious health concerns of the country.16 Functional medicine is an effective response to this call for a new model of care. It was born out of collaborations among clinicians of many different disciplines and specialties, clinical laboratory specialists, health sciences researchers, health educators, health policy professionals, and healthcare administrators to address the rising incidence and cost of chronic disease. Over the past fifteen years, functional medicine has become an experienced voice in these discussions. This textbook is the result of our belief that a teaching tool is necessary to assist dedicated practitioners to develop competency with the functional medicine model, and to stimulate and support the emergence of new approaches to the education of future clinicians in all healthcare disciplines. It is our hope that this text-

)2

(c

from an understanding of the individual parts alone. In the functional medicine model, this has been termed the “web-like interconnections” of physiological processes and biochemical pathways. Robustness is the ability that complex biological systems have to maintain homeostasis in the face of changing environmental conditions. In functional medicine, this is termed “homeodynamics.” The greater the degrees of physiological freedom individuals have, the more robust their health. For example, very simple EKG patterns are indicative of cardiac disease, whereas the more chaotic fine structure of heart rhythm (i.e., a homeodynamic pattern) is associated with cardiovascular fitness. Modularity refers to a system that is comprised of functional units working together to produce an outcome that cannot be produced by any of the units working independently. An example of this concept in functional medicine is the view of the immune, endocrine, and nervous systems as parts of one super-system, the neuroendocrineimmune system. Only by looking at that system as a whole, and not at each of its units in isolation, can the practitioner fully understand the complex presentation of multiple signs and symptoms that patients so often exhibit. Seventy-eight percent of healthcare expenditures are now for the treatment of chronic diseases, and most physicians are not adequately trained to deal with these complex problems.8 In functional medicine, it is our conviction that developing a healthcare system that effectively manages (and prevents) chronic disease will depend upon our ability to apply a systems biology approach to medicine. Functional medicine incorporates many aspects of this approach, each of which plays a vital role. Identifying and following biomarkers of function that can be used as indicators of the onset of disease, and also as markers of the success of interventions, is an extremely important activity in functional medicine. Using a patient-centered rather than a disease-centered model emphasizes the importance of eliciting the patient’s story, and incorporates mindfulness and the narrative tradition.9 Recognizing that the extent and severity of chronic conditions in middle to late life are, to a large extent, the outcome of environmental insults received at any point from conception forward allows for a focus on long-term prevention to be integrated into clinical practice.10 Harnessing the healing power of the mind-body interaction is also important to func-

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All iv

Preface

References

book is but the first edition of what will be an evolving chronicle of the successful development and implementation of the functional medicine model for the effective prevention and treatment of chronic diseases. Many individuals and organizations provided financial support for the development of this book, and many clinicians, educators, and scientists contributed to the content. For their vision, their commitment to excellence, and their generosity, we dedicate this book to them.

1. 2. 3. 4. 5. 6. 7.

Jeffrey S. Bland, PhD, FACN Founder and Founding Board Chair The Institute for Functional Medicine

8. 9.

(c

)2

10.

0

01

11. 12.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Bork P, Serrano L. Towards cellular systems in 4D. Cell. 2005;121:511-13. Kirschner MW. The meaning of systems biology. Cell. 2005;121;503-04. Liu ET. Systems biology, integrative biology, predictive biology. Cell. 2005;121:505-06. Marks J. What it Means to be 98% Chimpanzee. The University of California Press, Los Angeles, 2001. Fries J. Aging, natural death and the compression of morbidity. N Engl J Medicine. 1980;303:130-5. http://nihroadmap.nih.gov/buildingblocks/ Aderem A. Systems biology: Its practice and challenges. Cell. 2005;121:511-13. Holman H. Chronic disease—the need for a new clinical education. JAMA. 2004; 292:1057-9. Connelly JE. Narrative possibilities: using mindfulness in clinical practice. Perspect Biol Med. 2005;48:84-94. Fogel RW. Changes in the disparities in chronic diseases during the course of the 20th century. Perspect Biol Med. 2005;48:S150-S165. Hoffman GA, Harrington A, and Fields HL. Pain and the placebo: what we have learned. Perspect Biol Med. 2005; 48:248-65. Selye H. Forty years of stress research: principal remaining problems and misconceptions. Can Med Assoc J. 1976;115:53-6. Osler W. Masters in medicine: nurse and patient. RI Med J. 1971;54:33-6. Olshansky SJ, Passaro DJ, Hershow RC, Hayflick L, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005;352:1138-45. Anderson GF. Medicare and chronic conditions. N Eng J Med. 2005;353:30508. Grove A. Efficiency in the health care industries. JAMA. 2005;294:490-1.

13.

14.

15. 16.

e

in

ic

ed

v

Textbook of Functional Medicine

)2 (c

0 01

e in ic ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

vi

Foreword: Textbook of Functional Medicine July 1, 2010 Mark Hyman, MD Chairman, The Institute for Functional Medicine

of all federal spending will be allocated to Social Security, Medicare, and Medicaid.9 As the science and practice of medicine transition from the acute-care, reductionist model that evolved from the germ theory of disease to a systems model based on networks of biologic function—a model that has emerged from the genomic revolution—clinical practice, medical education, and health research must all evolve and adapt to make the transition successful.10 A fundamental re-orientation of clinical problem solving is required, expanding the diagnostic focus from the disease-based ICD-9 classification system to include assessment of patterns of dysfunction within complex networks of biologic systems, which are at the root of all disease.11 Functional medicine provides a new model of healthcare delivery and practice that addresses the drivers of chronic diseases such as cardiovascular disease, diabetes, obesity, cancer, autoimmune and allergic conditions, digestive, mood, and cognitive disorders by translating existing research into clinical practice through the lens of systems biology. Most chronic disease is preventable, and much of it is reversible, if a comprehensive, individualized approach addressing genetics, diet, nutrition, environmental exposures, stress, exercise, and psychospiritual needs is implemented through integrated clinical teams and based on emerging research.12 Functional medicine provides a practical clinical framework for understanding how the body’s physiologic systems are linked together and how their function is influenced by both environment and genetics.13 Clinical medicine can and must shift to an applied systems medicine—personalized, predictive, preventive, and participatory.14 The Textbook of Functional Medicine shifts our paradigm from organ-based diseases to functional dynamic systems. It is the first robust clinical model that effectively applies the promise of systems biology. Arising from direct observation and assimilation of seemingly

)2

(c

Shifts in thinking do not come easily in science. Thomas Kuhn, in The Structure of Scientific Revolutions, warns that changes of “normative” science rarely come from within. We are at a moment in medical history that requires a new way of interpreting and processing data, a new operating system to successfully address our global epidemic of chronic disease.1 Practitioners need a new set of lenses through which to interpret and act on clinical information. The Textbook of Functional Medicine presents those new lenses, and the science that validates them. In this groundbreaking text, we learn: • a new way of seeing the epidemic of chronic disease based on underlying causes, and • a focus on developing treatment models that can restore balance within dysfunctional biological systems and networks.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

in

ic

ed

Current medical models are reductionist in nature, producing fragmented, organ-based, specialist-focused care that results in increased costs and poor outcomes.2 Disastrously, primary care is a dying field3,4,5 at the same time that primary care diseases are increasing at dramatic rates. Applied in practice, functional medicine can reinvigorate primary care by training practitioners to prevent, treat, and often cure chronic conditions more effectively and at lower cost than the conventional medical paradigm.6 The urgency for practitioners to learn and adopt more effective clinical tools for prevention, treatment, and management of chronic disease is underscored by the fact that more than 75% of healthcare costs—$2.3 trillion—is now spent on chronic disease.7 By 2040 (at current growth rates and if we don’t act soon), health care costs will absorb 34% of our GDP8 and nearly 80%

vii

Textbook of Functional Medicine

disparate scientific evidence, a view of biology emerges that delivers a new operating system for the maintenance of health and the prevention of disease. It is essential reading for any practitioner or scientist involved in health care in the 21st century.

References 1.

2. 3.

4.

8.

9.

10.

e

14.

in

13.

ic

12.

ed

11.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

7.

0

6.

01

5.

)2

(c

Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: Overcoming impediments to prevention and control. JAMA. 2004;291(21):2616-2622. http://www.dartmouthatlas.org. Health Care Spending, Quality and Outcomes, February 27, 2009 Harris C. Primary care in medical education: The problems, the solutions. AAMC Reporter, March 2010. Accessed June 14, 2010 at http://www.aamc.org/newsroom/reporter/march10/ primarycare.htm Colwill JM, Cultice JM, Kruse RL. Will generalist physician supply meet demands of an increasing and aging population? Health Affairs. 2008;27(3):w232ñw241. Howell JD. Reflections on the past and future of primary care. Health Affairs. 2010;29(5):760-5. Hyman MA. The failure of risk factor treatment for primary prevention of chronic disease. Altern Ther Health Med. 2010 MayJun;16(3):60-3. Centers for Disease Control. Accessed June 6, 2010 at http:// www.cdc.gov/chronicdisease/resources/publications/AAG/ chronic.htm Council on Economic Affairs. Executive Office of the President. The Economic Case for Health Care Reform. June 2009. Accessed July 1, 2010 at http://www.whitehouse.gov/blog/The-Economic-Case-forHealth-Care-Reform/ Edwards C, DeHaven T. War between the generations: Federal spending on the elderly set to explode. Cato Institute Policy Analysis, September 2003. Accessed June 14, 2010 at http:// www.cato.org/pubs/pas/pa488.pdf. Jones DS, Hofmann L, Quinn S. 21st Century Medicine: A New Model for Medical Education and Practice. The Institute for Functional Medicine: Gig Harbor, WA; 2009. Hyman MA. Functional diagnostics: Redefining disease. Altern Ther Health Med. 2008 Jul-Aug;14(4):10-4. Review. American College of Preventive Medicine. Lifestyle Medicine—Evidence Review. June 30, 2009. Available at: http://www.acpm.org/ LifestyleMedicine.htm. Accessed September 18, 2009. Loscalzo J, Kohane I, Barabasi AL. Human disease classification in the postgenomic era: A complex systems approach to human pathobiology. Mol Syst Biol. 2007;3:124 Snyderman R, Langheier J. Prospective health care: The second transformation of medicine. Genome Biol. 2006;7(2):104.

viii

Contents Section I Chapter 1

Introduction The Vision and Mission of The Institute for Functional Medicine

3

What is Functional Medicine?

01



5 Introduction to Functional Medicine

)2

Chapter 2

(c

David S. Jones, Sheila Quinn

5

David S. Jones, Jeffrey S. Bland, Sheila Quinn

History of Functional Medicine

0



10

Chapter 3

lM na tio d. un rve r F se fo re te ts itu h st rig In All

David S. Jones, Jeffrey S. Bland

Why Functional Medicine? 

15 Importance of Improving Management of Complex, Chronic Disease

15

David S. Jones, Sheila Quinn 

Our Aging Population and the Centrality of Diet, Lifestyle, and Environment

18

David S. Jones, Sheila Quinn 

Functional Medicine Incorporates Genomics Jeffrey S. Bland

Chapter 4

20

Training Clinicians in New Approaches to Care

27

Sheila Quinn, David S. Jones

Chapter 5

Changing the Evidence Model 

33 Functional Medicine and the Emerging Research Base



33

ed

David S. Jones

Clinical Decision Making—A Functional Medicine Perspective

39

e

in

ic

Joseph E. Pizzorno, Jr.

Section II Chapter 6

Principles of Functional Medicine Functional Medicine is Science-Based

49

DeAnn Liska

Chapter 7

Biochemical Individuality and Genetic Uniqueness 

55 Functional Medicine and Biochemical Individuality: A Paradigm Shift in Medicine Mark Hyman, Sidney M. Baker, David S. Jones



Development of the Knowledge Base in Biochemical Individuality

63

DeAnn Liska

Chapter 8

Patient-centered Care: Antecedents, Triggers, and Mediators Leo Galland

Chapter 9

Homeostasis: A Dynamic Balance

93

Joseph J. Lamb

ix

79

55

Textbook of Functional Medicine

Chapter 10 Web-like Interconnections: The Complex Human Organism 

Web-like Interconnections of Physiological Factors

97

97

DeAnn Liska, Dan Lukaczer 

Organ System Function and Underlying Mechanisms: The Interconnected Web

99

Alex Vasquez

Chapter 11 Health as a Positive Vitality

107

Nancy Sudak

Chapter 12 Healthy Aging: The Promotion of Organ Reserve

111

David S. Jones, Jeffrey S. Bland, Sheila Quinn

Section III The Building Blocks 

)2

(c

Chapter 13 Environmental Inputs Diet and Nutrients Air and Water

Physical Exercise William J. Evans



Psychosocial Influences John Tatum



Trauma

140

Jayne Alexander 

Xenobiotics

147

John Cline 

Microorganisms Patrick Hanaway



129

lM na tio d. un rve r F se fo re te ts itu h st rig In All



127

0

Jeffrey S. Bland

01

Jeffrey S. Bland 

123 123

Radiation

153

Carol R. McMakin

137

150

Chapter 14 Influence of Mind and Spirit DeAnn Liska

165

ic

ed e

in

Section IV Fundamental Physiological Processes Chapter 15 Communications: Intracellular and Extracellular

171

Gary Darland

Chapter 16 Bioenergetics and Biotransformation

183

Gary Darland

Chapter 17 Digestion and Excretion

189

DeAnn Liska, Jeffrey S. Bland

Chapter 18 The Biology of Inflammation: A Common Pathway in Cardiovascular Diseases,

Part I

203

Peter Libby

x

Contents

Section V

Fundamental Clinical Imbalances

Chapter 19 Hormonal Imbalances 

215 Female Hormones: The Dance of the Hormones, Part I

215

Bethany Hays 

Male Hormones

234

Daniel Cosgrove 

The Epidemic of Insulin Insensitivity

245

Dan Lukaczer

Chapter 20 Neurological Imbalances

257

Catherine Willner

Chapter 21 Oxidation-reduction Imbalances

265

Catherine Willner

)2

(c

Chapter 22 Detoxification and Biotransformational Imbalances

275

DeAnn Liska, Michael Lyon, David S. Jones Robert Rountree

299

0

01

Chapter 23 Immune Imbalances and Inflammation

Chapter 24 Digestive, Absorptive, and Microbiological Imbalances Chapter 25 Structural Imbalances Alex Vasquez

327

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Thomas Sult

339

Section VI A Practical Clinical Approach

Chapter 26 Clinical Approaches to Environmental Inputs 

Diet and Nutrition Mark Hyman



347

347

Micronutrient Insufficiency Leads to DNA and Mitochondrial Damage Bruce N. Ames

388

ed

Chapter 27 Clinical Approaches to Immune Imbalance and Inflammation

405 The Biology of Inflammation: A Common Pathway in Cardiovascular Diseases, Part II

in

ic



Peter Libby

e



Inflammation and Autoimmunity: A Functional Medicine Approach Alex Vasquez



Essential Fatty Acids

418

Robert H. Lerman

Chapter 28 Clinical Approaches to Gastrointestinal Imbalance 

Digestion and Absorption

435

Thomas Sult 

Balance of Flora, GALT, and Mucosal Integrity Patrick Hanaway



The Enteric Nervous System

453

Michael D. Gershon 

The “4R” Program

462

Dan Lukaczer

xi

444

435

409

405

Textbook of Functional Medicine

Chapter 29 Clinical Approaches to Structural Imbalance 

Physical Fitness and Exercise

481

481

David Musnick 

Manipulative Therapy and Functional Medicine: Clinical Interactions between Structure and Function 493 David Wickes

Chapter 30 Clinical Approaches to Energy Production and Oxidative Stress 

501 Bioenergetics, Mitochondrial Function and Oxidative Stress in Functional Medicine

501

Jeffrey S. Bland 

Oxidative Stress and Autism

512

Woody R. McGinnis 

Oxidative Stress and Glycemic Control

526

Dan Lukaczer

Genetic and Environmental Influences on Detoxification

)2



(c

Chapter 31 Clinical Approaches to Detoxification and Biotransformation

543

543

Michael Lyon, Jeffrey S. Bland, David S. Jones

Systemic In-office Detoxification

01



554

Walter J. Crinnion

0



Home-based Detoxification



The Gut-Liver Axis Mary James

556

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Peter Bennett

562

Chapter 32 Clinical Approaches to Hormonal and Neuroendocrine Imbalances 

Cellular Messaging, Part I

581

581

Jeffrey S. Bland, David S. Jones 

Cellular Messaging, Part II—Tissue Sensitivity and Intracellular Response

590

Jeffrey S. Bland, David S. Jones 

The Hypothalamus-Pituitary-Adrenal Axis Michael Lumpkin



Managing Insulin and Glucose Balance Dan Lukaczer



ed

Fibroids and Endometriosis

635

ic

Joel M. Evans

Neurotransmitters: A Functional Medicine Approach to Neuropsychiatry

in



638

e

Jay Lombard 

618

Perimenopause, Menopause, and Women’s Health: The Dance of the Hormones, Part II Bethany Hays



610

Thyroid 644 Lara Pizzorno, William Ferril

Chapter 33 Stress, Spirituality, Poverty, and Community—Effects on Health

669

Robert Hedaya

Section VII Putting It All Together Chapter 34 The Patient’s Story; the Clinician’s Thinking—A Place to Start Michael Stone, David S. Jones

xii

689

622

Contents

Chapter 35 Assessment and Therapeutic Strategy—A Place to Start 



703 Elimination Diet and Laboratory Testing 703 Dan Lukaczer, Barb Schiltz Identifying Practical Interventions that Help to Normalize Multiple Symptoms

709

Nancy Sudak, Virginia Shapiro

Chapter 36 The Healing Relationship 

713 Creating Effective Doctor-Patient Relationships

713

Edward Leyton 

Helping Patients Change Unhealthy Behaviors

722

Janice M. Prochaska, James O. Prochaska

Chapter 37 Case Presentations 

729 Metabolic Syndrome, Cardiovascular Disease, and Related Conditions: Extended Discussion 729

(c

Mark C. Houston

Full Case: Psoriatic Arthritis

)2



750

Kara N. Fitzgerald, Mark Hyman

Full Case: Attention Deficit Hyperactivity Disorder (ADHD)

01



768

0

Kara N. Fitzgerald, Mark Hyman

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Appendix

e

in

ic

ed

30 Top-Selling Drugs and 10 Top-Selling Herbal Supplements in the United States (2003) 789 Biographical Sketches for Contributing Authors 790 Comprehensive Elimination Diet—Sample Patient Handouts 800 7-Day Menu Plan 802 Recipes for 7-Day Menu (in alphabetical order) 804 Cytochrome P450 Enzymes: Drug and Natural Product Substrates, Inhibitors, and Inducers 815 Detailed Review of Systems 821 Adult Toxin Exposure Questionnaire 823 Child Toxin Exposure Questionnaire 828 Health Benefits of Exercise 833 Internet-based Resources for the Healthcare Practitioner 834 Medical Symptoms Questionnaire 838 Life Stress Questionnaire 840 Nutrient Deficiency Signs and Symptoms, by Nutrient 841 Nutrient Deficiency Signs and Symptoms, by Physical Exam Finding 849 Three-Day Diet Diary 857 Glossary 859

xiii

Textbook of Functional Medicine

Index

865

21st Century Medicine: A New Model for Medical Education and Practice

897

)2

(c 0

01 e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All xiv

Section I Introduction

01 )2 (c

0

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e in ic

)2 (c

0 01

e in ic ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Chapter 1 The Vision and Mission of The Institute for Functional Medicine David S. Jones, MD, and Sheila Quinn

(c

2. Teaching physicians and other healthcare providers the basic science and clinical applications of functional medicine; 3. Communicating with policy makers, practitioners, educators, researchers, and the public to disseminate the functional medicine knowledge base more widely.

)2

The Institute for Functional Medicine is a nonprofit, tax-exempt 501(c)3 educational organization that educates physicians and other healthcare practitioners in improving the management of complex, chronic disease through the use of functional medicine. IFM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. In addition to live CME courses, IFM publishes books, course syllabus and audio recordings from live courses, and hosts an online Member Forum. Detailed information about the Institute and its educational activities can be found at www.functionalmedicine.org. IFM’s long-term goals are perfectly described in a statement by Peter F. Drucker: “The product (of the nonprofit organization) is neither a pair of shoes nor an effective regulation. Its product is a changed human being. The nonprofit institutions are human-change agents.”1

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Purpose Statement The Institute provides continuing medical education for physicians and other healthcare professionals, publishes books and other educational materials, and offers clinicians a Forum for the shared exploration of emerging research and clinical applications to improve patient care and outcomes.

ed

Statement of Need

in

ic

The U.S. healthcare system fails to address the needs of many of our citizens. Many physicians have lost their passion for patient care;2 patients are disenchanted sufficiently with the focus of their health care to seek alternatives to conventional care in steadily increasing numbers;3,4 the numbers of uninsured grow as employers reduce their premium share or opt out of providing employee health insurance because of costs;5,6 and the U.S. ranks 37th in quality of health outcomes7 despite spending $1.6 trillion per year on health care.8 Research suggests that the sense of futility experienced by many healthcare providers stems from a loss of meaning and empowerment in the therapeutic relationship, created (in part) as our chaotic healthcare system has shifted focus from quality issues to cost issues.9,10,11,12,13 A paradigm shift is required to

e

Vision Statement The vision of the Institute for Functional Medicine is to improve the health of individuals worldwide by continuous improvement in healthcare practices.

Mission Statement The mission of the Institute is to improve patient outcomes through prevention, early assessment, and comprehensive management of complex, chronic disease. We achieve this mission by: 1. Developing the functional medicine knowledge base as a bridge between research (both emerging and established) and clinical practice;

3

Section I Introduction re-enchant the practice of medicine for both the healthcare provider and the patient (the consumer of health care).14 It has been suggested that the holism inherent in the therapeutic relationship, plus an expansion of medical thinking beyond the diagnosis and the prescription pad, will re-involve the healthcare provider in the dual function of critical thinking and mindful involvement with the whole life of the patient.15,16,17 The Institute for Functional Medicine is committed to helping practitioners and patients achieve this important goal. Since IFM’s first incorporation in 1996, it has been dedicated to reducing the fragmentation of health care with a rigorous, science-based continuing educational program whose primary focus is on improving patient outcomes through more effective prevention, early assessment, and comprehensive management of complex, chronic disease. As our mission statement indicates, IFM intends to be just such a change agent as Drucker described, helping to better the health of people worldwide by changing the way health care is practiced. This textbook represents an important step in achieving IFM’s mission—putting into the hands of healthcare providers around the world a consistent, documented view of the philosophy, concepts, underlying science, and clinical applications of functional medicine so that, together, we can work toward the continued development of this extremely important approach to patient care.

9. 10.

11. 12. 13. 14.

15.

)2

(c

16. 17.

Kenagy JW, et al. Toward a value-based health care system. Am J Med. 2001;110:158-63. Chassin MR, Galvin RW. The urgent need to improve health care quality: Institute of Medicine national roundtable on health care quality. JAMA. 1998;280:1000-05. Branch WT. Is the therapeutic nature of the patient-physician relationship being undermined? Arch Intern Med. 2000;160:2257-60. Remen, RN. Recapturing the soul of medicine. West J Med. 2001;174:4-5. Marton, KI. Commentary: The secret to satisfaction: empowerment for all. West J Med. 2001;173:18-19. Institute for the Future. Health and Health Care 2010: The Forecast, the Challenge (2nd Edition). http://www.iftf.org/features/ library.html. Chapter 18: Expanded Perspective on Health: Beyond the Curative Model, pg 337. Dacher ES. Reinventing primary care. Altern Ther Health Med. 1995;1(5):29-34. Chiong W. Diagnosing and defining disease. JAMA. 2001;285:89-90. Johns MM. The time has come to reform graduate medical education. JAMA. 2001;286:1075-76.

0

01

5.

6.

7. 8.

e

4.

in

3.

Peter F. Drucker, Managing the Nonprofit Organization (New York: HarperCollins, 1990), p. xiv. Hurd NE. Physician, heal thyself. Minnesota Medicine. July 2002:85. [Accessed at http://www.mnmed.org/publications/MNMed2002/ July/Hurd.html] Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 1998;280(18):1569-75. Centers for Disease Control and Prevention, US Dept of Health and Human Services. Advance Data from Vital and Health Statistics. Complementary and Alternative Medicine Use Among Adults: United States, 2002. Number 343, May 27, 2004. Cooper PF, Vistnes J. Workers’ decisions to take-up offered health insurance coverage: assessing the importance of out-of-pocket premium costs. Med Care. 2003;41(7 Suppl);III35-III43. Ku L. The number of Americans without health insurance rose in 2001 and continued to rise in 2002. Int J Health Serv. 2003;33(2):359-67. O’Connor, K. We can corral health costs by keying on prevention. Seattle Times, June 7, 2002. Levit K, Smith C, Cowan C, et al. Health spending rebound continues in 2002. Health Aff. 2004;23(1):147-59.

ic

2.

ed

1.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

References

4

Chapter 2 What is Functional Medicine?  

Introduction to Functional Medicine History of Functional Medicine

)2

(c Introduction to Functional Medicine

01

David S. Jones, MD, Jeffrey S. Bland, PhD, and Sheila Quinn

0

A 2003 article in the British Medical Journal1 generated the following editorial comment: “It is almost a daily occurrence for primary care doctors to encounter patients whose symptoms are probably not due to discernible organic cause.” Many of these symptoms appear to be related to chronic inflammatory complaints of unknown origin. Because no specific disease can unequivocally be attached to these complaints, the following question arises: What physiological processes/mechanisms result in the expression of these signs and symptoms? Could their underlying “organic cause” be related to altered function in the absence of observed pathology? A major challenge for medicine in the 21st century will be to move toward a thorough understanding of physiological mechanisms that underlie disease rather than simply labeling later-stage effects with the names of diseases. “What should we say to patients with symptoms unexplained by disease?” asks the article associated with the editorial comment quoted above. The authors suggest that, for most patients, using the term “functional,” as in “functional illness,” would be more socially acceptable than “medically unexplained symptoms.” Historically, the term “functional” has been used pejoratively in medicine. It has implied either a disability associated with geriatric medicine or a psychiatric problem. Now, the term “functional” is being used to describe a manifestation of changes in basic physiological processes that produce symptoms of increasing duration, intensity, and frequency. These symptoms often

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

represent the first signs of a later-stage, pathophysiologically definable disease. So, the term becomes applicable not only to diseases of unknown origin, but to early alterations in function that clearly move a patient toward chronic disease over the course of a lifetime. A new model of medicine is emerging to describe these altered physiological processes that presage the onset of histopathologically defined disease. This model takes the term “functional” beyond psychosomatic illness to define a state of chronic dysfunction associated with altered physiological processes that create a physiological alarm state.

What is Functional Medicine?

ic

e

in

Functional medicine is a dynamic approach to assessing, preventing, and treating complex chronic disease. Functional medicine helps clinicians identify and ameliorate dysfunctions in the physiology and biochemistry of the human body as a primary method of improving patient health. Functional medicine acknowledges that chronic disease is almost always preceded by a lengthy period of declining function in one or more of the body’s systems. Returning patients to health requires reversing (or substantially improving) the specific dysfunctions that have contributed to the disease state. Those dysfunctions are, for each of us, the result of lifelong interactions among our environment, our lifestyle, and our genetic predispositions. Each patient, therefore, represents a unique, complex, and interwoven set of influences on

5

Section I Introduction focus on restoring health and function, rather than simply controlling signs and symptoms. Functional medicine could be characterized, therefore, as “upstream medicine” or “back to basics”—back to the patient’s life story, back to the processes wherein disease originates, and definitely back to the desire of healthcare practitioners to make people well, not just manage symptoms.

intrinsic functionality that have set the stage for the development of disease or the maintenance of health.

The Functional Medicine Domain One way to conceptualize where functional medicine falls in the continuum of health and health care is to examine the functional medicine “tree.” In its approach to a patient care model for complex, chronic disease, functional medicine encompasses the whole domain represented by the graphic shown in Figure 2.1, but concentrates on the section below Organ System Diagnosis, which differentiates it from the conventional medical model. Assessment and treatment first address the patient’s core clinical imbalances, fundamental physiological processes, environmental inputs, and genetic predispositions, rather than heading straight for the diagnosis. (These elements are explored in detail and thoroughly documented in separate sections of this book. Here in the Introduction, we provide an overview of the content and concepts.) Diagnosis is not excluded from the functional medicine model, but the emphasis is on understanding and improving the functional core of the human being as the starting point for intervention. Functional medicine practitioners reason that scientific evidence strongly indicates that impaired physiological processes, if not corrected, lead to significant clinical imbalances in essential body systems. If left in a dysfunctional state, those clinical imbalances often progress to more significant signs and symptoms that may be the precursors or actual indicators of a disease state that can be diagnosed. Improving balance and functionality in these basic processes creates momentum toward health. Conventional medicine normally acts either when a diagnosis can be made, or when signs and symptoms are severe enough (or the patient is persistent enough) to demand a clinical intervention. Functional medicine practitioners certainly do intervene when a diagnosis has already been made, but they also evaluate functionality at a much earlier stage, often averting (or deferring for a substantial period of time) the disease outcome or its secondary effects. And, in all cases, functional medicine clinicians focus on restoring balance to the dysfunctional systems by strengthening the fundamental physiological processes that underlie them, and by adjusting the environmental inputs that nurture or impair them. This approach leads to therapies that

Principles

)2

(c

These basic principles characterize the functional medicine paradigm: • An understanding of the biochemical individuality of each human being, based on the concepts of genetic and environmental uniqueness; • Awareness of the evidence that supports a patientcentered rather than a disease-centered approach to treatment; • The search for a dynamic balance among the internal and external factors in a patient’s body, mind, and spirit; • Familiarity with the web-like interconnections of internal physiological factors; • Identification of health as a positive vitality—not merely the absence of disease—emphasizing those factors that encourage the enhancement of a vigorous physiology; and • Promotion of organ reserve as the means to enhance the health span, not just the life span, of each patient.

0

01

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

in

ic

Each of these principles is discussed in depth in the Principles section, and the evidence supporting their inclusion is presented there.

Environmental Inputs Environmental inputs (at the base of the medicine tree graphic) include the basic building blocks of life, as well as the primary influences on them. When we talk about influencing “gene expression,” we are interested in the interaction between “environment” in the broadest sense and any genetic predispositions with which a person may have been born. Many environmental factors that affect genetic expression are (or appear to be) a matter of choice (such as diet and exercise), but others are very difficult for the individual patient to alter or escape (air and water quality, toxic exposures), and still

6

Chapter 2 What is Functional Medicine? economic status—if you are poor, for example, it may be impossible to choose more healthful food, decrease stress in the workplace and at home, or take the time to exercise and rest properly.

others may be the result of unavoidable accidents (trauma, exposure to harmful microorganisms in the food supply through travel). Some factors that may appear modifiable are heavily influenced by the patient’s

)2

(c 0

01 e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All Figure 2.1 The continuum of health and health care

7

Section I Introduction grate this rich understanding of the underlying functional mechanisms of disease with therapeutics and prevention. In the second two years, conventional clinical training heavily emphasizes teaching/learning based on organ system diagnosis.2 This approach—aggregating the patient’s signs and symptoms into groupings that follow organ system declensions—has given us both the power and the weakness of specialization (e.g., the breakdown of medicine into cardiology, neurology, gastroenterology, pulmonology, nephrology, dermatology, hematology, hepatology, endocrinology, the surgical specialties, and so forth). Specialists become exceedingly knowledgeable in a well-defined subset of the human organism, but they often evaluate and treat diseases within their specialty area as though the inevitable crosstalk among all organ systems does not occur. Focusing predominantly on organ system diagnosis without examining the underlying physiology that produced the patient’s signs, symptoms, and disease often leads to managing patient care by matching diagnosis to pharmacology. The job of the healthcare provider then becomes a cookbook exercise in finding the right “recipe”—the drug or procedure that best fits the diagnosis (not necessarily the patient). Every medical problem thus becomes a personal health issue in search of a pharmacological agent or surgical procedure3 and that leads to a significant curtailment of the critical thinking pathways: “Medicine, it seems, has little regard for a complete description of how a myriad of pathways result in any clinical state.”4 Even more important, the pharmacologic treatments specific to each specialty are often implemented without careful consideration of the physiological effects across all organ systems and physiological processes (and genetic variations).5 Pharmaceutical companies have exploited this weakness. Did you ever see a drug ad that urges the practitioner to carefully consider the impact of all other drugs being taken by the patient before prescribing a new one? The marketing of drugs to specific specialty niches and the use of sound-bite sales pitches that suggest discrete effects skew healthcare thinking toward this narrow, linear logic, as notably exemplified by the COX-2 inhibitor drugs that were so wildly successful on their introduction, only to be subsequently withdrawn or substantially narrowed in use due to collateral damage.6,7 Pharmacological and medical hardware interests also strongly influence the research that is done and the

)2

(c

Whatever the nature of these “inputs,” their influence on the human organism is indisputable, and they are often powerful agents in the search for health. Ignoring them in favor of the “quick fix” of writing a prescription means the cause of the underlying dysfunction may be obscured, but is usually not eliminated. The functional medicine practitioner takes the elements listed below into consideration when working with a patient to reverse dysfunction or disease and restore health: • Diet (type and quantity of food, food preparation, calories, fats, proteins, carbohydrates) • Nutrients (both dietary and supplemental) • Air • Water • Microorganisms (and the general condition of the soil in which food is grown) • Physical exercise • Trauma • Psycho-social factors (including family, work, community, economic status, stress) • Xenobiotics • Radiation

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Environmental inputs are intimately connected with the functional medicine principle of dynamic balance mentioned above. The importance of this critical interweaving between internal and external factors in a patient’s body, mind and spirit is fully explored later in the book.

ic

ed

Fundamental Physiological Processes

e

in

The fundamental physiological processes that ultimately determine health or disease include: • communication, both outside and inside the cell; • bioenergetics, or the transformation of food, air, and water into energy; • replication, repair, and maintenance of structural integrity, from the cellular to the whole body level; • elimination of waste; • protection and defense; and • transport and circulation. These fundamental physiological processes are usually taught in the first two years of medical training, where they are appropriately presented as the foundation of modern, scientific medical care. However, subsequent training in the clinical sciences often fails to fully inte-

8

Chapter 2 What is Functional Medicine? medicine practitioner. The foundational principles of how the human organism functions—and how its systems communicate and interact—are essential to the process of linking ideas about multifactorial causation with the perceptible effects we call disease or dysfunction. To assist clinicians in this process, functional medicine has adapted and organized a set of core clinical imbalances that function as the intellectual bridge between the rich basic science literature delineating physiological mechanisms of disease (first two years of medical training) and the clinical studies, clinical experience, and clinical diagnoses of the second two years of medical training. The core clinical imbalances serve to marry the mechanisms of disease with the manifestations and diagnoses of disease. (Re-examine the medicine tree graphic to appreciate how the core clinical imbalances fit within the total framework of health care.)

)2

(c

information that reaches physicians about new drugs and procedures.8,9,10 Our national research establishment—both private and governmental—is heavily focused on drug development and medical devices technology, rather than multifactorial, individualized, lifestyle-focused interventions. Physicians (and now patients as well) are subjected to the disproportionate impact the drug industry’s ad campaigns have on information about treatment approaches for disease—everything is centered on taking a drug,11 rather than helping patients change behavior. By controlling research topics,12 selecting what data will be published,13,14 and dominating continuing medical education programs,15,16,17 the pharmaceutical industry often replaces complex thinking with more simplistic approaches relying on pharmaceuticals.18 Even our less commercial research models (at NIH, for example) all too often concentrate on “single disease–single agent–single outcome” methodologies. Examination of lifestyle and the attendant physiological and health consequences seldom receive needed research support because the medical-industrial complex that surrounds conventional training and practice is driven by these powerful commercial interests. (Lifestyle approaches are also more difficult to study prospectively, but the work certainly can be done with the will and the resources.) Fortunately, a stronger voice from within the ranks of medical educators and practitioners is emerging on behalf of re-evaluating the influence of commercial interests on our healthcare system—from education to research to clinical practice.19,20 Many mainstream publications are including articles by leading medical thinkers that patient-centered health care requires a broader focus than simply labeling the problem (diagnosis) and selecting the right drug.21 The functional medicine approach to assessment, both before and after diagnosis, charts a course using different navigational assumptions. Every health condition instigates a quest for information centered on understanding when and how the specific biological system(s) under examination spun out of control to begin manifesting dysfunction and/or disease. Analyzing all the elements (information from the patient’s story, signs, symptoms, and laboratory assessment) through a matrix focused on functionality requires critical thinking that is quite different than matching diagnosis with drug and hardware interventions. A deeper understanding of biochemistry and physiology is required of a functional

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Core Clinical Imbalances

e

in

ic

ed

The practice of functional medicine is characterized by an examination of the core clinical imbalances that underlie the expression of disease. Those imbalances arise as environmental inputs such as diet, nutrients (including air and water), exercise, toxins, and trauma are processed (see above list of the fundamental processes involved) through a unique set of genetic predispositions, attitudes, and beliefs. The core clinical imbalances that arise from malfunctions within this complex system include: • Hormonal and neurotransmitter imbalances • Oxidation-reduction imbalances and mitochondropathy • Detoxification and biotransformational imbalances • Immune and inflammatory imbalances • Digestive, absorptive, and microbiological imbalances • Structural imbalances from cellular membrane function to the musculoskeletal system

Imbalances such as these are the precursors to the signs and symptoms by which we detect and label (diagnose) organ system disease. These imbalances arise from dysfunction or defect within the fundamental physiological processes that cut across all organ systems, and they alert the healthcare provider to pay attention to the full expression of disease and dysfunction. Each of these imbalances is explored in considerable detail later in the book, and the underlying evidence supporting this approach to patient care is thoroughly discussed. The most important precept to remember about functional medicine is that restoring balance—in the

9

Section I Introduction patient’s environmental inputs and in the body’s fundamental physiological processes—can be both a precursor and a concomitant activity to evaluating and treating chronic illness, and to improving health. It involves much more than treating symptoms.

nosis in the realm of chronic illness—such as the many conditions of chronic inflammation whose proud names end in “-itis,” and autism, schizophrenia, depression, anxiety, cardiovascular disease, and a host of otherwise eponymous, classical, and respectable diseases— is for us not the end of a diagnostic road, but the first step, to be followed by the … [consideration of unique individual needs]. These questions are not applied to “curing the disease” but to healing the person. This approach is based on the recognition that individuality … [has] a spiritual as well as a biological foundation in the sense that each of us is a unique creature. Hence our patients are denied dignity when given a group identity (diagnosis) and a group treatment (the “treatment of choice” for that diagnosis).23

Short Description of Functional Medicine Functional medicine is dedicated to prevention, early assessment, and improved management of complex, chronic disease by intervening at multiple levels to correct core clinical imbalances and thereby restore each patient’s functionality and health to the greatest extent possible.

(c

Functional medicine evolved from a medical paradigm that, instead of emphasizing the primacy of diagnosis and pathology, focuses on the antecedent events that precede the onset of diagnosis (cf. the notion of “upstream medicine,” discussed above under The Functional Medicine Domain). Leo Galland, MD, elaborated this principle first in the early 1990s in his unpublished, but widely disseminated paper, Patient-Centered Diagnosis: A Guide to the Rational Treatment of Patients as Individuals,24 later expanded and published in 1997 as The Four Pillars of Healing.25 Patient-centered diagnosis depends on knowledge of the mediators, triggers, and antecedents of the patient’s specific disease (discussed in detail in Chapter 8). According to Dr. Galland, arriving at an accurate, detailed, structured assessment of the patient requires a collaborative context within which the patient’s story includes:

)2

History of Functional Medicine

01

David S. Jones, MD, and Jeffrey S. Bland, PhD

0

If contrast is the essence of vision, then clearly delineating the differences between present-day conventional medicine and functional medicine will help improve our understanding of the road being pioneered by functional medicine. In his commentary in 2003, The Medicine We Are Evolving,22 Sidney MacDonald Baker, MD, postulates that current conventional medicine rests on two primary principles: 1. The fundamental subject of medical concern is disease; 2. The inquiry as to health rests first on the naming of the patient’s disease.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

aspects of the patient that had previously been ignored. We were interested in the effects of the common components of life: a patient’s thoughts and beliefs, home or work environment, exposure to potential toxins, and allergens, food and drink, stressful life events, social interactions, patterns of physical activity.

e

in

ic

ed

He points out that treatment is then prescribed for the disease without rigorous consideration of the patient’s unique individual needs, which may include the need to be rid of something toxic, allergenic or infectious, or the need to add something vital that is missing, or both. Dr. Baker describes the difference between the acuteillness legacy of conventional medicine and today’s functional medicine model that is focused on prevention and treatment of chronic, complex illnesses (the dominant medical problems experienced in our modern, industrialized, hygienic society):

The evaluation investigates the patient’s history, including family history and clues regarding genetic and social inheritance, the environmental/emotional conditions affecting the patient’s health, and those factors that continue to mediate the dysfunction and/or disease. The patient’s narrative always includes clues that will eventually inform the physician about the underlying mechanisms of dysfunction, without “segregation of biological and psychosocial dimensions.”26 This model derives from the integration of research in molecular biology and behavioral psychology about the influences that lead to the clinical manifestation of disease. One approach of this kind has been labeled the “biopsychosocial model,”

How do we think differently? The emerging school of thought [functional medicine] does not deny the usefulness to the patient and physician of diagnostic groups that allow us the comfort of knowing “what you’ve got.” We are careful to keep in mind that a diagnosis is an idea we form about groups of people and properly belongs to the group, not an individual. Making a diag-

10

Chapter 2 What is Functional Medicine? ronment. He discovered alkaptonuria, which led to the understanding of phenylketonuria and the role of the phenylalanine-restricted diet in its management. In 1902, Dr. Garrod wrote, “It might be claimed that what used to be spoken of as a diathesis of a disease is nothing else but chemical individuality. It is nearly true to say that the factors which confer upon us our predisposition and immunities from disease are inherent in our very chemical structure, and even in the molecular groupings which went to the making of the chromosomes from which we sprang.”29

and it helps clinicians understand “how suffering, disease, and illness are affected by multiple levels of organization, from the societal to the molecular.”27 Starting in the early 1980s, Jeffrey Bland, PhD, first developed the fully elaborated model of functional medicine that now includes both the six principles and the fundamental clinical imbalances that underlie the dysfunctional devolution of health into disease. Writing in the preface of his 2004 seminar series syllabus,28 Dr. Bland states: It amazes me that this accumulated body of information … now comprises more than 2000 pages and 5000 referenced articles demonstrating the importance of diet, nutritional intervention, lifestyle and environment on both the prevention and management of virtually every chronic disease … . We are involved in what Thomas Kuhn termed a “paradigm shift” in our understanding of the origin and treatment of agerelated chronic diseases. The discovery of the code of the human genome and the recognition that our function is determined by much more than just our genome is a revolution in thinking. Our health and disease patterns after infancy are not “hardwired” deterministically by our genes, but rather a consequence of the interaction of genetic uniqueness with environmental factors. Our experiences wash over our genes to give rise over time to how we look, act, feel and our disease pattern. This is truly a change in thinking about the origin of disease that requires a similarly bold change in how we treat disease.

Linus Pauling, PhD

(c

)2

Dr. Pauling made extraordinary contributions to the way we view the origin of disease. His article in Science magazine in 1949 on the origin of sickle cell anemia taught us that single gene mutations could contribute to disorders that cut across organ systems and produce multiple symptoms. In this article he introduced the term “molecular medicine.”30 Dr. Pauling explained that in sickle cell anemia, a single point gene mutation on the heavy chain of the globin molecule of hemoglobin could contribute to a conformational change in the way the hemoglobin molecule was structured in three dimensions. That conformational change affected the way oxygen bound to the heme portion of the hemoglobin molecule and changed the relationship between the molecule and its oxygen absorption/desorption. The change in shape of that molecule changed the shape of the red cell, because hemoglobin made up about threequarters of the volume of a red cell. The red cell then became sickle-shaped, and this sickle would “cut” its way through the vasculature, creating the pain and disability of sickle cell crisis.31 Dr. Pauling predicted in 1949 that the molecular origin of disease would have extraordinary implications. As we learned more about the origin of these diseases, he believed, we would find ways to modify the expression and function of these genes to prevent the expression of disease. In 1997, 48 years after Dr. Pauling proposed this model of the potential power of molecular medicine, a paper in The New England Journal of Medicine validated his thesis. That article explained that administering hydroxy urea intravenously to patients who carried the genetic trait of sickle cell anemia could prevent the hemoglobinopathies associated with this genetic disorder.32 Hydroxy urea upregulated the

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

in

ic

ed

This model emerges from the groundwork of six great innovators who carved out from the domain of molecular medicine the foundational concepts underpinning functional medicine. The six pioneers of this new medical paradigm are Archibald Garrod (1902), Linus Pauling (1949), Roger Williams (1956), Abram Hoffer (1957), Hans Selye (1979), and Bruce Ames (2002). Let us pause and reflect on the contributions of these six pioneers who have improved our understanding of the human organism and the factors that contribute either to ongoing health or to the progression toward chronic, degenerative diseases.

Archibald Garrod, MD Dr. Garrod was first to discover the diseases of genetic metabolism in the early 20th century. (He investigated the genetic metabolism diseases of infancy.) Although those diseases originated in the genes, he said, the ultimate expression of the diseases depended on the exposure of those genes to factors in the envi-

11

Section I Introduction of schizophrenics unique chemicals that represented the oxidative byproducts of adrenaline.35 He found that these substances produced central nervous system toxicity. As a result of these discoveries, Dr. Hoffer proposed that certain forms of mental illness resulted not from bad early childhood experiences, but as a consequence of altered brain chemistry.36 He found that increased doses of the common B vitamins, niacin and pyridoxine, could treat these conditions in some schizophrenic patients.37 Dr. Hoffer, with the synthesis of a new idea that incorporated biochemical genetic individuality, nutritional modulation of gene expression, and functional physiology, provided the bridge that allowed psychiatry to enter the field of biologically based, functional therapy.

expression of fetal hemoglobin in these patients and “diluted” the amount of sickle cell hemoglobin, resulting in a reduction of sickle cell crisis.

Roger Williams, PhD

)2

(c

Dr. Roger Williams, a professor of biochemistry at University of Texas at Austin and past President of the American Chemical Society, discovered members of the B-complex vitamin family, including pantothenic acid. Dr. Williams’ book, Biochemical Individuality, published in 1956, proposed a role of various nutrients in preventing what he called “genetotrophic diseases.”33 Genetotrophic diseases are those for which genetic uniqueness creates demands for specific nutrients beyond the average to facilitate optimal function and prevent premature disease. Dr. Williams theorized that when those specific needs are not met in a given individual, disease results. Dr. Williams believed the major chronic degenerative diseases of aging—heart disease, stroke, cancer, diabetes, and arthritis—were related to genetotrophic imperfections. In his model, the unique genes of each individual require different levels of nutrition and a specific lifestyle for optimal health. The consequences of not meeting the specific needs of the individual are expressed, over several decades, as degenerative disease “of unknown origin.” In the category of what he called genetotrophic diseases, Dr. Williams even included diseases of mental illness, childhood diseases, behavior disorders, and alcoholism. He believed they all were related to the mismatch of genes and environment. At a genetic level, the individual needed a different level of nutrients to promote proper phenotypic expression. If that need was not met, the resulting undernutrition would manifest as chronic disease in midlife. This very powerful concept revolutionized our thinking about the origin of agerelated diseases.34 In defending his concept of biochemical individuality, Dr. Roger Williams said, “Nutrition is for real people. Statistical humans are of little interest. People are unique. We must treat real people with respect to their biochemical uniqueness.”

01

Hans Selye, MD, PhD

0

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

As the father of the physiological definition of the word “stress,” Dr. Selye introduced to both medical professionals and healthcare consumers the role of the mind in the function of the body.38 Dr. Selye’s tremendous insight gave birth to the rapidly evolving field of psychoneuroimmunology, which is redefining the way health practitioners view the impact of lifestyle and behavior on health. The combination of the physiology of stress and the understanding of the influence of perceived stress on genetic expression served as a powerful driver for the evolution of functional medicine. Although Dr. Selye was never awarded a Nobel Prize for his contributions, many historians of 20th century medicine believe his insights on the role of behavior and environment in health represent one of the most important factors shaping the new medicine.

Bruce Ames, PhD Dr. Bruce Ames, Professor of Biochemistry and Molecular Biology, and Director of the National Institute of Environmental Health Science Center, University of California, Berkeley, published his landmark paper in 2001.39 His team’s research provides the bench science to substantiate Williams’ postulates on genetotrophic diseases. Ames shows in his encyclopedic review paper that “as many as one-third of mutations in a gene result in the corresponding enzyme having an increased Michaelis constant, or Km (decreased binding affinity), for a coenzyme, resulting in a lower rate of reaction.” Some

Abram Hoffer, MD, PhD As a psychiatrist who also held a doctorate in organic chemistry, Dr. Hoffer in the 1950s provided a unique perspective on mental illness. He discovered in the urine

12

Chapter 2 What is Functional Medicine? people carry polymorphismsi that are more critical in determining the outcome of their health history. He goes on to argue that studies have shown that administration of higher than dietary reference intake (DRI) levels of cofactors (specific vitamins and minerals) to these polymorphic genes restores activity to near-normal and even normal levels. He concludes, “Nutritional interventions to improve health are likely to be a major benefit of the genomics era.” The functional medicine model rests on the stout shoulders of these worthy researchers and clinicians. They pioneered the concepts that postulated that many agents modify gene expression in such a way as to create different phenotypes. They provided the breakthrough science that demonstrates that significant influences in this process include diet, exercise, stress, environmental, and lifestyle factors. Molecules of functional importance transmit messages and receptors receive them. The transmitters are the molecules we call the mediators. The receivers are the membrane receptor binding and soluble receptor sites that translate the messages into altered gene expression and altered function. It is possible to manipulate both the messages and their reception on the basis of things we do every day, by the way we think, act, eat, and feel, by where we live, and by the nature of our relationships and our spiritual belief systems. All these factors influence the mediating molecules and can lead to an expanding health paradigm. An informational rubric encompasses communicating and receiving the right messages to be in synchrony with our genes to give rise to healthy function. These six individuals pioneered the new medicine for the 21st century by establishing the scientific basis for recognizing that our genes generally do not determine our disease. The awareness that our environments are powerful agents influencing the genetic expression of both health and disease represents a major shift in medical thinking.40 The utility of this model within the medi-

cal paradigm is no longer in question. It is just a question of how long it will take for this model to be fully integrated within the standard practice of medicine.

References 1.

2. 3. 4. 5.

(c

6.

)2

7.

0

01

8.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Stone J, Wojcik W, Durrance D, et al. What should we say to patients with symptoms unexplained by disease? The “number needed to offend.” BMJ. 2003;3:89-90. Magid CS. Developing tolerance for ambiguity. JAMA. 2001;285(1):88. Ely JW, Osheroff JA, Gorman PN, et al. A taxonomy of generic clinical questions: classification study. BMJ. 2000; 321:429-32. Rees J. Complex disease and the new clinical sciences. Science. 2002; 296:698-701. Radford T. Top scientist warns of “sickness” in US health system. BMJ. 2003;326:416. Vioxx: lessons for Health Canada and the FDA. CMAJ. 2005;172(11):5. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. The Lancet. 2004;364:2021-29. DeAngelis C. Conflict of interest and the public trust. JAMA. 2000;284(17):2237-38. Prosser H, Almond S, Walley T. Influences on GPs’ decision to prescribe new drugs—the importance of who says what. Fam Pract. 2003:20(1):61-68. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: A reflection of treatment effects or adverse events? JAMA. 2003;290(7):921-28. Goodman B. Do drug company promotions influence physician behavior? West J Med. 2001;174:232-33. DeAngelis CD, Fontanarosa PB, Flanagin A. Reporting financial conflicts of interest and relationships between investigators and research sponsors. JAMA. 2001;286(1):89-91. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003;326:1171-75. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326:1167-76. Relman AS. Separating continuing medical education from pharmaceutical marketing. JAMA. 2001;285(15):2009-12. Relman AS. Your doctor’s drug problem. New York Times, November 18, 2003. Opinion. Accessed at [http://www.nytimes.com/2003/ 11/18/opinion/18RELM.html?pagewanted=print&position=], 11/ 19/03. Drug-company influence on medical education in USA. (editorial) The Lancet. 2000;356:781. Connor S. Glaxo chief: Our drugs do not work on most patients. Common Dreams News Center, December 8, 2003. Accessed at [www.commondreams.org/cgi-bip/print_cgi?file=headlines02/ 1208-02.htm], 12/17/03. DeAngelis CD, Fontanarosa PB, Flanagin A. Reporting financial conflicts of interest and relationships between investigators and research sponsors. JAMA. 2001;286(1):89-91. Relman AS. Separating continuing medical education from pharmaceutical marketing. JAMA. 2001;285(15):2009-12. Radford T. Top scientist warns of “sickness” in US health system. BMJ. 2003;326:416. Baker, SM. The medicine we are evolving. Integr Med. 2003;(1)1:14-15.

9.

10.

11. 12.

13.

14.

18.

19. i

A polymorphic gene is an alternate form of a wild gene present in >1% of the population. The most common polymorphic genes are single nucleotide polymorphisms (SNPs) that result in translational proteins and enzymes with decreased functionality. We all share at least 99.9% of the nucleotide code of our species’ genome. The SNPs are what make us unique within our species. The translation of our genome message that includes our SNPs results in our individual phenotype. [Burghes, et al. Science. 2001;293: 2213–14.]

20. 21. 22.

13

e

17.

in

16.

ic

ed

15.

Section I Introduction

)2

(c

23. Ibid. 24. Galland L. Patient-centered diagnosis: A guide to the rational treatment of patients as individuals. 1991. Unpublished. 25. The Four Pillars of Healing: How the New Integrated Medicine— The Best of Conventional and Alternative Approaches—Can Cure You. New York: Random House, 1997. 26. Galland L. Patient-centered diagnosis: A guide to the rational treatment of patients as individuals. 1991. Unpublished. 27. Borrell-Carrio F, Suchman AL, Epstein RM. The biopsychosocial model 25 years later: principles, practice, and scientific inquiry. Ann Fam Med. 2004;2:576-82. 28. Bland J. Nutrigenomic modulation of inflammatory disorders: Arthralgia, coronary heart disease, PMS, and menopause-associated inflammation: 2004 Seminar Series. Gig Harbor, WA: IFM, 2004. www.functionalmedicine.org 29. Garrod, A. The incidence of alkaptonuria: a study in chemical individuality. Lancet. 1902;2:1616-20. 30. Pauling L, Itano H, Singer SJ, Wells I. Sickle cell anemia, a molecular disease. Science. 1949;110: 543-48. 31. Itano H, Pauling L. A rapid diagnostic test for sickle cell anemia. Blood. 1949;4:66-68. 32. Lubin B. Sickle cell disease and the endothelium. N Engl J Med. Nov. 1997;337(22):1623-25. 33. Williams R. Biochemical Individuality. New York: John Wiley and Sons, 1956. 34. Williams R, Deason G. Individuality in vitamin C needs. Proc Nat Acad Sci USA. 1967;67:1638-41. 35. Hoffer A. Epinephrine derivatives as potential schizophrenic factors. J Clin Exp Psychopathol Q Rev Psychiatry Neurol. 1957;18(1):27-60. 36. Hoffer A. Chronic schizophrenic patients treated ten years or more. Journal of Orthomolecular Medicine. 1994;9(1):7-34. 37. Hoffer A. Effect of niacin and nicotinamide on leukocytes and some urinary constituents. CMAJ. 1956;74:448-51. 38. Selye H. Stress and the reduction of distress. J S Carolina Med Assoc. 1979:562-66. 39. Ames BN, Elson-Schwab I, Silver EA. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased Km): relevance to genetic disease and polymorphisms. Am J Clin Nutr. 2002;75:616-58. 40. Bland J. Genetic Nutritioneering. Lincolnwood, IL: Keats, a division of NTC/Contemporary Publishing Group, Inc., 1999.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 14

Chapter 3 Why Functional Medicine?  

)2

(c



Importance of Improving Management of Complex, Chronic Disease Our Aging Population and the Centrality of Diet, Lifestyle, and Environment Functional Medicine Incorporates Genomics

01

Importance of Improving Management of Complex, Chronic Disease

0

David S. Jones, MD, and Sheila Quinn

lM na tio d. un rve r F se fo re te ts itu h st rig In All

The Larger Context

practice is often astonishingly large—particularly in the area of complex, chronic illness.3 This is one of the reasons that today’s healthcare providers are not adequately trained to manage the increasing burden of complex, chronic disease. The 20th century took on—and, to a great extent mastered—the challenges of providing health care for acute conditions (injury and life-threatening illness). Knowledge and technology grew apace, and so did costs; measures no one thought possible 100 years ago have become readily available. Organ transplants, re-attachment of severed limbs, life-support systems, new drugs, infection control procedures, laparoscopic explorations and surgeries—the list is extensive. But at the same time that our healthcare system was becoming dependent on advances in acute care, other influences were superseding acute conditions as the greatest threats to American health: increasingly stressful and sedentary lifestyles,4,5,6 industrial pollution7 of air, water, and earth8 leading to devitalized (and sometimes dangerous9,10,11) food, overconsumption (rising rates of obesity) but undernutrition,12 and fragmented family and community ties (social isolation13,14,15). These influences have helped to create an overwhelming burden of chronic disease that we do not yet train our healthcare providers to treat or prevent effectively.16 Among other contributing factors: • Disease prevention has too often been conceptualized as immunization and early diagnosis, an approach that is far too limited. Effective prevention

e

in

ic

ed

Despite the fact that non-genetic factors that are modifiable—including diet, overweight, inactivity, and environmental exposures such as smoking—account for 70–90% of mortality in the U.S.,1 physician education, training, and reimbursement are most often focused on treating disease using drugs and surgery rather than comprehensive patient-centered treatments focused on the individual. For example, as reported in a study published in the British Medical Journal,2 clinical questions in primary care can be categorized into a limited number of generic types and frequency. The four most common question types were: 1. What is the drug of choice for condition x? 2. What is the cause of symptom x? 3. What test is indicated in situation x? 4. What is the dose of drug x? This shortsighted approach to health care should give us all cause for serious concern, because it is perpetuating a system that is far too costly and increasingly ineffective for the prevention and management of chronic diseases whose root causes are to be found in a much more complex perspective on patients’ lives.

A Critical Problem The gap between emerging research in basic sciences and integration of new knowledge into clinical

15

Section I Introduction of chronic disease today requires understanding individual genetic vulnerabilities (20–30% of chronic disease risk) and the effect of lifestyle upon those individual variations (70–80% of the risk). • Physicians highly trained primarily in conventional diagnosis and treatment (drugs, surgery, radiation) are not well qualified to apply prevention-focused interventions such as nutrition, diet, and exercise to help patients minimize their risk of suffering from one or more of the major chronic diseases in America (heart disease, diabetes, autoimmune disease, mental illness, and cancer).17 • In addition to prevention strategies, many complex, chronic diseases are very responsive to dietary and various lifestyle interventions.18 But clinicians without these skills are literally at the mercy of the pharmaceutical industry. “Doctors are taught about drugs by agents of the pharmaceutical industry, which works hard to persuade them to select the newest and most expensive medications—even in the absence of scientific evidence that they are any better than older, less costly ones.”19 Or, we would add, even in the presence of evidence that many non-drug interventions are therapeutically effective and significantly less expensive.20,21

the cost increases in Year 2000, while representing only 9% of total spending;25 and • are expected to rise to $3.1 trillion over the next 10 years (from a level of $1.4 trillion in 2001).26

)2

(c

What does the American public get for this exorbitant price tag? • A nation with 43.6 million uninsured in 200227 (while every other Westernized nation provides basic coverage to all its citizens). • An excessively high serious medical error rate (highest among the U.S., Canada, the UK, Australia, and New Zealand), including (in 1994) 160,000 deaths from adverse drug reactions (ADRs).28 • An unacceptable portion (45%) of Americans failing to receive “indicated care”29 including, notably, preventive care. • A healthcare system that is thought by many to be “in imminent danger of collapse.”30

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Increasing Economic Burden

Add to this volatile mix the projection that onethird of the people born in the year 2000 will eventually have diabetes31—perhaps the most costly of the chronic diseases when all its comorbidities and secondary complications are considered32—and we believe that no further evidence is necessary to justify a sea change in our approach to health care. There will be many ideas about the best changes to consider, but this textbook is being written, in part, to ensure that all those who are interested in the assessment, prevention, and treatment of chronic disease know what functional medicine has to offer. There are, of course, other powerful societal drivers for the problems described above. Among them are the demand for fast and easy, high-fat, high-sugar foods; the demand for expensive testing (such as CAT scans or MRIs) and expensive drugs; and the increasingly sedentary nature of most jobs (tied to a desk) and personal lifestyles (centered around television and other passive entertainment experiences). It is important that all sectors share the responsibility for empowering healthful choices—the individual and his/her family, the workplace, the residential and civic communities, the marketplace, and the healthcare system. This book addresses needs that exist within the healthcare system, but does not in any way discount the vital influence of other elements of society. We do, however, call upon clinicians to let their voices and their work be stronger and more insistent in the call for prevention and health, rather

e

in

ic

ed

The American healthcare system is predicated on a huge myth—that the more a society spends on health care, the better the health of its population will be. We justify having—by far—the costliest healthcare system in the world by deluding ourselves that we therefore also have the best health in the world. However, our romance with ever newer and more expensive drugs, technology, and surgeries has not achieved what we have been led to expect. Consider just a few of the many significant statistics available on this subject: National health expenditures: • increased 69% between 1990 and 2000, to a per capita cost of $4,637, which is 68.5% higher than our closest competitor (Germany) and more than 2½ times as much as the UK;22,23 • increased at a rate 4–5 times that of inflation in most years of that decade (a time of relatively low inflation in other industries);24 • were disproportionately affected by the cost of prescription drugs, which were responsible for 21% of

16

Chapter 3 Why Functional Medicine? digm shift in the intellectual matrix needed for integrated care for the chronically ill:

than concentrating their formidable knowledge, intelligence, and skills on after-the-fact interventions.

These studies demonstrate the futility of reductionistically carving up patients on the basis of individual conditions and sending them to the diabetes program on Monday, the cardiac program on Tuesday, the arthritis program on Wednesday, and the depression program on Thursday. What is needed is a model of care that addresses the whole person and integrates care for the person’s entire constellation of comorbidities. This generalist approach does not deny the value of specialty care, which can offer expertise and unique services to the care of patients with chronic illness. But the generalist approach affirms a central role for the primary care clinician as the coordinator and integrator of specialty care and other referral services, working in partnership with the patient and other health care personnel to optimize overall physical functioning, mental health, and well-being.36

Functional Medicine and the Chronic Care Model

)2

(c

In the inaugural issue of the Annals of Family Medicine,33 the lead editorial focused on the need for a new paradigm for the primary care disciplines. The present intellectual frameworki taught in our medical education system fails to address the web-like interactions of multiple comorbidities for chronically ill patients. The power of organ-system medicine and the scientific research based on this model have brought us to the doorstep of the 21st century where, despite huge advances in disease detection, pharmacology, and surgical interventions, we are ill-equipped for the century’s greatest challenge—an aging population with ever-increasing rates of (largely preventable, often reversible) chronic disease. The dominance of the existing heuristic (rule of thumb and experience) and reductionist model has fragmented medical care into specialty and sub-specialty care, which drives costs upward34 and conflicts with the need for a comprehensive, integrated approach to chronically ill patients with multiple comorbidities. In Grumbach’s insightful editorial, Chronic Illness, Comorbidities, and the Need for Medical Generalism,35 he opens: “It is said that when students enter medical school, they care about the whole person, and by the time they graduate, all they care about is the hole in the person. Current medical education inculcates many of the dominant values of modern medicine, reductionism, specialization, mechanistic models of disease and faith in a definitive cure.” He suggests that the dominant paradigm now being taught is most applicable in the context of acute illness (e.g., trauma and infection). However, the dominant illnesses of the 21st century are and will be the chronic diseases (e.g., diabetes, heart disease, arthritis, and dementia, among others). In this context, the reductionist model fails to address (what he believes is) the most germane issue: “Cure is rarely possible, but improved functional status with amelioration of symptoms of pain and dysfunction and longer life (health span) through a thorough understanding of secondary prevention is possible.” He goes on to describe the para-

01

0

IFM has been an innovator in this field for more than two decades. Functional medicine is not a unique and separate body of knowledge, but it does represent a different way of applying the scientific and clinical information that emerges from the research literature and from the clinical practices of many disciplines. Functional medicine emphasizes a definable and teachable process of integrating multiple knowledge bases within a pragmatic intellectual matrix that focuses on functionality at several levels as the key to health. Functional medicine uses the patient’s story as an essential tool for integrating diagnosis, signs and symptoms, and evidence of clinical imbalances into a comprehensive approach to improve both the patient’s environmental inputs and his or her physiological function. It is a clinician’s discipline, and it directly addresses the need to transform the practice of primary care. Functional medicine can substantially improve the existing Chronic Care Model,37 which comprises six basic elements to foster productive interactions between patients and providers: 1. Patient self-management support; 2. Delivery system design (team-based delivery of care); 3. Decision support (consistent with scientific evidence and patient preferences); 4. Clinical information system (organizes individual patients and patient populations to receive appropriate levels of care); 5. Organizational support; and 6. Community support.

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

i

The intellectual framework and filter taught and then used by primary care practitioners will, from here on, be called the intellectual matrix.

17

Section I Introduction Functional medicine directly addresses the restoration of health, looking for common factors among various symptoms, diagnoses, and comorbidities that can be affected by intervening to improve function at the cellular level and the organ level. The functional medicine matrix takes into direct consideration the patient’s lifestyle and diet, genetic predispositions, and core clinical imbalances, seeking a multifactorial and individualized approach that will reach beneath symptoms to restore function and generate momentum toward health. Too often the patient care process is seen as complete when a diagnosis is achieved and a drug is prescribed. In functional medicine, the diagnosis is the beginning of the journey, and the patient’s past and continuing story is the central driver.

)2

(c

The strength of the Chronic Care Model is the acknowledgment that optimal care relies on healthcare team building involving the top levels of the organization as well as the caregivers, and integrating support for patient self-management. However, what is missing and central to success in this effort is an intellectual matrix that can filter research and clinical evidence to achieve a coherent focus applicable to the unique set of signs and symptoms presented by the individual patient. No such matrix now exists outside of the functional medicine model. The Chronic Care Model is still grounded in the heuristic, organ-system based, reductionist thinking that is inadequate to the task.38 As presently configured, that model will run into the same wall: chronic illness and multiple comorbidities are difficult to handle because the fundamental, underlying clinical imbalances have not been clearly delineated as the starting point for understanding chronic, complex illness. Even the coordination of resources as described in the Chronic Care Model will inevitably fall significantly short of the goal if the focus of this integrated collaboration is not properly identified. Functional medicine helps to identify the proper focus from a multidisciplinary, patient-centered model that all caregivers can learn and apply. The Chronic Care Model appears to assume that the best we can do for a patient with chronic disease and comorbidities is to minimize the progression of the disease through the consistent and complete application of existing standards of care. There’s no implicit or explicit anticipation of actually restoring health, and no recognition that unless we can restore health (to varying degrees in different patients), the huge impact of chronic disease on the healthcare system and the economy will be virtually unchecked. One might summarize the problem in this manner: • if assessment and treatment are not fully integrated with prevention, • if therapeutic interventions are not expanded to include a primary emphasis on diet, exercise, and lifestyle, • and if health and disease are not perceived as existing on a continuum, along which the patient’s placement can move towards health (even in the presence of significant chronic disease and comorbidities), • then the emphasis is always going to be on palliative care, and the costs are always going to be excessive.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Our Aging Population and the Centrality of Diet, Lifestyle, and Environment David S. Jones, MD, and Sheila Quinn

Healthy Aging Matters

e

in

ic

ed

Researchers have estimated “the cost to our society resulting solely from the triad of coronary heart disease, diabetes, and obesity alone is nearly half a trillion dollars!”39 Since most of the chronic disease burden occurs in the last decades of life, the importance of healthy aging can, therefore, hardly be overstated. However, it isn’t an aging population, per se, that increases the economic burden on the healthcare system. It’s an older population that has either more disease, or more years of life with disease, or both. Booth et al.40 point out that “the advances made against modern chronic diseases over the past 30 years have come to a halt.” Today in North America and most of the Westernized world, people are living longer, and, for many, those additional years are filled with the cost and effort of managing multiple chronic diseases. We have no idea whether or not there is an upper limit to life expectancy—all past predictions about such limits have been exceeded, in a steady, linear climb of about 2.5 years per decade for the past 150 years.41 So, we may as well assume that the upper boundary will continue to advance, which means we will be providing expensive, intensive healthcare services to a growing number of older citizens who will be living with more heart disease, more diabetes, and

18

Chapter 3 Why Functional Medicine? as a strong economy, an educated and well-compensated workforce, and supportive communities, but discussion of those issues is beyond the scope of this book.) Research is emerging in a continuous and expanding stream to demonstrate the therapeutic effectiveness of lifestyle interventions for the treatment of many chronic diseases. Using type 2 diabetes as an example can help us understand more clearly what’s at stake. Consider the following facts: • The incidence of diabetes is rising rapidly—it’s a red flag bearing the message that something important has gone awry.58 • “100% of the increase in prevalence of type 2 diabetes and obesity in the U.S. during the latter half of the 20th century must be attributed to a changing environment interacting with genes, since 0% of the human genome has changed during this time period.”59 • Diabetes is being diagnosed in ever younger patients—so we will be paying for their care for many, many more years if we don’t act now.60,61 • It is a very costly disease. In 2002, the total cost of diabetes was $132 billion/year—$92 billion in direct medical costs and $40 billion in disability, work loss, and premature mortality.62 This is a 35% increase over the 1997 total.63 In just five years, we added $34 billion/year to the healthcare budget from diabetes alone. (If this doesn’t scare us, what will?) • Diabetes has many genetic links and new information is emerging all the time about how those can be identified.64,65,66 Clinicians will increasingly be paying attention to genes at risk through ethnicity and family history, thus bringing genomics (environment acting on genes) into play.67 • Diabetes increases the risk of many other chronic diseases, including various neurological conditions,68,69 heart disease,70,71 kidney disease,72,73 stroke,74 and cancer.75,76 Today’s growth in the incidence of diabetes will lead directly to increases in many other diseases as the diabetic population ages. • For most type 2 diabetics, the disease can be prevented, delayed, or reversed.77,78

)2

(c

more arthritis, cancer, and other complex chronic diseases for 30–40 years, rather than 10–20. At least, that’s what current projections indicate. There are many who believe, however, that a different goal is within our reach: “In the ideal case, the healthy citizens of a modern society will survive to an advanced age with their vigor and functional independence maintained, and morbidity and disability will be compressed into a relatively short period before death occurs … .”42 There is research to support this hypothesis: “Not only do persons with better health habits survive longer, but in such persons, disability is postponed and compressed into fewer years at the end of life.”43 And, even more to the point, successful aging is often the result of factors under at least some personal control: “our weight, our exercise, our education … our abuse of cigarettes and alcohol … our relationship with our spouse, and our coping styles can [all] be modified. A successful old age … may lie not so much in our stars and genes as in ourselves.”44 To be sure, there is much about the process of aging that we cannot yet understand or control. Aging is certainly associated with increasing incidence of disease and disability on a population-wide basis. However, research is making it increasingly clear that there are many behaviors (diet, exercise, stress reduction)45,46,47,48 and treatments (antioxidants, essential fatty acids, minerals, certain amino acids, the B vitamins, and much more)49,50,51 that can counteract the functional decline that leaves us vulnerable to disease and disability as we age.52 Functional medicine helps to bring this knowledge into clinical practice, both for prevention and for treatment.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Centrality of Diet and Exercise in Prevention and Treatment A healthcare system that is primarily dependent on the prescription pad for therapeutic success will inevitably be far more costly in the long run53 than one that brings lifestyle and environment to the fore. Diet, exercise, stress reduction, and active lifestyles are the most effective—and least costly—tools for lifelong disease prevention; there are numerous studies that validate this assertion, providing data on everything from pancreatic cancer54 to sarcopenia55 to very costly diseases such as heart disease and diabetes.56,57 (We do not mean to discount the huge impact of broad societal influences such

It’s hard to read this condensed set of facts about diabetes and not wonder, “What’s gone wrong?” This is a (mostly) preventable disease, about which a great deal is known; it causes great human suffering if not prevented;

19

Section I Introduction alded a new age in medicine. The seeds that were planted then are only now coming into bloom. Rabinowitz and Poljak commented in 2003 that we are seeing the emergence of a new primary-care model built on the molecular medicine discoveries of the last 50 years.80 This primary-care model integrates the concept of host/environment interaction in framing a better understanding of the origin of disease and its potential treatment, individualized to the patient. Until very recently, we have tended to believe that diseases are “hard-wired” into our genes as a consequence of genetic uniqueness. This belief has caused us to forget or overlook the important variable of environment and its role in modulating the expression of genes. As these authors point out:

)2

(c

it costs us tens of billions of dollars each year; and it’s now hitting our children. What is standing in the way of turning this around? It’s certainly not a lack of information—even a quick search of the literature turns up hundreds of relevant research articles in every field from endocrinology to epidemiology to psychology. At the risk of offering an oversimplified explanation, one reason seems intuitively obvious: We do not have a healthcare system, or healthcare practitioners, with the skills, time, and will to do what needs to be done. We have a healthcare system that forces practitioners to focus on seeing the most patients in a day, for the smallest investment of professional time and effort, with quick access to drugs (and highly vulnerable to pharmaceutical industry pressure and patient demands). This scenario cannot help but obscure the real answers to the problem. Functional medicine offers a way to change this scenario. Practitioners can begin approaching patient care from a different perspective, with a broader set of tools, and with an empowered patient as ally and partner. Helping the doctor—and the patient—to fully understand the critical factors that affect functionality, aging, disease, and health over a lifetime will help create a more cost-effective healthcare system, and lead to longer health spans for our citizens.

0

01

These (molecular genetic) developments, however, raise the concern that both physicians and patients could fall into a trap of biological determinism, believing that one’s genetic and metabolic makeup far outweighs the role of environmental factors in disease. Such thinking fails to acknowledge that most health outcomes are the result of interactions between host factors and environmental factors.81

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Although the human genome contains only between 30,000 and 35,000 genes, millions of variations of these genes, called single nucleotide polymorphisms (SNPs), exist within the gene pool. These polymorphisms occur as variations in which the least common allele is present in at least 1% or more of the population. Researchers have found that when these SNPs are present in a gene it means a person has two different genes coding for the same function. Only recently have we understood that many of these SNPs lead to differences in the phenotype of an individual, and that how these differences may be expressed depends upon environmental factors. One major environmental factor that modifies gene expression is the individual’s nutritional status. Both macro- and micronutrients can influence the expression of genes, the translation of the genetic message into active protein, and that protein’s ultimate influence in controlling metabolic function.82,83,84,85,86 The effective integration of these concepts into the educational model so that patient assessment and treatment can be personalized to the patient’s own genetic uniqueness represents a great challenge for modern medicine. It has been postulated that medical nutrition education is very near a “tipping point” that will herald rapid changes in the existing system vis-à-vis these exciting concepts.87 Functional medicine has been addressing

Functional Medicine Incorporates Genomics Jeffrey S. Bland, PhD

in

ic

ed

Genomics—The Genetics-Environment Interface

e

April 25, 2003, represented the 50th anniversary of the publication describing the structure of DNA, in the journal Nature, by Watson and Crick.79 That classic paper contained the prophetic comment, “It has not escaped our attention that the specific pairing (of the DNA bases) we have postulated immediately suggests a possible coping mechanism for the genetic material.” This paper (and companion papers that appeared in the same issue of Nature by Wilkins, Strokes, and Wilson, and by Franklin and Gosling) created a paradigm shift in medicine that has taken 50 years to be integrated into its curriculum. The concept that disease mechanisms originate at the molecular biological level and are related to intricacies of interaction between the environment and genes and their expression her-

20

Chapter 3 Why Functional Medicine? these issues and training clinicians to understand and use the concepts for many years. (According to Gladwell, the tipping point is the moment when an idea, trend, or social behavior crosses a threshold, “tips,” and spreads like wildfire.88 Broad examples from medicine include the discovery of the polio vaccine, the identification of insulin as a treatment for type 1 diabetes, the 1964 Surgeon General’s Report on the health effects of cigarette smoking, and the McGovern Committee and the 1979 Surgeon General’s Report on Health Promotion and Disease Prevention. Another tipping point may be the changes stemming from the Human Genome Project that are leading to a new definition of medical nutrition education.) As evidence that we are near the tipping point in medical education, Tel Aviv University recently incorporated into its medical curriculum a course titled “Introduction to Pharmacogenomics: Towards Personalized Medicine.”89 As investigators learn how different individuals metabolize substances based on their genetic uniqueness, we learn more about the important roles specific nutrients play in modifying the expression of metabolic patterns in the individual. Diet, lifestyle, and environment have significant influence on the way an individual can metabolize specific substances based upon his or her genetic uniqueness. We are seeing the first applications of genomic medicine in the area of pharmacogenomics. Pharmacogenomics is defined as the unique metabolism of various substances based on an individual’s genetic uniqueness. A great deal of research is being done to study individual variations in reactions to drugs and that body of research will contribute enormously to our understanding of personalized medicine.

will increasingly require knowledge of genomics, geneenvironment interactions, the expanding role of pharmacogenomics in drug and food therapies, and genetic applications to clinical practice.90

)2

(c

The development of nutrigenomic concepts will assist clinicians in understanding the varied responses of different patients to specific nutritional therapies. An example is the wide inter-individual variation in blood lipid and lipoprotein responses to dietary change.91 A diet that is low in fat and high in unrefined complex carbohydrate may in one individual be effective in lowering total blood lipids. In another individual with a different genotype, however, the same diet may actually increase specific members of the lipid and lipoprotein families. Similarly, some individuals, when placed on a higher-protein, low-carbohydrate diet, may have reductions in their blood lipid profiles, while others may have elevations of blood lipids on the same diet. Fogg-Johnson and Kaput provide a good restatement for us to consider:

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Effects of the Human Genome Project are surfacing in anticipated and unanticipated areas. One of the key discoveries from the project is the existence of individual differences in gene sequences that result in differential response to environmental factors, such as diet. Those genetic differences, single nucleotide polymorphisms (SNPs, pronounced snips), are the key genetic enabler of the emerging scientific discipline called nutrigenomics or nutritional genomics. … The science of nutrigenomics is the study of how naturally occurring chemicals in foods alter molecular expression of genetic information in each individual.92

e

in

ic

ed

Since approximately 1990, nutrition research has undergone a gradual shift in focus from epidemiology and physiology to molecular biology and genetics. This shift has resulted in a growing realization that we cannot understand the effects of nutrition on health and disease without determining how nutrients act at the molecular level. Müller and Kersten note: “There has been a growing recognition that both macronutrients and micronutrients can be potent dietary signals that influence the metabolic programming of cells and have an important role in the control of homeostasis.”93 In every respect, the transition occurring within medical nutrition is epic in its impact and scope. Nutrition-focused practitioners are at a pivotal point in the history of their practice. Kauwell’s observations are particularly pertinent: “Armed with the findings of the Human Genome Project and related research, dietetics practitioners will have the potential to implement more

Nutrigenomics Linus Pauling was a pioneer in alerting physicians to the importance of nutrients in modulating physiological processes at the biomolecular level and ultimately giving rise to the phenotype of health or disease. The interface between genomics and nutrition is now defined as the field of “nutrigenomics.” As Kozma observed: Information from the Human Genome Project will dramatically change health care for the dietetic and nutrition discipline. Approaches to risk assessment including obtaining family history, diagnosis, prevention, early intervention, and management of nutritional issues will evolve through the application of nutritional genomics. Dietetic and nutrition specialists

21

Section I Introduction

Toward a Systems Biology Approach

efficient and effective nutrition intervention strategies aimed at preventing and delaying the progression of common chronic diseases.”94

As we write in 2005, the systems biology approachii for analyzing individual effects of nutrients on function is not yet available, but a number of clearly identified relationships that connect specific SNPs, nutrient sensitivity, and disease risk are now understood. Petricoin and Liotta predicted in 2003 that clinical applications of proteomics, which involve the use of molecular genetic technologies at the bedside, will result in patient-tailored therapies.96 Work at the Institute for Systems Biology in Seattle, Washington, has demonstrated the success of an integrated system for understanding cellular physiology based on the interaction of genomic expression, proteomics influences, and their role in controlling metabolism.97 Although this work is in its early stages, the “proof of concept” that a systems biology approach can be used for evaluating the impact of genetic expression, proteomic activity, and their roles in controlling metabolism, supports an optimistic perspective for the future of personalized and functional medicine.

Genomics and Proteomics: Importance for the Future of Nutrition Intervention

)2

(c

A central feature of this paradigm shift in medical nutrition is the recognition that not all genes within the human genome are expressed in every cell simultaneously. Instead, the expression is selective to the cell type and cell environment. The study of the synchronous activation of families of genes to yield various proteins that ultimately regulate metabolic function is called “proteomics.” A large body of information exists about the number of genes, chromosomal localization, gene structure, and gene function. Scientists are only now beginning to understand the orchestrated way the proteins expressed from these genes control metabolism.95 For example, researchers have found that in some cells only 50% (approximately) of the genes transcribed to form the specific messenger RNA (mRNA) are translated into active proteins. The action point in the control of cellular physiology is therefore the combination of genetic transcription (expression), active protein formation, and control of metabolism that has been termed the “phenome.” The phenotype of the cell is a complex process or system of interacting events related to genetic expression, protein synthesis, protein activation, and metabolic regulation. By evaluating genetic expression through the production of specific mRNAs, the synthesis of specific proteins from those mRNAs, and ultimately the effect of those proteins on metabolic function, we can establish biomarkers of health and disease. From this understanding, we can evaluate the role of specific nutrients on this process in the individual patient. Although this may at first seem to be a daunting task, new screening technologies and powerful systems of bioinformation analysis are emerging to hasten the day when such interventions are a real option in clinical care.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Upstream vs. Downstream Medicine

e

in

ic

ed

In the last few decades, much medical research has focused primarily on discovering specific molecules that inhibit enzyme function “downstream” in a complex physiological process. The search for molecules with the selective ability to inhibit specific enzyme-mediated steps, such as angiotensin-converting enzyme inhibitors (ACE inhibitors), selective serotonin reuptake inhibitors (SSRIs), H2 blockers, and selective cyclooxygenase-2 inhibitors (COX-2 inhibitors), has succeeded in fueling the growth of the multibillion-dollar pharmaceutical industry (not without serious consequences for some patients with some of these drugs). Genomic and proteomic research has begun to demonstrate, however, that rather than blocking specific enzymes downstream in a complex biological system associated with a specific disease, it can be even more effective to develop new approaches that would selectively regulate the expression of various alarm molecules upstream in the metabolic process that are associated with the disease. The emphasis of such research is to identify tissue-selective “upstream” modulators of ii

Systems biology seeks to explain complex biological systems, such as the cell, through the integration of many different types of information.

22

Chapter 3 Why Functional Medicine? genomic and proteomic expression. The objective is to identify ways to normalize the functional changes associated with early disease risk without adversely affecting other tissues engaged in similar metabolic processes.

6.

7. 8.

The Rise of Personalized Medicine 9.

This revolutionary shift in thinking suggests that substances consumed in the diets of various cultures for thousands of years may have profound influence on gene expression and proteomic outcome. It may also help explain the epidemiological observations that certain diets are associated with reduced disease risk. As Willett pointed out, the integration of extensive epidemiological research with the discoveries being made in nutrigenomics will give rise to a new personalized medicine using diet, lifestyle, and environment as principal tools in both prevention and treatment of specific chronic diseases.98 Burke wrote, “Evidence is now emerging of the complex interactions between genes and the environment in the causation of many diseases, and the study of the interactions represents the next important step in genomic research. Efforts to understand the molecular mechanisms that underlie complex diseases will build on insights and strategies developed in the study of single-gene diseases.”99 From these concepts, new clinical tools and programs are emerging to help apply medical nutrition in ways that will make it more effective in improving patient outcomes, and that approach is a key component of the functional medicine model, and thus an urgently needed element in modern clinical care.

10. 11. 12. 13.

)2

(c

14.

0

01

15.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Ishizaki M, Morikawa Y, Nakagawa H, et al. The influence of work characteristics on body mass index and waist to hip ratio in Japanese employees. Ind Health. 2004;41(1):41-49. Pohanka M, Fitzgerald D. Urban sprawl and you: how sprawl adversely affects worker health. AAOHN J. 2004;52(6):242-46. Valent F, Little D, Bertollini R, et al. Burden of disease attributable to selected environmental factors and injury among children and adolescents in Europe. Lancet. 2004;363(9426):2032-39. Weisburger JH. Hazards of fast food. Environ Health Perspect. 2004;112(6);336. Hightower J. Methyl mercury reference dose: response to Schoen. Environ Health Perspect. 2004;112(6);337-38. Silbergeld EK. Arsenic in food. Environ Health Perspect. 2004;112(6):338-39. Fletcher RF, Fairfield KM. Vitamins for chronic disease prevention in adults. JAMA. 2002;287(23):3127-29. Albus C, Jordan J, Herrmann-Lingen C. Screening for psychosocial risk factors in patients with coronary heart disease—recommendations for clinical practice. Eur J Cardiovasc Prev Rehabil. 2004;11(1):75-79. O’Keefe JH, Poston WS, Haddock CK, et al. Psychosocial stress and cardiovascular disease: how to heal a broken heart. Compr Ther. 2004;30(1):37-43. Linfante AH, Allan R, Smith SC, Mosca L. Psychosocial factors predict coronary heart disease, but what predicts psychosocial risk in women. J Am Med Womens Assoc. 2003;58(4):248-53. Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA. 2004;291(21):2616-22. “Recent evidence has shown that suboptimal levels of vitamins, even well above those causing deficiency syndromes, are risk factors for chronic diseases such as cardiovascular disease, cancer, and osteoporosis. A large proportion of the general population is apparently at increased risk for this reason … . Physicians often do not ask about vitamin use. Patients may not volunteer information about their vitamin use, fearing that the physician would disapprove of unconventional use of vitamins.” Fairfield KM, Fletcher RH. Vitamins for chronic disease prevention in adults. JAMA. 2002;287:3116-26. Herman WH, Hoerger TJ, Brandle M, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142:323-32. Relman AS. Your doctor’s drug problem. The New York Times, November 18, 2003. Brody S, Preut R, Schommer K, Schurmeyer TH. A randomized controlled trial of high dose ascorbic acid for reduction of blood pressure, cortisol, and subjective responses to psychological stress. Psychopharmacology (Berl). 2002;159(3):319-24. Renaud S, Lanzmann-Petithory D. Dietary fats and coronary heart disease pathogenesis. Curr Atheroscler Rep. 2002;4:419-24. California HealthCare Foundation and Wilson, KB. Health Care Costs 101. October 2002. Davis K, Cooper BS. American Health Care: Why So Costly? Invited Testimony before the Senate Appropriations Committee, Subcommittee on Labor, Health and Human Services, Education and Related Agencies; Hearing on Health Care Access and Affordability: Cost Containment Strategies. June 11, 2003. California HealthCare Foundation and Wilson, KB. Health Care Costs 101. October 2002. Ibid.

16.

17.

18.

3.

4.

5.

21. 22. 23.

24. 25.

23

e

2.

20.

“For most diseases contributing importantly to mortality in Western populations, epidemiologists have long known that nongenetic factors have high attributable risks, often at least 80 or 90%, even when the specific etiologic factors are not clear.” Willett WC. Balancing life-style and genomics research for disease prevention. Science. 2002; 296:695-97. Ely JW, Osheroff JA, Gorman PN, et al. A taxonomy of generic clinical questions: classification study. BMJ. 2000;321:429-32. “ … the gap between the clinician and the basic scientist has increased, not diminished, in the last quarter century.” Rees J. Complex disease and the new clinical sciences. Science. 2002:296:698-701. Manson JE, Skerrett PJ, Greenland P, VanItallie TB. The escalating pandemics of obesity and sedentary lifestyle. A call to action for clinicians. Arch Intern Med. 2004;164(3):249-58. Kaplan JR, Manuck SB. Ovarian dysfunction, stress, and disease: a primate continuum. ILAR J. 2004;45(2):89-115.

in

1.

ic

ed

19.

References

Section I Introduction 50. Oakley GP. Eat right and take a multivitamin (Edit). N Engl J Med. 1998;338(15):1060-61. 51. Ames BN. Micronutrients prevent cancer and delay aging. Toxicol Lett. 1998;102-103:5-18. 52. McMurdo MET. A healthy old age: realistic or futile goal? BMJ. 2000;321:1149-51. 53. Gross DJ, Scholdelmeyer SW, Raetzman SO. Trends in manufacturer prices of brand name prescription drugs used by older Americans—first quarter 2004 update. AARP Issue Brief, June 2004. 54. Gapstur SM, Gann P. Is pancreatic cancer a preventable disease? JAMA. 2001;286(8):967-68. 55. Roubenoff R, Castaneda C. Sarcopenia—understanding the dynamics of aging muscle. JAMA. 2001;286(10):1230-31. 56. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345(11):790-97. 57. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. 58. Narayan KMV, Boyle JP, Thompson TJ, et al. Lifestime risk for diabetes mellitus in the United States. JAMA. 2003; 290(4):1884-90. 59. Booth FW, Gordon SE, Carlson CJ, Hamilton MT. Waging war on modern chronic diseases: primary prevention through exercise biology. J Appl Physiol. 2000; 88:774-87. 60. Dabelea D, Hanson RL, Bennett PH, et al. Increasing prevalence of Type II diabetes in American Indian children. Diabetologia. 1998;41:904-10. 61. Fagot-Campagna A. Emergence of type 2 diabetes mellitus in children: epidemiological evidence. J Pediatr Endo Metab. 2000;13:1395-1402. 62. National Diabetes Information Clearinghouse (NDIC). [http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm] Accessed 12/30/2003. 63. National Diabetes Information Clearinghouse (NDIC). [http:// www.niddk.nih.gov/health/diabetes/pubs/dmstats/dmstats.htm] Accessed 7/8/2002. 64. Sale MM, Freedman BI, Langefeld CD, et al. A genome-wide scan for type 2 diabetes in African-American families reveals evidence for a locus on chromosome 6q. Diabetes. 2004;53(3):830-37. 65. Zouari Bouassida K, Chouchane L, Jellouli K, et al. Polymorphism of stress protein HSP70-2 gene in Tunisians: susceptibility implications in type 2 diabetes and obesity. Diabetes Metab. 2004;30(2):175-80. 66. Rich SS, Bowden DW, Haffner SM, et al. Identification of quantitative trait loci for glucose homeostasis: the insulin resistance atherosclerosis study (IRAS) family study. Diabetes. 2004;53(7):1866-75. 67. Kaufman FR. Type 2 diabetes mellitus in children and youth: a new epidemic. J Pediatr Endocrinol Metab. 2002;25(Suppl2):737-44. 68. Ott A, et al., Diabetes mellitus and the risk of dementia—The Rotterdam Study. Neurology. 1999;53:1937-42. 69. Klein JP, Waxman SG. The brain in diabetes: molecular changes in neurons and their implications for end-organ damage. Lancet. 2003;2:548-54. 70. Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290:891-97. 71. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898-904. 72. Rychlik I, Sulkova S. Diabetes mellitus and chronic renal insufficiency. Vnitr Lek. 2003;49(5):395-402. [Article in Czech] 73. Mohanram A, Toto RD. Outcome studies in diabetic nephropathy. Semin Nephrol. 2003;23(3):255-71.

)2

(c

26. Centers for Medicare and Medicaid Services (CMS). Report published in online Health Affairs Journal. [http://www.healthaffairs.org/ WebExclusives/Heffler_Web_Excl_020703.htm] Accessed February 10, 2003. 27. The Commonwealth Fund. Top 20 Health Policy Stories/Issues of 2003. [http://www.cmwf.org/programs/topten_2ndpg.asp] Accessed December 23, 2003. 28. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA. 1998;279(15):1200-05. 29. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348(26):2635-45. 30. Bloom, F. (President, American Association for the Advancement of Science) BBC News, February 14, 2003. [http://news.bbc.co.uk/1/ hi/in_depth/sci_tech/2003/Denver_2003/2760101.stm] Accessed 8/1/2003. 31. Centers for Disease Control, June 15, 2003. 32. Simpson SH, Corabian P, Jacobs P, Johnson, JA. The cost of major comorbidity in people with diabetes mellitus. CMAJ. 2003;168(13):1661-67. 33. Stange KC, et al. Ann Fam Med. 2003;1(1):2-4. The Annals is published through a collaborative effort by 6 family medicine organizations to address the need for the development of an integrated body of knowledge and a generalist paradigm. 34. Davis K, Cooper BS. American Health Care: Why So Costly? Invited Testimony before the Senate Appropriations Committee, Subcommittee on Labor, Health and Human Services, Education and Related Agencies; Hearing on Health Care Access and Affordability: Cost Containment Strategies. June 11, 2003. 35. Grumback K. Chronic illness, comorbidities, and the need for medical generalism. Ann Fam Med. 2003;1(1):4-7. 36. Ibid. 37. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA. 2002;288:1775-79. 38. Starfield B, Lemke KW, Bernhardt T, et al. Comorbidity: implications for the importance of primary care in 'case' management. Ann Fam Med. 2003;1(1):8-14. 39. Booth FW, Gordon SE, Carlson CJ, Hamilton MT. Waging war on modern chronic diseases: primary prevention through exercise biology. J Appl Physiol. 2000; 88:774-87. 40. Ibid. 41. Oeppen J, Vaupel JW. Broken limits to life expectancy. Science, 2002;296:1029-31. 42. Campion EW. Aging better. N Engl J Med. 1998; 338(15):1064-66. 43. Vita AJ, Terry RB, Hubert HB, Fries J. Aging, health risks, and cumulative disability. N Engl J Med. 1998;338:1035-41. 44. Vaillant GE, Mukamal K. Successful aging. Am J Psychiatry. 2001;158(6):839-47. 45. Campbell AJ, Robertson MC, Gardner MM, et al. Randomised controlled trial of a general practice programme of home based exercise to prevent falls in elderly women. BMJ. 1997;315:1065-69. 46. Stewart KJ. Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension. JAMA. 2002;288(13):1622-31. 47. Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA. 2002; 287(24):3223-29. 48. Armstrong AM, Chestnutt JE, Gormley MJ, Young IS. The effect of dietary treatment on lipid peroxidation and antioxidant status in newly diagnosed noninsulin dependent diabetes. Free Rad Biol Med. 1996;21(5):719-26. 49. Roberts K, Dunn K, Jean SK, Lardinois CK. Syndrome X: Medical nutrition therapy. Nutr Rev. 2000; 58(5):154-60.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 24

Chapter 3 Why Functional Medicine? 98. Willett WC. Balancing life-style and genomics research for disease prevention. Science. 2002;296(5568):695-98. 99. Burke W. Genomics as a probe for disease biology. N Engl J Med. 2003;349:969-74.

)2

(c

74. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Influence of impaired fasting glucose on the incidence and prognosis of atherosclerosis in various vascular regions. Z Kardiol. 2004;93(Suppl4):IV48-55. [Article in German] 75. Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology. 2002;63(4):317-32. 76. Hu FB, Manson JE, Liu S, et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst. 1999;91:542-47. 77. Centers for Disease Control: Diabetes Public Health Resource. CDC Statements on Diabetes Issues. [http://www.cdc.gov/diabetes/news/ docs/lifetime.htm] Accessed 12/31/2003. 78. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345(11):790-97. 79. Double helix 50th anniversary collection. Nature. 2003;422(6934):787-929. 80. Rabinowitz PM, Poljak A. Host-environment medicine. A primary care model for the age of genomics. J Gen Intern Med. 2003;18:222-27. 81. Ibid. 82. Darnton-Hill I, Margetts B, Deckelbaum R. Public health nutrition and genetics: implications for nutrition policy and promotion. Proc Nutr Soc. 2004;63(1):173-85. 83. Bauer M, Hamm A, Pankratz MJ. Linking nutrition to genomics. Biol Chem. 2004;385(7):593-96. 84. Desiere F. Towards a systems biology understanding of human health: interplay between genotype, environment and nutrition. Biotechnol Annu Rev. 2004;10:51-84. 85. Ruden DM, De Luca M, Garfinkel, MD, et al. Drosophila nutrigenomics can provide clues to human gene-nutrient interactions. Annu Rev Nutr. 2005;25:499-522. 86. Pool-Zobel BL, Selvaraju V, Sauer J, et al. Butyrate may enhance toxicological defence in primary, adenoma and tumor human colon cells by favourably modulating expression of glutathione S-transferases genes, an approach in nutrigenomics. Carcinogenesis. 2005:Mar 3;[Epub ahead of print]. 87. Kushner RF. Will there be a tipping point in medical nutrition education? Am J Clin Nutr. 2003;77:288-91. 88. Gladwell M. The Tipping Point: How Little Things Can Make a Big Difference. Boston; Little, Brown: 2000. 89. Gurwitz D, Weizman A, Rehavi M. Education: teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. Trends Pharmacol Sci. 2003;24(3):122-25. 90. Kozma C. The interface between genomics and nutrition. Top Clin Nutr. 2003;18(2):73-80. 91. Masson LF, McNeill G, Avenell A. Genetic variation and the lipid response to dietary intervention: a systematic review. Am J Clin Nutr. 2003;77:1098-111. 92. Fogg-Johnson N, Kaput J. Nutrigenomics: an emerging scientific discipline. Food Technol. 2003;57(4):60-67. 93. Muller M, Kersten S. Nutrigenomics: goals and strategies. Nat Rev Genet. 2003;4:315-22. 94. Kauwell GP. A genomic approach to dietetic practice. Are you ready? Top Clin Nutr. 2003;18(2)81-91. 95. Daniel H. Genomics and proteomics: importance for the future of nutrition research. British J Nutr. 2002;87(suppl 2):S305-S11. 96. Petricoin EF, Liotta LA. Clinical applications of proteomics. J Nutr. 2003;133:2476S-484S. 97. Ideker T, Thorsson V, Ranish JA, et al. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science. 2001;294:929-34.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 25

Section I Introduction

)2 (c

0 01

e in ic ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

26

Chapter 4 Training Clinicians in New Approaches to Care Sheila Quinn and David S. Jones, MD

Functional Medicine: A Model of Integrated Care to Address Systemic Health Issues

)2

(c

an understanding of functional medicine, for we are equally concerned with whether the raw materials of health (or disease), including genetic predispositions, are present in the patient’s life. • An emphasis is placed on learning to assess and improve underlying functional imbalances in six core areas that comprise the “engines” that drive the patient toward health or disease (Fundamental Clinical Imbalances Section). • The more didactic information presented in the first five sections is brought into context for the provider in A Practical Clinical Approach. Here the functional medicine matrix—a tool for simplifying the complex science into a manageable clinical approach—is the underlying structure. This section demonstrates how to obtain, sort, and qualify the different kinds of patient information so as to generate a strong indicator to the clinician of the most useful way to “pull on the web” of interconnecting issues presented by the patient. • Finally, the last section, Putting it All Together, helps clinicians understand some of the most important patient care issues that are commonly experienced in functional medicine.

01

Functional Medicine Can Be Taught

0

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Functional medicine synthesizes and applies scientific evidence from the biomedical research literature in fields such as biochemistry, physiology, immunology, and nutrition. Unlike alternative medical disciplines (such as acupuncture or chiropractic or naturopathic medicine), it does not require that conventional providers master different languages/tools of health care, nor does it require that alternative providers give up the tenets of their respective disciplines. It can be taught to, and used by, all healthcare providers with a background in the basic medical and clinical sciences, regardless of the particular profession a practitioner belongs to (within the limits of specific training and licensure, of course). This makes functional medicine uniquely suited to multidisciplinary, integrated clinical settings, as well as to use by individual practitioners. This textbook is organized around the information and approach that IFM uses to teach clinicians, and exemplifies the kind of clinical thinking and patient management that characterize many functional medicine practitioners: • A thorough understanding of the core context and concepts of functional medicine (Principles Section) helps to distinguish the functional medicine approach. • Teaching functional medicine often requires refreshing and expanding the clinician’s knowledge of biochemistry and physiology (Fundamental Physiological Processes Section). • A strong appreciation for the importance of environmental inputs (Building Blocks Section) is vital to

Thus, functional medicine can be taught to any clinician who has an open mind and an eagerness to twist the kaleidoscope and look at patient care from new angles. It is a matter of acquiring, analyzing, classifying, and prioritizing information in different ways, and then applying therapeutic (or preventive) measures that are aimed at correcting the imbalances that underlie organ-system disease. If the clinician doesn’t address the underlying imbalances—and understand how they arise and how they can be ameliorated—it is much less likely that restoration of health will be the ultimate

27

Section I Introduction Conventional providers and alternative providers alike are able to integrate functional medicine thinking into their existing knowledge base because underneath the superstructures created by the many professions, an abiding interest in “functionality”—how things work and what to do when they don’t—is a shared terrain. Some learners may not have a strong science background, and may thus need to intensify their knowledge of biochemistry and physiology, but some with a strong science education may have to learn clinical nutrition and to appreciate the contributions of (for example) botanicals and chiropractic. In these diverse ways, functional medicine helps create a bridge between conventional and alternative practitioners and approaches—a place where there is mutuality of ideas and interests, and where the patient’s needs can come first. This common meeting ground will enhance the delivery of integrated care and contribute to the development of respectful and productive professional relationships among healthcare providers.

outcome. Functional medicine approaches patient care with the confidence that restoring and maintaining health are achievable goals.

Functional Medicine is Discipline-Neutral

)2

(c

Functional medicine is discipline-neutral—the field is accessible to any health practitioner who has a fairly standard Western medical science background. There are significant advantages to this “neutrality,” particularly as the nation’s healthcare system becomes more and more open and adaptive to integrated care concepts: • Patients with chronic disease often use multiple care-givers from a variety of fields. It is extremely valuable to the patient (and to the efficient delivery of care) when those practitioners have a common “language” for discussing patient health. Functional medicine creates a unifying mind-set and information architecture about health and disease, regardless of widely varied clinician training and skills. • Although the science underlying functional medicine is complex, the application of therapeutic and prevention-oriented approaches is often relatively straightforward; patients can understand it and so can practitioners from many different backgrounds. Functional medicine creates a more level playing field between and among patients and providers. • We have had a very hierarchical healthcare system for many years in the United States; as a result, turf battles between professions are common and patients often get caught in the crossfire. With the cross-disciplinary nature of functional medicine, those problems can be minimized or eliminated.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Focused Training is Needed to Change the Existing Model of Care

in

ic

ed

The postgraduate healthcare education industry encompasses many different methods of delivering information to clinicians: textbooks, journal articles, and professional conferences are among the most common. The sizable investment made in these activities year after year ought to create a significant obligation to demonstrate that they substantially improve the care that patients receive. Unfortunately, emerging research is demonstrating quite convincingly that the changes created by conventional continuing medical education or CME (journal articles and conferences) are much less significant than most practitioners realize. Consider just a few selected quotations: • “lecture results in only the lowest level of behavioral change.”1 • “the best predictor of knowledge of blood pressure treatment [for example] is a physician’s year of graduation from medical school.”2 • “Unfortunately, most of the clinical questions generated at the point of care go unanswered.”3 • “traditional medical care delivery methods are failing to adapt by responding too slowly to rapidly changing new medical evidence.”4

e

Functional medicine is firmly grounded in scientific principles and data but adopts a flexible, eclectic perspective on medicine. The use of dietary interventions, clinical nutrition, exercise therapy, mind-body-spirit issues, botanical medicines, physical medicine, and even energy medicine (e.g., acupuncture) can all be integrated into functional medicine teaching and practice when the science warrants it. The use of drugs and/or surgery does not disappear, but lifestyle interventions assume a certain primacy (where appropriate)—both because of their lower cost and because of their long-term role in restoration of health and prevention of disease (or complications of disease).

28

Chapter 4 Training Clinicians in New Approaches to Care actual behavior. We offer help with understanding how to change in Chapter 36—it may be structured as “helping patients to change unhealthy behaviors,” but it is just as useful in making any kind of personal change, in one’s life or one’s practice. We think of you—the current and future functional medicine practitioners—as our partners in developing the information base and improving the effectiveness of the training. Please stay in communication with us about what really does—and does not—make a difference in the way you actually practice and how your patients have fared.

• “[M]any of the implications from research, although black and white to the researcher, are not immediately compelling to the practitioner … .”5 • “Uneven uptake of research findings—and thus inappropriate care—occurs across different health care settings, countries and specialties … .”6 • “Didactic sessions do not appear to be effective in changing physician performance.”7 And, very significantly: • “In addition to being disconnected temporally and spatially from the actual delivery of care, CME has too often failed to deliver the most important and useful information to clinicians: patient-oriented evidence on common or important problems that has the potential to change practice.”8

)2

(c

Mentoring and Follow-Up Are Needed in Addition to CME If it can be established, as we believe and have expounded on at some length in earlier in this section, that certain changes are urgently needed in our current healthcare system, particularly for complex chronic disease, then the question immediately arises, “If information alone is insufficient, how can such change be achieved?” There are several important pathways to address: 1. Change the way physicians and other practitioners are taught. As noted above, we do know that how a physician is taught is often an extremely powerful predictor of how he/she will practice. A lot of CME effort is devoted to trying to change and update what was learned in medical school. New practitioners should be emerging from their training already prepared to practice effective, integrated care in multidisciplinary settings. The Textbook of Functional Medicine can contribute by providing a broader view of the underlying mechanisms of health (and disease prevention), by linking the basic sciences and the research literature with effective clinical approaches, and by strengthening the priority that is placed upon understanding the key influences on gene expression. 2. Find ways to make continuing medical education more effective. While the research on effectiveness of CME is not voluminous, it does present a rather alarming assessment of CME effectiveness in changing physician behavior (see above). The picture goes something like this: didactic presentations may improve knowledge but are unlikely to change behavior;10 single interventions on a particular subject are much less likely to change behavior

0

01

This disconnection from “evidence that matters” is of great concern to IFM and to functional medicine leaders and practitioners. We spend a lot of time and effort— unsupported by the deep pockets of the pharmaceutical industry or the organizational backing of medical schools, societies, or hospitals—developing courses and symposia that deliver information. We work diligently to ensure the clinical relevance of that information and to focus on the problems that cost the healthcare system the most in dollars and cost patients the most long-term distress—complex, chronic disease. But if this is not the most effective way to deliver “patient-oriented evidence that matters” (POEMs) then we want to change it. Meeting that challenge head-on has brought us to this book. While information alone may not change clinician behavior very significantly, high quality information is an absolutely essential ingredient in the mix— necessary, but not sufficient. Developing a comprehensive textbook—where the evidence base is clearly demonstrated and the clinical connections to that evidence are made clear—seems an important step. Delivering this comprehensive information base so that clinicians can learn at their own pace, in their own homes and offices, and in response to clinical questions that arise at the point of care, may enable us to increase our effectiveness and—a prime consideration—perhaps redirect the focus of our onsite courses to more interactive, clinically specific education. We hope that the book’s users will take on a personal “commitment to change.” There is evidence to show that “physicians who expressed a commitment to change were significantly more likely to change”9 their

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 29

Section I Introduction than multiple, varied interventions (rare);11 complex changes are more difficult than simple ones;12 information that is not relevant to questions that arise at the point of care is unlikely to change behavior;13 even CME that changes physician behaviors with some efficacy may not change patient outcomes;14 practitioners may find change difficult if the system within which they practice is not proactive and responsive;15 and yet physicians still like CME.16 They attend it with great regularity and frequency, rely on it for their continued learning, and are often quite willing to make a commitment—in the moment of learning—to change.17

(c

from your colleagues. Over time, you will get to know these professionals, and you can begin independent dialogues by emailing directly to those whose expertise is most helpful to you. • Review the regular “Article of the Week” postings by the Forum Consultant, who will also chime in on Forum Host or member postings by offering links to key research or relevant articles. • Speak up about functional medicine. Share your education and clinical experiences with colleagues and patients. If you are an experienced functional medicine practitioner, offer to mentor a colleague who is new to the field. Recommend this book to your local hospital library, or buy an extra copy and donate it to the school where you received your professional training. In other words, expand the functional medicine community through your own efforts. The opinion of a respected colleague can be very influential.

)2

How can this massive, nationwide (costly) effort to bring good continuing education to the fore, and to use information as an effective change agent, be enhanced? There are certainly many more questions than answers on this vital topic, but two findings that have emerged with some consistency are these: mentoring is an important element and follow-up is critical. Practitioners need continuing contact with skilled and respected colleagues who can give feedback on new information and ideas, and whose collaboration can be sought about key clinical questions that directly affect patients.18 IFM provides you—the reader of this book—and other interested practitioners considerable support for the effective integration of functional medicine into practice through its vibrant, interactive online community (www.functionalmedicine.org). On the fully searchable IFM Member Forum (information about membership is available at http://www.functionalmedicine.org/ membercommunity/becomemember.asp), you can participate in a variety of ways: • Engage with the experts who post as Forum Hosts on “Topic of the Week.” Cases are presented, emerging evidence is discussed, and stimulating questions are posed. Some discussions involve dozens of respondents and are highly interactive. Forum Hosts are a valuable resource for all functional medicine practitioners, even experienced ones. • Post a question or issue of your own. Is a particular patient troubling you, or are there conditions or approaches you want clinical guidance on? Any member can initiate a post (although you may want to search the Forum first to see whether the topic has been explored before). You are likely to receive very thoughtful and generous responses

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All References 1.

e

in

ic

ed

Stancic N, Mullen PD, Prokhorov AV, et al. Continuing medical education: what delivery format do physicians prefer? J Cont Ed Health Prof. 2003;23:162-67. 2. Sackett DL, Richardson WS, Rosenberg W, Haynes RB, eds. Evidence-based medicine: how to practice and teach EBM. 1st Ed. New York: Churchill-Livingstone, 1997. 3. Ebell MH, Shaughnessy A. Information mastery: integrating continuing medical education with the information needs of clinicians. J Cont Ed Health Prof. 2003;23:S53-S62. 4. Prather SE, Jones DN. Physician leadership: Influence on practicebased learning and improvement. J Cont Ed Health Prof. 2003;23:S63-S72. 5. Lomas J. Teaching old (and not so old) tricks: effective ways to implement research findings. In Dunn EV, Norton PG, Stewart M, Tudiver F. Disseminating Research/Changing Practice. Thousand Oaks, CA: Sage; 1994. 6. Foy R, Eccles M, Grimshaw J. Why does primary care need more implementation research? Fam Pract. 2001;18(4):353-55. 7. Davis D, O’Brien MAT, Freemantle N, et al. Impact of formal continuing medical education: do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes? JAMA. 1999;282(9):867-74. 8. Ebell MH, Shaughnessy A. Information mastery: integrating continuing medical education with the information needs of clinicians. J Cont Ed Health Prof. 2003;23:S53-S62. 9. Wakefield J, Herbert CP, Maclure M, et al. Commitment to change statements can predict actual change in practice. J Cont Ed Health Prof. 2003;23:81-93. 10. Stancic N, Mullen PD, Prokhorov AV, et al. Continuing medical education: what delivery format do physicians prefer? J Contin Educ Health Prof. 2003;23(3):162-67. 11. Robertson MK, Umble KE, Cervero RM. Impact studies in continuing education for health professions: update. J Contin Educ Health Prof. 2003;23(3):146-56.

30

Chapter 4 Training Clinicians in New Approaches to Care

)2

(c

12. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients’ care. Lancet. 2003;362:1225-30. 13. Cervero RM. Place matters in physician practice and learning. J Contin Educ Health Prof. 2003;23(Suppl 1):S10-S18. 14. Markert RJ, O’Neill SC, Bhatia SC. Using a quasi-experimental research design to assess knowledge in continuing medical education programs. J Contin Educ Health Prof. 2003;23(3):157-61. 15. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients’ care. Lancet. 2003;362:1225-30. 16. Stancic N, Mullen PD, Prokhorov AV, et al. Continuing medical education: what delivery format do physicians prefer? J Contin Educ Health Prof. 2003;23(3):162-67. 17. Wakefield J, Herbert CP, Maclure M, Dormuth C, et al. Commitment to change statements can predict actual change in practice. J Contin Educ Health Prof 2003;23(2):81-93. 18. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients’ care. Lancet. 2003;362:1225-30.

0

01 e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 31

Section I Introduction

)2 (c

0 01

e in ic ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

32

Chapter 5 Changing the Evidence Model  

Functional Medicine and the Emerging Research Base Clinical Decision Making—A Functional Medicine Perspective

)2

(c Functional Medicine and the Emerging Research Base

0

01

David S. Jones, MD

Understanding the Limitations of the Randomized Controlled Trial (RCT)

lM na tio d. un rve r F se fo re te ts itu h st rig In All

assiduously to understand RCT study designs, including identification of pitfalls and types of bias.5,6,7,8,9 The proponents of the RCT as the gold standard for unbiased research results have moved forward in the applied medical fields, both in primary and specialty care. They have developed systems for grading recommendations based on a “research quality scale” that ranks methodologies in descending order of accepted best evidence:10,11 • Systematic reviews and meta-analyses of RCTs • RCTs • Non-randomized intervention studies • Non-experimental studies • Expert opinion

ic

ed

The scientific method disciplines the creative process of human inquiry. In the applied biological sciences (e.g., clinical medicine) prior to World War II, evaluation of emerging therapeutics was mainly the purview of recognized leaders in the medical profession, based primarily on their clinical impressions, without the touchstone of any systematic controls.1 To temper the quality of evidence and render a “truer” judgment with less personal bias, elite postwar researchers developed the randomized controlled trial (RCT) protocol. The major characteristics of this method include blinded assessment (of subjects, investigators, or both) in the presence of a placebo control, random assignment to comparable groups, and inferential statistics as a surrogate for establishing causation.2 This methodology (RCT) found its most ardent advocates in the sphere of pharmacological therapeutic interventions, specifically drug studies (using, most often, single agents). With development of powerful pharmaceuticals, the imperative for a scientifically rigorous methodology for asking systematic questions about efficacy, benefits, risks, and causation has proved ever more important (cf. the thalidomide tragedy of the late 1950s and the early 1960s3 and the unpredicted results of the more recent HERS RCT research vis-à-vis female hormone replacement therapy4). In the ensuing 60 years, the advocates for the RCT model have worked

e

in

The very influential schema called evidence-based medicine (EBM) has emerged using these hierarchical assumptions as foundational suppositions: A new paradigm for medical practice is emerging. Evidence-based medicine de-emphasizes intuition, unsystematic clinical experience, and pathophysiologic rationale as sufficient grounds for clinical decision making and stresses the examination of evidence from clinical research. Evidence-based medicine requires new skills of the physician including efficient literature searching and the application of formal rules of evidence evaluating the clinical literature.12

Evidence-based practice requires the integration, patient by patient, of the physician’s clinical expertise and judgment with the best available relevant external evidence. Sackett in 1996 described EBM in this way: “Evidence based medicine is the conscientious, explicit,

33

Section I Introduction • Practicing physicians often fail to obtain available relevant evidence. • Medical knowledge and clinical performance deteriorate over time without the leavening of newer evidence influencing clinical decisions. • Traditional continuing medical education (CME) is inefficient and generally does not improve clinical performance without a disciplined methodology of inclusion of new evidence into clinical practice. • The discipline of evidence-based medicine can keep the physician up-to-date.

and judicious use of current best evidence in making decisions about the care of individual patients. The practice of evidence based medicine means integrating individual clinical expertise with the best available external clinical evidence from systematic research. … Good doctors use both individual clinical expertise and the best available external evidence and neither alone is enough.”13 The process of evidence-based medicine is summarized below.14,15 • Select specific clinical questions from the patient’s problem(s). • Search the literature or databases for relevant clinical information. • Appraise the evidence for validity and usefulness to the patient and practice. • Implement useful findings in everyday practice.

)2

(c

The clinical application of basic research has been slowed by two major issues. The first problem that has impeded the successful application of EBM to the daily specifics of patient care is the complex nature of the translation of research studies to the individual patient’s unique clinical problem(s)—what Larry Weed called knowledge coupling.18,19,20 John Hampton, Professor of Cardiology, University Hospital, Nottingham, England, in a review titled “Evidence-based Medicine, Opinion-based Medicine, and Real-world Medicine,” reasons: “Clinical trials will tell us what treatments are effective, but not necessarily which patients should receive them … . Treatment must always be tailored to the individual patient.”21 Added to this methodologic conundrum are the realworld exigencies of daily clinical practice that make it virtually impossible to collate and filter all relevant evidence prior to direct application to the unique needs of the patient. Imagine a clinic where, after each therapeutic encounter—thorough history taking accompanied by a complete physical exam—a problem list is developed that is then carefully subjected to a medical literature search and analysis. The practice of clinical medicine will not tolerate the inertia of such a process.22 These practicalities of real-time clinical practice have slowed the integration of new research into the clinical care of patients who are often in desperate need of interventions based on emerging evidence. To assist the practicing physician’s effective inclusion of new evidence into daily practice, both governmentsponsored and commercially affiliated organizations have moved EBM forward with a collation of filtered studies called Patient-Oriented Evidence that Matters (POEMs).23 It is now possible to search these specific databases, or self-developed relevant databases that review groups of studies that directly link research findings with specific clinical problems. The development of

01

0

As discussed in several of the aforementioned papers, the combining of these elements can be viewed as a Venn diagram (Figure 5.1), where the best outcomes occur when all three elements are represented.

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Figure 5.1 Optimal outcomes: Applying evidence-based medicine to the real world

Arguments in favor of evidence-based medicine include the following:16,17 • Increasingly available new evidence can and should lead to major changes in patient care.

34

Chapter 5 Changing the Evidence Model focused on treating chronic disease using drugs and surgery rather than comprehensive patient-centered treatments focused on the individual. It becomes easier to see that the second major issue impeding the application of emerging research is the absence of an adequate filtering system (evidence design) and application architecture (or information matrix) for the focus of 21st century medical needs: complex, chronic illness. Funding of research continues to be primarily focused on pharmacologic answers to these complex, chronic problems, leaving discerning clinicians without the EBM tools and information for addressing their patients’ complex needs. In a cogent paper in The Lancet (van Weel and Knottnerus, 1999),32 the difficulties of using evidence in the context of the individual patient with complex, chronic illness are discussed and specific obstacles are identified: • EBM tends to concentrate on research methodology and reduce clinical practice to the technical implementation of research findings. • Comorbid conditions are the usual justified reason for the exclusion of patients from RCTs, so the very patients most in need of usable evidence (e.g., those with complex, chronic conditions) are often not in the cohorts of patients being studied, leaving the findings from the research trials very limited in their applicability. • In general practice, treatment usually consists of various elementary interventions. Combinations of evidence-based interventions do not sum to a plan that is evidence-based. Interactions between single interventions may increase or decrease their efficacy (even under ideal trial conditions) when cobbled together into a comprehensive plan. • Clinical research does not focus on the overall outcome of composite interventions because of the complexity of such studies and the absence of welldeveloped tools for studying such approaches. • Drug interventions have been studied more extensively than non-pharmacological interventions, in part due to the technical and methodological difficulties in the design of RCTs for non-drug interventions. • This situation is a particular problem in general practice, where the use of educational, dietary, and lifestyle interventions is attractive because of their resonance with the principle of “maximum effect using minimum resources.”

)2

(c

robust and thorough databases of POEMs is an ongoing commitment of institutions throughout the industrialized world.24,25 A second major issue has proved to be a Gordian knot that has not yet been unraveled. If medical care were as simple as identifying the clinical problem followed by the prescription of an appropriate single pharmacologic agent, then the EBM system, as presently configured and applied, would work if appropriate POEMs were available for each medical problem. However, the dream and heritage from half a century of medicalization of the daily health problems of our patients have not proved remedial to the widely accepted notion of “better living through chemistry.”26 (Most POEMs and most studies in the Cochrane Collection are research trials of pharmacologic therapeutic interventions.) In fact, acute medical problems are the only medical problems that appear to predictably respond as envisioned by the conventional medical paradigm. However, greater than 70% of health problems presenting to clinicians today are chronic, complex medical issues27 for which the underlying assumptions of the RCT and medical education based on this assumption simply fail to provide satisfactory answers. Halsted Holman, MD, of Stanford Medical School, editorialized in JAMA in 2004: “Chronic disease is now the principal cause of disability and use of health services and consumes 78% of health expenditures.”28 Within this population with chronic, complex illness, non-genetic factors that are modifiable by lifestyle changes—including diet, overweight, inactivity and environmental exposures such as smoking—account for 70–90% of mortality in the U.S.29 Add to this the projection from the Centers for Disease Control and Prevention (CDC) that one-third of the people born in the year 2000 will eventually have diabetes,30 which is probably the most costly of the chronic diseases when all of its comorbidities and secondary complications are considered.31 With similar disturbing statistics in hand, Holman goes on to point out that, “Chronic disease requires a practice of medicine quite different from that used for acute disease … Unfortunately, few if any schools are preparing their students adequately for the roles they and their patients need to play.” Despite these sobering facts, physician education, training, and reimbursement, as well as research designs for clinical studies that physicians will depend upon for clinical decision making, continue to be

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 35

Section I Introduction ‘Evidence’ of ‘Evidence-based Medicine,’” echoes similar reservations.35 Larry Culpepper and Thomas Gilbert, in their Lancet commentary, “Evidence and Ethics,” focus this same reservation in the primary care arena of patient care.36 In summation, the reductionist simplicity of the double-blind, placebo-controlled trial frequently does not work for the significant questions now facing 21st century primary care practitioners in the one-on-one decision making characteristic of clinical medicine. The statistical and mathematical sophistication needed for multi-variable analysis of the clinical context of patients with complex, chronic illness, in the interface between the patient’s unique environmental context and genomic card catalog of possibilities, simply does not now exist. We are in the transitional stage of realizing that our tools of evidence are inadequate to the challenge posed by emerging evidence from our scientific community that demonstrates that the world works through complex mechanisms operating simultaneously. These complex questions cannot be reduced to the relatively simple single-agent, single-condition research for which the RCT methodology is so well suited.37,38,39 We cannot continue to ignore where the truly significant questions reside, regardless of the difficulty and elusiveness of the answers needed to address the problems inherent in chronic, complex diseases. The RCT tool was developed during a specific period in our medical history and worked well to adjudicate between the traditionalists who claimed that clinical experience trumped bench science and the scientists who perceived the value in systematic inquiry. Major strides in treatment have occurred in the intervening 50 to 60 years as a result of the shift in opinion toward the use of RCT methodology. But we are now at another nodal decision point, unique to our cultural and medical evolution. We need a more sophisticated tool to shed light on the nature of the web-like interweaving of mechanisms at work in the chronic, complex illnesses under scrutiny.40,41

• The structure of RCT methodology assumes the consequences of individual variability in response to treatment will “wash out” if the subject pool is large enough and the statistical analyses sophisticated enough. While this may be true for populations, it seriously limits the applicability of the research in primary care, which is delivered one patient at a time.

)2

(c

According to van Weel and Knottnerus, the driving force behind EBM should be a coherent system of fundamental research of pathophysiology and humanities, combined with careful clinical observations, on which systematic (RCT-based) evidence of effectiveness is superimposed. Existing clinical practice should be supported or, if erroneous, corrected on the basis of this coherent system. They go on to propose that “two complementary approaches are needed to strengthen the evidence base of non-pharmacological interventions and complex multifaceted strategies. First, the generic characteristics of complex interventions must be acknowledged as essential for its evaluation. Second, a methodology to allow the assessment of complex effects should be further developed.”33 They share the concern that EBM has de-evolved into primarily a discussion of “research methodology and [has] reduce[d] clinical practice to the technical implementation of research findings.” Dr. David Mant in his seminal paper, “Can Randomized Trials Inform Clinical Decisions about Individual Patients?” takes a slightly different tack in exploring the irony that the RCT combines strength of concept for the population being studied with weakness of specific application to the individual patient:34

0

01

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

The paradox of the clinical trial is that it is the best way to assess whether an intervention works, but is arguably the worst way to assess who will benefit from it. … However, the nub of the argument for me is that randomized controlled trials are primarily about medical interventions and not patients. In clinical trials, patients are randomized to allow a comparison of intervention efficacy unbiased by the individuality of the patient. This methodological approach provides society with powerful protection against witch-doctoring, and helps us eliminate the inefficiencies in the provision of medical care described by Cochrane. But the methodological minimization of information on effectiveness in relation to the individual patient leaves an evidence gap for clinicians.

Complex Conditions, Complex Models The emerging research on underlying mechanisms of dysfunctional processes that lead to diagnosable disease has outpaced the ability of existing clinical research methods to keep up with useful evaluation of the information. The complexity of the developing “explanatory models” has been serially addressed in the Annals of Fam-

Dr. Alan Feinstein, from the Department of Medicine, Yale University, in his article, “Problems in the

36

Chapter 5 Changing the Evidence Model gene map of susceptibilities/potentialities that, in turn, communicates constantly with the ever-changing environment within which the patient lives. No RCT can possibly inform, in a specific way, the appropriate clinical roadmap for assessment and planning for therapeutic interventions in this complex environment.52 Dr. Richard Horton, editor-in-chief of The Lancet, addressed this issue in an editorial titled, “The Precautionary Principle”:

ily Medicine, a peer-reviewed medical journal “dedicated to advancing knowledge essential to understanding and improving health and primary care,” including the development of methodology and theory for addressing this conundrum.42 In the article, “The Biopsychosocial Model 25 Years Later: Principles, Practice, and Scientific Inquiry,”43 the authors critique the limitations of the conventional biomedical model and the research methodologies that evolve from this model, and preview the evolving model of “complexity and causality” and the nested model of “structural causality”:

We must act on facts, and on the most accurate interpretation of them, using the best scientific information. That does not mean we must sit back until we have 100% evidence about everything. Where the state of the health of the people is at stake, the risks can be so high and the cost of corrective action so great, that prevention is better than cure. We must analyze the possible benefits and cost of action and inaction. Where there are significant risks of damage to the public health, we should be prepared to take action to diminish those risks even when the scientific knowledge is not conclusive, if the balance of likely costs and benefits justifies it.53

)2

(c

Few morbid conditions could be interpreted as being of the nature “one microbe, one illness”; rather, there are usually multiple interacting causes and contributing factors. Thus, obesity leads to both diabetes and arthritis; both obesity and arthritis limit exercise capacity, adversely affecting blood pressure and cholesterol levels; and all of the above, except perhaps arthritis, contribute to both stroke and coronary artery disease. Some effects (depression after a heart attack or stroke) can then become causal (greater likelihood of a second similar event). … These observations set the stage for models of circular causality that describe how a series of feedback loops sustain a specific pattern of behavior over time.44,45,46 Complexity science is an attempt to understand these complex recursive and emergent properties of systems47,48 and to find interrelated proximal causes that might be changed with the right set of interventions.49

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

One such intermediate tool that addresses this second major problem in applying emerging scientific evidence to clinical problems has been developed. This algorithm for critically assessing interventions in the context of complex, chronic illness has the mnemonic “STEPed Care”: Safety (an analysis of adverse effects that patients and providers care about), Tolerability (pooled drop-out rates from large clinical trials), Effectiveness (how well the intervention[s] work and in what patient population[s]), and Price (costs of intervention, but also cost-effectiveness of therapy).54 Clinicians who are armed with this tool can arrange the emerging evidence about underlying mechanisms of disease in the clinical context of their patients’ problems and can apply this matrix of STEPed Care, bringing the best of new evidence to the unique needs of their patients. To do more is to place patients in danger, teetering on the insubstantial edge of research, but to do less is unconscionable. For example, starting in the 1970s emerging research suggested that public health measures to ensure folate nutriture for women in the childbearing years, especially prior to conception, could markedly affect the incidence of spina bifida as well as other congenital neural tube anomalies in newborns.55,56,57,58,59

David Deutsch, in The Fabric of Reality, describes the need for a next step in using the science of underlying mechanisms of disease in the clinical setting of medicine:

e

in

ic

ed

The science of medicine is perhaps the most frequently cited case of increasing specialization seeming to follow inevitably from increasing knowledge, as new cures and better treatments for more diseases are discovered. But as medical and biochemical research comes up with deeper explanations of disease processes (and healthy processes) in the body, understanding is also on the increase. More general concepts are replacing more specific ones as common, underlying molecular mechanisms are found for dissimilar diseases in different parts of the body. Once a disease can be understood as fitting into a general framework, the role of the specialist diminishes. … Physicians … can look up such facts as are known. But [more importantly] they may be able to apply a general theory to work out the required treatment, and expect it to be effective even if it has never been used before.50

The real question facing every discerning, informed clinician in a patient-oriented clinic51 is how to bring relevant, graded, emerging scientific evidence to the complex list of problems made unique by the patient’s

37

Section I Introduction public and profession is intensifying.”65 Horton describes his answer to this dilemma as follows: “Application, synthesis, and reflection—these are my personal wishes for a renaissance in clinical medicine. It is not concerned with hierarchies of evidence; it is not dependent on up-to-date literature alone as the arbiter of clinical decision making; it does not proselytize a bottom-line approach to the reading of new research. Rather, it is about preferring interpretations to conclusions, external validity to internal validity, context to the highly controlled—and artificial—experimental environment.”66 Our patients are clamoring for this “renaissance” and the “largely skeptical and indifferent response to them has isolated physicians within an unattractive provincial and narrow island of medicine, a medicine that has become intellectually self-admiring of its scientistic purity and, as a consequence, self-deluding and self-defeating.”67 We are again facing a paradigm shift,68 ironically birthed by the original attempt to construct an evidence-based medical system. Thomas Kuhn69 has described scientific paradigms as ways of looking at the world that define both the problems that can legitimately be addressed and the range of admissible evidence that may bear on their solution.

)2

(c

However, it was not until March 1996 that the U.S. Food and Drug Administration (FDA) authorized addition of folic acid to enriched grain products. By 2001, a report in JAMA substantiated a 19% reduction in the birth prevalence of neural tube defects following the FDA’s decision.60 This delay of over two decades was and is unjustified. Discerning practitioners were applying the principles inherent in the STEPed Care process 15 years before the mandated action of the FDA, bringing to their patients of childbearing age and to their newborns the critical benefits of emerging research about folic acid at a much earlier actionable point. Drs. Mark Hyman, Joseph Pizzorno, and Andrew Weil wrestled with this dilemma in the reconfiguration of the medical research perspective at this branching point in our evolution of medical technologies. In their 2004 commentary in Alternative Therapies, they propose a middle-ground approach for best addressing the real problems both clinicians and patients face at this time:61

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Medical science is imprecise and the tools of analysis and research are imperfect despite our best intentions. No statistical model or research methodology can accurately predict the outcome in all humans who vary greatly in habits and genes. Medicine has in recent years been humbled in its hunger to help by its mistakes including hormone replacement therapy,62 which in the end hurt rather than helped the heart, the “lipids only hypothesis” of cardiovascular disease that ignores the important role of inflammation,63 and the belated,64 sober end to our love affair with COX-2 inhibitors. Uncertainty is common in medicine. In the face of uncertainty, we must take a broader view, step back from the canvas of individual studies and meta-analyses and view the landscape of medicine and scientific inquiry as a whole, while understanding the limitations and value of different tools of research. We require all the tools in order to create sense and be sensible in a shifting sea of data points. The goal of seeking an informed balanced overview is to help us create understanding from knowledge, to sort through the facts and place them in the context of biologic principles, against the backdrop of all we know. Then we ask ourselves if the new data fit into the landscape or appear like a polar bear in a desert. We must also recognize that the questions we ask, how we ask them, and why, all inform the answers we receive. The responsibility of the scientist is to filter the research, place it in context, provide hope where appropriate and caution where necessary, but most importantly to be an informed, measured guide to a public seeking to gain health and ameliorate suffering.

When defects in an existing paradigm accumulate to the extent that the paradigm is no longer tenable, the paradigm is challenged and replaced by a new way of looking at the world. Medical practice is changing, and the change, which involves using the medical literature more effectively in guiding medical practice, is profound enough that it can appropriately be called a paradigm shift.70

ed

e

in

ic

The practice of EBM needs to return to its original mission of integrating evidence to inform clinical experience and to expand the understanding of basic mechanisms of health and disease.71,72 This will help to reverse the decade-long plunge into the narrow focus on “the discussion of research methodology, reducing clinical practice to the technical implementation of research findings.”73,74 Alternate study designs and statistical methodologies are now being evaluated for analyzing complex data sets.75 A middle ground has been defined, creating a broader appreciation for the clarity that RCTs can bring without the obsequious and inappropriate hegemony that has characterized the debate over the last decade.76 As concluded by Larry Dossey in his “Notes on the Journey”: “One of the greatest impediments to progress in science

We are also at a branch point in the evolution of clinical medicine where the “dissonance that exists between

38

Chapter 5 Changing the Evidence Model

Challenges for the Functional Medicine Clinician

is to assume that our fundamental concepts are basically complete. They have never been.”77 We still have miles to go in our journey to understand the appropriate scientific methods that can reliably discipline the creative process of human curiosity about efficacy, benefits, risks, and causation of human suffering and its remediation. The new paradigm will recursively inform and redirect the EBM paradigm shift developed during the 1990s. IFM and functional medicine are already adapted to this changing model, making use of both existing and emerging research, and educating clinicians to bring the best of both worlds to their patients. It is our hope that this textbook will provide convincing evidence of the value of that mission.

)2

(c

The personalization of care achievable through the functional medicine approach is the only real solution to the crisis of chronic disease facing us today. (This subject has been explored deeply in Chapters 1 through 4.) However, to practice this form of medicine is difficult, complex, and requires higher standards of decision making by clinicians. The functional medicine approach to diagnosis demands not only that we determine what disease the patient is suffering from, which can be challenging, but also what the patient’s underlying physiological dysfunctions are, and the underlying cause(s), which is a complex process.

01

Sumatriptan or Magnesium?

Clinical Decision Making—A Functional Medicine Perspective

0

Consider the clinician who wants to practice the best medicine and therefore reads not only standard medical journals but also the nutrition research. The clinician decides to compare sumatriptan to magnesium for a patient suffering migraine headache. Looking at a metaanalysis of various triptans in the treatment of migraine patients, the clinician would conclude that 100 mg of sumatriptan is likely effective in 59% of patients.78 (Efficacy is defined as relief of headache pain within two hours.) Being a responsible clinician, he/she would also consider adverse drug reactions and would see that the placebo-subtracted proportion for patients with at least one adverse drug reaction (ADR) is 13%; for at least one central nervous system symptom, 6% (3.0–9.0%); and for at least one chest symptom, 1.9% (1.0–2.7%). The clinician might compare these data with other triptans, and choose rizatriptan instead, since it shows somewhat better efficacy and consistency, and similar tolerability. In contrast, looking at the research for magnesium, the clinician would find a response of 41.6% from oral magnesium. This reduction in attack frequency in the magnesium group compared to 15.8% in the placebo group might be compelling, but the incidence of ADRs of diarrhea (18.6%) and gastric irritation (4.7%) would likely preclude use.79 Not surprisingly, the conventional practitioner would very likely make an EBM decision and choose rizatriptan over magnesium. However, digging deeper would show a dramatic difference in response to magnesium based on serum ionized magnesium levels (IMg2+). Eighty-nine percent of those responding to intravenous magnesium showed

Introduction

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Joseph E. Pizzorno, Jr., ND

e

in

ic

ed

As 21st century health care moves from a diseasebased approach to a more patient-centric system that can address biochemical individuality to improve health and function (see Chapter 8), clinical decision making becomes more complex. Accentuating the problem is the lack of a clear standard for this more complex functional medicine approach. While there is relatively broad agreement in Western medicine for what constitutes competent assessment of disease and identification of related treatment approaches, the complex functional medicine model posits multiple and individualized diagnostic and therapeutic approaches, most or many of which have reasonable underlying science and principles, but which have not been rigorously tested in a research or clinical setting. (For a discussion of the limitations of the current RCT model in testing multifactorial and individualized approaches, see the preceding discussion in this chapter.) This has led to non-rigorous thinking and sometimes to uncritical acceptance of both poorly documented diagnostic procedures and ineffective therapies, resulting in less than optimal clinical care. In this discussion, we will address the challenges of clinical decision making in a functional medicine practice, looking at various models of human decision making and identifying strategies to improve their application in the healthcare setting.

39

Section I Introduction How do clinicians make diagnostic and therapeutic decisions? What influences clinical decision making? What data contribute to accurate decisions? What induces errors into a clinician’s decisions? How can we improve the accuracy and reliability of clinical thinking? What happens when the complexity becomes too great? While we seldom think about the process of decision making, our ability to do it efficiently and accurately impacts our every interaction with patients. Unfortunately, research has shown that clinical critical thinking skills need more attention in order to avoid systematic logic errors and misinterpretation of the actual predictive value of various types of patient information. Improving the reliability of the information clinicians use to make decisions is obviously critical. To that end, evidence-based medicine has become a recurrent theme in the medical research and academic literature. A recent survey showed that virtually all (122 of 126) LCME-accredited (Liaison Committee on Medical Education) medical schools included EBM as a required course of at least 20 hours.83 However, formal courses devoted specifically to critical thinking are rare. Utilizing the AAMC (American Association of Medical Schools) curriculum search tools found only six institutions with courses that included one of the terms “decision” or “critical” or “analytic,” and the hour allocations were low. Obviously, critical thinking is informally taught in many courses and clinical rotations. Nonetheless, it seems to receive limited formal attention. A survey of 417 U.S. internal medicine residency programs found formal clinical decision making training (critical appraisal, searching for evidence, posing a question, and applying it in decision making) in only 99 of 269 (37%) institutions that responded.84 A Cochrane review of the research evaluating the effect of teaching critical thinking skills to healthcare professionals already caring for patients found a remarkable 25% improvement in clinical accuracy.85 However, the Cochrane review also said there were too few properly designed and conducted studies to be confident in the size of the improvement or its actual clinical significance. Nonetheless, the well-documented evidence of frequent clinician error and its role in the incidence of suboptimal care and adverse clinical outcomes is compelling. One widely reported epidemiological study that reviewed published reports found that 4 to 18% of consecutive outpatient visits result in adverse effects, with

)2

(c

low pretreatment serum magnesium levels, while only 37.5% of non-responders had a low IMg2+ level.80 Digging even deeper, the clinician would notice that magnesium is twice as effective if the patient also suffers a prodromal aura.81 Conventional diagnosis of migraine is pretty straightforward, although atypical presentations are probably more common than previously recognized.82 The causes, however, are myriad. A research team at SaluGenecists, Inc., performed a comprehensive review of the research literature (over 10,000 research articles studied; 1,000 cited) and identified at least 27 different physiological dysfunctions that can lead to the clinical presentation of migraine headache. Patients get to migraine via complex, individual pathways. Further, there are research reports to be studied concerning approximately 40 different “natural medicine” approaches to migraine (nutritional, herbal, and lifestyle therapies). And 20 environmental toxins may need to be evaluated in order to normalize physiological dysfunctions. The clinical decision-making process has now become far more complex than simply diagnosing migraine and prescribing a triptan! This two orders of magnitude increase in complexity dramatically increases the need for rigorous decision making. Considering a human’s approximately 4,000 enzyme systems, 1,000 chemical mediators (these two numbers are my estimates, I could not find an actual count), 2,000,000 possible single nucleotide polymorphisms (SNPs), approximately 250 nutrients known to be important in human health, and several thousand endogenous and exogenous xenobiotics, the true size of the challenge becomes readily apparent.

0

01

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

Clinical Decision Making How Good Are We at Critical Thinking? How do we expand upon the current disease-based diagnosis and treatment model to achieve a clinically effective understanding of the biochemical, physiological, and environmental uniqueness of our patients? What diagnostic challenges does this expanded model create for clinicians? One of the most important services a clinician provides his or her patients is decision making. Disease diagnosis, physiological function assessment, determining optimal treatment, limiting adverse drug reactions—all involve critical thinking skills.

40

Chapter 5 Changing the Evidence Model one study asserting that up to 69% of the adverse events were preventable with better decision making.86 It appears undeniable that patients receive a lower quality of care than would be expected considering the high level of practitioner training and the huge body of research now available. The need for accurate decision making is even more critical when clinicians adopt the principles and practices of functional medicine.

Table 5.1 MYCIN vs. Students and Clinicians (1980) Healthcare expert

What Can We Learn From Artificial Intelligence (A.I.) Research? One way to improve critical thinking skills is to better understand how humans make decisions. As computers became available with enough power to mimic human thinking processes, researchers had to rigorously dissect how humans make decisions. While most of the early research centered on the creation of chess programs that could match human masters, of particular relevance here is the effort to duplicate the thinking processes of healthcare professionals. Interest in this area increased dramatically with the publication of MYCIN (1980), an “expert system” that came out of research at Stanford University in the late 1970s. What caught the imagination of the A.I. and healthcare communities was that, for blood-borne infections, MYCIN outperformed not only medical students and residents, but also infectious disease fellows and medical school faculty (see Table 5.1). How did it do this? By having logicians and programmers work with a group of infectious disease experts to exhaustively determine all the “rules” they used to determine which bacterial species caused a blood-borne infection and the optimal intervention for its eradication. Converting their knowledge into software logic required that the clinicians exhaustively think through how they make decisions. This level of rigor resulted in better decision making, not only because the model was able to incorporate the best thinking of many experts, but also because it applied those rules consistently with every patient. According to Enrico Coiera (Foundation Chair in Medical Informatics, Faculty of Medicine, University of New South Wales, Australia), “If physiology literally means ‘the logic of life,’ and pathology is ‘the logic of disease,’ then health informatics is the ‘logic of healthcare.’”87

Score

Perfect score

80

Medical student

24

Resident

36

Actual hospital outcome

46

Infectious disease fellow

48

)2

(c

Medical school faculty MYCIN

34–50 52

01

0

There are now over 70 A.I. tools in use in conventional medicine to improve diagnosis (actually outperforming clinicians in some areas), avoid drug interactions, interpret x-rays and laboratory tests, teach medical students, and perform other tasks (see Judith Federhofer’s excellent review at www.computer. privateweb.at/judith). We can continue to learn much about the mechanics of medical decision making and areas of potential error by formally coding our decisionmaking processes into computer programs. These programs consistently reproduce our thinking processes so that they can be subjected to evaluation. By identifying where our decisions lead to correct or incorrect outcomes, we can refine our thinking and improve our use of evidence and patient data.

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

in

Artificial Intelligence—Many Ways of Thinking Studying the types and diversity of artificial intelligence systems (called expert systems when they are used to duplicate experts in a field of study) that have been developed to mimic human thinking is very informative. In general, five types have been used in medicine (there are actually many more types of A.I., but these are the most common in health care): • Rules-based systems • Case-based reasoning (CBR) • Neural networks • Fuzzy logic • Bayesian networks

41

Section I Introduction in the database. This method duplicates human pattern matching pretty well, i.e., once you’ve seen a patient with classic migraine, others are easy to recognize.

This discussion may appear daunting, but we will draw from it some straightforward guidance. Busy clinicians can’t be expected to calculate all the probabilities before making recommendations for each patient, but their critical thinking skills can be improved by understanding better how decisions are made.

Neural Networks Neural networks make no effort at understanding how humans think nor do they develop algorithms. Rather, they look at human decision making as a “black box.” By using a large number of examples of desired behaviors, they attempt to match input (signs and symptoms) to outputs (diagnoses or therapies). The computer software is set up to be similar to the parallel processing architecture of the brain. This process may match human thinking at a very early age, but does not help us much when trying to understand adult reasoning processes.

Rules-based Systems

)2

(c

Rules-based systems are fairly straightforward. They look like flowcharts with “If … then” statements. Many clinical guidelines are based on this model. Figure 5.2 shows a diagram modified from a flowchart developed by Herb Joiner-Bey, ND, for Nancy Sudak, MD’s article on a functional medicine approach to migraine headache, published in volume 2.6 of Integrative Medicine: A Clinician’s Journal. Each branch point is simply an “If … then” logic statement. This matches human reasoning well in simple cases, especially when pathognomonic decision points are available (like Koplik’s spots in measles).

01

Fuzzy Logic

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

The concept of fuzzy logic puts me in awe of human creativity. The idea here is to look at particular information and attempt to determine the level of uncertainty. It could be described simply as a rules system with probabilities or uncertainties added.

Bayes Inference

e

in

ic

ed

An expert system used frequently in medical diagnostic systems is Bayesian inference, based on the probability theory of the Rev. Thomas Bayes, an 18th century mathematician. This heuristic reasoning system makes inferences based on the rigorous mathematics of the predictive value of information. His formula for determining the predictive value of information can be simply stated as: P(D|F) = P(F|D)*P(D) / P(F) where: D= Decision (e.g., disease) F= Finding (e.g., symptom) P(D) = The a priori probability of the decision (e.g., the incidence of a disease in the general population) P(F) = The a priori probability of the finding (e.g., the incidence of a symptom in the general population) P(D|F) = Probability of the decision given the finding P(F|D) = Probability of the finding, given the presence of the decision

Figure 5.2 Migraine flowchart

Case-based Reasoning Case-based reasoning (CBR) starts by accumulating and evaluating a large number of “solved” cases to determine the characteristics of the successfully treated patients. It then tries to match new patients with patients

42

Chapter 5 Changing the Evidence Model The Bayes formula can be restated in terms of sensitivity and specificity: P(D|F) = P(D)*TP / (P(D)*TP + (1-P(D))*FP) Or P(D|F) = P(D)*TP/P(F) That looks pretty complicated, but the main takeaway is that the probability of the decision’s accuracy is inversely proportional to the a priori probability of the finding. In other words, the more prevalent a piece of information (a finding or symptom) is in the population, the less predictive it is in a specific patient. Intuitively, this makes sense. As you may recall from your study of statistics long ago, the issues of sensitivity and specificity are extremely important. They are frequently used in laboratory medicine where they provide us guidance on the usefulness of specific tests. For example, a lab test may be very sensitive, i.e., is abnormal very frequently when the disease is present. However, if it has a high false positive (low specificity, where FP = 1-specificity), meaning the result is frequently abnormal even when the disease is not present, it is not very useful. The value of this kind of an inference-based expert system is that it mimics human thinking well (human brains are remarkably effective inference engines). If the mathematically rigorous Bayes thinking is used, decisions can be more accurate, and long chains of logic can be used (see Figure 5.3). This is the method used by casinos to calculate odds and by the Mars Lander to pick a site and land on it safely. Equally important, this system can be used to map human biochemistry, and we can learn a lot from it about the strengths and weaknesses of human thinking processes.

MIGRAINE

)2

(c

Biogenic amine imbalance

MAOase underactivity

UV light overexposure

Decrease exposure

Catecholamine depletion

PHE OHase underactivity

Tobacco alkaloid reaction

Decrease exposure

Indolamine depletion

TYR OHase underactivity

Chlorodimeform exposure

Decrease exposure

Excessive platelet aggregation

PNMTase underactivity

Tricyclic antidepressants

Find alternatives

Excessive histamine

TYRphosphorylation underactivity

Folate deficiency

Increase folates

Neuron hypersensitivity

SAM deficiency

Increase SAM and SAM nutrients

NMDA - Receptor overactivity

Vitamin B6 deficiency

Increase vitamin B6

Electron transport disrupted

Copper deficiency

Increase copper

01

Figure 5.3 Bayesian inference network

0

Note: Each arrow indicates a Bayesian inference.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

in

ic

ed

Others have asserted that the failure to learn how to make decisions under uncertainty is the leading cause of excessive diagnostic testing and inappropriate treatments.90 Obviously, reliable evidence is critical for effective decision making. However, too often evidence is confused with decision making. The quality of evidence is now evaluated (several EBM scales exist, typically ranking evidence from 1 for meta-analysis to 5 for anecdotal evidence), which may be helpful, but clinical decision making is not only about the ranking of evidence; it is also about making choices in the face of uncertainty. The failure to train doctors about clinical uncertainty has been called “the greatest deficiency of medical education throughout the twentieth century.”91

e

Lessons from the Reverend Bayes

The Role of Uncertainty in Medical Error

Rigorously dealing with uncertainly is exactly the problem addressed by the Bayes probability formulas. Consciously utilizing the false positive to balance the true positive in order to accurately portray the true level of uncertainty significantly improves the reliability of decision making. It does this by removing our overestimation of the certainty of decisions, pointing to the need for more information to improve accuracy. Through the use of the true positive (sensitivity) and false positive (1-specificity), the mathematically correct strength of an inference can be determined—that is, the clinician can better understand the true predictive value of evidence.

A strong case can be made that underappreciation of uncertainty is a major cause of error in medicine.88 McNeil has argued that the major hidden barriers to better health care result from a lack of discussion about the impact of uncertainty in medicine.89 She enumerates three sources of uncertainty that cloud decision making: 1. uncertainty as a result of lack of convincing evidence, 2. uncertainty about the applicability of research evidence to clinical care, and 3. uncertainty about interpretation of data.

43

Section I Introduction The Bayesian calculations required for accurate inferential information highlight a vulnerability in the human thinking process that is relevant to functional medicine: using only the true positive and ignoring the false positive when making complex decisions in an area of high uncertainty skews the decision making. Stated differently, failing to consider the population prevalence of the evidence and the intervention leads to false confidence on the part of the clinician.

The Bayes formula may look daunting, but its use can be surprisingly easy. In fact, there are available on the Internet simple Bayes calculators (I have one that runs in Excel that I am happy to share; contact me at: [email protected]). However, the clinician does not need to make the calculation every time. After using the formula a few times, the needed modifications to decision making become more intuitive. Let’s look again at that migraine patient. It appears that 41.6% of migraine patients respond to oral magnesium. How do you determine which ones will respond? What evidence is most predictive? Muscle cramps are a common sign of magnesium deficiency. The true positive (TP) is 48%. If the patient is experiencing muscle cramps with the migraine, the clinician might then assume that magnesium is very likely to work. However, muscle cramps are common in the general population (27.5%92) so the false positive (FP) is actually quite high, 25%. Therefore, the predictive value using the Bayes formula is that we’ve only increased the true confidence in magnesium being useful for the patient from 41.6% to 62%. This is still not very good, considering the potential for side effects. Consider, instead, mitral valve prolapse as an indication of magnesium deficiency. Its TP is only 14%, which on the surface seems less compelling than muscle cramps. However, its prevalence in the population is low (4%93) so its FP is also low, only 3%. Therefore its predictive value is significantly higher—using the Bayes calculation, our confidence is now 80%—much more compelling! In addition, the incidence of an adverse reaction is now much less because we are now unlikely to be giving magnesium to a patient who does not need it. This comparison is useful because we can see clearly that one piece of evidence appears on the surface to be more useful since it has high sensitivity, but it is actually much less useful than lower sensitivity evidence that has a much lower false positive. The simple rule: If the prevalence in the general population of a piece of evidence (a symptom or other finding) is high, even though it may be highly associated, its predictive value is actually weak. Therefore, before the clinician can confidently make a recommendation, the right kind of evidence, i.e., that with a high ratio of TP to FP, needs to be gathered (e.g., discovering whether the patient suffers a prodromal aura, measuring magnesium levels, and so forth).

Summary

)2

(c

Uncertainty is a fact of life in health care. It arises from many sources: incomplete or inaccurate patient data; evidence that is not as good as we would like; and making inaccurate inferences from the evidence and data. Lack of awareness about this uncertainty principle leads to excessive confidence in our conclusions. Erroneously believing we have made a good decision results in stopping the evidence-gathering process prematurely. The clinical impact, then, is greater frequency of ineffective therapies and increased risk of ADRs. What can clinicians do? There are three relatively straightforward steps that all healthcare practitioners can take: 1. Improve the quality of the evidence we use (the evidence to be considered ranges from more accurate eliciting of patient data to better understanding of underlying physiology and biochemistry, the influence of environment on gene expression, and the effectiveness of assessment tools and therapeutic strategies). 2. Understand the true predictive value of evidence by considering not only the true positive but also the critical false positive, i.e., become more aware of the population prevalence of the evidence and data we use and learn how to calculate their effect upon certainty. 3. Continue evidence gathering (especially evidence with a high true-positive to false-positive ratio) until the level of certainty supports a reasonable level of confidence in the efficacy and safety of the intervention.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Removing overassessment of accuracy from clinical decision making helps us prioritize where additional information has to be gathered so that we can provide the best possible care for our patients.

44

Chapter 5 Changing the Evidence Model

References 1.

2. 3. 4.

5. 6. 7. 8.

29. “For most diseases contributing importantly to mortality in Western populations, epidemiologists have long known that nongenetic factors have high attributable risks, often at least 80 or 90%, even when the specific etiologic factors are not clear.” Willett, WC. Balancing life-style and genomics research for disease prevention. Science. 2002,296:695-97. 30. Centers for Disease Control, June 15, 2003. 31. Simpson SH, Corabian P, Jacobs P, Johnson JA. The cost of major comorbidity in people with diabetes mellitus. CMAJ. 2003, 168(13):1661-67. 32. Weel CV, Knottnerus JA. Evidence-based interventions and comprehensive treatment. Lancet. 1999;353:916-18. 33. Ibid. 34. Mant D. Can randomized trials inform clinical decisions about individual patients? Lancet. 1999;353:743-46. 35. Feinstein AR, Horwitz RI. Problems in the “evidence” of “evidencebased medicine.” Am J Med. 1997;103:529-35. 36. Culpepper L, Gilbert TT. Evidence and ethics. Lancet. 1999;353:829-31. 37. Ibid. 38. Hyman M, Pizzorno J, Weil A. A rational approach to antioxidant therapy and vitamin E. Altern Ther Health Med. 2005;11(1):14-17. 39. Kossman M, Bullrich S. Systematic chaos: self-organizing systems and the process of change. In: Masterpasqua F, Perna PA, eds. The Psychological Meaning of Chaos: Translating Theory into Practice. Washington, DC: American Psychological Association; 1997. 40. Cerutti A, Sinorini MG. Non-linear algorithms for processing biological signals. Comput Methods Programs Biomed. 1996; 51:51-73. 41. Smart A, Martin P, Parker M. Tailored medicine: whom will it fit? Bioethics. 2004; 18:322-42. 42. Borrell-Carrio F, Suchman AL, Epstein RM. The Biopsychosocial Model 25 years later: principles, practice, and scientific inquiry. Ann Fam Med. 2(6):576-82. 43. Borrell-Carrio F, et al. The biopsychosocial model 25 years later: Principles, practice, and scientific inquiry. Ann Fam Med. 2004; 2(6):576-82. 44. Mackie JL. Causes and conditions. Amer Philosoph Q. 1965;2:245-64. 45. Mackie JL. The Cement of the Universe. A Study of Causation. Oxford UK: Oxford University Press; 1974. 46. Bateson G. Steps to an Ecology of Mind: A Revolutionary Approach to Man’s Understanding of Himself. New York, NY: Ballantine Books; 1972. 47. Fraser SW, Greenhalgh T. Coping with complexity: educating for capability. BMJ. 2001;323:799-803. 48. Miller WL, Crabtree BF, McDaniel R, Stange KC. Understanding change in primary care practice using complexity theory. J Fam Pract. 1998; 46:369-76. 49. Borrell-Carrio F, et al. The biopsychosocial model 25 years later: Principles, practice, and scientific inquiry. Ann Fam Med. 2004; 2(6):576-82. 50. David Deutsch. The Fabric of Reality. New York, NY: Penguin Press; 1997:16. 51. Little P, et al. Preferences of patients for patient centred approach to consultation in primary care: observational study. BMJ. 2001;322:1-7. 52. Mant D. Can randomized trials inform clinical decisions about individual patients? Lancet. 1999;353:743-46. 53. Horton R. Commentary: The new new public health of risk and radical engagement. Lancet. 1998;352(9124):251-52. 54. Abby SL, et al. Homocysteine and cardiovascular disease. J Am Board Fam Pract. 1998;11(5):391-98.

9.

0

01

10.

)2

(c

Marks HM. The progress of experiment: science and therapeutic reform in the United States, 1900-1990. Cambridge: Cambridge University Press, 1995. Kaptchuk TJ. Intentional ignorance: a history of blind assessment in medicine. Bull Hist Med. 1998;72(3):389-433. http://www.thalidomide.ca/en/index.html Rossouw JE, Anderson GL, Prentice RI, et al. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33. Sackett DL. Bias in analytic research. J Chronic Dis. 1979;32:51-63. Slinger R, Moher D. How to assess new treatments. West J Med. 2001;174(3):182-6. Jadad AR. The randomized controlled trial gets a middle-aged checkup. JAMA. 1998;279:319-20. Dossey L. How should alternative therapies be evaluated? An examination of fundamentals. Altern Ther Health Med. 1995;1(2):6-10, 79-85. Kiene H. A critique of the double-blind clinical trial. Part 1. Altern Ther Health Med. 1996;2(1):74-80. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323:334-36. Guyatt GH, Sinclair J, Cook, DJ, Glasziou P. Users' guides to the medical literature: XVI. How to use a treatment recommendation. JAMA. 1999;281(19):1836-43. Evidence-based medicine. A new approach to teaching the practice of medicine. Evidence-Based Medicine Working Group. JAMA. 1992;268(17):2420-25. Sackett, DL. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312:71-72. Geyman JP. Evidence-based medicine in primary care: an overview. J Am Board Fam Pract. 1998;11:46-56. Rosenberg W, Donald A. Evidence based medicine: an approach to clinical problem-solving. BMJ. 1995;310:1122-26. Sackett DL. Evidence-based medicine: how to practice and teach EBM. New York: Churchill Livington, 1997:2-16. Davidoff F, et. al. Evidence based medicine. BMJ. 1995; 310:1085-86. Weed LL, Zimny NJ. The problem-oriented system, problemknowledge coupling, and clinical decision making. Phys Ther. 1989;69(7):565-8. Weed LL. Medical Records, Medical Education, and Patient Care. The Problem-Oriented Record as a Basic Tool. Chicago: Year Book Medical Publisher, Inc.: 1970. Weel CV, Knottnerus JA. Evidence-based interventions and comprehensive treatment. Lancet. 1999;353:916-18. Hampton JR. Evidence-based medicine, opinion-based medicine, and real-world medicine. Perspect Biol Med. 2002;45(4):549-68. Grahame-Smith D. Evidence based medicine: Socratic dissent. BMJ. 1995;310:1126-27. Definition of POEMs published in tips from other journals. Am Fam Physician. 2005;71(1):153. http://www.InfoPOEMs.com www.ahrq.gov/clinic/epcix.htm A DuPont advertising slogan. 1939. http://heritage.dupont.com/ touchpoints/tp_1939/depth.shtml http://www.cdc.gov/pcd/issues/2004/apr/04_0006.htm Holman H. Chronic disease—the need for a new clinical education. JAMA. 2004;292(9):1057-59.

12.

13. 14. 15. 16. 17. 18.

23. 24. 25. 26. 27. 28.

e

22.

in

21.

ic

20.

ed

19.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

11.

45

Section I Introduction 81. Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalgia. 2002;22:345-53. 82. Rains JC, Penzien DB, Lipchik GL, Ramadan NM. Diagnosis of migraine: empirical analysis of a large clinical sample of atypical migraine (IHS 1.7) patients and proposed revision of the IHS criteria. Cephalalgia. 2001;21(5):584-595. 83. Barzansky B, Etzel SI. Educational programs in US medical schools, 2002–2003. JAMA.2003;290:1190-96. 84. Green ML. Evidence-based medicine training in internal medicine residency programs a national survey. J Gen Intern Med. 2000;15:124-33. 85. Parkes J, Hyde C, Deeks J, Milne R. Teaching critical appraisal skills in health care settings. Cochrane Database Syst Rev. 2001;(3):CD001270. 86. Wiengart SN, Wilson RM, Gibberd RW, Harrison B. Epidemiology and medical error. BMJ. 2000;320:774-7. 87. Coiera E. Guide to Health Informatics. Arnold Publications, London, 2003. 88. Editorial. Lifting the fog of uncertainty from the practice of medicine. BMJ. 2004;329:1419-20. 89. McNeil BJ. Hidden barriers to improvement in the quality of care. N Engl J Med. 2001;345: 1612-20. 90. Haynes B. Bridging the gap between the Cochrane Collaboration and clinical practice. Plenary presentation. 12th Cochrane Colloquium, Ottawa, 3 October 2004. 91. Ludmerer KM. Time to heal. New York: Oxford University Press, 1999. 92. Naylor JR, Young JB. A general population survey of rest cramps. Age Ageing. 1994;23(5):418-20. 93. Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med. 1999;341:1-7.

)2

(c

55. Speidel BD. Folic acid deficiency and congenital malformation. Dev Med Child Neurol. 1973;15(1):81-83. 56. Biale Y, Lewenthal H, Ben-Adereth N. Letter: Congenital malformations and decreased blood level of folic acid induced by antiepileptic drugs. Acta Obstet Gynecol Scand. 1976;55(2):187. 57. Laurence KM. Prevention of neural tube defects by improvement in maternal diet and preconceptional folic acid supplementation. Prog Clin Biol Res. 1985;163B:383-88. 58. Milunsky A, Jick H, Jick SS, et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA. 1989;262(20):2847-52. 59. From the Centers for Disease Control. Use of folic acid for prevention of spina bifida and other neural tube defects—1983-1991. JAMA. 1991;266(9):1190-91. 60. Honein MA, et al. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA. 2001;285(23):2981-86. 61. Hyman M, Pizzorno J, Weil A. A rational approach to antioxidant therapy and vitamin E. Altern Ther Health Med. 2005;11(1):14-17. 62. Rossouw JE, Anderson GL, Prentice RI, et al. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33. 63. Ridker PM. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J. 2004;148:S19-S26. 64. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8):954-59. 65. Horton R. Interpretive medicine: a manifesto. Md Med J. 1997;Suppl:5-8. 66. Ibid. 67. Ibid. 68. Evidence-based medicine. A new approach to teaching the practice of medicine. Evidence-Based Medicine Working Group. JAMA. 1992;268(17):2420-25. 69. Kuhn TS. The structure of Scientific Revolutions. Chicago, Ill: University of Chicago Press; 1970. 70. Evidence-based medicine. A new approach to teaching the practice of medicine. Evidence-Based Medicine Working Group. JAMA. 1992;268(17):2420-25. 71. Ibid. 72. Sackett, DL. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312:71-72. 73. Weel CV, Knottnerus JA. Evidence-based interventions and comprehensive treatment. Lancet. 1999;353:916-18. 74. Greenhalgh T, et. al. Learning in Practice. BMJ. 2003;326:142-45. 75. Bland, J. Alternative therapies—a moving target. Altern Ther Health Med. 2005;11(2):2-4. 76. Jonas WB. Researching alternative medicine. Nat Med. 1997;3(8):824-27. 77. Dossey L. A journal and a journey. Altern Ther Health Med. 1995;1(2):6-9. 78. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22(8):633-58. 79. Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia. 1996;16:257-63. 80. Mauskop A, Altura BT, Cracco RQ, Altura BM. Intravenous magnesium sulfate rapidly alleviates headaches of various types. Headache. 1996;36:154-60.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 46

Section II Principles of Functional Medicine

01 )2 (c

0

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e in ic

Chapter 6 Functional Medicine is Science-Based DeAnn Liska, PhD torial nature of chronic conditions, along with the emerging understanding of just how biochemically unique we all are, has collided with our model of basing clinical decisions primarily, if not solely, on a narrow definition of science. In Chapter 5 of this book, a very detailed and carefully documented analysis of the history and limitations of the current scientific research model was presented. Here, as we open our discussion of the principles of functional medicine, we will look at how one of the basic principles—that functional medicine is science based—plays out against that background. Functional medicine embraces the challenge of incorporating the newest scientific literature into its model of clinical care; advances in our understanding of fundamental physiological and biochemical processes can only enhance the clinician’s ability to treat patients with complex, chronic disease. Science is a critical tool for improving our understanding of the underlying clinical imbalances that lead to disease, and also a lens through which we can examine, describe, and adapt to the biochemical individuality of each patient. It is by understanding these imbalances that clinicians can help patients change the course of a disease. Therefore, a functional medicine practitioner must stay abreast of the current literature and be willing to challenge beliefs and current dogma. Functional medicine does not identify a single goldstandard method for considering something relevant or useful. Functional medicine practitioners incorporate many different sources of scientific information into the medical decision-making process: basic science, clinical experience, and the principles explored in this section are all important elements in the model. Using this approach requires a paradigm shift from the focus

(c

Introduction

)2

Lewis Thomas, the eminent physician essayist, called medicine “the youngest science” in his 1983 book of the same title. He observed at that time that such discoveries as antibiotics and the structure of DNA had made medicine more of a science, in which it could conduct experiments that test hypotheses about disease-causing agents and their curative interventions.1 He clearly identified the 20th century promise of the “science of medicine”— suggesting that we would not only have absolute answers to what causes disease and dysfunction, but we would also be able to “cure” disease. Indeed, the 20th century did see an influx of new technologies, new pharmaceuticals, and a deeper understanding of the biochemical underpinnings of disease. Furthermore, the promise of the “cure” has been enhanced by such findings as the frank vitamin deficiency diseases that are cured by nutrient repletion and the bacterial-based infectious diseases that can be eradicated by antibiotic treatment.2 Western medicine, in particular, is driven by technological advances and built upon the notion that everything that is relevant can be tested, proved (or disproved), and, with those results, a direct solution can be found. However, this new “science of medicine” has not been able, so far, to stem the rising pandemic of chronic disease. Likewise, scientific literature is accumulating more and more evidence that the promise of directly curing conditions such as rheumatoid arthritis, type 2 diabetes, cancers, and Alzheimer’s with a simple approach is not realistic. Moreover, the influx of new scientific information over the past several decades has continued to increase, while the ability of the average clinician to review that information and understand its relevance to a real-life patient is limited by time constraints and the sheer volume of material. The multifac-

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 49

Section II Principles of Functional Medicine of the late 20th century—that there is a single valid model for useful evidence—to the broader view that all the relevant science and information should be reviewed and understood. Overall, that’s the mission of this text—to help all of us make that leap to a new approach, wherein science and evidence in many forms are valuable to an innovative and clinically relevant model of care.

alter their response to exogenous hormones, when compared to younger women.6,7,8 Testing a single, defined intervention is, however, different than managing a patient with one or more chronic, complex, multifactorial conditions. A comprehensive approach to preventing and treating such conditions has not been amenable to study through the RCT model. Moreover, most often, a statistically significant, “successful” therapy is effective in barely more than 50% of patients.9,10,11,12 Even if the therapy is highly successful in a trial, studies indicate that patients in randomized controlled trials are often not typical of those seen in clinical practice.13,14 (Indeed, with data indicating that adverse drug reactions from properly prescribed drugs rate as the fourth most common cause of death in hospitalized patients, consumers, government agencies, and practitioners are often left to question whether medicine does more harm than good.15) In 2002, David Brown asserted in a Washington Post article that “Evidence-based medicine is likely to transform the entire field.”16 The actual definition of EBM varies, but the Centre for Evidence-Based Medicine at the University of Toronto defines it as “the integration of best research evidence with clinical expertise and patient values.”17 Much of the literature about EBM, however, has centered on how best to score the evidence, creating a hierarchy in which some evidence has great value and other evidence has much less value. Although the definition of EBM includes the words “clinical expertise” and “patient values,” the evidence base used is primarily, if not exclusively, drawn from RCT data. This focus on finding the “best” data often disregards the needs of the individual patient. For example, in a 1997 discussion on evidence-based disease management published in JAMA,18 the relevant skills for employing EBM were described as “precisely defining a patient problem, proficiently searching and critically appraising relevant information from the literature, and then deciding whether, and how, to use this information in practice.” Not only does this description focus on “precisely defining a patient problem,” which is often difficult to do for multifactorial, complex conditions, but the implication that the “evidence” comes primarily (or only) from the literature directly “relevant” to that problem. The web-like nature of physiological processes seems a misfit in this type of evidence model.

Science and Evidence-based Medicine (EBM)

)2

(c

The emergence of the scientific method as central to medicine has changed the face of health care. Clinical trials have become the primary method of establishing medical benefit. The randomized, placebo-controlled, double-blind clinical trial (DB/PC RCT) has come to dominate the field. Without data from an RCT showing a statistically significant effect, an intervention is considered unproved, which many take to mean “not beneficial.” This has led to the attempt to find the “best” medicine from the “perfect” data: an evidence-based approach to medicine. Certainly, the testing of many approaches that were in common practice has made a strong and highly beneficial impact on medical practice. For example, estrogen replacement therapy (ERT) was considered a standard practice for decades. Maintaining estrogen levels in women over 50 at levels similar to those for younger women was thought to be beneficial, and early observational studies suggested that the benefit extended to the cardiovascular system. However, more recent investigations of ERT, utilizing the RCT, did not support the findings from those early observational studies, indicating instead that some women on ERT may be at increased risk for thrombotic events and stroke, especially within the first two years of beginning ERT.3,4 The trials that showed increased risk of ERT generally included postmenopausal women who were not exhibiting symptoms of the menopause transition, such as hot flushes, whereas the benefit of exogenous hormones was observed in studies with younger women. As noted by Rosano et al.,5 “several biological reasons may have contributed to the divergent findings from observational studies and RCTs.” Older women may have fewer estrogen receptors, or a different pattern of expression of these receptors, and also may be more susceptible to inflammation and thrombotic events, factors that could

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 50

Chapter 6 Functional Medicine is Science-Based a psychiatrist, and had several courses of antibiotics, she found an internist who again changed her antibiotics and, eventually, her strep appeared to improve. Her other symptoms, including debilitating, unremitting fatigue, did not. In her own words:

While the goal of EBM is laudable (to improve clinical practice by using interventions that have stood the test of thorough investigation), the actual practice is not clear. In a study on why general practitioners do not implement so-called “best evidence” from research studies, Freeman and Sweeney19 found the doctorpatient relationship to be particularly relevant. “Evidence is not implemented in a simple linear way, as some definitions of evidence based practice imply, but in an evolving process whereby reciprocal contributions from the doctor and the patient over time influence how evidence ultimately is used.” The following excerpts from a 1997 editorial in the British Medical Journal clarify some of the issues that are still with us today:20

)2

(c

I kept returning to see this doctor, hoping she could find some way to make me feel better. She couldn’t, and I could see that it was wearing on her. In September, I was so weak that on a ride over to her office I had to drop my head to my knees to avoid passing out. When the nurse entered, I was lying down, holding my head, the room swimming around me. She took my blood pressure: 70/50. The doctor came in. She wouldn’t look at me. “I don’t know why you keep coming here,” she said, her lips tight. I told her that I felt faint and asked about my blood pressure. She said that it was normal and left, saying nothing else. She then went to see my mother, who was in the waiting room. “When is she going to realize that her problems are all in her head?” the doctor said. I returned home, lay down, and tried to figure out what to do. My psychiatrist had found me to be mentally healthy, but my physicians had concluded that if my symptoms and the results of a few conventional tests didn’t fit a disease they knew of, my problem had to be psychological. Rather than admit that they didn’t know what I had, they made a diagnosis they weren’t qualified to make. Without my physician’s support, it was almost impossible to find support from others. People told me I was lazy and selfish. Someone lamented how unfortunate Borden was to have a girlfriend who demanded coddling. Some of Borden’s friends suggested that he was foolish and weak to stand by me. “The best thing my parents ever did for my deadbeat brother,” a former professor of his told him, “was to throw him out.” I was ashamed and angry and indescribably lonely.

0

01

We face the problem that criteria for internal and external validity (that is, clinical applicability) may conflict. Clinical studies are usually performed on a homogeneous study population and exclude clinically complex cases for the sake of internal validity. Such selection may not, however, match the type of patients for whom the studied intervention will be considered … . Studies on the effectiveness of clinical care may also not easily attain internal validity. An example is the evaluation of the many interventions that cannot be blinded, such as many non-pharmacological procedures … . Thus, in seeking internally valid evidence that is externally valid for clinical practice, we need “medicine based” studies that include, not ignore, clinical reality and its inherent difficulties … . In reviewing clinical evidence we must be reluctant to adopt too detailed criteria for good and bad science and to freeze criteria for validity. Study methods themselves need to evolve.

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Science and the Patient-centered Approach

in

Hillenbrand’s condition had begun suddenly, with symptoms assumed to be from food poisoning. These were soon followed by swollen lymph nodes and a persistent strep infection. At the time, chronic fatigue was not recognized as a diagnosable condition by mainstream medicine. There was no “evidence base” to explain her condition, but there was science. Patients having symptom complexes consistent with what we now call chronic fatigue syndrome have been described in the medical literature for centuries and have, at various times, been categorized with names such as post-viral fatigue and chronic Epstein-Barr virus (EBV) syndrome.22 In fact, a few years before Hillenbrand first experienced symptoms, Behan et al.23 published an analysis of 50 cases of post-viral fatigue and concluded: “A metabolic disorder, caused by persistent virus infection

e

Studying the body’s function from a scientific perspective is a demanding process; bringing in the patient’s perspective makes it even more complex. To bring these issues into clearer focus, we will examine a real-life case that is a matter of public record.

A Case of Chronic Fatigue Syndrome In an essay titled “A Sudden Illness,” Laura Hillenbrand, author of the best-selling book Seabiscuit: An American Legend, describes her continuing battle with chronic fatigue syndrome, which began in 1987 before the syndrome was accepted by mainstream medicine.21 One of her symptoms was a chronic strep infection. After a year in which she had seen several internists and

51

Section II Principles of Functional Medicine and associated with defective immunoregulation, is suggested as the pathogenetic mechanism.” The year in which her symptoms began, Buchwald, Komaroff and colleagues published a report in which they found abnormalities in immune cells of chronic fatigue patients.24 In March of 1988, the first working definition of chronic fatigue syndrome was published in the Annals of Internal Medicine.25 While Hillenbrand was experiencing debilitating symptoms, being treated only with antibiotics for her chronic strep, and feeling very much alone, the literature available at the time actually showed that she was, in fact, not alone. When faced with a patient such as Hillenbrand (one of the “walking wounded,” so familiar to clinicians everywhere), where the research base does not yet offer clear answers, it is important to remember that science is still there to help. Exploring the underlying physiological pathways that appear to be involved would be a functional medicine approach. The therapeutic plan could then be designed to support the healthy, balanced function of those pathways, while also removing any known or postulated triggers (e.g., strep infection) that are acting upon those pathways to exacerbate symptoms. A patient may not be “cured,” but can have improved function. A clinician may not know the answers, but can have a place to start. In this particular case, the association with immune function was deducible from the symptom pattern experienced by Hillenbrand, as well as from the available literature. The science was there in terms of indicating that a possible connection between these symptoms and immune dysfunction could exist. Unfortunately, to this date, an indisputable evidence base describing the underlying immune imbalances in chronic fatigue syndrome is still not available. Waiting for that level of evidence before treating the patient would leave many a patient still hearing their clinician say, “I don’t know why you keep coming here.” Data are accumulating to show how complex these chronic conditions are. Not only do syndromes such as chronic fatigue and fibromyalgia have significant overlap in symptoms and biochemistry, but gene expression profiles indicate that differential expression patterns can be identified; these conditions may well represent sub-groups of specific metabolic imbalances.26,27,28 In fact, in 1996, the Royal Colleges of Physicians, Psychiatrists, and General Practitioners provided this summary of the evidence:29

Chronic Fatigue Syndrome (CFS) is not a single diagnostic entity. It is a symptom complex which can be reached by many different routes. The conceptual model of CFS needs to be changed from one determined by a single cause/agent to one in which dysfunction is the end stage of a multifactorial process. Although it is important to recognize the role of factors that precipitate the condition, greater understanding is required of factors that predispose individuals to develop the illness, and those that perpetuate disability.

)2

(c

Simply stated, not every CFS patient will be the same and the focus on underlying pathways is now being seen as the way to medically manage CFS. In the functional medicine approach, the focus on those sciences that elucidate underlying pathways and clusters of symptoms is absolutely critical to prevention and treatment of complex, chronic disease. These “functionalities” in physiology and biochemistry help us to identify varying patterns within a given diagnostic category and undertake a search for common underlying factors in patients with a number of different debilitating symptoms, conditions, or diseases.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Applying Science in Clinical Practice

e

in

ic

ed

Many evidence-based evaluations target whether a single intervention works. This is a different question than evaluating whether a patient improves in a clinical practice. Therefore, although published research is helpful as a guide, it is often not directly reflective of what a clinician faces when working with an individual patient. Moreover, the development of research methodologies has focused heavily on single-agent interventions, such as pharmaceuticals. Many of the integrative approaches that take into account the entirety of a patient’s experience (e.g., diet, lifestyle, environmental exposure) are not amenable to being studied using these methodologies. As stated in a discussion in The Lancet:30 Drug interventions have been studied more extensively than non-pharmacological interventions, because of requirements for drug registration and the technical and methodological difficulties in the design of RCTs for non-drug interventions. This situation is a particular problem for general practice. According to the principle of “maximum effect, minimum resources,” patients’ education, diets, and lifestyles are, in theory, particularly attractive. Generally, such interventions cannot be assessed under adequately masked conditions, so “contamination” of trial groups will threaten internal validity. So, it is not surprising that a literature search fails to find convincing evidence of effectiveness of avoidance of house-

52

Chapter 6 Functional Medicine is Science-Based deepening our understanding about the complexities of life and the various effects of our actions. Functional medicine relies on science and incorporates it deeply into patient-centered care in an analytical and integrative model.

dust mite allergens. However, absence of proof of effect is different from proof of lack of effect. Even if there is insufficient clinical research available to support its case, exposure to allergen has a key role in the pathophysiology of airways inflammation. Consequently, the concept of asthma makes avoidance of allergens a logical measure even in the absence of direct support from a RCT.

References

Advances in our understanding of how the body functions at the most basic level are integral to functional medicine. Science-based functional medicine, then, is the incorporation of science within the context of the patient’s experiences and biochemical individuality. It is not a prescription that can be tested in a simple RCT; it is not a clinical algorithm directing that each patient with condition X is treated with a clearly defined therapy. Functional medicine urges the practitioner to become adept at the art of reviewing the best and most recent scientific research, both basic and clinical sciences, as part of the process of developing a personalized approach for a patient-centered practice of medicine. As stated by Aaron and Buchwald:31

1. 2.

3. 4.

)2

(c

5.

0

01

6. 7.

9.

Finally, describing an illness as “unexplained” should not be taken to mean “unexplainable” or “imaginary.” Researchers and providers involved with patients who have unexplained clinical conditions would do well to remember Osler’s statement that the study of medicine “begins with the patient, continues with the patient and ends … with the patient.”

Summary

10. 11.

12.

Functional medicine looks at the emerging science, and digs deep into the way these findings influence our ideas about how the body functions at the physiological and biochemical level. Functional medicine uses the core clinical imbalances as the matrix upon which to organize the science, and includes basic science, clinical trials, case reports, and clinical experience (anecdotal data) to understand a patient’s situation. In functional medicine, clinical trials are one piece of the puzzle, not the only source of evidence. Functional medicine requires an active interaction with the scientific literature. It requires a clinician to keep up with new findings in human physiology and biochemistry; it requires a clinician to integrate the current findings into the model of how problems begin and where the imbalances may lie; it requires a thought process that cannot be directly correlated to an evidence-scoring system. It requires science to continue

13.

14.

15.

16.

17. 18. 19. 20. 21.

53

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

8.

Thomas L. The Youngest Science. New York:Viking Press. 1983. Liska DJ, Bland JS, Medcalf D. Evaluating the benefits of functional foods. In: Yalpani M, ed. New Technologies for Healthy Foods & Nutraceuticals. Shrewsbury, MA: ATL Press. 1997:287-300. Staren ED, Omer S. Hormone replacement therapy in postmenopausal women. Am J Surg. 2004;188(2):136-49. Samsioe G. HRT and cardiovascular disease. Ann NY Acad Sci. 2003;997:358-72. Rosano GM, Vitale C, Lello S. Postmenopausal hormone therapy: lessons from observational and randomized studies. Endocrine. 2004;24(3):251-54. Ibid. Harman SM, Brinton EA, Clarkson T, et al. Is the WHI relevant to HRT started in the perimenopause? Endocrine. 2004;24(3):195-202. Wagner JD, Kaplan JR, Burkman RT. Reproductive hormones and cardiovascular disease mechanism of action and clinical implications. Obstet Gynecol Clin North Am. 2002;29(3):475-93. Connor S. Glaxo chief: Our drugs do not work on most patients. Interview with Allen Roses, worldwide vice-president of genetics at GlaxoSmithKline (GSK), December 10, 2003. Accessed at http:// www.ghchealth.com/glaso-chief-our-drugs-do-not-work-on-mostpatients.html on August 14, 2005. Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nat Rev Genet. 2003;4(12):937-47. Nicol MJ. The variation of response to pharmacotherapy: pharmacogenetics—a new perspective to ‘the right drug for the right person’. Medsurg Nurs. 2003;12(4):242-49. Kirsch I. The emperor’s new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevention & Treatment. 2002;5:1-11. Geyman JP. Evidence-based medicine in primary care: an overview. J Am Board Fam Pract. 1998;11:46-56. Zarin DA, Young JL, West JC. Challenges to evidence-based medicine: A comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network. Soc Psychiatry Psychiatr Epidemiol. 2005;40:27-35. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200-05. Brown D. First, Do the Trials. Then, Do No Harm. http://www. washingtonpost.com/ac2/wp-dyn/A38313-2002Aug2?language= printer Accessed 8/15/02. What is EBM? http://www.cebm.utoronto.ca/intro/whatis.htm Accessed January 8, 2005. Ellrodt G, Cook DJ, Lee J, et al. Evidence-based disease management. JAMA. 1997;278:1687-92. Freeman AC, Sweeney K. Why general practitioners do not implement evidence: qualitative study. BMJ. 2001;323:1-5. Knottnerus A, Dinant GJ. Medicine based evidence, a prerequisite for evidence based medicine. BMJ. 1997;315:1109-10. Hillenbrand, L. A Sudden Illness. From: The New Yorker. July 7, 2003.

Section II Principles of Functional Medicine

)2

(c

22. Clauw DJ, Chrousos GP. Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation. 1997;4:134-53. 23. Behan PO, Behan WM, Bell EJ. The postviral fatigue syndrome—an analysis of the findings in 50 cases. J Infect. 1985;10:211-22. 24. Caligiuri M, Murray C, Buchwald D, et al. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol. 1987;139:3306-13. 25. Holmes GP, Kaplan JE, Gantz NM, et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med. 1988;108:387-89. 26. Aaron LA, Buchwald D. A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med. 2001;134:868-81. 27. Powell R, Ren J, Lewith G, et al. Identification of novel expressed sequences, up-regulated in the leucocytes of chronic fatigue syndrome patients. Clin Exp Allergy. 2003;33:1450-56. 28. Vernon SD, Unger ER, Dimulescu IM, et al. Utility of the blood for gene expression profiling and biomarker discovery in chronic fatigue syndrome. Dis Markers. 2002;18:193-99. 29. Wessely S. Chronic fatigue syndrome. Summary of a report of a joint committee of the Royal Colleges of Physicians, Psychiatrists and General Practitioners. J R Coll Physicians Lond. 1996;30:497-504. 30. van Weel C, Knottnerus JA. Evidence-based interventions and comprehensive treatment. Lancet. 1999;353:916-18. 31. Aaron LA, Buchwald D. A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med. 2001;134:868-81.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 54

Section II Principles of Functional Medicine

)2 (c

0 01

e in ic ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

47

)2 (c

0 01

e in ic ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Chapter 7 Biochemical Individuality and Genetic Uniqueness  

Functional Medicine and Biochemical Individuality: A Paradigm Shift in Medicine Development of the Knowledge Base in Biochemical Individuality

)2

(c Functional Medicine and Biochemical Individuality: A Paradigm Shift in Medicine

01

Mark Hyman, MD, Sidney MacDonald Baker, MD, and David S. Jones, MD

0

serve to illustrate the unnecessary delays common to incorporating new discoveries into practice: • When Edward Jenner developed the therapeutic technique of vaccinating against smallpox in 1797, the Royal Society of London scolded him for risking his reputation on something “so much at variance with established knowledge, and withal so incredible.” • When the Hungarian physician Ignaz Semmelweis discovered that physicians’ unwashed hands caused fatal infections among new mothers at the University of Vienna in the 1850s, he lost his academic position, dying disgraced. • When the American writer and physician Oliver Wendall Holmes published an article on the prevention, through hand washing, of “childbed fever,” his observations brought him bitter abuse. • Alexander Fleming discovered penicillin in 1929. But there was a delay of 12 years before he, W.H. Florey, and E.B. Chain first used it therapeutically.3 Together, with their scientific teams, they changed the concept of anti-biotics. • Kilmer McCully, the prodigy pathologist from Harvard, first proposed the role of folate deficiency and the resultant homocysteinemia connection to cardiovascular disease in the late 1960s.4 His hypothesis caused his banishment from the pathology department at Harvard Medical School and Massachusetts General Hospital because of the clear conflict his theory represented to the then-dominant

Introductioni

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Discovery consists of seeing what everybody has seen and thinking what nobody has thought. —Albert Szent-Györgyi, 1937 Nobel Laureate in Physiology and Medicine: the scientist who isolated vitamin C

e

in

ic

ed

In the Structure of Scientific Revolutions,1 Thomas Kuhn analyzed the process of changing scientific paradigms. He described how in each discipline of science, new advances and theories are slow to be adopted but, once accepted, they assume the position of “normal science.” They become foundational to collective beliefs and theories in a new iteration of scientific leaders. Overturning “normal science” often requires decades of accumulated evidence to succeed against the old theories that wane as their ability to explain new data is eroded. Medicine is replete with examples of “normal science” becoming obsolete in retrospect. With change, the newer theories that have been ignored—not because of lack of merit but because of their poor fit with the established paradigm— clearly present a more robust model of explanation.2 There are many examples of resistance to change in the history of medicine. A few medical vignettes can i

This part of Chapter 7 was adapted by David Jones, MD, from two articles: Hyman M. Paradigm shift: The end of “normal science” in medicine; Understanding function in nutrition, health, and disease. Alt Ther. 2004;10(5):10-93. Baker SM. The medicine we are evolving. Integrative Med. Dec 2002/Jan 2003;1(1):14-15. Many thanks to Doctors Hyman and Baker, and to both journals, for permission to adapt these publications.

55

Section II Principles of Functional Medicine and surgery.17 The cost attributed to the harm caused by the chaos in our medical system has been estimated at over $200 billion. There are other significant problems endemic to our medical system and conventional medical paradigm: 1. The randomized controlled trial (RCT) is fundamentally ill suited to the assessment of lifestyle and nutritional interventions, individualized therapies, and long-latency deficiency diseases.18 (This topic is addressed, from a variety of perspectives, in both Chapter 5 and Chapter 6.) 2. The lack of publication of negative medical trials19 promotes a positive bias in the medical literature, suggesting an unrealistic proportion of successes and supporting the primacy of pharmacological interventions. 3. Direct-to-consumer pharmaceutical marketing,20,21 and heavy marketing of off-label uses of medications to physicians, including conventional hormone replacement therapy,22 create misinformation and encourage inappropriate prescribing practices by healthcare providers.23,24 4. The many financial conflicts of interest25,26 inherent in the practice of funding research by private industry skew the emphasis on what should be studied and lead to suppression of conclusions that don’t suit the funding source.27,28,29,30 One of the well-known examples of the latter was the research-based comparison between generic thyroxine and Synthroid. The pharmaceutical company prevented the publication of the study that it had funded because the outcome was not favorable to the trade name drug.31,32 With the exception of the National Institutes of Health and some private foundations, most of the research agenda is set by the pharmaceutical industry. 5. The funding, control and orchestration of most postgraduate education for physicians by the pharmaceutical industry33,34 lead to a clear bias for the primacy of pharmacologic interventions.35,36,37

cholesterol model of atherosclerosis. Fortunately, he endured, working in relative obscurity at a small Veterans Administration hospital in Rhode Island, eventually vindicated by research from Europe. His model, in the current context of cardiovascular disease as primarily an expression of inflammation, has added to our understanding of metabolic and immunological connections to the development of atheromatous plaque, as well as other diseases associated with aging.

)2

(c

Medicine is also replete with discarded therapies that were well accepted at the time, such as the removal of the colon or all the teeth to treat chronic disease, or, more recently, low-fat diets for weight loss and the prevention of cardiovascular disease,5 and/or conventional hormone therapy for prevention of heart disease in postmenopausal women.6,7 We are again at the edge of a major transitional period.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Chronic Disease and the Failure of the Current Medical Paradigm

e

in

ic

ed

One of the most compelling, current problems in medicine is the failure of the conventional model of medical diagnosis and treatment to successfully address the burden of chronic disease that affects 125 million Americans in our society. Our current approach does not attempt, in a systematic manner, to effectively diagnose and treat the underlying causes of chronic disease, found in the complex interaction of genes, lifestyle, and environment. As a nation, we spend $1.6 trillion on health care each year. This represents 15% of our gross national product (GNP) or approximately $5,000 per person per year, or more than double the percent of GNP spent by any other nation on health care. Despite this, we are 12th out of 13 industrialized nations in 16 major indicators of the health status of a population, such as life expectancy and infant mortality.8,9 In fact we are 27th in life expectancy; Cuba is 28th. Yet that may not be the most problematic issue. Recent data point to the dangers of the medical care that evolves from our current paradigm. Our own healthcare system can do great harm. Our system of disease management has been estimated to be anywhere from the 1st to the 3rd leading cause of death in our hospitalized patient population,10 resulting from hospital infections,11,12 atypical drug reactions,13 bedsores,14 medical errors,15 negligence,16 unnecessary procedures,

In addition, recent research suggests that more of the same care is not necessarily better. In areas where there are more physicians, there is a higher cost of care. There is also less patient satisfaction and worse outcomes than comparable areas with a lower cost of care.38,39 Studies of compliance with agreed-upon standards for care and prevention show that, in spite of higher costs of medical

56

Chapter 7 Biochemical Individuality and Genetic Uniqueness care within the U.S., these standards are not met. There is a frequent lack of implementation of clinical science to clinical practice. For example, only 40% of patients receive aspirin after myocardial infarction.40 A recent study of adults in 12 metropolitan areas found that only 54.9% of patients received the recommended preventive, acute, or chronic care, using 439 indicators in 30 acute and chronic conditions. The authors conclude, “The deficits we have identified in adherence to recommended processes for basic care pose serious threats to the health of the American public. Strategies to reduce these deficits in care are warranted.”41

Many professionals within conventional medicine feel that the most important single reason for the deficits in our healthcare system is that we are locked into an old paradigm in medicine, “normal medicine.”42,43 The model we use to diagnose and treat disease is based on “normal” science; the single-invader, single-disease, and single-drug model of medicine. While practitioners of the healing arts are schooled in the basic sciences of anatomy, physiology, biochemistry, cell biology, genetics, epidemiology, pathology, and pharmacology—each of which encompasses its own science—no body of knowledge exists within the dominant medical culture that can be construed as “medical science.”44

(c

)2

The Fallacy of Misplaced Concreteness Lara Pizzorno, MA Div, MA Lit, LMT Alfred North Whitehead’s “fallacy of misplaced concreteness” is essentially a more logically rigorous statement of the common saying that “we err when we mistake the map for the territory.” When humans interact with the world, we interpret the full experience via abstraction; we generalize from the specific observation (the “concrete”) to create an idea. This is essential and logically acceptable, so long as we do not equate, and therefore significantly diminish, the actual experience with our working conception of it. Unfortunately, we often do confound the concrete experience with the abstract idea, assuming our abstractions equal the totality of the reality. The tunnel vision which results prevents us from seeing more of what is actually before us. Science is not free of this error, with the result that new insights are typically met with hostility, and their application and benefits suppressed an average of 50 years before joining the ranks of what is considered the “standard of care.” As Whitehead cautions, “It is impossible to overemphasize the point that the key to the process of induction [the sine qua non of scientific reasoning], as used either in science or our ordinary life, is to be found in the right understanding of the immediate occasion of knowledge in its full concreteness … . We find ourselves amid insoluble difficulties when we substitute for this concrete occasion a mere abstract … . ”* Avoiding the fallacy of misplaced concreteness is not a task to be underrated by even the most scientifically adept. Such assumptions “appear so obvious that people do not know what they are assuming because no other way of putting things has ever occurred to them.” Whitehead reminds us that “Almost all really new ideas have a certain aspect of foolishness when they are first produced,” possibly due to the fact that we form our systems of thought “by the rough and ready method of suppressing what appear to be irrelevant details. But when we attempt to justify this suppression of irrele-

01

0

vance, we find that, though there are entities left corresponding to the entities we talk about, yet these entities are of a high degree of abstraction.” Whitehead identified this problem as the primary obstacle to the advancement of science; it occurs when we allow our paradigm to limit our powers of observation. In medical terms, the fallacy of misplaced concreteness appears in the form of the abstract entities called “diseases,” which are simply a constellation of symptoms that often appear together, not an actual entity. While grouping symptoms in this manner is convenient, if the abstraction controls the interaction we have with the patient, we hamper our ability to see the individual who exhibits any symptom or grouping of symptoms (disease) in his or her unique way. In addition, by narrowing our focus to an abstract entity we call “migraine” or “irritable bowel syndrome” or “diabetes,” we limit our inspection of the individual’s dysfunctions to a predefined set of details, thus potentially missing what may be crucial for that person. Scientific studies that regress to the mean exemplify this fallacy. The data based on the “representative sample,” having lost all the specificity that defines a real human being, are then used to provide recommendations most applicable to an equally “representative” individual, in other words, to no one at all. Such findings tell us everything we need to know about someone who doesn’t exist. Functional medicine offers us both an awareness of how the fallacy of misplaced concreteness operates to limit the effectiveness of medicine, and a way to cut through it. Only the integration of (necessarily) abstract science with concrete individual specificity—the patientcentered, individualized approach that is the hallmark of functional medicine—will enable us to provide a much more accurate and effective assessment.

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

*All quotations from Whitehead AN. Process and Reality.

57

Section II Principles of Functional Medicine • The inquiry as to health rests first on the naming of the patient’s disease. • Treatment is prescribed for the disease.

We have yet to embrace the new paradigm that, for the first time, allows us to personalize medicine. We have the opportunity to focus on optimizing function and enhancing health by understanding the complex high-order functioning of the human being. The new paradigm allows us to remediate disease, not by symptom suppression, but by assessing and treating the cause of dysfunction and illness. Van Ommen, in “The Human Genome Project and the Future of Diagnostics, Treatment and Prevention,” published in The Lancet in 1999, foretells this paradigm transition in medicine:

In the past, the legacy and momentum of our focus on acute illness have permitted us to remain diseasefocused long after chronic illness replaced acute illness as the dominant problem in our modern, industrialized, hygienic society.46 The medicine we are developing begins to address the following linguistic, statistical, and logical errors of the present paradigm of conventional medicine: 1. The concept that diseases are entities and can cause symptoms is entirely without scientific support. It is a linguistic error that forges a false map in the imagination of professionals and lay people.47 2. The idea that each patient’s diagnostic and treatment options can be based on determinations of averages is a misuse of statistics when it serves as a diagnostic and therapeutic guide for each unique individual. 3. The maxim that assumptions to explain an event should not be multiplied beyond necessity (Occam’s razor) is the logical partner of the one-disease, onetreatment approach of mainstream medicine, particularly in the framework of chronic illness. 4. Medicine is the only field claiming a scientific basis in which general systems theory48—i.e., that everything is interconnected—has not become the acknowledged basis for inquiry. Linear causality remains the accepted basis for medical etiology.

)2

(c

The combination of large-scale gene-expression analysis with pharmacological and nutritional studies will ultimately allow the stratification of individuals by their genetically determined abilities for drug and nutrient metabolism. Tailor-made treatments and lifestyle regimens will improve the effectiveness of therapies and reduce side effects. This will apply equally to monogenic disease and more complex gene-environment interaction disorders, like cardiovascular disease, cancer, hypertension, arthritis, migraine, epilepsy, Parkinson’s disease, and Alzheimer’s disease.45

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

How Do We Change Paradigms?

ed

In order to move today’s model toward the future, we need to think differently. This functional school of thought does not deny the usefulness to the patient and physician of diagnostic groups that allow us to identify in some codified way “what the patient has.” We are careful to keep in mind, however, that a diagnosis is an idea we form about groups of people and properly belongs to the group, not to an individual. Making a diagnosis in the realm of chronic illness—such as the many conditions of chronic inflammation whose names end in “itis,” as well as autism, schizophrenia, depression, anxiety, cardiovascular disease, and a host of other recognized diseases—is for us not the end of a diagnostic road, but only the first step. The fundamental subject of medical concern is the human individual. The logic of inquiry rests on two questions of need: • Does this person have an unmet individual need? • Does this person need to be rid of something toxic, allergic, or infectious?

e

in

ic

Despite the crumbling of the healthcare system around us,49,50 we have held onto this system of differential diagnosis, biochemical homogeneity, and pharmaceutical therapy as the answer to most chronic lifestyle and long-latency nutritional deficiency diseases. However, there is an alternative model for organizing and perceiving the problems in modern terms. There are a number of organizing principles and themes that underlie nearly all disease (see Chapter 2). This new medical paradigm emerges from the basic and clinical sciences literature. The exploration of the needed shift from our current model to the origins of illness and the maintenance of health, as well as the identification of appropriate investigations, interventions, and therapies for chronic, complex illnesses, both require a new intellectual architecture. The explication of a functional methodology is the central mission for this textbook.

These principles are antithetical to the implicit emphasis of the current conventional medical paradigm, which could be described as follows: • The fundamental subject of medical concern is disease.

58

Chapter 7 Biochemical Individuality and Genetic Uniqueness

A New Paradigm: Understanding and Enhancing Function

is now less useful in understanding mechanisms and guiding innovative therapies in health and illness. Finally, we can move toward understanding and treating disease with a dynamic, functional model based on an intricate understanding of the nature of the interaction of the genome with the environment, especially in the field of nutrigenomics.55 The story of the role of nutrients in health and disease is a useful model to help us shift from a medical model based on pathology to one based on deviations from optimal function, with an understanding of the process of de-volution of health into chronic, complex illnesses. A fundamental change in perspective has occurred with the development of genomics, proteomics, metabolomics, and the evolution of nutrigenomics.56 Nutrigenomics is the use of nutrients of varying and sometimes high doses to influence gene expression, with the goal of not simply treating disease, but also of optimizing function.57 The development of the “-omics” and the applications of nutrigenomics are poised to change medicine forever from a pathology-based science to a function-based science.58

)2

(c

The science of medicine is perhaps the most frequently cited case of increasing specialization seeming to follow inevitably from increasing knowledge, as new cures and better treatments for many diseases are discovered. But as medical biochemical research comes up with deeper explanations of disease processes (and healthy processes) in the body, understanding is also on the increase. More general concepts are replacing more specific ones as common, underlying molecular mechanisms are found for dissimilar diseases in different parts of the body. Once a disease can be understood as fitting into a general framework, the role of the specialist diminishes. Physicians … may be able to apply a general theory to work out the required treatment, and expect it to be effective even if it has never been used before.51

0

01

There is much in medicine and science that we cannot perceive with our current way of seeing. A new framework and new organizational concepts are needed in a science with very few true “theories.”52 Linus Pauling remarked years ago that “although medicine is largely based on the sciences, it has not yet become a science.”53 We need a unifying theory of health and disease. We are only now on the verge of forming a clear picture of what that might look like. A theory can be defined as “a set of facts, propositions, or principles analyzed in their relation to one another and used, especially in science, to explain phenomena.”54 Scientific theory, unlike hypothesis, is most often the result of years of investigation. Medicine has come of age and we are at the transitional edge of development of an entirely different gestalt and theory of health and disease. The science of medicine today is maturing and the old concept of the single agent (bacterium) causing a single disease (infection) treated with a single molecule (antibiotic) is being replaced by our understanding of complex, higher-order functions. We are finally able to peer into the underlying mechanisms of disease and aging, illuminated by the light of genomics, proteomics, metabolomics, and nutrigenomics. Medicine is nearly ready to discard the old descriptive, phenomenological approach that emerged from the exigencies of medical practice in the early 20th century, where infectious disease was primary and the Pasteur model of outside invaders ruled. The organization of medicine into sub-specialties is an artifact of descriptive medicine that bears little relevance to biological principles. The current classification of diseases (ICD-9)

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Example of the New Paradigm: Nutrients Beyond Deficiency Diseases

e

in

ic

ed

The old paradigm of diagnosis and classification of diseases into organ system pathologies (corresponding fairly closely to medical specialties) becomes less meaningful in the light of our understanding of the basic mechanisms of dysfunction in the human body. One disease may have multiple causes, and one initiating factor may cause multiple diseases. Atherosclerotic cardiovascular disease (CVD) and celiac disease provide clear examples of this concept. We recognize cardiovascular disease by its pathology: atherosclerotic plaques. However, the development of plaques can be triggered by multiple factors. These include insulin resistance,59 folate deficiency and hyperhomocysteinemia,60 occult infections,61 heavy metal toxicity,62,63 inherited dyslipidemias, stress, and other factors that increase inflammation.64 The diagnosis and treatment of each of these antecedent conditions varies, and the success of medical therapy rests on making the proper assessment of the etiologic factors involved (and they are often multiple).65 Prescribing the classic low-fat diet, usually high in refined carbohydrates, along with a beta-blocker and a statin for CVD can—counter to expectation—actually

59

Section II Principles of Functional Medicine uation program ensued, looking for underlying mechanisms of dysfunction that could explain his disorders. With appropriate investigation, it was found that most of his diagnoses could be explained by something he was eating—gluten-containing foods—that caused the “many-headed hydra” of his inflammatory disorders.67,68 Tests confirmed the diagnosis of celiac disease, that had been missed for over 40 years. Within six months, he was off most of his medications, lost 25 pounds, and stabilized his blood pressure. He had no more symptoms of asthma, his bowel movements normalized, and his hair grew back. A 2002 review of celiac disease in The New England Journal of Medicine69 catalogued the myriad diseases that can be caused by immune-mediated gluten sensitivity, including anemia, osteoporosis, autoimmune diseases, thyroid dysfunction, schizophrenia, and psoriasis. Each of the patient’s conditions could have been triggered by multiple factors; but, for him, eating glutencontaining foods was the cause of his symptoms. His genetic susceptibilities required that he not eat a particular food protein in order to maintain health and prevent triggering his symptoms.

)2

(c

exacerbate the underlying problem in the patient with insulin resistance, or may miss entirely the key underlying mechanism (e.g., occult infection) in a different patient. Both are precursor conditions that can lead to the end point of CV dysfunction. Let’s illustrate this point with some patient stories. A 56-year-old patient with severe CVD, after interventions including two angioplasties and a CABG (coronary artery bypass graft), suffered a stroke. The evaluations and treatments he experienced prior to his stroke were considered “standard of care” for his diagnosis. However, with further evaluation after his stroke, through the lens of functional assessment, he was found to have a marked elevation of homocysteine (22 mmoles/liter with normal 6–8 mmoles/liter). He was tested genetically and found to have a specific genetic uniqueness, homozygous 677C to T polymorphism of MTFHR (methylenetetrahydrofolate reductase). This SNP (single nucleotide polymorphism) produces a variant enzyme that requires extraordinarily high doses of folate to facilitate coenzyme binding and MTHFR enzyme activity. His treatment plan focused on his genetic, proteomic, and metabolomic uniqueness. With appropriate nutrient intervention, his serum homocysteine equilibrated into the normal range, and he had no further demonstrable progression of his atherosclerosis.66 Another patient report exemplifies both the functional medicine methodology as well as the problems inherent in our current disease classification system. At 57, the patient described himself in general good health, eagerly planning a climb of Mt. Kilimanjaro. However, it was noted in his comprehensive workup that he took 15 different medications: prescriptions for colitis, asthma, alopecia areata, and hypertension. He was being treated in a standard manner by an internist, a gastroenterologist, a pulmonologist, and a dermatologist, all of whom made the correct “diagnosis” and provided the appropriate medications for each diagnosis. However, by filtering the patient’s signs and symptoms through the lens of underlying pathways, it was apparent that all of the patient’s “diseases” had an inflammatory component that manifested across organ systems (and speciality domains). None of his physicians had searched for the underlying mechanism, nor apparently considered this assessment (an across-systems inflammatory process) relevant. Their treatments were based solely on diagnoses relevant to their specialties. An eval-

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

The Diverse Roles of Nutrients

e

in

ic

ed

How we think about essential nutrients in general has been shaped by the vitamin deficiency diseases through which they were historically discovered. Vitamins are still defined by single deficiency diseases, such as pellagra, beriberi, scurvy, and rickets. That thinking is the basis for the current dietary reference intakes (DRIs), which recommend the minimum amount to prevent deficiency diseases, not the variable amounts needed by a polymorphic population for optimal health—sometimes hundreds of times the DRIs. Most physicians and consumers do not realize that DRIs are based simply on the minimum amount of a nutrient necessary to prevent an index deficiency disease. Applied clinical medicine has failed to recognize that nutrients are multifunctional substances with many roles. For example, in recent reviews,70,71 vitamin D has not only been implicated in prevention of rickets, but may have a role in treating or preventing heart disease, multiple sclerosis, polycystic ovary syndrome, depression, epilepsy, type 1 diabetes, and cancer. Folate not only prevents megaloblastic anemia, but also prevents neural tube defects, and is a key factor in preventing many cases of cardiovascular disease, dementia, depres-

60

Chapter 7 Biochemical Individuality and Genetic Uniqueness sion, and colon and breast cancer.72 Magnesium plays a role in over 300 enzyme reactions. Conventional thinking has been biased against the therapeutic use of vitamins in disease and has avoided the question of whether vitamins have a role in optimizing health.73 Study of nutrients over the long term has been complicated by the fact that the desired outcomes being tracked involve primarily the absence of problems rather than a defined dysfunction or remediation. This is in direct opposition to pharmaceutical agents, which are meant to alter pathology. Nutrients restore normal function; they do so by optimizing normal biological functions, mostly through their actions as coenzymes in biochemical reactions. We have approximately 30,000 genes. The most common type of variation in the human genome is the SNP, where a single base differs between individuals (being A instead of G, for example). SNPs occur about once every 1000 base pairs in the genome, making up the bulk of the 3 million variations found in the genome. The frequency of a particular polymorphism tends to remain stable in the population. (Genome information from genome.wellcome.ac.uk.) These SNPs create unique biochemical needs within the population. One-third or more of them affect coenzyme-binding sites for vitamins or nutrients, and therefore have a role in disease and dysfunction.74 Bruce Ames, in his landmark review of genetic variant enzymes and vitamin therapy, stated: “Our analysis of metabolic disease that affects cofactor binding, particularly as a result of polymorphic mutations, may present a novel rationale for high-dose vitamin therapy, perhaps hundreds of times the normal dietary reference intakes (DRI) in some cases.”75 Our current nutritional recommendations do not accommodate the broad and varied roles of nutrients in human biology. Also absent is the consistent clinical question: “What does this individual need that she or he has failed to get?” For example, the person may need to add vitamins, minerals, essential amino acids and essential fatty acids, accessory and conditionally essential nutrients.76 In many cases, a single nutrient may catalyze hundreds of biochemical reactions; suboptimal levels may lead to cellular and molecular dysfunction that is not recognized as a “deficiency” disease.77 The notion that higher doses may be needed for the optimal functioning of the total organism is not widely taught, despite new evidence that suboptimal nutrient status may contribute to “long-latency” defi-

)2

(c

ciency diseases that are epidemic, such as cardiovascular disease, cancer, osteoporosis, neurodegenerative disease, and immune dysfunction.78 Nutritional science has been seen as a secondary factor in health, something best left to the dietitian.79 Historically, nutrition was taught at the state agricultural schools in the department of home economics. The “real” science was, of course, being pursued by the scientists at the universities, in the departments of chemistry, physics, and biology. Until recently, physicians educated within this biased system of learning have abdicated their responsibility to study the science and practice of nutrition. Clear nutritional guidelines and consensus have been hard to achieve despite emerging evidence of importance. We need to cultivate different tools of assessment and research that allow us to better answer questions about nutrition and nutraceutical therapies.80

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Long-latency Disease: A Further Example of the New Medicine

e

in

ic

ed

Dr. Robert Heaney is a Professor of Medicine at Creighton University in Omaha, Nebraska. He won the 2003 E.V. McCollum Award of the American Society for Clinical Nutrition in recognition of his contributions to nutritional science and medicine, particularly in the field of osteoporosis and calcium physiology. In his E.V. McCollum Award lecture, he stated that the fundamental flaw in the establishment of recommended nutrient intakes is the presumption that if a nutrient intake is sufficient to prevent the index deficiency disease, then it is adequate for the optimal functioning of the total organism. He suggested that this narrow viewpoint overlooks two important facts. First, there are long-term consequences of lesser degrees of deficiency that may operate through similar mechanisms as the index disease; and second, there may be very different mechanisms involved in the development of long-latency deficiency diseases. In his lecture, he also tackled the difficult question of the adequacy of the standard research tools in this area of multi-factorial causality (see also Chapters 5 and 6, plus this chapter’s discussion, How Do We Change Paradigms?). He suggested the increased use of observational research to better infer causality in nutrition. The appropriate methodology for ferreting out the causal agents for the absence of a problem—research for benefit rather than harm—runs straight into the controversy surrounding the belief that double-blind RCTs are the

61

Section II Principles of Functional Medicine reducing osteoporotic fracture risk by one-third. Additionally, vitamin D has other roles. It has been shown that serum 25(OH) vitamin D concentrations are inversely associated with prostate and squamous cell cancers. The underlying mechanism for this effect appears to be as follows: people with low sun exposure or increased skin pigmentation are less able to make calcitriol (biologically active 1,25-dihydroxyvitamin D) within tissues in an amount adequate to control cell proliferation and reduce oncogenesis. Heaney hypothesizes that protective serum levels of 25(OH) vitamin D, for prevention of oncogenesis, may be much greater than current reference values. In that same paper, he describes the multiple conditions that may arise from a single nutrient deficiency, the multifunctional nature of nutrients, and the need for higher intakes for optimal health: “Inadequate intake of specific nutrients may produce more than one disease, may produce them by more than one mechanism, and may require several years for the consequent morbidity and mortality to be sufficiently evident to be clinically recognizable as ‘disease.’” He also suggests that the intakes of nutrients required to prevent the non-index diseases are often higher than required to prevent the index disease; for example, preventing osteoporosis requires four times the vitamin D needed to prevent rickets; similarly, preventing neural tube defects requires four times the intake of folate needed to prevent anemia.

gold-standard methodology for all scientific studies. He proposed that we can safely use the usual principles for causal inference from observational data in the nutritional context:81 … biological plausibility, correct temporal sequence, dose-response relations, experiments of nature found in inborn errors of metabolism and demonstration of causal connection in animal models. These principles are all well understood in a general way, and what … may have been lacking up till now was the conviction within the field of nutrition that long-latency deficiency diseases exist, that they are nutritional problems, and that the use of such inferential and investigative stratagems may be both appropriate and necessary.

)2

(c

In the paper he adapted from his E.V. McCollum Award Lecture (“Long-latency Deficiency Disease: Insights from Calcium and Vitamin D”),82 he lays the groundwork for a new conceptualization of the role of nutrients in health and disease. In effect, he turns nutritional science on its head by saying, “Prove to me that we don’t need higher levels of nutrients for health.”

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Because the current recommendations are based on the prevention of the index disease only, they can no longer be said to be biologically defensible. The preagricultural human diet, insofar as it can be reconstructed, may well be a better starting point for policy. …. Such a diet would have had at least some of the following features: high protein intake, low glycemic index, high calcium intake, high folic acid intake, an alkaline ash residue and high vitamin D input. It is in this nutritional context that human physiology is adapted. The burden of proof should fall on those who say that these more natural conditions are not needed and that lower intakes are safe.

ed

Nutrigenomics: An Organizing Principle of the New Paradigm

ic

He laments that nutritional science has been largely ignored by practicing physicians. His perspective finds support in Dr. Jim Kaput’s more recent paper, “Nutritional Genomics: The Next Frontier in the Post Genomic Era.”83 Dr. Heaney used the examples of calcium, vitamin D, and folate to illuminate the multi-functional nature of nutrients in complex, higher-order functioning in biology. Vitamin D has been classically associated with the prevention of rickets and osteoporosis. Current recommended levels for vitamin D intake are benchmarked to the prevention of rickets, the presumption being that if patients do not have rickets or osteomalacia, then their vitamin D intake is adequate. Evidence indicates otherwise; increasing vitamin D levels in the blood to the upper levels of the reference range improves calcium absorption efficacy by two-thirds,

e

in

Imagine a drug that could cure within days or weeks a fatal disease using a very small dose, without toxicity, and with a 100% success rate. Such a drug does not exist and probably will never exist; but this is the power and potential of nutrients. They function within the genetic and evolutionary necessities of the cell to enhance and facilitate optimal biological functioning. They are vital to our very survival. Their effectiveness in curing deficiency diseases is dramatic, but their role in the prevention and management of long-latency chronic diseases is more frequently relevant to most daily clinical practice. Many patients worry about the dangers of medications; their compliance with pharmaceuticals is disturbingly low, as 20% of prescriptions go unfilled and 85% are never refilled.84 The decision to see a doctor should not be measured by concern for risk and danger,

62

Chapter 7 Biochemical Individuality and Genetic Uniqueness but by the opportunity and anticipation of enhanced health and well-being. Herein lies the potential of nutrigenomics and the new medical paradigm that allows us to understand the integrative function of complex organisms, and the essential and primary role of nutrition in maintaining that function. This new paradigm shifts us from disease treatment and disease prevention to health promotion.85 The study of nutrigenomics86 spearheads a radical transformation in medicine akin to the change in physics that occurred when the deficiencies of Newtonian physics were illuminated by discoveries in quantum mechanical physics and Albert Einstein’s theory of relativity. We have entered an era where genetic predisposition replaces Mendelian genetic determinism, where biochemical individuality replaces biochemical homogeneity, and where the importance of the biological terrain or internal milieu exceeds that of the external invader. However, acceptance of the change, seeing what is right in front of us, is difficult. As R.D. Laing states in The Voice of Experience,87 “Our way of looking is not easily disturbed by what it sees, let alone by what it cannot see.” Kaput summarizes the concepts of nutrigenomics, a foundational component of the new functional paradigm of medicine, in a way that should give us pause and cause us to examine our outdated beliefs:

dietary intervention based on knowledge of nutritional requirement, nutritional status, and genotype (i.e., “individualized nutrition”) can be used to prevent, mitigate, or cure chronic disease.88

)2

(c

Nutrigenomics is a fulcrum point for placing a lever of change in our current medical paradigm. Kaput describes the robustness of this paradigm (“the next frontier in the post genomic era”) as having the potential to radically change our approach to health and disease. In fact, for the first time in medicine, we have the opportunity to not only treat disease but to create a context for health. The adoption of new organizing principles and concepts that form the basis of the new medical paradigm can help us successfully navigate health and illness in the 21st century.

01

0

Development of the Knowledge Base in Biochemical Individuality

lM na tio d. un rve r F se fo re te ts itu h st rig In All

DeAnn Liska, PhD

Introduction

Our ideas of health and disease have changed dramatically in the past several decades. Once, we talked of illness as something we caught and could control; now, we talk about being susceptible to the forces around us because of our genes. Once, we understood the role of genetics in disease as important only with respect to the defined “inherited diseases of metabolism,” in which a dysfunctional gene that directly leads to a disease (such as maple syrup disease, or phenylalaninemia) is passed on from generation to generation. An inherited disease of metabolism is discrete: you either have it or you don’t. And, if you have it, you can manage it but you can’t eradicate it. As seen in the Cathy cartoon on page 64, our understanding of “genetic predisposition” has been influenced by the concept of genetic determinism. We have believed that the genes we inherit are static and, like flood waters that grab us and pull us downstream against our will, we must succumb to a more powerful force. However (and fortunately), the emerging data from investigations that focus on understanding the integration of environmental triggers with genetic constitution indicate that we can manage most of these predispositions. Once we know where and how we are susceptible, we can improve the match between our

e

in

ic

ed

The interface between the nutritional environment and cellular/genetic processes is being referred to as “nutrigenomics.” Nutrigenomics seeks to provide a molecular genetic understanding for how common dietary chemicals (i.e., nutrition) affect health by altering the expression and/or structure of an individual’s genetic makeup. The fundamental concepts of the field are that the progression from a healthy phenotype to a chronic disease phenotype must occur by changes in gene expression or by differences in activities of proteins and enzymes, and that dietary chemicals directly or indirectly regulate the expression of genomic information. We present a conceptual basis and specific examples for this new branch of genomic research that focuses on the tenets of nutritional genomics: 1) common dietary chemicals act on the human genome, either directly or indirectly, to alter gene expression or structure; 2) under certain circumstances and in some individuals, diet can be a serious risk factor for a number of diseases; 3) some diet-regulated genes (and their normal, common variants) are likely to play a role in the onset, incidence, progression, and/or severity of chronic diseases; 4) the degree to which diet influences the balance between healthy and disease states may depend on an individual’s genetic makeup; and 5)

63

Section II Principles of Functional Medicine

)2

(c 0

01 lM na tio d. un rve r F se fo re te ts itu h st rig In All

CATHY © 2001 Cathy Guisewite. Reprinted with permission of UNIVERSAL PRESS SYNDICATE. All rights reserved.

individual’s specific environment—that continuous exposure to “inputs” (experiences, nutrients, activity, toxins, medications, etc.) that influences our genes. It is this combination of factors that accounts for the endless variety of phenotypic responses—those biochemically unique individuals we see every day in our offices and clinics. Biochemical individuality is dependent upon the DNA that is present at the moment of conception in each individual and, therefore, a discussion of biochemical individuality includes understanding how DNA is expressed and influenced.

e

in

ic

ed

environmental exposures and our own unique profiles to improve health outcome and longevity. This is the promise of 21st century medicine. And, since our genetic constitution is unique, this is the historical and scientific basis for biochemical individuality.

Biochemical Individuality in Functional Medicine Biochemical individuality is not a new topic in functional medicine; it has been one of the underlying principles since the early 1980s. Although the unique genetic profile of an individual may be the most obvious way in which we are all “biochemically individual,” in functional medicine this concept has long been defined as comprising the interaction of genetics and environment. We understand biochemical individuality to mean that each individual has a unique physiological and biochemical composition, based upon his or her individual genetic make-up, that interacts with the

A Brief Look at the History of Biochemical Individuality The first work upon which the field of genetics is based came from the Augustinian monk, Gregor Mendel, who found that phenotypic traits in peas could be

64

Chapter 7 Biochemical Individuality and Genetic Uniqueness sequences of not meeting the specific needs of the individual are expressed, over several decades, as degenerative disease “of unknown origin.” In his model, at the genetic level, an individual has a need for a different level of nutrients to promote proper phenotypic expression. If that need is not met, the resulting “undernutrition” will manifest as chronic disease in midlife. Although medicine did not initially embrace the concepts of genetotrophic disease and biochemical individuality, they have consistently gained more attention since the 1980s. It is now fashionable within science to talk about “individual responses.” Much of this progress has come as a result of the technological advances that have allowed us to dissect DNA. Over the past two decades, individual genes have been identified and many of their functions have been described. The dogma of gene expression (Figure 7.1) was defined. The understanding of viral integration into the genes in specific cells, and the identification of mitochondrial DNA as separate but integrated in every cell have also enhanced our realization that each and every person is unique at the level of DNA.

)2

(c

passed down from generation to generation. His work was published in 1866, but remained in obscurity until around 1900, when it was rediscovered and promoted by several scientists. Although the concept of genes and inheritance was taking a forefront at the time, Archibald Garrod cautioned in 1902 that the chemical behavior (metabolism) of different individuals varied in ways that were independent of genetics. Dr. Garrod discovered alkaptonuria, which led to the understanding of phenylketonuria and the role of phenylalaninerestricted diets in its management. Although he studied a classic model of inherited disease, he noted that “variations of chemical behavior … are probably present everywhere in minor degrees” and stated “as no two individuals of a species are absolutely identical in bodily structure neither are their chemical processes carried out on exactly the same lines.”89 The renowned biochemist, Roger Williams, PhD, was the first to use the term “biochemical individuality” in his classic book of the same name, published in 1956.90 In this work, he described how the anatomical and physiological variations among people are related to their varied responses to the environment and to their differing nutritional needs. He pointed out that even identical twins could differ in their requirements for optimal function, based upon the fact that they developed in different environments in utero, a concept that is beginning to accumulate scientific support (discussed further below). In addition, he noted that although identical twins share the same genes their differing nutritional and developmental environments also can contribute to different expression of these genes as they grow older. Dr. Williams came upon the idea of biochemical individuality in his work with nutrition and chronic disease. In 1950, he published an article in The Lancet titled “The Concept of Genetotrophic Disease,” in which he proposed a role for nutrients in the prevention of chronic disease.91 Genetotrophic diseases are those for which genetic uniqueness creates a demand for specific nutrients beyond the average intake to facilitate optimal function and prevent premature disease. Dr. Williams theorized that when those specific needs are not met in a given individual, disease results. He further proposed that the major chronic degenerative diseases of aging are genetotrophic. That is, the unique genes of each individual require different levels of nutrition and a specific lifestyle for optimal health. The con-

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All Allele 1 Allele 2

Cytoplasm Nucleus Introns

Exons

DNA

Gene

Transcription

Primary RNA transcript

ed

Add 5' cap and poly(A) tail

RNA cap

AAAA

in

ic e

mRNA

mRNA

RNA Splicing AAAA Export AAAA Translation

Protein

Figure 7.1 Dogma of gene expression A schematic from the chromosome to gene in a cell. A gene comprises a small section of DNA on a chromosome. Each gene has two alleles (the two copies, one from each parent). A person can have two different alleles (polymorphisms), which is called a heterozygote. If the two alleles are the same, it is called a homozygote.

65

Section II Principles of Functional Medicine The Human Genome Project represented a major international commitment among scientists and provided the human genome sequence for 99% of the genecoding DNA in April 2003, which corresponded with the 50-year celebration of Watson, Crick, and Franklin’s discovery of the structure of DNA. The implications of this work, especially as they relate to medicine, are still unfolding, but they have already begun to change the way we view health and disease. As discussed in a 2003 review in the Archives of Internal Medicine:92

DNA

RNA Transcription

Nuclear Membrane

Nuclear RNA

The individualization of treatments has been one of the strongest therapeutic tools, while also one of the greatest challenges of the pregenomic era. Individuals with apparently identical clinical problems may respond very differently to a specific treatment, and this has generally been accepted as an insoluble problem. However, with the availability of comprehensive genetic and molecular profiles, it will probably become possible to respond to disease with individualized strategies based on genetic profiles.

)2

(c

Transport to cytoplasm for protein synthesis (Translation)

0

01

mRNA

lM na tio d. un rve r F se fo re te ts itu h st rig In All

The promise is to be able to fully use genetic information for individualized clinical management plans; the challenge remains to understand the multiple connections and patterns that are emerging from these data. This field is extremely active, and new findings continue to emerge each day. The areas most developed to date are briefly reviewed below, but the reader is encouraged to stay abreast of the emerging research on a regular basis.

Figure 7.2 mRNA to protein A schematic showing the general dogma of gene transcription and translation. A gene is transcribed into RNA, which is transported to the cytoplasm as mRNA. The mRNA carries the information of one gene, and is translated to make protein in the cell's cytoplasm.

Today, we know that the human genome is composed of approximately 3,164.7 million base pairs, which contrasts to the smallest bacterium genome of 600,000 DNA base pairs. Human DNA is arranged into 23 (physically separate) chromosomes, each of which contains between 50 million and 250 million base pairs. The human genome is estimated to encode 30,000 genes. An average gene-encoding region on human DNA is around 3,000 base pairs, but gene size can vary greatly from very small to extremely large (over 2 million base pairs). The gene density of DNA is about one gene per every 100 kilobases. The functions associated with over 50% of the discovered genes are unknown. Updates on the human genome can be obtained at the Human Genome Project Information site on the internet: http:// www.ornl.gov/sci/techresources/Human_Genome/ project/info.shtml. Much of the DNA within the gene contains information that isn’t transcribed, but acts to regulate the expression of the gene. This non-coding DNA is particularly important for signal transduction pathways. The amount of DNA in the human genome that directly encodes protein is only about 2% and each gene contains several areas of non-coding DNA that are involved

ed

The Human Genome and Single Nucleotide Polymorphisms

e

in

ic

DNA is described by its base pair composition. DNA is composed of four molecules called bases: A (adenine), G (guanine), T (thymine), and C (cytosine). A strand of DNA is composed of these four bases in different orders, like beads on a string. Each strand of DNA has a complement strand (its pair), and the bases pair off as A to T, and C to G. Therefore, the complement or pair strand of DNA is like a mirror copy that is used to provide a copy within the cell. The primary strand is the one that provides the blueprint for mRNA through a process called transcription. The mRNA is then transported to the cytoplasm, where protein is made in a process called protein translation (see Figure 7.2). The process of reading the DNA is called gene expression. Common definitions in the field of genetics and molecular biology are provided in Table 7.1.

66

Chapter 7 Biochemical Individuality and Genetic Uniqueness

Table 7.1 Definitions for Common Terminology in the Study of Genes The functional and physical unit of heredity passed from parent to offspring. Genes are pieces of DNA that contain the information necessary for making a cell, such as the information to make structural proteins and enzymes.

Genome

The DNA code that comprises the complete genetic composition of an organism. As an analogy, this would be the entire encyclopedia of information, or DNA, to encode one person. Each cell contains a genome, but a cell only uses the portions of the genome relevant for its specific functions.

DNA (deoxyribonucleic acid)

The chemical substance that forms the genome. DNA is composed of four specific compounds, or nucleotides: guanine (G), adenine (A), cytosine (C), and thymine (T).

mRNA (messenger RNA)

A fragment of RNA that is read from the genome (or DNA blueprint). An mRNA carries with it only the information related to one gene, so it is the molecule within the cell that transfers the information from the DNA, which contains the blueprint of all genes, for one specific gene that can then be transported to the site where the protein will be made. As an analogy, if DNA is the encyclopedia of a person’s genotype, the mRNA is a photocopy of one page of that encyclopedia.

)2

(c

Gene

0

01

The process of making proteins from DNA, or reading the DNA.

Genotype

The internally encoded information of an organism (or genome).

Phenotype

The outward, physical manifestation of an organism (the interplay of environment and genotype).

Transcription

The process of making an mRNA from DNA that occurs within the nucleus of the cell. For example, during transcription, the section of DNA that contains the information for a specific gene is copied into an mRNA molecule, which is much smaller and can be transported to the site where proteins are made within the cell.

Translation

The process that occurs within the cell in which a protein is generated from mRNA. In this process, the mRNA is read by the cell’s protein generation machinery to make a specific protein that can be used within the cell or transported to another site, where it will affect function.

Wild-type

The most common DNA sequence for a specific gene. This term is mainly used for comparative purposes in scientific literature to identify a standard sequence that can be compared to other sequences for identification of DNA mutations.

Mutation

A general term to describe a change in an individual’s DNA sequence (genotype) from the defined wild type (the most common sequence, considered the standard for that gene). This change may or may not lead to a change in phenotype (e.g., point mutations, multiple mutations, deletions, duplications, somatic mutations).

Polymorphism

A difference in DNA sequence from the most common sequence that occurs at a consistent frequency and is maintained in the population. To be considered a polymorphism, a DNA sequence must be present in at least 1% of the population. Many polymorphisms result in proteins that are still active, but the activity differs (slower or faster) than the most common sequence.

SNPs (Single Nucleotide Polymorphisms)

A change at a single site (single base pair) in a DNA sequence as compared to the most common sequence that occurs in at least 1% of the population. SNPs can lead to proteins that are more or less active than those from the most common sequence, and are considered to account for much of the variability seen among different individuals (i.e., biochemical individuality).

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Gene expression

67

Section II Principles of Functional Medicine severe disease or alteration of structure, they are maintained in the population and passed from generation to generation. It is estimated that around 3 million SNPs will eventually be identified; 1.8 million have already been found. SNPs can occur anywhere in the DNA, but the ones that occur on or around genes hold the most interest for researchers. Associating a SNP with a specific functional outcome holds promise for helping to personalize health care and prevention for individual patients; we may be able to intervene before a condition becomes established. [Note: Updates on SNPs can be found at the International HapMap Project Web site at: http:// snp.cshl.org/.]

in gene regulation (see Figure 7.3). The DNA that is not contained within the genes is known to function in managing structure and conformation of the DNA, which also influence whether a gene is recognized and transcribed within a cell; however, the specific function of much of the DNA in our cells is unknown. Promoter

Gene

Exon 1 Chromosomal DNA

Exon 2

Exon 3 Intron 2

Intron 1

Transcription (RNA synthesis)

(c Exon 2

)2

Exon 1 Nuclear RNA

How SNPs Alter Function

Exon 3

01

SNPs can affect the phenotype of an individual in a variety of ways. A SNP in the body of a gene may encode a protein, such as an enzyme, leading to what seems to be a minor change in structure of the protein. In many cases, this is only one amino acid change, but the change can alter the activity of the protein such that it is more active (e.g., binds its substrate more tightly) or less active. The protein may have lower stability (so that it is present but at an apparently lower concentration), or higher stability (so the protein is at an increased concentration because it is broken down less quickly). SNPs can also occur in areas of the DNA that are involved in gene regulation but may not directly alter the protein, so that the gene is transcribed more or less readily. The ultimate effect of these SNPs can be seen as “tweaks” in the metabolic pathway functions. Individuals having these SNPs may not process and excrete a toxin as quickly as the general population, or their need for a nutrient cofactor may be higher because of lowered ability to bind a specific nutrient and maintain activity. Not all SNPs have medical significance; determining those that most influence various conditions or responses to interventions is a challenge. Moreover, most of the SNPs that are relevant will lead to only a small change, such as a decrease in an enzyme’s activity, but not the on-off type of change seen with heritable disorders of metabolism. Taken together with the multifactorial nature of metabolic pathways and the myriad influences on chronic diseases, the combined effects of different SNP patterns are likely to be of greatest value in understanding susceptibility to particular diseases or conditions.

RNA Splicing

0 Figure 7.3 Noncoding regions of DNA

Exon 2

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Exon 1 Messenger RNA

Exon 3

A schematic showing the structure of a gene. Each gene in the DNA has exons (segments that will be included in the mRNA), and introns (segments that will be selectively removed before the RNA leaves the nucleus). The role of introns in gene expression is not fully understood, but they are thought to play a role in regulation of gene expression. Some polymorphisms that affect phenotype have been shown to occur in intron sections of genes, thereby altering a protein's activity by influencing how well the gene is expressed and ultimately how much protein is actually made.

e

in

ic

ed

Defining the structure and sequence of the human genome has helped us understand the genetic differences that occur as mutations. A mutation is any change in DNA over the most common sequence, called the wild type. A mutation can come in many forms: a whole section of DNA may be deleted; a large section may be inserted where it doesn’t belong; a small deletion or insertion can also occur. Most of these, if they are large changes, lead to observed differences in structure or function, or even death in utero, and they occur in less than 1% of the population. Very small changes that alter the function of an enzyme, making it more active or less able to function, but not obliterating its function completely, occur more regularly. These types of changes are generally at one base site, and so they are called single nucleotide polymorphisms; they occur in at least 1% of the population. Because SNPs are not an embryonic lethal mutation, or an inherited single-gene mutation that leads to a

68

Chapter 7 Biochemical Individuality and Genetic Uniqueness Analyzing many SNPs at once can be done using microarray technology, but understanding the myriad patterns that emerge from this analysis will take many years of work. Therefore, the integration of these new findings is being seen first in cases in which one particular change (one SNP) is found to influence a response, such as in the metabolism of a drug that occurs primarily through one specific pathway. A few areas have led the way to integrating individualized genetic information in ways that are influencing medicine today, and those are reviewed below.

Not only is the issue of adverse events a major concern, but drug efficacy is also influenced by biochemical individuality and is becoming a focus of discussion in medicine. For example, in a 2003 news story, Allen Roses, the worldwide vice-president of genetics at GlaxoSmithKline, observed: “The vast majority of drugs—more than 90%—only work in 30 or 50% of the people. I wouldn’t say that most drugs don’t work. I would say that most drugs work in 30 to 50% of people. Drugs out there on the market work, but they don’t work in everybody.”98 For example, it is known that codeine is ineffective for pain relief in about 10% of the population. In order to be efficacious, codeine must first be converted to morphine in the body, a reaction that requires the cytochrome P450 enzyme CYP2D6, and 10% of the population has a SNP in the CYP2D6 gene that results in a less active protein.99 The issue, then, is how to predetermine who will respond and who won’t and—even more immediate— who will respond with an ADR that may be fatal. This has led to the definition of the field of pharmacogenomics or pharmacogenetics. Research in pharmacogenetics began by identifying allelic variations in genes (primarily SNPs) and has expanded to include identifying new drug targets. All definitions for pharmacogenetics revolve around how the body uses and metabolizes pharmacologic agents. A specific example of biochemical individuality and drug response can be shown with the thiopurine Smethyltransferase (TPMT) protein, which is the enzyme that breaks down the drug 6-mercaptopurine. This drug is a chemotherapeutic agent used for acute lymphoblastic leukemia, a deadly form of cancer that afflicts approximately 2,400 children in the United States every year. Between 10 and 15% of people metabolize this drug either too quickly (resulting in lowered efficacy of a standard dose of the drug) or too slowly (resulting in accumulation of lethal levels), based upon the presence of a mutation in the TPMT gene. A genetic test now exists to determine whether this mutation is present before the drug is given to a patient. Warfarin is a narrow-spectrum anticoagulant drug with a wide interindividual variation in dosage. The risk of serious hemorrhage during warfarin therapy ranges from 1.3 to 4.2 per 100 patient years of exposure. Therefore, it is important to find ways to quickly and effectively determine the best dosage for a patient. Warfarin is composed of two enantiomers—R-warfarin

Adverse Drug Reactions and Pharmacogenomics

)2

(c

A widely cited study published in JAMA in 199893 brought to the fore a key issue in medicine: that pharmaceutical agents are one of the most commonly identified causes of adverse events. The pharmaceutical companies develop products based on the notion that one drug will work for everyone at the same dose, the “one-size-fits-all” model. However, the meta-analysis presented in the JAMA article indicated that 2.2 million patients (6.7%) had adverse drug reactions (ADRs) in 1994, and 106,000 patients (0.32%) died as a result of them. Moreover, the analysis used a conservative method to reduce any contribution from errors in administration, overdose, drug abuse, therapeutic failures, and “possible ADRs” and, therefore, the findings represent only drug reactions from properly prescribed and administered drugs. The conclusion was that adverse drug reactions from properly prescribed medications represent between the fourth and sixth leading cause of death in the United States. Although this publication spurred much comment after it appeared,94 it identified a key area of concern that had not yet been fully accepted: adverse drug reactions occur in a high number of individuals with no direct explanation. For several years after publication of this study, a number of articles on the mechanisms of ADRs were published. Researchers began to recognize that a key factor in ADRs is biochemical individuality—specifically, variability in drug metabolism due to polymorphisms in genes for drug metabolizing enzymes.95 At a given dose of drug, the range in variability of patient responses is 4-fold to 40-fold (i.e., 400% to 4000%).96 The president and CEO of New Jersey-based Orchid BioSciences has been quoted as saying that “more money is spent on adverse drug response than on drug development.”97

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 69

Section II Principles of Functional Medicine ously encountered compounds or metabolites. Our bodies have an extensive network of responses to manage these new and unknown substances and, because the environment is unique to each individual, these responses are at the core of what we mean by “biochemical individuality.”

and S-warfarin—which are metabolized differently. The S-warfarin is metabolized by the 2C9 cytochrome P450 (CYP2C9), whereas the R-form is metabolized by the CYP1A2 and CYP3A4 enzymes. The CYP2C9 gene is known to have two relatively common SNPs, one resulting in an enzyme that is only 5% as active as the wild type, and another that leads to an enzyme that is 12% as active as the wild type. To understand the role of these polymorphisms in warfarin therapy, Aithal et al.100 compared the SNP pattern in low-dose patients (1.5 mg per day or less) with control patients and found patients in the low-dose group were six times more likely to have a low-activity SNP than the control patients. Moreover, further studies have demonstrated that using the common 5 mg per day dose initially in patients with the SNP that leads to the most compromised 2C9 activity causes an increase in the international normalized ratio and a significant risk of bleeding.101 Patients with SNPs in 2C9 have been shown to be at greater risk for major bleeding complications in some studies, but not in all.102,103,104 It is becoming prudent practice to genotype for CYP2C9 before beginning warfarin therapy to reduce the risk of ADRs and to decrease medical expenditures.105,106 These examples illustrate how findings in pharmacogenomics support the concept of biochemical individuality. The benefit to patients today is great; the potential benefit, as the knowledge base grows, is huge. In a systematic review of ADRs, Phillips et al.107 published a list of the most common pharmaceuticals that are involved in ADRs (see Table 7.2). In this growing field, many more examples become available every year. The best resources for up-to-date information are the internet, product manufacturers, and specific laboratories that test for SNPs.

Table 7.2 Commonly Identified Drugs in Adverse Drug Reactions Category

Name(s) of Drug

)2

(c

Atenolol, metoprolol

Angiotensin-converting enzyme inhibitor

Lisinopril

Diuretic

Furosemide, hydrochlorothiazide

0

01

Beta-blockers

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Diltiazem, verapamil

Inotropic agent/pressor

Digoxin

NSAID

Aspirin, ibuprofen, naproxen, piroxicam

Tricyclic antidepressants

Imipramine HCl, nortriptyline HCl

Selective serotonin reuptake inhibitor

Fluoxetine

Antibiotics, antitubercular agents

Amoxicillin, erythromycin, isoniazid, rifampin

Anticoagulant

Warfarin sodium

A 2001 report suggested that between $568 billion and $793 billion is spent per year in Canada and the United States on environmentally caused disease.108 We are exposed to a great number of environmental compounds during the course of our lifetime (see Chapter 13 for a discussion of xenobiotics), and many of these compounds show little relationship to previ-

Prednisone

e

Detoxification and Biochemical Individuality

in

Role of Environment in Shaping Biochemical Individuality

ic

Corticosteroid

ed

Calcium channel blocker

Anticonvulsants

Carbamazepine, phenytoin

Antidiabetic agent

Insulin

Bronchodilators

Theophylline

Electrolytes

Potassium

Antiemetic or antihistamine

Meclizine HCl

Table was compiled from Phillips et al., JAMA. 2001;286(18):2273.

The pathways that have received the most attention to date are the phase I and phase II detoxification

70

Chapter 7 Biochemical Individuality and Genetic Uniqueness act, variation in sulfur-dependent pathways is a particularly intriguing area of study. A significant number of individuals who display sensitivity to environmental compounds have impaired sulfation of endogenous compounds, particularly phenolic compounds. In addition, impairment in the sulfation detoxification pathway is associated with such conditions as Alzheimer’s disease, Parkinson’s disease, motor neuron disease, rheumatoid arthritis, and delayed food sensitivity.124 Because the sulfur-dependent detoxification pathway depends upon the availability of the sulfur cofactor, and this cofactor is obtained from precursors in the diet, such as methionine, cysteine, and inorganic sulfur, this is an example of a critical interaction involving the environment, nutrition, and genetics.

)2

(c

enzyme systems, in part because they are involved in drug metabolism and are, therefore, the focus of pharmacogenomics, but also because they are the first-line enzyme defense systems for our interaction with the environment.109,110 Since these systems are designed to manage environmental exposure, they are also regulated by the environment. Specific detoxification pathways may be induced or inhibited depending on the presence of various dietary or exogenous compounds.111 Gender, lifestyle habits, nutriture, and health status also influence the relative activities of various detoxification enzymes. Moreover, the detoxification enzymes show a wide variety of polymorphisms. A number of other genes are also involved with management of environmental compounds as well. (Please see Chapters 22 and 31 for more detailed discussions of the mechanisms and clinical implications of detoxification.) Polymorphisms in phase I or phase II enzymes have been associated with increased prevalence and/or risk of many conditions including asthma; cancers of the breast, prostate, lungs, esophagus, stomach, and pancreas; multiple chemical sensitivity; and cardiovascular disease.112,113,114,115,116,117,118 Other enzymes also play important roles in our environmental exposure risks. For example, a polymorphism in the human paraoxonase (PON1) gene—which encodes a high-density lipoprotein-associated enzyme that exerts an antiatherogenic effect by protecting low-density lipoproteins (LDL) against oxidation—has been found to influence both sensitivity to specific insecticides or nerve agents, and the risk of cardiovascular disease.119 The PON1 polymorphism has also been associated with neurological symptoms in Gulf War syndrome.120 Lung cancer mortality is related to smoking; however, only about 15% of the individuals who smoke will be afflicted with this cancer.121 Tobacco smoke contains a multitude of carcinogens, but many of these carcinogens must be metabolized before they are damaging to the body. It is apparent that much variability exists in these processes.122 For example, polymorphisms in the glutathione S-transferase (GST) gene have received much attention with respect to health risks from smoking. This enzyme is involved in detoxification of tobacco carcinogens, and studies have found that specific polymorphisms in the GST gene are related to the risk of developing coronary heart disease for smokers.123 Although we can cite many examples showing how the environment and specific genetic composition inter-

01

Biochemical Individuality and Nutrition

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Diet is known to have a major impact on chronic disease prevention and management, so it may be no surprise that the diet-gene interaction is the object of much interest from the research community. A new field of study—nutritional genomics (or nutrigenomics)—has been identified to help us understand the effect of nutrients on DNA:

ic

ed

The link between diet and health is well established, but renewed interest in which dietary components are biologically active and how they exert their effects is being fuelled by the development of nutritional genomics … . Such techniques can facilitate the definition of optimal nutrition at the level of populations, particular groups, and individuals. This in turn should promote the development of food derived treatments and functionally enhanced foods to improve health.125

e

in

So prevalent is this understanding that it has even found its way onto the front page of consumer magazines such as Newsweek, which had a cover story on “Diet and Genes” in January 2005 that included discussions of the role of ingredients in broccoli (e.g., indole3-carbinol), green tea catechins, and components of soy on gene expression.126 Unfortunately, many of these discussions still focus on a one-size-fits-all model for nutrition. However, the impact that the human genome project has had on the scientific knowledge underlying individualization of pharmaceutical interventions is also encompassing nutrition. Emerging data indicate we will soon be able to individualize nutrient interventions, as well as gain a much better understanding of the implications of biochemical individuality for nutrition-oriented public policy.127,128

71

Section II Principles of Functional Medicine MTHFR gene has received much research attention (see Figure 7.4).

Known genetic polymorphisms that affect nutrition include the hereditary hemochromatosis-linked gene (HFE), which is associated with iron overload; transferrin receptor polymorphisms that influence iron requirements; SNPs in the vitamin D receptor that are associated with bone integrity; SNPs that influence lipid metabolism and cardiovascular health, such as the apolipoproteins and LDL-receptor lipoprotein lipase; and the relationship among PPAR polymorphisms, saturated fat intake, and insulin.129,130 Presence of specific SNPs can alter the body’s metabolism in ways that can be directly observed (as with a disease like hemochromatosis or elevated lipids), or the effects can be more subtle. For example, the ability to observe what is happening at the DNA level has provided evidence that subclinical deficiencies are involved in genome instability, leading to increased DNA damage.131 The carotenoids, vitamins C, E, and B12, folate, niacin, and zinc appear to be particularly important for genome stability.132 Bruce Ames, who has studied the effect of nutrients on oxidative stress and DNA integrity, has noted that as many as one-third of all mutations in a gene result in the corresponding enzyme having an increased Michaelis constant (Km) for a coenzyme, which means the enzyme has a decreased affinity for its vitamin cofactor.133 A decreased binding affinity results in a lower rate of reaction and, as noted by Ames, many of these effects can be ameliorated by administration of high doses of the cofactor. (Chapter 26 contains a discussion by Ames on micronutrient insufficiency.) Perhaps the best understood example integrating findings in nutrition, genetics, and metabolism is that of folate and methylation. Folate is involved in generation of the methylation cofactor S-adenosylmethionine (SAM). A deficiency in SAM is associated with congenital abnormalities, certain cancers, cardiovascular disease, neural tube defects, and peripheral neuropathies. A deficiency in SAM results from disruption in folate metabolism. Cells are highly susceptible to folate deficiency during states of increased folate turnover since they do not accumulate excess folate. Impaired folate metabolism results from insufficient folate intake; gastrointestinal disorders that result in malabsorption; SNPs in genes encoding key pathway enzymes, especially methylenetetrahydrofolate reductase (MTHFR); increased folate catabolism; and deficiencies in vitamins B6, B12, or iron, which are also necessary in the folate-methylation pathway.134 Of these, a SNP in the

Folate

Methionine

THF B12

5, 10 - CH2 - THF CH3 - B12

MTHFR

Homocysteine

5 - CH3 - THF B12

(c

Figure 7.4 MTHFR SNP

)2

Function of methylenetetrahydrofolate reductase (MTHFR). MTHFR is required for reduction of 5,10-methylenetetrahydrofolate (5,10-CH2-THF) to 5-methyltetrahydrofolate (5-CH3-THF) which serves as a methyl donor for the remethylation of homocysteine to methionine through methylation of cobalamin (vitamin B12) to methylcobalamin (CH3-B12). The most common SNP in this pathway is in the MTHFR, which results in a decreased activity of the MTHFR enzyme, thus influencing the balance of the homocysteine cycle.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

in

ic

ed

The MTHFR polymorphism results in a thermolabile enzyme that is about 50% less active than the wild-type enzyme. Epidemiological studies have shown that this polymorphism, in the presence of low folate intake, results in elevated blood homocysteine levels and is associated with a higher risk of cardiovascular disease.135 Silaste et al.136 investigated the plasma homocysteine effects of a low-folate versus a high-folate diet on individuals with SNPs related to metabolism of homocysteine, including the MTHFR gene and the methionine synthase gene. The groups did not initially vary in baseline homocysteine levels. However, after the high-folate diet, although the individuals with the SNP in the MTHFR gene had a smaller increase in serum folate than those with the wild-type gene (55% compared to 85%, respectively), their blood homocysteine levels decreased more (18%) than those without the SNP (11%). A similar effect was also noted with the methionine synthase gene. A study on the effect of diet on MTHFR polymorphisms, in which 322 men and 252 women participated, noted that about 41% of the individuals had wild-type genes at both alleles (the same gene site on each of the two chromosomes), whereas 48% had one wild-type gene and one with the SNP (heterozygotes), and 11% had SNPs on both alleles (homozygote polymorphism). The group that was homozygous for the polymorphism had higher homocysteine concentrations initially (15.8 ± 9 mol/L) than either of the other two groups (11.3 ± 8

72

Chapter 7 Biochemical Individuality and Genetic Uniqueness and 10.8 ± 9 mol/L).137 The study found that adherence to a Mediterranean diet was associated with reduced homocysteine in individuals with either of the alleles containing the SNP for the MTHFR, but not in those individuals who had only the wild-type genes. This study suggests that some individuals may be more responsive to specific dietary interventions than others, based upon the presence of specific DNA sequences.

ably the same for both individuals. This introduces the concept of epigenetic effects. Epigenetics is the study of heritable changes in DNA function without a change in DNA sequence. Epigenetics includes mechanisms that alter activation and expression of genes, such as methylation at specific sites on DNA, histone acetylation, and modification of DNA function by RNA. Therefore, although a major focus of today’s research is on identifying gene sequences and polymorphisms, it is important to heed the following caution expressed eloquently by Walter Willett,143 from the Harvard School of Public Health:

Effects of Early Life on Biochemical Individuality An intriguing area of research is the effect of early life on gene expression patterns. In a research review published in the journal Science in September 2004,138 Gluckman and Hanson discuss the hypothesis that some chronic diseases in adulthood are influenced by environmental factors in the periconceptual, fetal, and infant phases of early life, a model called the “development origins of health and disease.” We often think that chronic degenerative disease appears in mid-life as a consequence of something we did in mid-life, but this model suggests that very early life can influence patterns of gene expression and the risk of developing certain diseases.139 In particular, studies in several mammalian species demonstrate that manipulation of the periconceptual, embryonic, fetal, or neonatal environment can lead to altered postnatal cardiovascular and/ or metabolic function.140,141,142 Most of these influences appear to be related to diet and include maternal undernutrition, low-protein diet, or high-fat diet. Factors such as nutrition, stress, and environmental toxins in early phases of life may combine to set in motion a trajectory leading toward dysfunction in middle age. This presents an entirely different responsibility for the healthcare system (and for all of us, as future patients); rather than just waiting until disease develops, a patient’s health plan needs to begin at the time of (or even before) conception.

)2

(c

Genetic and environmental factors, including diet and life-style, both contribute to cardiovascular disease, cancers, and other major causes of mortality, but various lines of evidence indicate that environmental factors are most important. Overly enthusiastic expectations regarding the benefits of genetic research for disease prevention have the potential to distort research priorities and spending for health. However, integration of new genetic information into epidemiologic studies can help clarify causal relations between both life-style and genetic factors and risks of disease. Thus, a balanced approach should provide the best data to make informed choices about the most effective means to prevent disease.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Proteomics and Metabolomics

In a concept paper in the journal Nature, Paul Nurse,144 from the Cell Cycle Laboratory at Lincoln’s Inn Fields Laboratories, London, wrote:

e

in

ic

ed

Many of the properties that characterize living organisms are also exhibited by individual cells. These include communication, homeostasis, spatial and temporal organization, reproduction, and adaptation to external stimuli. Biological explanations of these complex phenomena are often based on the logical and informational processes that underpin the mechanisms involved … . Most experimental investigations of cells, however, do not readily yield such explanations, because they usually put greater emphasis on molecular and biochemical descriptions of phenomena. To explain logical and informational processes on a cellular level, therefore, we need to devise new ways to obtain and analyze data, particularly those generated by genomic and post-genomic studies.

Epigenetic Effects We now know that biochemical individuality is more than just a difference in gene sequence. One can easily postulate today that two fertilized eggs placed in different in utero environments will develop into individuals with different physiology. In a fascinating twist, studies with identical twins have also shown us that biochemical individuality can occur even when the genetics are the same and the environment is presum-

Clearly, today’s understanding of genomics represents just the tip of the proverbial iceberg with respect to a full understanding of how the body functions and, from that, the differences among us. The genome may be the blueprint for the proteins and structures in our

73

Section II Principles of Functional Medicine body, but it is the proteins that carry out functions, and the small molecules that result from protein activities that are the pillars of the signaling and communication activities throughout our bodies. Since many changes occur at once, and specific interactions or patterns can result in different outcomes, new technologies have been developed to look at multiple genes at one time. These are collectively called “microarray analysis technology” or the “gene array.” These different gene expression patterns can result in a variety of different protein activity patterns. “Proteomics” is the term that has been coined to describe the study of multiple proteins at once, or protein expression/activity patterns. Proteomics is more difficult to perform from a technological standpoint, since each protein is chemically different. DNA is chemically the same; it’s the pattern of bases in the DNA that changes. Gene array technology and large-scale genotyping are increasing our knowledge base every day.145 Likewise, although proteomics is still in its infancy, technologies are also changing how medical research is being conducted.146,147 The greatest promise for understanding biochemical uniqueness is likely to manifest through a deeper understanding at the level of the metabolome. The scientific community is in the process of developing the technologies to quantify entire classes of metabolites; understanding the pattern of these metabolites is called “metabolomics.”148 The metabolome looks at entire biochemical pathways to understand the integrated effects of environment, toxins, nutrients, and genetics on complex metabolic regulation and tissue composition. Through the use of genomics, proteomics, and metabolomics, we can better understand, for example, the 50% concordance rate in identical twins for developing diseases such as type 1 diabetes, or the complexity of establishing breast cancer risk.149 These technologies may even change how we look at disease. As stated by Gerling et al. in the January 2003 issue of Archives of Internal Medicine:150

treatment. Indeed, our present difficulties in defining the gene(s) involved in many of the major diseases may be because we are studying large pools of very divergent molecular “syndromes” with the same clinical presentation. This may also explain why many treatments are only effective in certain patients.

Biochemical Individuality and the Future

)2

(c

Biochemical individuality is not such a new concept; it’s our understanding of what it really means that is continuing to evolve. The concept of genetic predisposition is a way of indicating that we are all different, that we may have a gene that “predisposes” us to some particular condition, but the condition may not be realized unless certain other factors are also present. We are already seeing that the success of the Human Genome Project is creating a better understanding of biochemical individuality and how it can be used to improve disease prevention and management. However, fully implementing this knowledge to improve health outcomes depends on several further developments in research technology. In particular, we must develop the following technical capacities: 1. the ability to detect genetic variation that is silent or undetectable at the level of the phenotype; 2. the ability to analyze the role of epigenetics in genetic variation; 3. the ability to quantify the impact of environment on specific genetic variation patterns; 4. the ability to identify patterns of protein activities through proteomics; and 5. the ability to fully integrate changes in metabolism and entire metabolic pathways by pattern analysis.

0

01

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

As stated eloquently by Robert Eckhardt151 in a review on genetics and nutritional individuality: The latest nutritional guidelines (Murphy 2001)ii incorporate recommended daily allowance for some 30 nutrients. If the metabolic pathway influencing nutritional requirements for each of these nutrients was affected independently by only two alternative alleles at a single genetic locus (almost certainly a substantial underestimate of systemic complexity), then we should expect that the number of alternative genotypes would be 330 or in excess of 200 trillion; three alternative alleles would raise the level of potential diversity to 630, i.e., over a billion times higher. The advancing wave of

Since many different genetic defects and molecular pathways may produce clinically indistinguishable disease presentations, many disorders currently viewed as single entities may become divided into large numbers of distinct molecular diseases, with treatment increasingly targeted at the unique primary molecular defect. This will challenge currently accepted definitions of terms such as disease, disorder, and syndrome, as each may come to denote particular genetic components or signature molecular abnormalities, or imply an optimal mode of genetically based and/or conventional

ii

Murphy SP. How consideration of population variance and individuality affects our understanding of nutritional requirements in human health and disease. J Nutr. 2001;131:361S-65S.

74

Chapter 7 Biochemical Individuality and Genetic Uniqueness knowledge about the human genome has confirmed the idea that each of us must be genetically unique in our nutritional needs.

24. Mack A. Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm. 2003;9(6):559-68. 25. Kassirer JP. Financial conflicts of interest in biomedical research. N Engl J Med. 1993;329:570-71. 26. Shamasunder B, Bero L. Financial ties and conflicts of interest between pharmaceutical and tobacco companies. JAMA. 2002;288(6):738-44. 27. Korn D. Conflicts of interest in biomedical research. JAMA. 2000;284(17):2234-38. 28. Choudhry NK, et al. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA. 2002;287(5):612-17. 29. Nathan DG, Weatherall DJ. Academic freedom in clinical research. N Engl J Med. 2002;347:1368-71. 30. Bekelman JE, et al. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289:454-65. 31. Dong B, Hauck W, Gambertoglio J, et al. Bioequivalence of generic and brand-name levothyroxine. JAMA. 1997;277:1205-13. 32. Rennie D. Thyroid storm. JAMA. 1997;277:1238-43. 33. Holmer A. Industry strongly supports continuing medical education. JAMA. 2001;285:2012-14. 34. Steinbrook R. Perspective: Commercial support and continuing medical education. N Engl J Med. 2005;352(6):534-35. 35. Relman A. Separating continuing medical education from pharmaceutical marketing. JAMA. 2001;285:2009-12. 36. Relman A. Your Doctor’s Drug Problem. The New York Times. Nov 18, 2003. 37. Goodman B. Do drug company promotions influence physician behavior? West J Med. 2001;174:232-33. 38. Fisher ES. The implications of regional variations in medicare spending. Part 2: Health outcomes and satisfaction with care. Ann Intern Med. 2003:138(4);288-98. 39. Fisher ES. Medical care—is more always better? N Engl J Med. 2003;349(17):1665-67. 40. Lenfant C. Shattuck lecture: Clinical research to clinical practice— lost in translation? N Engl J Med. 2003;349:868-74. 41. McGlynn EA. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348:2635-45. 42. Holman H. Chronic disease—the need for a new clinical education. JAMA. 2004;292(9):1057-59. 43. Johns MME. The time has come to reform graduate medical education. JAMA. 2001;286(9):1075-76. 44. Crookshank FG. The importance of a theory of signs: critique of language in the study of medicine. Supplement II. In: Ogden CK, Richards IA. The Meaning of Meaning. New York, NY: Harcourt Brace; 1923. 45. Van Ommen GJB. The human genome project and the future of diagnostics, treatment and prevention. Lancet. 1999;354:5-10. 46. Holman H. Chronic disease—the need for a new clinical education. JAMA. 2004;292(9):1057-59. 47. Crookshank FG. The importance of a theory of signs: critique of language in the study of medicine. Supplement II. In: Ogden CK, Richards IA. The Meaning of Meaning. New York, NY: Harcourt Brace; 1923. 48. Bertalanffy L. General systems theory. New York, NY: Brazillier, 1971. 49. Radford T. Top scientist warns of “sickness” in US health system. BMJ. 2003;326:416. 50. Lundberg GD. Severed Trust: Why American Medicine Hasn’t Been Fixed. New York, NY; Basic Books. 2000. 51. Deutch D. The Fabric of Reality. New York, NY: Penguin Putnam Inc.: 1997.

Furthermore, although much of the initial focus of genomics, proteomics, and metabolomics has been on ADRs, drug metabolism, environmental interactions, and nutrient needs, research in inflammation and immune system function is also finding distinct, important differences that affect health.152,153,154,155 Taken together, the differential effects of the genomics, environment, nutrition, and epigenetic influences indicates that we are all, clearly, biochemically individual.

7. 8. 9. 10.

11.

17.

18. 19. 20. 21. 22. 23.

e

15. 16.

in

14.

ic

13.

ed

12.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

5. 6.

0

3. 4.

01

2.

Kuhn TS. The Structure of Scientific Revolutions. Chicago, Ill: University of Chicago Press; 1970. Goodwin JS, Goodwin JM. The tomato effect: rejection of highly efficacious therapies. JAMA. 1984;251(18);2387-90. http://www.uh.edu/engines/epi1015.htm McCully K. Homocysteine, folate, vitamin B6 and cardiovascular disease. JAMA. 1998:279(5);392-93. Taubes, G. The soft science of dietary fat. Science. 2001;291:2536-45. Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. JAMA. 2002;288(3):366-68. Nelson HD, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288(7):872-81. Starfield B. Is US health really the best in the world? JAMA. 2000;284(4):483-85. Starfield B. Deficiencies in US medical care. JAMA. 2000;284(17):2184-85. Zhan C, Miller M. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. JAMA. 2003;290:1868-74. Fourth Decennial International Conference on Nosocomial and Healthcare Associated Infections. Morb Mortal Wkly Rep. 2000;49(7):138. Weinstein RA. Nosocomial infection update. Special issue. Emerg Infect Dis. 1998;4(3):416-20. Lazarou J, Pomeranz B, Corey P. Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998;279:1200-05. Barczak CA, Barnett RI, Childs EJ, Bosley LM. Fourth national pressure ulcer prevalence survey. Adv Wound Care. 1997;10:4. Leape LL. Error in medicine. JAMA. 1994;272(23):1851-57. Brennan TA, et al. Incidence of adverse events and negligence in hospitalized patients. N Engl J Med. 1991;324:370-76. US Congressional House Subcommittee Oversight Investigation. Cost and Quality of Health Care: Unnecessary Surgery. Washington, DC: Government Printing Office. 1976. Heaney R. Long-latency deficiency disease: insights from calcium and vitamin D. Am J Clin Nutr. 2003;78:912-19. Fonda, D. Curbing the drug marketers. Time. July 5, 2004: p 40-42. Rosenthal MB, Berndt ER, Donohue JM, et al. Promotion of prescription drugs to consumers. N Engl J Med. 2002;346(7):498-505. Wolfe SM. Direct-to-consumer advertising--education or emotion promotion? N Engl J Med. 2002;346(7):524-26. Fonda D. Curbing the drug marketers. Time. July 5, 2004; p 40-42. Adams C, Young A. Prescription for trouble: Drugmakers pushing risky off-label uses on physicians. Nov 4, 2003, Knight Ridder, www.freep.com/news/health/drugs4_20031104.htm.

)2

1.

(c

References

75

Section II Principles of Functional Medicine 79. Vickers A, Zollman C. ABC of complementary medicine: Unconventional approaches to nutritional medicine. BMJ. 1999;319:1419-22. 80. Heaney RP. Editorial: Vitamin D, nutritional deficiency, and the medical paradigm. J Clin Endocrinol Metab. 2003:88(11):5107-08. 81. Heaney R. Long-latency deficiency disease: insights from calcium and vitamin D. Am J Clin Nutr. 2003;78:912-19. 82. Ibid. 83. Kaput J, Rodriguez RL. Nutritional genomics: the next frontier in the post genomic era. Physiol Genomics. 2004;16:166–77. 84. Pharmaceutical Patient Compliance and Disease Management. http://www.PharmaDiseaseManagement.com. 85. Breslow L. From disease prevention to health promotion. JAMA. 1999;281:1030-33. 86. Muller M. Nutrigenomics: goals and strategies. Nat Rev Genet. 2003;4:315-22. 87. Laing RD. The Voice of Experience. New York, NY: Pantheon; 1982. 88. Kaput J, Rodriguez RL. Nutritional genomics: the next frontier in the post genomic era. Physiol Genomics. 2004;16:166–77. 89. Eckhardt RB. Genetic research and nutritional individuality. J Nutr. 2001;131:336S-39S. 90. Williams RJ. Biochemical Individuality: The basis for the genetotrophic concept. New Canaan, CT: Keats Publ. 1998. 91. Williams RJ, Beerstecher E Jr, Berry LJ. The concept of genetotrophic disease. Lancet. 1950;1(7):287-89. 92. Gerling IC, Solomon SS, Bryer-Ash M. Genomes, transcriptomes, and proteomes. Arch Intern Med. 2003;163:190-98. 93. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998;279:1200-5. 94. Letters to JAMA: Adverse drug reactions in hospitalized patients. JAMA. 1998;280:1741-43. 95. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions. JAMA. 2001;286:2270-79. 96. Cohen JS. Ways to minimize adverse drug reactions. Postgraduate Med. 1999;106:163-172. 97. Wortman M. Medicine gets personal. Tech Rev. 2001;January/February:72-78. 98. Connor S. Glaxo chief: Our drugs do not work on most patients. Accessed online December 11, 2003 at: http://news.independent. co.uk/low_res/story.jsp?story=471139&host=3&dir=505. 99. Abbott A. With your genes? Take one of these, three times a day. Nature. 2003;425(6960):760-62. 100. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1998;353:717-19. 101. Palkimas MP Jr, Skinner HM, Gandhi PJ, Gardner AJ. Polymorphism induced sensitivity to warfarin: a review of the literature. J Thromb Thrombolysis. 2003;15:205-12. 102. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1998;353:717-19. 103. Ogg MS, Brennan P, Meade T, Humphries SE. CYP2C9*3 allelic variant and bleeding complications. Lancet. 1999;354:1124. 104. Palkimas MP Jr, Skinner HM, Gandhi PJ, Gardner AJ. Polymorphism induced sensitivity to warfarin: a review of the literature. J Thromb Thrombolysis. 2003;15:205-12. 105. Topic E, Stefanovic M, Samardzija M. Association between the CYP2C9 polymorphism and the drug metabolism phenotype. Clin Chem Lab Med. 2004;42(1):72-78.

)2

(c

52. Lafaille R. Towards the foundation of a new science of health. In: Lafaille R, Fulder S, eds. Towards a New Science of Health. New York, NY: Routledge, 1993:p. 13. 53. Pauling, Linus. How to Live Longer and Feel Better. Avon Books, 1986. 54. Encarta®World English Dictionary. 1999. Microsoft Corporation. All rights reserved. Developed for Microsoft by Bloomsbury Publishing Plc. 55. Kornman KS, Martha PM, Duff GW. Genetic variations and inflammation: a practical nutrigenomics opportunity. Nutrition. 2004;20(1):44-49. 56. Chopra SS. Preparing for personalized medicine. JAMA. 2004;291(13):1640-45. 57. Kaput J, Rodriguez RL. Nutritional genomics: the next frontier in the postgenomic era. Physiol Genomics. 2004;16:166-77. 58. Kornman KS, Martha PM, Duff GW. Genetic variations and inflammation: a practical nutrigenomics opportunity. Nutrition. 2004;20(1):44-49. 59. Norhammar A. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002;359:2140-44. 60. McCully K. Homocysteine, folate, vitamin B6 and cardiovascular disease. JAMA. 1998:279(5);392-93. 61. Murat V. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA. 2002;288:2724-31. 62. Gullar L. Mercury, fish oils and the risk of myocardial infarction. N Engl J Med. 2002;347:1747-54. 63. Yoshizawa K. Mercury and the risk of coronary heart disease. N Engl J Med. 2002;347:1755-60. 64. Ridker P. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-65. 65. Kaput J. Diet-disease gene interactions. Nutrition. 2004;20:26-31. 66. Patient report from Mark Hyman, MD. 67. Hadjivassiliou M, et al. Gluten sensitivity: a many-headed hydra. BMJ. 1999;318:1710-11. 68. Fasano A. Celiac disease—How to handle a clinical chameleon. N Engl J Med. 2003;348(25):2568-70. 69. Farrell RJ, Kelly CP. Celiac sprue. N Engl J Med. 2002;346:180-88. 70. Holick M. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease and osteoporosis. Am J Clin Nutr. 2004;79:362-71. 71. Vasquez A, Manso G, Cannell J. The clinical importance of vitamin D (cholecalciferol): a paradigm shift with implications for all healthcare providers. Altern Ther Health Med. 2004;10(5):28-36. 72. Ames B. Cancer prevention and diet: Help from single nucleotide polymorphisms. Proc Natl Acad Sci USA. 1999;96(22):12216-18. 73. Goodwin JS, Tangum MR. Battling quackery: attitudes about micronutrient supplements in American medicine. Arch Intern Med. 1998;158(9):2187-91. 74. Ames B. Cancer prevention and diet: Help from single nucleotide polymorphisms. Proc Natl Acad Sci USA. 1999;96(22):12216-18. 75. Ames B. High dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased Km): relevance to genetic disease and polymorphisms. Am J Clin Nutr. 2002:75:616-58. 76. Baker SM. The medicine we are evolving. Integr Med. Dec 2002/Jan 2003;1(1):14-15. 77. Fairfield K. Vitamins for chronic disease prevention in adults. JAMA. 2002;287:3116-26. 78. Ames B. A role for supplements in optimizing health: the metabolic tune-up. Arch Biochem Biophys. 2004;423:227-34.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 76

Chapter 7 Biochemical Individuality and Genetic Uniqueness 128. Stover PJ, Garza C. Bringing individuality to public health recommendations. J Nutr. 2002;132:2476S-80S. 129. Gibney MJ, Gibney ER. Diet, genes and disease: implications for nutrition policy. Proc Nutr Soc. 2004;63:491-500. 130. Elliott R, Ong, TJ. Science, medicine, and the future. BMJ. 2002;324:1438-42. 131. Fenech M. Micronutrients and genomic stability: a new paradigm for recommended dietary allowances (RDAs). Food Chem Toxicol. 2002;40:1113-17. 132. Fenech M. Recommended dietary allowances (RDAs) for genomic stability. Mutation Res. 2001;480-81:51-54. 133. Ames BN. A role for supplements in optimizing health: the metabolic tune-up. Arch Biochem Biophys. 2004;423(1):227-34. 134. Stover PJ, Garza C. Bringing individuality to public health recommendations. J Nutr. 2002;132:2476S-80S. 135. Gibney MJ, Gibney ER. Diet, genes and disease: implications for nutrition policy. Proc Nutr Soc. 2004;63:491-500. 136. Silaste M-L, Rantala M, Sämpi M, et al. Polymorphisms of key enzymes in homocysteine metabolism affect diet responsiveness of plasma homocysteine in healthy women. J Nutr. 2001;131:2643-47. 137. Dedoussis GV, Panagiotakos DB, Chrysohoou C, et al. Effect of interaction between adherence to a Mediterranean diet and the methylenetetrahydrofolate reductase 677CT mutation on homocysteine concentrations in healthy adults: the ATTICA Study. Am J Clin Nutr. 2004;80:849-54. 138. Gluckman PD, Hanson MA. Living with the past: evolution, development, and patterns of disease. Science. 2004;305:1733-36. 139. Coe CL, Lubach GR. Prenatal origins of individual variation in behavior and immunity. Neurosci Biobehav Rev. 2005;29(1):39-49. 140. Rhind SM, Rae MT, Brooks AN. Environmental influences on the fetus and neonate—timing, mechanisms of action and effects on subsequent adult function. Domest Anim Endocrinol. 2003;25(1):3-11. 141. Roghair RD, Lamb FS, Miller FJ Jr, et al. Early gestation dexamethasone programs enhanced postnatal ovine coronary artery vascular reactivity. Am J Physiol Regul Integr Comp Physiol. 2005;288(1):R46-53. 142. Jones RD, Morice AH, Emery CJ. Effects of perinatal exposure to hypoxia upon the pulmonary circulation of the adult rat. Physiol Res. 2004;53:11-17. 143. Willett WC. Balancing life-style and genomics research for disease prevention. Science. 2002;296:695-98. 144. Nurse P. Understanding cells. Nature. 2003;424(6951):883. 145. Kennedy GC, Matsuzaki H, Dong S, et al. Large-scale genotyping of complex DNA. Nature Biotechnol. 2003;21(10):1233-37. 146. Liotta LA, Ferrari M, Petricoin E. Written in blood. Nature. 2003;425(6961):905. 147. Leung D, Hardouin C, Boger DL, Cravatt BF. Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nature Biotechnol. 2003;21(6):687-91. 148. German JB, Roberts MA, Fay L, Watkins SM. Metabolomics and individual metabolic assessment: the next great challenge for nutrition. J Nutr. 2002;132:2486-87. 149. Dumitrescu RG, Cotarla I. Understanding breast cancer risk— where do we stand in 2005? J Cell Mol Med. 2005;9(1):208-21. 150. Gerling IC, Solomon SS, Bryer-Ash M. Genomes, transcriptomes, and proteomes. Arch Intern Med. 2003;163:190-98. 151. Eckhardt RB. Genetic research and nutritional individuality. J Nutr. 2001;131:336S-39S. 152. Francesshi C, Olivieri F, Marchegiani F, et al. Genes involved in immune response/inflammation, IGF1/insulin pathway and response to oxidative stress play a major role in the genetics of human longevity: the lesson of centenarians. Mech Ageing Dev. 2005;126(2):351-61.

)2

(c

106. You JH, Chan FW, Wong RS, Cheng G. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy—a decision analysis. Thromb Haemost. 2004;92(3):590-97. 107. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions. JAMA. 2001;286:2270-79. 108. Muir T, Zegarac M. Societal costs of exposure to toxic substances: economic and health costs of four case studies that are candidates for environmental causation. Environ Health Perspect. 2001;109 Suppl 6:885-903. 109. Ingelman-Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutation Res. 2001;482:11-19. 110. Meyer UA, Zanger UM, Grant D, Blum M. Genetic polymorphisms of drug metabolism. Adv Drug Res. 1990;19:198-241. 111. Liska DJ. The detoxification enzyme systems. Altern Med Rev. 1998;3:187-198. 112. Tamer L, Calikoglu M, Ates NA, et al. Glutathione-S-transferase gene polymorphisms (GSTT1, GSTM1, GSTP1) as increased risk factors for asthma. Respirology. 2004;9(4):493-98. 113. Sazci A, Ergul E, Utkan NZ, et al. Catechol-O-methyltransferase Val 108/158 Met polymorphism in premenopausal breast cancer patients. Toxicology. 2004;204(2-3):197-202. 114. Nakazato H, Suzuki K, Matsui H, et al. Association of genetic polymorphisms of glutathione-S-transferase genes (GSTM1, GSTT1 and GSTP1) with familial prostate cancer risk in a Japanese population. Anticancer Res. 2003;23(3C):2897-2902. 115. Shi WX, Chen SQ. Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer, and bladder cancer in Chinese population. World J Gastroenterol. 2004;10(13):1961-63. 116. Ockenga J, Vogel A, Teich N, et al. UDP glucuronosyltransferase (UGT1A7) gene polymorphisms increase the risk of chronic pancreatitis and pancreatic cancer. Gastroenterology. 2003;124(7):1802-8. 117. McKeown-Eyssen G, Baines C, Cole DE, et al. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. Int J Epidemiol. 2004;33(5):971-978. 118. Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med. 2003;54:371-392. 119. Ibid. 120. McKeown-Eyssen G, Baines C, Cole DE, et al. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. Int J Epidemiol. 2004;33(5):971-78. 121. http://adam.about.com/reports/000072_3.htm 122. Miller MC III, Mohrenweiser HW, Bell DA. Genetic variability in susceptibility and response to toxicants. Toxicology Lett. 2001;120:269-80. 123. Tamer L, Ercan B, Camsari A, et al. Glutathione S-transferase gene polymorphism as a susceptibility factor in smoking-related coronary artery disease. Basic Res Cardiol. 2004;99(3):223-29. 124. McFadden SA. Phenotypic variation in xenobiotic metabolism and adverse environmental response: focus on sulfur-dependent detoxification pathways. Toxicology. 1996;111:43-65. 125. Elliott R, Ong, TJ. Science, medicine, and the future. BMJ. 2002;324:1438-42. 126. Underwood A, Adler J. Diet & Genes. Newsweek. 2005;January 17: 40-48. 127. Gibney MJ, Gibney ER. Diet, genes and disease: implications for nutrition policy. Proc Nutr Soc. 2004;63:491-500.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 77

Section II Principles of Functional Medicine 153. Felley-Bosco E, Andre M. Proteomics and chronic inflammatory bowel disease. Pathol Res Pract. 2004;200(2):129-33. 154. Kornman KS, Martha PM, Duff GW. Genetic variations and inflammation: a practical nutrigenomics opportunity. Nutrition. 2004;20:44-49. 155. van der Pouw Kraan TC, Kasperkovitz PV, Verbeet N, Verweij CL. Genomics in the immune system. Clin Immunol. 2004;111(2):175-85.

)2

(c 0

01 e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 78

Chapter 8 Patient-centered Care: Antecedents, Triggers, and Mediators Leo Galland, MD

(c

impact of illness on social and psychological function, factors that aggravate or ameliorate symptoms, and factors that predispose to illness or facilitate recovery. This information is necessary for establishing a functional treatment plan. The importance of understanding the patient’s experience of his/her illness cannot be overemphasized. Extensive research on doctor-patient interactions indicates that doctors who fail to pay attention to the patient’s concerns miss important clinical information. The conventional diagnostic paradigm, differential diagnosis, leads doctors to ignore or denigrate information that patients consider important, or that influences individual prognosis.2,3,4 Not only does this ignorance impair the effectiveness of treatment,5 it generates considerable dissatisfaction among patients.6,7,8 Extensive research done within the context of conventional medical care reveals what most patients know: doctors do not pay enough attention to what their patients have to say. A study done at the University of Rochester found that most patients have three reasons for visiting a physician, are interrupted within 18 seconds of starting to tell their stories, and never get the chance to finish.9 Although doctors excuse this behavior by citing lack of time, it would have taken an average of one minute and rarely more than three minutes for a complete list of problems to be elicited. Even when doctors know what their patients’ concerns are, they typically ignore them.10 Most patients have different ideas about their illnesses than their doctors and some form of clarification or negotiation is needed for an effective therapeutic alliance to be established.11 A study that carefully analyzed taped transcripts of visits to a medical clinic found that patients attempted

)2

It is more important to know what person has the disease than which disease the person has. —William Osler

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

The purpose of this chapter is to present an organizational structure for assessment of patients as unique individuals, an approach I have called person-centered diagnosis.1 The goal of person-centered diagnosis is to enable healers to develop individualized treatment plans that are based upon an understanding of the physiological, environmental, and psychosocial contexts within which each person’s illnesses or dysfunctions occur. The information you need to effectively apply this organizational structure fills the remainder of this textbook. My goal here is to describe and illustrate the structure. To create it, you must start by eliciting all of the patient’s concerns. In actively listening to the patient’s story, you attempt to discover the antecedents, triggers and mediators that underlie symptoms, signs, illness behaviors, and demonstrable pathology. Functional medicine is based upon treatment that is collaborative, flexible, and focused on the control or reversal of each person’s individual antecedents, triggers and mediators, rather than the treatment of disease entities.

Eliciting the Patient’s Story The first step in patient-centered care is eliciting the patient’s story in a comprehensive manner. It is the functional medicine practitioner’s job to know not just the ailments or their diagnoses, but the physical and social environment in which sickness occurs, the dietary habits of the person who is sick (present diet and pre-illness diet), his beliefs about the illness, the

79

Section II Principles of Functional Medicine gration of antecedents (genes and the factors controlling their expression) with mediators (the downstream products of gene activation). Mediators, triggers, and antecedents are not only key biomedical concepts, they are also important psychosocial concepts. In personcentered diagnosis, the mediators, triggers, and antecedents for each person’s illness form the focus of clinical investigation.

to clarify or challenge what their doctor had said in 85% of the visits. Their requests were usually ignored or interrupted.12 Understanding the patient’s perspective allows the doctor to work in a collaborative way with patients, giving information that helps the patient make healthful choices.13 The more information the patient receives from the doctor and the more actively the patient is involved in making decisions about treatment, the higher the level of mutual satisfaction, and the better the clinical outcome.14,15,16,17,18 A systematic review of randomized clinical trials and analytic studies of physician-patient communication confirmed a positive influence of quality communication on health outcomes.19 Such a collaborative relationship depends upon the practitioner recognizing and acknowledging the patient’s experience of the illness. Useful questions to ask include: • How are you hoping that I can help you today? • What do you believe is the source of your problems? • What kind of treatment are you looking for? • What do you most fear about your illness? • What impact have your symptoms had on your life?

Antecedents and the Origins of Illness

)2

(c

Understanding the antecedents of illness helps the physician understand the unique characteristics of each patient as they relate to his or her current health status. Antecedents may be thought of as congenital or developmental. The most important congenital factor is gender: women and men differ markedly in susceptibility to many disorders. The most important developmental factor is age; what ails children is rarely the same as what ails the elderly. Beyond these obvious factors lies a diversity as complex as the genetic differences and separate life experiences that distinguish one person from another. Congenital factors may be inherited or acquired in utero. They can most readily be evaluated from a comprehensive family history, including mother’s health before and during pregnancy. Genomic analysis, which is now commercially available, can supplement the family health history as a tool for investigating unique nutritional needs or individual variability in sensitivity to environmental toxins.20,21 The most common single gene disorders in North America, celiac disease and hemochromatosis, may be confirmed by the presence of genetic markers, but should first be suspected from abnormalities in routine lab tests. Elevated serum ferritin concentration or transferrin saturation should prompt genetic testing for the alleles associated with hereditary hemochromatosis.22 Increased small intestinal permeability, as measured by the inexpensive, noninvasive and under-utilized lactulose/mannitol challenge test, has a sensitivity approaching 100% for untreated celiac disease.23 Abnormal intestinal permeability should prompt the measurement of celiacspecific immune markers in patients with chronic fatigue, autoimmune disorders, or chronic gastrointestinal complaints of any type. Normal intestinal permeability in patients consuming gluten almost always excludes celiac disease as a consideration; however, this may not necessarily be the

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Organizing and Analyzing the Patient’s Story

e

in

ic

ed

What modern science has taught us about the genesis of disease can be represented by three words: triggers, mediators, and antecedents. Triggers are discrete entities or events that provoke disease or its symptoms. Microbes are an example. The greatest scientific discovery of the 19th century was the microbial etiology of the major epidemic diseases. Triggers are usually insufficient in and of themselves for disease formation, however. Host response is an essential component. Identifying the biochemical mediators that underlie host responses was the most productive field of biomedical research during the second half of the 20th century. Mediators, as the word implies, do not “cause” disease. They are intermediaries that contribute to the manifestations of disease. Antecedents are factors that predispose to acute or chronic illness. For a person who is ill, they form the illness diathesis. From the perspective of prevention, they are risk factors. Knowledge of antecedents has provided a rational structure for the organization of preventive medicine and public health. Medical genomics seeks to better understand disease by identifying the phenotypic expression of diseaserelated genes and their products. The application of genomic science to clinical medicine requires the inte-

80

Chapter 8 Patient-centered Care: Antecedents, Triggers, and Mediators • When is the last time you felt really well for more than a few days at a time? • During the six months preceding that date, did you experience any illness or major stress, change your use of medication or dietary supplements, or make any significant life changes?

case for other gluten-sensitive disorders. Because celiac disease and gluten-sensitive disorders are common, have protean manifestations, and can be well controlled by nutritional interventions, intestinal permeability should be a routine component of the laboratory testing for antecedents of illness. The treatment of choice for frank hemochromatosis is phlebotomy, but mild iron overload without frank hemochromatosis is more common than the full-blown disease. These patients generally have only one of the alleles associated with the disease, but have elevated transferrin saturation and/or ferritin. They are not treated with phlebotomy, and should be treated with dietary interventions. They should not take iron or vitamin C supplements, because vitamin C reduces iron to its more toxic form. Some familial disorders may reflect intra-uterine rather than genetic influences. Twin studies of hypertension, for example, indicate a higher concordance for blood pressure between identical twins with a common placenta than identical twins with separate placentas.24 Presumably, the shared placenta mediates subtle nutritional influences that affect a tendency toward chronic illness in adulthood. Post-natal developmental factors that govern the predisposition to illness include nutrition, exposure to toxins, trauma, learned patterns of behavior, and the microbial ecology of the body. Sexual abuse in childhood, for example, is associated with an increased risk of abdominal and pelvic pain syndromes among women.25,26 Recurrent otitis media increases the risk of a child developing attention deficit disorder,27,28 an effect that is not associated with hearing loss but may result from the effects of antibiotics on the microbial ecology of the gut. Precipitating events are critical antecedents that closely precede the development of chronic illness. They represent a boundary in time: before this event, the person was considered healthy; since the event, the person has become a patient. Understanding the nature of the precipitating event may aid in unraveling the triggers and mediators that maintain the state of illness. The most common precipitating events among my patients are a period of severe psychosocial distress, an acute infection (sometimes treated with antibiotics), exposure to environmental toxins at work or home, or severe nutrient depletion related to illness or crash dieting. Useful questions for uncovering precipitating events include:

Other publications of this author present cases in which cryptogenic illness was found to be precipitated by foreign travel, antibiotic use, dietary changes,29 smoldering infection, or the illness of a spouse.30

Triggers and the Provocation of Illness

)2

(c

A trigger is anything that initiates an acute illness or the emergence of symptoms. The distinction between a trigger and a precipitating event is relative, not absolute; the distinction helps organize the patient’s story. As a general rule, triggers only provoke illness as long as the person is exposed to them (or for a short while afterward), whereas a precipitating event initiates a change in health status that persists long after the exposure ends. Common triggers include physical or psychic trauma, microbes, drugs, allergens, foods (or even the act of eating or drinking), environmental toxins, temperature change, stressful life events, adverse social interactions, and powerful memories. For some conditions, the trigger is such an essential part of our concept of the disease that the two cannot be separated; the disease is either named after the trigger (e.g., “strep throat”) or the absence of the trigger negates the diagnosis (e.g., concussion cannot occur without head trauma). For chronic ailments like asthma, arthritis, or migraine headaches, multiple interacting triggers may be present. All triggers, however, exert their effects through the activation of host-derived mediators. In closed-head trauma, for example, activation of NMDA receptors, induction of nitric oxide synthase (iNOS), and liberation of free intra-neuronal calcium determine the late effects. Intravenous magnesium at the time of trauma attenuates severity by altering the mediator response.31,32 Sensitivity to different triggers often varies among persons with similar ailments. A prime task of the functional practitioner is to help patients identify important triggers for their ailments and develop strategies for eliminating them or diminishing their virulence. Although the identification and elimination of triggers is not a foreign concept in conventional medicine, many physicians neglect the search. A study was

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 81

Section II Principles of Functional Medicine functions involve multiple mediators, so that redundancy is the rule, not the exception. The most striking characteristic of biochemical mediators is their lack of disease specificity. Each mediator can be implicated in many different, apparently unrelated diseases, and every disease involves multiple chemical mediators in its formation.

conducted by telephone in which practicing physicians were asked how they would treat a new patient with abdominal pain, who had a recent diagnosis of gastritis made by a specialist in another town. Almost half were ready to put the patient on acid-lowering therapy without asking about the patient’s use of aspirin, alcohol or tobacco, all of which are potential triggers for gastritis. The authors of the study concluded, “In actual practice, ignoring these aspects of the patient may well have reduced or even negated the efficacy of other therapeutic plans implemented.”33

Table 8.1 Common Illness Mediators Biochemical

Hormones Neurotransmitters Neuropeptides Cytokines Free radicals Transcription factors

Subatomic

Ions Electrons Electrical and magnetic fields

Mediators and the Formation of Illness

)2

(c

A mediator is anything that produces symptoms, damage to tissues of the body, or the types of behaviors associated with being sick. Mediators vary in form and substance. They may be biochemical (like prostanoids and cytokines), ionic (like hydrogen ions), social (like reinforcement for staying ill), psychological (like fear), or cultural (like beliefs about the nature of illness). A list of common mediators is presented in Table 8.1. Illness in any single person usually involves multiple interacting mediators. Biochemical, psychosocial, and cultural mediators interact continuously in the formation of illness. Cognitive/emotional mediators determine how patients appraise symptoms and what actions they take in response to that appraisal.34 They may even modulate the symptoms themselves. People in pain, for example, experience more pain when they fear that pain control will be inadequate than when they believe that ample pain management is available.35 Perceived self-efficacy (the belief in one’s ability to cope successfully with specific problems) is a cognitive mediator that determines coping with illness. People with a high degree of health self-efficacy usually adapt better to chronic disease, maintaining higher levels of activity, requiring lower doses of pain medication, adopting healthier lifestyles, and cooperating with prescribed therapies, compared to people with low self-efficacy.36 Self-management education is designed to enhance selfefficacy,37 and has been shown to improve the clinical outcome for patients with several types of chronic disease, including asthma,38 arthritis,39,40,41 and diabetes.42 The biochemical mediators of disease listed in Table 8.1 are best known for their ability to promote cellular damage. Most are organized into circuits and cascades that sub-serve homeostasis and allostasis. In these networks, each mediator is multi-functional and most

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Fear of pain or loss Feelings or personal beliefs about illness Poor self-esteem, low perceived self-efficacy Learned helplessness Lack of relevant health information

Social/cultural

Reinforcement for staying sick Behavioral conditioning Lack of resources due to social isolation or poverty The nature of the sick role and the doctor/patient relationship

ic

ed

Cognitive/emotional

e

in

Mediator networks that regulate inflammatory and neuroendocrine stress responses have been the subject of intensive research with important clinical implications. A detailed discussion of these networks is outside the scope of this chapter, but they are addressed in Chapters 19, 23, 27, and 32; see the index for further crossreferencing. Comprehensive reviews have appeared elsewhere.43,44,45,46 Within the framework of functional medicine, a key feature of biochemical mediators is the natural rhythm of mediator activity, which is strongly influenced by the common components of life: diet, sleep, exercise, hygiene, social interactions, solar and lunar cycles, age, and sex. Aging, illness, and chronic psychological distress upregulate activity of the inflammatory and neuroendocrine-stress response networks. Regular physical activity downregulates both.

82

Chapter 8 Patient-centered Care: Antecedents, Triggers, and Mediators

Integrating the Patient’s Story

ing, a self-administered questionnaire completed by the patient before the interview may help to prompt responses and improve memory of remote events. For many patients with complex, chronic health problems, it may be useful to take a detailed life history before seeking detailed information about present symptoms. Problems that emerge from such a review have to be addressed for a successful outcome of treatment. Dealing with the present concerns by themselves almost never succeeds for patients in this group.

After listening to the concerns that led each patient to seek a consultation in functional medicine, the clinician makes a series of distinctions: 1. For patients whose main concern is optimal health and prevention, ask about present and past health problems and the family health history. If these supply no indication of illness susceptibility, then turn your attention to risk factors for future illness: weight, fitness, type and level of physical activity, dietary pattern, sleep habits, use of alcohol, drugs, tobacco, firearms, environmental exposures at home and work, travel, sources of stress and pleasure, degree of involvement with others, spiritual beliefs and practices, sexual relationships, hopes and fears for the future. 2. For patients with an active health problem, always ask, “What was your health like before this problem began?” An intake questionnaire that asks about previous health problems is also helpful, because it gathers information in a different fashion concerning what the patient was like prior to the present illness. Such a tool is condition-specific, not openended. The two approaches complement one another. a. Some patients will say that they were really healthy prior to their present illness. In that case, look for a precipitating event. If you or the patient can identify one, then ask about ongoing triggers that bear some relationship to the precipitating event. For example: if the precipitating event was marital or job stress, focus on stress-related psychological triggers. If the precipitating event was an environmental exposure, focus on ongoing exposures to volatile chemicals or mold. b. The most challenging patients will usually indicate that their health was poor even before their present illness. In that case, take a detailed, chronological history from birth to the present that includes information about early life experience (including illness, injury and abuse), school and work performance, diet, drug and medication use, leisure activities, travel, family life, sexual experiences, habits, life stressors, and places of residence. Because gathering this data can be very time consum-

)2

(c

Whatever rapport you establish with patients initially, maintaining the therapeutic relationship usually depends upon significant improvement in symptoms or in a sense of well-being within a few days to a few weeks of the initial evaluation. This is most efficiently achieved by addressing the triggers that provoke symptoms and helping the patient decrease exposure to them. When triggers cannot be identified or avoided, then symptomatic improvement must rest on control of mediator activation. A combination of the two will usually produce the most satisfactory long-term benefits.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Assessment of Triggers

e

in

ic

ed

A comprehensive search for triggers requires that you know the following about your patient: each drug—prescription, over-the-counter or recreational—that the patient has used and when; nutritional habits and each dietary supplement used and when; what effects the patient noted from the use of each substance; sources of stress—life events, environmental exposures, thoughts or memories, and social interactions—and when they occurred in relation to symptoms. Elicit the patient’s own ideas about possible triggers by asking, “What do you think causes or aggravates your symptoms?” The patient’s observations may be insightful and accurate in ascribing causality. Of course the patient’s—and the clinician’s—observations can also mislead, or focus on non-essential factors. Teach patients to challenge their own observations by looking for consistency and replicability, wherever possible. Suggest alternative theories for the patient to consider and explain that the search for triggers works best as a collaborative effort between patient and doctor. The patient’s ability to recognize triggers is an important step in self-care.

83

Section II Principles of Functional Medicine particle air pollution and daily mortality rates, even at levels of pollution considered safe by the World Health Organization.71 In the industrialized world, most people spend most of their time indoors, and indoor air pollution has become a serious cause of morbidity. Studies using experimental chambers have shown that volatile organic compounds (VOCs) released from building materials, furnishings, office machines, and cleaning products can cause irritation of the respiratory system in humans and animals at levels 100 times weaker than permissible exposure levels or the World Health Organization Indoor Air Guidelines.72,73,74 Controlled experiments with people who describe themselves as sensitive to VOCs confirm that VOC exposure causes headache, fatigue, and difficulty concentrating. People who deny such sensitivity also experience symptoms, but do not experience mental impairment when exposed. Air samples of buildings with and without “sick building” complaints have established an association between VOC exposure and human sickness.75,76,77,78 A questionnaire can elicit important information about environmental exposures at home and at work. The open-ended question, “Has your work or home environment been a concern to you?” should be accompanied by a checklist of potential exposures. Microbial triggers for chronic illness present a particular challenge, as exemplified by the many facets of Helicobacter pylori infection. Originally isolated from the gastric mucosa of patients with gastritis and peptic ulcer disease, H. pylori has been implicated in the pathogenesis of NSAID gastropathy,79 gastric carcinoma,80 lymphoma,81 and a variety of extra-digestive disorders, including ischemic heart disease,82 ischemic cerebrovascular disorders,83 rosacea,84 Sjögren’s syndrome,85 Raynaud’s syndrome,86 food allergy,87 vitamin B12 deficiency,88 and open-angle glaucoma.89 For elderly patients with open-angle glaucoma and incidental H. pylori infection of the stomach, eradication of H. pylori by antibiotics was associated with improved control of glaucoma parameters at two years.90 The mechanism by which H. pylori aggravates open-angle glaucoma is unknown, but may result from the ability of H. pylori colonization of the gastric tract to trigger the local and systemic release of platelet-activating factor, inflammatory cytokines, and vasoactive substances. In the case of untreated H. pylori infection, noninvasive screening tests, including serum antibodies, stool antigens, and C-14 breath testing, are available. For

)2

(c

Food and environment supply important triggers for the practice of functional medicine. Food intolerance is a very common phenomenon, reported by 33% of the population in one large study.47 Relatively few of these reactions (4–14%) are due to true food allergies. Most food intolerance has no clear immunologic basis. Mechanisms include sensitivity to the pharmacological effect of alkaloids, amines or salicylates in food.48,49,50,51 Histamine poisoning from scombroid fish and tyramineinduced headache are dramatic examples.52 Although most food intolerance is short-lived, severe chronic illness can occur, and the food trigger may elude identification unless the physician starts the investigation with a high index of suspicion. Gluten intolerance, with its protean manifestations, is probably the best example. Affecting about 2% of people of European ancestry,53 gluten intolerance is common and often unrecognized. In addition to being the essential trigger for celiac disease, gluten sensitivity may be manifest in patients with neurological disorders of unknown cause,54 cerebellar degeneration,55 dermatitis herpetiformis,56 failure to thrive,57 pervasive developmental delay,58 inflammatory arthritis,59,60,61,62,63 psoriasis,64,65 Sjögren’s syndrome,66,67 and schizophrenia.68,69 The different presentations of gluten sensitivity may derive from genetic differences among affected patients.70 Published studies on food intolerance and your patients’ symptoms may be found through the National Library of Medicine. If the patient has a disease diagnosis, an internet search may reveal previously observed associations between specific foods and the patient’s condition. Access PubMed over the internet (www.pubmed.gov) and run a search that cross-references the name of the patient’s condition with “Hypersensitivity, food” and also with “Food, adverse reactions.” Both of these are Medline Subject Headings (MeSH). There is no MeSH listing for “food allergy” or “food intolerance.” Your search will be more efficient if you list the patient’s condition as it appears in MeSH. A negative search does not eliminate food intolerance as a trigger for the condition being searched, but the number of positive findings may surprise you.i Health effects of ambient air quality are as important as those of foods. Numerous studies conducted in U.S. cities demonstrate a close correlation between fine-

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

i Medical cybrarian Valerie Rankow ([email protected]) has assisted the author with this search strategy and with numerous other, more complex searches.

84

Chapter 8 Patient-centered Care: Antecedents, Triggers, and Mediators • Are there people in whom you can confide? • How satisfied are you with your marriage/family/ friends/social life? • How much support do you receive in dealing with your health problems? • How often do you feel loved or cared for?

other types of infection, inquiring about the previous response of a given symptom or symptom complex to antibiotics may be useful. In 1988, physicians at the University of Minnesota conducted a study in which they administered intravenous cephalosporins to patients with various types of arthritis who also manifested antibodies to Borrelia burgdorferi. Most of these patients were not thought to have Lyme disease. Some met diagnostic criteria for rheumatoid arthritis, some for osteoarthritis, and some for spondyloarthropathies. The response to antibiotics was quite variable and ranged from no response to dramatic and sustained improvement. The authors noted that improvement in arthritis following antibiotics was not related to the patient’s clinical diagnosis or the level of anti-Borrelia antibody. The best predictor of a positive response to the experimental treatment was a previous history of improvement of arthritis associated with the use of antibiotics.91 The most comprehensive way to ask the antibiotic question is: “During the time you have had symptom X, have you taken antibiotics for any reason? Which antibiotic? Did symptom X change while you were taking the drug?” Among patients with chronic diarrhea of unknown cause, for example, some will report that their gastrointestinal symptoms improved when taking a specific antibiotic; others will report that they worsened. The first case suggests that bacteria or protozoa sensitive to the antibiotic may be causally related to the patient’s gastrointestinal problems. Repeating the antibiotic prescription can establish if this response is replicable. If so, therapy can focus on treating the microbe and understanding why a single course of antibiotics was ineffective. The second case suggests that depletion of bacteria by antibiotics and concomitant increase in antibiotic-resistant organisms, including yeasts, may be contributing to diarrhea, and treatment can focus on restoration of normal intestinal flora.

Assessment of Biochemical Mediators

)2

(c

Understanding the biochemical alterations associated with a conventional disease diagnosis can be helpful in understanding the biochemical mediators of each person’s illness. Inflammation is believed to play a critical role not only in response to infection and in the classic inflammatory diseases, but also in the pathogenesis of coronary artery disease, diabetes, cancer, depression, and the negative health effects associated with obesity and with aging.92,93,94,95,96,97,98 The orchestration of mediator signals in the inflammation and neuroendocrine-stress networks, as they interact with one another, is critical for normal physiological functions (e.g., the architecture of sleep, the repair of injury, and the response to infection), and for the dysfunctional physiology central to the pathogenesis of most of the major chronic diseases.99,100,101 Most chronic disease is associated with chronic inflammation, but the patterns of immune response that underlie inflammation are not always the same. Patients with type 1 diabetes mellitus, Crohn’s disease or any other disorder categorized by granuloma formation or excessive cell-mediated immune responses are likely to have an immune response to common triggers in which the Th1 component is upregulated and not subject to the normal downregulation provided by Th2 activity. Their mediator response to inflammatory stimulation produces excessive levels of gamma interferon and interleukin-12 (IL-12), key Th1-related cytokines.102 Patients with severe depression often show a loss of negative feedback in the HPA axis. Urinary free cortisol is elevated; the diurnal pattern may be disrupted, with increased PM cortisol secretion and blunting of dexamethasone suppression. This phenomenon appears to be driven at the level of the hypothalamus, not the adrenals, because spinal fluid corticotropin-releasing hormone (CRH) is elevated.103 Several groups of researchers in the late 1990s speculated that impaired synaptic function due to a deficit of omega-3 fatty acids may contribute to the CNS dysfunction of patients with depressive illness104,105,106,107 (although some large recent

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Assessment of Psychosocial Mediators Useful questions for eliciting a person’s beliefs about his/her illness are: • What do you think has caused your problem? • What do you most fear about your problem? • How much control do you think you have over your symptoms? Useful questions for eliciting information about the nature and sources of social support include:

85

Section II Principles of Functional Medicine studies do not show the same patterns108,109). Omega-3 fatty acid levels tend to be lower in blood samples than in control populations. The key component appears to be eicosapentaenoic acid (EPA). To utilize the vast database of available information about biochemical disease mediators, integrative clinicians should consider three strategies. First, maintain upto-date knowledge of disease pathophysiology by reading reviews in mainstream journals on mechanisms of disease or on specific mediators. In reading these, pay special attention to the types of mediators mentioned and their functions within the networks that involve inflammation, oxidative stress, and neuroendocrine balance. Second, attend workshops and courses that emphasize integrative physiology, sponsored by institutions like IFM, the New York Academy of Sciences, the Center for Mind-Body Medicine, and the American College for Advancement in Medicine.110 Third, employ knowledge of the most common biochemical imbalances in chronically ill North Americans and the influence of diet, nutrition, and dietary supplements on these imbalances.

)2

(c

The physician can help patients who are suffering from isolation by calling this isolation to the attention of family members or friends, or by attempting to connect the patient with a support group or community agency. Possibly, there is nothing that can be done to relieve the patient’s isolation, but the doctor’s awareness and acknowledgment of it can be important to the patient and serve to enhance the therapeutic relationship.113 If potential triggers have been identified, an assessment of the patient’s ability to control exposure to them is important. For patients who are reluctant to make major dietary or environmental changes, explain that each avoidance is an experiment that the patient can direct with your guidance. If eliminating foods (and reintroducing those foods as a challenge) has no effect on symptoms or measurable physiologic parameters, do not encourage the patient to persist in the avoidance of those foods, whatever the results of in vitro allergy tests may be. The patient will have enough work to do following a healthy diet. Food intolerance is only meaningful if its effects can be demonstrated in real life. For microbial triggers, the decision to use prescription antimicrobial drugs or natural products with antimicrobial activity may require negotiation. If the situation is not critical, it is usually worthwhile honoring the patient’s preferences and intuition. Understanding the ways in which mediators are modulated by diet enables creative nutritional therapies to be applied. Salicylic acid, the major metabolite of aspirin, suppresses activation of the nuclear transcription factor NFB, an anti-inflammatory effect that is independent of cyclooxygenase inhibition114 and may be responsible for some effects of low-dose aspirin therapy.115 Vegetables are rich sources of natural salicylates and vegetarians may have serum concentrations of salicylic acid as high as those of people ingesting 75 mg of aspirin a day.116 Dietary fatty acids may have profound effects on the network of inflammatory mediators, altering prostanoid synthesis, PPAR activity, and the response to cytokines like IL-1.117,118,119 They have subtler effects on the neuroendocrine-stress response network, modulating neuronal responses to serotonergic and adrenergic transmission.120 Therapy with omega-3 fatty acids provides an excellent example of nutritional modulation of disease activity though alteration of biochemical mediators.121 Three principles can guide this type of therapy. The first utilizes knowledge of the pathophysi-

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Treatment Planning

e

in

ic

ed

A functional medicine treatment plan should be collaborative and dynamic. Collaborative means that patient and practitioner work together to set goals and priorities. Dynamic means that the treatment plan is adjusted as needed in response to feedback. Your knowledge of the patient’s beliefs about his/her illness and perceived self-efficacy are essential for collaborative treatment. An appropriate therapeutic intervention for dysfunctional beliefs is the giving of information. Patients have an intense need for explanations about the causes of their diseases.111 They want to know how they came to be sick, so that they can attach some meaning to the illness,112 what to expect from the illness, and what they can do to relieve symptoms or speed recovery. Information of this type can reduce anxiety (even when the diagnosis itself is frightening), increase feelings of personal control, and improve the ability to cope with pain. People change their behaviors more readily when they receive information about the importance and the nature of the changes they need to make, help with setting goals, and measuring progress. The kind of information needed is personal, not statistical. It must answer the question, “What can I do?”

86

Chapter 8 Patient-centered Care: Antecedents, Triggers, and Mediators

Summary

ology of specific inflammatory and CNS disorders. Using this model, omega-3 therapy has been successfully applied to the treatment of patients with rheumatoid arthritis,122 inflammatory bowel disease,123 coronary artery disease,124 peripheral vascular disease,125 dysmenorrhea,126 cystic fibrosis,127 migraine headaches,128 schizophrenia,129,130 atopic eczema,131 and multiple sclerosis.132,133 Because the fatty acid composition of the contemporary Western diet differs significantly from Paleolithic and ancestral diets, reflecting a marked decrease in omega-3 consumption relative to total fat, the response of so many unrelated disorders to EFA supplementation may indicate that EFAs are not merely working as nutraceutical agents, but that EFA dietary status is important for disease pathogenesis. The second method rests upon the clinical evaluation of an individual’s fatty acid status using clinical parameters that are independent of disease activity. Prasad has stated that the best test for nutritional adequacy is a functional test.134 Determine a parameter to follow and measure how administration of the nutrient(s) in question affects that parameter. This method can be applied to the use of EFA therapy in clinical practice. Stevens et al., studying boys with ADHD and a randomly selected population of schoolchildren, found a correlation between low concentrations of omega-3 EFAs, learning and behavior problems, and symptoms associated with EFA deficiency (thirst, dry skin, and dry hair).135,136 Evaluating the presence of these symptoms in patients and observing how they change with EFA supplementation is a quick guide to EFA status that may be used clinically to evaluate the EFA contribution to mediator imbalance. This author’s method for doing this has been described elsewhere.137 Finally, it is possible to measure the levels of fatty acids in plasma and erythrocyte phospholipids, although guidelines for the level of change in fatty acid profiles needed to produce a known clinical effect have only been reported for patients with rheumatoid arthritis, in whom clinical improvement requires that eicosapentaenoic acid (EPA) account for 5% of fatty acids in plasma phospholipids.138 The successful application of nutritional therapies, especially dietary interventions, and other self-care practices, as part of a therapeutic plan is very helpful in enhancing self-efficacy among patients. Enhancement of self-efficacy should always be a cardinal goal of treatment in functional medicine.

)2

(c

Functional medicine is essentially patient centered, rather than disease centered. A structure is presented for uniting a patient-centered approach to diagnosis and treatment with the fruits of modern clinical science (which evolved primarily to serve the prevailing model of disease-centered care). The core scientific concepts of disease pathogenesis are antecedents, triggers, and mediators. Antecedents are factors, genetic or acquired, that predispose to illness; triggers are factors that provoke the symptoms and signs of illness; and mediators are factors, biochemical or psychosocial, that contribute to pathological changes and dysfunctional responses. Understanding the antecedents, triggers, and mediators that underlie illness or dysfunction in each patient permits therapy to be targeted to the needs of the individual. The conventional diagnosis assigned to the patient may be of value in identifying plausible antecedents, triggers or mediators for each patient, but is not adequate by itself for the designing of patient-centered care. Applying the model of person-centered diagnosis to patients facilitates the recognition of disturbances that are common in people with chronic illness. Diet, nutrition, and exposure to environmental toxins play central roles in functional medicine because they may predispose to illness, provoke symptoms, and modulate the activity of biochemical mediators through a complex and diverse set of mechanisms. Explaining those mechanisms is a key objective of this textbook. A patient’s beliefs about health and illness are critically important for self-care and may influence both behavioral and physiological responses to illness. Perceived self-efficacy is an important mediator of health and healing. Enhancement of patients’ self-efficacy through information, education, and the development of a collaborative relationship between patient and healer is a cardinal goal in all clinical encounters.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All References 1. 2. 3. 4.

87

Galland L, “Person-Centered Diagnosis,” in Power Healing. New York:Random House, 1997, pp 52-97. Reiser SJ. The era of the patient. Using the experience of illness in shaping the missions of health care. JAMA. 1993;269:1012-1017. Beckman HB, Frankel RM. The effect of physician behavior on the collection of data. Ann Intern Med. 1984;101:692-696. Frankel R. Talking in interviews: a dispreference for patient-initiated questions in physician-patient encounters. In Studies in Ethnomethodology and Conversation Analysis. No. 1. G Psathas, ed. The International Institute for Ethnomethodology and Conversa-

Section II Principles of Functional Medicine

5. 6.

7.

8. 9. 10. 11.

17. 18.

19.

24. 25.

26. 27.

28.

e

23.

in

22.

ic

21.

ed

20.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

16.

0

15.

01

14.

)2

13.

(c

12.

29. Galland, L. A New Definition of Patient-Centered Medicine. In Integrative Medicine, Principles for Practice. Edited by B. Kligler and R. Lee, 2004. New York, McGraw Hill, pp 71-101. 30. Galland, L. Power Healing. New York:Random House, 1997, pp 52-114. 31. Cernak I, Savic VJ, Kotur J, et al. Characterization of plasma magnesium concentration and oxidative stress following graded traumatic brain injury in humans. J Neurotrauma. 2000;17(1):53-68. 32. Vink R, Nimmo AJ, Cernak I. An overview of new and novel pharmacotherapies for use in traumatic brain injury. Clin Exp Pharmacol Physiol. 2001;28(11):919-921. 33. Avorn J, Everitt DE and Baker MW. The neglected medical history and therapeutic choices for abdominal pain: A nationwide study of 799 physicians and nurses. Arch Intern Med. 1991;151:694-98. 34. Kleinman A, Eisenberg L, Good B. Culture, illness and care. Clinical lessons from anthropologic and cross-cultural research. Ann Intern Med. 1978;88:251-58. 35. O'Leary A. Self-efficacy and health. Behav Res Ther. 1985;23(4):437-51. 36. Holden G. The relationship of self-efficacy appraisals to subsequent health-related outcomes: a meta-analysis. Soc Work Health Care. 1991;16:53-93. 37. Bodenheimer T, Lorig K, Holman H, Grumbach K. Patient selfmanagement of chronic disease in primary care. JAMA. 2002;288:2469-75. 38. Wilson SR, Scamagas P, German DF, et al. A controlled trial of two forms of self-management education for adults with asthma. Am J Med. 1993;94:564-76. 39. Mullen PD, LaVille EA, Biddle AK, Lorig K. Efficacy of psychoeducational interventions on pain, depression, and disability in people with arthritis: a meta-analysis. J Rheumatol. 1987;14 (suppl 15):33-39. 40. Schiaffino KM, Revenson TA, Gibofsky A. Assessing the impact of self-efficacy beliefs on adaptation to rheumatoid arthritis. Arthritis Care Res. 1991;4:150-57. 41. Lorig KR, Mazonson PD, Holman HR. Evidence suggesting that health education for self-management in patients with chronic arthritis has sustained health benefits while reducing health care costs. Arthritis Rheum. 1993;36:439-46. 42. Litzelman DK, Slemenda CW, Langefeld CD, et al. Reduction of lower extremity clinical abnormalities in patients with non-insulin dependent diabetes mellitus. A randomized, control trial. Ann Intern Med. 1993;119:36-41. 43. Habib KE, Gold PW, Chrousos GP. Neuroendocrinology of stress. Endocrinol Metab Clin North Am. 2001;30:695-728. 44. Miller DB, O'Callaghan JP. Neuroendocrine aspects of the response to stress. Metabolism. 2002;51(6 Suppl 1):5-10. 45. Petrovsky N. Towards a unified model of neuroendocrine-immune interaction. Immunol Cell Biol. 2001;79:350-57. 46. Chikanza IC, Grossman AB. Reciprocal interactions between the neuroendocrine and immune systems during inflammation. Rheum Dis Clin North Am. 2000;26:693-71. 47. Bender AE, Matthews DR. Adverse reactions to foods. Br J Nutr. 1981;46:403-7. 48. Moneret-Vautrin DA. Food antigens and additives. J Allergy Clin Immunol. 1986;78:1039-46. 49. Kniker WT, Rodriguez M. Non-IgE mediated and delayed adverse reactions to food or additives. In Handbook of Food Allergies, ed. JC Breneman, 1987, New York, Marcel Dekker, pp 125-161. 50. Perry CA, Dwyer J, Gelfand JA, et al. Health effects of salicylates in foods and drugs. Nutr Rev. 1996;54(8):225-40. 51. Lovenberg W. Some vaso- and psychoactive substances in food: amines, stimulants, depressants and hallucinogens. In Toxicants Occurring Naturally in Foods. (2nd Ed). Eds:Committee on Food

tion Analysis and University Press of America. Washington D.C. 1990:231-262. Roter DL, Hall JA. Physician interviewing styles and medical information obtained from patients. J Gen Intern Med. 1987;2(5):325-29. Bartlett EE, Grayson M, Barker R, et al. The effects of physician communications skills on patient satisfaction; recall and adherence. J Chronic Dis. 1984;37:755-64. Smith RC, Hoppe RB. The patient's story: integrating the patientand physician-centered approaches to interviewing. Ann Intern Med. 1991;115:470-477. Sanchez-Menegay C, Stalder H. Do physicians take into account patients' expectations? J Gen Intern Med. 1994;9:404-406. Beckman DB, Frankel RM The effect of physician behavior on the collection of data. Ann Intern Med. 1984;101:692-696. Sanchez-Menegay C, Stalder M. Do physicians take into account patients' perspectives? J Gen Intern Med. 1994;9:404-406. Freidin RB, Goldin L, Cecil RR. Patient-physician concordance in problem identification in the primary care setting. Ann Intern Med. 1980;93(3):490-93. Tucket D. Meetings Between Experts: An Approach to Sharing Ideas in Medical Consultations. London and New York, Tavistock Publications, 1985. Hall JA, Roter DL, and Katz NR, Meta-analysis of correlates of provider behavior in medical encounters. Med Care. 1988;28:657-75. Kaplan SH, Greenfield S, Ware JE Jr. Assessing the effects of physician-patient interactions on the outcomes of chronic disease. Med Care. 1989;27 Suppl 3:S110-127. Ades PA, et al, Predictors of cardiac rehabilitation participation in older coronary patients. Arch Intern Med. 1992;152:1033-35. Mullen PD. Efficacy of psychoeducational interventions on pain, depression and disability in people with arthritis: a meta-analysis. J Rheumatol. 1987;14 Suppl 15:33-39. Wilson SR, et al. A controlled trial of self-management education for adults with asthma. Am J Med. 1993;94:564-576. Lorig KR, Mazonson PD, Holman HR. Evidence suggesting that health education for self-management in patients with chronic arthritis has sustained health benefits while reducing health care costs. Arthritis Rheum. 1993;36:439-46. Teutsch C. Patient-doctor communication. Med Clin North Am. 2003;87(5):1115-45. Guengerich FP. Functional genomics and proteomics applied to the study of nutritional metabolism. Nutr Rev. 2001;59:259-62. Pennie W, Pettit SD, Lord PG. Toxicogenomics in risk assessment: overview of an HESI collaborative research program. Environ Health Perspect. 2004;112:417-19. Pietrangelo A. Hereditary hemochromatosis—a new look at an old disease. N Engl J Med. 2004;350:2383-97. Vogelsgang H, Schwarzenhofer M, Oberhuber G. Changes in gastrointestinal permeability in celiac disease. Dig Dis. 1998;16:333-36. Phillips DW. Twin studies in medical research. (letter) Lancet. 1993;342:52. Romans S, Belaise C, Martin J, et al. Childhood abuse and later medical disorders in women. An epidemiological study. Psychother Psychosom. 2002;71(3):141-50. Lampe A, Solder E, Ennemoser A, et al. Chronic pelvic pain and previous sexual abuse. Obstet Gynecol. 2000;96(6):929-33. Hagerman RJ, Falkenstein AR. An association between recurrent otitis media in infancy and later hyperactivity. Clin Pediatr (Phila). 1987;26(5):253-57. Adesman AR, Altshuler LA, Lipkin PH, Walco GA. Otitis media in children with learning disabilities and in children with attention deficit disorder with hyperactivity. Pediatrics. 1990;85(3):442-6.

88

Chapter 8 Patient-centered Care: Antecedents, Triggers, and Mediators

52. 53. 54.

55.

56.

57.

)2

(c

58.

73. Dockery DW, Schwartz J, Spenger JD. Air pollution and daily mortality: association with particulates and acid aerosols. Environ Res. 1992;59:362-73. 74. Dockery DW, Pope A, Xu X, et al. An association between air pollution and mortality in six U.S. cities. N Engl J Med. 1993;329:1753-59. 75. Hodgson MJ, Frohlinger J, Permar E, et al. Symptoms and microenvironmental measures in non-problem buildings. J Occup Med. 1991;35:527-33. 76. Hodgson MJ. Buildings & health. Health Environ Dig. 1993;7:1-3. 77. Norback D, Torgen M, Edling C. Volatile organic compounds, respiratory dust and personal factors related to the prevalence and incidence of SBS in primary schools. Br J Ind Med. 1990;47:733-41. 78. Hodgson M. Field studies on the sick building syndrome. In Sources of indoor air contaminants: Characterizing emissions and health impacts. Tucker WG, Leaderer BP, Molhave L, Cain WS, eds. Ann N Y Acad Sci. 1992;641:21-36. 79. Chan FK, To KF, Wu JCY, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomized trial. Lancet. 2002;359:9-13. 80. Uemara N, Okamoto S, Yamamoto S, et al. Helicobacter pylori and the development of gastric cancer. N Engl J Med. 2001;345:784-89. 81. Wotherspoon AC, Dogliani C, Diss TC, et al. Regression of primary low-grade B-cell lymphoma of mucosal-associated lymphoid tissue after eradication of Helicobacter pylori. Lancet. 1993;342:575-77. 82. Mendall MA, Goggin OM, Molineaux N, et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J. 1994;71:437-39. 83. Markus HS, Mendel MA. Helicobacter pylori: a risk factor for ischemic cerebrovascular disease and carotid atheroma. J Neurol Neurosurg Psychiatry. 1998;64:104-7. 84. Szlachcic A, Sliwowski Z, Karczewska E, et al. Helicobacter pylori and its eradication in rosacea. Physiol Pharmacol. 1999;50:777-86. 85. Aragona P, Magazzu G, Macchia G, et al. Presence of antibodies against Helicobacter pylori and its heat-shock protein 60 in the serum of patients with Sjögren’s syndrome. J Rheumatol. 1999;26:1306-11. 86. Gasbarrini A, Franceschi F, Arnuzzi A, et al. Extradigestive manifestations of Helicobacter pylori gastric infection. Gut. 1999;45 (suppl):I9-I12. 87. Matysiak-Budnik T, Heyman M. Food allergy and Helicobacter pylori. J Pediatr Gastroenterol Nutr. 2002;34:5-12. 88. Kaptan K, Beyan C, Ural AU, et al. Helicobacter pylori: is it a novel causative agent in vitamin B12 deficiency? Arch Intern Med. 2000;160:1349-53. 89. Kountouras J, Mylopoiulos N, Boura P, et al. Relationship between Helicobacter pylori infection and glaucoma. Ophthalmology. 2001;108:599-604. 90. Kountouras J, Mylopoulos N, Chatzopoulos D, et al. Eradication of Helicobacter pylori may be beneficial in the management of chronic open-angle glaucoma. Arch Intern Med. 2002;162:1237-44. 91. Caperton EM, Heim-Duthoy KL, Matske GR, et al. Ceftriaxone therapy of chronic inflammatory arthritis: a double-blind placebocontrolled trial. Arch Intern Med. 1990;150:1677-82. 92. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999;353:1649-52. 93. Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;2823:2131-35. 94. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-26.

Protection, Food & Nutrition Board, National Research Council. Natl. Acad. Sci. Press. Washington DC. 1973, pp 170-188. Somogyi JC. Natural toxic substances in food. World Rev Nutr Diet. 1978;29:42-59. Catassi C, Ratsch IM, Fabiani E, et al. Coeliac disease in the year 2000: exploring the tip of the iceberg. Lancet. 1994;343:200-3. Hadjivasssiliou M, Gibson A, Davies-Jones GAB, et al. Does cryptic gluten sensitivity play a part in neurological illness? Lancet. 1996;347:369-71. Hadjivasssiliou M, Grunewald RA, Chattopadhyay AK, et al. Clinical, radiological, neurophysiological, and neuropathological characteristics of gluten ataxia. Lancet. 1998;352:1582-85. Collin P, Reunala T. Recognition and management of the cutaneous manifestations of celiac disease: a guide for dermatologists. Am J Clin Dermatol. 2003;4(1):13-20. Wolff A, Berger R, Gaze H, et al. IgG, IgA and IgE gliadin antibody determinations as screening test for untreated coeliac disease in children, a multicentre study. Eur J Pediatr. 1989;148(6):496-502. Jyonouchi H, Sun S, Itokazu N. Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiol. 2002;46(2):76-84. Ramos-Remus C, Bahlas S, Vaca-Morales O. Rheumatic features of gastrointestinal tract, hepatic, and pancreatic diseases. Curr Opin Rheumatol. 1997;9(1):56-61. Falcini F, Ferrari R, Simonini G, et al. Recurrent monoarthritis in an 11-year-old boy with occult coeliac disease. Successful and stable remission after gluten-free diet. Clin Exp Rheumatol. 1999;17(4):509-11. Kallikorm R, Uibo O, Uibo R. Coeliac disease in spondyloarthropathy: usefulness of serological screening. Clin Rheumatol. 2000;19(2):118-22. Slot O, Locht H. Arthritis as presenting symptom in silent adult coeliac disease. Two cases and review of the literature. Scand J Rheumatol. 2000;29(4):260-63. Bagnato GF, Quattrocchi E, Gulli S, et al. Unusual polyarthritis as a unique clinical manifestation of coeliac disease. Rheumatol Int. 2000;20(1):29-30. Lindqvist U, Rudsander A, Bostrom A, et al. IgA antibodies to gliadin and coeliac disease in psoriatic arthritis. Rheumatology (Oxford). 2002;41(1):31-37. Michaelsson G, Gerden B, Hagforsen E, et al. Psoriasis patients with antibodies to gliadin can be improved by a gluten-free diet. Br J Dermatol. 2000;142(1):44-51. Teppo AM, Maury CP. Antibodies to gliadin, gluten and reticulin glycoprotein in rheumatic diseases: elevated levels in Sjögren's syndrome. Clin Exp Immunol. 1984;57(1):73-78. Collin P, Korpela M, Hallstrom O, et al. Rheumatic complaints as a presenting symptom in patients with coeliac disease. Scand J Rheumatol. 1992;21(1):20-23. Dohan, FC. Is celiac disease a clue to the pathogenesis of schizophrenia? Ment Hyg. 1969;53(4):525-29. Vlissides DN, Venulet A, Jenner FA. A double-blind gluten-free/gluten-load controlled trial in a secure ward population. Br J Psychiatry. 1986;148:447-52. Karell K, Korponay-Szabo I, Szalai Z, et al. Genetic dissection between coeliac disease and dermatitis herpetiformis in sib pairs. Ann Hum Genet. 2002;66(6):387-92. Schwartz J, Dockery DW. Particulate air pollution and daily mortality in Steubenville, Ohio. Am J Epidemiol. 1992;135:12-19. Schwartz J, Dockery DW. Increased mortality in Philadelphia associated with daily air pollution concentrations. Am Rev Respir Dis. 1992;145:600-4.

62.

63.

64.

69.

70.

71. 72.

e

68.

in

67.

ic

66.

ed

65.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

61.

0

60.

01

59.

89

Section II Principles of Functional Medicine 116. Blacklock CJ, Lawrence JR, Wiles D, et al. Salicylic acid concentrations in the serum of subjects not taking aspirin: comparison of salicylic acid concentrations in the serum of vegetarians, non-vegetarians and patients taking low-dose aspirin. J Clin Pathol. 2001;54:553-55. 117. Calder PC, Grimble RF. Polyunsaturated fatty acids, inflammation and immunity. Eur J Clin Nutr. 2002:56 Suppl 3:S14-19. 118. Chambrier C, Bastard JP, Rieusset J, et al. Eicosapentaenoic acid induces mRNA expression of peroxisome proliferator-activated receptor gamma. Obes Res. 2002;10:518-25. 119. Diep QN, Touyz RM, Schiffrin EL. Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogenactivated protein kinase. Hypertension. 2000;36:851-55. 120. Chalon S, Vancassel S, Zimmer L, et al. Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission. Lipids. 2001;36:937-44. 121. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002;21(6):495-505. 122. Belch JJF, Ansell D, Madhok R, et al. Effects of altering dietary essential fatty acids on requirements for non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis: a double blind placebo controlled study. Ann Rheum Dis. 1988;47:96-104. 123. Stenson WF, Cort D, Rodgers J, et al. Dietary supplements with fish oil in ulcerative colitis. Ann Intern Med. 1992;116:609-14. 124. Gapinski JP, VanRuiswyk V, Heudebert GR, Schectman GS. Preventing restenosis with fish oils following coronary angioplasty. Arch Int Med. 1993;153:1595-1601. 125. Nestares T, Lopez-Jurado M, Urbano G, et al. Effects of lifestyle modification and lipid intake variations on patients with peripheral vascular disease. Int J Vitam Nutr Res. 2003;73(5):389-98. 126. Harel Z, Biro FM, Kottenhahn RK, Rosenthal SL. Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents. Am J Obstet Gynecol. 1996;174(4):1335-38. 127. Lawrence R, Sorrell T. Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet. 1993;342:465-69. 128. McCaren T, Hitzeman R, Smith R, et al. Amelioration of severe migraine by fish oil (n-3) fatty acids. Am J Clin Nutr. 1985;41:874. 129. Yao JK, Magan S, Sonel AF, et al. Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 2004;71(3):171-76. 130. Fenton WS, Dickerson F, Boronow J, et al. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry. 2001;158(12):2071-74. 131. Mayser P, Mayer K, Mahloudjian M, et al. A double-blind, randomized, placebo-controlled trial of n-3 versus n-6 fatty acid-based lipid infusion in atopic dermatitis. J Parenter Enteral Nutr. 2002;26(3):151-58. 132. Nordvik I, Myhr KM, Nyland H, Bjerve KS. Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol Scand. 2000;102(3)143-49. 133. Bates D, Cartlidge NEF, French JM, et. al. A double-blind controlled trial of n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1989;52:18-22. 134. Prasad AS. Zinc in growth and development and spectrum of human zinc deficiency. J Am Coll Nutr. 1988;7(5):377-84. 135. Stevens LJ, Zentall SS, Deck JL, et al, Essential fatty acid metabolism in boys with attention deficit hyper activity disorder. Amer J Clin Nutr. 1995;62:761–68.

)2

(c

95. Abramson JL, Vaccarino V. Relationship between activity and inflammation among apparently healthy middle-aged and older adults. Arch Int Med. 2002;162:1286-92. 96. Maes M. Major depression and activation of the inflammatory response system. In Cytokines, Stress and Depression, edited by Danzer et al. Kluwer Academic/Plenum Publishers. New York. 1999, pp 25-46. 97. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology. 2002;16:217-26, 229. 98. Franceschi C, Ottaviani E. Stress, inflammation and natural immunity in the aging process: a new theory. Aging (Milano). 1997;9(4 Suppl):30-31. 99. Elenkov IJ, Chrousos GP. Stress hormones, proinflammatory and anti-inflammatory cytokines, and autoimmunity. Ann NY Acad Sci. 2002;966:290-303. 100. Petrovsky N. Towards a unified model of neuroendocrine-immune interaction. Immunol Cell Biol. 2001;79:350-57. 101. Jessop DS, Harbuz MS, Lightman SL. CRH in chronic inflammatory stress. Peptides. 2001;22:803-07. 102. Libby P. Inflammation: a common pathway in cardiovascular diseases. Dialogues Cardiovasc Med. 2003;8:59-73. 103. Wong ML, Kling MA, Munson PJ, et al. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci USA. 2000;97(1):325-30. 104. Maes M, Christophe A, Delanghe J, et al. Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res. 1999;85(3):275-91. 105. Peet M, Murphy B, Shay J, et al. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry. 1998;43(5):315-19. 106. Adams PB, Lawson S, Sanigorski, A, et al. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids. 1996;31 Suppl:S157-61. 107. Stoll AL, Locke CA, Marangell LB, Severus WE. Omega-3 fatty acids and bipolar disorder: a review. Prostaglandins Leukot Essent Fatty Acids. 1999;60:329-37. 108. Hakkarainen R, Partonen T, Haukka J, et al. Food and nutrient intake in relation to mental wellbeing. Nutr J. 2004;3:14. 109. Jacka EN, Pasco JA, Henry MJ, et al. Dietary omega-3 fatty acids and depression in a community sample. Nutr Neurosci. 2004;7(2):101-06. 110. www.acam.org; www.functionalmedicine.org 111. Korsch BM, Gozzi EK, Francis V. Gaps in doctor-patient communication. I: Doctor-patient interaction and patient satisfaction. Pediatrics. 1968;42:855-71. 112. Williams GH, Wood PHN. Common-sense beliefs about illness: a mediating role for the doctor. Lancet. 1986;328:1435-37. 113. Eisenberg L. What makes persons “patients” and patients “well.” Am J Med. 1980;69(2):277-86. 114. Gautam SC, Pindolia KR, Noth CJ, et al. Chemokine gene expression in bone marrow stromal cells: downregulation with sodium salicylate. Blood. 1995;86(7):2541-50. 115. Giggs GA, Salmon JA, Henderson B, Vane JR. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and anti-inflammatory activity. Proc Nat Acad Sci USA. 1987;84:1417-20.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 90

Chapter 8 Patient-centered Care: Antecedents, Triggers, and Mediators 136. Stevens LJ, Zentall SS, Abate ML, et al. Omega-3 fatty acids in boys with behavior, learning and health problems. Physiol Behav. 1996;59:75-90. 137. Galland L. Power Healing. New York: Random House, 1997, pp. 156-162. 138. Clelland LG, Proudman SM, Hall C, et al. A biomarker of n-3 compliance in patients taking fish oil for rheumatoid arthritis. Lipids. 2003;38:419-24.

)2

(c 0

01 e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 91

Section II Principles of Functional Medicine

)2 (c

0 01

e in ic ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

92

Chapter 9 Homeostasis: A Dynamic Balance Joseph J. Lamb, MD Homeostasis is defined in Stedman’s Medical Dictionary as: 1. The state of equilibrium (balance between opposing pressures) in the body with respect to various functions and to the chemical compositions of the fluids and tissues. 2. The processes through which such bodily equilibrium is maintained.5

(c

Introduction

)2

The next principle of the functional medicine paradigm is the importance of the search for dynamic balance among the internal and external factors in a patient’s body, mind, and spirit. Human life is dependent upon an intricate balance of minerals,1 water,2 organic molecules, and high-energy chemical bonds. Ever since the coalescing of the first molecules capable of replication, and the development of the first cells capable of creating an internal environment, organisms have been characterized by cellular organization, growth and metabolism, reproduction, and heredity. They have also interacted with the external environment. From these simple beginnings have come the great diversity of all plant and animal life and the majesty of human life. Despite the vast complexity inherent in the organization of a human being, the system operates within relatively narrow limits for healthy balance, as dictated by our biochemistry.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

This balance of chemical interactions defines how well and how long our bodies function. In their classic Textbook of Medical Physiology, Guyton and Hall describe this automatic process:

ed

The very fact that we remain alive is almost beyond our own control, for hunger makes us seek food and fear makes us seek refuge. Sensations of cold make us provide warmth. Other forces cause us to seek fellowship and to reproduce. Thus, the human being is actually an automaton, and the fact that we are sensing, feeling and knowledgeable beings is part of this automatic sequence of life … .6

in

ic

In the conventional model, this equilibrium is often viewed at its simplest solely as a balance of internal factors alone. However, our understanding of these unique forces has evolved as our understanding of human genomics, cell signaling pathways, and the mind-body connection has developed. C.H. Waddington in 1968 “introduced the term homeorrhesis to capture the idea that what living things really hold ‘constant is not a single parameter, but a time extended course of change, that is to say, a trajectory.’”7 And in a series of papers beginning in1979, J.E.Yates described a physical biology model for the description of motion and changes at all biological levels of organization which he called homeodynamics. 8 And yet, functional medicine envisions an even more vibrant and active dynamic. Taking into account

e

Homeostasis and Homeodynamics Of necessity, the cells of our bodies, with their own unique intracellular environment, are also bathed in a unique external environment: the extracellular fluid. One of the first to explore the concept of balance, the 19th century French physiologist, Claude Bernard, described the extracellular fluid as the “milieu interieur” or internal environment.3 In 1929, Walter Cannon, the noted Harvard physiologist who first advanced the “fight vs. flight” hypothesis, formally suggested “the name homeostasis for the functional organization by which an organism will retain its original condition after a transient perturbation that is not actually damaging.”4

93

Section II Principles of Functional Medicine the concepts of biochemical individuality and health as a positive vitality (not the simple absence of disease), homeodynamics is the constant and vital process of balancing external and internal factors to achieve a healthy functional state.9 Indeed, as described in the Textbook of Natural Medicine,10

A pivotal study by Lichtenstein et al., exploring the causation of cancer in a pooled cohort of monozygotic and dizygotic twins from Sweden, Denmark, and Finland, found that “statistically significant effects of heritable factors were observed for prostate cancer (42%), colorectal cancer (35%), and breast cancer (27%).”13 While they found familial (hereditary or nonhereditary) factors for many types of cancer, the rates of concordance between twins were generally below 10%. They estimated the contribution of non-shared environmental factors for different cancers to range from 58% to 82%. This study demonstrates that environmental inputs, including diet and nutrients, air and water, exercise, toxic load from the environment, and psychosocial factors and how we interpret them, contribute significantly to our phenotypic expression. This freedom from genetic determinism is a liberating concept of functional medicine. We are thus given the wonderful opportunity to provide our patients with patient centered, biochemically individualized lifestyle and nutritional interventions to assist them in maintaining their unique homeodynamic balance.

)2

(c

The term “homeodynamic” describes a range of continuously occurring metabolic and physiologic activities that enable an individual to adapt to changing circumstances, stresses, and experiences. The homeodynamics of one’s health are constantly at work to enable a person to function as a unique individual. Supporting health at a homeodynamic level may require one to focus attention on cellular processes or organ function at sites that seem to be far removed from the patient’s area of discomfort, and at levels that may be unusual from a conventional point of view.

01

0

The recent focus on energy production and mitochondrial dysfunction, oxidative stress, neuroexcitotoxicity, and inflammation manifested by glial activation as causes of neurodegenerative diseases provides an excellent example of this model.11 Inherent in this sense of balance are the mechanisms by which the organism controls and maintains this homeodynamic stability and flexibility. Classically, we know of the negative and positive feedback cycles of allopathic and functional medicine. Naturopathic and functional medicines also acknowledge that there are two internal forces, a higher and a lower drive, which maintain this unique individual internal balance. These two forces together constitute the profound self-generated ability to heal, classically known in the naturopathic tradition as vis medicatrix naturae. The lower drive is, in many ways, the classic automatic balance described by Guyton and Hall. This inherent internal healing mechanism can be augmented greatly by the higher drive. “The higher drive is the power of the mind and emotions to intervene and affect the course of health and disease by depressing or stimulating the internal capacities.”12 Thus, the great diversity that creates biochemical individuality is not the simple genetically determined outcome of biochemical interactions written into our genotypes at birth. Instead, this welcome diversity is a reflection of the interaction of genetic, environmental, and mind-body factors that allow each human to have the unique breadth of experience that characterizes human life.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Homeodynamic Balance: Physiological Processes

e

in

ic

ed

The maintenance of this unique balance of pathophysiological processes is coordinated by a variety of communication systems, both neural and hormonal. Classically, these systems involve the secretion of a chemical messenger or hormone to act either locally (both on an intracellular as well as an intercellular level) or more distantly (intercellular level). These chemical messengers and hormones can be classified into two distinct groups by the site of action in the target cell. The first group, including polypeptide hormones as well as monoamines and prostaglandins, does not enter the cell, but instead interacts with cell membrane receptors to signal change via second-level messengers such as cyclic adenosine monophosphate, inositol triphosphate, and diacylglycerol, and also by stimulation of the nucleotide regulatory peptides (Gproteins) that bind guanosine triphosphate.14 The second group enters the cell and interacts with a diverse collection of nuclear receptors. These receptors, for thyroid and steroid hormones, vitamin A and D derivatives, endogenous metabolites, phytonutrients, and xenobiotics, “are structurally related and collectively

94

Chapter 9 Homeostasis: A Dynamic Balance referred to as the nuclear receptor super family.”15 As many of the ligands for these receptors have not been identified, these undefined receptors have been labeled the orphan nuclear receptors. The peroxisome proliferator-activated receptors (PPARs) are one subfamily of nuclear receptors and are activated by endogenous intermediate metabolites of polyunsaturated fatty acids. PPAR, expressed primarily in adipocytes, has a crucial role in adipocyte differentiation as well as a probable role in modulating insulin sensitivity.16 Memisglu and his colleagues have investigated the link between a PPAR polymorphism and dietary fat intake in relation to body mass.17 They showed that total dietary fat intake was positively associated with body mass index (BMI) among homozygous wild-type individuals but not among carriers of a variant allele. Additionally, they demonstrated that monounsaturated fat was inversely related to BMI among carriers of the variant allele. They concluded that the PPAR genotype modulates physiological responses to dietary fat. Conversely, environment—in the form of dietary fat intake—has direct influence on our genotype, pushing the resultant phenotype toward obesity. Vitamins have been shown to have central roles in metabolism both as substrate and important cofactors in enzymatic conversions. Two vitamins, specifically vitamins A and D, are also messengers with specific nuclear receptors. Cantorna and her colleagues have explored the effect of vitamin D in experimental autoimmune encephalomyelitis (EAE), a mouse model for multiple sclerosis (MS).18 They showed that development of EAE was completely prevented by pretreatment with 1,25-dihydroxyvitamin D3 and that disease progression was also prevented by treatment with 1,25dihydroxyvitamin D3. They conclude that their findings “provide strong evidence that vitamin D status may be an important factor in determining the incidence of MS and that it is a physiologically important immune system modulator.”19 Another example of environmental influence on metabolism and disease expression is indole-3-carbinol (I3C). I3C is an endogenous metabolite of glucosinolates in the Brassica family of vegetables—specifically broccoli, cauliflower, cabbage, kale, and Brussels sprouts. I3C has been found to exert a chemopreventive effect on breast cancer by inducing tumor cell apoptosis20 and by stimulation of tumor-suppression genes.21

)2

(c

Certainly, one of the most interesting recent advances is the recognition of the diverse group of phytonutrient and environmental influences that provide information through the orphan nuclear receptors. These receptors may have developed for these specific molecules because their presence in the external environment was a measure of the safety of this outer environment. When our hunter-gatherer ancestors ate a diet rich in the appropriate phytonutrients and fatty acids, these messages of bounty signaled that it was safe to grow, to reproduce, indeed to come out of the sheltering caves. When the diet shifted, orphan nuclear receptors may have recognized the changing pattern of nutrient-based information and secreted messages of alarm and inflammation that instead stimulated pathways of conservation as they sought shelter for the dark winter months. Further research will offer functional medicine practitioners a broader understanding of the influence of environment on our genotype and new opportunities to modulate this interaction.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All Summary

e

in

ic

ed

Each individual is much more than the simple product of genetic expression directing the construction of shared building blocks. Instead, phenotypic expression is the unique product of an ever-changing dance between genes and environment as the individual strives to create a unique, harmonious balance. Homeodynamic physiologic processes modulate the constant interplay of environmental inputs with our genetic programming. Modifiable lifestyle choices and nutritional choices can influence the expression of wellness or disease by our biochemically unique metabolisms.

References 1. 2.

3. 4.

5.

95

Kurokawa K. How is plasma calcium held constant? Milieu interieur of calcium. Kidney Int. 1996;49(6):1760-64. Acher R. Water homeostasis in the living: molecular organization, osmoregulatory reflexes and evolution. Ann Endocrinol (Paris). 2002;63(3):197-218. Guyton AC, Hall JE. Textbook of Medical Physiology. Philadelphia: W.B. Saunders Company, 2000, p.1. Yates FE. From Homeostasis to Homeodynamics—Energy, Action, Stability, Senescence. 2002. http://www.biodynamic healthaging.org/Abstracts/YatesNIAsynopsis.pdf. p.1 Hensyl WR (Ed.). Illustrated Stedman’s Medical Dictionary. Baltimore: Lippincott Williams and Wilkins, 2000.

Section II Principles of Functional Medicine 6. 7.

8.

9. 10. 11. 12.

18.

19. 20.

21.

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

17.

0

16.

01

15.

)2

14.

(c

13.

Guyton AC, Hall JE. Textbook of Medical Physiology. Philadelphia: W.B. Saunders Company, 2000, p.1. Waddington CH; Towards a Theoretical Biology, Vol. One. Aldine, Chicago: Prolegomena, 1968 in Yates FE. From Homeostasis to Homeodynamics—Energy, Action, Stability, Senescence. 2002. http://www.biodynamichealthaging.org/Abstracts/YatesNIA synopsis.pdf. p.1 Yates FE. From Homeostasis to Homeodynamics—Energy, Action, Stability, Senescence. 2002. http://www.biodynamichealthaging. org/Abstracts/YatesNIAsynopsis.pdf. p.1 Pizzorno JE Jr., Murray MT. Textbook of Natural Medicine. Edinburgh; Churchill Livingstone, 1999. p.10. Ibid. Willner C. An overview of the pathophysiology of neurodegenerative disorders. Altern Ther Health Med. 2004;10:26-34. Pizzorno JE Jr., Murray MT. Textbook of Natural Medicine. Edinburgh; Churchill Livingstone, 1999. p.57. Lichtenstein P, et al. Environmental and heritable factors in the causation of cancer. N Engl J Med. 2000;343:78-85. Ganong WF. Review of Medical Physiology. Stamford, Connecticut; Appleton & Lange, 1997. Larsen PR, et al. William’s Textbook of Endocrinology. Philadelphia; Elsevier Science (USA), 2003, p. 35. Larsen PR, et al. William’s Textbook of Endocrinology. Philadelphia; Elsevier Science (USA), 2003, p. 36. Memisoglu A, et al. Interaction between a peroxisome proliferatoractivated receptor gamma gene polymorphism and dietary fat intake in relation to body mass. Hum Mol Genet. 2003;12:2923-29. Cantorna MT. et al. 1,25-dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA. 1996;93:7861-64. Ibid. Sarkar FH, et al. Bax translocation to mitochondria is an important event in inducing apoptotic cell death by indole-3-carbinol treatment of breast cancer cells. J Nutri. 2003;133:2434S-39S. Firestone GL, et al. Indole-3-carbinol and 3-3’-diindolymethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp1 transcription factor interactions. J Nutri. 2003;133:2448S-55S.

96

Chapter 10 Web-like Interconnections: The Complex Human Organism 

Web-like Interconnections of Physiological Factors Organ System Function and Underlying Mechanisms: The Interconnected Web

)2

(c



01

0

Web-like Interconnections of Physiological Factors Introduction

lM na tio d. un rve r F se fo re te ts itu h st rig In All

DeAnn Liska, PhD, and Dan Lukaczer, ND

many different functions and systems, and the situations in which no major imbalance can be found, but several pathways seem to be off-center, or skewed enough to affect overall the pattern of health. The web is multidirectional—multiple factors can underlie a single condition, and multiple conditions can be influenced by a single dysfunctional process or imbalanced system. Therefore, instead of looking for a single “root cause” of a disease and finding the “cure” from a single pill, in functional medicine we ask what is unbalanced, what has shifted the flow of biochemical information, energy, physical structure, and emotions too far to one side or the other of a healthy range, thus skewing the web. For many conditions, especially conditions associated with aging—like Alzheimer’s disease, heart disease, or various arthritic conditions—finding a single root cause that will explain all the occurrences in all people is not possible. No single culprit exists and no single pill will cure these conditions in every patient. Instead, there are many influences, and there may be many imbalances, each contributing something to the outcome. Scientists and clinicians unraveling the web are likely to find a very complex set of interrelationships among myriad factors for each of these conditions. In functional medicine, we ask about the patterns that are present and how these patterns are aiding or taking away from optimal function. Although every person is unique, with a unique set of genes interacting with the

e

in

ic

ed

Science is a process of unraveling a phenomenon; persistence in the process, until the phenomenon is understood at deeper levels, is absolutely necessary. The body, however, isn’t like a mystery novel; there isn’t one villain to be found among a number of innocent bystanders caught up in the action. The body is much more complex, continually interacting with the environment and responding in minute ways. Take something as simple as the breath we take thousands of times a day. The rhythm of breath is affected by a brief noise, stopping it for a moment, or a smell, making us take a shorter quick huff or a longer, deep inhalation. All of this we may do with little conscious awareness. Looking in a mirror, it’s easy to think that the body is solid and formed, with little change in any given moment. But we are not statues. Our bodies are fully interconnected, complex, functioning organisms in which we have a constant flow of air, fluids, and energy upon a mutable matrix; nothing is ever still inside our bodies. Every twitch, every thought, every touch of the world around us on our skin elicits a response, causing a biochemical change that influences another change and then another. This is the web of our being, and in functional medicine, we use the model of a web to understand this complexity. The web model can explain the situations in which one major imbalance influences

97

Section II Principles of Functional Medicine cemia occurs as the liver continues to secrete normal amounts of glucose into a greatly expanded plasma glucose pool.4 With increasing hyperglycemia, there is a further reduction in beta cell function (possibly as a result of glucotoxicity) and a further drop in insulin. It is estimated that the vast majority of the 16 million people diagnosed with type 2 diabetes in the U.S. carry the underlying pathophysiology of insulin resistance.5 Many factors play into that situation: overweight, sedentary lifestyle, dietary choices, stress, and genetics are some of the most important. While muscle and adipose tissue are generally resistant to the imbalanced insulin signal, other tissues are not, and a cascading host of metabolic consequences and dysfunction ensues. Elevated insulin directly stimulates lipogenesis in arterial tissue and enhances the growth and proliferation of arterial smooth muscle cells; hyperinsulinemia decreases fibrinolysis by stimulating plasminogen activator inhibitor-1 (PAI-1),6,7 which is associated with an increased risk for coronary thrombosis; and hyperinsulinemia leads to increased hepatic production of triglycerides (TG) and inhibition of high-density lipoproteins (HDL). Elevated TG and depressed HDL are important risk factors for coronary heart disease (CHD). These skewed pathways ultimately result in an increased incidence of CHD.8,9,10 Insulin resistance also plays a key role in hypertension; as much as 50% of the hypertensive population appears to be insulin resistant.11 It has been proposed that a large segment of essential hypertension is caused by enhanced renal sodium reabsorption in the distal tubule, which is promoted by hyperinsulinemia.12 Hyperinsulinemia may also play a role by altering internal sodium and potassium distribution in a direction that is associated with increased peripheral vascular resistance.13 Insulin appears to work through other mechanisms as well to increase sympathetic nervous system activity and thus peripheral resistance.14 Furthermore, insulin resistance and hyperinsulinemia appear to have a critical relationship to androgen hormonal modulation. Research over the past 10 years has linked insulin with PCOS.15 Studies have shown that high circulating insulin may stimulate ovarian cytochrome P450c17 and 17,20-lyase enzymes in predisposed women, resulting in elevations in serum and free unbound testosterone, which are associated with the signs and symptoms seen in PCOS. Insulin influences the androgenic state, not only by directly affecting the metabolism of ovarian androgens, but also indirectly by

environment in a distinct, personal way, there are some major pathways we can monitor that will help us see where the imbalances are most likely to be found. Fundamentally, we look for the major points of activity on the web that, when skewed, are likely to influence many different parts of a person’s biochemistry and physiology. The applications of this principle—web-like interconnections—are deeply explored throughout the chapters in Section VI: A Practical Clinical Approach. Here, we simply present the principle for your consideration.

Web-like Interconnections of Cellular Insensitivity to Insulin Signaling

(c

)2

Let’s look at one example of a complex underlying physiological dysfunction that can manifest in a variety of ways: the dysfunction of cellular insensitivity to insulin signaling. It is an excellent model for visualizing the interconnections of complex, chronic disease. Commonly referred to as the insulin resistance syndrome or metabolic syndrome, this multifaceted condition weaves its way through a web of interactions that manifest in a multitude of dysfunctions. Over 60 years ago, Dr. H.P. Himsworth used the term “insulin insensitivity” to describe his observation that diabetes was not generally associated with low insulin levels but with cellular insensitivity to insulin.1 It took another 40 years until a consensus was reached on this radical notion. It is now clear that the vast majority of patients with type 2 diabetes have an insulin insensitivity that impairs their ability to adequately dispose of glucose; further, this defect—if discovered before frank diabetes is present—is predictive of the development of the disease.2,3 As prescient an observation as it was, Himsworth probably did not fully understand the broader implications of his discovery. There is now a substantial and growing body of evidence that suggests insulin resistance is an underlying biochemical imbalance in not only type 2 diabetes, but cardiovascular disease (CVD), hypertension, polycystic ovary syndrome (PCOS), and even colon and some breast cancers. How does insulin insensitivity relate to diabetes? Fundamentally, individuals who develop type 2 diabetes have a decline in the insulin secretory response. With insulin levels declining, circulating free fatty acids (FFAs)—which are normally suppressed by insulin—then rise. FFAs, in turn, stimulate hepatic glucose production. Without the normal insulin inhibitory signal, hypergly-

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 98

Chapter 10 Web-like Interconnections: The Complex Human Organism

Summary

regulating circulating levels of sex hormone-binding globulin (SHBG). Insulin has been shown to lower the production of SHBG.16 SHBG binds to testosterone and estrogens, making them biologically unavailable and thus lowered SHBG indirectly increases the delivery of unbound and bioavailable testosterone to tissues.17 Insulin resistance also appears to be related to certain forms of cancer. One hypothesis has postulated a link between colorectal cancer, insulin resistance, and hyperinsulinemia.18 While the epidemiological data are not completely consistent, the two largest prospective studies to date do support a modest correlation between colorectal cancer risk and diabetes.19,20 Even more recently, speculation has centered on the link between hyperinsulinemia and breast cancer.21 It has been known for some time that exposure of breast tissue to estrogens increases the risk of estrogen receptor-positive breast cancers. It is also well established that only the estrogens that are unbound to SHBG are biologically available to receptors on target cells. As mentioned, insulin inhibits the formation of SHBG. While SHBG binds to both testosterone and estrogen, it binds preferentially to testosterone, so decreased levels of SHBG result in increased levels of free unbound estrogen.22 A more graphic representation of these and other relationships can be seen in Figure 10.1.

)2

(c

As can be seen in this brief analysis, a specific dysfunction can result in myriad symptoms and can be caused by myriad factors. In this example, the imbalance is not confined to the single molecule, insulin; rather, it manifests in how the body secretes and responds to insulin. Promoting a healthy insulin response may involve many different factors. It is only by examining the web-like interconnections among these symptoms and factors that we can achieve a comprehensive assessment for the patient. As functional medicine clinicians, we examine the underlying imbalances; we ask ourselves what preceded and what triggered them; we look at upstream and downstream effects; and then we search for interventions that can affect the underlying interconnected pathways so that normal and even optimal function can be restored. Understanding how to rebalance important pathways in the body—establishing healthy and balanced weblike interconnections—is the key to reestablishing a healthy pattern of function.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Organ System Function and Underlying Mechanisms: The Interconnected Web Alex Vasquez, DC, ND

Environmental Inputs Sedentary lifestyle decreased insulin sensitivity.

Introduction

ed

Understanding the scientific basis and clinical applications of functional medicine and a “whole patient” approach to health care requires that clinicians fully appreciate the interconnectedness of organ system function with biochemical and physiological processes. Simplistic models of health and disease developed decades ago may no longer be accurate or clinically useful insofar as they fail to reflect the more recently discovered complex and multifaceted interrelationships. (Figure 10.2 uses the functional medicine matrix to depict some of this complexity.) As discussed earlier in this chapter, numerous mechanisms mediate these interrelationships, including, but not limited to, those that can be described as biochemical, hormonal, neurological, immunological, piezoelectric, and physical or mechanical. Ultimately, we are forced to dissolve the artificial intellectual boundaries we have created between organ systems and expand our appreciation

Hyperglycemia reactive oxygen species (ROS) microvascular Injury, atherosclerotic changes, and complications of diabetes.

e

Insulin Resistance/ Metabolic Syndrome

in

Energy Production/ Oxidative Stress

Immune/Inflammatory Imbalance Obesity (adipose tissue) adipokines Inflammation risk of CVD.

ic

High-glycemic-index diet Insulin secretion Insulin sensitivity.

Hormonal and Neurotransmitter Imbalance Mind and Spirit Stress, particularly in women high-glycemicindex diet obesity.

insulin testosterone: PCOS. insulin free unbound estrogen: breast cancer. Insulin sensitivity altered sodium and potassium distribution increased peripheral vascular resistance and hypertension.

Figure 10.1 Web-like interconnections: Insulin resistance syndrome

99

Section II Principles of Functional Medicine detoxification) and overall health (e.g., immune response) by numerous mechanisms and with positive effects or negative consequences. (See Chapter 13 for a detailed discussion of microorganisms.) The various organs and tissues of the gastrointestinal tract perform the complex functions of digestion, absorption, exclusion, excretion, immunologic defense, antigen sampling, and temporary storage of food residues and other substances that have been ingested. The mucosa is selectively permeable and allows the absorption of nutrients and other molecules via transcellular and paracellular routes. Compromise of mucosal integrity due to injury from antigens, infection, systemic inflammation, or toxicants such as ethanol or nonsteroidal anti-inflammatory drugs, increases absorption of potentially harmful substances that are normally excluded when mucosal integrity has not been breached. Materials that are harmless when rejected by the selectivity of the intestinal mucosa can, when inappropriately absorbed, serve as a source of inflammatory and immunogenic stimuli for the embedded macrophages in the liver (Kupffer cells) and also for the systemic immune system and the brain’s embedded astrocytes and microglia. This phenomenon is clearly demonstrated by the neurological complications and focal white-matter lesions seen in the brains of patients sensitized to the dietary antigen gluten; in this scenario, it appears that dietary antigens cross a damaged mucosal lining and escape filtration by the liver to produce a systemic inflammatory response that manifests clinically as neurologic disease.23,24 It seems likely that other antigens are also capable of inducing a systemic inflammatory response in susceptible individuals. The two most voluminous substances in the gastrointestinal tract are food antigens and microbial metabolites and debris, notably lipopolysaccharides (LPS, endotoxin) from gram-negative bacteria. These foreign substances normally excluded by an intact mucosa can serve as mediators of physiologic disruption (hence the importance of their exclusion), and indeed this is what has been observed in experimental and clinical data. For example, in patients with autism, increases in inflammatory mediator production are seen following exposure of monocytes to dietary allergens and LPS.25 We also note that LPS is a potent inhibitor of numerous cytochrome P450 biotransformation pathways, thus leading to impaired drug metabolism as demonstrated in recent clinical trials.26,27 The implica-

of individual molecules, cellular messengers, and the physiologic mechanisms that mediate intercellular communication and coordinate inter-organ function. Environmental Inputs Diet, Nutrition, Exercise, Trauma

Immune and Inflammatory Balance

Oxidative Stress and Energy Production

Detoxification

Gastrointestinal Status

Hormones and Neurotransmitters

Structural

(c )2

Mind, Spirit, Emotions, and Community

01

0

Figure 10.2 Web-like interconnections of the functional medicine matrix

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

in

ic

ed

The following discussion provides some specific examples of this profound interconnectedness that is a foundational principle of functional medicine. In this section, we will survey current research literature documenting the interconnected nature of some key organ systems and disease processes. With these examples, clinicians will better appreciate how the gastrointestinal, immune, cardiac, neurologic, and other systems interact with and depend upon each other for optimal physiologic function. Likewise, clinicians will understand more completely how essentially any dysfunction or lesion in the body can have clinically significant implications and distant adverse effects. From this perspective, individualized clinical interventions can be designed and employed to deliver better health outcomes.

Gastrointestinal Tract and Liver While the liver and the gastrointestinal tract share an obvious anatomic connection via the portal circulation, the functional clinical implications of this connection are often not fully appreciated. Not only is the gastrointestinal tract the recipient of massive amounts of “external information” in the form of nutrients, toxicants, and allergens that weigh in at more than 1,538 pounds (700 kilograms) per year, but the gastrointestinal tract is also a reservoir for the several hundred species and subspecies of yeast, bacteria, and other microbes with the potential to modify hepatic function (e.g.,

100

Chapter 10 Web-like Interconnections: The Complex Human Organism a wide range of clinical manifestations including rhinoconjunctivitis, chronic sinusitis, dermatitis, epilepsy, migraine, hypertension, joint inflammation, and mental depression.38,39 The immunopathogenesis generally includes multiple mechanisms and is not limited to mediation via IgE antibodies and histamine. Indeed, the pathophysiology of “food allergy” is commonly seen with numerous (not singular) aberrations in physiologic function, including responses mediated by or resultant from antibodies (including IgE, IgG, and/or possibly IgA classes of antibodies), cytokine-mediated responses (e.g., TNF-), increased intestinal permeability, occult gastrointestinal inflammation, and alterations in gastrointestinal microflora.40 To be more complete, our conceptualization of “food allergy” must also include awareness of enterometabolic disorders (i.e., the interconnections between food, intestinal flora, and systemic health41) as well as contributions from neurogenic inflammation (i.e., the translation of immunogenic inflammation to a neurologic signal with systemic proinflammatory effects42). Aberrations in gastrointestinal microflora can provoke a cascade of physiologic responses that may lead to widespread physiologic imbalances and result in a variety of clinical manifestations that may or may not conform to a recognized pattern or named disease even though the patient is highly symptomatic.43 Furthermore, we can conclude from recent literature that the concept of molecular mimicry is now well established and that it provides us a model with which to apprehend the induction of immune dysfunction (especially autoimmunity) by microorganisms with immunogenic epitopes that are structurally similar to those in human tissues.44 Thus, the link between “dysbiotic” gastrointestinal flora such as Klebsiella pneumoniae and systemic immune-mediated inflammatory disorders such as ankylosing spondylitis and chronic uveitis has a biological and scientific basis. Individualized assessment and treatment of such dysbiotic loci, whether in the gut, genitourinary tract, or nasopharynx, are likewise supported by current research and offer the hope of cure rather than an endless and additive cycle of anti-inflammatory and anti-rheumatic drugs. For example, evidence now shows that the systemic autoimmune disease Wegener’s granulomatosis may be triggered and perpetuated by molecular mimicry with occult respiratory infections caused by Staphylococcus aureus, and that eradication of the infection can result in clinical improvement and

)2

(c

tions of these data are profound and correlate closely with phenomena observed in clinical practice, namely that patients with irritable bowel syndrome—a condition causatively associated with both food intolerance and bacterial overgrowth of the small bowel—commonly report environmental sensitivity and medication intolerance. One plausible answer to the conundrum of the chronically unwell patient—typified by the patient with chronic fatigue or environmental illness—now becomes clear: overgrowth of the small bowel with LPS-producing bacteria leads directly to the gastrointestinal symptoms of gas and bloating, with immune system activation,28 and also reduces hepatic clearance of metabolites, toxicants, and xenobiotics to which the patient eventually becomes sensitized (immunologically and/or non-immunologically). This explains, at least in part, the rationale for and impressive clinical efficacy associated with the implementation of clinical therapeutics that simultaneously improve intestinal microecology, improve mucosal integrity, and provide biochemical/nutritional support for the processes of detoxification.29,30

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Gastrointestinal Tract and Immune System

e

in

ic

ed

Any discussion of the role of the gastrointestinal tract in relation to the immune system must include a view of the gut that is inclusive of its contents of food antigens, intraluminal microbes, and their debris and metabolic products. When the gut is simply pictured as a passive semi-sterile tube with food entering one end and feces exiting the other, then it would appear an unlikely locus of immunogenic stimulation and neurogenic inflammation that can have systemic health consequences.31,32,33,34,35 Conversely, appreciation of the manifold quantitative and qualitative variables that can exist hidden from both the clinician’s external view and the endoscopist’s internal camera enables practitioners to have a more realistic perspective on the influence that gastrointestinal function, dietary antigens, and microflora can have on extra-gastrointestinal processes and overall health.36,37 The combination of a hypersensitive/dysregulated immune system and exposure to dietary antigens sets the stage for the clinical phenomenon commonly described as “food allergy.” Diverse in frequency, duration, severity, and quality, these immune-mediated adverse reactions to foods can precipitate or exacerbate

101

Section II Principles of Functional Medicine examples are Parkinson’s disease and the autistic spectrum disorders. Indeed, the strength of evidence supporting the hepato-gastrointestinal link with these “neurologic” conditions is so strong that it could be logically argued that any treatment of these conditions that does not address the hepatic and enteric aspects of these diseases is therapeutically incomplete. Although Parkinson’s disease was once considered idiopathic, we now recognize it as being a multifaceted disorder associated with defective mitochondrial function, impaired xenobiotic detoxification, and occupational and/or recreational exposure to toxicants, particularly pesticides. These associations align to create a new model for the illness based on exposure to neurotoxicants such as pesticides,56 which are ineffectively detoxified57 and then accumulate in the brain,58 inducing mitochondrial dysfunction59 and oxidative stress,60 and leading to the death of dopaminergic neurons. Therefore, from the perspective of both prevention and treatment, the clinical approach to Parkinson’s disease must include pesticide avoidance and optimization of detoxification to prevent the neuronal accumulation of neurotoxic mitochondrial poisons. The plan must also include optimization of nutritional status, antioxidant capacity, and mitochondrial function.61 The view that autism is a behavioral problem unfortunately continues to permeate present-day medical treatment of this condition, and many pediatricians and psychiatrists still advise only behavioral therapy and medicalization with psychoactive pharmaceuticals, particularly selective serotonin reuptake inhibitors (SSRIs).62,63 While these interventions produce modest improvements over those seen in control groups, neither intervention remotely addresses the complex underlying physiology nor offers the possibility of cure, and SSRI use in children is highly controversial due to the association with increased incidence of suicide.64 We now know that autism is a multifaceted disorder associated with gastrointestinal inflammation, nutritional deficiencies,65 multiple food allergies and intolerances,66 impairments in liver detoxification and resultant accumulation of xenobiotics, the majority of which have neurotoxic and/or immunotoxic effects.67 Thus, autism is not a behavioral disorder per se; rather, it is a gastrointestinal-allergic-immunological-toxicantnutritional-environmental disorder, and the behavioral/ cognitive abnormalities are symptoms of the underlying complex and interconnected pathophysiology. See

reduced need for ongoing anti-rheumatic medication.45,46,47 In addition to molecular mimicry, microbes (i.e., occult infections and environmental exposures) can also alter immune regulation by serving as a source of superantigens, which cause widespread and multifaceted immune dysfunction with resultant proinflammatory effects contributing to the exacerbation of allergy and autoimmune disease.48

Immune System and Cardiovascular System

)2

(c

The role of subclinical inflammation in the etiopathogenesis of atherosclerosis is no longer an issue of conjecture, as it has become a well-established aspect of the disease process. Even slight elevations in high-sensitivity C-reactive protein are associated with a significantly increased risk for cardiovascular morbidity and mortality in otherwise “apparently healthy” individuals.49 With the increasing irrefutability of these data, pharmaceutical companies have scrambled to develop and sell drugs that can reduce this low-level inflammation, while physicians with a broader perspective have directed their energies toward intensifying their patient-centered search for the source(s) of inflammation in each individual patient. For example, subclinical inflammation can result from dietary indiscretion,50 disturbed sleep,51 and vitamin D deficiency;52 in any of these situations, addressing the underlying causes of the inflammation with multicomponent nutritional/ lifestyle interventions may deliver more effective health improvement than can the long-term use of inflammation-suppressing medications.53,54,55

0

01

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

Gastrointestinal Tract, Liver, and Neurologic System The last several years have witnessed an increased appreciation for the influence that the gut and liver have on the brain, and advancements in functional assessments are now documenting analytically what was at one point known only clinically—that the status of the gut and liver have profound effects on the functioning of the brain. Evidence supporting the existence of a clinically important gut-brain interconnection has been published consistently over many decades and in major journals; see Chapters 28 (discussion by Gershon) and 31 (discussion by James) for analyses of these complex interactions. Today, among the most poignant

102

Chapter 10 Web-like Interconnections: The Complex Human Organism multifunctional molecule that acts as a neurotransmitter as well as a proinflammatory messenger. While the clinical implications of these data are yet to be clarified, they clearly demonstrate that the immune system is sensitive to mechanical stimuli.

Chapter 30 (discussion by McGinnis) for an in-depth analysis of autism and oxidative stress.

Musculoskeletal System, Neurologic System, and Immune System The adverse effects of a dysregulated immune system upon the musculoskeletal system are well known for their contributions to autoimmune diseases such as rheumatoid arthritis. In this classic scenario, the immune system is the effector, and periarticular structures, synovium, and joint surfaces are the targets of inflammatory and destructive processes that result in joint destruction and pain that affect the musculoskeletal and neurologic systems, respectively. This model holds that the direction of events flows from the immune system (autoimmunity) to the musculoskeletal system (target site) to the nervous system (perception of pain). This popular model must be updated in light of current research. The phenomena of neurogenic inflammation and neuronal plasticity demonstrate the active, effector functions of the sensory nervous system and exemplify the extent to which the Cartesian model of the sensory nervous system (i.e., as exclusively afferent and passively receptive) is no longer valid.68,69 Much of the musculoskeletal inflammation seen in clinical practice appears due, in large part, to inflammation that originates from and is mediated by the sensory nervous system through the release of proinflammatory mediators from sensory nerves in periarticular tissues. 70,71 Furthermore, evidence is accumulating that neurogenic inflammation can result from a heterogenous group of diverse stimuli, including allergens, environmental chemicals, and pain distant from the site of arthritis.72,73 Likewise, evidence that intentional relaxation74 as well as acupuncture75 can modulate inflammatory pathophysiology indicates that psycho-emotional variables and nonbiochemical therapeutics are important clinical considerations for patients with inflammatory diseases. Evidence also suggests that musculoskeletal therapeutics such as spinal manipulation may influence immune responsiveness. Brennan et al.76,77 showed that chiropractic spinal manipulation resulted in an acute increase in phagocytic capacity of polymorphonuclear neutrophils, and that this result was seen only following authentic (versus sham) manipulation, and that the effect was proportional to the increase in serum levels of substance P, a

Beyond Biochemistry and Neurophysiology: Piezoelectricity as a Mechanism for Intersystem Connectedness

)2

(c

Piezoelectricity, the continuum between mechanical stress and bioelectric conduction, is a well-established aspect of organic matter, affecting all vertebrates and, therefore, humans. Notably, the nervous system in general and the spinal cord in particular demonstrate an intrinsic dipole moment that is demonstrable across species of vertebrates.78,79 In 1977, Lipiski from Tufts University School of Medicine80 summarized the current research of the day and speculated on the effects of spinal manipulation, yoga, and acupuncture as mediated via the body’s inherent pyroelectric and piezoelectric properties. Lipinski’s literature review (particularly including the work of Bassett81) suggests that “piezoelectricity present in many biological systems may theoretically control cell nutrition, local pH, enzyme activation and inhibition, orientation of intra- and extra-cellular macromolecules, migratory and proliferative activity of cells, contractility of permeability of cell membranes, and energy transfer.” With these concepts and possibilities considered, we can construct a conceptual bridge linking mechanical stimuli such as massage, manipulation, exercise, and yoga, and (neuro)electrical stimuli such as acupuncture, meditation, prayer and intentionality, to plausible biochemical/physiological effects that translate into observed clinical benefits. This integrated model helps to explain the effects of “energetic” therapeutics such as moxibustion, acupuncture, and yoga that may be mediated by nonbiochemical physiologic mechanisms. Furthermore, this model also helps us to understand hitherto unexplainable phenomena such as the well-reported sensitivity that some people display to changes in the weather and the positioning of their bodies in relation to electromagnetic fields of the planet, electrical equipment, and power lines. Piezoelectricity may also be the physiologic conduit that transmits the effects of “distance healing,” prayer, and intentionality.82,83,84

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 103

Section II Principles of Functional Medicine

Summary

9.

Human physiology is complex and treatment plans must be multifaceted to reflect this complexity. Cells, tissues, and organ systems work in concert—not in isolation—and therefore effective intervention generally requires improvement in numerous organ systems. As the artificial boundaries between organ systems dissolve, a unifying theme emerges, namely that the attainment, preservation, and re-establishment of health must be all-encompassing. Programs and paradigms related to the treatment of disease and the attainment of optimal health must reflect appreciation of environmental, physical, mental/emotional, nutritional, biochemical, hormonal, immunologic, neurologic, and gastrointestinal components of our existence that coalesce without boundaries to make the human body and our experience of life itself. Thus, new frontiers in health care will be reached not solely when new discoveries occur, but also when the integration of these discoveries into a cohesive, multifaceted, unified healthcare model prepares the way for more accurate understanding and more effective interventions. Healthcare providers of diverse backgrounds (ND, DC, MD, DO, RD, RN, LAc, and others) can and must work together to offer scientifically based, multifactorial interventions that are adapted to the specific needs of individual patients.

10.

11.

12.

13. 14.

)2

(c

15.

01

16.

0

18.

19. 20.

21.

1.

5.

6.

7.

8.

25.

26.

27.

28. 29. 30.

104

e

4.

24.

in

3.

23.

ic

2.

Reaven GM. Insulin resistance and human disease: a short history. J Basic Clin Physiol Pharmacol. 1998;9(2-4):387-406. Reaven GM. Insulin resistance in non-insulin-dependent diabetes mellitus. Does it exist and can it be measured? Am J Med. 1983;74:3-17. Lillioja S, Mott D, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. N Engl J Med 1993;329:1988-92. Reaven, GM. Pathophysiology of insulin resistance in human disease Physiol Rev. 1995;75(3):473-85. Centers for Disease Control and Prevention (CDC). National Diabetes Awareness Month—November 1997. Morb Mortal Wkly Rep. 1997;46:1013-1026. Potter van Loon BJ, Kluft C, Radder JK, et al. The cardiovascular risk factor plasminogen activator inhibitor type I is related to insulin resistance. Metabolism. 1993;42:945-49. Juhan-Vague I, Pyke SD, Alessi MC, et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation. 1996;94(9):2057-063. Reaven GM. Are triglycerides important as a risk factor for coronary disease? Heart Dis Stroke. 1993;2:44-48.

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 17.

22.

References

Laws A, King AC, Haskell WL, et al. Relation of fasting plasma insulin concentration to high-density lipoprotein cholesterol and triglyceride concentration in men. Arterioscler Thromb. 1991;11:1636-42. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol. 1992;70:733-37. Zavaroni I, Coruzzi P, Bonini L, et al. Association between salt sensitivity and insulin concentrations in patients with hypertension. Am J Hypertens. 1995;8:855-58. Zavaroni I, Mazza S, Dall'Aglio E, et al. Prevalence of hyperinsulinaemia in patients with high blood pressure. J Intern Med. 1992;231:235-40. Ibid. Gans RO, Donker AJ. Insulin and blood pressure regulation. J Intern Med Suppl. 1991;735:49-64. Nestler J. Insulin resistance effects on sex hormones and ovulation in the polycystic ovary syndrome. From Contemporary Endocrinology: Insulin Resistance, Edited by G. Reaven and A. Laws. Humana Press Inc., Totowa, NJ, 1999. 347-365. Singh A, Hamilton-Fairley D, Koistinen R, et al. Effect of insulinlike growth factor-type 1 (IGF-I) and insulin on the secretion of sex-hormone binding globulin and IGF-I binding protein (IBP-I) by human hepatoma cells. J Endocrinol. 1990;124:R1-3. Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991;72:83-89. Giovannucci E. Insulin and colon cancer. Cancer Causes Control. 1995;6:164-79. Weiderpass E, Gridley G, Nyren O, et al. Diabetes mellitus and risk of large bowel cancer. J Natl Cancer Inst. 1997;89:660-661. Will J, Galuska D, Vinicor F, et al. Colorectal cancer: another complication of diabetes mellitus? Am J Epidemiol. 1998;147:816-25. Kaaks R. Nutrition, hormones, and breast cancer: is insulin the missing link? Cancer Causes Control. 1996;7:605-25. Rosner W. The functions of corticosteroid-binding globulin and sex-hormone-binding globulin: recent advances. Endocr Rev. 1990;11:80-91. Kieslich M, Errazuriz G, Posselt HG, et al. Brain white-matter lesions in celiac disease: a prospective study of 75 diet-treated patients. Pediatrics. 2001 Aug;108(2):E21. Burk K, Bosch S, Muller CA, et al. Sporadic cerebellar ataxia associated with gluten sensitivity. Brain. 2001;124(Pt 5):1013-19. Jyonouchi H, Sun S, Itokazu N. Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiology. 2002;46:76-84. Shedlofsky SI, Israel BC, Tosheva R, Blouin RA. Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women. Br J Clin Pharmacol. 1997;43(6):627-32. Shedlofsky SI, Israel BC, McClain CJ, et al. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest. 1994;94:2209-14. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA. 2004;292(7):852-58. Bland JS, Bralley JA. Nutritional upregulation of hepatic detoxification enzymes. J Appl Nutr 1992;44:2-15. Bland JS, Barrager E, Reedy RG, Bland K. A Medical Food-Supplemented Detoxification Program in the Management of Chronic Health Problems. Altern Ther Health Med. 1995;1:62-71.

Chapter 10 Web-like Interconnections: The Complex Human Organism 52. Vasquez A, Manso G, Cannell J. The Clinical Importance of Vitamin D (Cholecalciferol): A Paradigm Shift with Implications for All Healthcare Providers. Alternative Therapies in Health and Medicine 2004; 10: 28-37. 53. Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA. 2004;292(12):1433-39. 54. Topol EJ. Failing the public health—rofecoxib, Merck, and the FDA. N Engl J Med. 2004;351:1707-9. 55. Orme-Johnson DW, Herron RE. An innovative approach to reducing medical care utilization and expenditures. Am J Manag Care. 1997;3(1):135-44. 56. Ritz B, Yu F. Parkinson's disease mortality and pesticide exposure in California 1984-1994. Int J Epidemiol. 2000;29(2):323-9. 57. Menegon A, Board PG, Blackburn AC, et al. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet. 1998;352(9137):1344-46. 58. Kamel F, Hoppin JA. Related Articles, Association of pesticide exposure with neurologic dysfunction and disease. Environ Health Perspect. 2004;112(9):950-58. 59. Parker WD Jr, Swerdlow RH. Mitochondrial dysfunction in idiopathic Parkinson disease. Am J Hum Genet. 1998;62(4):758-62. 60. Davey GP, Peuchen S, Clark JB. Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration. J Biol Chem. 1998;273(21):12753-57. 61. Kidd PM. Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management. Altern Med Rev. 2000;5(6):502-29. 62. Bryson SE, Rogers SJ, Fombonne E. Autism spectrum disorders: early detection, intervention, education, and psychopharmacological management. Can J Psychiatry. 2003;48(8):506-16. 63. Couper JJ, Sampson AJ. Children with autism deserve evidencebased intervention. Med J Aust. 2003;178(9):424-25. 64. Kondro W. UK bans, Health Canada warns about antidepressants. CMAJ. 2004;171:23. 65. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998;351(9103):637-41. 66. White JF. Intestinal pathophysiology in autism. Exp Biol Med (Maywood). 2003;228(6):639-49. 67. Edelson SB, Cantor DS. Autism: xenobiotic influences. Toxicol Ind Health. 1998;14:553-63. 68. Richardson JD, Vasko MR. Cellular mechanisms of neurogenic inflammation. J Pharmacol Exp Ther. 2002;302(3):839-45. 69. Boal RW, Gillette RG. Central neuronal plasticity, low back pain and spinal manipulative therapy. J Manipulative Physiol Ther. 2004;27(5):314-26. 70. Gouze-Decaris E, Philippe L, Minn A, et al. Neurophysiological basis for neurogenic-mediated articular cartilage anabolism alteration. Am J Physiol Regul Integr Comp Physiol. 2001;280(1):R115-22. 71. Lee JC, Salonen DC, Inman RD. Unilateral hemochromatosis arthropathy on a neurogenic basis. J Rheumatol. 1997;24(12):2476-78. 72. Bascom R, Meggs WJ, Frampton M, et al. Neurogenic inflammation: with additional discussion of central and perceptual integration of nonneurogenic inflammation. Environ Health Perspect. 1997;105 Suppl 2:531-37. 73. Meggs WJ. Neurogenic switching: a hypothesis for a mechanism for shifting the site of inflammation in allergy and chemical sensitivity. Environ Health Perspect. 1995;103(1):54-56. 74. Lutgendorf S, Logan H, Kirchner HL, et al. Effects of relaxation and stress on the capsaicin-induced local inflammatory response. Psychosom Med. 2000;62(4):524-34.

)2

(c

31. Meggs WJ. Neurogenic switching: a hypothesis for a mechanism for shifting the site of inflammation in allergy and chemical sensitivity. Environ Health Perspect. 1995;103(1):54-56. 32. Richardson JD, Vasko MR. Cellular mechanisms of neurogenic inflammation. J Pharmacol Exp Ther. 2002;302(3):839-45. 33. Kirkwood KS, Bunnett NW, Maa J, et al. Deletion of neutral endopeptidase exacerbates intestinal inflammation induced by Clostridium difficile toxin A. Am J Physiol Gastrointest Liver Physiol. 2001;281(2):G544-51. 34. Bascom R, Meggs WJ, Frampton M, et al. Neurogenic inflammation: with additional discussion of central and perceptual integration of nonneurogenic inflammation. Environ Health Perspect. 1997;Mar;105 Suppl 2:531-37. 35. Gouze-Decaris E, Philippe L, Minn A, et al. Neurophysiological basis for neurogenic-mediated articular cartilage anabolism alteration. Am J Physiol Regul Integr Comp Physiol. 2001;280(1):R115-22. 36. Inman RD. Antigens, the gastrointestinal tract, and arthritis. Rheum Dis Clin North Am. 1991;17(2):309-21. 37. Galland L. Intestinal protozoan infection is a common unsuspected cause of chronic illness. J Advancement Med. 1989;2: 539-552. 38. Vasquez A. Integrative Orthopedics: Concepts, Algorithms, and Therapeutics. The art of creating wellness while effectively managing acute and chronic musculoskeletal disorders. Updated Edition (August 2004). Houston; Natural Health Consulting Corp. WellBodyBook.com Pages 404-418. 39. Gaby AR. The role of hidden food allergy/intolerance in chronic disease. Altern Med Rev. 1998;3(2):90-100. 40. Vasquez A. Integrative Orthopedics: Concepts, Algorithms, and Therapeutics. The art of creating wellness while effectively managing acute and chronic musculoskeletal disorders. Updated Edition (August 2004). Houston; Natural Health Consulting Corp. WellBodyBook.com Pages 404-418. 41. Hunter JO. Food allergy—or enterometabolic disorder? Lancet. 1991;338(8765):495-96. 42. Meggs WJ. Neurogenic switching: a hypothesis for a mechanism for shifting the site of inflammation in allergy and chemical sensitivity. Environ Health Perspect. 1995;103(1):54-56. 43. Galland L. Intestinal protozoan infection is a common unsuspected cause of chronic illness. J Advancement Med. 1989;2: 539-552. 44. Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med. 1999;341(27):2068-74. 45. Popa ER, Stegeman CA, Kallenberg CG, Tervaert JW. Staphylococcus aureus and Wegener’s granulomatosis. Arthritis Res. 2002;4(2):77-79. 46. George J, Levy Y, Kallenberg CG, Shoenfeld Y. Infections and Wegener’s granulomatosis—a cause and effect relationship? QM. 1997;90(5):367-73. 47. Van Putten JW, van Haren EH, Lammers JW. Association between Wegener’s granulomatosis and Staphylococcus aureus infection? Eur Respir J. 1996;9(9):1955-57. 48. Hemalatha V, Srikanth P, Mallika M. Superantigens—Concepts, clinical disease and therapy. Indian J Med Microbiol 2004;22:204-211. 49. Koenig W, Pepys MB. C-reactive protein risk prediction: low specificity, high sensitivity. Ann Intern Med. 2002;136(7):550-52. 50. Liu S, Manson JE, Buring JE, et al. Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr. 2002;75(3):492-98. 51. Yokoe T, Minoguchi K, Matsuo H, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation. 2003;107:1129-34.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 105

Section II Principles of Functional Medicine

)2

(c

75. Joos S, Brinkhaus B, Maluche C, et al. Acupuncture and moxibustion in the treatment of active Crohn's disease: a randomized controlled study. Digestion. 2004;69(3):131-39. 76. Brennan PC, Kokjohn K, Kaltinger CJ, et al. Enhanced phagocytic cell respiratory burst induced by spinal manipulation: potential role of substance P. J Manipulative Physiol Ther. 1991;14(7):399-408. 77. Brennan PC, Triano JJ, McGregor M, et al. Enhanced neutrophil respiratory burst as a biological marker for manipulation forces: duration of the effect and association with substance P and tumor necrosis factor. J Manipulative Physiol Ther. 1992;15(2):83-89. 78. Athenstaedt H. Pyroelectric and piezoelectric properties of vertebrates. Ann NY Acad Sci. 1974;238:68-94. 79. Athenstaedt H. “Functional polarity” of the spinal cord caused by its longitudinal electric dipole moment. Am J Physiol. 1984;247(3 Pt 2):R482-87. 80. Lipinski B. Biological significance of piezoelectricity in relation to acupuncture, Hatha Yoga, osteopathic medicine and action of air ions. Med Hypotheses. 1977;3(1):9-12. 81. Bassett CA. Biologic significance of piezoelectricity. Calcif Tissue Res. 1968;1(4):252-72. 82. Byrd RC. Positive therapeutic effects of intercessory prayer in a coronary care unit population. South Med J. 1988;81(7):826-29. 83. Matthews DA, Marlowe SM, MacNutt FS. Effects of intercessory prayer on patients with rheumatoid arthritis. South Med J. 2000;93(12):1177-86. 84. Astin JA, Harkness E, Ernst E. The efficacy of “distant healing”: a systematic review of randomized trials. Ann Intern Med. 2000;132(11):903-10.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 106

Chapter 11 Health as a Positive Vitality Nancy Sudak, MD

The Goal of Health is More than the Absence of Frank Disease

)2

(c

trained to be qualified surveyors of vitality. A comprehensive medical history should include inquiry about habits that establish health as well as behaviors that erode it. Functional medicine practitioners evaluate patients through physical findings, objective laboratory measures, and a comprehensive appraisal of an individual’s environmental inputs, which typically include: dietary habits, quality of air, water and soil, toxic and infectious exposures, exercise patterns, social relationships, behavior, stress management techniques, and spiritual centering practices. The word “health” is derived from the Old English “hal,” meaning wholeness, being whole, hale, sound, or well.2 In current parlance, we recognize that wholeness signifies full function of the body-mind-spirit. In this light, it is not extreme to expect to feel fully alive, vibrant, and even joyful when healthy. Since much of the population reports chronic symptoms in the absence of authenticated disease,3 patients are led to believe that it is normal to feel unwell in the face of a clean bill of health. It is now evident that the overweight adult population in the U.S. constitutes the majority;4 thus, it has become standard to be overweight. Obviously, the solution is not to rework our height and weight charts to accommodate an obese population, but to become conscious that what appears to be most common in our culture is not necessarily healthy. By adopting a more optimistic and functional approach to wellness, we define health as positive vitality, rather than mere absence of disease. This attitude promotes consideration of features that fortify our physiology to promote wellness, instead of concentrating on negative factors that give rise to illness. We are aware of literally thousands of highly useful disease markers. However, ruling out disease by using

0

01

The disease model is compatible with a managed care setting, in which insurance reimbursement for services is predicated upon codified diagnoses. The problem with this practice is that it fails to acknowledge the zone of dysfunction that occurs between optimal health and diagnosable disease. Although a working understanding of disease is both critical and useful, it can be enlightening to acknowledge that a disease is not a bona fide entity, but rather a label we affix to clinical patterns of signs and symptoms. When no “disease” can be found, this model becomes less relevant, and clinicians are often at a loss to identify effective treatments beyond palliative pharmaceuticals. We lose the opportunity to transform health and move the patient back toward wellness when we adhere to this model; regenerative potential is diminished as one advances further toward chronic disease on this continuum. Clearly, waiting until disease identifies itself before developing meaningful therapeutic strategies is detrimental to our patients and costly for our healthcare system overall. An unfortunate result of employing the disease model is that the concept of health has come to be equated with the absence of disease. Patients who return from medical evaluations relative to symptoms frequently report, “The doctor said there’s nothing wrong with me.” Though patients tend to be relieved when no major disease is discovered, they may also be distressed by the discrepancy between their sensation of being unwell and the physician’s assertion that all findings are normal. Significant morbidity and psychological distress may ensue,1 particularly if the physician’s attitude is dismissive. Because the focus of medical education is on disease, not wellness, physicians are not specifically

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 107

Section II Principles of Functional Medicine stantly experiencing his or her environment to produce a certain quality of life. Our daily behaviors are fundamental to the production of our internal and external environments, and represent the most powerful influences upon our physiology. These daily choices contribute directly to biochemical function and may include: diet quality and quantity, micronutrient adequacy, level of physical exercise, action of the hypothalamic-pituitary-thyroid-adrenal axis, toxic or infectious exposures, and emotional experiences of joy, fear, hostility, connectedness, etc. Negative influences include frequent application of lawn pesticides, regular ingestion of transfatty acids, frequently skipping meals, and excessive activation of the stress response, whereas positive influences are exemplified by purposeful avoidance of xenobiotics, adequate daily intake of pure water, essential fatty acids, antioxidants, and regular use of stress management techniques. When we refer to an individual as being “highly functional,” we are often making a judgment of someone’s ability to be physically or intellectually industrious. A principal driving force behind feeling energetic, creative, and productive is vigorous cellular and biochemical function. Assessing the core clinical imbalances of a patient is predicated upon understanding the body’s major molecular mediators (e.g., cytokines, immunoglobulins, antioxidants, stress hormones, neurotransmitters, fatty acids). Our health is determined by the complex interplay of these biologic modifiers as they cut across multiple organs. (See sections IV and V of this book for detailed information about these important influences.) The further we depart from daily healthy lifestyle practices, the less molecular support we provide to our metabolic functions, and if this process continues, cellular resiliency declines and we have begun to pave the road toward dysfunction and disease. We may feel less physically and emotionally lively as this path unfolds. We can easily think of instances of how the mind affects the body. A classic example of this concept is the well-documented effect of mindfulness meditation in reducing chronic pain.11 Another common example is the association between hostility and increased risk for myocardial infarction.12 The effect of the body on the mind is equally observable, since physiologic variables clearly contribute to emotional and cognitive welfare. Straightforward examples of molecular mediators that modulate brain function include: blood glucose levels,

)2

(c

laboratory measures doesn’t necessarily rule in good health. Positive indicators of wellness may be found to some degree on objective testing (e.g., cellular nutrient levels, beneficial flora cultures, antioxidant levels, hormone metabolites). A diagnosis of being truly healthy will depend on favorable physical exam findings and laboratory evaluations, of course, but the patient’s story of how vital and fully functional he or she feels must figure prominently in the clinician’s assessment. Patients who report feeling unwell despite unrevealing evaluations tend to benefit from a functional medicine approach since broad areas of dysfunction are identifiable and treatable through supportive and restorative measures.

01

Importance of Functionality to Quality of Life

0

Illnesses and symptoms, whether acute or chronic, may generally be traced to one or more functional disturbances within the functional medicine “web.” Functional status is characteristically diminished in keeping with the magnitude of symptoms. To use a simple example of immune system dysregulation, a person with an itchy patch of atopic dermatitis on one ankle is less likely to experience a decline in functionality than someone with generalized urticaria. When we are highly symptomatic, discomfort becomes a leading influence from which we cannot be readily distracted, and a greater degree of debility is anticipated. When functional capacity weakens, we can also expect quality of life to decline. Health-related quality of life is a multifaceted concept that reflects the outcome of an illness on a patient’s evaluation of his or her functional status and emotional wellbeing. Abundant reports in the medical literature confirm the harmful impact of illness or chronic symptoms on quality of life observed in conditions such as: osteoarthritis,5 chronic fatigue syndrome,6 obesity,7 insomnia,8 childhood migraines,9 and hip fractures.10 Good health—full functionality on every level—is achieved by favorable interactions between our genes and our environment. When we understand that our genes have not changed substantially from those of our Paleolithic progenitors, but that our modern environment has been radically altered since that era, we appreciate that our journey to maintain positive vitality must involve manipulating our environment advantageously to match the physiology of our genes. No two people share identical genetic activity; each individual is con-

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 108

Chapter 11 Health as a Positive Vitality to take time for your illness.” We understand that our daily actions collectively represent the most significant factor of control over our health. Decision making in this regard occurs many times within a 24-hour period. When we become mindful of our immediate options to produce better health outcomes, we may ask ourselves many questions as we navigate through the day: • Shall I eat a full breakfast or just have a doughnut during my break? • Shall I walk to work or drive? • Should I exercise today or sleep later? • Which would suit my needs better—a slice of pizza on-the-run or a meal of lean protein, fresh vegetables, and whole grains that I actually sit down to eat? • Should I watch a rerun of my favorite sit-com or go to bed earlier? • Should I try to remain gluten-free for a few weeks to see if my headaches improve? • Will application of lawn pesticides to kill the dandelions on my lawn affect my health and that of the planet adversely?

)2

(c

neurotransmitters, essential fatty acids, and B vitamins.13 However, less obvious biochemical mediators may have a profound impact on function. For example, if dietary intake of gluten is inappropriate for a given individual’s physiology, psychiatric and emotional disturbances may be seen.14,15 Certain people may become sluggish and unmotivated after succumbing to a carbohydrate craving. Many patients who implement a comprehensive elimination diet experience unanticipated abatement of chronic symptoms long considered part of their normal physiologic landscape. In this way, they learn that diet is an environmental input that is critically important in determining function and vigor. Spiritual connection represents another dimension of being that affects quality of life. Though difficult to quantify in research, the role of spirituality in health care has been receiving increasing attention.16 Geriatric patients reporting greater degrees of spirituality tended to more highly appraise their health status.17 The American Psychiatric Association’s Board of Trustees has passed a resolution stating that “it is useful for clinicians to obtain information on the religious or ideologic orientation and beliefs of their patients so that they may properly attend to them in the course of treatment.” Religious commitment appears to be correlated with decreased risk for depression, substance abuse, hypertension, and other chronic health problems.18 In a recent survey, greater than 75% of patients believed that spiritual issues should be addressed routinely in clinical care.19 Practitioners who engage with patients’ spirituality will bring more meaning to healthcare delivery and the therapeutic relationship. A practical approach to accomplishing this goal is discussed in Chapter 33. Though conventional medicine seems to have partitioned mind and spirit from body, the functional medicine approach embraces these essential elements of wholeness as they affect one another within the matrix of core areas of function. Quality of physiologic function is generated by the performance of daily behaviors, by and large within the sphere of our control. We maximize wellness of body-mind-spirit when we consistently implement practices that strengthen our unique constitutions, and learn to reject those that seem to impair vitality and optimal function. As biochemically unique individuals, we must each determine which environmental inputs are ideal in defining our personal health. The functional medicine model embraces the old adage “If you don’t take time for your health, you’ll have

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

in

ic

ed

Once it becomes habitual to ask these questions and to mindfully implement the healthier options, making optimal choices becomes self-perpetuating. If we are paying attention, we can quickly realize how much better we feel when we show a preference for those selections better matched to our physiology. The functional medicine paradigm illustrates the art of living well as the basis for health and well-being. Symptoms or impairment of vitality will prompt a trained practitioner to investigate for functional imbalances. Functional medicine has the potential to revolutionize healthcare delivery, not only as a result of its anticipatory and preventive nature, but because the identification and supportive treatment of underlying contributing factors is the most effective means of addressing the health of the individual. By recognizing and treating functional disturbances, physicians can guide patients toward more advantageous environmental inputs, thereby saving millions of dollars in healthcare expenditures. Functional medicine physicians routinely state that they have become re-enchanted with medical practice; once they have learned the application of nutritional biochemistry and functional physiology, they have at their disposal an extensive array of tools that are quite satisfying to implement.

109

Section II Principles of Functional Medicine

References 1.

2. 3.

4.

5.

6.

)2

(c

7.

Kroenke K, Arrington ME, Mangelsdorff D. The prevalence of symptoms in medical outpatients and the adequacy of therapy. Arch Int Med. 1990;150:1685-89. The Century Dictionary: An Encyclopedic Lexicon on the English Language. New York: The Century Co., 1913. Kroenke K, Mangelsdorff D. Common symptoms in ambulatory care: incidence, evaluation, therapy, and outcome. Am J Med. 1989;86:262-66. Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 19992002. JAMA. 2004;291:2847-50. Fontaine, K. Arthritis and health related quality of life. Johns Hopkins Arthritis. Available on-line at http://www.hopkinsarthritis.som.jhmi.edu/mngmnt/qol.html Solomon L, Nisenbaum M, Reyes M, et al. Functional status of people with chronic fatigue syndrome in the Wichita, Kansas population. Health and Quality of Life Outcomes 2003;1:48. Doll HA, Petersen SEK, Stewart-Brown SL. Obesity and physical and emotional well-being: associations between body mass index, chronic illness, and the physical and mental components of the SF-36 questionnaire. Obesity Res. 2000;8(2):160-70. Katz DA, McHorney CA. The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract. 2002;51:229-35. Powers SW, Patton SR, Hommel KA, Hershey AD. Quality of life in childhood migraines: clinical impact and comparison to other chronic illnesses. Pediatrics. 2003;112:e1-e5. Available on-line at http://pediatrics.aappublications.org/cgi/reprint/112/1/e1 Hill SE, Williams JA, Senior JA, et al. Hip fracture outcomes: quality of life and functional status in older adults living in the community. Aust NZ J Med. 2000;30:327-32. Kabat-Zinn J, Lipworth L, Burney R, Sellers W. Four-year follow-up of a meditation-based program for the self-regulation of chronic pain: treatment outcomes and compliance. Clin J Pain. 1987;2:159-73. Chaput LA, Adams LS, Simon JA, et al. Hostility predicts recurrent events among postmenopausal women with coronary heart disease. Am J Epidemiol. 2002;156:1092-99. Rogers PJ. A healthy body, a healthy mind: long-term impact of diet on mood and cognitive function. Proc Nutr Soc. 2001;60:135-43. Correspondence, author unknown. Coeliac disease and psychiatric disorders in childhood: guilty by association. Acta Paediatr. 2001;90:1082-83. Dohan FC, Martin L, Grasberger JC, et al. Antibodies to wheat gliadin in blood of psychiatric patients: possible role of emotional factors. Biol Psych. 1972;5(2):127-37. Daaleman TP. Religion, spirituality, and the practice of medicine. J Am Board Fam Pract. 2004;17:370-76. Daaleman TP, Perera S, Studenski S. Religion, spirituality, and health status in geriatric outpatients. Ann Fam Med. 2004;2:49-53. Matthews DA, McCullough ME, Larson DB, et al. Religious commitment and health status: a review of the research and implications for family medicine. Arch Fam Med. 1998;7:118-24. Plotnikoff, G. Should medicine reach out to the spirit? Understanding a patient’s spiritual foundation can guide appropriate care. Postgrad Med. 2000;108(6) available on-line at http:// www.postgradmed.com/issues/2000/11_00/editorial_nov.htm

10.

11.

12.

13.

18.

19.

e

17.

in

16.

ic

15.

ed

14.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

9.

0

01

8.

110

Chapter 12 Healthy Aging: The Promotion of Organ Reserve David S. Jones, MD, Jeffrey S. Bland, PhD, and Sheila Quinn

Aging and Disease: Rectangularizing the Morbidity Curve

(c

Introductioni

)2

For nearly 20 years, we have used the term “organ reserve” in functional medicine as a marker for healthy aging. Our assumption has been that if we enable our patients to reduce oxidative stress and inflammation, improve the match of genes to environment, support healthy lifestyles, and improve micronutrient repletion, we will be creating greater flexibility and adaptability (degrees of freedom) in the aging human organism, enabling people to live out their years with longer periods of health and vitality and shorter periods of disease and debility prior to death. The research base, however, has yet to precisely define “organ reserve”; nor are we yet able to measure or specify the effects of all these preventive measures on the reserve capacity of our organs (hearts, lungs, livers, kidneys, brains, etc.) to respond to life’s insults—illness, trauma, loss, chronic stress, and poor lifestyles. It is difficult, therefore, to describe a causal link between the concept of organ reserve and the phenomenon of healthy aging. It is, however, a useful concept—a kind of shorthand term that encompasses the physiological benefits of the functional medicine approach to health. With that caveat, let’s explore some aspects of theories about aging and how we can help patients to more years of optimal health.

0

01

Suggestions from anthropological data estimate that our earliest ancestors lived on average only about 18 years, and that by the time of the Roman Empire, life expectancy was still not much over 22 years. In the interval from that point to the start of the 20th century, life expectancy at birth doubled to 45 years.1,2 “Throughout most of the 20th century, death rates declined dramatically at every age in developed nations, and life expectancy at birth rose rapidly. For example, life expectancy at birth for U.S. females increased from 48.9 years in 1900 to 79.0 in 1995.”3

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

in

ic

ed

Ageing [sic] is a biological puzzle of long standing, particularly because it manifests itself over a wide range of biological systems, tissues and functions. … But ageing is not a function. Ageing can be defined as an endogenous progressive deterioration in age-specific components of fitness.4 It is not actively selected for. It is instead a secondary effect of the decline in the force of natural selection with age.5,6 From such theory it follows that many loci, and many biochemical pathways, are expected to produce the deleterious effects of ageing, because it is a secondary side-effect of normal evolution.”7

If it is true that the forces of natural selection lose hegemony in the years following fecundity (the aging years), but that the forces of selection have set in place the genetic mechanisms that define the biologic context of adaptive possibilities, then new models for understanding aging and constructive interventions, in terms of both public health recommendations and individual healthcare strategies, are required. In 1980, James Fries discussed in The New England Journal of Medicine “a set of predictions” on aging, natural death, and the compression of morbidity.8 In his

i

This chapter was adapted from “Healthy aging and the origins of illness: Improving the expression of genetic potential,” which was published by the authors in Integrative Medicine: A Clinician’s Journal. Dec 2003/Jan 2004;2(6):16-25. Many thanks to the journal for permission to adapt this article.

111

Section II Principles of Functional Medicine ages at death); whereas compression of morbidity refers to increasing concentration of illness and disability into the latter years of life.14 The calculations of life expectancy contain statistical Gordian knots that preoccupy many researchers in the field of aging. Behind the pure intellectual interest in aging and life expectancy lurk important public policy issues that will not be explored here.ii The fundamental debate is between those who believe increases in longevity will proceed more slowly in the future than they have in the past, eventually stopping entirely, and those who believe the data do not support such a conclusion. The hypothesis presented by Carnes and Olshansky,15 postulating that animal and human data suggest that species “possess an intrinsic mortality signature,” falls into the first category:

)2

(c

paper, he challenged the popular notion that aging is necessarily associated with increased morbidity and disability. He also suggested that, in developed countries, with substantial improvements in public health measures, nutrition, and medical care, people would approach greater parity between “expected biological life span” and actual years of functional life. As summarized in a reflective editorial published in the same journal 18 years later: “In the ideal case, the healthy citizens of a modern society will survive to an advanced age with their vigor and functional independence maintained, and morbidity and disability will be compressed into a relatively short period before death occurs at around the age of 85 years.”9 This has become known as the Fries hypothesis and as the rectangularizing of the morbidity curve based on maintenance of organ reserve. In 1998, again in the NEJM, Anthony Vita and colleagues (including James Fries) presented evidence collected from a study of 1,741 University of Pennsylvania alumni over a period of 32 years.10 Their extensive data supported the notion that healthful lifestyle activities were associated with less loss of function (disability) and fewer chronic illnesses during the life span. In this study, the lifestyle factors showing the greatest correlation with differences between the upper and lower levels of risk were: (1) smoking, (2) body mass index, and (3) patterns of exercise. An accompanying editorial summarized the findings: “In the group with the lowest level of risk, the onset of functional disability was postponed by about five years. In the group with the highest level of risk—those who had a body mass index of 26 or higher, smoked 30 or more cigarettes per day, and got no regular vigorous exercise—there was both an earlier onset of disability and a greater level of cumulative disability, as well as more disability in the final year of life for the 10% of the cohort that had died.”11 In the Harvard Study of Adult Development, George E. Vaillant corroborated the importance of the same risk factors—smoking, obesity, and exercise—but added two emotional components, stable marriage and “mature defenses,” as important differentiating factors of successful aging.12,13 However, subsequent analyses of the Fries hypothesis have demonstrated that the rectangularization Fries described is actually composed of two elements, mortality and morbidity, and they should be analyzed separately. Compression of mortality refers to an increasing concentration of ages at death (decreased variability of

01

0

Imagine a population completely protected from extrinsic causes of death, but denied access to any medical intervention that might influence (i.e., postpone the age of death) intrinsic processes—the goal for most control groups in studies involving laboratory animals. Assuming the population is representative of the species from which it came, the life expectancy for this hypothetical population is an estimate of the upper limit for the average life span of individuals within this species—an upper limit imposed by the intrinsic mortality signature.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

in

ic

ed

The conundrum of life expectancy or species-specific intrinsic mortality signature rests squarely on the implicative enfolding of the natural processes of aging occurring always in real time within an incalculably complex environment that interacts with the inherent genetics and biological processes of each individual within the species. We are learning that risks of disease and agerelated decline are unique to each patient, and that phenotypic expression appears to be more vulnerable to environmental pressures than to genetic influences.16 Many in this field assert that the extension of functional life spaniii and life expectancyiv as seen in the 20th century is unlikely to be duplicated in the 21st century. The large incremental improvements in public health measures, nutrition, and medical care associated with the increases in life expectancy in the 20th century are not reproducible in the 21st century without “modifying endogenous ii

The U.S. Social Security Administration, for example, must predict the size of future beneficiary populations. If, as some researchers believe, the agency is underestimating future increases in longevity, the Social Security system will be subject to some very significant unplanned-for financial burdens. [Roush W. Live long and prosper? Science. 1996;273:42-46.]

112

Chapter 12 Healthy Aging: The Promotion of Organ Reserve biological processes inherent to aging.”17 Olshansky and Carnes go on to assert: “There are no life-style changes, surgical procedures, vitamins, antioxidants, hormones, or techniques of genetic engineering available today with the capacity to repeat the gains in life expectancy that were achieved during the 20th century.” However, a 2002 article by Oeppen and Vaupel18 disputes their contentions. Using life expectancy data for the world’s most long-lived populations, they show evidence of a “regular stream of continuing progress” as represented by a linear climb from 1840 to 2000. During that period, record life expectancy broke every prediction advanced, usually within just a few years: “Bestpractice life expectancy has increased by 2.5 years per decade for a century and a half.” Not to mince words, Oeppen and Vaupel conclude: “This mortality research has exposed the empirical misconceptions and specious theories that underlie the pernicious belief that the expectation of life cannot rise much further.” Wilmoth19 concurs: “Extrapolation rides the steady course of past mortality trends, whereas popular and scientific discussions of mortality often buck those historical trends, in either an optimistic or pessimistic direction … [E]arlier arguments about an imminent end to gains in human longevity have often been overturned, sometimes quite soon after they were put forth.” In another paper published in 2000, he argued further that this contrarian view is based on data that show that “the most significant trend now affecting longevity in industrialized societies is the decline of death rates among the elderly.”20,21 In 1999, Wilmoth and Horiuchi also demonstrated through demographic statistical methods that rectangularization of mortality is not a necessary and concomitant association with mortality decline.22 Myers and Manton, in 1984, had shown that the standard deviation of deaths above age 60 in the United States increased rather than decreased between 1962 and 1979, in spite of the decline in death rates.23 In the old-

)2

(c

est-old populations in developed countries there has been an unexplained expansion, rather than a compression of mortality (greater variability of the ages at death).24,25,26 Also, the overall rectangularity of the survival curve and the limits of longevity are not irrevocably linked as initially postulated by Fries in 1980. In the original theory, as the survival curve rectangularized, the limits of longevity would be substantially revealed. As shown by James Vaupel and associates,27 as well as others,28 as early as the 1950s and into the 1990s, there was a general loss in the rectangularization of the survival curve as the limits of longevity came very much into question due to the well-documented rise in improved survival at older ages.29,30,31 For example, the number of centenarians has doubled approximately every 10 years since 1950.32 We enter the 21st century in need of a general theory on population aging,33,34 and humbled by the awareness that “our understanding of the complex interactions of social and biological factors that determine mortality levels is still imprecise.”35 It is clear that the present sustained increase in life expectancy from birth is now due to the mortality decline at the highest ages,36 even if as yet unexplained. We have entered a transition in population biodemographics within the developed countries where fecundity and mortality are lower and causes of death are less associated with infectious diseases and/or accidental death, and more associated with degenerative and age-related causes. Research is ongoing to delineate the subtle differences and causes of (a) life expectancy, (b) disease-free life expectancy, and (c) disability-free life expectancy. Contemporary research has substantiated Fries’ 1980 prediction that chronic illness can be postponed by changes in lifestyle, contradicting the anticipated forecast of an ever older, ever more feeble, and ever more expensive-to-care-for populace. Although his first prediction that the length of human life is fixed has proved erroneous, his second prediction that many of the “markers” of aging can be modified, has proved prescient.37 His charge that “acute illness has ceased to be the major medical problem in the United States,” and that “chronic illness now is responsible for more than 80% of all deaths and for an even higher fraction of cases of total disability” has only recently received the attention it deserved.38 Fries challenged the medical establishment to focus on both the elements of aging (senescence) and a strategy

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

iii Life span refers to a specific individual’s length of life. For example, the verified oldest-age-at-death of a member of a species establishes the maximum life span for that species. Therefore, maximum life span is always greater than life expectancy. The oldest fully authenticated age to which any human has ever lived is 122 years and 164 days, by Jeanne-Louise Calment. She was born in France on February 21, 1875 and died at a nursing home in Arles, southern France on August 4, 1997 (Guinness Book of Records). iv Life expectancy is a statistical measure of a population; it is actuarially derived and is especially sensitive to improvements in life expectancy at birth rather than later improvements in survival.

113

Section II Principles of Functional Medicine of postponement, rather than cure, for the chronic diseases. In order to construct therapeutic interventions around validated elements that can enhance healthy aging and the compression of morbidity, researchers are teasing out those mechanisms that are associated with death from natural aging, as well as those consequent to chronic illness. For most of us, death will be preceded by a decline in function, and we would all like that period of decline to be as brief as possible. Achieving that goal requires that physicians and patients alike understand what contributes to age-related decline and disease, and what mitigates against the involution of physical, psychological, and social vigor. We need a deeper understanding of the complex interaction of aging and decreased functional reserve, and the interwoven associations with illness, so that—as clinicians—we do not fail to give our patients the best possible chance for maximum health and function as they age.

youth become uncommon—are selected against— because their possessors often die before reproducing. … (However) in contrast to deleterious genes that act early, those that sap vitality in later years would be expected to accumulate readily in a population, because parents with those genes will pass them to the next generation before their bad effects interfere with reproduction. (The later the genes lead to disability, the more they will spread, because the possessors will be able to reproduce longer.)54

)2

(c

These ideas have produced some very interesting research into the mitigation of the inevitable ravages of oxidative damage as the organism ages. For example, rat studies performed by Dr. Ames and his associates showed that feeding “old rats” the normal mitochondrial metabolites acetylcarnitinevi and lipoic acidvii for a few weeks restores mitochondrial function, lowers oxidants to the level of a young rat, and increases ambulatory activity to a level usually seen only in young rats.55,56,57 These animal studies suggest plausible underlying mechanisms of aging as well as possible restorative interventions. Dr. Ames summarizes: “With age, increased oxidative damage to proteins and lipid membranes, particularly in mitochondria, causes a deformation of structure of key enzymes, with a consequent lessening of affinity (Km) for the enzyme substrate; an increased level of the substrate restores the velocity of the reaction, and thus restores function.”58 Studies are now being conducted with human subjects using DNA microarray technology as an assay.59 Young and old rat lymphocytes and young and old human leukocytes will be compared as a measure of interventional success. Ames and his associates have termed this research searching for the metabolic tune-up. They hope to determine the levels of micronutrients that mitigate against DNA damage. By using DNA microarray technology, the experimental interventions can be assayed for enhanced or worsened genomic stability. They are presently working their way through all of the established micronutrients that have shown an association between deficiency and DNA damage. However, in the end, tuning-up the metabolism will require an understanding of the cross-connections between the

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Mechanisms of Aging

e

in

ic

ed

A number of modelsv have been proposed to account for the observable effects of aging on living organisms.39,40,41,42,43,44,45 The model proposed by Denham Harman, MD, PhD, in 1956,46 has developed in the intervening half century the greatest number of advocates and the most robust repository of research.47,48 Dr. Harman proposed that the accumulated effects of oxidative damage from normal metabolism create mischief for members of all sex-dependent species after the reproductive years, although, as mentioned earlier, there may also exist extenuating factors in the oldest-old.49,50 A number of lines of thinking converge around Harman’s free radical theory of aging.51,52,53 The evolutionary biologists explain aging as a sidebar to the underlying mechanisms and processes of natural selection. As explained by Michael Rose in 1999: Heritable traits persist and become prevalent in a population—they are selected, in evolutionary terms—if those properties help their bearers to survive into reproductive age and produce offspring. The most useful traits result in the most offspring and hence in the greatest perpetuation of the genes controlling those properties. Meanwhile traits that diminish survival in

vi

Carnitine is an amino acid that facilitates transport of free fatty acids across the cell membrane of the mitochondria. vii Lipoic acid (a powerful antioxidant), CoQ10, tetrahydrofolate, and glutathione are part of the mitochondrial multi-enzyme complexes intricately involved with oxidative phosphorylation, cellular respiration, and Krebs cycle-derived cellular ATP/energy production within mitochondria.

v Not covered here are the models based on the arrays of alleles differentiating long-lived from shorter-lived individuals within species populations, programmed aging as a specific development end point (the aging gene model), and the role of telomerase in cellular aging. (See endnotes associated with the referenced sentence.)

114

Chapter 12 Healthy Aging: The Promotion of Organ Reserve inadequate levels of the B vitamins in his/her diet to appropriately respond to these environmental stressors.66 As Nada Abumrad pointed out, “Nutritional support can be tailored to the individual genotype to favor beneficial phenotypic expression or to suppress processes that lead to later pathology.”67 This recognition gives individuals much greater control over their health as they age than they would have if all sickness were simply a natural consequence of advancing age. The pluri-potential qualities of our life depend on the vast array of information within our genome and how/what signals are—and have been—generated to induce expression from our genome.viii When Watson and Crick68 published their benchmark research on the structure of DNA in 1953, they little suspected their discovery would initiate a revolution in medicine. They could not know it would empower a revolution of choice for the kind of “health probability” an individual can select, as he/she grows older.69 Watson and Crick’s discovery heralded the dawn of what has been called “genomic medicine.” For clinicians it represents the age of personalized medicine.70 We now know that even diseases (like cancer) that we once thought were “all in the genes” are caused by interactions between our gene matrix and environmentally derived signals transduced at the cell membrane interface and then translated through genetic processing.

unique genetic constitution and the unique nutrient needs of the individual.60 The thrust of this present research was presaged by Ames’ proposal in his 1998 paper that micronutrient inadequacy is genotoxic:61

)2

(c

Micronutrient deficiency may explain, in good part, why the quarter of the population that eats the fewest fruits and vegetables (5 portions a day is advised) has about double the cancer rate for most types of cancer when compared to the quarter with the highest intake … . Eighty percent of American children and adolescents and 68% of adults do not eat five portions a day. Common micronutrient deficiencies are likely to damage DNA by the same mechanism as radiation and many chemicals, [and] appear to be orders of magnitude more important. Remedying micronutrient deficiencies is likely to lead to a major improvement in health and an increase in longevity at low cost.

01

0

The Origins of Illness: A Mismatch Between Genes and Environment

lM na tio d. un rve r F se fo re te ts itu h st rig In All

“Most of us believe we age by genetically predetermined processes that are beyond our control … and hope we have gotten the genetic luck of the draw.”62 For many years, medical professionals and the lay public alike believed that we could do little to prevent the associated illnesses of aging, as they were thought to be principally a deterministic result of our genetic inheritance. In the past 15 years, however, as researchers have deciphered the genome locked into Homo sapiens’ 23 pairs of chromosomes, this deterministic model of sickness has been found by most scientists in the field to be incorrect.63 Genes do not code for specific diseases of aging.64 Instead, they code for various strengths and weaknesses in the human constitution that give rise to resistance or susceptibility factors for age-related diseases. Some people get the “luck of the draw” and have more resistance genes to factors associated with 21st century living. For most people, however, the occurrence of illness as we age is a result of the blending of genetic susceptibility factors with environmental exposures.65 The multifactorial “genes for heart disease” or “genes for cancer” may never be translated into actual disease expression unless the individual plunges these less resistant genes into an environment that triggers his or her unique constitution. For example, the susceptibility within the array of “genes for heart disease” may not result in heart disease until the person eats a diet rich in saturated fat, smokes, lives a lifestyle that enhances frequent high tides of his/her stress hormones, and/or has

From Genotype to Phenotype: The Role of Individual Susceptibility

e

in

ic

ed

In an article published in the NEJM in 2000, investigators from the Karolinska Institute in Sweden reported on 44,788 pairs of twins from their extensive health and human services registries. (One of the benefits of the socialized medical system in Sweden, Denmark, and Finland is the huge databases of patients’ demographics and health outcome histories.) This specific study showed that identical twins do not experience cancer at the same rate. In fact, the study reported, “Inherited genetic factors make a minor contribution to susceptibility to most types of neoplasms. This finding indicates that the environment has the principal role in causing sporadic cancer.”71

viii In Matt Ridley’s (1999) GENOME: The Autobiography of a Species In 23 Chapters, he uses the analogy of a book of life in 23 chapters to highlight the connection between what has been found in the gene mapping discoveries to this point in the genome project (30,000 to 35,000 gene sequences derived from 2.9 billion nucleotide codes in the 23 paired chromosomes).

115

Section II Principles of Functional Medicine restores activity to near-normal and even normal levels. He concludes that “nutritional interventions to improve health are likely to be a major benefit of the genomics era.” It is also recognized now that nutritional status and specific nutrients modify drug metabolism, and the impact is unique to the genotype of the individual. Researchers have recently discovered that specific nutrients modify the expression and function of detoxification genes.76,77,78 Cruciferous vegetables, which include broccoli, cauliflower, Brussels sprouts, and cabbage, contain nutrients called glucosinolates. These substances break down in the digestive tract to produce chemicals such as indole-3-carbinol, sulfurophane, and phenylisothiocyanate. These chemicals, in their turn, activate specific genes that help detoxify cancer-producing substances.79 The mechanism by which specific nutrients help protect individuals with certain genotypes is just now being fully explored. Other nutrients, such as glutathione, CoQ10, vitamins C and E, the B-complex nutrients (including folic acid, B12, and B6), and the essential minerals zinc, copper, and selenium, all assist the genes in protecting against heart disease, stroke, dementias, cancer, and diabetes.80,81,82,83,84 Genetic uniqueness may cause some individuals to require 100 times as much of a particular vitamin, mineral, or accessory nutrient as another for good health.85 For example, “a common polymorphism exists for the gene that encodes the methylene tetrahydrofolate reductase (MTHFR) enzyme, which converts 5,10-methylene tetrahydrofolate to 5-methyltetrahydrofolate, required for conversion of homocysteine to methionine … . Individuals with the MTHFR 677 TT genotype had a significantly higher risk of CHD, particularly in the setting of low folate status.”86 Elevated homocysteine is associated with depression, heart disease, stroke, colon and breast cancers, and dementia.87 If susceptible individuals consume a diet that for most people would be “adequate” in these nutrients, they run the risk of developing a disease of aging such as heart disease. Kilmer McCully recently wrote: “There is an urgency to this matter. There are 500,000 people dying every year from heart disease, and millions more suffering.”88 As Willett and Stampfer pointed out in a December 2001 article in the NEJM, the daily consumption of a well-balanced multivitamin and mineral supplement now makes sense from a number of lines of research.89

)2

(c

In 1950, Roger Williams wrote a paper titled “The Concept of Genetotrophic Disease.”72 In this Lancet article, Williams advanced the bold concept that a number of diseases whose origins were unknown at that time could be understood as conditions associated not with malnutrition, but with undernutrition based on the individual’s unique genetic needs. He postulated that heart disease, cancer, diabetes, arthritis, schizophrenia, and even alcoholism could be considered to have “genetotrophic origin.” Williams’ concept, rooted in genetics and biochemistry, proposed that undernutrition would result in suboptimal metabolisms within susceptible individuals, which would, in turn, increase the potential for chronic illness developing over decades of living. Medicine did not at that time embrace the genetotrophic model for the origin of disease, and the concept remained dormant for 50 years. The results of the Human Genome Project in the late 20th century and the revolution in understanding how diet and specific macro- and micronutrients influence gene expression have recently made Williams’ concepts seem prescient. He appears to have predicted the transition in medicine from a largely empirical meta-science to a predictive science based on unified mechanisms of disease. We now know that the mechanisms that result in the initiation and progression of most age-related chronic illnesses have their origin, at least in part, in the genetotrophic concept.73,74 The recent publication of a landmark paper by Ames et al.75 provides the bench-science substantiation needed to flesh out Williams’ postulates. Ames shows in his encyclopedic review paper that “as many as onethird of mutations in a gene result in the corresponding enzyme having an increased Michaelis constant, or Km (decreased binding affinity), for a coenzyme, resulting in a lower rate of reaction.” Some people carry polymorphismsix that are more critical in determining the outcome of their health history. He goes on to argue that studies have shown that administration of higher than dietary reference intake (DRI) levels of cofactors (specific vitamins and minerals) to these polymorphic genes

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

ix

A polymorphic gene is an alternate form of a wild gene present in >1% of the population. The most common polymorphic genes are single nucleotide polymorphisms (SNPs) that result in translational proteins and enzymes with decreased functionality. We all share at least 99.9% of the nucleotide code of our species’ genome. The SNPs are what make us unique within our species. The translation of our genome message that includes our SNPs results in our individual phenotype. [Burghes, et al. Science. 2001;293:2213-14.]

116

Chapter 12 Healthy Aging: The Promotion of Organ Reserve environment to minimize the risks of age-related chronic disease. We hope that this book will help the readers to do just that.

We inherit more than our genes. Through custom, habit, and patterning, we also inherit nutrition and lifestyle habits. The interaction of genetic uniqueness with lifestyle results in the illnesses many people associate with aging. A dramatic example can be seen today in the stunning increase in cases of type 2 diabetes90,x and the estimate that “as many as 1 in 4 apparently healthy Americans are at risk of developing ‘Syndrome X,’ a metabolic derangement that is a major contributor to coronary artery disease”91 and a likely precursor to type 2 diabetes. There is clear and compelling evidence from many sources that diet and lifestyle are the culprits, since (as noted above) the human genome itself has not changed in this period of time.

References 1.

2. 3. 4. 5. 6.

(c

)2 01

Summary

7. 8.

0

People are living longer—that’s indisputable. We know that how we live those extra years is an abiding issue. Medical education, research, and practice need to shift focus, looking at the complex issues involved in the origins of illness and healthy aging. The evidence is very strong that illness is not a predetermined consequence of aging92,93 and that age-related decline can probably be substantially compressed (in length and in severity) by better management of the interaction between our genetic uniqueness and the overall environment to which we expose our genes throughout our lifetimes.94 Ongoing research will help us understand the mechanisms by which the environment affects our genes, and we will be able to intervene sooner, targeting very specific risks and vulnerabilities inherent to the individual. Tailored recommendations for diet, nutritional pharmacology,95 pharmacogenomics, lifestyle change (including “mind-body” issues), structural and physical medicine, and exercise96,96,97 are already important in improving the expression of genetic potential, and will become more clinically useful and focused as the evidence base expands. The doctors of the 21st century will need to understand how to assess patients’ genotypes,98,99,100 how to personalize treatment for their individual needs, configuring patient interventions to improve lifestyle and

11. 12. 13. 14.

15.

16.

17.

18.

23. 24. 25. 26. 27.

x

Booth et al. report “a sixfold increase in prevalence of Type 2 diabetes between 1958 and 1993” and lament the fact that such ailments “usually thought only to affect individuals of middle age or older will now affect our children at a much earlier age, drastically decreasing their quality of life over a much longer period than previous generations.”

28.

117

e

22.

in

20. 21.

ic

19.

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

9. 10.

Carnes BA, Olshansky SJ, Gavrilov L, et al. Human longevity: nature vs. nurture—fact or fiction. Perspect Biol Med. 1999;42(3):422-41. Wilmoth JR, et al. Increase of maximum life-span in Sweden, 18611999. Science. 2000;289:2366-68. Olshansky JS, Carnes BA, Desesquelles A. Prospects for human longevity. Science. 2001;291:1491-92. Rose MR. Evolutionary Biology of Aging. Oxford Univ. Press. 1991. Hamilton WD. The moulding of senescence by natural selection. J Theor Biol. 1966;12:12-45. Charlesworth B. Evolution in Age-structured Populations, 2nd. Ed. Cambridge University Press. 1994. Rose MR, Long AD. Ageing: The many-headed monster. Curr Biol. 2002;12(9):R311-12. Fries JF. Aging, natural death and the compression of morbidity. N Engl J Med. 1980;303:130-35. Campion EW. Aging better. N Engl J Med. 1998;338(15):1064-66. Vita AJ, Terry RB, Hubert HB, Fries JF. Aging, health risks, and cumulative disability. N Engl J Med. 1998;338(15):1035-41. Campion EW. Aging better. N Engl J Med. 1998;338(15):1064-66. Vaillant GE, Aging Well. Little, Brown: Boston, 2002. Vaillant GE, Mukamal K. Positive aging. Am J Psychiatry. 2001;158:839-47. Wilmoth JR, Horiuchi S. Rectangularization revisited: variability of age at death within human populations. Demography. 1999;36(4):475-95. Carnes BA, Olshansky SJ, Gavrilov L, et al. Human longevity: nature vs. nurture—fact or fiction. Perspect Biol Med. 1999;42(3):422-41. Willett WC. Balancing life-style and genomics research for disease prevention. Science. 2002;296:695-98. Olshansky JS, Carnes BA, Desesquelles A. Prospects for human longevity. Science. 2001;291:1491-92. Oeppen J, Vaupel JW. Broken limits to life expectancy. Science. 2002;296:1029-31. Wilmoth, JR. The future of human longevity: a demographer’s perspective. Science. 1998;280:395-97. Ibid. Yashin AI, et al. Genes, demography, and life span: the contribution of demographic data in genetic studies on aging and longevity. Am J Hum Genet. 1999;65:1178-93. Wilmoth JR, Horiuchi S. Rectangularization revisited: variability of age at death within human populations. Demography. 1999;36(4):475-95. Myers, GD, Manton KG. Compression of morality: myth or reality? Gerontologist. 1984:24(4):346-53. Rothenberg R, Lentzner HR, Parker RA. Population aging patterns: the expansion of mortality. Soc Sci. 1991;46(2):S66-70. Wilmoth JR, et al. Increase of maximum life-span in Sweden, 18611999. Science. 2000;289:2366-68. Rose MR, Mueller LD. Ageing and immortality. Philos Trans R Soc Lond B Biol Sci. 2000;355:1657-62. Vaupel JW. The remarkable improvements in survival at older ages. Philos Trans R Soc Lond B Biol Sci. 1997;352:1799-1804. Zimmer Z, et al. Changes in functional limitation and survival among older Taiwanese. 2002;56:265-76.

Section II Principles of Functional Medicine 29. Robine JM, et al. Determining Health Expectancies. Chichester: John Wiley; 2002:75-101. 30. Oeppen J, Vaupel JW. Broken limits to life expectancy. Science. 2002;296:1029-31. 31. White KM. Longevity advances in high-income countries, 1955-96. Popul Dev Rev. 2002;28:59-76. 32. Jeune B, Vaupel JW, eds. Exceptional Longevity: from Prehistory to Present. Odense: Odense University Press; 1995:109-16. 33. Robine JM, Michel JP. Looking forward to a general theory on population aging. J Gerontol. 2004;59A(6):590-97. 34. Shock NW. Mortality and measurements of aging. In: Strehler BL, Ebert JD, Glass HB, Shock NW, eds. The biology of aging. Washington, DC: American Institute of Biological Sciences, 1960:14-29. 35. Wilmoth JR. The future of human longevity: a demographer’s perspective. Science. 1998;280:395-97. 36. Vaupel JW, Carey JR, et al. Biodemographic trajectories of longevity. Science. 1998;280:855-60. 37. Fries JF. Aging, natural death and the compression of morbidity. N Engl J Med. 1980;303:130-35. 38. Holman H. Chronic disease—The need for a new clinical education. JAMA. 2004;292(9):1057-59. 39. Rose MR. Can human aging be postponed? Sci Am. December 1999:106-111. 40. Friedrich MJ. Biological secrets of exceptional old age. JAMA. 2002;288(18):2247-52. 41. Hayflick L. The future of ageing. Nature. 2000;408:267-69. 42. Guarente L, Kenyon C. Genetic pathways that regulate ageing in model organisms. Nature. 2000;408:255-62. 43. Martin GM, Oshima J. Lessons from human progeroid syndromes. Nature. 2000;408:263-66. 44. Fossel M. Telomerase and the aging cell. JAMA. 1998;279(21):1732-35. 45. Mariotti S, Sansoni P, Barbesino G, et al. Thyroid and other organspecific autoantibodies in healthy centenarians. Lancet. 1992;339:1506-8. 46. Harman D. Aging: A theory based on free radical and radiation chemistry. J Gerontol. 1956:11:298-300. 47. Smith KC ed. Aging, Carcinogenesis, and Radiation Biology. Plenum, New York, 1976. 48. Pryor WA ed. Free Radicals in Biology (Academic, New York), Vols. 1-4. (1976-1980) 49. Beckman KB, Ames BN. The free radical theory of aging matures. Physiol Rev. 1998;78:547-81. 50. Wallace DC, Melov S. Radicals r’ aging. Nat Genet. 1998;19:105-6. 51. Harman D. The aging process. Proc Natl Acad Sci U S A. 1981;78(11:)7124-28. 52. Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci USA. 1994;91:10771-78. 53. Wallace DC. A mitochondrial paradigm for degenerative diseases and ageing. 2001 Ageing vulnerability: causes and interventions. Wiley, Chi Chester (Novartis Foundation Symposium 235) p 247-266. 54. Rose MR. Can human aging be postponed? Sci Am. December 1999:106-111. 55. Hagen TM, Ingersoll RT, Wehr CM, et al. Acetyl-L-carnitine fed to old rats partially restores mitochondrial function and ambulatory activity. Proc Natl Acad Sci USA. 1998;95:9562-66. 56. Hagen TM, Ingersoll RT. Liu J, et al. (R)-alpha-Lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J. 1998;13:411-8. 57. Hagen TM, Wehr CM, Ames BN. Mitochondrial decay in aging: reversal through dietary supplementation of acetyl-L-carnitine and

58.

59. 60. 61. 62. 63.

64.

(c

65.

)2

01

66.

0

67. 68. 69.

70.

71.

72.

73. 74. 75.

76.

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

N-tert-butyl-alpha-phenylnitrone. Ann NY Acad Sci. 1998;854;214-23. Ames BN. CV available from University of California Berkeley, Mailing address: CHORI, 5700 Martin Luther King Jr. Way, Oakland, CA 94609. Eisen MB, Brown PO. DNA arrays for analysis of gene expression. Methods Enzymol. 1999;303:179-205. Sutherland, GR. Just how long can we live? Med J Aust. 2000;173:594-96. Ames BN. Micronutrients prevent cancer and delay aging. Toxicol Lett. 1998;102-103:5-18. Bland JS. Genetic Nutritioneering. Keats Publishing: Lincolnwood, IL. 1999. p. 81. Booth FW, Gordon SE, Carlson CJ, Hamilton MT. Waging war on modern chronic diseases: primary prevention through exercise biology. J Appl Physiol. 2000;88:774-87. McMurdo M. A healthy old age: realistic or futile goal? BMJ. 2001;321:1149-51. Subramanian G, Adams M, Venter JC, Broder S. Implications of the human genome for understanding human biology and medicine. JAMA. 2001;286(18):2296-307. Willett, WC. Balancing life-style and genomics research for disease prevention. Science. 2002;296:695-97. Abumrad N. The gene-nutrient-gene loop. Curr Opin Nutr Metab Care. 2001;4:407-10. Watson J, Crick F. A structure for deoxyribose nucleic acid. Nature. 1953;171:737. Willett, WC. Balancing life-style and genomics research for disease prevention. Science. 2002;296:695-97. Liotta LA, Kohn EC, Petricoin EF. Clinical proteomics: personalized molecular medicine. JAMA. 2001;286(18):2211-14. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark and Finland. N Engl J Med. 2000;343(2):78-85. Williams R, Beerstecher E Jr, Berry LJ. The concept of genetotrophic disease. Lancet. 1950;1(6599):287-89. Bell J. The new genetics in clinical practice. BMJ. 1998;316(7131):618-20. Kaprio J. Genetic epidemiology. BMJ. 2000;320:1257-59. Ames BN, Elson-Schwab I, Silver EA. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased Km): relevance to genetic disease and polymorphisms. Am J Clin Nutr. 2002;75:616-58. N-Acetylcysteine therapy for acetaminophen overdose. Emerg Med. 2000;8:26-32. Weber A, Jager R, Klinger G, et al. Can grapefruit juice influence ethenylestradiol bioavailability? Contraception. 1996;53:41-47. Pantuck EJ, et al. Stimulatory effect of brussels sprouts and cabbage on human drug metabolism. Clin Pharmacol Ther. 1979;25:88. Nijhoff WA, Grubben JA, Nagengast FM, et al. Effects of consumption of brussels sprouts on intestinal and lymphocytic glutathioneS-transferases in humans. Carcinogenesis. 1995;16(61):2125-28. Meydani M. Dietary antioxidants modulation of aging and immune-endothelial cell interaction. Mech Ageing Dev. 1999;111:123-32. Young-in K. Methylenetetrahydrofolate reductase polymorphisms, folate, and cancer risk: a paradigm of gene-nutrient interactions in carcinogenesis. Nutr Rev. 2000;58(7):205-17. Ames BN. Micronutrients prevent cancer and delay aging. Toxicol Lett. 1998;102-103:5-18. Armstrong AM, Chestnutt JE, Gormleh MJ, Young JS. The effect of dietary treatment on lipid peroxidation and antioxidant status in

77. 78. 79.

80.

81.

82. 83.

118

Chapter 12 Healthy Aging: The Promotion of Organ Reserve

84.

85.

86.

87.

88.

94.

95.

96. 97. 98.

e

in

101.

ic

100.

ed

99.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

93.

0

92.

01

91.

)2

90.

(c

89.

newly diagnosed noninsulin dependent diabetes. Free Radic Biol Med. 1996;21(5):719-26. Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA. 2002;287(24):3223-37. Ames BN. Elson-Schwab, I, Silver, EA. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased Km): relevance to genetic disease and polymorphisms. Am J Clin Nutr. 2002;75:616-58. Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C T Polymorphism and risk of coronary heat disease: a meta-analysis. JAMA. 2002;288(16):2023-32. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med. 2002;346(7):467-83. McCully K, McCully M. The Heart Revolution (HarperPerennial: New York), 1999. p. 188. Willett WC, Stampfer MJ. What vitamins should I be taking, doctor? N Engl J Med. 2001;345(25):1819-24. Booth FW, Gordon SE, Carlson CJ, Hamilton MT. Waging war on modern chronic diseases: primary prevention through exercise biology. J Appl Physiol. 2000;88:774-87. Roberts K, Dunn K, Sandra JK, Lardinois CD. Syndrome X: medical nutrition therapy. Nutr Rev. 2000;58(5):154-60. Cassel CK. Use it or lose it: activity may be the best treatment for aging. JAMA. 2002;288(18):2333-35. Friedrich MJ. Biological secrets of exceptional old age. JAMA. 2002;288(18):2247-52. Reed DM, Foley DJ, White LR, et al. Predictors of healthy aging in men with high life expectancies. Am J Public Health. 1998;88(10):1463-68. Halliwell BH. Establishing the significance and optimal intake of dietary antioxidants: the biomarker concept. Nutr Rev. 1999:57(4):104-13. Friedrich MJ. Women, exercise and aging. JAMA. 2001;285(11):1429-31. Tall AR. Exercise to reduce cardiovascular risk—how much is enough? N Engl J Med. 2002;347(19):1522-24. Stewart KJ. Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension. JAMA. 2002;288(13):1622-31. Gerling IC, Solomon SS, Bryer-Ash M. Genomes, transcriptomes, and proteomes. Arch Intern Med. 2003;163:190-198. Martin ER, Lai EH, Gilbert JR, et al. SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. Am J Hum Genet. 2000;67:383-94. Watts G. Unmasking the secret of life. BMJ. 2002;325:736.

119

Section II Principles of Functional Medicine

)2 (c

0 01

e in ic ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

120

Section III The Building Blocks

01 )2 (c

0

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e in ic

)2 (c

0 01

e in ic ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Chapter 13 Environmental Inputs  



Diet and Nutrients Jeffrey S. Bland, PhD

Introduction

lM na tio d. un rve r F se fo re te ts itu h st rig In All



0



01



)2



(c



Diet and Nutrients Air and Water Physical Exercise Psychosocial Influences Trauma Xenobiotics Microorganisms Radiation

nately, it is not possible to attack causality in many chronic diseases without dealing with multiple environmental factors. Fortunately, we do know that the outcome, or phenotype, can be affected by modifying the environment. Yet, we are not using this information effectively to modify our approach to health care. We need this new, primary model for addressing both the prevention and management of chronic disease. That is the central theme of functional medicine.

e

in

ic

ed

A historical review of our understanding of chronic diseases affirms that we now know these are primarily “lifestyle diseases.” This gene-environment connection, in which certain genetic strengths and weaknesses are powerfully influenced by environmental choices, gives rise to the patient’s health phenotype. The phenotype is a result of the interaction of the genotype with environmental factors: genomics influence proteomics,i which influence metabolomics, which ultimately give rise to phenomics, or how an individual looks, acts, and feels. Genes are expressed as a consequence of the environment in which they are immersed. Environment-gene interactions give rise to the expression of the diseases of the culture. No medicine or therapy can prevent the interaction between genes and environment. Unfortu-

Diet and Nutrients: The Emerging Evidence An editorial about the relationship among environmental “inputs” such as diet, lifestyle, and longevity appeared in the Journal of the American Medical Association, authored by Drs. Eric Rimm and Meir Stampfer, well-respected epidemiologists at the Departments of Epidemiology and Nutrition at the Harvard School of Public Health.1 They discussed the work of Ancel Keys, who worked at the University of Minnesota and was a pioneer in the discovery of new research methods linking nutrition and disease. He is credited with discovering that saturated fat intake is a risk factor for cardiovascular disease (CVD) and that unsaturated fat intake

i Proteomics applies the techniques of molecular biology, biochemistry, and genetics to analyzing the structure, function, and interactions of the proteins produced by the genes. Metabolomics provides an overview of the metabolic status and biochemical events associated with a cellular or biological system, describing their dynamic responses to genetic and environmental modulation. Phenomics attempts to integrate the information provided by these areas of study into a holistic picture of the complete organism (individual).

123

Section III The Building Blocks cause and cause-specific mortality.” (If we could prescribe a drug that would lower mortality of all causes by 50%, with virtually no side effects, wouldn’t we all jump on that bandwagon? One has to wonder why we are not hearing a clarion call from all stakeholders for a major shift in our thinking about health care.) A companion paper is titled “Effect of a Mediterranean-style Diet on Endothelial Dysfunction and Markers of Vascular Inflammation in the Metabolic Syndrome.”4 This study analyzed work done in the outpatient department of the Division of Metabolic Diseases at the Second University of Naples in Italy. The investigators assessed the effect of a Mediterranean-style diet on endothelial function and vascular inflammatory markers in patients with metabolic syndrome. “After 2 years, patients following the Mediterranean-style diet consumed more foods rich in monounsaturated fat, polyunsaturated fat, and fiber and had a lower ratio of omega-6 to omega-3 fatty acids. Total fruit, vegetable, and nut intake, whole grain intake, and olive oil consumption were also significantly higher in the intervention group. The levels of physical activity increased in both groups by approximately 60%,” mainly by walking for a minimum of 30 minutes per day. The researchers concluded that “a Mediterranean-style diet might be effective in reducing the prevalence of the metabolic syndrome and its associated cardiovascular risk.” Reductions in high-sensitivity Creactive protein (hs-CRP), interleukin-6 (IL-6), interleukin-7 (IL-7), and interleukin-18 (IL-18), markers for immunological functional changes, were also realized (for hs-CRP levels, p=.01 and for IL-6, p=.04). The conclusion is that implementation of an improved diet and lifestyle program results in remarkable changes in inflammatory patterns and improved insulin sensitivity. The recent “demonstration by epidemiological studies that an elevated serum IGF-1 level is associated with an increased relative risk of developing a number of epithelial cancers”5 broadens the scope of concern.

is associated with a lower risk of CVD. Rimm and Stampfer state:

)2

(c

Nearly 50 years ago, Keys recognized the enormously divergent rates of heart disease around the world, even after adjusting for differences in age. Although coronary disease was and remains the leading cause of death in the United States and many developed and developing countries, it was almost non-existent in the traditional cultures of Crete and Japan. Rates of cancer at various sites also differ enormously—up to 100fold—in different populations. The rapid changes in rates of many of these diseases over time and studies that show increases in chronic disease rates among migrants from traditional to Westernized cultures demonstrate that relatively swift changes in disease rates cannot be attributed solely to genetic differences between populations. Instead, they are likely due to differences in lifestyle, with dietary factors and physical activity the leading candidates … . Although understanding of the relation of lifestyle and health outcomes will continue to be refined, information available now is sufficient to take action.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

in

ic

ed

Rimm and Stampfer conclude by saying that studies on positive lifestyle practices and their mechanisms tend to be supported by the historical research record: “As a society, the United States spends billions on chronic disease treatments and interventions for risk factors. Although these are useful and important, a fraction of that investment to promote healthful lifestyles for primary prevention among individuals at all ages would yield greater benefit.”2 Many studies from the 1990s through today emphasize the importance of diet and the environment in the prevention and management of heart disease. Pertinent studies are reported in two 2004 JAMA papers linking specific diets to heart disease prevention. The first is titled “Mediterranean Diet, Lifestyle Factors, and 10year Mortality in Elderly European Men and Women.”3 This HALE Project (Healthy Ageing: a Longitudinal Study in Europe) is an interesting study. It comprises individuals enrolled in the Survey in Europe on Nutrition and the Elderly: a Concerned Action (SENECA) and the Finland, Italy, and the Netherlands Elderly (FINE) studies. It included 1,507 apparently healthy men and 832 women, aged 70 to 90 years in 11 European countries. This cohort study was conducted between 1988 and 2000. After looking at hazard ratios of various lifestyle and diet considerations, the authors concluded that, “among individuals aged 70 to 90 years, adherence to a Mediterranean diet and healthful lifestyle is associated with a more than 50% lower rate of all-

Diet and the Importance of Carbohydrate Type When we speak of the Mediterranean diet, we are not necessarily talking about a diet high in protein and low in carbohydrate. In fact, this style of diet is reasonably high in carbohydrate. However, the carbohydrate is highly unrefined, fiber-rich, and plant-phytonutrientrich, which has a different physiological effect on function than does carbohydrate in white starch or sugar. Carbohydrate is not the villain here; rather, the type of

124

Chapter 13 Environmental Inputs pocyte physiology, centrally mediated appetite, and peripheral cells such as muscle cells. It is a much more complex story than just getting glucose from starch. We are talking about the metabolic signaling events that occur through the consumption of complex, unrefined, or minimally refined food that is high in complex carbohydrate. Quoting from a 2004 review paper that appeared in Nutrition Reviews:

carbohydrate is what’s important. “White” in carbohydrate (to simplify) is devoid of all the agents necessary for appropriate metabolism and physiochemical control—gastric emptying, release of glucose in a timerelease fashion, and the rhythmic effect it has on the neuroendocrine-immune system through the proper release of energy molecules such as glucose and fatty acids. We should be speaking more about glycemic load and glycemic response than simply talking about percentages of protein, fat, or carbohydrate. Glucose and insulin levels can be raised postprandially by giving protein at high levels. The important feature in the construction of a diet that manages chronic disease is to balance both amount and type of macronutrients, micronutrients, and phytochemicals so that they impact the genomics of the individual with an improved health phenotype. While that balance may vary from person to person, depending on genetics and environment, there are some factors that are important for all of us; one of them is the glycemic response of the diet.6

)2

(c

The apparent paradox that ad-libitum intake of highfat foods produces weight loss might be due to severe restriction of carbohydrate depleting glycogen stores, leading to excretion of found water, the ketogenic nature of the diet being appetite suppressing, the high protein-content being highly satiating and reducing spontaneous food intake, or limited food choices leading to decreased energy intake. Long-term studies are needed to measure changes in nutritional status and body composition during the low-carbohydrate diet, and to assess fasting and postprandial cardiovascular risk factors and adverse effects.8

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

To compress morbidity, rectangularize the survival curve, and develop an effective chronic disease prevention and management program, diet must be used in an intelligent manner, and personalized to the patient’s needs so as to result in an improved health phenotype.

Glycemic Index, Glycemic Load, Dietary Fiber Intake, and the Incidence of Type 2 Diabetes

The glycemic and insulin response after eating (more information on this can be found in Chapter 32) plays an important role in determining long-term risk of CVD. The concept that individuals carry different metabolic sensitivities to the glycemic load of the diet is supported in an article that appeared in 2004 in the American Journal of Clinical Nutrition (“Glycemic Index, Glycemic Load, and Dietary Fiber Intake and Incidence of Type 2 Diabetes in Younger and Middle-aged Women”).7 This is one of many papers with the same theme, documenting that a diet high in rapidly absorbed carbohydrate and low in cereal fiber is associated with increased risk of type 2 diabetes. A diet high in fiber-rich carbohydrate from cereal fiber is associated with a lower risk of heart disease. It promotes a reduction in the relative risk of type 2 diabetes, metabolic syndrome, and insulin resistance.

Gluten Contamination of Commercial Oat Products

e

in

ic

ed

As we change environmental inputs to introduce a higher complex-carbohydrate, minimally processed type of dietary regime, what about the relative effect that the potentially allergenic component of grains might have, including gluten and other reactive proteins? (Issues of gluten sensitivity arise throughout this book; see the index for cross-referencing.) There are certain grain-related products that are low in or devoid of gluten, such as oats. An interesting article published in The New England Journal of Medicine (“Gluten Contamination of Commercial Oat Products in the United States”)9 suggests, however, that certain commercially available oats are not, in fact, gluten-free. The author states that while there is quite a bit of published literature suggesting that people with celiac disease or gluten sensitivity can consume moderate amounts of uncontaminated oats, because they are low in or devoid of gluten, high variability in gluten content has been reported in batches of oats, suggesting contamination with gluten not native to oats, probably as a consequence of being processed in the same plant where

Whole Grain Intake and Insulin Sensitivity Whole grain intake is more than just carbohydrate. Grains contain a rich array of soluble and insoluble fiber, as well as hundreds of different phytochemicals. All of these influence insulin and glucose control through their effects on absorption, liver enzyme activities related to gluconeogenesis, glycogen synthesis, adi-

125

Section III The Building Blocks are just two examples that should alert us to the power of such an approach. Throughout the rest of this book, you will come across many more. The 219GT polymorphism and a diet rich in saturated fat. Certain people have specific single nucleotide polymorphisms (SNPs) and are more susceptible to the oxidative types of reactions and lipoprotein abnormalities associated with the inflammatory profile. For instance, individuals with the 219GT polymorphism carry a much higher sensitivity to saturated fat in the diet, increasing susceptibility to inflammation and increasing the relative risk of coronary atherosclerosis, metabolic syndrome, and type 2 diabetes. Such individuals need to pay special attention to the kind of fat they ingest. They can be thought of as “yellow canaries,” alerting us to the presence of higher susceptibilities in the human genome to certain types of environmental inputs.12 Positive role of essential fatty acids. The literature is replete with studies indicating the positive role that omega-3 balanced diets or omega-3 supplemented diets have on reestablishing proper function of the neuroendocrine-immune system and the inflammation profile. For instance, a paper in the Journal of Nutrition described how an -linolenic acid-rich diet reduced inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women.13 DHA, as well as EPA, also has a positive role in reducing cardiovascular risk and lowering inflammatory potential in women.14 Chronic inflammation does not result in increased risk of CVD alone, but rather relates to the whole family of chronic diseases. (A detailed discussion of essential fatty acids can be found in Chapter 27.)

wheat is processed. Gluten-sensitive individuals are urged to recognize that contamination of commercial oats in the United States with gluten grains such as wheat, barley, and rye is a legitimate concern. We should not assume that all oats are gluten-free. While they would be low in gluten relative to wheat, there may be some contamination. (This may explain why some people with gluten sensitivity have experienced a reaction to oats.)

Glycemia, Insulinemia, and Food Proteins

)2

(c

What about the argument that eating more protein leads to improved glucose tolerance? One paper which represents current thought is titled “Glycemia and Insulinemia in Healthy Subjects after Lactose-equivalent Meals of Milk and Other Food Proteins: The Role of Plasma Amino Acids and Incretins.”10 The authors of this paper conclude that food proteins differ in their capacity to stimulate insulin release, possibly by differentially affecting the early release of a messenger molecule called incretin. Incretin hormones and insulinotropic amino acids may stimulate higher insulin output, insulin resistance, and glycemia. This paper demonstrates that differing food proteins may have remarkably different effects on postprandial insulin and glucose levels. Those that appear to have the lowest influence on postprandial glucose are foods containing milk and soy proteins (although casein has been shown to raise postprandial insulin11). Food proteins that have higher postprandial glycemic responses include beef proteins and some meat and fish proteins. We need to keep in mind that the macronutrient ratio alone of carbohydrate, fat, and protein does not really tell us what we need to know clinically about how individual foods affect particular glucose and insulin responses and, therefore, influence chronic disease risk.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All Summary

At this time, we are witnessing a virtual epidemic in the increase of metabolic syndrome, type 2 diabetes, obesity, CAD, hypertension, and the epithelial cancers. The increased incidence of these conditions arises from a change in the functional metabolic state of the individual due to changing diet and lifestyle factors. One compelling perspective on these issues has been provided by Dr. Loren Cordain (and others), whose work focuses on the “growing awareness that the profound changes in the environment (e.g., in diet and other lifestyle conditions) that began with the introduction of agriculture and animal husbandry ~10,000 years ago

Tailoring the Diet to Genetic Risk Tailoring the diet to the patient’s need can have significant positive benefits in improving the translation of the genotype into a healthy phenotype. Personalization of the diet can result in reduced inflammatory potential through normalization of neuroendocrineimmune system function (see Chapter 26 for an indepth discussion of using diet and nutrients to reduce inflammation). The outcome of this strategy is to reduce the risk and progression of chronic disease. Here

126

Chapter 13 Environmental Inputs cell and metabolized, hydrogen ions are moving at rapid rates across membranes, ions are being transported against gradients, and oxidation-reduction reactions are occurring at diffusion-controlled rates. All of these dynamic processes are regulated by master switches at the executive level in the control of metabolism, both locally and at the whole-person levels. This system is fueled by nutrients that support the energetics necessary to maintain homeodynamic flexibility, or “degrees of freedom.”16 The most stable physiological system is the system with the greatest homeodynamic flexibility.17,18 This is the state that might be defined as having the greatest potential for functional health. Redundancy is built into physiology to allow multiple processes to provide routes to the maintenance of homeostasis. The more pathways available, the greater the metabolic degrees of freedom, and the more resilient the functional physiology. As a person loses metabolic degrees of freedom, it results in the loss of “organ reserve,” as defined by James Fries,19 and increases the risk or severity of illness. An example of this is the electrocardiogram (EKG). The most complex EKG is found in the fine structure (i.e., physiological degrees of freedom) of the fit, young athlete.20 The simplest EKG is the flat-line of a person who has lost all physiological resiliency. The task of the functional medicine practitioner is to find ways of increasing the patient’s physiological degrees of freedom which, in turn, increase functional reserve of the patient. Two environmental factors that have great impact on homeodynamic control of physiology are air and water.

)2

(c

occurred too recently on an evolutionary time scale for the human genome to adjust.”15 The challenge for today’s clinicians and patients is how to create a different gene expression pattern so that good health and a rectangularizing of the survival curve can be achieved in a 21st century environment. To begin with, we must apply the same level of effort to these issues that we applied in the last 100 years to acute care, with its myriad (and often miraculous) drug and surgical interventions. Nothing less will suffice. When the wrong information is delivered to the genes in the form of a diet or lifestyle poorly matched to a person’s needs, or from a toxic exposure, those genes create an environment in the body (the so-called phenotype, the phenomics of the individual) that is unwary, ill at ease, uncomfortable, and prepared to do battle. This results in chronic immunological activation or imbalance. This shift from acute threats to chronic dysfunction is the challenge of 21st century medicine. Many variables are influential—not only diet, but stress, toxins in the environment, endotoxins in the gut, chronic infection, and mechanical trauma, such as over-training in athletes. Myriad environmental factors can shift the balance in the immunological system, creating in various tissues the message of inflammation which, in turn, is related to the etiology of most chronic disease.

0

01

Jeffrey S. Bland, PhD

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Air and Water

in

ic

From a functional medicine perspective, physiology is in a homeodynamic state of interaction with the environment. What may appear to be “homeostasis” is, in actuality, very dynamic. An analogy is the flight of a humming bird. It can hold itself stationary, or in “stasis,” at the flower to sip the nectar but, as we know from time-lapse photography, it is actually flapping its wings “dynamically” to overcome gravity. So it is with human physiology. We assume that, because blood sugar, pH, osmolarity, and cellular redox potential don’t change much in the healthy individual, homeostasis is a natural set point for physiology. At the cell biological and molecular levels, however, there is significant dynamic function going on at any one time in order to maintain what is perceived as homeostasis. Blood gases are constantly being exchanged, glucose and fats are being taken up by the

Oxygen as a Limiting Nutrient

e

The air we breathe is composed of approximately 20% diatomic molecular oxygen. This oxygen supports aerobic metabolism. In the absence of proper oxygen delivery to the cell, metabolic degrees of freedom are significantly reduced and functional reserve is compromised. The cell, tissue, or organ that is oxygen-deprived loses its homeodynamic potential and shifts to the primitive state of anaerobic metabolism, or fermentation. In this case, the cells become more acidic and pH drops, electrolytes are disturbed, and reduction-oxidation chemistry is modified. In clinical medicine, we associate these conditions with ischemic hypoxia or, in the extreme, anoxia.21 In these cases, oxygen becomes the limiting nutrient for function and new homeostatic

127

Section III The Building Blocks centration of substances within cells increases, pH changes, and enzyme function is altered. Muscle cramping, sore muscles, reduced mental clarity, constipation, fatigue, and increased sensitivity to toxic substances all increase during states of dehydration. In these cases, water becomes the limiting nutrient for support of functional physiology.

levels of blood sugar, blood gases, osmolarity, and redox result that are associated with degrees of ill health or disease.22,23 Conditions that can result in oxygen becoming the limiting nutrient include, as examples: • anemia • vascular injury • ischemic events due to vasoconstriction • poisoning • respiratory depression • pulmonary dysfunction • compromised musculoskeletal fitness

The Importance of Assessing Air and Water Adequacy In a functional medicine assessment, the adequacy of air (i.e., oxygen) and water to maintain functional organ reserve should be a first-stage priority. The use of body composition measurements using bioimpedance analysis30 can provide information about both intraand intercellular water status. Pulse and heart rate, along with physical assessment of oxygen saturation and tissue-specific signs of ischemia, can provide information concerning the adequacy of oxygen. Often, clinicians assume adequacy of both oxygen and water because they are so readily available, and if the patient doesn’t display overt symptoms of hypoxia or dehydration, no further evaluation is done. By concentrating on the signs and symptoms of chronic tissue deprivation of either oxygen or water, clinicians can identify many patients in need of therapy in these areas. Proper intervention to improve tissue oxygen and water delivery will improve homeodynamic control and functional physiological reserve.

)2

(c

Historically, most cultures have had a traditional activity (a “therapy”) designed to improve oxygen delivery to tissues, and a number of these activities have been investigated for their health effects.24,25,26 Examples include: • deep-breathing exercises • yoga • rebreathing • dance • physical therapy • stress reduction (meditation) • dietary factors to improve blood chemistry • physical fitness training and athletic competition

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

At the Institutes for the Achievement of Human Potential in Philadelphia, parents of brain-injured children are taught exercises for their children that improve oxygen delivery to the brain.27 The positive impact these therapies have on improving function in braininjured children has been documented from hundreds of thousands of examples around the world.

ed

Health Effects of Air and Water Pollution

in

ic

An extensive literature on health effects of environmental pollution is available to the interested reader. This short introduction to air and water as building blocks of health would be incomplete, however, without at least mentioning the significant impact that industrialization has had on the quality of air and water. Water. From the fish we eat, which are now significant sources of toxins such as mercury31 and pesticides (see, for example, the discussion on xenobiotics to be found further on in this chapter), to substances we add to water as a function of general public use32 (chlorine, fluoride, softening agents), to bacterial or parasitic agents found as a result of contamination or overuse,33 pure water on this planet has become a diminished resource. All of these problems have significant health implications, ranging from neurological damage34 to res-

e

Water as a Limiting Nutrient The second most important substance in maintaining homeodynamics and functional reserve is water. The majority of the human body is composed of water. The water that makes up our body composition plays a very important role within cells in maintaining structure and function. Intercellular water binds to proteins, carbohydrates, and nucleic acids to maintain their proper function. When dehydrated, the structure of critical cellular biomolecules is adversely affected, reducing their function.28,29 All systems are influenced by dehydration, resulting in reduced energy production, neurotoxicity, and alteration in the function of every organ. As water is lost and not replaced, the con-

128

Chapter 13 Environmental Inputs piratory problems35 to gastrointestinal ailments.36 Access to safe water for drinking, bathing, and normal household use is a very important part of a healthy life—one of which we are most aware when it no longer exists. Air. “Increased levels of particulate air pollution are associated with increased respiratory and cardiovascular mortality and morbidity as well as worsening of asthma.”37 One of the most distressing aspects of air pollution is its disproportionate effect on babies and children. One study reported that “studies on infant mortality and exposure to particles show an outstanding consistency in the magnitude of the effects, despite the different designs used”; the effect is estimated to be about a 5% increase in post-neonatal mortality for all causes and around 22% for respiratory diseases.38 That’s a heavy price to pay, and it’s paid by our youngest and most vulnerable patients. That is not to imply that adults are somehow protected. A 2005 study suggested that particulate air pollutants in Scandinavia are responsible for approximately 3,500 deaths per year.39 “The annual cost of human exposure to outdoor air pollutants from all sources is estimated to be between $40 to $50 billion … . The death toll from exposure to particulate air pollution generated by motor vehicles, burning coal, fuel oil, and wood is estimated to be responsible for as many as 100,000 fatalities annually in the United States.”40

Physical Exercise William J. Evans, PhD

Introduction

)2

(c

Virtually every system in the human body is affected in some way by increasing levels of physical activity. Exercise encompasses a broad range of activities; it can be defined as increased (above resting) muscular activity and may be categorized as anaerobic (sprinting), endurance (aerobic), or resistive (weight lifting). Resistive exercise is defined as muscle contracting a few times against a heavy load or with high tension. This type of exercise is also termed progressive resistance training (PRT) when the load or intensity is progressively increased as an individual becomes stronger. PRT is distinctly different from aerobic or endurance exercise, in which muscles contract against little or no resistance. Anaerobic exercise makes use of phosphocreatine and/or glycogenolysis for energy production. This type of exercise is generally thought of as a sprinting type of exercise; however, an extremely deconditioned patient, such as an individual with chronic obstructive pulmonary disease or heart failure may perform anaerobic exercise simply by getting out of bed and walking across a room. The adaptive response to regularly performed exercise has been repeatedly demonstrated to have remarkably beneficial effects. The list of these adaptive responses is extensive. The Centers for Disease Control and Prevention, along with the American College of Sports Medicine, has suggested that everyone should accumulate at least 30 minutes of exercise on most (preferably all) days.41 This recommendation is based on evidence of a substantial decrease in all-cause mortality resulting from a moderate amount of increased physical activity.42,43 The American Heart Association has stated that inactivity is a primary risk factor for cardiovascular disease.44,45,46 Because far more Americans are inactive than those who have elevated cholesterol or who smoke, it is the predominant risk factor for heart disease in the United States. This review will focus on the acute and chronic adaptations to exercise with particular attention to substrate use and effects on risk factors for chronic disease and aging.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Summary

e

in

ic

ed

It can be easy to lose sight of the critical importance of adequate oxygenation and hydration of tissues as key factors in health. Air and water are taken for granted, particularly in industrialized countries and particularly by people who are mostly healthy—we breathe, we drink fluids, we give it little thought. Unfortunately, in today’s world, we must pay attention to the sufficiency and quality of our air and water, and clinicians must consider whether a patient may be suffering from deprivation or contamination of these most vital building blocks to health, even when the effects may be diffuse and difficult to detect. With problems this pervasive, we cannot afford to take anything for granted.

129

Section III The Building Blocks

Aerobic Exercise

and women above the age of 60 years old. A number of studies have demonstrated that the age-related decline in VO2max is ameliorated by physical activity.54,55,56,57 Bortz and Bortz58 reviewed endurance event data from master athletes up to age 85 and noted that the decline in performance occurred at a rate of 0.5%/yr. They concluded that this decline of 0.5%/year may represent the effects of age (or “biological” aging) on VO2max, and the remainder of the decline may be the result of an increasingly sedentary lifestyle. However, Rosen et al.59 examined predictors of this age-associated decline in VO2max and concluded that VO2max declines at the same rate in athletic and sedentary men and that 35% of this decline is due to sarcopenia. Aerobic exercise has long been an important recommendation for the prevention and treatment of many of the chronic diseases typically associated with old age. These include type 2 diabetes mellitus (and impaired glucose tolerance), hypertension, heart disease, and osteoporosis. Emerging research is also demonstrating an important role for exercise in treatment and prevention of certain cancers and neurodegenerative diseases.60,61,62,63,64,65,66 Regularly performed aerobic exercise increases insulin action. The responses of initially sedentary young (age 20–30) and older (age 60–70) men and women to three months of aerobic conditioning (70% of maximal heart rate, 45 minutes/day, three days per week) were examined by Meredith et al.67 They found that the absolute gains in aerobic capacity were similar between the two age groups. However, the mechanism for adaptation to regular submaximal exercise appears to be different between old and young people. Muscle biopsies taken before and after training showed a more than two-fold increase in oxidative capacity of the muscles of the older subjects, while that of the young subjects showed smaller improvements. Another study found that “exercise training exerts antioxidative effects in the skeletal muscle in chronic heart failure, in particular, due to an augmentation in activity of radical scavenger enzymes.”68 In addition, skeletal muscle glycogen stores in the older subjects, significantly lower than those of the young men and women initially, increased significantly. The degree to which the elderly demonstrate increases in maximal cardiac output in response to endurance training is still largely unanswered. Seals and co-workers69 found no increases after one year of endurance training while, more recently, Spina et al.70 observed that older

)2

(c

Maximal aerobic exercise capacity is termed VO2max. VO2 (volume of oxygen consumed during maximal aerobic exercise) is defined by the Fick equation: VO2 = Cardiac Output • Arterio - venous oxygen difference. VO2max is expressed as either: ml O2 consumed • kg-1 body weight • min-1 or L O2 consumed • min-1 . ml • kg-1 • min-1 The latter formula is most often used to define an individual’s aerobic capacity, as differences in body weight are controlled for. The Fick equation demonstrates that there are two important determiners of VO2max: central factors that control the delivery of oxygen to skeletal muscle and the capacity of skeletal muscle to extract and utilize oxygen for ATP during exercise. Regularly performed aerobic exercise increases VO2max through the following mechanisms: 1. increased cardiac output resulting from a plasma volume expansion (approximately 15%); 2. increased stroke volume as a result of cardiac hypertrophy; and 3. improved capacity to extract and use oxygen by skeletal muscle.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

in

ic

ed

This enhanced oxidative capacity of muscle is due to increased capillarization, mitochondrial density, and myoglobin content. Under most conditions, the delivery of oxygen limits maximal aerobic performance. Increasing blood hemoglobin concentration (from anemic to normal or from normal to super-normal) has been demonstrated to increase VO2max and submaximal exercise performance.47,48,49,50 Anemia due to malnutrition has been demonstrated to limit functional status and work capacity. On the other hand, aerobic exercise performance in athletes can be substantially improved by increasing hemoglobin levels above normal through the use of recombinant human erythropoietin.51 Maximal aerobic capacity (VO2max) declines with advancing age.52 This age-associated decrease in VO2max has been shown to be approximately 1%/yr between the ages of 20 and 70 years old. This decline is likely due to a number of factors including decreased levels of physical activity, changing cardiac function (including decreased maximal cardiac output), and reduced muscle mass. Flegg and Lakatta53 determined that skeletal muscle mass accounted for most of the variability in VO2max in men

130

Chapter 13 Environmental Inputs groups with retinopathy, serum glucose was significantly associated with the number of hemorrhages.76 These relationships were independent of body composition, abdominal obesity or the presence of type 2 diabetes. The relationship between aging, body composition, activity, and glucose tolerance was also examined in 270 female and 462 male factory workers aged 22 to 73 years, none of whom were retired.77 Plasma glucose levels, both fasting and after a glucose load, increased with age, but the correlation between age and total integrated glucose response following a glucose load was weak: in women only 3% of the variance could be attributed to age. When activity levels and drug use were factored in, age accounted for only 1% of the variance in women and 6.25% in men. The fact that aerobic exercise has significant effects on skeletal muscle may help explain its importance in the treatment of glucose intolerance and type 2 diabetes. Seals and co-workers78 found that a high-intensity training program showed greater improvements in the insulin response to an oral glucose load compared to lower intensity aerobic exercise. However, their subjects began the study with normal glucose tolerance. Kirwan and co-workers79 found that nine months of endurance training at 80% of the maximal heart rate (4 d/wk) resulted in reduced glucose-stimulated insulin levels; however, no comparison was made to a lower intensity exercise group. Hughes and co-workers80 demonstrated that regularly performed aerobic exercise without weight loss resulted in improved glucose tolerance and rate of insulin-stimulated glucose disposal, as well as increased GLUT4 levels in older subjects with impaired glucose tolerance. GLUT4 is the glucose transporter protein found in skeletal muscle. The amount and/or the activation of this transporter protein is thought to be a rate-limiting step in the transport of glucose into muscle cells. In this investigation, a moderate intensity aerobic exercise program was compared to a higher intensity program (50 vs. 75% of maximal heart rate reserve, 55 min/day, 4 day/wk, for 12 weeks). No differences were seen between the moderate and higher intensity aerobic exercise on glucose tolerance, insulin sensitivity, or muscle GLUT4 (the glucose transporter protein in skeletal muscle) levels, indicating perhaps that a prescription of moderate aerobic exercise should be recommended for older men or women with type 2 diabetes (or at high risk for type 2 diabetes) to help to ensure compliance with the program.

men increased maximal cardiac output while healthy older women demonstrated no change in response to endurance exercise training. If these gender-related differences in cardiovascular response are real, it may explain the lack of response in maximal cardiac output when older men and women are included in the same study population.71

Aerobic Exercise and Carbohydrate Metabolism

)2

(c

The two-hour plasma glucose level measured during an oral glucose tolerance test increases by an average of 5.3 mg/dL per decade, and fasting plasma glucose increases by an average of 1 mg/dL per decade.72 The NHANES II study demonstrated a progressive increase of about 0.4 mM/decade of life in mean plasma glucose value 2h after a 75 g oral glucose tolerance test (OGTT, providing a specific amount of glucose drink in a solution and measuring the changes in plasma glucose over a 2 to 3 hour period) (n = 1,678 men and 1,892 women).73 Shimokata and coworkers74 examined glucose tolerance in community-dwelling men and women ranging in age from 17 to 92. By assessing level of obesity, pattern of body fat distribution, activity and fitness levels, they attempted to examine the independent effect of age on glucose tolerance. They found no significant differences between the young and middle-aged groups; however, the old groups had significantly higher glucose and insulin values (following a glucose challenge) than the young or middle-aged groups. They concluded: “The major finding of this study is that the decline in glucose tolerance from the early-adult to the middle-age years is entirely explained by secondary influences (fatness and fitness), whereas the decline from mid-life to old age still is also influenced by chronological age. This finding is unique. It is also unexplained.” However, it must be pointed out that anthropometric determination of body fatness becomes increasingly less accurate with advancing age and does not reflect the intra-abdominal and intramuscular accumulation of fat that occurs with aging.75 The results of this study may be due more to an underestimate of true body fat levels than age, per se. These age-associated changes in glucose tolerance can result in type 2 diabetes and the broad array of associated abnormalities. In 1995, in a large population of elderly men and women (older than 55 years), serum glucose and fructosamine levels were seen to be higher in subjects with retinopathy compared with those without and, within the

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 131

Section III The Building Blocks rence of type 2 diabetes in those who are at the greatest risk for developing this disease.91 Thus, regularly performed aerobic exercise is an important way for older people to improve their glucose tolerance.

Endurance training and dietary modifications are generally recommended as the primary treatment in the non-insulin-dependent diabetic. Cross-sectional analysis of dietary intake supports the hypothesis that a low-carbohydrate/high-fat diet is associated with the onset of type 2 diabetes.81 This evidence, however, is not supported by prospective studies in which dietary habits were not related to the development of type 2 diabetes.82,83 The effects of a high-carbohydrate diet on glucose tolerance and lipoproteins have been equivocal.84,85,86,87 Hughes et al.88 compared the effects of a high-carbohydrate (60% CHO and 20% fat)/high-fiber (25g dietary fiber/1000 kcal) diet with and without three months of high intensity (75% max heart rate reserve, 50 min/day, 4 d/wk) endurance exercise in older, glucose-intolerant men and women. Subjects were fed all of their food on a metabolic ward during the three-month study and were not allowed to lose weight. These investigators observed no improvement in glucose tolerance or insulin-stimulated glucose uptake in either the diet or the diet plus exercise group. The exercise plus high-carbohydrate diet group demonstrated a significant and substantial increase in skeletal muscle glycogen content and, at the end of the training, the muscle glycogen stores would be considered to be saturated. Since the primary site of glucose disposal is skeletal muscle glycogen stores, the extremely high muscle glycogen content associated with exercise and a high-carbohydrate diet likely limited the rate of glucose disposal. Thus, when combined with exercise and a weight maintenance diet, a high-carbohydrate diet had a counter-regulatory effect. It is likely that the value of a high-carbohydrate/high-fiber diet lies in its effect on reducing excess body fat, which may be an important cause of the impaired glucose tolerance. Recently, Schaefer and co-workers89 demonstrated that older subjects consuming an ad libitum high-carbohydrate diet lost weight. There appears to be no attenuation of the response of elderly men and women to regularly performed aerobic exercise when compared to those seen in young subjects. Increased fitness levels are associated with reduced mortality and increased life expectancy. A 2005 review pointed out that these effects appear to be primarily as a result of protection against cardiovascular disease and type 2 diabetes. The authors suggest that “regular exercise induces suppression of TNF- and thereby offers protection against TNF-induced insulin resistance.”90 Increased fitness has been shown to prevent the occur-

Exercise and Weight Loss

)2

(c

Aerobic exercise is generally prescribed as an important adjunct to a weight loss program. Aerobic exercise combined with weight loss has been demonstrated to increase insulin action to a greater extent than weight loss through diet restriction alone. In the study by Bogardus et al.,92 diet therapy alone improved glucose tolerance, mainly by reducing basal endogenous glucose production and improving hepatic sensitivity to insulin. Aerobic exercise training, on the other hand, increased carbohydrate storage rates and, therefore, “diet therapy plus physical training produced a more significant approach toward normal.” However, aerobic exercise (as opposed to resistance training) combined with a hypocaloric diet has been demonstrated to result in a greater reduction in resting metabolic rate (RMR) than diet alone.93 Heymsfield and co-workers94 found aerobic exercise combined with caloric restriction did not preserve fat-free mass (FFM) and did not further accelerate weight loss when compared with diet alone. This lack of an effect of aerobic exercise may have been due to a greater decrease in RMR in the exercising group. In perhaps the most comprehensive study of its kind, Goran and Poehlman95 examined components of energy metabolism in older men and women engaged in regular endurance training. They found that endurance training did not increase total daily energy expenditure due to a compensatory decline in physical activity during the remainder of the day. In other words, when elderly subjects participated in a regular walking program, they rested more, so that activities outside of walking decreased and thus 24-hour calorie expenditure was unchanged. However, older individuals who had been participating in endurance exercise for most of their lives have been shown to have a greater RMR and total daily energy expenditure than did age-matched sedentary controls.96 Ballor et al.97 compared the effects of resistance training to that of diet restriction alone in obese women. They found that resistance exercise training results in increased strength and gains in muscle size as well as preservation of FFM during weight loss. These data are similar to the results

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 132

Chapter 13 Environmental Inputs of Pavlou et al.98 who used both aerobic and resistance training as an adjunct to a weight loss program in obese men and demonstrated preservation of FFM. Two important studies were carried out by Jakicic and co-workers,99,100 examining exercise intensity and duration and their effects on weight loss. In the first study, exercise advice was provided to three groups of overweight women losing weight. All three groups were told to exercise for a total of 40 minutes each day. One group was told to perform all 40 minutes of exercise in one bout; a second group was told to perform 40 minutes of exercise in four 10-minute bouts throughout the day; and the members of the third group were given the same advice as the second group (intermittent exercise) but were provided with a motorized treadmill for their homes. The study found that the duration of the exercise bout was not important. However the total number of minutes exercised per week, irrespective of the group, had the most important effect on total weight loss and maintenance of the weight loss. The second study101 examined the effects of exercise intensity on weight loss (high vs. moderate aerobic exercise). Researchers found that intensity had very little effect on total weight loss, but that, once again, total number of minutes exercised/week was the most important factor. These studies suggest that 150 minutes/wk may be a threshold for exercise having a significant effect on weight loss and maintenance.

)2

(c

weight that can be lifted with one contraction. Strength conditioning results in an increase in muscle size, and this increase in size is largely the result of increased contractile proteins. The mechanisms by which the mechanical events stimulate an increase in RNA synthesis and subsequent protein synthesis are not well understood. Lifting weight requires that a muscle shorten as it produces force. This is called a concentric contraction. Lowering the weight, on the other hand, forces the muscle to lengthen as it produces force. This is an eccentric muscle contraction. These lengthening muscle contractions have been shown to produce ultrastructural damage (microscopic tears in contractile proteins muscle cells) that may stimulate increased muscle protein turnover.103

01

0

Effects of Resistance Exercise and Insulin on Protein Metabolism

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Strength Training

ed

Hormonal and nutritional factors, particularly the availability of insulin and amino acids, have important effects in the control of muscle protein synthesis.104,105 For example, starvation reduces the rate of protein synthesis in skeletal muscle by more than 50% compared to the rate seen in fed animals. This inhibition of protein synthesis (also seen in muscle from diabetic animals) is a result of an impairment in the initiation phase of protein synthesis.106,107 The mechanism through which insulin regulates protein synthesis initiation involves phosphorylation of the translational regulator eukaryotic initiation factor 4E (eIF-4E)-binding protein 1 (4E-PB1).108 Insulin-like growth factor 1 (IGF-1) results in the phosphorylation of 4E-BP1 and dissociation of the 4E-BP1 • eIF-4E complex in cells in culture (muscle cells that are grown in a medium containing appropriate nutrients and growth factors).109 IGF-1 has also been shown to stimulate protein synthesis in rats in vivo110 and in muscle in perfused hind limb preparations.111 These studies also suggest that insulin plays a permissive role in the effect of IGF-1 in stimulating muscle protein synthesis. Studies of insulin secretion after resistance, but not endurance, exercise provide evidence for insulin’s role in maintaining muscle mass. King et al.112 and Dela et al.113 showed that arginine-stimulated insulin secretion is decreased with endurance training. In contrast, acute resistance exercise in rats has been shown to increase insulin secretion.114 As reviewed above, regular aerobic exercise is known to increase insulin sensitivity and glucose tolerance. In addition to its effects on insulin

e

in

ic

While endurance exercise has been the more traditional means of increasing cardiovascular fitness, the American College of Sports Medicine currently recommends strength or resistance training as an important component of an overall fitness program. This is particularly important in the elderly where loss of muscle mass and weakness are prominent deficits. Strength conditioning or progressive resistance training (PRT) is generally defined as training in which the resistance against which a muscle generates force is progressively increased over time. PRT involves few contractions against a heavy load. The metabolic and morphological adaptations resulting from resistance and endurance exercise are quite different. Muscle strength has been shown to increase in response to training between 60 and 100% of the 1 repetition maximum (1RM).102 1 RM is the maximum amount of

133

Section III The Building Blocks does not increase the rate of protein synthesis in nonexercised muscle; using a resistance exercise model, we have also demonstrated that resistance exercise does not stimulate an increase in the rate of protein synthesis. It was only with the addition of insulin that an exerciseinduced increase in the rate of soleus and gastrocnemius protein synthesis was seen. This effect of insulin stimulation on the rate of protein synthesis was preserved with advancing age.

action, aerobic exercise training results in decreased insulin secretion.115 Regularly performed endurance exercise in young men is associated with an insulin pulse profile in the resting fasted state characterized by less insulin secreted per burst but a similar number of bursts over a 90-minute period. These researchers suggested that training-induced elevations in target-tissue sensitivity to insulin may reduce the requirement for pulsatile insulin secretion. This coordinated response keeps glucose concentrations constant. Dela et al.116 demonstrated that aerobic exercise training decreases both arginine- and glucose-stimulated insulin secretion, indicating, they conclude, a profound -cell adaptation. A single bout of concentric exercise is a recognized enhancer of insulin action, while eccentric exercise transiently impairs whole body insulin action for at least two days after the bout.117 We have demonstrated that eccentric exercise can result in a long-term delay in the rate of glycogen synthesis.118 The decreased insulin action and delayed glycogen synthetic rate have been shown to result from decreased rate of glucose transport rather than decreased glycogen synthase activity.119 This transient resistance to insulin and impaired resynthesis of glycogen can result in a systemic hyperinsulinemia that may result in an increase in the rate of muscle protein synthesis. Our laboratory has demonstrated agerelated differences in the insulin response to hyperglycemia following a single bout of eccentric exercise.120 Two days following upper and lower body eccentric exercise, younger subjects demonstrated a pronounced pancreatic insulin response during a hyperglycemic clamp, while this response was blunted in healthy elderly men. The effects of resistance exercise on insulin availability appear to be opposite those of endurance exercise and, thus, net protein accretion is stimulated with resistance exercise. Insulin has been demonstrated to have profoundly anabolic effects on skeletal muscle. In the resting state, insulin has been demonstrated to decrease the rate of muscle protein degradation. Stable isotope amino acid studies in humans121,122 clearly demonstrate that insulin inhibits whole body protein breakdown in vivo and stimulates muscle protein synthesis rate in human skeletal muscle123 and in insulin-deficient rats. However, in non-diabetic animals, this effect was not seen. Fluckey et al.124,125 have argued that insulin is not likely to stimulate muscle protein synthesis in quiescent muscle. We have demonstrated that an insulin infusion

Protein Requirements and Exercise

)2

(c

High-intensity resistance training is clearly anabolic in both young and older individuals. Data from our laboratory demonstrate a 10 to 15% decrease in N-excretion at the initiation of training that persists for 12 weeks. That is, progressive resistance training improved N-balance; thus, older subjects performing resistance training have a lower mean protein requirement than do sedentary subjects. This effect was seen at a protein intake of 0.8g and 1.6g, indicating that the effect of resistance training on protein retention may not be related to dietary protein intake. These results are somewhat at variance with our previous research demonstrating that regularly performed aerobic exercise causes an increase in the mean protein requirement of middleaged and young endurance athletes.126 This difference likely results from increased oxidation of amino acids during aerobic exercise that may not be present during resistance training. Strawford et al.127 also demonstrated similar effects of resistance exercise training on nitrogen balance in patients with HIV-related weight loss. The investigators examined the effects of an anabolic steroid (oxandrolone, 20 mg/d, and placebo) and high-intensity resistance training in 24 eugonadal men with HIV-associated weight loss (mean = 9% body weight loss). Both groups showed significant nitrogen retention and increases in LBM, weight, and strength. The mean gains were significantly greater in the oxandrolone group than in the placebo group in nitrogen balance, accrual of FFM, and strength. Results were similar whether or not patients were taking protease inhibitors. These results confirm the positive effects of resistance exercise on nitrogen retention and protein requirements. These studies, taken as a whole, demonstrate the powerful effects of resistance exercise training on protein nutriture. The anabolic effects have important implications in the treatment of many wasting diseases

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 134

Chapter 13 Environmental Inputs mented, and non-exercise control). The non-exercising subjects who received the supplement reduced their habitual dietary energy intake so that total energy intake was unchanged. In other words, the supplement did not add to total energy intake, but rather substituted one source of energy (the supplement) for another (their meals). More recently (in the same study population), we demonstrated that combined weight lifting and nutritional supplementation increased strength by 257  62% (p = 0.0001) and type II fiber area by 10.1  9.0% (p = 0.033), with a similar trend for type I fiber area (+12.8  22.2%).131 Exercise was associated with a 2.5-fold increase in neonatal myosin (a form of myosin found in growing muscle) staining (p = 0.0009) and an increase of 491  137% (p < 0.0001) in IGF-1 staining. Ultrastructural damage increased by 141  59% after exercise training (p = 0.034). Strength increases were largest in those with the greatest increases in myosin, IGF-1, damage, and caloric intake during the trial. Frail, very old elders respond robustly to resistance training with musculoskeletal remodeling, and significant increases in muscle area are possible with resistance training in combination with adequate energy intakes. It should be pointed out that this was a very old, very frail population with diagnoses of multiple chronic diseases. The increase in overall levels of physical activity have been a common observation in our studies.132,133,134 Since muscle weakness is a primary deficit in many older individuals, increased strength may stimulate more aerobic activities like walking and cycling. Strength training may increase balance through improvement in the strength of the muscles involved in walking. Indeed, ankle weakness has been demonstrated to be associated with increased risk of falling in nursing home patients.135 However, balance training, which may demonstrate very little improvement in muscle strength, size, or cardiovascular changes, has also been demonstrated to decrease the risk of falls in older people.136 Tai Chi, a form of dynamic balance training that requires no new technology or equipment, has been demonstrated to reduce the risk of falling in older people by almost 50%.137 As a component of the National Institute on Aging FICSIT trials (Frailty and Injuries: Cooperative Studies of Intervention Techniques), individuals aged 70+ were randomized to Tai Chi (TC), individualized balance training (BT), and exercise control education (ED) groups for 15 weeks.138 In a follow-up assessment four months post-intervention, 130 subjects responded

and conditions such as cancer, HIV infection, aging, chronic renal failure, and undernutrition seen in many very old men and women. By effectively lowering dietary protein needs, resistance exercise can limit further losses of skeletal muscle mass while simultaneously increasing muscle strength and functional capacity.

Resistance Exercise and Aging

)2

(c

Our laboratory examined the effects of high-intensity resistance training on the knee extensors and flexors (80% of 1RM, 3 days/week) in older men (age 60–72 years). The average increases in knee flexor and extensor strength were 227% and 107% respectively. CT scans and muscle biopsies were used to determine muscle size. Total muscle area by CT analysis increased by 11.4% while the muscle biopsies showed an increase of 33.5% in type I fiber area and 27.5% increase in type II fiber area. In addition, lower body VO2max increased significantly while upper body VO2max did not, indicating that increased muscle mass can increase maximal aerobic power. It appears that age-related loss in muscle mass may be an important determinant in the reduced maximal aerobic capacity seen in elderly men and women.128 Improving muscle strength can enhance the capacity of many older men and women to perform many activities such as climbing stairs, carrying packages, and even walking. We applied this same training program to a group of frail, institutionalized elderly men and women (mean age 90  3 years, range 87-96).129 After eight weeks of training, the 10 subjects in this study increased muscle strength by almost 180% and muscle size by 11%. More recently, a similar intervention on frail nursing home residents demonstrated not only increases in muscle strength and size, but increased gait speed, stair climbing power, and balance.130 In addition, spontaneous activity levels increased significantly while the activity of a non-exercised control group was unchanged. In this study, the effects of a protein/calorie supplement combined with exercise were also examined. The supplement consisted of a 240 mL liquid supplying 360 kcal in the form of carbohydrate (60%), fat (23%), and soy-based protein (17%), and was designed to augment caloric intake by about 20%, and provide one-third of the RDA for vitamins and minerals. The men and women who consumed the supplement and exercised gained weight compared to the three other groups examined (exercise/control, non-exercise supple-

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 135

Section III The Building Blocks weeks of training when compared to their pre-training energy requirements. This increase in energy needs came about as a result of an increased resting metabolic rate, the small energy cost of the exercise, and what was presumed to be an increase in activity levels. While endurance training has been demonstrated to be an important adjunct to weight loss programs in young men and women by increasing their daily energy expenditure, its utility in treating obesity in the elderly may not be great. This is because many sedentary older men and women do not spend many calories when they perform endurance exercise, due to their low fitness levels. Thirty to 40 minutes of exercise may increase energy expenditure by only 100 to 200 kcals with very little residual effect on calorie expenditure. Aerobic exercise training will not preserve lean body mass to any great extent during weight loss. Resistance training can preserve or even increase muscle mass during weight loss and, therefore, may be of genuine benefit for those older men and women who must lose weight.

)2

(c

to exit interview questions asking about perceived benefits of participation. Both TC and BT subjects reported increased confidence in balance and movement, but only TC subjects reported that their daily activities and their overall life had been affected; many of these subjects had changed their normal physical activity to incorporate ongoing TC practice. The data suggest that when mental as well as physical control is perceived to be enhanced, with a generalized sense of improvement in overall well-being, older persons’ motivation to continue exercising also increases. Province et al.139 examined the overall effect of many different exercise interventions on reducing falls in the FICSIT trials. While separate interventions were not powered to make conclusions about their effects on the incidence of falls in an elderly population, the researchers concluded that “all training domains, taken together under the heading of ‘general exercise’ showed an effect on falls, this probably demonstrates the ‘rising tide raises all boats’ principle, in which training that targets one domain may improve performance somewhat in other domains as a consequence. If this is so, then the differences seen on fall risk due to the exact nature of the training may not be as critical compared with … not training at all.” It’s important to note that in addition to regular strength and balance training, other elements play an important role in bone health and preventing falls; specifically, reducing psychotropic medication and diet supplementation with vitamin D and calcium (discussed further below) have also been shown to be effective.140,141 The use of a community-based exercise program for frail older people was examined in a group of predominantly sedentary women over age 70 with multiple chronic conditions.142 The program was conducted with peer leaders to facilitate its continuation after the research demonstration phase. In addition to positive health outcomes related to functional mobility, blood pressure maintenance, and overall well-being, this intervention was successful in sustaining active participation in regular physical activity through the use of peer leaders selected by the program participants. In addition to its effect on increasing muscle mass and function, resistance training can also have an important effect on energy balance.143 Men and women participating in a resistance training program of the upper and lower body muscles required approximately 15% more calories to maintain body weight after 12

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All Bone Health

e

in

ic

ed

The increased calorie need resulting from strength training may be a way for the elderly to improve their overall nutritional intake when the calories chosen are nutrient-dense foods. In particular, calcium is an important nutrient to increase. Calcium intake was found to be a limiting nutrient in the diet of free-living elderly men and women in the Boston Nutritional Status Survey, which assessed free-living and institutionalized elderly men and women.144 Careful nutritional planning is needed to reach the recommended calcium levels of 1500 mg/d for postmenopausal women with osteoporosis or using hormone replacement therapy, and 1000 mg/d for postmenopausal women taking estrogen. An increased calorie intake from calcium-containing food is one method to help achieve this goal. In one of the very few studies to examine the interaction of dietary calcium and exercise, we studied 41 postmenopausal women consuming either high-calcium (1462 mg/d) or moderate-calcium (761 mg) diets. Half of these women participated in a year-long walking program (45 min/d, 4 d/wk, 75% of heart rate reserve). Independent effects of the exercise and dietary calcium were seen. Compared with the moderate-calcium group, the women consuming a high-calcium diet displayed reduced bone loss from the femoral neck, independent of whether the women exercised.

136

Chapter 13 Environmental Inputs demonstrated to provide an important mechanism for the post-myocardial infarction patient to improve fitness and reduce the risk of a second event, exercise can greatly improve fitness and reduce much of the fatigue associated with cancer and its treatment. The proven effects of resistance training to enhance nitrogen retention and increase muscle size and strength can provide positive benefits for patients with wasting diseases such as HIV infection and cachexia. Resistance exercise may prove to have powerful effects on patients with chronic renal failure who must consume low-protein diets to slow the progression of their disease. Exercise therapy for those patients forced to undergo extended periods of inactivity during dialysis could also improve functional status and decrease the fatigue associated with disuse. The potential value of a reasonable and well thought out exercise program is great, and the exploration of this value should be a high priority for researchers.

)2

(c

The walking prevented a loss of trabecular bone mineral density seen in the non-exercising women after one year. Thus, it appears that calcium intake and aerobic exercise are both independently beneficial to bone mineral density at different sites. The effects of 52 weeks of high-intensity resistance exercise training were examined in a group of 39 postmenopausal women.145 Twenty were randomly assigned to the strength training group (2 days/week, 80% of 1RM for upper and lower body muscle groups). At the end of the year, significant differences were seen in lumbar spine and femoral bone density between the strength-trained and sedentary women. However, unlike other pharmacological and nutritional strategies for preventing bone loss and osteoporosis, resistance exercise affects more than just bone density. The women who strength trained improved their muscle mass, strength, balance and overall levels of physical activity. Thus, resistance training can be an important way to decrease the risk for an osteoporotic bone fracture in postmenopausal women. Muscle strength training can be accomplished by virtually anyone. Many healthcare professionals have directed their patients away from strength training in the mistaken belief that it can cause undesirable elevations in blood pressure. With proper technique, the systolic pressure elevation during aerobic exercise is far greater than that seen during resistance training. Muscle strengthening exercises are rapidly becoming a critical component of cardiac rehabilitation programs, as clinicians realize the need for strength and endurance for many activities of daily living. There is no other group in our society that can benefit more from regularly performed exercise than the elderly. While both aerobic and strength conditioning are highly recommended, only strength training can stop or reverse sarcopenia. Increased muscle strength and mass in the elderly can be the first step toward increased physical activity and a realistic strategy for maintaining functional status and independence for the remaining life span.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All Summary

in

ic

ed

Exercise exerts a powerful acute and chronic effect on virtually every system in the human body. In assessing these effects and prescribing exercise, it is important to keep in mind the very different effects of aerobic vs. resistance exercise. Both forms of exercise are recommended and should be a component of a comprehensive program of disease prevention and health promotion. Chapter 29 presents information on helping patients structure and maintain a balanced exercise program.

John Tatum, MD

e

Psychosocial Influences Introduction

An examination of the building blocks of health would be incomplete without an evaluation of the pivotal role played by psychosocial influences. Even in ancient times, this view was not unknown: Hippocrates (460–377 BC) is thought to have said, “It is better to know the patient who has the disease than it is to know the disease which the patient has.” A substantial part of “knowing the patient” includes understanding the psychosocial influences that have shaped, and continue to influence, our patients (and ourselves). While this material is not

Exercise in the Treatment of Chronic Disease The effects of exercise in treating chronic debilitating disease are largely unexplored. For example, fatigue is the most common complaint of patients with cancer, yet the most common advice provided by oncologists is for increased rest. Just as cardiac rehabilitation has been

137

Section III The Building Blocks intended to review extensively the factors and theories underlying psychological well-being (there is, after all, substantial literature devoted to the field and readily accessible to the reader), we do want to emphasize the importance of the clinician’s continuing attention to the subject. A further discussion of mind/body issues, including the effects of spirituality, community, and poverty on health, can be found in Chapter 33. Here, we undertake a brief review of stress, as a marker for the profound effects that psychosocial influences have on the development of each human being.

Selye first noticed in medical school that patients with various illnesses had many symptoms in common, such as “coated tongues, aches and pains, loss of appetite, and inflamed tonsils.”154 He later noticed a generalized syndrome in laboratory animals exposed to various noxious agents, which he described as the “general adaptation syndrome.”155 Selye distinguished distress from eustress, stating, “the fact that eustress causes much less damage than distress graphically demonstrates that it is ‘how you take it’ that determines, ultimately, whether you can adapt successfully to change.”156,157

Historical Emergence of Stress as a Recognized Factor in Health

Chronic vs. Acute Stress

)2

(c

Since the word stress has been used in so many different ways, describing external events and internal reactions, Bruce McEwen suggested the term allostasis, as opposed to homeostasis, to describe the physiologic response of the body in the face of a challenge.158 Robert Sapolsky, in his well-received book, Why Zebras Don’t Get Ulcers, explains that, unlike us, the zebra has an episode of stress only when the lion is in pursuit; otherwise, he is physiologically calm.159 Chronic stress (which most people experience) and its cumulative effects comprise what McEwen terms allostatic load. “Allostatic load does not always denote a failure of the body’s efforts to cope with change or emergency. We can create it for ourselves by living in a way that makes for internal imbalance.” Some examples of self-generated stress are not getting enough sleep, eating an unhealthy diet, and not getting enough exercise.160 The importance of cumulative stress, or the allostatic load, was illustrated by the Holms and Rahe Social Readjustment Rating Scale. Points were assigned to life stressors, both positive and negative, and the higher the total number of points, the greater the likelihood of illness.161 Further discussion of allostatic load and its effects can be found in the following section on trauma.

0

01

In the modern age, the first to write extensively about stress and use the term was Walter Cannon, whose work during World War I, and on into the 1930s, helped to establish the “groundwork for understanding the physiology of mind-body interactions.”146,147 Hans Selye (1907–1982), who gave full credit to Cannon’s work, reintroduced the term and is considered the “father of stress,” although the term was not actually used in the original short article in 1936.148 His use of the word stress was derived from the physical sciences and engineering; through his work, the term evolved from a description of purely physical influences to encompass the biologic sphere as well.149 His final definition of the term became: “Stress is the nonspecific response of the body to any demand made upon it.”150 In the words of one writer, “Selye’s last main contribution to the stress concept was the recognition that, despite our different psychologic and cerebral reactions, both negative and positive stressors (i.e., distress and eustress) elicit virtually identical corticoid/catecholamine responses.”151 Even more specifically, “different stressors elicit different patterns of activation of the sympathetic, nervous, and adrenomedullary hormonal systems.”152 As both scientists and clinicians know, activation of those systems eventually involves the entire mind-body of the patient. The fact that thinking and psychosocial influences affect genetic expression and have long-term neurochemical consequences was demonstrated by the work of Nobel Laureate Eric Kandel, who said, “Stated simply, the regulation of gene expression by social factors makes all bodily functions, including all functions of the brain, susceptible to social influences.”153

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Health Effects of Stress Increased stress has been associated with many health conditions that are widely discussed in the medical literature and readily accessible to the reader. Some of the most familiar (with a few interesting recent citations) include cardiovascular disease,162,163 gastrointestinal disease,164 and hormone dysfunctions,165 all of which have active, ongoing explorations that continue to produce interesting data.

138

Chapter 13 Environmental Inputs same degree of ill effects from the same stress. Sapolsky, professor of biology and neuroscience at Stanford University, and recipient of a McArthur Foundation “genius grant,” describes a series of experiments with rats in which a second rat receives the same electric shock as the first. The second rat does not develop an ulcer if: • there is a companion rat it can bite, • it has a piece of wood it can gnaw on, • it has a warning before the shock, • it can press a lever it thinks will reduce its shock, • the shocks are fewer than expected, and/or • it is accompanied by a second rat it likes.173

The etiological role of stress in disease was demonstrated in a well-designed prospective study of firstyear medical students who were followed for a year. The prediction that there would be a measurable weakening of the immune system and an increase in illness at exam time was confirmed.166 The proinflammatory cytokine IL-6 has been shown to be one mediator of stress-induced illness. The daily burden of caregivers has been recognized as particularly stressful, and the effects of that stress, including elevated IL-6 levels, have been shown to continue after the loss of the loved one.167 Chronic stress also raises cortisol levels,168 which have been shown to damage the brain.169 Studies on psychosocial factors and cancer risk are inconclusive at this time.170 Individuals under stress show less DNA repair, animals show decreases in the DNA repair enzyme methyltransferase, and examination stress increases the ability of a tumor-promoting agent to block apoptosis.171,172 Stress prepares the organism for an emergency, but chronic stress impairs health through a complex array of physiologic functions initiated by the release in the hypothalamus of corticotropin-releasing factor (CRF). CRF triggers the release of adrenocorticotropic hormone, or ACTH, from the pituitary, which in turn causes the release of cortisol from the adrenal cortex. Cortisol helps maintain blood glucose levels but (as noted above) chronic stress or chronic administration of pharmacological cortisol preparations causes insulin resistance, hypertension, redistribution of fat in the body, decreased protein synthesis, and decreased DNA repair. Furthermore, the immune system is weakened through a decrease in the production of blood cells, antibodies, and gamma globulins, but also through an inhibition of the production of the proinflammatory interleukins IL-1, IL-2, and IL-6; tumor necrosis factor; and gamma interferon. This shift in resources from ongoing maintenance and repair of the organism to allout defense is understandable when fleeing the lion, but harmful when chronic, as discussed eloquently by Sapolsky in Why Zebras Don’t Get Ulcers.

)2

(c

Sapolsky translates these studies to humans, observing that stress-related illness is less likely to happen if: • we have an outlet for our frustration, • we have “a hobby” or diversion, • we have predictive information, • we have a real or imagined sense of control, • we can interpret a stress favorably, and/or • we have social connectedness.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

in

ic

ed

Thus, more important than the amount of stress is one’s reaction to it, and that reaction is influenced by many factors. In his review article, “How the Mind Hurts and Heals the Body,” Oakley Ray describes four classes of coping skills that improve one’s ability to handle stress.174 The first of these is knowledge. “With knowledge [or] information, comes an empowerment, a belief that the world is understandable, controllable, and friendly. Perhaps the most stressful situation is the ambiguity that comes from an awareness that one has inadequate and incomplete information.”175 If education can be seen as a measure of knowledge, and perhaps the ability to acquire knowledge, increased years of education should be associated with longevity,176 and indeed they are. Interestingly, however, subsequent research has shown that the association with education is “explained in full by the strong association between education and income.”177 As the authors go on to point out, with a strong match to Sapolsky’s list (shown above): Persons in lower socioeconomic strata have increased exposure to a broad range of psychosocial variables predictive of morbidity and mortality. This includes (1) a lack of social relationships and social supports; (2) personality dispositions, such as a lost sense of mastery, optimism, sense of control, and selfesteem or heightened levels of anger and hostility; and (3) chronic and acute stress in life and work, including the stress of racism, classism, and other

Some Determinants of Individual Responses to Stress Although chronic stress and total cumulative stress increase the chance of illness, genetic, psychological, and social factors also play important modifying roles. For example, not all rats of the same strain suffer the

139

Section III The Building Blocks influenced by (mediators) psychosocial experiences. The psychosocial portion of a comprehensive traditional medical history would include birthplace and subsequent moves, parental information including parenting style, sibling information, history of abuse or neglect, academic history, sexual history, marital history, children (including miscarriages and abortions), occupational history, and history of substance abuse. Research suggests the importance of paying particular attention to stress, loss, attitude, knowledge, beliefs, social support, and spirituality, as they have a direct impact on health and outcome, as described above.

phenomena related to the social distribution of power and resources.

(c

The second coping skill Ray describes is “inner resources.” This refers to the “beliefs, assumptions, and predictions” one learns growing up, including whether life is seen positively or negatively.178 Valliant and Mukamal spoke of “involuntary mental mechanisms that adaptively alter inner or outer reality in order to minimize distress.”179 Rotter introduced the important concept of locus of control,180 and Kamen and Seligman talked of explanatory style.181 Again, these elements map back to Sapolsky’s list in a very substantive way. Ray’s third class of coping skills is social support. “In general, … the larger the social support system is, the lower the mortality rate.”182,183 (More on this subject can be found in Chapter 33.) The fourth class of coping skills Ray describes is spirituality (also discussed further in Chapter 33). He refers to Oxman, Freeman, and Manheimer’s 1995 study. “Those who professed no strength and comfort from religion were three times as likely to die in this six-month period [after elective open heart surgery] as those who said they drew strength and comfort from religion. Those who did not participate in group activities were four times more likely to die than those who did.”184 Other studies have shown similar findings.185 There are many other psychosocial influences on health in modern life that the clinician needs to be cognizant of. Among the many that have been studied, some pertinent ones in today’s highly mobile, globalized world include natural catastrophe,186,187,188 disaster,189 terrorism,190,191 and immigrant status (acculturation).192 Common experiences such as loss of a loved one, relocation, and loss of employment have been researched for decades.

)2

Trauma

0

01

Jayne Alexander, DO

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Introduction

When a rock is dropped to the bottom of a lake it not only disrupts the column of water through which it falls, but it also alters the dynamics of the entire body of water. Similarly, trauma, typically a directed force, not only disrupts or distorts the human body along the path of impact, but also potentially alters the dynamics of the entire organism. This discussion will consider some of the physiologic and mechanical principles involved in trauma. Clinical considerations relevant to the post-stabilization, office-based patient will be presented.

ed

e

in

ic

Anatomic and Physiologic Response to Trauma Starting with embryonic development and continuing throughout life, the living human body functions in part as a spatially oriented metabolic field engaged in the conduct of spatially ordered metabolic processes.194 Trauma can be viewed as a force that distorts or disrupts the body’s spatial organization, or anatomy, to an extent that exceeds its ability to immediately return to its normal orientation and function. The dominant physiologic concerns in the stabilized trauma patient are the effects of distortion mechanics, cellular breakdown secondary to frank tissue disruption, and consequent local and systemic responses. Non-incisive trauma, such as strain, spares its recipient the frank tissue disruption that occurs in

Summary This brief examination of psychosocial influences as key building blocks in patient health reveals that we cannot overemphasize the importance of taking a thorough psychosocial history as part of routine health care. Psychosocial factors influence health through the interconnected information systems of the mind, the endocrine system, the nervous system, and the immune system,193 so the clinician cannot discount the possibility that the physical effects that brought the patient to the office may have been initiated by (triggers) and/or

140

Chapter 13 Environmental Inputs antigens to lymph nodes and the vigor of the subsequent immune response.iii,203,204 The body’s response to trauma involves both the peripheral and central nervous systems. The peripheral nervous system (PNS) has two components: a somatic component, the efferent fibers of which innervate skeletal muscle, and an autonomic component which innervates most other tissues and organs.iv Both components carry sensory fibers, or primary afferent fibers, from somatic or visceral tissues to the central nervous system (CNS) via the dorsal horn of the spinal cord. These primary afferents are of two types—myelinated, largecaliber fibers, or A afferents, and non-myelinated, smallcaliber fibers, or B afferents. The large-fiber system is typically involved in discriminative touch and proprioception, and the small-fiber system is involved in nociception, the detection of damaging or noxious stimuli. The small-caliber fibers, commonly referred to as primary afferent nociceptors, or PANs, are responsive to mechanical, chemical, and thermal stimulation. Lowlevel stimulation of PANs is perceived as crude touch or contact, whereas more intense stimulation is perceived as pain. Under conditions of repetitive stimuli, PANs are subject to sensitization—a lowering of the threshold of activation, which leads to the development of facilitation and hyperalgesia.205 Nociceptive information is conveyed by somatic and visceral afferents to the dorsal horn of the spinal cord, and then ascends the cord to the midbrain, primarily via the anterolateral system. The forebrain limbic system, which processes emotional content, has descending projections to the midbrain. A major area of convergence of this ascending nociceptive and descending emotional information is a cluster of norepinephrine-producing

)2

(c

incisive trauma. However, neural, vascular, and lymphatic elements that course within strained tissues are, themselves, subject to the forces of strain.195 The resulting distortion sets the stage for mechanical compromise that can manifest as pain, swelling, and functional impairment. Incisive and non-incisive trauma that frankly disrupts tissue integrity initiates the process of inflammation, beginning with the release of substances such as neuropeptides from peripheral nerve terminals, histamine from mast cells, prostaglandins from capillary endothelial cells, and cytokines from white blood cells.196 Consequent increased local blood flow and increased capillary permeability contribute to fluid pooling in the extravascular space, or interstitium, and to the manifestation of edema. The presence of fibrinogen in the interstitial fluid and the infiltration of leukocytes leads to clotting, phagocytosis, and lysosomal degradation.197 Within three to five days of disruptive trauma, granulation tissue, which is rich in fibroblasts and small, budding blood vessels, typically begins to form. Granulation tissue fibroblasts, some of which have characteristics of smooth muscle cells, are involved in the synthesis of glycosaminoglycans and collagen, favoring the former in the early stages of healing and the latter as healing advances.198 The neovasculature’s loosely constructed interendothelial junctions allow extravasation of yet more proteins into the already protein-rich interstitium, a process that further contributes to the formation of interstitial edema.199 It is the critically important task of the lymphatics to remove inflammatory exudate from the interstitium.ii,200,201 The efficiency with which that task is performed governs the length of time that the interstitium is exposed to lysosomes, proinflammatory cytokines, and other irritants. Their persistence in the interstitium can contribute to pain, via stimulation of primary afferent nociceptors, to delayed healing, and eventually to fibrosis.202 Additionally, under conditions of venous stasis, the efficiency of lymphatic drainage inevitably affects the rate of delivery of nutriture and medication to the site of injury, as well as the rate of presentation of

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

iii Of clinical significance is the understanding that osmotic and hydrostatic gradients do not account for the uptake of exudates from the interstitium by initial lymphatics. Rather, pulsatile fluid waves, consistent with arteriolar vasomotion, pass through the interstitial fluid and contribute to the opening and closing of the initial lymphatic. [Intaglietta M, Gross JF. Vasomotion, tissue fluid flow and the formation of lymph. Intl J Microcirc: Clin and Exper. 1982;1:55-65.] Once within the lymphatic vessels, the movement of lymph is supported intrinsically by a distension-sensitive myogenic pump, and extrinsically by such mechanical forces as intestinal peristalsis and thoracic respiration as well as by neural and humoral mediators. [Schmid-Schonbein GW. Microlymphatics and lymph flow. Physiol Rev. 1990;70(4):987-1028.] iv The autonomic nervous system (ANS) sends fibers to all tissues except hyaline cartilage, centers of intervertebral discs, and parenchymal tissues of the CNS. [Willard, FH. Autonomic nervous system. In Ward RC, ed. Foundations for Osteopathic Medicine. 2nd Ed. Philadelphia: Lippincott Williams and Wilkins, 2003.]

ii

Among the substances found in lymph are proteins, histaminase, neutrophilic lysosomes, prostaglandin E, interleukin-1, and antigens [References 200, 201 (p. 937), and Atkinson, TP. Histamine and serotonin. In Gallin JI, et al. Inflammation: Basic Principles and Clinical Correlates. New York: Raven Press, 1992, p. 196.]

141

Section III The Building Blocks Release of norepinephrine from the hypothalamus increases the activity of the sympathetic nervous system (SNS). This has the effect of increasing heart rate, respiratory rate, blood pressure and cardiac output, dilating large muscular arteries and bronchioles, decreasing gastrointestinal system activity, and mediating numerous other changes that prepare the body for aggressive or defensive action.209 Sympathetic fibers follow blood vessels to all lymphoid organs and surround T-cells, many of which have receptors for norepinephrine. Norepinephrine has the effect of increasing the rate of T-cell differentiation, enabling a short-term response to a broad array of antigens. The rate of cell division, however, is decreased, compromising the long-term effectiveness of the response.210 Analogous to the distorting effect that a falling rock has on the entire body of water into which it falls is the effect of trauma on the entire human organism. Various researchers and clinicians have considered the living human body as a single metabolic field,v a matrix field211 or a fluid field,212 and have considered the effects of distortion on the field as a whole. In his later years, Nobel laureate Albert Szent-Györgyi stated, “Whenever we separate two things, we lose something, something which may have been the most essential feature.”213 To the physician trained in subtle manual sensing, distortions of the whole, when present, are manually perceptible and reveal essential organizational qualities of the entire organism.

)2

(c

cells called the locus coeruleus (see Figure 13.1). The locus coeruleus releases norepinephrine through projections to the forebrain, the spinal cord, the hippocampus, the hypothalamus, and to cardiovascular and respiratory centers located in the brain stem.206 When the hypothalamus, which also receives emotional input, is stimulated by norepinephrine from the locus coeruleus, it responds by releasing both corticotropin-releasing hormone (CRH) and norepinephrine. CRH, in turn, stimulates the locus coeruleus to release more norepinephrine, thereby establishing a feed-forward loop between the locus coeruleus and the hypothalamus. Additionally, CRH causes the anterior pituitary to release adrenocorticotropin (ACTH). ACTH, via systemic circulation, stimulates the release of glucocorticoids such as cortisol from the adrenal cortex, resulting in, among other things, gluconeogenesis and suppression of the release of cytokines.207 Under normal conditions, following short-term physical or emotional stress, elevated cortisol levels will serve to downregulate this hypothalamic-pituitary-adrenal (HPA) axis. In addition to being activated by emotional stress, hormonal stimulation, and nociceptive impulses, the HPA axis is also activated by cytokines released in response to trauma, infection, histamine, and inflammation.208 This intersystemic integration is designated as the neuroendocrine immune system.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Obtaining the History

in

ic

ed

The Patient with a History of Trauma

e

Obtaining the history of a stabilized, office-based patient has various components. One should consider the type of trauma and the mechanical forces involved, predisposing factors or antecedents, the duration or “age” of the trauma, and the patient’s overall state of health and metabolic reserve.

v German embryologist E. Blechschmidt describes metabolic fields as “those morphologically definable regions, at all levels of spatial resolution, which contain spatially ordered metabolic movements.” This he applies to cells, tissues, organs, and the whole organism at any stage of development. [Blechschmidt, E. The Ontogenetic Basis of Human Anatomy. Berkeley: North Atlantic Books, 2004, p22.].

Figure 13.1 Generalized schema of effect of noxious or emotionally charged input to the central nervous system

142

Chapter 13 Environmental Inputs pregnancy and her attitude toward the pregnancy should be solicited. APGAR scores and knowledge of the quality, or robustness, of the first cry are additional meaningful indicators of anatomic and physiologic health or compromise. Auto, pedestrian and bicycle accidents, sports injuries, and falls can potentially involve open or closed head injury, fractures, sprains, and strains. Consideration of vectors of force as well as distribution of force is particularly pertinent in this form of trauma.222,223,224 Becker states,

Type of trauma. Patients who are seen in the office have often experienced trauma of the momentuminertia type, wherein a moving body or object has impacted the patient’s body, exemplified by an object falling on the head; or the moving patient has impacted a stationary object, as in hitting one’s head on the overhead storage compartment of an airliner. Information regarding the direction and degree of force should be obtained. Knowledge of individual vectors of force is fundamental to the diagnosis of contrecoup injuries, whiplash, and complex impact injuries. Determination of resultant vectors can guide the discerning clinician to consider areas of occult or asymptomatic trauma and potential functional compromise. Traumas that are not of the momentum-inertia type involve a variety of forces that will be addressed in subsequent sections. Common sources of trauma that may precipitate a patient’s visit to the office, and that should be solicited as part of any new patient’s history, include the following: • Birth • Motor vehicle, pedestrian, and bicycle accidents • Falls, sports injuries, and blows to the head • Dental and orthodontic procedures • Surgical procedures and wounds • Physical, sexual, and emotional abuse including domestic violence, child and elder abuse, abusive child-rearing practices, and exposure to abuse in the role of a witness • Loss

)2

(c

“In circumstances of trauma, thousands of cells have had their inertial patterns suddenly disturbed … into new patterns that include force factors … . Thereafter, the central nervous system must include this new data in every voluntary and involuntary use of the local areas involved and in varying degrees throughout the entire body physiology … . This is in addition to the local injuries that have been endured by the body, which are usually the only thing treated by the physician.”225

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

A history of participation in ice skating, gymnastics, horseback riding, or contact sports should automatically put the physician on the lookout for the effects of trauma. Fracture need not occur for falls, blows, and other momentum-inertia type injuries to be functionally significant. Intraosseous strain typically precedes, but does not always result in, fracture. In the experience of this author, the presence of strain—interosseous, intraosseous, and that involving soft tissue—can contribute to delayed healing and to pain that persists beyond apparent healing. It therefore behooves the physician to solicit the mechanical details of even those falls and accidents that the patient appends with the assuring comment that “nothing was broken.” Many dental procedures (for example, extractions and applications of prostheses) involve the use of compressive, distractive, or torsional force, and orthodontia relies on low-grade force sustained over time to accomplish its goals. Even in the most skilled professional hands, the use of some force is inevitable. The force of extraction, for instance, may be transmitted to the mandible, maxilla, or pre-maxilla from which a tooth is removed, and with the use of excess force or torsion, the force may extend to one of the many bones with which these three articulate, potentially affecting sinus, vestibular, and cranial nerve function, and precipitating cephalgia.226 Having a potentially similar effect is the commonly used orthodontic palate expander, which, in

e

in

ic

ed

In obtaining a birth history, one should ascertain the duration and mechanism of labor, whether cesarean section was necessary, and whether forceps or vacuum extraction was used.214,215 Prolonged engagement in the maternal pelvis during a long and difficult labor subjects the infant cranium to considerable compressive force, potentially resulting in cranial nerve dysfunction or plagiocephaly.216,217,218,219 Difficulty sucking, for example, is typically the result of hypoglossal nerve irritation, a condition which can be promptly corrected by the skillful application of a decompressive manual procedure.220 In the event of cesarean section, presurgical engagement in the birth canal requiring forceful retraction into the uterus is a scenario which, in this author’s experience, has been associated with neonatal torticollis. Since, among other things, maternal HPA axis activation is associated with intrauterine growth retardation,221 the physical and emotional health of the mother during

143

Section III The Building Blocks Clinical observations correlate. In the clinical experience of the author and her colleagues, the fluid field in patients who have experienced physical or psychological attack is often perceived as being compressed or regressed toward the physiologic midline. By contrast, in loss, there may be an actual perceived absence in an aspect of the fluid field with a compensatory shift of the midline, giving physiologic corroboration to the affectionate aphorism “my other half.” Antecedents. It is incumbent upon the physician to endeavor to determine the etiology or background related to the patient’s trauma. Trauma can be preceded and precipitated by cardiovascular and cerebrovascular events, neurological phenomena such as tumor and seizure, visual impairment, and alcohol intoxication. Trauma can result from inattention secondary to fatigue, anxiety, or preoccupation. Trauma can also be a potential consequence of occupation, lifestyle, and familial or interpersonal relationships. Determining and addressing with the patient those factors which are causal or predisposing to trauma is a valuable and sometimes critical contribution of the clinician.

)2

(c

decompressing the maxillary arch, inevitably transmits compression to other areas of the cranium. Surgical procedures are inherently disruptive to anatomy and physiology. A clean surgical incision in a healthy patient should undergo healing by first intention with minimal loss of tissue. Nonetheless, collagenous scars are avascular and acellular and do represent an interruption in tissue continuity. Large wounds involving extensive loss of cells undergo healing by second intention, a process that involves a more intense inflammatory reaction and more extensive wound contraction than does healing by first intention. Predictably, this process sets the stage for more extensive scarring and fibrosis.227 Obtaining a history of abuse and the witnessing thereof requires sensitivity and an understanding that such history may be compensatorily suppressed, unavailable to the patient’s consciousness, or literally lacking in verbal narrative.228 A tempo of interviewing should be adopted that affords patients the opportunity to assess the intent and integrity of the clinician before being called upon to reveal sensitive personal information. Once the physician is entrusted with such information, it is imperative that referral, if necessary, be made with a clearly conveyed attitude of support and respect, lest patients feel abandoned in the wake of their disclosure. Often overlooked are those who witness abuse. Witnesses are, themselves, traumatized, being caught in the psychological conflict of affiliation with either the perpetrator or the victim.229 Of diagnosing the psychological and behavioral aftermath of abusive trauma, Herman admonishes that:

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Long-term Consequences of Unresolved Trauma

ic

ed

The persistent effects of unresolved trauma manifest through a variety of mechanisms which operate locally, intersystemically, and within the patient as a whole. Compensatory structural changes. Asymmetric falls on the buttocks, one-legged falls in holes, and forced “splits” in dance classes can dramatically shift the plane of orientation of both the body of the sacrum and the sacral base. Compensatory structural changes in the form of scoliosis can be the result. Fibrosis. Trauma that is incisive or disruptive to tissues leads to fibrosis, the extent of which is affected in part by the efficiency of drainage of inflammatory exudate by the lymphatics in the post-traumatic period.231 Fibrotic tissue interrupts the integrity and function of the tissues it transects, and limits the range or freedom of motion of the tissues involved. Functional impairment and discomfort, as exemplified by adhesive capsulitis and post-surgical, intra-abdominal adhesions, can ensue. Facilitation. Spinal facilitation, a state of sensitization of the interneuronal pool, occurs as a result of prolonged or excessive stimulation of primary afferent nociceptors, as well as from direct neuronal injury or inhibitory interneuron death, and is a mechanism underlying chronic pain.232 Maintained in a state of

e

in

Concepts of personality organization developed under ordinary circumstances are applied to victims, without any understanding of the corrosion of personality that occurs under conditions of prolonged terror. Thus, patients who suffer from the complex aftereffects of chronic trauma still commonly risk being misdiagnosed as having personality disorders.230

Loss, in the context of trauma, is unique. Unlike other forms of trauma in which the integrity of the organism is disrupted by an added force, the integrity of the organism, in loss, is disrupted by virtue of absence. In this author’s experience, patients have reported pain in the midepigastric area for a number of days following loss, perhaps harkening to the “severing of heartstrings.” Others having lost a spouse or intimate partner have reported a feeling of “irregularity” or concavity on the side of their body next to which the loved one slept.

144

Chapter 13 Environmental Inputs persistent low-grade activation to a chronically elevated baseline, is termed allostatic load.vi,237,238 (This concept is also discussed in the preceding essay on psychosocial influences on health.) In the present discussion, it was established that somatic and visceral trauma, psychological trauma, chronic pain, inflammation, and facilitation all serve to activate the locus coeruleus-norepinephrineHPA axis. Unresolved trauma clearly places a significant demand on the body and, over time, is a major contributor to the development of allostatic load. The effects of allostatic load established to date are multiple. In a study involving 1,189 men and women, aged 70–79 years at outset, participants were assessed with respect to allostatic load, cognitive functioning, and physical functioning.239 Participants with highest allostatic load scores performed most poorly with respect to cognitive and physical functioning and, on eight-year follow-up, higher baseline allostatic load scores predicted greatest loss in cognitive and physical functioning.240 Related to an aspect of cognitive functioning is the hippocampus, which is involved in verbal and contextual memory. The hippocampus is rich in cortisol receptors, and normally participates in a feedback loop controlling release of CRH from the hypothalamus.241,242 Persistently elevated levels of cortisol are toxic to hippocampal neurons, and lead to neuronal atrophy or death and loss of memory.243,244 Prolonged HPA axis activation in infancy and childhood takes its toll, inhibiting the production of growth hormone and somatomedin C.245 This contributes to the condition of “failure to thrive,” in which caloric intake does not promote weight gain. Early loss of a parent (due primarily to parental separation) and physical and sexual abuse during childhood both carry an increased risk of major depression during adulthood.246 A history of major depression is among the strongest predictors of cardiovascular risk, depression being associated with increased resting heart rate, decreased heart rate variability, and increased plasma norepinephrine.247 Chronic elevation of cortisol inhibits bone formation,

)2

(c

constant partial or subthreshold excitation, and responsive to subnormal levels of input from peripheral and autonomic PANs, facilitated levels of the spinal cord are easily stimulated. Once stimulated, signals are sent to the locus coeruleus, which invokes the locus coeruleusnorepinephrine-HPA axis and results in increased sympathetic tone and cortisol output. Under conditions of facilitation, norepinephrine, released from the locus coeruleus in response to input from a facilitated level of the spinal cord, stimulates the hypothalamus, overpowering the normal downregulatory effect of cortisol.233 This results in unmitigated stimulation of the hypothalamus which leads to its sustained release of norepinephrine and CRH and the consequent increase in both sympathetic tone and adrenal elaboration of cortisol. Peripherally, the effects of facilitation may be identified by the presence of tissue texture changes, hyperalgesia, altered ease or range of motion, and anatomic asymmetry of the affected region—a constellation of findings referred to in osteopathic literature as somatic dysfunction.234 Although a facilitated level of the cord may interact with higher centers as previously described, the facilitated reflex arc can also operate independently of higher input. Resolution of the somatic dysfunction associated with facilitation, which can be accomplished manually, allows normalization of somatic afferent input, and, barring persistent visceral input, enables normalization of HPA and autonomic function.235 Viscerosomatic and somatovisceral reflexes. In addition to potentially subjecting the patient to sympathetic and HPA overdrive, facilitation also predisposes the body to the establishment of viscerosomatic and somatovisceral reflexes. Facilitation of an interneuronal pool affects outflow to both visceral and somatic structures innervated by the facilitated level of the cord.236 Thereby, facilitation that was originally established in response to persistent inflammation or mechanical irritation from an unresolved visceral trauma can, via somatic efferents, affect the skeletal muscle innervated by the same spinal level. Conversely, facilitation secondary to unresolved musculoskeletal injury can result in chronic increased autonomic stimulation of segmentally related viscera. Allostatic load. The cumulative, long-term effect or toll taken on the body by frequent, repetitive activation of the autonomic nervous system, HPA axis, and cardiovascular, metabolic, and immune systems, or by their

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

vi Based on the word allostasis, which is akin to the term homeodynamics. The term refers to the coordinated, broad intersystemic (particularly neuroendocrine immune) range of variability that enables the body to maintain stability in the face of protracted challenge. This is distinguished from homeostasis, which maintains discrete, physiologic parameters such as pH and electrolyte balance within a more finite operating range. (The principles of dynamic balance and homeostasis are discussed in Chapter 9.)

145

Section III The Building Blocks approach treatment differently. However, common goals of treatment and principles to apply in planning treatment will likely apply to most clinicians and should be addressed. Promoting efficient exchange of all the fluids of the body is of fundamental importance. Healing is supported and adverse inflammatory and degenerative effects are averted by efficient fluid exchange. Nutrients, both endogenous and exogenous, are delivered and wastes are removed via the fluids of the body. Nutrients will not arrive at their desired destination if the destination or its access routes are in a state of stasis. Similarly, waste products and inflammatory exudates will not be removed if the routes of egress are not open and functioning. Also fundamental to the resolution of trauma is the downregulation of afferent input. Attenuation of facilitation and elimination of the sources of nociceptive stimulation can contribute significantly to normalization by reducing input to the SNS and HPA axis. In this author’s experience, this can often be accomplished by manually engaging and augmenting the corrective and generative physiologic processes that are operant in the patient’s body. Ultimately, it must be acknowledged that the physician is an assistant, and the capacity for healing is inherent to the patient.

)2

(c

and women with a history of depressive illness have a greater frequency of decreased bone mineral density.248 Childhood abuse additionally predisposes to adult anxiety disorders, panic disorder, attempted suicide, post-traumatic stress disorder (PTSD), and likelihood of developing PTSDvii in response to other traumas.249 Sensitization or hyperactivity of CRH circuits secondary to stress early in development is hypothesized to explain the psychological sequelae.250 Females who experience PTSD from childhood sexual abuse demonstrate daily elevation of norepinephrine, epinephrine, dopamine and cortisol levels, and have a tendency toward obesity.251 Abused females additionally have an increased rate of premenstrual syndrome, asthma, spastic colitis, and dysmenorrhea.252 Male veterans, by comparison, who developed PTSD in combat, demonstrate an elevated norepinephrine-to-cortisol ratio, and an increased incidence of cardiovascular disease, gastrointestinal symptoms, chronic pain, and rheumatism.253 Chronically elevated cortisol and catecholamine levels lead to immunosuppression and decreased cellular immunity, which, in turn, leads to increased severity of the common cold and increased titers of coldvirus antibody.254 Elevated cortisol also promotes insulin resistance.255 This results in increased output of insulin, which has been shown to be excitatory to the sympathetic nervous system.256 (For discussion of the inflammatory effects of increased insulin output, see Chapter 30.) Chronic sympathetic hyperactivity elevates blood pressure and increases cardiac workload, thereby contributing to endothelial dysfunction, coronary spasm, left ventricular (LV) hypertrophy, and serious dysrhythmias. Persistently elevated blood pressure accelerates atherosclerosis, which increases the risk of myocardial infarction.257 When coexistent with LV dysfunction, increased sympathetic tone is the most sensitive predictor of cardiac and arrhythmic mortality.258 Increased sympathetic tone impedes development of collateral circulation following arterial occlusion.259

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All Case Studies

e

in

ic

ed

The following cases from the author’s experience are offered in abbreviated form to illustrate potential and uncommonly considered consequences of trauma. Case 1. Concussion and macroscopic distortion. During the winter of my freshman year in osteopathic school, one of my classmates fell on the ice, landing hard on his back and hitting the back of his head. His glasses went flying. When he retrieved them, they fit poorly, and he presumed they had been bent in the fall. In the following hours, he experienced headache, difficulty focusing, unsteadiness on his feet, and “did not feel like himself.” Later that day he reported his symptoms to one of his clinical professors who, on examination, found evidence of the impact, and administered an osteopathic treatment aimed at reestablishing structural balance. Following the treatment, my classmate “felt like himself,” and when he donned his glasses, they fit perfectly, indicating that it was not his glasses that had been warped, but his head. This illustrated to those of us present the capacity of the living cranium to

Supporting the Patient’s Health Details of treatment are not within the purview of this chapter, and clinicians of varying backgrounds will vii

PTSD is characterized by hyperarousal, intrusion (vivid flashbacks and nightmares of the traumatic event), and constriction (anesthesia, detachment, passivity). [Reference 227, p35.]

146

Chapter 13 Environmental Inputs

Summary

deform on impact. We were left by the professor, as I will leave the reader, to consider the potential consequences of sudden distortion, or “warping,” of the human cranium on such phenomena as extraocular muscle function, vestibular function, occlusion, venous sinus drainage, cranial nerve function, etc. Case 2. Hyperthyroidism. Prior to arriving at my office, this 34-year-old mother of five was anticipating an ablative procedure for symptoms of hyperthyroidism of sudden onset two months earlier. Her history revealed that prior to, and within the same month of, her symptoms’ onset she had fallen head over heels down a flight of stairs with her six-month-old daughter in her arms. On exam, her pulse was 110, speech was rapid and voice high-pitched, thyroid was palpably enlarged and she had lost 15 pounds. She complained of headache, feeling hot, “rubber legs,” dyspnea, and dysarthria. Potentially relevant findings included sternoclavicular and acromioclavicular compression, upper left costovertebral compression, segmental cervical restriction and paracervical hypertonicity, occipito-temporal compression, and positional asymmetry of the temporals. Manual osteopathic treatment was administered to restore ease and function to the involved area. On follow-up four days later, the patient reported no recurrence of dyspnea, no “rubber legs,” fewer headaches and improved energy; pulse was 90. Over the following weeks her condition improved and resolved.

Trauma is one of many challenges presented to our patients. Its proper identification and thorough resolution can have effects that reach beyond the individual. When unresolved, trauma can dampen and defeat the human spirit. However, when resolved, trauma has the potential to impart understanding and can augment the human capacity for compassion.

Xenobiotics John Cline, MD

(c

)2

Introduction

01

0

The building blocks of health include both harmful and beneficial influences upon human biology and individual genetic and biochemical uniqueness. One of the harmful environmental inputs that clinicians must pay increasing attention to is xenobiotic exposure. The word xenobiotic is defined as “a chemical substance that is foreign, and usually harmful, to living organisms.”260 Xenobiotics are also known as persistent organic pollutants (POPs), which are carbon-containing chemicals that have been introduced into the environment in everincreasing numbers. In fact, it has been estimated that there have been over 80,000 of these chemicals introduced into the environment since World War II.261 There is a growing body of scientific evidence documenting serious health problems that arise secondary to the exposure and accumulation of POPs in humans.262 There are few environmental issues that have aroused more public concern than the harmful effects of POPs in the general population, especially when it concerns the health and welfare of children. Despite the volume of scientific literature published, this subject remains controversial as there are huge financial issues at stake.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Clinical Pearls

e

in

ic

ed

1. Attend to areas where forces accumulate, e.g., a fall on an outstretched hand may give rise to upper arm or shoulder symptoms if compressive forces are not resolved. 2. When a patient requires a boot-type cast, attempt to match its height in the other shoe. This will help to avoid low back pain and the initiation of scoliotic mechanics. 3. In managing fractures, treatment prior to casting aimed at decreasing or eliminating strain in interosseous, intraosseous, and soft tissues can potentially reduce the development of pain and dependent edema. 4. Solicit a history of trauma from every new patient, and consider trauma as an etiologic or contributing factor in illnesses of unknown or “idiopathic” etiology. Symptoms not typically associated with trauma may, in fact, have a traumatic etiology.

History It is interesting to note that pesticides as we know them today did not exist before World War II. Organophosphate pesticides were developed as nerve gases, and the phenoxyherbicides such as 2,4-D were designed to destroy the Japanese rice crops (with later use as a component of Agent Orange, a substance used to defoliate large areas in jungle warfare).263 Following World

147

Section III The Building Blocks Nunavik in northern Canada. These aboriginal people consume the fat of seals, beluga and narwhal whales. These people have been found to have high body burdens of POPs.271

War II, these chemicals were put to use in many applications, including agricultural production, spraying of neighborhoods for mosquito eradication, and home and garden use. In the 1950s and onward, epidemiologists became concerned about the health effects of exposure to POPs. Initially, studies of wildlife communities demonstrated reproductive, developmental, endocrine, immunologic, and carcinogenic effects.264,265,266 There were high rates of malformed genitalia, aberrant mating behavior, sterility, cancer, and immune system and thyroid dysfunction. United States epidemiologists began to notice a rise in the incidence of non-Hodgkin’s lymphoma (NHL), observing that these cases were clustered in agricultural areas. This phenomenon paralleled pesticide use, causing some researchers to postulate that there was a causal link. In 1962, Rachel Carson’s book, Silent Spring, was truly revolutionary in bringing this issue into political and public awareness.267 It was followed in 1996 by Our Stolen Future, which documented the health effects of these endocrine-disrupting chemicals.268 In 1996, a number of governments participated in the Intergovernmental Forum on Chemical Safety and agreed upon a list of 12 POPs to be eliminated from the environment. These 12 have been dubbed the “Dirty Dozen.” In 2001, the United Nations Environment Program sponsored the Binding Convention on Persistent Organic Pollutants held in Stockholm, Sweden, and there was a call for an immediate ban on 11 of the Dirty Dozen. The list of these dozen POPs and their sources are found in Table 13.1. It should be noted that DDT was still allowed to be used in developing countries to control mosquitoes in malaria prevention.

Health Effects of POPs

)2

(c

The available epidemiological evidence suggests that the health effects of POPs in humans are similar to those in animals in the same range of exposures. Human studies have demonstrated negative effects of POPs on neurodevelopmental, thyroid, estrogen, and immune function.272,273,274,275 Exposures to all of the commonly used pesticides, such as phenoxyherbicides, organophosphates, carbamates, and pyrethrins, have shown positive associations with adverse health effects. Furthermore, the carcinogenic effects of certain POPs have been well demonstrated. Triazine herbicides increase breast cancer risk; carbamate and phenoxyherbicides increase lung cancer risk; use of indoor insecticides is associated with brain cancer and lymphocytic leukemia in children.276 In pregnant women, higher levels of polychlorinated biphenyls (PCBs) have been shown to adversely affect the brain development of their children. The affected children were initially found to have decreased visual recognition scores,277 followed by decreased performance on short-term memory testing.278 By age 11, these children were found to have lower average IQ scores and were delayed in reading comprehension.279 Furthermore, there was evidence of altered gendertypical play behavior, with less masculinized play in boys and more in girls.280 There was also decreased ability to control inappropriate responses, as is found in children with attention deficit hyperactivity disorder.281 There is also growing concern about the impact of flame retardants on human health. There are 175 types of flame retardants and the brominated flame retardants (BFRs) make up the majority. Tetrabromobisphenol A is the most widely used BFR. In vitro studies have demonstrated that it is hepatotoxic, immunotoxic, and neurotoxic. In addition, it acts as an endocrine disruptor with estrogen-like properties. The primary toxic effect is as a disruptor of thyroid homeostasis.282 Furthermore, the level of polybrominated diphenyl ethers (PBDEs, another type of flame retardant) is rising in humans, as recently demonstrated in a study of people

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Properties of POPs POPs are persistent because they resist photolytic, biological, and chemical degradation. They can take as long as one century to biodegrade.269 They are carbon containing and hence organic. They are lipophilic pollutants accumulating in the fatty tissues of organisms. Furthermore, they bioaccumulate up the food chain leaving those at the top with high concentrations in their tissues. Most of the POPs are semivolatile which allows them to travel thousands of miles in the air before they settle.270 An example of this is the Inuit of

148

Chapter 13 Environmental Inputs

Table 13.1 Environmental and Dietary Sources of Persistent Organic Pollutants (the “Dirty Dozen”) Type

Environmental Sources

Examples of Dietary Sources

Byproducts of petrochemical industry and chlorine bleaching in pulp and paper mills; hospital and municipal incinerators

Meat, poultry, and dairy products; sport fish (e.g., lake trout, salmon, walleye); wildlife (e.g., waterfowl and waterfowl eggs, muskrat, otter, moose, deer)

PCBs

“Fire resistant” synthetic products made before 1977, old electrical equipment, leaky containers in PCB disposal sites

Great Lakes fish (e.g., lake trout, salmon), Arctic marine mammals, breast milk

Aldrin

Pesticide used against insects in the soil to protect crops such as corn and potatoes

Dairy products, meat, fish, oils and fats, potatoes, root vegetables

Chlordane

Broad-spectrum contact insecticide used on vegetables, grains, maize, oilseed, potatoes, sugar cane, beets, fruits, nuts, cotton, and jute

DDT

Pesticide widely used during World War II to protect soldiers and civilians against diseases spread by insects

Fish, dairy products, fat of cattle, hogs, poultry and sheep, eggs, vegetables, breast milk

Dieldrin

Insecticide used to control insects in soil

Same as for aldrin

Endrin

Foliar (leaf) insecticide used on field crops such as cotton

Current dietary exposure thought to be minimal because of restricted use

Heptachlor

Nonsystemic stomach and contact insecticide used to control insects in soil

Detected in the blood of U.S. and Australian cattle in 1990; current dietary exposure thought to be minimal because of restricted use

HCB

Fungicide used for seed treatment

HCB-treated grain; current dietary exposure thought to be very low because of severely restricted use

Mirex

Stomach insecticide used to control ants, termites, and mealy bugs

Meat, fish, wild game, marine bird eggs, sea mammals

Toxaphene

Contact insecticide used primarily on cotton, cereal, grains, fruits, nuts, and vegetables and used to control ticks and mites in livestock

Dietary exposure thought to be very low because of restricted use; however, there is a local problem with some fish in Lake Superior

)2

(c

Dioxins, furans

0

01

Use has been severely restricted, so food does not appear to be a major pathway of exposure now; air may be a pathway because of past use in termite control (in the United States)

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Legend: PCBs = polychlorinated biphenyls DDT = dichlorodiphenyltrichloroethane HCB = hexachlorobenzene

Source: Contaminant profiles. In: Health and the Environment. The Health and Environment Handbook for Health Professionals. Ottawa: Health Canada; 1998. Cat no H46-2/98-2111. Available from: http://dsp-psd.pwgsc.gc.ca/Collection/H46-2-98-211E-18.pdf

149

Section III The Building Blocks living in the remote Faroe Islands. The concentration of PBDEs in human breast milk rose threefold between 1987 and 1999.283 Breastfed Faroese children were also found to be 0.59 kg lighter and 1.5 cm shorter than non-breastfed children. The transfer through the breast milk of the contaminants methylmercury and PCBs fully explained the attenuated growth parameters.284

Microorganisms

Recommendations and Summary

Introduction

One of the most comprehensive reviews of the subject of xenobiotics is the document, Systematic Review of Pesticide Human Health Effects.285 The conclusions are as follows: • The scientific literature does not support the concept that some pesticides are safer than others. • Reducing exposure is the best advice. Given the wide range of commonly used home and garden products associated with adverse health effects, the focus should be on reduction of exposure to all pesticides.

Microorganisms include viruses, bacteria, fungi, protozoa, algae, and nematodes, roughly in increasing order of size. They are the oldest form of life on earth and are found virtually everywhere. Bacteria have been present on earth for more than 2.5 billion years. The combined weight of all microbial life is thought to be about 25 times more than all animal life combined.287 Thus, humans have evolved fully in the presence of bacteria. Not only are we not alone, but we are required to live in mutual balance with this vast array of microorganisms. This relationship can be defined as symbiotic (at least one partner profits without hurting the other), commensal (partners that coexist without detriment but without obvious benefit), and pathogenic (in which there is damage to the host). The critical interface between the human body and its internal and external environments manifests itself on many levels: the food we eat, the air we breathe, and the lifestyle we choose are all “environmental inputs” that influence our genetic material continuously. The interaction between the body (through the epidermal, respiratory, oropharyngeal, and gastrointestinal interfaces) and the myriad microbes in the environment provides benefits to both parties. The biologic terrain where humans and microorganisms interact must remain in homeostatic balance to provide the correct milieu for the body to function optimally. In this model, bacteria and other microorganisms are not usually considered dangerous, invasive, and pathogenic. Pathogenicity among microorganisms is the exception, not the rule. Considering the huge population of bacteria and viruses in our environment and in our own bodies, it is a relatively rare occurrence that these typically symbiotic relationships become harmful. Rather, imbalanced microbial growth may be indicative of an alteration in the biologic terrain.

Patrick Hanaway, MD A mighty creature is the germ, Though smaller than the pachyderm, His strange delight he often pleases, By giving people strange diseases. —Ogden Nash

)2

(c

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

in

ic

ed

Furthermore, low-dose exposure is not necessarily safe exposure; “no evidence of harm” is not equivalent to “evidence of no harm.” We are currently able to characterize the risks for only a small number of the 80,000+ POPs that have been released into our environment. There are incalculable combinations of chemicals, environmental breakdown molecules, and metabolites that need to be evaluated for safety in humans. Unfortunately, we presently have a knowledge void, and the phrase “no evidence of harmful effects” can hide the greater truth that there is simply no evidence at all.286 Each one of us needs to avoid exposure to POPs as much as possible and have intact and healthy detoxification systems. For the clinician, it is imperative to help patients understand this diffuse, but increasingly heavy burden our bodies are being asked to handle because it is one of the environmental inputs that has significant effects upon health. Further discussion of the clinical implications of the toxic burden, including detoxification (its processes and applications) and polymorphisms that can predispose to more significant problems, can be found in Chapter 22 and Chapter 31.

150

Chapter 13 Environmental Inputs Colonization of gut flora begins immediately after birth and is nearly complete after the first week of life, but quantity and species vary markedly over the first six months of life.293 More than 500 species have been noted, each with numerous strains identified by molecular probes.294 Overall, the number of bacteria present in the gastrointestinal lumen is 10-fold greater than the number of cells in the human body,295 with more than 100 times the human genome’s DNA content.296 Studies demonstrate that bacteria differentially colonize the neonatal and infant gastrointestinal tract based upon a number of environmental factors, including the mode of delivery (Cesarean section or vaginal delivery),297 hygiene measures, environmental contaminants, maternal flora, age at birth, and type of feeding.298 Nutritional inputs from breastfeeding, bottle feeding, and introduction of solid food provide the initial substrate for growth of varying species of bacteria within the gut.299 Other environmental factors, including more aggressive standards of hygiene, have led to a delayed development pattern and even an absence of certain groups of bacteria in the commensal flora of neonates.300

)2

(c

The symbiotic organisms living in and on us have more than 100 times the amount of genetic material that the entire human genome has.288 The Human Genome Project tells us that at least 223 human proteins have significant homology with bacterial proteins, suggesting direct horizontal transfer from bacterial genes.289 While the age of antibiotics has led us to focus on microbes (and bacteria in particular) as pathogens, an understanding of the co-evolution of humans and microorganisms is critical for our health and well-being. Discussions on this point date back to ancient medical systems, but the most well-known debate on this matter was between Pasteur and Béchamp. Pasteur postulated that “germs” were the primary cause of illness, while Béchamp argued that the “inner terrain” was the most important factor.290 Noted 19th century pathologist Rudolph Virchow is reported to have said, “mosquitoes seek the stagnant water, but do not cause the pool to become stagnant.”291 Microorganisms are ubiquitous and nowhere is this more important than the critical role of the large and dynamic bacterial community present within the gastrointestinal tract. Evidence demonstrates that bacteria have co-evolved to support digestion, absorption, metabolism, and development of the immune system. Disruption of this mutual balance between the physical body and these commensal microorganisms leads to both acute and chronic disease.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Hygiene Hypothesis

In 1989, Strachan301 coined the term “hygiene hypothesis.” As stated, the theory is that increased prevalence of allergy and atopic illness in industrialized countries is a result of the decrease in exposure to common infections during early life, secondary to smaller family size. A number of studies have confirmed this relationship, but there is no direct evidence for a protective role of infections. Many have attempted to extend this hypothesis, based upon epidemiologic evidence, to include the role of antibiotics, vaccines, and anti-microbial soaps, but their effects have not been proved.302 Immunologically plausible explanations have been demonstrated.303 Current research focuses on the role of nutrition, timing, and gut flora maturation on immunologic development.304

Commensal Flora in the Gastrointestinal Tract

e

in

ic

ed

At birth, the human body is sterile. Colonization of the skin epithelia and the mucosal membranes starts immediately after birth and evolves quickly over the first days of life.292 These species play a critical role in the dynamic education of the adaptive immune system, promoting balance and strength in the under-developed immune system. More than a century ago, the Russian scientist Eli Metchnikov discussed the clinical importance of gastrointestinal flora. He promoted the health benefits of taking live bacterial cultures as a means of supporting the colonic microflora. Research on microbial ecology has grown rapidly since the early 1990s, particularly because of the inherent role of the gastrointestinal flora in the development of the immune system. It appears that our co-evolutionary relationship with these organisms is used as a primer for regulation of the immune system.

Breastfeeding has been recognized to have an important role in the nutrition of the infant. Nutritive and immunologic components of breast milk have been studied for years, but the effects of essential fatty acids and oligosaccharides as stimulants for commensal flora are now better understood. From an evolutionary perspective, the gut has been finely tuned to develop based upon the dietary presence of breast milk over the first 1–3 years of life. The immunoregulatory role of breast milk and infant nutrition has come to the fore.305

151

Section III The Building Blocks

Colonization of Gastrointestinal Flora

permeable gastrointestinal epithelium identifies and responds to pathogens, while minimizing the immune reaction to food antigens and commensal flora. Through the process of co-evolution, the body has mastered a number of methods to identify microbes and develop the adaptive immune system, based upon the proper timing and presence of the bacterial stimuli. The body responds differentially to bacterial stimuli and responds to a variety of structural components on each bacterium. Recent evidence demonstrates that immunostimulatory DNA316 may derive from the copious amounts of bacterial DNA present in the gastrointestinal tract. The epithelial mucosa is equipped with pattern recognition receptors (PRRs) that recognize bacterial DNA from commensal bacteria and modulate immune function.317 Thus, our immune system is dynamically educated by the presence of commensal, symbiotic, and pathogenic bacteria at the interface of the intestinal epithelium. The gut flora interacts with our innate immunity and influences the adaptive immune response in an important dialogue between our immune system and the environment. Commensal bacteria are also able to modulate expression of host genes involved in important intestinal functions, including nutrient absorption, mucosal stimulation, xenobiotic metabolism, and intestinal maturation.318 Understanding the “cross-talk” between bacteria and the immune system helps us better understand the relative continuum between pathogenic and non-pathogenic relationships.

)2

(c

There is a significant alteration in the gut flora of the neonate over the first week of life, depending upon the food source. Classically, we see the introduction of E. coli and strep species during the first few days of life, giving way to bifidobacteria, bacteroides, and clostridium. Breast-fed infants then develop a predominance of bifidobacteria, first noted by Tissier in 1905.306 Bottlefed infants show a more diverse pattern of colonization.307 A number of internal and external factors influence the adherence and succession of microbes within the gastrointestinal tract, including feeding habits,308 hygiene,309 stress,310 antibiotics,311 bacteria-host communication, and gene expression.312 Many species have evolved to peacefully co-exist within the gastrointestinal tract. With more than 500 species identified and more than 100 trillion bacteria “in residence,” the necessity of a mutually beneficial relationship is clear. While the sub-species and quantities of bacteria will vary over time, the families and species of commensal flora remain relatively constant within an individual over the course of a lifetime. The gastrointestinal microflora can, however, be modified by diet and environmental factors, and those changes can significantly affect health. Humans and bacteria have co-evolved to offer mutual benefit. The positive health effects of these bacteria include: energy salvage from carbohydrate fermentation, synthesis of B and K vitamins, production of short-chain fatty acids (SCFAs) such as n-butyrate to act as metabolic substrate for colonocytes, lowering pH, producing anti-microbial compounds, and stimulating the immune system.313 Nearly 70% of the human immune system is localized in the digestive tract. The mucosal surface of the gastrointestinal tract would cover the area of a doubles tennis court (if stretched out flat), and is approximately 200x the surface area of the skin. Defense against microbes is mediated by the early reactions of innate immunity, followed by the reaction of adaptive immunity. Innate immunity includes the skin, mucosal epithelia, cytokines, and phagocytes. These non-specific defense mechanisms provide defense against common pathogens, but the innate immune response stimulates the adaptive immune system and influences the nature of the adaptive response.314 The process of “oral tolerance” is an important example of this.315 The semi-

0

01

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

in

ic

Altered Balance in the Human Micro-Organism Environment

e

Hooper and Gordon319 have highlighted the effects of imbalance within this complex ecosystem. The increasing prevalence of allergy and atopy are associated with alterations of intestinal colonization and decreased tolerance to common food proteins and inhaled allergens. Treatment with probiotics can help to shift these symptoms back to normal.320 The pathogenesis of inflammatory bowel disease (IBD), a condition that is becoming substantially more common, appears to involve an abnormal activation of the immune system. IBD results from an inappropriate and exaggerated mucosal immune response to normal constituents of the mucosal microflora. Host genetic background may determine the susceptibility to intestinal inflammation

152

Chapter 13 Environmental Inputs enzymes that create every physiologic function do not float in an intracellular soup; they are attached to the cytoplasmic matrix and perform their chemistry in a solid state context created by this intracellular structure. Water molecules line the matrix forming a system that functions as a semiconductor, sharing electrons and allowing the transmission of energy and information throughout the system.322 Understanding this model becomes important when considering the influences that create damage or constitute a threat to the health of the system, as well as those that may have the potential to heal.

and normal mucosal microflora appears to maintain the inflammatory process.321 Overall, we see that these critical gene-environment interactions highlight immunologic dysregulation arising from the combination of varied bacterial species (commensal and pathogenic), altered adaptive immune system activation, and multiple antigenic stimuli. It appears that diet (as prebiotics and antigens) plays an important role with each of these factors.

Summary From an evolutionary perspective, our genome has not changed over the past 50 years, but the incidence of chronic disease has become epidemic. Playing a vital role in the development of chronic diseases are the changes in our diet and various other environmental factors (see, for example, the discussion on Diet and Nutrients at the head of this chapter) that no longer provide the proper milieu for the gastrointestinal tract to properly activate the immune system. Our genetic predispositions have not prepared us to successfully manage the current lifestyle, dietary, and environmental patterns we face today. We must work to balance each of these inputs to re-align our immune systems for optimal function. As we explore the foundations of normal physiology, we must develop new therapeutic strategies to re-establish a proper relationship with our “old friends,” because microorganisms are one of the key environmental inputs to health.

)2

(c

Ionizing Radiation

0

01

The health risks of environmental x-ray exposure are well documented and easy to understand. Ionizing radioactive energy (x-rays) includes a spectrum of high-energy unseen particles that move through the cell, creating physical damage to intracellular structures. DNA seems particularly sensitive to such damage, and different organs may have different responses to exposure.323 X-rays are useful for medical imaging because the bone and more dense body structures absorb x-rays that pass through less dense structures. The x-rays that pass through the softer tissues create the images on film that we see as diagnostic x-rays. The damaging intracellular effects of x-rays are used therapeutically in cancer treatment to destroy the DNA of malignant cells. Environmental exposure to x-rays includes the ionizing radiation produced by the sun and exposure to altitudes at which the atmospheric protection against x-ray exposure is reduced (e.g., during activities such as mountain climbing and air travel). Radon gas and natural radioactivity found in certain types of rock and brick create residential exposure risk. Ionizing radiation is a potent carcinogen and injures living cells by damaging the DNA. X-rays create some direct damage to the DNA by splitting bonds, but most of the damage is indirectly generated by free radicals that create intracellular injury and DNA damage. Hydroxyl radicals (OH) are considered to be the most damaging of all free radicals and are created by splitting the water molecules that line the intracellular and extracellular matrix. Immune system cells seem particularly vulnerable, as do bone marrow cells.324 Exposure to x-rays increases the risk of breast, colon, lung and ovarian cancer, basal cell

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

in

Radiation

e

Carol R. McMakin, MA, DC

Introduction To understand the effects of environmental radiation exposure on the human system, it is important to understand that, from a biophysics perspective, the human body is an electromagnetic semiconductor matrix that allows for instantaneous communication among all cells and tissues in the system. Every physiologic process and biochemical reaction takes place in this semiconductor matrix. Every cell in the body is filled with a cytoplasmic matrix or cytoskeleton that is connected by integrins across the cell surface to every other cell surface and membrane in the body. The

153

Section III The Building Blocks lower death rate and bleeding incidence when they were pre-fed on cabbage prior to receiving x-ray exposure.330 Ginkgo biloba: When Ginkgo biloba was administered to Chernobyl recovery workers, it protected them from further chromosomal damage.331 Melatonin is an antioxidant that protects DNA, lipids, and proteins from free-radical damage. It works by stimulating the activities of antioxidant enzymes and scavenging free radicals directly or indirectly. Among known antioxidants, melatonin is a highly effective scavenger of (OH), hydroxyl free radicals. Melatonin is distributed widely in organisms and in all cellular compartments, and it quickly passes through all biological membranes. Lymphocytes that were pre-treated with melatonin exhibited a significant and concentrationdependent decrease in the frequency of radiationinduced chromosome damage, as compared with irradiated cells that did not receive the pre-treatment.332 Siberian and Korean ginseng doubled the life span of rats exposed to prolonged x-rays at a total dose of 1,620 to 7,000 rads.333

carcinoma, and leukemia. Radiation exposure reduces the level of both vitamin E and vitamin C in bone marrow.325 The reduction may be either a direct or an indirect effect, as these vitamins are used to counteract the free radicals produced by the x-ray exposure.

Protecting the Patient

)2

(c

How can the clinician help patients to protect themselves from the effects of exposure to ionizing radiation? There is evidence to suggest that antioxidants and other natural substances are protective against the damaging effects of ionizing radiation. Beta carotene: Serum concentrations of oxidized conjugated dienes (an index of lipid peroxidation) were significantly increased in children who were exposed to high levels of irradiation, as compared to children in low radiation areas, following the Chernobyl (nuclear reactor) disaster in Russia. Supplementation with natural beta carotene 40 mg per day for three months resulted in a significant decrease in serum conjugated diene levels after one and three months.326 Lycopene: An animal study using mice demonstrated the ability of lycopene to protect against the detrimental effects of radioactivity exposure. This protection was double that of beta carotene. This effect is likely attributable to lycopene’s antioxidant properties.327 Lipoic acid: This study involved radiation victims in Chernobyl. Lipoic acid reduced free radical damage caused by radiation exposure. One group of 16 children given 400 mg of lipoic acid daily for 28 days showed significant reductions in both white blood cell free radical activity and urinary excretion of radioactive isotopes, compared to a control group of 12 children.328 Vitamin E: A second group of 14 children given 400 mg lipoic acid plus 200 mg vitamin E daily for 28 days showed an even greater reduction in urinary excretion as compared to both the lipoic acid and control groups. Vitamin C improves the ability of the body to resist the toxic effects of exposure to radioactivity. Guinea pigs that were supplemented with large dosages of vitamin C (10 gram equivalent) combined with bioflavonoids were able to withstand twice the known lethal dosages of radioactivity.329 Cabbage, broccoli: Cabbage and broccoli were protective in reducing radiation damage and mortality from radiation exposure in animal studies. Guinea pigs exposed to whole-body x-radiation demonstrated a

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Nonionizing Radiation

e

in

ic

ed

The risks of nonionizing radiation exposure are less clearly documented. The controversy arising from Robert Becker’s research in the 1980s (and his books, The Body Electric334 and Cross Currents335) still reverberates through the research community. Becker stated that the ever-increasing spectra of electromagnetic exposure— “electro-pollution,” including FM radio waves, microwaves, and other electromagnetic fields to which humans are being exposed—create biological effects. Animal studies show chronic stress responses in animals exposed to increased levels of electromagnetic fields (EMF), demonstrated by increased body weight and alterations in neuroendocrine function. (Becker claimed that the Department of Defense interfered with research funding aimed at finding any detrimental effects from radio waves or electromagnetic fields. The military uses these EMF bands for communication and tracking.) The commercial, legal, and financial consequences of any documented link between electromagnetic exposure and cancer are enormous. It is no wonder that researchers (such as Becker) who discover such links find themselves attacked in the public and even in the scientific press.

154

Chapter 13 Environmental Inputs therapies. Upton Sinclair expected to write an exposé on Abrams’s “quackery” for Pearson’s Magazine in 1922, but the published article was titled “House of Wonders.” Sinclair was impressed by the clinical results and the hope they offered to patients. In 1934, the American Medical Association declared that electromagnetic therapies were “unscientific” and moved medicine toward the use of drugs and surgery. The study of electromagnetic therapies and the beneficial effects of electromagnetic therapeutic fields on biological systems dropped out of medical research and into the realm of biophysics. Robert Becker’s ground-breaking work (described above) on the electromagnetic nature of biological tissue and the beneficial effects of direct current (DC) fields in tissue regeneration revolutionized the treatment of nonunion fractures and wound healing. The current author resurrected frequencies used in the 1920s by Abrams and others, using a battery-operated (DC) microcurrent device as a frequency generator, and began using those frequencies to treat myofascial pain and nerve pain with a technique called “frequency specific microcurrent” in 1997.338,339 Very specific clinical responses to over 100 frequencies have been noted, including those thought to remove inflammation, remodel scar tissue, alleviate concussion, eliminate the herpes virus, and stop bleeding. Two frequencies used simultaneously produced unprecedented log scale reductions in inflammatory peptides during a 90-minute treatment in fibromyalgia patients. The changes in cytokines correlated directly with reductions in pain scores.340 Blinded animal research conducted at the University of Sydney by Vivienne Reeve, PhD demonstrated that the frequency to “remove inflammation” (40hz) in the “immune system” reduced lipoxygenase-mediated inflammation by 62% in four minutes in a mouse model. The reduction was time dependent and all animals responded. Three other frequency combinations tested produced no reduction in inflammation. Prescription and non-prescription anti-inflammatory medications tested with this same model reduced swelling by 45%.341 The research and early clinical experiences in this area are promising and suggest there is potential therapeutic benefit of electromagnetic and frequency-specific therapies.

)2

(c

Robert P. Liburdy published a number of papers between 1984 and 1993 documenting the effects of electromagnetic fields on cells. In 1984 he found that radiofrequency radiation affects the immune system by altering human immunoglobulin on T and B lymphocytes. The effect takes place at power levels below the current OSHA recommended safety limit of 0.4 WKg-1.336,337 He published several papers documenting the effects of 12 mg, 60Hz fields, such as those found in the home and workplace, on breast cancer cells. Both tamoxifen and melatonin inhibit the growth of cultured human breast cancer cells. He found that the 12 mg, 60Hz field blocked melatonin’s natural oncostatic action on estrogen positive MCF-7 human breast cancer cells grown in cell culture. The next study showed the same environmental electromagnetic fields inhibit the oncostatic action of tamoxifen as well as melatonin, which implicates the estrogen receptor. The negative effect could be overridden by increasing the dose of melatonin and tamoxifen. There is some controversy over the effects of microwave radiation (from cell phones, FM radio stations, and television transmissions) and its ability to produce specific cancers. As long as there are such huge financial and liability issues involved in the funding and publication of research on this topic, sorting out the real risks on a true scientific basis seems difficult, if not impossible, at the current time. James Oschman observes that, “the Russian standard for maximum safe microwave exposure to avoid changes in brain activity is 1000 times less than the U.S. legal maximum.” Until further research is available, the reader is advised to be cautious and judicious in the selection of home and workplace locations relative to microwave and FM transmission towers, and in the use of cell phones. It has not been documented that the use of antioxidants serves the same protective function in EMF exposure as is seen in radiation exposure.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Beneficial Effects of Electromagnetic Therapies The beneficial and therapeutic effects of electromagnetic therapies have been studied since the early 1900s. The Albert Abrams Medical Clinic in San Francisco successfully treated tuberculosis, cancer, influenza and syphilis in 1920 using frequency-specific electromagnetic

155

Section III The Building Blocks

Summary

16. Fink PW, Kelso JA, Jirsa VK, de Guzman G. Recruitment of degrees of freedom stabilizes coordination. J Exp Psychol Hum Percept Perform. 2000;26(2):671-92. 17. Reynolds D, Carlson JM, Doyle J. Design degrees of freedom and mechanisms for complexity. Phys Rev E Stat Nonlin Soft Matter Phys. 2002;66(1 Pt 2):016108. 18. Buchanan JJ, Kelso JA. To switch or not to switch: recruitment of degrees of freedom stabilizes biological coordination. J Mot Behav. 1999;31(2):126-144. 19. Fries JF. Aging, natural death and the compression of morbidity. N Engl J Med. 1980;303:130-35. 20. Biffi A, Maron BJ, Verdile L, et al. Impact of physical deconditioning on ventricular tachyarrhythmias in trained athletes. J Am Coll Cardiol. 2004;44(5):1053-58. 21. Olson EE, McKeon RJ. Characterization of cellular and neurological damage following unilateral hypoxia/ischemia. J Neurol Sci. 2004;227(1):7-19. 22. Mielke JG, Wang YT. Insulin exerts neuroprotection by counteracting the decrease in cell-surface GABA receptors following oxygenglucose deprivation in cultured cortical neurons. J Neurochem. 2005;92(1):103-13. 23. Ziliene V, Reingardiene D, Tereseviciute N, Slavinskas R. Diagnosis of acute respiratory failure and nosocomial pneumonia. Medicina (Kaunas). 2004;40(11):1124-29. 24. Raghuraj P, Ramakrishnan AG, Nagendra HR, Telles S. Effect of two selected yogic breathing techniques of heart rate variability. Indian J Physiol Pharmacol. 1998;42(4):467-72. 25. Raub JA. Psychophysiologic effects of Hatha Yoga on musculoskeletal and cardiopulmonary function: a literature review. J Altern Complement Med. 2002;8(6):797-812. 26. Okura T, Nakata Y, Tanaka K. Effects of exercise intensity on physical fitness and risk factors for coronary heart disease. Obes Res. 2003;11(9):1131-39. 27. www.iahp.org/hurt/schedule.html 28. Rochette LM, Patterson SM. Hydration status and cardiovascular function: effects of hydration enhancement on cardiovascular function at rest and during psychological stress. Int J Psychophysiol. 2005;56(1):81-91. 29. Duning T, Kloska S. Steinstrater O, et al. Dehydration confounds the assessment of brain atrophy. Neurology. 2005;64(3):548-50. 30. Zaluska WT, Malecka T, Swatowski A, Ksiazek A. Changes of extracellular volumes measured by whole and segmental bioimpedance analysis during hemodialysis in end-stage renal disease (ESRD) patients. Ann Univ Mariae Curie Sklodowska [Med.]. 2002;57(2):337-41. 31. Webb J. Use of the ecosystem approach to population health: the case of mercury contamination in aquatic environments and riparian populations, Andean Amazon, Napo River Valley, Ecuador. Can J Public Health. 2005;96(1):44-46. 32. Rohner AL, Pang LW, Iinuma G, et al. Effects of upcountry Maui water additives on health. Hawaii Med J. 2004;63(9):264-65. 33. Yoder JS, Blackburn B, Craun GF, et al. Surveillance for waterbornedisease outbreaks associated with recreational water—United States, 2001-2002. MMWR Surveill Summ. 2004;53(8):1-22. 34. Webb J. Use of the ecosystem approach to population health: the case of mercury contamination in aquatic environments and riparian populations, Andean Amazon, Napo River Valley, Ecuador. Can J Public Health. 2005;96(1):44-46. 35. Rohner AL, Pang LW, Iinuma G, et al. Effects of upcountry Maui water additives on health. Hawaii Med J. 2004;63(9):264-65. 36. Yoder JS, Blackburn B, Craun GF, et al. Surveillance for waterbornedisease outbreaks associated with recreational water—United States, 2001-2002. MMWR Surveill Summ. 2004;53(8):1-22.

The pervasiveness of radiation, both in the natural environment and from manmade sources, makes it a key environmental input in today’s world. There are important distinctions between the effects of ionizing vs. nonionizing radiation, but overall it seems clear that less is better than more. There are foods and supplements that can help patients protect themselves from radiation damage; clinicians should become familiar with these and assist patients with known high levels of radiation exposure to take precautionary measures.

0

01

2. 3.

Rimm EB, Stampfer MJ. Diet, lifestyle, and longevity—the next steps? JAMA. 2004;292(12):1490-92. Ibid. Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean Diet, lifestyle factors, and 10-year mortality in elderly European men and women. JAMA. 2004;292(12):1433-39. Esposito K, Marfella R, Ciotola M, et al. Effect of a Mediterraneanstyle diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome. JAMA. 2004;292(12):1440-46. Yakar S, Leroith D, Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models. Cytokine Growth Factor Rev. 2005;16(4-5):407-20. Grossman T. Latest advances in antiaging medicine. Keio J Med. 2005;54(2):85-94. Schulze MB, Liu S, Rimm EB, et al. Glycemic index, glycemic load, and dietary fiber intake and incidence of type 2 diabetes in younger and middle-aged women. Am J Clin Nutr. 2004;80:348-356. McKeown NM. Whole grain intake and insulin sensitivity: evidence from observational studies. Nutr Rev. 2004;62(7):286-91. Thompson T. Gluten contamination of commercial oat products in the United States. N Engl J Med. 2004;351(19):2021-22. Nilsson M, Stenberg M, Frid AH, et al. Glycemia and insulinemia in healthy subjects after lactose-equivalent meals of milk and other food proteins: the role of plasma amino acids and incretins. Am J Clin Nutr. 2004;80:1246-53. Westphal S, Kastner S, Taneva E, et al. Postprandial lipid and carbohydrate responses after the ingestion of a casein-enriched mixed meal. Am J Clin Nutr. 2004;80(2):284-90. Moreno JA, Perez-Jimenez F, Marin C, et al. Apolipoprotein E gene promoter—219GT polymorphism increases LDL-cholesterol concentrations and susceptibility to oxidation in response to a diet rich in saturated fat. Am J Clin Nutr. 2004;80:1404-9. Zhao G, Etherton TD, Martin KR, et al. Dietary -linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women. J Nutr. 2004;134:2991-97. Giltay EJ, Gooren LJ, Toorians AW, et al. Docosahexaenoic acid concentrations are higher in women than in men because of estrogenic effects. Am J Clin Nutr. 2004;80:1167-74. Cordain L, Eaton SB, Sebastian A, et al. Origins and evolution of the Western diet: health implications for the 21st century. Am J Clin Nutr. 2005;81:341-54.

)2

1.

(c

References

5.

6. 7.

8. 9.

14.

15.

e

13.

in

12.

ic

11.

ed

10.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

4.

156

Chapter 13 Environmental Inputs 57. Rogers MA, JM Hagberg, WH Martin, AA Ehsani, and JO Holloszy. Decline in VO2 max with aging in master athletes and sedentary men. J Appl Physiol;68:2195-2199,1990. 58. Bortz WM 4th, Bortz WM 2nd. How fast do we age? Exercise performance over time as a biomarker. J Gerontol A Biol Sci Med Sci. 1996;51(5):M223-5. 59. Rosen M J, JD Sorkin, AP Goldberg, JM Hagberg, and I Katzel. Predictors of age-associated decline in maximal aerobic capacity: A comparison of four statistical models. J. Appl. Physiol. 84:21632170,1998. 60. Visovsky C, Dvorak C. Exercise and cancer recovery. Online Journal of Issues in Nursing. 2005;10(2):http://nursingworld.org/ojin/ hirsh/topic3/tpc3_2.htm 61. Correa Lima MP, Gomes-da-Silva MH. Colorectal cancer: lifestyle and dietary factors. Nutr Hosp. 2005;20(4):235-41. 62. Kirshbaum M. Promoting physical exercise in breast cancer care. Nurs Stand. 2005;19(41):41-8. 63. Haydon AM, Macinnis R, English D, Giles G. The effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut. 2005;June 21;[Epub ahead of print]. 64. Kiraly MA, Kiraly SJ. The effect of exercise on hippocampal integrity: review of recent research. Int J Psychiatry Med. 2005;35(1):75-89. 65. Orngreen MC, Olsen DB, Vissing J. Aerobic training in patients with myotonic dystrophy type I. Ann Neurol. 2005;57(5):754-7. 66. Perez-Avila I, Fernandez-Vietez JA, Martinez-Gongora E, et al. [Effects of a physical training program on quantitative neurological indices in mild stage type 3 spinocerebelar ataxia patients.] Rev Neurol. 2004;39(10):907-10. 67. Meredith CN, WR Frontera, EC Fisher, et al. Peripheral effects of endurance training in young and old subjects. J. Appl. Physiol. 66:2844-2849,1989. 68. Linke A, Adams V, Schulze P, et al. Antioxidative effects of exercise training in patients with chronic heart failure. Circulation. 2005;111:1763-1770. 69. Seals DR, J M Hagberg, BF Hurley, AA Ehsani, and JO Holloszy. Endurance training in older men and women: cardiovascular responses to exercise. J Appl Physiol: Respirat Environ Exercise Physiol;57:1024-1029,1984. 70. Spina RJ, T Ogawa, WM Kohrt, WH Martin III, JO Holloszy, and AA Ehsani. Differences in cardiovascular adaptation to endurance exercise training between older men and women. J Appl Physiol; 75:849-855,1993. 71. Seals DR, JM Hagberg, BF Hurley, AA Ehsani, and JO Holloszy. Endurance training in older men and women: cardiovascular responses to exercise. J Appl Physiol: Respirat Environ Exercise Physiol;57:1024-1029,1984. 72. Davidson MB. The effect of aging on carbohydrate metabolism. A review of the English literature and a practical approach to the diagnosis of Diabetes Mellitus in the elderly. Metabolism;28:688705,1979. 73. Hadden WC, and MI Harris. Prevalence of diagnosed diabetes, undiagnosed diabetes, and impaired glucose tolerance in adults 2074 years of age: United States, 1976-1980. In: DHHS PHS publ. no. 87-1687. Washington, D.C.: U. S. Govt. Printing Office, 1987. 74. Shimokata H, DC Muller, JL Fleg, J Sorkin, AW Ziemba, and R Andes. Age as independent determinant of glucose tolerance. Diabetes;40:44-51,1991. 75. Borkan GA, DE Hults, and F Gerzoff. Age changes in body composition revealed by computed tomography. J. Gerontol. 38:673677,1983. 76. Stolk RP, JR Vingerling, PTVM de Jong, et al. Retinopathy, glucose and insulin in an elderly population: The Rotterdam study. Diabetes;44:11-15,1995.

)2

(c

37. Frampton MW, Utell MJ, Zareba W, et al. Effects of exposure to ultrafine carbon particles in healthy subjects and subjects with asthma. Res Rep Health Eff Inst. 2004;Dec (126):1-47. 38. Lacasana M, Esplugues A, Ballester F. Exposure to ambient air pollution and prenatal and early childhood health effects. Eur J Epidemiol. 2005;20(2):183-99. 39. Forsberg B, Hansson HC, Johansson C, et al. Comparative health impact assessment of local and regional particulate air pollutants in Scandinavia. Ambio. 2005;34(1):11-19. 40. Chalupka S. Environmental health: an opportunity for health promotion and disease prevention. AAOHN J. 2005;53(1):13-28. 41. Pate, RR, M Pratt, SN Blair, et al. Physical activity and public health: a recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA;273:402-407,1995. 42. Blair, SN. Physical activity, physical fitness, and health. Res. Quart. Exer. Sport;64:365-376,1993. 43. Blair, SN, HW Kohl, RS Paffenbarger, DG Clark, KH Cooper, and LW Gibbons. Physical fitness and all-cause mortality. JAMA;262:2395-2401,1989. 44. Anonymous. Statement on exercise. A position statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association. Circulation;81:396-8,1990. 45. Fletcher GF, G Balady, SN Blair, et al. Statement on exercise: benefits and recommendations for physical activity programs for all Americans. A statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association. Circulation;94:857-62,1996. 46. Fletcher GF, SN Blair, J Blumenthal, et al. Statement on exercise. Benefits and recommendations for physical activity programs for all Americans. A statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart association. Circulation;86:340-4,1992. 47. Celsing F, J Nystrom, P Pihlstedt, B Werner, and B Ekblom. Effect of long-term anemia and retransfusion on central circulation during exercise. Journal of Applied Physiology;61:1358-62,1986. 48. Ekblom B. Factors determining maximal aerobic power. Acta Physiologica Scandinavica. Supplementum;556:15-9,1986. 49. Ekblom B, AN Goldbarg, and B Gullbring. Response to exercise after blood loss and reinfusion. Journal of Applied Physiology;33:175-80,1972. 50. Ekblom B, G Wilson, and PO Astrand. Central circulation during exercise after venesection and reinfusion of red blood cells. Journal of Applied Physiology;40:379-83,1976. 51. Berglund B, and B Ekblom. Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men. Journal of Internal Medicine;229:12530,1991. 52. Buskirk ER, and JL Hodgson. Age and aerobic power: the rate of change in men and women. Federation Proc;46:1824-1829,1987. 53. Flegg JL, and EG Lakatta. Role of muscle loss in the age-associated reduction in VO2max. J. Appl. Physiol. 65:1147-1151,1988. 54. Dehn MM, and RA Bruce. Longitudinal variations in maximal oxygen intake with age and activity. Journal of Applied Physiology;33:805-7,1972. 55. Dill DB, S Robinson, and JC Ross. A longitudinal study of 16 champion runners. Journal of Sports Medicine & Physical Fitness;7:427,1967. 56. Pollock ML, C Foster, D Knapp, JL Rod, and DH Schmidt. Effect of age and training on aerobic capacity and body composition of master athletes. Journal of Applied Physiology;62:725-31,1987.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 157

Section III The Building Blocks 97. Ballor DL, VL Katch, MD Becque, and CR Marks. Resistance weight training during caloric restriction enhances lean body weight maintenance. Am. J. Clin. Nutr. 47:19-25,1988. 98. Pavlou KN, WP Steffee, RH Lerman, and BA Burrows. Effects of dieting and exercise on lean body mass, oxygen uptake, and strength. Med. Sci. Sports. Exerc. 17:466-471,1985. 99. Jakicic JM, BH Marcus, KI Gallagher, M Napolitano, and W Lang. Effect of exercise duration and intensity on weight loss in overweight, sedentary women: a randomized trial. JAMA;290:132330.,2003. 100. Jakicic JM, C Winters, W Lang, and RR Wing. Effects of intermittent exercise and use of home exercise equipment on adherence, weight loss, and fitness in overweight women: a randomized trial. JAMA;282:1554-60,1999. 101. Jakicic JM, BH Marcus, I Gallagher, M Napolitano, and W Lang. Effect of exercise duration and intensity on weight loss in overweight, sedentary women: a randomized trial. JAMA;290:132330.,2003. 102. McDonagh MJN, and CTM Davies. Adaptive response of mammalian skeletal muscle to exercise with high loads. Eur. J. Appl. Physiol. 52:139-155,1984. 103. Evans WJ, and J G Cannon. The metabolic effects of exerciseinduced muscle damage. In: Exercise and Sport Sciences Reviews, edited by J. O. Holloszy. Baltimore: Williams & Wilkins, 1991, p. 99-126. 104. Kelly J, and LS Jefferson. Control of peptide-chain initiation in rat skeletal muscle. Development of methods for preparation of native ribosomal subunits and analysis of the effect of insulin on formation of 40S initiation complexes. J. Biol. Chem. 260:6677-6683,1985. 105. Rannels DE, AE Pegg, SR Rannels, and LS Jefferson. Effect of starvation on initiation of protein synthesis in skeletal muscle and heart. Am J. Physiol. E126-E133,1978. 106. Kelly J, and LS Jefferson. Control of peptide-chain initiation in rat skeletal muscle. Development of methods for preparation of native ribosomal subunits and analysis of the effect of insulin on formation of 40S initiation complexes. J. Biol. Chem. 260:6677-6683,1985. 107. Rannels DE, AE Pegg, SR Rannels, and LS Jefferson. Effect of starvation on initiation of protein synthesis in skeletal muscle and heart. Am J. Physiol. E126-E133,1978. 108. Flynn A, and CG Proud. The role of eIF-4 in cell proliferation. Cancer Surv. 27:293-310,1996. 109. Graves LM, KE Bornfeldt, GM Argast, et al. cAMP- and rapamycinsensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells. Proc. Natl. Acad. Sci. USA;92:7222-7226,1995. 110. Jacob R, X Hu, D Niederstock, et al. IGF-I stimulation of muscle protein synthesis in the awake rat: permissive role of insulin and amino acids. Am. J. Physiol. 270:E60-E66,1996. 111. Jurasinski CV, and TC Vary. Insulin-like growth factor I accelerates protein synthesis in skeletal muscle during sepsis. Am. J. Physiol. 269:E977-E981,1995. 112. King DD, MA Staten, WM Kohrt, GP Dsalsky, D Elahi, and JO Holloszy. Insulin secretory capacity in endurance-trained and untrained young men. Am. J. Physiol. 259:E155-E161,1990. 113. Dela F, KJ Mikines, BA Tronier, and H Galbo. Diminished argininestimulated insulin secretion in trained men. J. Appl. Physiol. 69:261-267,1990. 114. Fluckey JD, WJ Kraemer, and PA Farrell. Pancreatic islet insulin secretion is increased after resistance exercise in rats. J. Appl. Physiol. 79:1100-1105,1995. 115. Engdahl JH, JD Veldhuis, and PA Farrell. Altered pulsatile insulin secretion associated with endurance training. Journal of Applied Physiology;79:1977-85,1995.

)2

(c

77. Zavaroni I, E Dall’Aglio, F Bruschi, et al. Effect of age and environmental factors on glucose tolerance and insulin secretion in a worker population. J Am Geriatr Soc;34:271-275,1986. 78. Seals DR, J M Hagberg, BF Hurley, AA Ehsani, and JO Holloszy. Effects of endurance training on glucose tolerance and plasma lipid levels in older men and women. JAMA;252:645-649,1984. 79. Kirwan JP, WM Kohrt, DM Wojta, RE Bourey, and JO Holloszy. Endurance exercise training reduces glucose-stimulated insulin levels in 60- to 70-year-old men and women. Journal of Gerontology;48:M84-M90,1993. 80. Hughes VA, MA Fiatarone, RA Fielding, et al. Exercise increases muscle GLUT4 levels and insulin action in subjects with impaired glucose tolerance. Am. J. Physiol. 264:E855-E862,1993. 81. Marshall JA, RF Hamman, and J Baxter. High-fat, low-carbohydrate diet and the etiology of non-insulin-dependent diabetes mellitus: the San Luis Valley Diabetes Study. Am. J. Epidemiol. 134:590603,1991. 82. Feskens EJM, and D Kromhout. Cardiovascular risk factors and the 25-year incidence of diabetes mellitus in middle-aged men. Am. J. Epidemiol. 130:1101-1108,1989. 83. Lundgren J, C Benstsson, G Blohme, et al. Dietary habits and incidence of noninsulin-dependent diabetes mellitus in a population study of women in Gothenburg, Sweden. Am. J. Clin. Nutr. 52:708712,1989. 84. Ebbeling CB, Leidig MM, Sinclair KB, et al. Effects of an ad libitum low-glycemic load diet on cardiovascular disease risk factors in obese young adults. Am J Clin Nutr. 2005;81:976-82. 85. Borkman M, Campbell LV, Chisholm DJ, Storlien LH Comparison of the effects on insulin sensitivity of high carbohydrate and high fat diets in normal subjects. J Clin Endocrinol Metab. 1991;72(2):432-7. 86. Garg A, Grundy SM, Koffler M. Effect of high carbohydrate intake on hyperglycemia, islet function, and plasma lipoproteins in NIDDM. Diabetes Care. 1992;15(11):1572-80. 87. Garg A, Grundy SM, Unger RH. Comparison of effects of high and low carbohydrate diets on plasma lipoproteins and insulin sensitivity in patients with mild NIDDM. Diabetes. 1992;41(10):1278-85. 88. Hughes VA, MA Fiatarone, RA Fielding, et al. Long term effects of a high carbohydrate diet and exercise on insulin action in older subjects with impaired glucose tolerance. Am. J. Clin. Nutr. 62:426433,1995. 89. Schaefer J, AH Lichtenstein, S Lamon-Fava, et al. Body weight and low-density lipoprotein cholesterol changes after consumption of a low-fat ad libitum diet. JAMA;274:1450-1455,1995. 90. Petersen AMW, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol. 2005;98:1154-62. 91. Helmrich SP, DR Ragland, RW Leung, and RS Paffenbarger Jr. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 325:147-152,1991. 92. Bogardus C, E Ravussin, DC Robbins, et al. Effects of physical training and diet therapy on carbohydrate metabolism in patients with glucose intolerance and non-insulin-dependent diabetes mellitus. Diabetes;33:311-318,1984. 93. Phinney SD, B M LaGrange, M O'Connell, and E Danforth Jr. Effects of aerobic exercise on energy expenditure and nitrogen balance during very low calorie dieting. Metabolism;37:758-765,1988. 94. Heymsfield SB, K Casper, J Hearn, and D Guy. Rate of weight loss during underfeeding: relation to level of physical activity. Metabolism;38:215-223,1989. 95. Goran MI, and ET Poehlman. Endurance training does not enhance total energy expenditure in healthy elderly persons. Am. J. Physiol. 263:E950-E957,1992. 96. Withers RT, DA Smith, RC Tucker, M Brinkman, and DG Clark. Energy metabolism in sedentary and active 49- to 70-year-old women. J. Appl. Physiol. 84:1333-1340,1998.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 158

Chapter 13 Environmental Inputs 136. Wolfson L, R Whipple, J Judge, P Amerman, C Derby, and M King. Training balance and strength in the elderly to improve function. J. Am. Geriatr. Soc. 41:341-343,1993. 137. Wolf SL, HX Barnhart, NG Kutner, et al. Reducing frailty and falls in older persons: an investigation of Tai Chi and computerized balance training. Atlanta FICSIT Group. Frailty and Injuries: Cooperative Studies of Intervention Techniques [see comments]. J Am Geriatr Soc;44:489-97,1996. 138. Kutner NG, H Barnhart, SL Wolf, E McNeely, and T Xu. Self-report benefits of Tai Chi practice by older adults. J Gerontol B Psychol Sci Soc Sci;52:P242-6,1997. 139. Province MA, EC Hadley, MC Hornbrook, et al. The effects of exercise on falls in elderly patients: A preplanned meta-analysis of the FICSIT trials. JAMA;273:1341-1347,1995. 140. Kannus P, Uusi-Rasi K, Palvanen M, Paarkkari J. Non-pharmacological means to prevent fractures among older adults. Ann Med. 2005;37(4):303-10. 141. Holick MF. Vitamin D for health and in chronic kidney disease. Semin. Dial. 2005;18(4):266-75. 142. Hickey T, P A Sharpe, FM Wolf, et al. Exercise participation in a frail elderly population. J Health Care Poor Underserved;7:219-31,1996. 143. Campbell WW, MC Crim, VR Young, and WJ Evans. Increased energy requirements and body composition changes with resistance training in older adults. Am. J. Clin. Nutr. 60:167-175,1994. 144. Sahyoun N. Nutrient intake by the NSS elderly population. In: Nutrition in the Elderly: The Boston Nutritional Status Survey, edited by S. C. Hartz, R. M. Russell and I. H. Rosenberg. London: Smith-Gordon and Company, 1992, p. 31-44. 145. Nelson ME, MA Fiatarone, CM Morganti, et al. Effects of highintensity strength training on multiple risk factors for osteoporotic fractures. JAMA;272:1909-1914,1994. 146. Jacobs GD. The physiology of mind-body interactions: the stress response and the relaxation response. J Altern Complement Med. 2001;7(Suppl 1):S83-92. 147. McEwen BS. The End of Stress as We Know It. Washington, DC: Joseph Henry Press, 2002: p. 10-11. 148. Selye H. A syndrome produced by diverse nocuous agents. Nature. 1936;138:32. 149. Szabo S. Hans Selye and the development of the stress concept. Ann N Y Acad Sci. 1998;851:19-27. 150. Ibid, p. 19. 151. Ibid, p. 21. 152. Goldstein DS, McEwen B. Allostasis, homeostasis, and the nature of stress. Stress. 2002;5(1):55-8. 153. Kandel E. A new intellectual framework for psychiatry. Am J Psychiatry. 1998;155:457-69. 154. McEwen BS. The End of Stress as We Know It. Washington, DC: Joseph Henry Press, 2002: p. 11. 155. Selye H. A syndrome produced by diverse nocuous agents. Nature. 1936;138:32. 156. Selye H. Stress without Distress. McClelland and Stewart Ltd, Toronto, 1974. 157. Selye H. Stress in Health and Disease. Butterworths, Boston, 1976. 158. McEwen BS. The End of Stress as We Know It. Washington, DC: Joseph Henry Press, 2002: p. 5. 159. Sapolsky R. Why Zebras Don’t Get Ulcers. New York: WH Freeman, 1994. 160. McEwen BS. The End of Stress as We Know It. Washington, DC: Joseph Henry Press, 2002: p. 7-10. 161. Holms TH, Rahe RH. The social readjustment rating scale. J Psychosom Res. 1967;11:213-18. 162. Uchino BN, Holt-Lunstad J, Bloor LE, Campo RA. Aging and cardiovascular reactivity to stress: longitudinal evidence for changes in stress reactivity. Psychol Aging. 2005;20(1):134-43.

)2

(c

116. Dela F, KJ Mikines, BA Tronier, and H Galbo. Diminished argininestimulated insulin secretion in trained men. J. Appl. Physiol. 69:261-267,1990. 117. Kirwan JP, RC Hickner, KE Yarasheski, et al. Eccentric exercise induces transient insulin resistance in healthy individuals. J. Appl. Physiol. 70:2197-2202,1992. 118. O'Reilly KP, MJ Warhol, RA Fielding, et al. Eccentric exercise-induced muscle damage impairs muscle glycogen repletion. J. Appl. Physiol. 63:252-256,1987. 119. Asp S, and EA Richter. Decreased insulin action on muscle glucose transport after eccentric contractions in rats. J. Appl. Physiol. 81:1924-1928,1996. 120. Krishnan RK, JM Hernandez, et al. Age-related differences in the pancreatic beta-cell response to hyperglycemia after eccentric exercise. Am J Physiol;275:E463-70,1998. 121. Castellino P, L Luzi, DC Simonson, M Haymond, and RA DeFronzo. Effect of insulin and plasma amino acid concentrations on leucine metabolism in man. J. Clin. Invest. 80:1784-1793,1987. 122. Tessari P, S Inchiostro, G Biolo, R Trevisan, G Fantin, MC Marescotti, E Lori, A Tiengo, and G Crepaldi. Differential effects of hyperinsulinemia and hyperaminoacidemia on leucine-carbon metabolism in vivo. J Clin Invest;79:1062-1069,1987. 123. Biolo G, RY Fleming, and RR Wolfe. Physiologic hyperinsulinemia stimulates protein synthesis and enhances transport of selected amino acids in human skeletal muscle. J. Clin. Invest. 95:811819,1995. 124. Fluckey JD, LS Jefferson, TC Vary, and PA Farrell. Augmented insulin action on rates of protein synthesis following resistance exercise in rats. Am. J. Physiol. 270:E313-E319,1996. 125. Fluckey JD, WJ Kraemer, and PA Farrell. Pancreatic islet insulin secretion is increased after resistance exercise in rats. J. Appl. Physiol. 79:1100-1105,1995. 126. Meredith CN, MJ Zackin, WR Frontera, and WJ Evans. Dietary protein requirements and body protein metabolism in endurancetrained men. J. Appl. Physiol. 66:2850-2856,1989. 127. Strawford A, T Barbieri, M Van Loan, et al. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIVrelated weight loss: a randomized controlled trial [see comments]. JAMA;281:1282-90,1999. 128. Flegg JL, and EG Lakatta. Role of muscle loss in the age-associated reduction in VO2max. J. Appl. Physiol. 65:1147-1151,1988. 129. Fiatarone MA, EC Marks, ND Ryan, et al. High-intensity strength training in nonagenarians. Effects on skeletal muscle. JAMA;263:3029-3034,1990. 130. Fiatarone MA, EF O'Neill, ND Ryan, et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. The New England Journal of Medicine;330:1769-1775,1994. 131. Singh MA, W Ding, TJ Manfredi, et al. Insulin-like growth factor I in skeletal muscle after weight-lifting exercise in frail elders. Am J Physiol;277:E135-43,1999. 132. Fiatarone MA, EF O'Neill, ND Ryan, KM Clements, GR Solares, ME Nelson, SB Roberts, JJ Kehayias, LA Lipsitz, and WJ Evans. Exercise training and nutritional supplementation for physical frailty in very elderly people. The New England Journal of Medicine; 330:17691775,1994. 133. Frontera WR, CN Meredith, KP O'Reilly, and WJ Evans. Strength training and determinants of VO2 max in older men. J. Appl. Physiol. 68:329-333,1990. 134. Nelson ME, MA Fiatarone, CM Morganti, et al. Effects of highintensity strength training on multiple risk factors for osteoporotic fractures. JAMA;272:1909-1914,1994. 135. Whipple RH, LI Wolfson, and PM Amerman. The relationship of knee and ankle weakness to falls in nursing home residents. J. Am. Geriatr. Soc. 35:13-20,1987.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 159

Section III The Building Blocks 188. Chang CM, Connor KM, Lai TJ, et al. Predictors of posttraumatic outcomes following the 1999 Taiwan earthquake. J Nerv Ment Dis. 2005;193(1):40-46. 189. Terr LC, Bloch DA, Michel BA, et al. Children’s symptoms in the wake of Challenger: A field study of distant-traumatic effects and an outline of related conditions. Am J Psychiatry. 1999;156:1536-44. 190. Schuster MA, Stein BD, Jaycox LH, et al. A national survey of stress reactions after the September 11, 2001, terrorist attacks. N Engl J Med. 2001:345(20):1507-12. 191. North CS, Nixon SJ, Shariat S, et al. Psychiatric disorders among survivors of the Oklahoma City bombing. J Amer Med Assoc. 1999;282(8):755-62. 192. Skreblin L, Sujoldzic A. Acculturation process and its effects on dietary habits, nutritional behavior and body-image in adolescents. Coll Antropol. 2003;27(2):469-77. 193. Maier SF, Watkins LR, Fleshner M. Psychoneuroimmunology. The interface between behavior, brain, and immunity. Am Psychol. 1994;49(12):1004-17. 194. Blechschmidt E, Gasser RF. Biokinetics and Biodynamics of Human Differentiation. Springfield, IL: Charles C Thomas, 1978. 195. Korr IM. The spinal cord as organizer of disease processes: some preliminary perspectives. J Am Osteopath Assoc. 1976;76:35-45. 196. Willard FH. Nociception, the neuroendocrine immune system, and osteopathic medicine. In Ward RC, ed, Foundations for Osteopathic Medicine. 2nd Ed. Philadelphia: Lippincott Williams and Wilkins, 2003. 197. Robbins S, Cotran R, Kumar V. Inflammation and Repair. In Pathologic Basis of Disease. 3rd Ed. Philadelphia: WB Saunders Company, 1984. 198. Ibid. 199. Ibid. 200. Guyton AC, Hall JE. Textbook of Medical Physiology. 9th Ed. Philadelphia: WB Saunders Company, 1996, p309. 201. Movat HZ. The Inflammatory Reaction. New York: Elsevier, 1985. 202. Witte CL, et al. Pathophysiology of chronic edema, lymphedema, and fibrosis. In Staub NC and Taylor AE, eds, Edema. New York: Raven Press, 1984. 203. Movat HZ. The Inflammatory Reaction. New York: Elsevier, 1985. 204. Measel JW. The effect of the lymphatic pump on the immune response: preliminary studies on the antibody response to pneumococcal polysaccharide. J Am Osteopath Assoc. 1982 (1);82:28-31. 205. Willard FH. Nociception, the neuroendocrine immune system, and osteopathic medicine. In Ward RC, ed, Foundations for Osteopathic Medicine. 2nd Ed. Philadelphia: Lippincott Williams and Wilkins, 2003. 206. Ibid. 207. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immunemediated inflammation. N Engl J Med. 1995;332 (20):1351-62. 208. Willard FH. Nociception, the neuroendocrine immune system, and osteopathic medicine. In Ward RC, ed, Foundations for Osteopathic Medicine. 2nd Ed. Philadelphia: Lippincott Williams and Wilkins, 2003. 209. Willard FH. Introduction. In Willard FH and Patterson MM, eds, Nociception and the Neuroendocrine-Immune Connection—1992 International Symposium. Athens OH: American Academy of Osteopathy, 1994. 210. Carreiro JE. Nociception and the neuroendocrine immune system. In An Osteopathic Approach to Children. Edinburgh: Churchill Livingston, 2003. 211. Pischinger, A. Matrix and Matrix Regulation. Brussels: Haug International, 1991. 212. Jealous JS. The fluid body. Biodynamics of Osteopathy. CD audio text, in development. 2000, 2003, 2004, 2005. www.BioDO.com. Distributed through [email protected].

)2

(c

163. Gun Kang M, Baek Koh S, Suk Cha B, et al. Job stress and cardiovascular risk factors in male workers. Prev Med. 2005;40(5):583-88. 164. Bhatia V, Tandon RK. Stress and the gastrointestinal tract. J Gastroenterol Hepatol. 2005;20(3):332-39. 165. Berga SL, Loucks TL. The diagnosis and treatment of stress-induced anovulation. Minerva Ginecol. 2005;57(1):45-54. 166. Kiecolt-Glaser JK, Glaser R. Psychosocial moderators of immune function. Psychosom Med. 1987;49:13-34. 167. Kiecolt-Glaser JK, Kristopher JP, MacCallum RC, et al. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci. 2003:15; 990-95. 168. Tull ES, Sheu YT, Butler C, Cornelious K. Relationships between perceived stress, coping behavior and cortisol secretion in women with high and low levels of internalized racism. J Natl Med Assoc. 2005;97(2):206-12. 169. Gold SM, Dziobek I, Rogers K, et al. Hypertension and HPA axis hyperactivity affect frontal lobe integrity. J Clin Endocrinol Metab. 2005; March 22, 2005 (pre-pub citation). 170. Temoshok LR. Rethinking research on psychosocial interventions in biopsychosocial oncology: an essay written in honor of the scholarly contributions of Bernard H. Fox. Psychooncology. 2004;13(7):460-67. 171. Glaser R, Thorn, BE, Tarr KL, et al. Effects of stress on methyltransferase synthesis: an important DNA repair enzyme. Health Psychol. 1985;19(5):496-500. 172. Tomei LD, Kiecolt-Glaser JK, Kennedy S, Glaser R. Psychological stress and phorbol ester inhibition of radiation-induced apoptosis in human PBLs. Psychiatry Res. 1990;33:59-71. 173. Sapolsky R. Why Zebras Don’t Get Ulcers. New York: WH Freeman, 1994. 174. Ray O. How the mind hurts and heals the body. Am Psychol. 2004;59(1):29-40. 175. Ibid. 176. Kitagawa EM, Hauser M. Differential mortality in the United States: a study in socioeconomic epidemiology. Cambridge, Mass.: Harvard University Press, 1973. 177. Lantz PM, House JS, Lepkowski JM, et al. Socioeconomic factors, health behaviors, and mortality: results from a nationally representative prospective study of US adults. J Amer Med Assoc. 1997;279(21):1703-8. 178. Ray O. How the mind hurts and heals the body. Am Psychol.. 2004;59(1):29-40. 179. Vaillant GE, Mukamal K. Successful aging. Am J Psychiatry. 2001;158:839-47. 180. Rotter JB. Generalized expectancies for internal versus external control of reinforcement. Psychol Monogr. 1966;80;609. 181. Kamen L, Seligman MEP. Explanatory style and health. Curr Psych Res Rev. 1989;6:207-18. 182. Ray O. How the mind hurts and heals the body. Am Psychol. 2004;59(1): 29-40. 183. House JS, Landis KR, Umberson D. Social relationships and health. Science. 1988;241:540-45. 184. Ray O. How the mind hurts and heals the body. Am Psychol. 2004;59(1): 29-40. 185. Pargament KL, Koenig G, Tarakeshwar N, Hahn J. Religious struggle as a predictor of mortality among medically ill elderly patients: a 2-year longitudinal study. Arch Intern Med. 2001;161:1881-85. 186. Lima BR, Pai S, Toledo V, et al. Emotional distress in disaster victims. J Nerv Ment Dis. 1993;181(6):388-93. 187. Choul FH, Chou P, Lin C, et al. The relationship between quality of life and psychiatric impairment for a Taiwanese community postearthquake. Qual Life Res. 2004;13(6):1089-97.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 160

Chapter 13 Environmental Inputs 236. Willard FH. Nociception, the neuroendocrine immune system, and osteopathic medicine. In Ward RC, ed, Foundations for Osteopathic Medicine. 2nd Ed. Philadelphia: Lippincott Williams and Wilkins, 2003. 237. McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med. 1998;338:171-79. 238. Seeman TE , Singer BH, et al. Price of adaptation—allostatic load and its health consequences: MacArthur studies of successful aging. Arch Int Med. 1997;157(19):2259-68. 239. Ibid. 240. Seeman TE, McEwen BS, Rowe JW, et al. Allostatic load as a marker of cumulative biological risk: MacArthur studies of successful aging. Proc Natl Acad Sci U S A. 2001;98(8):4770-75. 241. McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med. 1998;338:171-79. 242. Willard FH. Nociception, the neuroendocrine immune system, and osteopathic medicine. In Ward RC, ed, Foundations for Osteopathic Medicine. 2nd Ed. Philadelphia: Lippincott Williams and Wilkins, 2003. 243. Sapolsky RM, Uno H, Rebert CS, Finch CE. Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J Neurosci. 1990;10(9):2897-902. 244. Willard FH. Nociception, the neuroendocrine immune system, and osteopathic medicine. In Ward RC, ed, Foundations for Osteopathic Medicine. 2nd Ed. Philadelphia: Lippincott Williams and Wilkins, 2003. 245. Carreiro JE. Nociception and the neuroendocrine immune system. In An Osteopathic Approach to Children. Edinburgh: Churchill Livingston, 2003, p 110. 246. Heim C, Newport DJ, Nemeroff CB, et al. Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA. 2000;284(5):592-97. 247. Curtis BM, O’Keefe JH. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. Mayo Clin Proc. 2002;77 (1):45-54. 248. McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med. 1998;338:171-79. 249. Heim C, Newport DJ, Nemeroff CB, et al. Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA. 2000;284 (5):592-97. 250. Ibid. 251. Lemieux AM, Coe CL. Abuse-related posttraumatic stress disorder: evidence for chronic neuroendocrine activation in women. Psychosom Med. 1995;57 (2):105-15. 252. Ibid. 253. Ibid. 254. McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med. 1998;338:171-79. 255. Willard FH. Nociception, the neuroendocrine immune system, and osteopathic medicine. In Ward RC, ed, Foundations for Osteopathic Medicine. 2nd Ed. Philadelphia: Lippincott Williams and Wilkins, 2003. 256. Scherrer U, Sartori C. Insulin as a vascular and sympathoexcitatory hormone. Circulation. 1997;96:4104-13. 257. McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med. 1998;338:171-79. 258. Curtis BM, O’Keefe JH. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. Mayo Clin Proc. 2002;77 (1):45-54. 259. Korr IM. Hyperactivity of sympathetic innervation: a common factor in disease. The collected papers of Irvin M. Korr. Vol 2. Indianapolis IN: The American Academy of Osteopathy, 1997. 260. Webster’s New World Dictionary of American English, 3rd College Edition.

)2

(c

213. Szent-Györgyi A. To see what everyone has seen, to think what no one has thought. Bio Bull. 1988;174:191-240. 214. Magoun HI. Infants and children. Osteopathy in the Cranial Field. 2nd Ed. Kirksville, MO: The Journal Printing Company, 1966. 215. Peitsch WK, Keefer CH, LaBrie RA, Mulliken JB. Incidence of cranial asymmetry in healthy newborns. Pediatrics. 2002;110(6):e72. 216. Ibid. 217. Miller RI, Clarren SK. Long-term developmental outcomes in patients with deformational plagiocephaly. Pediatrics. 2000;105 (2):e26. 218. Frymann V. Relation of disturbances of craniosacral mechanisms to symptomatology of the newborn: study of 1,250 infants. J Am Osteopath Assoc. 1966;65:1059-75. 219. Lay EM. Cranial field. In Ward RC, ed. Foundations for Osteopathic Medicine. Baltimore: Williams and Wilkins, 1997; pp 909-910. 220. Magoun HI. Entrapment neuropathy of the central nervous system. Part II. Cranial nerves I-IV, VI-VIII, XII. J Am Osteopath Assoc. 1968;67:779-87. 221. Carreiro JE. Nociception and the neuroendocrine immune system. In An Osteopathic Approach to Children. Edinburgh: Churchill Livingston, 2003, p 110. 222. Magoun HI. Whiplash injury: a greater lesion complex. J Am Osteopath Assoc. 1964;63(6):524-35. 223. Harakal JH. An osteopathically integrated approach to the whiplash complex. J Am Osteopath Assoc. 1975;74:941-55. 224. Lader E. Whiplash and related cervical trauma: its role in the development of idiopathic headache, myofascial pain, and degenerative osteoarthritis of the temporomandibular joint. The Dental Clinics of North America. July 1982. 225. Becker RE. The nature of trauma. In Life in Motion. Portland,OR: Rudra Press, 1997, pp 275-276. 226. Lay EM. The osteopathic management of temporomandibular joint dysfunction. In Gelb H, ed, Clinical Management of Head, Neck and TMJ Pain and Dysfunction. 2nd Ed. Philadelphia: WB Saunders Company, 1985. 227. Robbins S, Cotran R, Kumar V. Inflammation and Repair. In Pathologic Basis of Disease. 3rd Ed. Philadelphia: WB Saunders Company, 1984. 228. Herman JL. Trauma and Recovery. New York: Basic Books, 1997, p38. 229. Herman JL, Trauma and Recovery. New York: Basic Books, 1997, p7. 230. Herman JL, Trauma and Recovery. New York: Basic Books, 1997, p117. 231. Witte CL, Witte MH. Lymphatics in pathophysiology of edema. In Johnson, ed, Experimental Biology of the Lymphatic Circulation. Elsevier Science Publishers, 1985. 232. Willard FH. Nociception, the neuroendocrine immune system, and osteopathic medicine. In Ward RC, ed, Foundations for Osteopathic Medicine. 2nd Ed. Philadelphia: Lippincott Williams and Wilkins, 2003. 233. Carreiro JE. Nociception and the neuroendocrine immune system. In An Osteopathic Approach to Children. Edinburgh: Churchill Livingston, 2003, p 110. 234. Willard FH. Nociception, the neuroendocrine immune system, and osteopathic medicine. In Ward RC, ed, Foundations for Osteopathic Medicine. 2nd Ed. Philadelphia: Lippincott Williams and Wilkins, 2003. 235. Korr IM. The spinal cord as organizer of disease processes: (III) Hyperactivity of sympathetic innervation as a common factor in disease. J Am Osteopat Assoc. 1979;79:232-237.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 161

Section III The Building Blocks 282. Birnbaum LS, Staskal DF. Brominated flame retardants: cause for concern? Environ Health Perspect. 2004;112:9-17. 283. Fangstrom B, Strid A, Grandjean P, et al. A retrospective study of PBDEs and PCBs in human milk from the Faroe Islands. Environ Health. 2005;4(1):12. 284. Grandjean P, Budtz-Jorgensen E, et al. Attenuated growth of breastfed children exposed to increased concentrations of methylmercury and polychlorinated biphenyls. FASEB J. 2003;17(6):699-70. 285. Sanborn M, et al. Systematic review of pesticide human health effects. Ontario College of Family Physicians. 2004:1-186. www.ocfp.on.ca. 286. Shea KM. Protecting our children from environmental hazards in the face of limited data—a precautionary approach is needed. J Pediatr. 2004;145:153-56. 287. Xu J, Gordon JI. Honor thy symbionts. Proc Natl Acad Sci U S A. 2003;100:10452-59. 288. Macpherson AJ, Harris NL. Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol. 2004;4(6):478-85. 289. International human genome sequencing consortium: initial sequencing and analysis of the human genome. Nature. 200l;409:860-921. 290. Manchester KL. Antoine Béchamp: père de la biologie. Oui ou non? Endeavour. 2001;25:68-73. 291. Attributed. See http://www.universal-tao.com/article/sick.html. 292. Bengmark S. Ecological control of the gastrointestinal tract: the role of probiotic flora. Gut. 1998.42:2-7. 293. Bjorksten B. Effects of intestinal microflora and the environment on the development of asthma and allergy. Springer Semin Immunopathol. 2004;25(3-4):257-70. 294. Guarner F, Magdelena JR. Gut flora in health and disease. Lancet. 2003;361:512-19. 295. Bengmark S. Ecological control of the gastrointestinal tract: the role of probiotic flora. Gut. 1998.42:2-7. 296. Macpherson AJ, Harris NL. Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol. 2004;4(6):478-85. 297. Grolund MM, Lehtonen OP, Eerola E, Kero P. Fecal microflora in healthy infants born by different methods of delivery: permanent changes in intestinal flora after cesarean delivery. J Pediatr Gastroenterol Nutr. 1999;28:19-25. 298. Heavey PM, Rowland IR. The gut microflora of the developing infant: microbiology and metabolism. Microbial Ecol Health Dis. 1999;11:75-84. 299. Harmsen HJ, et al. Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. J Pediatr Gastroenterol Nutr. 2000;30:61-67. 300. Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. Am J Clin Nutr. 1999;69(Suppl):1035S-45S. 301. Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;299:1259-60. 302. Rook GAW, Brunet LR. Microbes, immunoregulation, and the gut. Gut. 2005;54:317-20. 303. Strachan DP. Family size, infection and atopy: the first decade of the “hygiene hypothesis.” Thorax. 2000;55(Suppl):S2-S10. 304. Prescott SL. Allergy: the price we pay for cleaner living? Ann Allergy Asthma Immunol. 2003;90(Suppl 3):64-70. 305. Harmsen HJ, et al. Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. J Pediatr Gastroenterol Nutr. 2000. 30:61-67.

)2

(c

261. Shea KM. Protecting our children from environmental hazards in the face of limited data—a precautionary approach is needed. J Pediatr. 2004;145:153-56. 262. Sanborn M, Cole D, Kerr K, et al. Systematic review of pesticide human health effects. Ontario College of Family Physicians. 2004:1-186. www.ocfp.on.ca. 263. Ibid. 264. Abelsohn A, Gibson BL, Sanborn MD, Weir E. Identifying and managing adverse environmental health effects: 5. Persistent organic pollutants. CMAJ. 2002;166(12). 265. Colborn T, vom Saal FS, Soto AM Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environ Health Perspect. 1993;101(5):378-84. 266. Johnson BL et al. Public health implications of persistent toxic substances in the Great Lakes and St. Lawrence basins. J Great Lakes Res. 1998;24(2):698-722. 267. Carson R. Silent Spring. 40th anniversary ed. New York: Houghton Mifflin; 2002. 268. Colborn T et al. Our Stolen Future. Toronto: Dutton; 1996. 269. Fisher BE. Most unwanted. Environ Health Perspect. 1999;107:A18-25. 270. Abelsohn A, Gibson BL, Sanborn MD, Weir E. Identifying and managing adverse environmental health effects: 5. Persistent organic pollutants. CMAJ. 2002;166(12). 271. Sandau CD, Ayotte P, Dewailly E, et al. Analysis of hydroxylated metabolites of PCBs and other chlorinated phenolic compounds in whole blood from Canadian Inuit. Environ Health Perspect. 2000;108:611-16. 272. Ribas-Fito N, Sala M, Kogevinas M, Sunyer J. Polychlorinated biphenyls (PCBs) and neurological development in children: a systematic review. J Epidemiol Community Health. 2001;55:537-46. 273. Brouwer A, Morse DC, Lans MC, et al. Interactions of persistent environmental organohalogens with the thyroid hormone system: mechanisms and possible consequences for animal and human health. Toxicol Ind Health. 1998;14:59-84. 274. Wade M. Human health and exposure to chemicals which disrupt estrogen, androgen and thyroid hormone physiology. Ottawa: Environmental and Occupational Toxicology Division, Environmental Health Directorate, Health Protection Branch, Health Canada. Available: www.hc-sc.gc.ca/ehp/ehd/bch/env_contaminants/ endocrine.pdf (accessed 2002 May 13). 275. Tryphonas H. The impact of PCBs and dioxins on children's health: immunologic considerations. Can J Public Health. 1998;89(Suppl 1):S49-52. 276. Sanborn M, Cole D, Kerr K, et al. Systematic review of pesticide human health effects. Ontario College of Family Physicians. 2004:1-186. www.ocfp.on.ca. 277. Jacobson SW, Fein GG, Jacobson JL, et al. The effect of intrauterine PCB exposure on visual recognition memory. Child Dev. 1985;56(4):853-60. 278. Jacobson JL, Jacobson SW, Humphrey HE. Effects of in utero exposure to polychlorinated biphenyls and related contaminants on cognitive functioning in young children. J Pediatr. 1990;116(1):38-45. 279. Jacobson JL, Jacobson SW. Intellectual impairment in children exposed to polychlorinated biphenyls in utero. N Engl J Med. 1996;335(11):783-89. 280. Vreugdenhil HJ, Slijper FM, Mulder PG, Weisglas-Kuperus N. Effects of perinatal exposure to PCBs and dioxins on play behavior in Dutch children at school age. Environ Health Perspect. 2002;110(10):A593-8. 281. Stewart P, Fitzgerald S, Reihman J, et al. Prenatal PC exposure, the corpus callosum, and response inhibition. Environ Health Perspect. 2003;111(13):1670-77.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 162

Chapter 13 Environmental Inputs 328. Korkina L, et al. Antioxidant therapy in children affected by irradiation from the Chernobyl nuclear accident. Biochem Soc Trans. 1993;21:314S. 329. Clark L. Are You Radioactive? Devin-Adair Pub, 1973. 330. Kurzer MS Reduced radiation damage from ingestion of cabbage family plants. Journal of Nutrition. 1997;127(5 Suppl):1047S-49S. 331. Emerit I, Oganesian N, Sarkisian T, et al. Clastogenic factors in the plasma of Chernobyl accident recovery workers: anticlastogenic effect of Ginkgo biloba extract. Radiat Res. 1995;144:198-205. 332. Vijayalaxmi R, Reiter RJ, Meltz ML. Melatonin protects human blood lymphocytes from radiation-induced chromosome damage. Mutat Res. 1995;346(1):23-31. 333. Ben-Hur E, Fulder S. Effect of P. ginseng saponins and Eleutherococcus S. on survival of cultured mammalian cells after ionizing radiation. Am J Chin Med. 1981;9:48-56. 334. Becker RO. The Body Electric. Morrow, New York, 1985. 335. Becker RO. Cross Currents: The Promise of Electromedicine, The Perils of Electropollution. Penguin Group, Inc, New York, 1990. 336. Liburdy RP, Wyant A. Radiofrequency radiation and the immune system. Part 3. In vitro effects on human immunoglobulin and on murine T- and B-lymphocytes. Int J Radiat Biol Stud Phys Chem Med. 1984;46(1):67-81. 337. Oschman JL. Energy Medicine: The Scientific Basis. Churchill Livingston: Edinburgh, 2000. 338. McMakin C. Microcurrent treatment of myofascial pain in the head, neck and face. Topics in Clinical Chiropractic. 1998;5(1):29-35. 339. McMakin C. Microcurrent therapy: a novel treatment method for chronic low back myofascial pain. Journal of Bodywork and Movement Therapies. 2004;8:143-53. 340. McMakin C. Cytokine changes with microcurrent treatment of fibromyalgia associated with cervical spine trauma. Journal of Bodywork and Movement Therapies. 2005;9(3):169-76. 341. Reeve V. University of Sydney, Department of Veterinary Science, personal communication, 2003.

)2

(c

306. Collins MD, Gibson GR. Probiotics, prebiotics, and symbiotics: approaches for modulating the microbial ecology of the gut. Am J Clin Nutr. 1999;69(Suppl):1052S-57S. 307. Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. Am J Clin Nutr. 1999;69(Suppl):1035S-45S. 308. Harmsen HJ, Wildeboer-Veloo AC, Raangs GC, et al. Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. J Pediatr Gastroenterol Nutr. 2000;30:61-67. 309. Bjorksten B. Effects of intestinal microflora and the environment on the development of asthma and allergy. Springer Semin Immunopathol. 2004;25(3-4):257-70. 310. Bosch JA, Turkenburg M, Nazmi K, et al. Stress as a determinant of saliva-mediated adherence and coadherence of oral and nonoral microorganisms. Psychosom Med. 2003;65:604-12. 311. Teitelbaum JE, Walker WA. Nutritional impact of pre-and probiotics as protective gastrointestinal organisms. Annu Rev Nutr. 2002;22:107-38. 312. Otte JM, Cario E, Podolsky DK. Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology. 2004;126:1054-70. 313. Mountzouris KC, McCartney AL, Gibson GR. Intestinal microflora of human infants and current trends for its nutritional modulation. Br J Nutr. 2002;87:405-20. 314. Cellular and Molecular Immunology. Fifth Edition. Abbas & Lichtman, Ed. Saunders, Philadelphia. 2003. 315. Brandtzaeg P. Current understanding of gastrointestinal immunoregulation and its relation to food allergy. Ann N Y Acad Sci. 2002;964:13-45. 316. Van Uden J, Rax E. Immunostimulatory DNA and applications to allergic disease. J Allergy Clin Immunol. 1999;104:902-10. 317. Jijon H, Backer J, Diaz H, et al. DNA from probiotic bacteria modulated murine and human epithelial and immune function. Gastroenterol. 2004;126:1358-73. 318. Hooper LV, Wong MH, Thelin A, et al. Molecular analysis of commensal host-microbial relationships in the intestine. Science. 2001;291:881-84. 319. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science. 2001;292:1115-18. 320. Kalliomaki M, Salminen S, Poussa T, et al. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebocontrolled trial. Lancet. 2003;361:1869-71. 321. Bouma G, Strober W. The immunologic and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521-33. 322. Oschman JL. Energy Medicine: The Scientific Basis. Churchill Livingston, Edinburgh, 2000 323. Umegaki K, Sugisawa A, Shin SJ, et al. Different onsets of oxidative damage to DNA and lipids in bone marrow and liver in rats given total body irradiation. Free Radic Biol Med. 2001;31(9):1066-74. 324. Umegaki K, Ikegami S, Inoue K, et al. Beta-carotene prevents x-ray induction of micronuclei in human lymphocytes. Amer J Clin Nutr. 1994;59(2):401-12. 325. Umegaki K, Aoki S, Esashi T. Whole body x-ray irradiation to mice decreases ascorbic acid concentration in bone marrow: comparison between ascorbic acid and vitamin E. Free Radic Biol Med. 1995;19(4):493-97. 326. Ben-Amotz A, Yatziv S, Sela M, et al. Effect of natural beta-carotene supplementation in children exposed to radiation from the Chernobyl accident. Radiat Environ Biophys. 1998;37:187-93. 327. Kapitanov AB, Pimenov AM, Obukhova LK, Izmailov DM. Radiation-protective effectiveness of lycopene. Radiats Biol Radioecol. 1994;34(3):439-45.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 163

Section III The Building Blocks

)2 (c

0 01

e in ic ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

164

Chapter 14 Influence of Mind and Spirit DeAnn Liska, PhD

Emerging Research on Spirituality and Health

(c

Introduction

As the changing research record indicates, an understanding of the role of spirituality in health and healing is attracting considerable attention of late. For example, a search of the National Library of Medicine database (PubMed) using the word “spirituality” shows that only 62 articles were published on this subject in the 20 years between 1970 and 1990, compared to 477 articles between 1990 and 2000, and more than double that number, 1226 articles, from 2000 to 2004. This increased interest was triggered by studies such as that of King and Bushwick, in which it was noted that 94% of patients admitted to hospitals believe that spiritual health is as important as physical health, and 77% believe that physicians should consider their patients’ spiritual needs, but only 20% of patients reported their physicians addressing spiritual issues with them in more than just a passing fashion.11 A 2003 study in which physicians were asked about their attitudes and preferences regarding spirituality in the medical encounter found that, of the 84.5% who indicated they should be aware of patients’ spirituality, most would not ask about spiritual issues unless a patient were dying.12 In a discussion on the role of spirituality and health, Levin makes this assertion:

)2

This chapter is the final entry in our Building Blocks section. We have given our attention to the effects on human health of various well-known and often wellresearched biological and physical factors, and their interaction with individual genetic predispositions: diet, nutrients, air, water, exercise, trauma, xenobiotics, microorganisms, and radiation. The psychosocial realm has also been discussed, and is a source of prolific research and myriad books and articles written about common (and uncommon) clinical approaches. We now turn our attention to the impact of spirituality as one of the key building blocks of health. Here, we will briefly introduce the subject, which is just beginning to make itself felt in research and scientific writing. (Further discussion can be found in Chapter 33.) Understanding the role of biochemical individuality (that is, genetic predisposition influenced by environment) is a cornerstone of functional medicine and has been demonstrated by such examples as the variety of differentially regulated detoxification enzymes,1,2,3 the relationship among body fat composition, blood pressure, and insulin resistance,4,5,6 and the myriad influences that determine risk of conditions such as CVD.7,8,9,10 All of these examples (and a great deal of this book) are about the physical nature of our being—the mechanisms that connect us with the physical world around us. Because these are physical, matter-based examples, we can test them. We can do genetic testing; we can devise assays to detect the result of a specific intervention. But the medicine of today involves more than just the physical, matterbased body; it also includes the spiritual experience of the patient.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

By excluding matters of spirit from clinical research and practice, physicians run the risk of leaving out a large piece of what it means to be a human being. If physicians sincerely wish to treat the whole person, they first will have to see their patients as more than just a body and a personality, or, worse, a collection of isolated organ systems.13

165

Section III The Building Blocks

Researching the Spirituality and Health Connection: Challenges and Early Findings

like meditation, prayer, yoga, and quigong because those can be seen (that is, the activities can be observed, recorded, and their before-and-after effects can be assessed). For example, in a controlled trial, specific daily practice of yoga was shown to increase plasma melatonin after three months.16 Intrinsic religiosity has also been associated with diurnal cortisol rhythm, as compared to subjects with low religiosity, who show apparent flattened cortisol patterns.17 Davidson et al.18 reported in 2003 that an eight-week program of mindfulness meditation before influenza vaccination led to an increase in antibody titer, as compared to non-meditating controls, which suggests an improvement in immune function with meditation. These are but a few of many fascinating examples of the general effect spiritual practices can have on health indicators. Should we expect that each patient can benefit similarly from these practices? In functional medicine, we would say that such practices will be filtered through the patient’s genetic predispositions and overall environment, so perhaps the answer is “no.” We know that stress hormone pathways and behaviors like anxiety are, at least in part, determined by certain genetic polymorphisms—that is, the polymorphic pattern of genes we inherit from our parents influences our response to stress and our susceptibility to conditions such as post-traumatic stress disorder. Continuing that train of thought, it is intriguing to speculate that at least some of these polymorphisms might also be involved in how responsive individual patients are to spiritual practices such as mindfulness meditation. Consider the finding that parallel polymorphisms in the acetylcholinesterase and paraoxonase 1 gene loci have been associated with anxiety scores.19 Research has also documented that psychosocial stress can lead to alteration in how the acetylcholinesterase gene is spliced, which then leads to different levels of acetylcholinesterase activity in the cell.20 Another study has reported an association between certain polymorphisms in the cytochrome P450 2D6 gene and harm avoidance; it has been postulated that this detoxification system may impact personality by influencing the generation of endogenous neurotransmitters in the brain.21 From these examples, it is not too far-reaching to suggest that many spiritual practices that are now being shown to influence the body’s biochemistry will be experienced differently by patients with different

)2

(c

Given the importance of this subject to patients and practitioners alike, it is valuable to spend a little time exploring some new findings that suggest there may be a physical, biochemical basis for spirituality. Interestingly, as with all other building blocks to health, this biochemical connection appears to be experienced differently by each of us; that is, spirituality (our experience of the divine) is another example of how we all show biochemical individuality. Moreover, the research is showing more clearly how our spirituality, life experience, and physical bodies (biochemistry) are all entwined in such a manner that ignoring one means leaving out part of the web. First, it is beneficial to define spirituality and religion, since these terms can be interpreted differently. The Oxford dictionary defines spirituality as “of the human spirit or soul, not physical or worldly.”14 Religion, in contrast, is more limited and means “a particular system of faith and worship.”15 Therefore, spirituality is the nonphysical component of a person, whereas religion is the institutional practice, or how spirituality is codified and acted on by a group or society. These definitions help to clarify why it is often easier to observe, report on, and quantify religion than it is to assess spirituality. In fact, this is one of the primary challenges in incorporating spirituality into a science-based discussion. There are other roadblocks as well. A primary issue is the historical conflict between “science” and “religion.” Many scientists and clinicians have been taught that spirituality is unscientific, not logical, and, therefore, not relevant to a Western, science-based approach to health and disease. Certainly, history is filled with examples of how science can challenge religious beliefs, and how religion can limit scientific progress. The tone of recent research, however, is showing that the 21st century may find a way to heal the rift between science and the spiritual—or, at least, to begin examining it objectively. Even when this relationship between “science” and “religion” is difficult, a functional medicine approach of treating the patient, not just the disease, means finding ways to incorporate attention to spirituality into clinical practice in a science-based manner. The difficulty of “measuring” spirituality challenges our current research models. Much work performed in the 1990s and early 2000s focused on spiritual practices

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 166

Chapter 14 Influence of Mind and Spirit spirituality. He reviews a study initially targeted to better understand smoking addiction, in which he recruited 1,000 men and women and obtained TCI questionnaire scores. He reports finding a large variation among the subjects in the subscore for spirituality on the TCI. Moreover, although some have suggested that patients who are more influenced by spiritual experiences are likely to be more “temperamental” or “anxious,” Hamer and colleagues found just the opposite. Subjects also provided biological samples, from which Hamer and his colleagues looked for a genetic explanation for the variation in the spiritual score on the questionnaire and keyed in on the vesicular monoamine transporter 2 gene (VMAT2). Although his work is intriguing, it has not been reproduced or thoroughly assessed by the scientific community. Furthermore, Hamer is the first to admit:

)2

(c

genetic propensities. Thus, we begin to perceive the biochemical individuality of spirituality. Possibly the most intriguing work on the interplay between biochemical individuality and spirituality has emerged from Thomas Bouchard’s group at the Department of Psychology, University of Minnesota, MN. Bouchard has investigated genetics and behavior by focusing on twins reared together or apart, and has concluded that there is now strong evidence that virtually all individual psychological differences are moderately to substantially heritable.22 In particular, he used a validated scale of intrinsic and extrinsic religiosity with 35 pairs of monozygous twins and 37 pairs of dizygotic twins reared apart and found that twin similarity could not be explained by environmental factors alone, but was only explained by a model containing genetic plus environmental factors.23 (Note that both genetics and environment must be included for the model to be effective.) The Temperament and Character Inventory (TCI)—a 240-question, standardized, validated, personality assessment that scores such behaviors as self-transcendence, transpersonal identification, and mysticism—has also been used to explore the interrelationship among genetics, biochemistry, and behavior. In an interesting report, Comings and colleagues obtained results suggesting an association between a polymorphism in the D4 dopamine receptor gene (DRD4) and scores on the selftranscendence scale of the TCI (p54) Early age menarche ( GI yeast infection Nausea Frequent antibiotic use ADHD

Detoxification and Biotransformation ADHD Food additives

10. 6-hour urine toxic metal challenge test with 250 mg DMPS (2,3-dimercapto-1-propane-sulphonic acid) provocation Hormone and Neurotransmitter Regulation

ADHD Dysgraphia Insomnia Anxiety

11. Plasma amino acids 12. Urine neurotransmitter metabolites

*Laboratory tests frequently pertain to multiple areas of imbalance, and therefore may be listed in more than one Matrix category.

770

Chapter 37 Case Presentations

Significant Laboratory Findings Organized According to the Functional Medicine Matrix Lifestyle Factors: Nutritional Imbalances Test

Results

95% Reference Interval

1. Red Blood Cell Minerals 2.5

L

3.3–7.7 ppm

Magnesium

15

L

18–40 ppm

260

LN

257–500 ppb

22

LN

19–41 ppb

1.7

LN

1.4–7.9 ppb

Copper

)2

Manganese

(c

Zinc

0

01

Chromium

lM na tio d. un rve r F se fo re te ts itu h st rig In All

headaches, insomnia, muscle cramps, and spasms.15 Copper and manganese are important cofactors in the antioxidant enzyme superoxide dismutase. Chromium as chromodulin may improve cellular glucose uptake by potentiating insulin receptor activity.16

LC was very low in zinc and magnesium; low-normal levels were reported for the rest of the minerals. These findings were not surprising given LC’s poor diet, GI inflammation, and cimetidine use. Zinc deficiency is implicated in asthma, atopic dermatitis, allergies, and ADHD.12-14 Magnesium deficiency is also implicated in Test 2. Serum Vitamins Vitamin E

Results mg/L

95% Reference Interval

LN

7.1–31.0

Vitamin A

0.55

LN

0.41–1.5

Beta-carotene

37; 22–144

100

>44; 19–362

60

>46; 31–112

785

H

330–630; 260–750

ed

Plasma free fatty acids (primarily palmitic acid) roughly approximate plasma triglyceride levels.17 The numerous high-normal saturated fatty acids indicated that, at 12 years old, LC probably had higher triglycerides as well, most likely caused by insulin-stimulated upregulation of liver fatty acid synthesis. Given LC’s high-sugar diet, early onset dysinsulinemia was not surprising. As discussed above, mild chromium deficiency could be another underlying factor contributing to dysinsulinemia. The elevated trans fatty acids (TFAs) were further evidence of LC’s poor food choices. TFAs are strongly implicated in metabolic syndrome and cardiovascular disease.18

e

in

ic

Of the polyunsaturated omega fatty acids, the inflammatory eicosanoid precursor arachidonic acid (AA) was very elevated. It was found in much greater quantity than the anti-inflammatory omega-3 fatty acid eicosapentaenoic acid (EPA), creating a relative deficiency of EPA. AA is implicated in the pathogenesis of allergies and asthma,19,20 while EPA insufficiency and a low EPA/AA ratio are implicated in ADHD.21,22 Comment: Had LC continued with his presenting diet and lifestyle, the plasma fatty acid analysis reveals the likelihood for continued inflammatory conditions as an adult, including possibly heart disease, diabetes, and cancer. Addressing these findings early not only treated his initial complaints, but significantly reduced his risk for a future of ill health.

772

Chapter 37 Case Presentations

Test

Results ug/mg creatinine

80% and 95% Reference Intervals

4. Urinary Organic Acids Kynurenate

3.0

HN

2.9; 4.7

Xanthurenate

0.9

HN

0.90; 1.50

When elevated, the organic acids above demonstrate a functional B6 insufficiency.23 A number of LC’s symp-

(c

Immune Surveillance and Inflammatory Process

)2 0

01

Test

toms may have been attributable to insufficient B6, including ADHD, mood disturbances, and insomnia.24

5. Serum Vitamin D 25 OH

Result

Reference Intervals

24 ng/m

L

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Hypovitaminosis D likely played a role in LC’s imbalanced immune response, contributing to both his chronic infections and hypersensitivities. Low vitamin D has been implicated in asthma, general development problems, and mood disorders.25 Optimal serum vitaTest

< 20 ng/mL: Insufficiency 20–40 ng/mL: Hypovitaminosis 40–100 ng/mL: Sufficiency > 100 ng/mL: Toxicity

min D is now thought to be between 40-70 ng/mL; individuals with serious diseases should maintain levels between 55–70 ng/mL.26

Milk, Cow’s (+4)

Mustard (+1)

Peanut (+4)

R. Seed (Canola) (+1)

Walnut (+1)

Yeast, Brewer’s (+2)

e

Cheese (+1)

in

Bean, Kidney (+1)

ic

ed

6. IgG (total) Reactive Foods*

* Results range from 0 = no reaction to +5 = severe reaction.

and GI inflammation.27-29 These sensitivities may be associated with the pathogenesis of atopic dermatitis, asthma, and ADHD.30-32

ELISA testing for IgG response to 90 different foods demonstrated a strong positive reaction to dairy and peanuts, and mild positive reactions (+1 or +2) to six other foods, suggesting intestinal hyperpermeability

773

Section VII Putting It All Together

Test

Result

7. IgG antigliadin

95 % Reference Interval

17

HN

0–19 units

LC’s IgG antigliadin antibodies were trending high at 17 units. Clinical experience warranted minimizing gluten intake. Digestion and Absorption Test #8: Complete Blood Count and Metabolic Panel

)2

(c 0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

LC’s serum chemistries and complete blood count were within normal limits, although his lymphocyte count was higher than his neutrophil count. Clinical experience suggested that this finding, when combined with his history of antibiotic use and complaint of anal itching, probably indicated a fungal or viral infection.

Test #9: Organic Acid Microbial Markers

Surprisingly, LC’s organic acid microbial markers were within normal limits, ruling against significant GI dysbiosis, although he did demonstrate intestinal hyperpermeability with multiple food sensitivities, as discussed above in “Immune Surveillance and Inflammatory Process.”

Detoxification and Biotransformation Result ug/g creatinine

ed

Test

95% Reference Interval

in

ic

Lead

e

10. Urine Toxic Metals (6-hour challenge test) 17

H

5

tions have been made to reduce safe threshold levels.34 Lead toxicity and environmental toxins such as household mold have been linked to cognitive and behavioral problems in children, including ADHD.35-38 Sources of lead include toys, paint, contaminated soil, lead plumbing, and glazed pottery.34 Since essential mineral deficiencies may allow for increased uptake of toxic metals,39 repletion prior to and during treatment of toxicity is important.

DMPS (2,3-dimercapto-1-propanesulfonic acid) provocation challenge demonstrated an elevated urine lead level in LC. While whole blood is considered the gold standard for identifying lead toxicity, urinary lead concentration has also been shown to increase with toxicity.33 Chelating agents have been shown to accelerate the urinary excretion of lead and therefore may be useful for revealing lead exposure. Lead exposure may produce cognitive deficits at levels commonly encountered in blood, and therefore numerous recommenda-

774

Chapter 37 Case Presentations

Hormonal and Neurotransmitter Regulation Test

Result

80% and 95% Reference Intervals

11. Plasma Amino Acids Tryptophan

36

Test

LN

Result ug/mg creatinine

>40; 26–62

80% and 95% Reference Intervals

5-Hydroxyindoleacetate

0

01

Homovanillate

)2

(c

12. Urine Neurotransmitter Metabolites 3.0

LN

3.2–16.7; 1.0–23.0

2.6

LN

2.7–14.0 1.2–39.0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

nin synthesis, B6 and magnesium, were both reported insufficient in LC (discussed above in “Lifestyle Factors: Nutritional Imbalances”). Genetic and metabolic research has linked imbalances of CNS dopamine and serotonin to ADHD with regard to uptake, synthesis, and breakdown, although there has not been a consistent pattern noted.40 Serotonin imbalance has also been implicated in insomnia41 and IBS.42

The urinary neurotransmitter metabolites for dopamine and serotonin, homovanillate (HVA) and 5-hydroxyindoleacetate (5-HIAA), were low normal in LC, suggesting lower total body neurotransmitter turnover. Corroborative evidence for the risk of serotonin insufficiency was found with low plasma tryptophan, the amino acid precursor to serotonin. Furthermore, 2 important nutrients involved in dopamine and seroto-

e

in

ic

ed

775

Section VII Putting It All Together

Summary of Initial Assessments, Laboratory Findings, Treatments, and Treatment Rationale Organized According to the Functional Medicine Matrix

Lifestyle Factors: Nutrient Imbalances Clinical Assessment and Diagnoses • • •

0

•

• • •

01

•

Recommended Treatment

Low RBC essential minerals Low serum vitamins A, E, and beta carotene Elevated plasma AA:EPA ratio Low B6 (organic acid functional markers) Elevated plasma saturated and trans fatty acids

)2

Nutrient deficiencies Fatty acid imbalance Anxiety Muscle spasms Audio sensitivity Hyperkeratosis pilaris

(c

• • • • • •

Laboratory Results

•

Treatment Rationale

Zinc citrate 20 mg; 1 tab QD Magnesium glycinate 120 mg; 2 caps QHS Multivitamin/mineral (MVM); 2 tabs QD

•

EPA/DHA 6:1; 1 cap BID

•

lM na tio d. un rve r F se fo re te ts itu h st rig In All •

•

Pyridoxal 5’ phosphate (activated B6) 50 mg; 1 cap QD Dietary changes as noted in “Immune Surveillance and Inflammatory Process” below

•

MVM for general nutrient needs with extra zinc for immune dysfunction, diarrhea and allergies, and magnesium for muscle cramps, insomnia, anxiety, and auto sensitivity. Anti-inflammatory omega3 fatty acid used to minimize proinflammatory arachidonic acid cascade as seen clinically with asthma, allergies, dermatitis hyperkeratosis pilaris B6: evidence supports its use in ADHD, serotonin metabolism, and methylation/sulfuration

e

in

ic

ed

776

Chapter 37 Case Presentations Immune Surveillance and Inflammatory Process Clinical Assessment and Diagnoses • • •

• •

Low serum vitamin D Multiple + IgG food sensitivities Elevated IgG antigliadin antibodies

•

• •

)2

Vitamin D3 1000 U; 1 cap QD Diet: Modified elimination diet based on test results. No dairy, peanuts, gluten, sugar, or trans fatty acids. Reduce saturated fat intake. Whole foods, minimally processed; organic diet. Organic dark chocolate is fine. (See also Nutritionist Comments below.)

Treatment Rationale • •

Serum vitamin D goal: 40–70 ng/mL Dietary changes based on clinical history, IgG food sensitivities, antigliadin antibodies, intestinal hyperpermeability, fatty acid deficiency, and suspected fungal overgrowth

*Also supportive: zinc, magnesium, probiotics

0

01

•

Hypovitaminosis D Multiple food sensitivities Intestinal hyperpermeability ADHD Asthma Allergies Headache Hives Sinusitis Atopic dermatitis Aphthous stomatitis PMH: diaper rash, otitis media FMH: food and environmental allergies, migraine headaches, sinusitis

Recommended Treatment

(c

• • • • • • • • •

Laboratory Results

lM na tio d. un rve r F se fo re te ts itu h st rig In All Digestion and Absorption

Clinical Assessment and Diagnoses • • • • •

•

Elevated lymphocyte: neutrophil ratio * +IgG food sensitivities, IgG antigliadin antibodies

Recommended Treatment

•

Fluconazole 100 mg; 1 tab QD x 30 days

•

Broad spectrum probiotics; 2 caps Q AM

Treatment Rationale •

•

e

in

ic

ed

•

Yeast overgrowth GERD IBS Pruritus ani Intestinal hyperpermeability Nausea

Laboratory Results

777

Clinical and laboratory evidence for Candida overgrowth. Clinical experience suggests longterm fluconazole with dietary changes for best outcome Probiotic therapy to support microbiota. Beneficial for treatment of intestinal hyperpermeability and immune hypersensitivity, food sensitivities, and IBS

Section VII Putting It All Together Detoxification and Biotransformation Clinical Assessment and Diagnoses • • •

Mild lead toxicity ADHD Food additives

Laboratory Results •

Elevated 6-hour urine lead after 250 mg DMPS (2,3-dimercapto-1propane-sulphonic acid) provocation

Recommended Treatment

Treatment Rationale

)2

(c

After 2 months on treatment protocol: Start DMSA (dimercaptosuccinic acid) 100 mg, one twice a day, every other week for 3 days (such as MTW), then 11 days off. Do this for 6 months and then repeat the DMPS challenge test

•

Dietary changes as noted in “Immune Surveillance and Inflammatory Process” above

•

0

01

•

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Oral chelation with DMSA is one of the main treatments for lead toxicity. Pulse dosing DMSA and concurrent detoxification and essential minerals supplementation will minimize adverse reactions. It is important to ensure normal kidney function and bowel movements and treat nutrient deficiencies first, particularly essential minerals, amino acid deficiencies, and impaired methylation

Hormone and Neurotransmitter Regulation Clinical Assessment and Diagnoses • • •

ADHD Dysgraphia Insomnia

Laboratory Results • •

Low-normal plasma tryptophan Low-normal urine HVA, 5HIAA

Recommended Treatment

•

Treatment Rationale

5HTP 50–100 mg QHS as needed for sleep

•

e

in

ic

ed

5HTP is a serotonin precursor. It will provide substrate for serotonin production while preserving tryptophan. CNS serotonin is methylated to produce melatonin. Increased serotonin may therefore help with insomnia

*Assessments, laboratory tests, and treatments frequently pertain to multiple areas of imbalance and may therefore be listed in more than one Matrix category.

778

Chapter 37 Case Presentations

Follow-up Visit at Two Months

chologist said his social skills are very good, age appropriate, and that she sees no problems at all. She also noted that LC seems very proud of himself and his new health and that he’s taking good ownership of all the changes in his diet. He even seems to be shrugging it off when the other kids at school tell him he’s an “alien” because he doesn’t drink soda. This was just such a fantastic meeting and I wanted to pass along the good news and say Thank You!

After starting his treatment, which included removing yeast and antigenic foods and adding the needed micronutrients and probiotics, LC’s mother stated that he was much less disruptive in the classroom. He was sleeping though the night. His headaches and runny nose improved. He hadn’t required cetirizine or flunisolide for some time. His asthma symptoms improved and were no longer triggered by cold. Light, sound, and smell sensitivities were reduced considerably. LC tolerated supplements and diet changes well, because he felt so much better when he followed the plan. No changes were made to LC’s treatment plan at his 2-month visit.

Laboratory Tests

)2

(c

Follow-up testing revealed normalization of the lymphocyte:neutrophil ratio and improvement in his nutritional status, including normalized levels of vitamin E and beta carotene, RBC minerals, and tryptophan. His saturated fatty acids and trans fatty acids were all within their normal ranges, reducing the concern for dysinsulinemia and confirming LC’s commitment to following dietary changes. He still required vitamins D and A. The dietary changes and supplement interventions reversed not only his presenting complaints, but radically improved the prognosis for his future health.

01

Follow-up Visit at Six Months

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

LC’s mother reported that he was free from his chronic symptoms for the first time in his life. His dysgraphia improved considerably (see Figures 37.6 and 37.7 for the pre- and post-treatment writing samples). He no longer required his medications, including antihistamines (cetirizine and cimetidine), bronchodilators, steroid inhaler, acetaminophen, and ibuprofen. His mood and behavior had stabilized, and his ability to focus improved greatly. His hyperactivity symptoms, including disruptiveness, irritability, and anxiety, were gone. His hives, asthma, runny nose and postnasal drip, anal itching, stomach aches, nausea, diarrhea, headaches, muscle cramps, and sensitivity to loud noises were all completely resolved. He slept soundly at night. He was doing well in school, academically and socially. Just after his 6-month follow-up, LC’s mother wrote the following: We had a meeting at LC’s school this morning, where the teachers, school counselor, parents, and principal all get together to review “the plan” for kids with special educational needs (in LC’s case prompted by the ADHD diagnosis). This was the first time in his entire schooling history that everything seems to be going well. The input from his teachers was that he is “a different kid” than they saw in the first half of the year and that they’re amazed by the difference. The school nurse hasn’t seen him [in months] (and he used to be in her office several times a week). The school psy-

The RD/Nutritionist’s Comments

e

in

ic

ed

LC made remarkable changes, and he was very motivated to do so because he received the immediate feedback of improved health. Most notable, of course, was the resolution of the ADHD symptoms. LC’s changes did not come overnight. Indeed, his was a “top-down” change, with his mother making the first moves toward wellness in her life, and experiencing the fruits of good health herself, and then bringing along her family. Wellness of this nature is an ecological shift, like a pebble tossed in a pond that ripples slowly to those around us. I had been working with LC’s mom for a long time before we saw LC. With his mom (as with most people) we started slowly. We did an initial clean-up of the worst (most problematic/toxic) foods in the house, and then removed one problem food per week from her diet. (Sometimes we would negotiate one food change a month. It’s important to move at the patient’s pace and ability to integrate change.)

779

Section VII Putting It All Together • • • • • • •

“Natural” versus “organic” Healthful, affordable foods Easy, quick recipe ideas Eating healthy on the go Eating well at restaurants Knowing the nutrient content of foods Relying on foods, rather than supplements, for long-term nutrient needs • Understanding the appropriate balance and quantity of food • Stress-free eating: rest and digest • Resources for healthy eating: cookbooks, internet sites

(c

Generally, when a child needs to make major dietary changes, it does require the family’s buy-in. A significant move away from being unconscious about what we eat toward paying very close attention to where food comes from, what it’s made of, the toxin and nutrient content, and the macronutrient composition requires a powerful and intentional return to our roots, how we evolved to eat. We must also pay attention to how we feel after we eat, and notice the impact of food on our health and well-being. We need to have everyone on board in the family, even if only a little, when thinking about food from this perspective. The home front is the nutritional frontier! To succeed with such changes, the basics need to be addressed: • Where to shop/what to buy • How to avoid antigenic foods • How to replace the foods being eliminated from the diet with healthy alternatives • How to read and understand food labels • Identifying hidden food additives and antigens

)2

The team approach to treatment in the case of LC was vital to his success. In addition to his medical doctor, he worked with me, a support RN, and of course his mother, father, and siblings. I am not sure we would have seen such a significant turnaround, as demonstrated by his writing specimens, without this approach to care.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 780

Chapter 37 Case Presentations

References 1.

2.

3.

4.

5. 6.

24.

25. 26. 27.

28.

29.

)2

01

8.

23.

(c

7.

Adi-Japha E, Landau YE, Frenkel L, Teicher M, Gross-Tsur V, Shalev RS. ADHD and dysgraphia: underlying mechanisms. Cortex. Aug 2007;43(6):700-709. Norris JM, Barriga K, Hoffenberg EJ, et al. Risk of celiac disease autoimmunity and timing of gluten introduction in the diet of infants at increased risk of disease. Jama. May 18 2005;293(19):2343-2351. Osborn DA, Sinn J. Soy formula for prevention of allergy and food intolerance in infants. Cochrane Database Syst Rev. 2004(3):CD003741. Kozyrskyj AL, Ernst P, Becker AB. Increased risk of childhood asthma from antibiotic use in early life. Chest. Jun 2007;131(6):1753-1759. Farooqi IS, Hopkin JM. Early childhood infection and atopic disorder. Thorax. Nov 1998;53(11):927-932. Shreiner A, Huffnagle GB, Noverr MC. The "Microflora Hypothesis" of allergic disease. Adv Exp Med Biol. 2008;635:113-134. Wickens K, Pearce N, Crane J, Beasley R. Antibiotic use in early childhood and the development of asthma. Clin Exp Allergy. Jun 1999;29(6):766-771. Evenepoel P. Alteration in digestion and absorption of nutrients during profound acid suppression. Best Pract Res Clin Gastroenterol. Jun 2001;15(3):539-551. Kon K, Ikejima K, Okumura K, et al. Role of apoptosis in acetaminophen hepatotoxicity. J Gastroenterol Hepatol. Jun 2007;22 Suppl 1:S49-52. Mielants H, Goemaere S, De Vos M, et al. Intestinal mucosal permeability in inflammatory rheumatic diseases. I. Role of antiinflammatory drugs. J Rheumatol. Mar 1991;18(3):389-393. Sharek PJ, Bergman DA. Beclomethasone for asthma in children: effects on linear growth. Cochrane Database Syst Rev. 2000(2):CD001282. Wintergerst ES, Maggini S, Hornig DH. Contribution of selected vitamins and trace elements to immune function. Ann Nutr Metab. 2007;51(4):301-323. Arnold LE, DiSilvestro RA. Zinc in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. Aug 2005;15(4):619-627. Yorbik O, Ozdag MF, Olgun A, Senol MG, Bek S, Akman S. Potential effects of zinc on information processing in boys with attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. Apr 1 2008;32(3):662-667. Altura BM, Altura BT. Tension headaches and muscle tension: is there a role for magnesium? Med Hypotheses. Dec 2001;57(6):705713. Lord RS, Bralley JA. Laboratory Evaluations for Integrative and Functional Medicine. 2nd ed. Duluth, GA: Metametrix Institute; 2008:113-114. Lord RS, Bralley JA. Laboratory Evaluations for Integrative and Functional Medicine. 2nd ed. Duluth, GA: Metametrix Institute; 2008:278. Mozaffarian D. Trans fatty acids - effects on systemic inflammation and endothelial function. Atheroscler Suppl. May 2006;7(2):29-32. Serrano-Mollar A, Closa D. Arachidonic acid signaling in pathogenesis of allergy: therapeutic implications. Curr Drug Targets Inflamm Allergy. Apr 2005;4(2):151-155. Wenzel SE. Arachidonic acid metabolites: mediators of inflammation in asthma. Pharmacotherapy. Jan-Feb 1997;17(1 Pt 2):3S-12S. Matsudaira T. Attention deficit disorders--drugs or nutrition? Nutr Health. 2007;19(1-2):57-60. Sorgi PJ, Hallowell EM, Hutchins HL, Sears B. Effects of an openlabel pilot study with high-dose EPA/DHA concentrates on plasma

30.

0

10.

11.

12.

13. 14.

19.

20. 21. 22.

34.

35.

36.

37.

38.

39.

40. 41. 42.

781

e

18.

33.

in

17.

32.

ic

16.

31.

ed

15.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

9.

phospholipids and behavior in children with attention deficit hyperactivity disorder. Nutr J. 2007;6:16. Council NRCUSCoDAFaNBNR. Human vitamin B6 requirements: proceedings of a workshop: Letterman Army. Washington, DC: National Academy of Sciences; 1976. Mousain-Bosc M, Roche M, Polge A, Pradal-Prat D, Rapin J, Bali JP. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. I. Attention deficit hyperactivity disorders. Magnes Res. Mar 2006;19(1):46-52. Holick MF. Vitamin D deficiency. N Engl J Med. Jul 19 2007;357(3):266-281. Cannell JJ, Hollis BW. Use of vitamin D in clinical practice. Altern Med Rev. Mar 2008;13(1):6-20. DeMeo MT, Mutlu EA, Keshavarzian A, Tobin MC. Intestinal permeation and gastrointestinal disease. J Clin Gastroenterol. Apr 2002;34(4):385-396. Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut. Oct 2004;53(10):1459-1464. Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science. Mar 25 2005;307(5717):1920-1925. Del Giudice MM, Rocco A, Capristo C. Probiotics in the atopic march: highlights and new insights. Dig Liver Dis. Dec 2006;38 Suppl 2:S288-290. Newmark SC. ADHD and food sensitivity. Altern Ther Health Med. May-Jun 2002;8(3):18; author reply 18. Schnoll R, Burshteyn D, Cea-Aravena J. Nutrition in the treatment of attention-deficit hyperactivity disorder: a neglected but important aspect. Appl Psychophysiol Biofeedback. Mar 2003;28(1):63-75. Fitzgerald KN-D, C; Lord, RS. Laboratory Evaluations for Integrative and Functional Medicine. In: Lord RBJ, ed. Atlanta: Metametrix Institute; 2008. Lord RS, Bralley JA. Laboratory Evaluations for Integrative and Functional Medicine. 2nd ed. Duluth, GA: Metametrix Institute; 2008:131. Banerjee TD, Middleton F, Faraone SV. Environmental risk factors for attention-deficit hyperactivity disorder. Acta Paediatr. Sep 2007;96(9):1269-1274. Braun JM, Kahn RS, Froehlich T, Auinger P, Lanphear BP. Exposures to environmental toxicants and attention deficit hyperactivity disorder in U.S. children. Environ Health Perspect. Dec 2006;114(12):1904-1909. Kidd PM. Attention deficit/hyperactivity disorder (ADHD) in children: rationale for its integrative management. Altern Med Rev. Oct 2000;5(5):402-428. Curtis LT, Patel K. Nutritional and environmental approaches to preventing and treating autism and attention deficit hyperactivity disorder (ADHD): a review. J Altern Complement Med. Jan-Feb 2008;14(1):79-85. Bressler JP, Olivi L, Cheong JH, Kim Y, Maerten A, Bannon D. Metal transporters in intestine and brain: their involvement in metalassociated neurotoxicities. Hum Exp Toxicol. Mar 2007;26(3):221229. Oades RD. Dopamine-serotonin interactions in attention-deficit hyperactivity disorder (ADHD). Prog Brain Res. 2008;172:543-565. Bucci L. Migraine, insomnia, reactive depression due to brain serotonin deficiency. Br J Psychiatry. Jun 1988;152:867-868. Sikander A, Rana SV, Prasad KK. Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clin Chim Acta. May 2009;403(1-2):47-55.

Section VII Putting It All Together

)2

(c 0

01 e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All Figure 37.6 LC’s Pre-treatment writing sample

782

Chapter 37 Case Presentations

)2

(c 0

01 e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All Figure 37.7 LC’s Post-treatment writing sample

783

Section VII Putting It All Together

)2

(c 0

01 e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All Figure 37.8 Completed matrix form for LC

784

Chapter 37 Case Presentations

Case at a Glance: ADHD History of Present Illness LC presented at age 12 with attention deficit hyperactivity disorder (ADHD), dysgraphia, environmental allergies, asthma, insomnia, eczema, canker sores, migraine headaches, muscle cramps, stomach pain, nausea, and diarrhea. LC was first diagnosed with ADHD at age 5. He repeated kindergarten because of attention and behavioral difficulties. He began methylphenidate (Ritalin® ) in 1st grade and continued to take it through 4th grade, although his behavior did not change significantly. The drug was discontinued in 4th grade due to growth retardation. Off the medication, he gained weight and increased his intake of junk food and deli meats. He continued to have trouble focusing in school and was still disruptive. He had never received a positive teacher report. He had severe dysgraphia, but excelled in math. His medications included: cetirizine (Zyrtec® ), albuterol, levalbuterol inhaler (Xopenex®), flunisolide (Nasarel or AeroBid®), cimetidine (Tagamet®), acetaminophen, and ibuprofen. He liked pasta, sweets, and ice cream despite the fact that he felt better avoiding dairy. Abbreviated Assessments, Laboratory Findings and Treatments Organized According to the Functional Medicine Matrix (Refer to full case presentation for details, including treatment rationale.) Clinical Assessment

Laboratory Results

(c

Lifestyle Factors: Nutrient Imbalances

)2 01

Low essential minerals Low vitamins A, E, beta carotene Elevated AA:EPA ratio Low B6 (organic acid markers) Elevated saturated and trans fatty acids

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Nutrient deficiencies Fatty acid imbalance Anxiety Muscle spasms Audio sensitivity Hyperkeratosis pilaris

Recommended Treatment

Zinc citrate Magnesium glycinate Multivitamin/mineral EPA/DHA Pyridoxal 5’ phosphate Dietary changes as noted below

Immune Surveillance and Inflammatory Process

Hypovitaminosis D Food sensitivities Intestinal hyperpermeability ADHD Asthma, allergies, headache, hives, sinusitis Atopic dermatitis Aphthous stomatitis

Low serum vitamin D Multiple + IgG food sensitivities Elevated IgG antigliadin antibodies

Vitamin D3 Dietary changes: Modified elimination diet based on test results. No dairy, peanuts, gluten, sugar, or trans fatty acids. Reduce saturated fat intake. Whole foods, minimally processed, organic diet. (Nutritionist comments available in full case presentation.)

Digestion and Absorption

Elevated lymphocyte:neutrophil ratio +IgG food sensitivities, IgG antigliadin antibodies

After 2 months on treatment protocol: Start DMSA (refer to full case presentation for details) Dietary changes as noted above

e

Elevated 6- hour urine lead after 250 mg DMPS (2,3-dimercapto-1-propane-sulphonic acid) provocation

in

Mild lead toxicity ADHD Food additives

ic

Detoxification and Biotransformation

Fluconazole Broad spectrum probiotics

ed

Yeast overgrowth GERD, IBS, pruritus ani Nausea

Hormone and Neurotransmitter Regulation ADHD, dysgraphia Insomnia

Low-normal plasma tryptophan Low-normal urine HVA, 5HIAA

5HTP 50–100 mg QHS as needed for sleep

6-Month Follow-up: LC’s mother reported that he was free from his chronic symptoms for the first time in his life. His dysgraphia improved dramatically (compare Figures 37.6 and 37.7 in full case presentation). He no longer required his medications, including antihistamines (cetirizine and cimetidine), bronchodilators, steroid inhaler, acetaminophen, and ibuprofen. His mood and behavior stabilized, and his ability to focus improved greatly. His hyperactivity symptoms, including disruptiveness, irritability, and anxiety, were gone. His hives, asthma, runny nose and postnasal drip, anal itching, stomachaches, nausea, diarrhea, headaches, muscle cramps, and sensitivity to loud noises were all completely resolved. He slept soundly at night. He was doing well in school, academically and socially (see mother’s comments in full case presentation). LC tolerated supplements and dietary changes well, because he felt so much better when he followed the plan.

785

Section VII Putting It All Together

)2 (c

0 01

e in ic ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

786

Appendix

)2 (c

0 01

e in ic ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

787

)2 (c

0 01

e in ic ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Appendix 30 Top-Selling Drugs and 10 Top-Selling Herbal Supplements in the United States (2003)

)2

(c 0

01

Drugs

x 1 million scripts

Herbs

lM na tio d. un rve r F se fo re te ts itu h st rig In All 68.95 49.78 44.07 36.43 32.71 29.73 29.65 29.35 28.27 27.57

St. John's Wort; Hypericum perforatum Echinacea Ginkgo biloba Saw palmetto Feverfew Garlic Ginger Ginseng Ephedra Valerian

e

in

ic

ed

Lipitor Synthroid Hydrocodone/Acetaminophen Norvasc Zoloft Toprol XL Hydrocodone/Acetaminophen* Zocor Prevacid Amoxicillin Albuterol Azithromycin Premarin Zyrtec Atenolol Levoxyl Celebrex Ambien Fosamax Allegra Nexium Furosemide Vioxx Singulair Ortho TriCyclen 28 Neurontin Cephalexin Effexor Hydrochlorothiazide Protonix Bold: Common adverse drug reaction *Different dosage than #3.

789

Textbook of Functional Medicine

Biographical Sketches for Contributing Authors (1966-1968), an Assistant Professor of Medical Computer Science at Yale (1969-1971), a family physician in the Community Health Care Center (1971-1978) in New Haven, Conn., Director of the Gesell Institute of Human Development (1978-1985), and in private practice in Connecticut and New York. He is co-author of Child Development (1982), The Years from 10 to 14 (1984), and the author of The Circadian Prescription (G.P. Putnam Sons, 2000) and Detoxification and Healing (Contemporary Books, 2003). He was co-founder in 1995 of the Defeat Autism Now! organization, with Bernard Rimland, PhD and Jon Pangborn, PhD, with whom he is coauthor of Autism: Effective Biomedical Treatments (2005). Dr. Baker was the 1999 recipient of the Linus Pauling Award from the Institute of Functional Medicine. He is an Associate Editor of Integrative Medicine: A Clinician’s Journal, and currently practices integrative medicine in Sag Harbor, New York. Peter Bennett, ND, is a naturopathic physician, best-selling author, and educator. He received his doctorate in naturopathic medicine in 1987 from Bastyr University. In addition to his training as a naturopathic doctor, Dr. Bennett completed a three-year degree program in Traditional Chinese Medicine (TCM) at the Northwest Institute of Acupuncture and Oriental Medicine (NIAOM) in Seattle, WA. He is also a board certified homeopathic physician (DHANP). In 1999, Dr. Bennett co-authored the 7-Day Detox Miracle (Prima Publishing, 2001), a safe, effective way to help people promote healing, lose weight, and increase energy. Dr. Bennett currently sees patients in Langley, BC where he focuses on providing individual biochemical assessment, and developing programs for optimum performance and recovery. Jeffrey S. Bland, PhD, FACN, CNS. Dr. Bland’s distinguished career in nutritional biochemistry has earned him international acclaim as educator, research professor, leader in the natural products industry, recognized expert in human nutrition and functional medicine, and visionary for the future of health care. Dr. Bland now serves as President and Chief Science Officer of Metagenics, Inc, and Chairman of the Board of Directors for The Institute for Functional Medicine, which he co-founded with his wife, Susan Bland, MA. John Cline, BSc, MD, utilizes an integrative approach in his medical practice. He is medical director

)2

(c

B. Jayne Alexander, DO, is a graduate of the Kirksville College of Osteopathic Medicine located in Kirksville, Missouri. As a student she was awarded an Undergraduate Fellowship in the Department of Osteopathic Theory and Methods and following graduation served a rotating internship at the Kirksville Osteopathic Health Center. Dr. Alexander is Board Certified with Special Proficiency in Osteopathic Manipulative Medicine by the American Osteopathic Association, and is trained in traditional and biodynamic osteopathic approaches. She serves on the faculty of the Sutherland Cranial Teaching Foundation, teaches with the New England-based A. Still Sutherland Study Group, and is a clinical preceptor for osteopathic students, interns and residents. Dr. Alexander has studied functional medicine since 1983, and completed the Institute for Functional Medicine’s AFMCP training in 1998 and 2001. She is currently engaged in private practice specializing in osteopathic manual medicine. Bruce N. Ames, PhD, is a professor of the Graduate School in Biochemistry and Molecular Biology, University of California, Berkeley, and a Senior Scientist at Children’s Hospital Oakland Research Institute. A member of the National Academy of Sciences, Dr. Ames served on their Commission on Life Sciences. He was a member of the board of directors of the National Cancer Institute—the National Cancer Advisory Board—from 1976 to 1982. He has received the General Motors Cancer Research Foundation Prize (1983); the Tyler Environmental Prize (1985); the Gold Medal Award, American Institute of Chemists (1991); Award for Excellence in Environmental Health Research (1995); the Honda Prize, Honda Foundation, Japan (1996); the Japan Prize (1997); the Robert A. Kehoe Award, American College of Occupational and Environmental Medicine (1997); the Medal of the City of Paris (1998); the U.S. National Medal of Science (1998); the Linus Pauling Award (2001); and the Thomas Hunt Morgan Medal from the Genetics Society of America (2004). Dr. Ames is among the few hundred most-cited scientists (in all fields), as a result of his 500+ publications. Sidney MacDonald Baker, MD, is a 1964 graduate of Yale Medical School where he completed his specialty training in pediatrics. He is board certified in pediatrics. He has been a Peace Corps volunteer in Chad, Africa

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 790

Appendix

the American Association of Naturopathic Physicians and received their first award for in-office research in 1999, and was awarded it a second time in 2002. He is an associate professor at Bastyr University, the National College of Naturopathic Medicine in Portland, OR, and the University of Bridgeport School of Naturopathic Medicine. He is professor and director of the Environmental Medicine Center of Excellence at Southwest College of Naturopathic Medicine. In 2001, he appeared three times with Barbara Walters on ABC’s “The View” and had a weekly Health Spot on Northwest Cable News from 1999 until 2003, giving viewers in Oregon, Washington, and Idaho up-to-date information on nutrition and health. Gary Darland, PhD, received his doctorate in microbiology from the University of Washington. He is Senior Director of Clinical Biology at Metaproteomics, LLC, a division of Metagenics, Inc. Dr. Darland joined HealthComm/Metagenics after 23 years of research experience in natural products, and biochemistry and microbial genetics at Merck Research Laboratories. Research activities at Merck revolved around microbial genetics and physiology and also included work in the area of human and animal drug metabolism. Prior to joining Merck, he was a visiting Fellow at the Centers for Disease Control in the Enteric Disease Section and an assistant professor at California Polytechnic University, San Luis Obispo. These activities have led to the publication of several papers dealing with drug metabolism and the biosynthesis of natural products. Joel M. Evans, MD, a board certified OB/GYN, is Founder and Director of The Center for Women’s Health in Darien, CT, where he practices integrative obstetrics and gynecology. A frequent lecturer on complementary and alternative medicine (CAM), Dr. Evans is an Assistant Clinical Professor of Obstetrics, Gynecology and Women’s Health at the Albert Einstein College of Medicine. In January 2001, he was honored as a Founding Diplomate of the American Board of Holistic Medicine. Dr. Evans’ book, The Whole Pregnancy Handbook (Gotham Books, 2005), details his unique approach to holistic pregnancy care. Dr. Evans is on the senior faculty of The Center for Mind/Body Medicine in Washington D.C. He teaches health professionals about the medical benefits of relaxation therapies at The Center’s basic and advanced training programs. He also lectures about nutrition and supplements at the Center’s Cancer Guides and Food as Medicine conferences. Dr. Evans

)2

(c

of the Cline Medical Centre in Nanaimo, British Columbia, Canada. He is also medical director for the Oceanside Functional Medicine Research Institute and has collaborated with Michael Lyon, MD on several research projects related to ADHD. Dr. Cline obtained a BSc in Biochemistry, followed by his MD and residency training in family medicine at the University of Calgary, Alberta, Canada. He has a particular interest in using various detoxification strategies and has taken further training through the American Board of Chelation Therapy, the American Academy of Neural Therapy, and is certified by the International Board of Clinical Metal Toxicology. In April 2005, he completed the physicians training course with the Centers for Advanced Medicine. He is writing a book for the general public about toxicity and detoxification. He has lectured extensively in the community, at medical conferences, and for The Institute for Functional Medicine. Daniel Cosgrove, MD, earned a psychobiology degree from UCLA and received an MD degree from Washington University in St. Louis. He completed internal medicine training at the University of Utah, and became board certified in both internal medicine and emergency medicine. He holds a clinical faculty appointment at Loma Linda University School of Medicine. Dr. Cosgrove is certified by the Federal Aviation Administration as a Senior Aviation Medical Examiner. He was the Medical Director of Airstar International Air Ambulance for many years. He has published several scientific articles. He is a principal investigator in the KIMS Human Growth Hormone Study. In 1997 Dr. Cosgrove founded the WellMax Center for Preventive Medicine, which is now located at the La Quinta Resort and Club. WellMax provides executive physicals but is best known for ongoing individualized healthcare, specializing in the early detection of disease through the creation and maintenance of a Personal Health Portfolio. Walter J. Crinnion, ND, received his degree in naturopathic medicine from Bastyr University (Seattle, Washington) in 1982 with the first graduating class. He opened a family practice and began to specialize in allergies and in treating chronic health problems caused by environmental chemical overload. In 1985 he opened the most comprehensive cleansing facility in North America for the treatment of chemically poisoned individuals. He has published several articles in peer-reviewed journals on the topic of environmental overload. He has served on the board of directors of

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 791

Textbook of Functional Medicine

at Harvard University and the New York University School of Medicine and trained in internal medicine at the NYU-Bellevue Medical Center. He has held faculty positions at New York University, Rockefeller University, the Albert Einstein College of Medicine, the State University of New York at Stony Brook, and the University of Connecticut. He has written over 30 scientific articles and textbook chapters and has lectured extensively on topics related to nutritional medicine, intestinal health and patient assessment. A board-certified internist, Dr. Galland is a Fellow of the American College of Physicians and the American College of Nutrition, an Honorary Professor of the International College of Nutrition, and has authored three books, Superimmunity for Kids (Dell, 1989), Power Healing (Random House, 1997), and The Fat Resistance Diet (Doubleday, 2006). In addition to a full-time private practice in New York City, Dr. Galland directs the Foundation for Integrated Medicine (www.mdheal.org), and Applied Nutrition, Inc., a medical software company (www.nutritionworkshop.com). Michael D. Gershon, MD, has published over 300 scientific papers, books, and chapters. His study of the cellular basis of the neuronal control of behavior brought the enteric nervous system (ENS)—discussed in his book, The Second Brain—to the attention of the general public and enhanced the esteem in which neurogastroenterologists are held. He was the first to propose, and ultimately to establish, that serotonin is an enteric neurotransmitter, and he has also studied the mechanisms by which the varicella zoster virus infects cells and then is assembled into infectious particles. Dr. Gershon received his BA degree in 1958, with distinction, from Cornell University. Upon graduating from Cornell Medical School in 1963, he was awarded the Polk Prize for the best academic record and the Borden Prize for undergraduate research. He then completed postdoctoral training in pharmacology with Edith Bülbring at Oxford University (England), before returning to Cornell as Assistant Professor of Anatomy in 1967. He was promoted to Professor before leaving Cornell to accept his current position as Chair of the Department of Anatomy and Cell Biology at Columbia University’s College of Physicians and Surgeons. Patrick Hanaway, MD, is a board-certified family physician with a medical degree from Washington University (St. Louis) and residency training at the University of New Mexico. Dr. Hanaway is also a board-certified holistic physician and currently sits on the American

)2

(c

has a special interest in helping those affected by the tragedies of war, and participated in the Center’s Mind/ Body Mission to Macedonia in 1999, where he traveled to U.N. refugee camps to help Kosavar refugees. Dr. Evans also worked with the FDNY firefighters to help them handle the many stresses caused by 9/11. William J. Evans, PhD, is director of the Nutrition, Metabolism, and Exercise Laboratory in the Donald Reynolds Department of Geriatrics at the University of Arkansas for Medical Sciences and a research scientist in the Geriatric Research, Education and Clinical Center (GRECC) at the Central Arkansas Veterans Healthcare System. He is a Professor of Geriatrics, Physiology, and Nutrition. From 1993 to 1997, he was director of the Noll Physiological Research Center at the Pennsylvania State University and, from 1982 to 1993, he served as Chief of the Human Physiology Laboratory at the USDA Human Nutrition Research Center on Aging at Tufts University. He is a Fellow of the American College of Sports Medicine, The American College of Nutrition, and an honorary member of the American Dietetic Association. Dr. Evans is the author or co-author of more than 190 publications in scientific journals. His research has examined the powerful interaction between diet and exercise in elderly people. He is the co-author of Biomarkers: The Ten Determinants of Aging You Can Control (Simon & Schuster, 1991) and authored AstroFit (Simon & Schuster, 2002). His work has been featured in numerous newspapers, including The New York Times, The Boston Globe, and The Chicago Tribune. William B. Ferril, MD, received a Bachelor of Science degree in Biochemistry and his Doctorate in Medicine from The University of California at Davis. He completed his post graduate education at Sacred Heart Medical Center in Spokane, Washington. For over 19 years, Dr. Ferril has practiced medicine on the Flathead Indian Reservation and adjacent areas of Montana. It was during this posting that Dr. Ferril compiled his data for a series of books on the biochemistry of the human body. He is the author of The Body Heals, Glandular Failure-Caused Obesity, and Why is My Doctor So Dumb? Healing 101. Dr. Ferril resides with his wife and children in Whitefish, MT where he continues research and private practice. Leo Galland, MD, is the recipient of the 2000 Linus Pauling Award from The Institute for Functional Medicine, for formulating key concepts underlying the discipline of functional medicine. He received his education

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 792

Appendix

getown University Department of Psychiatry. He has authored Understanding Biological Psychiatry (Norton, 1996) and The Antidepressant Survival Program: How to Beat the Side Effects and Enhance the Benefits of Your Medication (Crown, 2000). Mark C. Houston, MD, MSc, SCH, ABAAM, FACP, FAHA, is Clinical Professor of Medicine at Vanderbilt University School of Medicine, and Director of the Hypertension Institute, Vascular Biology and the Life Extension Institute, Saint Thomas Hospital in Nashville, TN. He is also Medical Director of Clinical Research, Section Chief of the Division of Nutrition, and Director of CME in the Hypertension Institute. Dr. Houston graduated from Vanderbilt Medical School, completed his medical internship and residency at the University of California, San Francisco, then returned to Vanderbilt Medical Center as chief resident in medicine. He is certified by the American Board of Internal Medicine; the American Society of Hypertension as a specialist in clinical hypertension (SCH); and the American Board of Anti-Aging Medicine (ABAAM). He completed a Master of Science degree in clinical human nutrition from the University of Bridgeport, Connecticut. He is Editor-inChief for the Journal of the American Nutraceutical Association (JANA), has published more than 120 articles and scientific abstracts, and completed over 70 clinical research studies. He co-authored the Handbook of Antihypertensive Therapy (Hanley and Belfus Inc., 2000), Vascular Biology in Clinical Practice (Hanley and Belfus Inc., 2002), and What Your Doctor May Not Tell You about Hypertension (Warner Books, 2003). Mark A. Hyman, MD, is Editor-in-Chief of Alternative Therapies in Health and Medicine. For nearly 10 years he was Co-Medical Director at Canyon Ranch in the Berkshires, an internationally acclaimed health resort, which is an affiliated practice with Harvard University’s Brigham and Women’s Hospital. He graduated with a BA from Cornell University in 1982 and Magna Cum Laude from the University of Ottawa School of Medicine in 1987 and from the University of San Francisco’s program in family medicine at Community Hospital of Santa Rosa. He is board certified in family medicine. He recently testified at the White House Commission on Complementary and Alternative Medicine Policy on health promotion and wellness, and met with and advised the Surgeon General on a new diabetes prevention initiative. He is on the editorial board of Integrative Medicine: A Clinician’s Journal. Dr. Hyman combines the

)2

(c

Board of Holistic Medicine. He received his bachelors degree from the University of Wisconsin in molecular biology and has done research and published papers in muscle biology, neurochemistry, lipid research, digestive disease, public health and prevention. Dr. Hanaway holds dual appointments as Medical Director for Family to Family: Your Home for Whole Family Health (Asheville, NC) and Medical Director for Great Smokies Diagnostic Laboratory. His current interests are in the research and clinical implementation of applied nutritional biochemistry, with an emphasis on digestion, immunology, prevention and wellness. Bethany Hays, MD, FACOG, is an obstetrician gynecologist with a career-long passion to find the best possible forms of healing and to incorporate them into her practice. That dream has come to a new level of realization with the opening of True North, A Center for Health and Healing, in Falmouth, Maine. This unique integrative practice was created by a group of practitioners of conventional and complementary modalities after nearly four years of dreaming and planning. The addition of functional medicine to her practice has added a new dimension and new excitement for Dr. Hays as well as a passion for the biochemistry she tried so hard to forget after the first year of medical school. She is an adjunct faculty member of The Institute for Functional Medicine, where she also serves on the board of directors. Robert J. Hedaya, MD, is a Fellow of the American Psychiatric Association and Clinical Professor of Psychiatry at Georgetown University Hospital where he teaches psychoendocrinology. He is founder of the National Center for Whole Psychiatry and is board certified by the American Board of Psychiatry and Neurology, the American Board of Adolescent Psychiatry, and certified as proficient in psychopharmacology by the American Society of Clinical Psychopharmacology. He has been a consultant to the National Institute of Mental Health. Dr. Hedaya obtained both a BA in psychology (Cum Laude, Phi Beta Kappa) and a medical degree at the State University of New York at Buffalo. Subsequently, he acquired specialized training in psychiatry at Georgetown University Hospital’s Department of Psychiatry, and at the National Institute of Mental Health. Dr. Hedaya received the Physician’s Recognition Award from the American Medical Association each year from 1983 through 1996. In June of 1993, 1997, and 1999, he was voted Outstanding Teacher of the Year by the Geor-

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 793

Textbook of Functional Medicine

in his community. He is the Past President of the St. Stephen’s & St. Agnes Alumni Association and the school physician at Episcopal High School in Alexandria. He is also the president of the Commonwealth Consultants Foundation, a local charity chartered to provide unique educational and social experiences for economically deserving children and young adults. Robert H. Lerman, MD, PhD, is Medical Director of MetaProteomics, Inc., a subsidiary of Metagenics, Inc., with major emphasis on clinical research at the Functional Medicine Research Center. Previously, he was Senior Medical Advisor and Director of Medical Education for IFM, Director of Clinical Nutrition at Boston Medical Center, and Clinical Associate Professor of Medicine at Boston University School of Medicine. Dr. Lerman is board certified in internal medicine and completed fellowships in nephrology and clinical nutrition. He received his MD degree from Jefferson Medical College and a PhD in nutritional biochemistry from M.I.T. He completed a rotating internship at Letterman Army Medical Center in San Francisco and an internal medicine residency at Tripler Army Medical Center in Honolulu, and attained the rank of major in the U.S. Army Medical Corps. He was Chief of Medicine at U.S. Army Hospitals in Berlin, Germany and Vicenza, Italy and Acting Chief of Nephrology at Soroka Medical Center in Beer Sheba, Israel. He has authored and co-authored numerous papers and book chapters in addition to lecturing widely. Edward Leyton, MD, CCFP, received his BSc (Hons.) in Biochemistry from the University of Western Ontario in 1970, and subsequently his MD degree in 1975. Since then he has trained in acupuncture with the Canadian Acupuncture Foundation (1979); gestalt therapy with the Gestalt Institute of Toronto (1976); and has followed the concepts of functional nutritional medicine as taught by Dr. Jeffrey Bland since 1982. More recently, Dr. Leyton has attained a master practitioner level in Neuro-Linguistic Programming (NLP) and is a certified hypnotherapist. He was an adjunct faculty member with The Institute of Functional Medicine, where he taught in the Applying Functional Medicine in Clinical Practice course. He is an adjunct academic staff member in the Department of Family Medicine, Queens University, Kingston, Ontario, an award recipient, and published author. Peter Libby, MD, is the Chief of Cardiovascular Medicine at Brigham and Women’s Hospital, Boston, MA, and Mallinckrodt Professor of Medicine at Harvard

)2

(c

best of conventional and alternative medicine with a blend of science, integrity, intuition and compassion. He is co-author of Ultraprevention, the 6-Week Plan that Will Make You Healthy for Life (Scribner, 2003), and The Detox Box, a Program for Greater Health and Vitality (Sounds True, 2004). He serves on the Board of Directors for The Institute for Functional Medicine. Mary James, ND, is a 1985 graduate of the National College of Naturopathic Medicine in Portland, Oregon. Dr. James was in private practice for several years in Portland, represented a nutraceutical company in the northeast, and has worked in medical education at Great Smokies Diagnostic Laboratory in Asheville, NC for more than 10 years. She has lectured widely within the U.S. and abroad, provided ongoing technical support to physicians, developed products, and authored an extensive array of therapeutic guides and technical articles, particularly in the areas of endocrinology and genomics. Dr. James is a member of the American Association of Naturopathic Physicians and serves on the Editorial Review Board of the Alternative Medicine Review. David Jones, MD, is President of The Institute for Functional Medicine. He has practiced as a family physician with emphasis in functional and integrative medicine for over 25 years. He is a recognized expert in the areas of nutrition, lifestyle changes for optimal health, and managed care, as well as the daily professional functions consistent with the modern specialty of Family Practice. Dr. Jones is the recipient of the 1997 Linus Pauling Award in Functional Medicine. He is also the Past President of PrimeCare, the Independent Physician Association of Southern Oregon (IPASO) representing the majority of physicians in the Southern Oregon area. He is author of Healthy Changes: Taking Charge of Your Health (HealthComm, 1996). Joseph J. Lamb, MD, is board certified in both internal medicine and holistic medicine. He is president of the Integrative Medicine Works in Alexandria, Virginia, and is an Assistant Clinical Professor of Medicine at George Washington University School of Medicine. Dr. Lamb works in partnership with his patients to create optimal health and well-being by using functional medical approaches including lifestyle modification, herbal and nutritional therapies, and cognitive therapy. He completed his graduate education at the Medical College of Virginia in Richmond and his residency at Presbyterian University of Pennsylvania Medical Center in Philadelphia. Dr. Lamb, a native Alexandrian, is active

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 794

Appendix

other dementias, autism, Asperger’s syndrome and ADHD. His research involves brain imaging and neuropsychopharmacology. Dr. Lombard has published several books including The Brain Wellness Plan (Kensington Press, 2000) and Balance Your Brain (Wiley, 2004), as well as numerous articles on topics related to brain health. Recently, Dr. Lombard was the medical consultant in the film, Manchurian Candidate, starring Denzel Washington and Meryl Streep. Dan Lukaczer, ND, received his undergraduate degree from Duke University in 1980 and his doctorate in naturopathic medicine from Bastyr University in 1991. From 1991 to 1995, he developed and maintained a private practice. In 1996, he became Director of Clinical Research for the Functional Medicine Research Center, a division of Metagenics, Inc., and served in that capacity until 2005. He is currently working as a senior research scientist for SaluGenecists Inc., a company that is developing evidence-based expert logic health diagnostic systems using advanced computer-based technology. Dr. Lukaczer has taught, lectured and written extensively on botanical and nutritional medicine. He is a core faculty member of The Institute for Functional Medicine and serves on IFM’s CME Advisory Committee. Michael D. Lumpkin, PhD, is a tenured Professor and Chairman of the Department of Physiology and Biophysics at Georgetown University School of Medicine. He earned his doctoral degree in physiology in 1981 from the University of Texas Southwestern Medical School in Dallas. He completed NIH-sponsored postdoctoral fellowship training in neuroendocrinology at Southwestern Medical Center in 1983. Dr. Lumpkin’s current research involves studying the stress-related mechanisms by which HIV/AIDS disrupts the neuroendocrine systems that regulate growth, immunity, and reproduction. From this work, he and his research group have produced a patent for treating AIDS-related wasting syndromes in adults and children. He is also a central participant in a large NIH-funded initiative to bring integrative medicine research and education to medical and graduate students at Georgetown. Dr. Lumpkin lectures extensively on the subjects of stress physiology and psychoneuroimmunology. He is an officer in two international scientific societies and serves on several boards of medical foundations. He lectures, instructs and facilitates groups in all aspects of neuroendocrinology, psychoneuroimmunology and mind-body medicine. He is a representative to the

)2

(c

Medical School. He directs the D.W. Reynolds Cardiovascular Clinical Research Center at Harvard. Dr. Libby’s research currently focuses on the role of inflammation in vascular diseases such as atherosclerosis. His clinical expertise includes general and preventive cardiology, and he has published extensively in medical journals. An editor of Braunwald’s Heart Disease, he also contributed two chapters on atherosclerosis to Harrison’s Principles of Internal Medicine. He has held numerous visiting professorships and has delivered over 40 named or keynote lectures. Dr. Libby is a member of the Association of American Physicians and the American Society for Clinical Investigation. An active member of the American Heart Association, he has served on its Executive Committees of the Councils on Arteriosclerosis, Circulation, and Basic Science. He consults frequently to the National Heart, Lung and Blood Institute, and also served a five-year term on the Board of Scientific Councilors. Dr. Libby earned his medical degree at University of California-San Diego, and completed his training in internal medicine and cardiology at the Peter Bent Brigham Hospital. DeAnn Liska, PhD, is Director of Technical Information and Scientific Publications at Metagenics’ Functional Medicine Research Center. She received her PhD in Biochemistry from the University of Wisconsin-Madison in 1987, where she performed her graduate thesis studies on several aspects of vitamin K biochemistry. She also did postgraduate studies in the Department of Biochemistry at the University of Washington as Senior Fellow and, subsequently, Research Assistant Professor, on the subject of nutrient and growth factor effects on gene expression. Dr. Liska has authored numerous papers in peer-reviewed journals, contributed to textbooks on nutrition, is on the Biotechnology and Biomedical Device Advisory Board for the Washington Technology Center. She holds four U.S. patents. Dr. Liska has been an invited speaker at national and scientific meetings, Chair of the Nutrition Division and a member of the Scientific Advisory Panel for the American Association of Cereal Chemists (AACC). She is a member of the National Science Teachers Association and the American Medical Writers Association and serves on IFM’s CME Advisory Committee. Jay Lombard, MD, is an Assistant Clinical Professor of Neurology at Cornell Medical School and Director of the Brain Behavior Center in Pomona, NY. He specializes in Behavioral Neurology including Alzheimer’s and

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 795

Textbook of Functional Medicine

at numerous conferences in the U.S., England, Canada and Australia on the subjects of fibromyalgia, and fibromyalgia associated with cervical trauma; and on the differential diagnosis and treatment of pain and pain syndromes, and sports injuries. David Musnick, MD, is board certified in internal medicine and sports medicine with 16 years of experience. He practices in Bellevue, Washington at the Comprehensive Medical Center, an integrative medical center. His practice focuses on orthopedic and sports medicine, pain management, and functional internal medicine. An expert in exercise prescription, Dr. Musnick is the author of Conditioning for Outdoor Fitness: Functional Exercise and Nutrition for Every Body (The Mountaineers Books, 2004). He teaches seminars on Exercise Prescription, Orthopedic Medicine and Pain Management. Dr. Musnick is on the faculty at the University of Washington, Dept. of Sports Medicine and Orthopedics, and was the instructor of Orthopedic Medicine and Sports Medicine for five years at Bastyr University. He serves on the CME Advisory Committee for The Institute for Functional Medicine. Joseph E. Pizzorno Jr., ND, is a leading authority on science-based natural medicine. A physician, educator, researcher, and expert spokesperson, Dr. Pizzorno was the Founding President (now Emeritus) of Bastyr University. He is also President of SaluGenecists, Inc. In 1996, he was appointed to the Seattle/King County Board of Health and the founding board of directors of the American Herbal Pharmacopoeia. In 2002, he became the founding editor of Integrative Medicine: A Clinician’s Journal. Dr. Pizzorno was appointed by President Clinton in December 2000 to the White House Commission on Complementary and Alternative Medicine Policy and, in November 2002, was appointed by President Bush’s administration to the Medicare Coverage Advisory Committee. In 2002, he was awarded “Naturopathic Physician of the Year” by the American Association of Naturopathic Physicians; in 2003, the American Holistic Medical Association recognized him as a “Pioneer in Holistic Medicine”; and in 2004, The Institute for Functional Medicine honored him with the Linus Pauling Award. Dr. Pizzorno is the author of Total Wellness and co-author of A Textbook of Natural Medicine, Handbook of Natural Medicine, Encyclopedia of Natural Medicine, Natural Medicine for the Prevention and Treatment of Cancer, and The Encyclopedia of Healing Foods (Atria Books, 2005).

)2

(c

Consortium of Academic Health Centers for Integrative Medicine. Dr. Lumpkin is the author of 180 scientific articles, book chapters, and abstracts. Michael Lyon, BSc, MD, is Medical and Research Director for the Canadian Center for Functional Medicine located in Coquitlam, BC. He heads up a team of clinicians and researchers dedicated to biotechnology and natural health product research. He is involved in collaborative clinical research with the University of Toronto and the Imperial College of Medicine in London, England in the field of obesity, diabetes, and appetite regulation; and with the University of British Columbia in the area of childhood learning and behavioral disorders. Dr. Lyon served as an Olympics team physician (1988-1992) and was also head of a National Sport Science Committee for Sport Canada. He has a long-standing interest in toxicology and he has lectured frequently on the subject. He is the author of Healing the Hyperactive Brain through the New Science of Functional Medicine (Focused Publishing, 2000), and co-author of Is Your Child’s Brain Starving? (Mind Publishing, 2002), and How to Prevent and Treat Diabetes with Natural Medicine (Riverhead Books, 2003). Woody R. McGinnis, MD, was educated at Dartmouth College and the University of Colorado. After volunteer medical work in rural Peru, he practiced general medicine in Arizona for many years. In 1993, Dr. McGinnis began studying nutritional influences on behavior. Nutritional treatment of autism and other behavioral disorders became the primary focus of his practice. In 2001, Dr. McGinnis committed to full-time research in behavioral nutrition. He initiated and coordinates the Oxidative Stress in Autism Study, a first-ofits-kind university collaboration measuring a broad range of oxidative markers in the urine, blood, and central nervous system of children with autism. The urinary Mauve Factor is an area of special interest for McGinnis, who proposes that Mauve is a biomarker for oxidative stress. He resides in Ashland, Oregon, with his wife, Julia, and two sons. To balance his work, he reads, plays frisbee, does yoga, picks blueberries and generally strives to exemplify a healthful, low-oxidizing lifestyle. Carolyn McMakin, MA, DC, is the clinical director of Integrated Pain Solutions and the Fibromyalgia and Myofascial Pain Clinic in Portland, Oregon. In addition to maintaining an active clinical practice, she teaches seminars on the use of Frequency Specific Microcurrent. She has lectured at the National Institutes of Health and

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 796

Appendix

panies and employers. In addition, through an alliance with the Channing Bete Company, Pro-Change is developing effectiveness tested programs for elementary, middle, and high schools that include obesity prevention, bullying prevention, and substance abuse prevention. Sheila Quinn, BS, has worked in health-related nonprofit organizations for more than 30 years, and in the healthcare arena itself for more than 45 years. Following twelve years as Co-founder and Vice President at Bastyr University and seven years as Executive Director of the American Association of Naturopathic Physicians, she became Senior Editor at IFM in late 2000. She has coauthored and edited many reports and publications, and was Managing Editor for IFM’s Clinical Nutrition: A Functional Approach, 2nd edition (2004). She helped to organize the Seattle Town Hall Meeting for the White House Commission on CAM Policy in October 2000. She served on the Steering Committee for the 2001 National Policy Dialogue to Advance Integrated Health Care: Finding Common Ground (and co-edited the final report). She is currently Board Chair and member of both the Executive Committee and the Education Task Force for the Integrated Healthcare Policy Consortium. Through her decades of work both inside and outside the healthcare mainstream, she has become knowledgeable about health-related public policy issues and is committed to helping create a safe and effective integrated healthcare system. She attended Reed College, Stanford University, and received a BS in accounting from City University. Robert Rountree, MD, received his medical degree from the University of North Carolina School of Medicine at Chapel Hill in 1980. He subsequently completed a residency in family and community medicine at the Milton S. Hershey Medical Center in Hershey, PA, after which he was certified by the American Board of Family Practice. He is a diplomate of the American Board of Holistic Medicine and has augmented his training with postgraduate studies in nutritional and herbal pharmacology and certification as a master practitioner of Neuro-Linguistic Programming. Dr. Rountree has provided his unique combination of traditional family medicine, nutrition, herbology, and mind-body therapy in Boulder, CO since 1983. He is co-author of three books on Integrative Medicine, Immunotics: A Revolutionary Way to Fight Infection, Beat Chronic Illness and Stay Well (Putnam, 2000), Smart Medicine for a Healthier Child (Avery Publishing, 1994) and A Parent’s Guide to Medical Emergencies (Avery, 1997). Dr. Rountree is an adjunct faculty

)2

(c

Lara Pizzorno, MA Div, MA Lit, LMT, was among the first 10 women to graduate from Yale Divinity School with a Masters in Divinity in 1973. She earned her second Masters in Literature from the University of Washington and is also a Licensed Massage Therapist. A member of the American Medical Writers Association with more than 25 years of experience writing and editing articles, books, and website content for physicians and the public, Lara is employed as Senior Medical Editor for SaluGenecists, Inc., in Seattle. Her favorite responsibility is reviewing and summarizing the nutrition-related research each month to update The World’s Healthiest Foods, a non-profit website created by SaluGenecists for the George Mateljan Foundation. Lara has attended all but one of the IFM symposia and is an AFMCP graduate. She is a contributing author to the Textbook of Natural Medicine (Churchill Livingstone, 3rd ed. 2005), lead author of Natural Medicine Instructions for Patients (Churchill Livingstone, 2002), and a co-author of The Encyclopedia of Healing Foods (Atria Books, 2005). James O. Prochaska, PhD, is Director of the Cancer Prevention Research Center and Professor of Clinical and Health Psychology at the University of Rhode Island. He is the author of over 250 publications, including three books, Changing for Good, Systems of Psychotherapy and The Transtheoretical Approach. He is internationally recognized for this work as a developer of the stage model of behavior change. He is the principal investigator for over $70 million in research grants for the prevention of cancer and other chronic diseases. Dr. Prochaska has won numerous awards including the Top Five Most Cited Authors in Psychology from the American Psychology Society; an Innovator’s Award from the Robert Wood Johnson Foundation and he is the first psychologist to win a Medal of Honor for Clinical Research from the American Cancer Society. Janice M. Prochaska, MSW, PhD, is President and CEO of Pro-Change Behavior Systems, Inc. and an adjunct professor in the Department of Human Development and Family Studies at the University of Rhode Island. Her business is dedicated to the scientific development and dissemination of Transtheoretical Modelbased change management programs. Through Small Business Innovation research grants from the National Institutes of Health, her company’s LifeStyle management programs for depression management, regular exercise, stress management, and weight management are being disseminated through health insurance com-

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 797

Textbook of Functional Medicine

programs. His career has offered him medical experiences and practice in Thailand, Alaska, eastern Sierras, Idaho, and Oregon. His interests and lectures have covered a wide range of topics, including bezoars to neonatal hypocalcemia, health issues with depleted uranium, exposure to Vitamin D and chronic disease. Nancy Sudak, MD, completed her medical education at Case Western Reserve University in 1989, and received her residency training in family practice in Duluth, Minnesota in 1992. Board certified in both family practice and holistic medicine, she is currently in private practice in an integrated chiropractic-medical clinic in Duluth. She is a clinical instructor for the University of Minnesota School of Medicine, an active board member of the American Board of Holistic Medicine, and an editorial board member for Integrative Medicine: A Clinician’s Journal. She attended the inaugural Applying Functional Medicine in Clinical Practice course by The Institute for Functional Medicine in 1998, which facilitated a comprehensive revitalization of her practice. She is an enthusiastic community speaker on various health-related topics. Thomas Sult, MD, practices family and functional medicine in St. Cloud, MN. He utilizes a full range of diagnostic and therapeutic interventions ranging from ultra-fast CT and genomic testing, to lifestyle counseling and meditation. Dr. Sult is an Assistant Clinical Professor of Medicine at the Department of Family and Community Medicine, University of MN, and an instructor for the Rural Health School of Medicine, a cooperative educational outreach program of the University of MN. He is also the Medical Director of A Chance to Grow, a multidisciplinary rehabilitation clinic for brain-injured children, in Minneapolis. Dr. Sult is board certified in family medicine and holistic medicine. He is a Fellow of the American Academy of Family Medicine and a graduate of Applying Functional Medicine in Clinical Practice. While spending two years at St. Georges School of Medicine in Grenada, West Indies, he was introduced to the herbal and shamanistic customs of the Grenadian “bush doctor.” Upon transfer to UCLA School of Medicine, Dr. Sult was introduced to Dr. Norman Cousins and the Division of Psychoneuroimmunology. Dr. Cousins became a close mentor to Dr. Sult and helped him form an understanding of the healing techniques he had witnessed in Grenada. John M. Tatum, MD, is Founder and Medical Director of Optimal Health & Learning Center in Winter Park,

)2

(c

member at The Institute for Functional Medicine, and serves on the advisory board for the Herb Research Foundation and on the editorial boards of The Journal of Alternative and Complementary Medicine, Alternative and Complementary Therapies, and Delicious! Living Magazine. Barb Schiltz, RN, MS, CN, has been a registered nurse for 40 years with an undergraduate degree in Foods and Nutrition and a Master’s Degree in Nutrition from Bastyr University. Since 1996, she has been working as a nutrition consultant and research nurse at The Functional Medicine Research Center (FMRC) in Gig Harbor, WA, monitoring patients undergoing clinical trials for irritable bowel disease, fibromyalgia, diabetes, ADHD, and PMS. Her passion was expressed in her Master’s Thesis, The Unique Role of Carbohydrate Metabolism in Regulation of Glycemic Index. Virginia Shapiro, DC, DACBN, has practiced functional medicine as a chiropractor since 1985. She earned her bachelor’s degree in biology at Carleton College in 1977, and her doctor of chiropractic degree at Northwestern University of Health Sciences in Minneapolis in 1985. In 1996 she completed her board certification in clinical nutrition by the American Chiropractic Board of Clinical Nutrition. A student of clinical nutrition and natural health care approaches, she has continued intensive postgraduate studies with a number of the most prominent holistic practitioners in the U.S. and the U.K. She has lectured to clinicians regarding clinical nutrition, essential fatty acid biology, nutrition in cardiovascular health, nutrition in mood and behavioral disorders, and applying functional medicine to women’s hormonal health. Her successful functional medicine practice, Northland Health and Wellness in Duluth, Minnesota, provides comprehensive medical, nutritional, and chiropractic services in a joyful, compassionate, and healing environment. Michael Stone, MD, MS, is a board certified family physician who practices in Ashland, Oregon with Leslie Stone, MD, and David Jones, MD. He has experience in rural and frontier family medicine, emergency medicine, and as a hospitalist. His undergraduate and graduate degrees are in human nutrition. He graduated from the University of Washington, and did his residency training in family practice at UCLA-Ventura, where he was chief resident, and also completed a teaching fellowship in family medicine. Dr. Stone has been an adjunct faculty at UCLA and University of Washington for primary care students in the Doctoring and RUOP

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 798

Appendix

chaired the Department of Diagnosis at NCC from 1980-1991, then he subsequently served as the Director of the Inpatient Facility, the Director of the Training and Assessment Center, the Dean of Clinics, the Vice President for Academic Affairs, and the Senior Vice President and Provost. He is board certified in diagnosis and internal disorders, and has been an adjunct faculty member of The Institute for Functional Medicine. He has lectured nationally and internationally on the diagnosis and management of chronic disorders. Catherine Willner, MD, is a practicing neurologist in Durango, Colorado. She received her formal training in Neurology at the Mayo Clinic including subspecialty training in autonomic, peripheral neurology as well as pain management. She remained on staff at the Mayo Clinic until 1997, at which time she relocated to Colorado to focus her practice on functional neurology. She is board certified in neurology and in pain management. Prior to pursuing her MD degree, Dr. Willner was enrolled briefly in the National College of Naturopathic Medicine when the program was in Kansas. Her interest in biochemical individuality, nutritional biochemistry and functional medicine, though somewhat on hold during the Mayo years, is currently thriving in Durango. She is an adjunct faculty member of The Institute for Functional Medicine, and created a clinical module in Functional Neurology for IFM.

)2

(c

Florida. Dr. Tatum completed his medical degree at the Medical College of Georgia and his specialty training in psychiatry at the Shepard and Enoch Pratt Hospital in Baltimore, MD. He specializes in functional medicine, wellness, psychiatry, psychotherapy, microcurrent therapy, ADHD, learning disabilities, relationship therapy, and personal growth. He uses quantitative electroencephalograms, neurofeedback, and Tomatis Listening Therapy. He was the first to introduce and write about the synergy of combining Tomatis sound stimulation with simultaneous learning disability remediation. Although the field of psychotherapy focuses mostly on cognitive behavioral therapy, Dr. Tatum believes it is what is programmed into the deeper unconscious that causes most people their repetitive psychological problems, and this can be accessed through the body’s subtle energy system. He has developed techniques for integrating bioenergetics into psychotherapy and has written and lectured on this at a national level. By using this multimodality approach and allying with the body’s powerful forces for healing and growth, people can achieve levels of healing and growth not possible with a medication-only model. Alex Vasquez, DC, ND, completed his undergraduate work in human biology by studying disorders of iron metabolism, and later published some of his findings in Nutritional Perspectives and Arthritis & Rheumatism. He graduated from Western States Chiropractic College with his Doctor of Chiropractic degree before attending Bastyr University, where he received his Doctor of Naturopathic Medicine degree. While maintaining a private practice in Seattle, Dr. Vasquez served as Adjunct Professor of Orthopedics, Rheumatology, and Radiographic Interpretation at Bastyr University, and he began work on his 486-page textbook, Integrative Orthopedics: The Art of Creating Wellness While Effectively Managing Musculoskeletal Disorders (Natural Health Consulting Corp., 2004). Dr. Vasquez has lectured nationally and internationally to professional audiences, and his articles and letters have been published by Journal of the American Medical Association, British Medical Journal, The Lancet, Alternative Therapies in Health and Medicine, and many other peer-reviewed medical journals. David Wickes, DC, is Executive Vice President and Provost at the Western States Chiropractic College in Portland, Oregon. He graduated in 1977 from the National College of Chiropractic (NCC) and completed a two-year residency in chiropractic family practice. He

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

2010 Edition Update

e

in

ic

ed

Kara N. Fitzgerald, ND, received her doctorate in naturopathic medicine from National College of Naturopathic Medicine in Portland, Oregon. She completed CNME-accredited postdoctoral training in laboratory science with concurrent residency training at an integrative medical center in Atlanta, Georgia. Dr. Fitzgerald is a contributing author to Laboratory Evaluations for Integrative and Functional Medicine and is co-authoring and editing a book of case studies in integrative medicine. She is adjunct faculty at The Institute for Functional Medicine. She also lectures internationally on the clinical application of functional laboratory interpretation. Dr. Fitzgerald maintains a clinical practice at Advanced Diagnostic, in New Haven, Connecticut.

799

Textbook of Functional Medicine

Comprehensive Elimination Diet—Sample Patient Handouts Introduction

Guidelines A 7-Day Menu Plan (including recipes) and three tables are included with these materials: • Table 1—Foods to Include and Exclude. Eat only the foods listed under “Foods to Include,” and avoid those foods shown under “Foods to Exclude.” If you have a question about a particular food, check to see if it is on the food list. You should, of course, avoid any foods (listed or not) to which you know you are intolerant or allergic. Some of these guidelines may change based upon your personal health condition and history. • Table 2—Shopping List • Table 3—Food Reintroduction Chart

)2

(c

The Comprehensive Elimination Diet is a dietary program designed to clear the body of foods and chemicals you may be allergic or sensitive to, and, at the same time, improve your body’s ability to handle and dispose of these substances. We have called this an “Elimination Diet” because we will be asking you to remove certain foods, and food categories, from your diet. The main rationale behind the diet is that these modifications allow your body’s detoxification machinery, which may be overburdened or compromised, to recover and begin to function efficiently again. The dietary changes help the body eliminate or “clear” various toxins that may have accumulated due to environmental exposure, foods, beverages, drugs, alcohol, or cigarette smoking. In our experience, this process is generally well tolerated and extremely beneficial. We obviously hope that you will find it useful too. There is really no “typical” or “normal” response. A person’s initial response to any new diet is highly variable, and this diet is no exception. This can be attributed to physiological, mental, and biochemical differences among individuals; the degree of exposure to, and type of “toxin”; and other lifestyle factors. Most often, individuals on the elimination diet report increased energy, mental alertness, decrease in muscle or joint pain, and a general sense of improved well-being. However, some people report initial reactions to the diet, especially in the first week, as their bodies adjust to a different dietary program. Symptoms you may experience in the first week or so can include changes in sleep patterns, lightheadedness, headaches, joint or muscle stiffness, and changes in gastrointestinal function. Such symptoms rarely last for more than a few days. We realize that changing food habits can be a complex, difficult and sometimes confusing process. It doesn’t have to be, and we think that we have simplified the process with information to make it a “do-able” process. Peruse this information carefully. Bon appétit!

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

A few suggestions that may be of help: • You may use leftovers for the next day’s meal or part of a meal, e.g., leftover broiled salmon and broccoli from dinner as part of a large salad for lunch the next day. • It may be helpful to cook extra chicken, sweet potatoes, rice, and beans, etc. that can be reheated for snacking or another meal. • If you are consuming coffee or other caffeinecontaining beverages on a regular basis, it is always wise to slowly reduce your caffeine intake rather than abruptly stop it; this will prevent caffeinewithdrawal headaches. For instance, try drinking half decaf/half regular coffee for a few days, then slowly reduce the total amount of coffee. • Select fresh foods whenever you can. If possible, choose organically grown fruits and vegetables to eliminate pesticide and chemical residue consumption. Wash fruits and vegetables thoroughly. • Read oil labels; use only those that are obtained by a “cold pressed” method. • If you select animal sources of protein, look for freerange or organically raised chicken, turkey, or lamb. Trim visible fat and prepare by broiling, baking, stewing, grilling, or stir-frying. Cold-water fish (e.g., salmon, mackerel, and halibut) is another excellent source of protein and the omega-3 essential fatty acids, which are important nutrients in this diet.

800

Appendix

Finally, anytime you change your diet significantly, you may experience such symptoms as fatigue, headache, or muscle aches for a few days. Your body needs time as it is “withdrawing” from the foods you eat on a daily basis. Your body may crave some foods it is used to consuming. Persevere. Those symptoms generally don’t last long, and most people feel much better over the next couple of weeks.

• Remember to drink at least two quarts of plain, filtered water each day. • Strenuous or prolonged exercise may be reduced during portions of this program (or even during the entire program) to allow the body to heal more effectively without the additional burden imposed by exercise. Adequate rest and stress reduction are also important to the success of this program.

)2

(c 0

01 e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 801

Textbook of Functional Medicine

7-Day Menu Plan This suggested day-by-day menu that can be followed for one week while on the Comprehensive Elimination Diet is intended only as a sample; it can be modified according to the patient’s preferences. Serving sizes in each recipe are approximate and can be adapted to the patient’s appetite. Foods from different days may be mixed and matched differently, according to the patient’s preferences. Substitutions are allowed as long restricted foods are avoided. For example, many instant or canned soups from the health food store are acceptable, but all labels must be read to be sure.

Dinner Broiled lamb chop Nutty green rice or mock mac’n cheese Cooked veggie mix: • steam broccoli, cauliflower, and carrots • toss with olive oil and herbs (oregano, thyme, basil, tarragon, etc.) Fruity spinach salad DAY 3

)2

(c

Breakfast Nutri-Ola or crispy brown rice or puffed rice or puffed millet cereal • served with rice or almond milk, topped with sliced berries Leftover applesauce bread or banana bread

01

DAY 1

0

Lunch Brown rice and black beans mix • topped with flax oil • garnished with chopped scallions and sliced avocado or guacamole Baking powder biscuits Tropical fruit salad • sliced mango, kiwi, and strawberries • topped with shredded unsweetened coconut and chopped walnuts or pecans

Lunch Lentil soup or split pea soup or black bean soup Sesame rice crackers or rice cakes Carrot and celery sticks Fresh figs, plums, or cherries

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Breakfast Cooked whole grain cereal (oatmeal, cream of brown rice, buckwheat, teff, or quinoa flakes) • served with rice, oat, or almond milk, cinnamon, and allowable sweetener of your choice • garnished with chopped walnuts, almonds, hazelnuts, or toasted pumpkin seeds • topped with fresh or frozen unsweetened fruit

Dinner Broiled or poached halibut Baked butternut or acorn squash, sprinkled with cinnamon Chopped zucchini, red peppers, garlic, and onion sautéed in olive oil, topped with basil Mixed green salad with vinaigrette dressing • choose greens from arugula, endive, radicchio, red leaf, romaine, butter head, Boston, cabbage, dandelion, escarole; add red cabbage, garbanzo beans, red onion, olives, carrots Mochi rice squares and fresh fruit

e

in

ic

ed

Dinner Broiled salmon Cooked millet or baked white or sweet potato or quinoa salad Oven-roasted veggies Mixed green salad with vinaigrette dressing Crispy rice squares or fresh apple

DAY 4

DAY 2

Breakfast Sweet potato delight and/or leftover Nutri-Ola square Cantaloupe half, filled with blueberries and sprinkled with cinnamon

Breakfast Fruit Smoothie: • blend rice or almond milk with ½ banana and/or pineapple slice and one or two ice cubes • add flax powder or other fiber if desired Applesauce bread or banana bread

Lunch Leftover brown rice and black beans mix or Halibut salad: • Mixed greens of your choice • chopped vegetables with garbanzo or kidney beans • leftover halibut cut into chunks • vinaigrette dressing Fresh banana or leftover crispy rice squares

Lunch Asparagus soup (or yesterday’s leftover soup) Cabbage salad Rice cakes with walnut butter Fresh peach or pear

802

Appendix

Dinner Skinless chicken, oven baked or broiled, sprinkled with garlic powder and tarragon Brown rice or wild rice, or basic kasha, dressed with flax or sesame oil Asparagus, cut into 1-inch pieces and stir-fried in olive oil and garlic Gingerbread

Dinner Roast turkey breast or broiled turkey burger or spiced lentil casserole Brown rice and peas Steamed broccoli, carrots, and/or green beans topped with flax oil and herbs of choice Baked apple DAY 7

DAY 5

Breakfast Toasted rice bread topped with pear butter or Rice pancakes topped with pear butter or sautéed apples Cantaloupe chunks

Breakfast Mochi rice waffles, topped with sautéed apples Fruit smoothie: • blend rice or almond milk with a peach and/or raspberries and one or two ice cubes • add flax powder or other fiber if desired

)2

(c

Lunch Turkey salad: • Mixed greens or mix of cannelini beans, celery, scallions, and apple chunks, • Nutty mayo or hummus Cucumber slices marinated in rice vinegar and dill Rice crackers Banana

0

01

Lunch Quinoa salad or Chicken salad: • mixed greens • leftover chicken, cut into pieces • your choice of guacamole or nutty mayo Beans and greens soup Rice cakes or rice bread with pear honey or unsweetened apple butter

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Dinner Rice pasta primavera or black beans and yellow rice Pickled beets Mixed green salad with cherry tomatoes and vinaigrette dressing Leftover breakfast rice pudding topped with dried apples

Dinner Fresh tuna, topped with herbs (tarragon, dill, or parsley), and broiled Rice pasta with olive oil and mock pesto or baked sweet potato topped with flax oil Steamed vegetables: kale or collard greens tossed with olive oil and garlic Mixed green salad with kidney beans and vinaigrette dressing Fresh fruit salad: mango and pineapple chunks, sliced kiwi

Snack Suggestions

ed

Rice cakes or rice crackers spread with: • almond or cashew nut butter or • apple butter or • pear honey Sesame rice crackers and hummus Fresh fruits (except orange) Fresh raw veggie wedges Nuts and seeds (except peanuts) Crispy rice squares, gingerbread Mochi rice squares, plain, with smashed berries or nut butters Sparkling mineral water or seltzer with unsweetened fruit juice

in

ic

DAY 6

e

Breakfast Meal in a muffin or breakfast rice pudding Rice milk, oat milk, or almond milk; berries, sweetener, and pecans Lunch Tuna salad: • leftover tuna, mashed and mixed with: • hummus (made with only natural food ingredients) Leftover beans and greens soup Baking powder biscuits Fresh pear or nectarine

803

Textbook of Functional Medicine

Recipes for 7-Day Menu (in alphabetical order) Applesauce Bread—Yields 14 slices

Remove peel from top third of each apple and arrange in a small baking dish. In a medium saucepan, combine other ingredients and bring to a boil, stirring frequently. Reduce heat and simmer 2–3 minutes, until slightly thickened. Distribute raisins, filling centers of each apple. Pour sauce over apples and bake, uncovered, at 350 degrees for 1 to 1½ hours. Baste occasionally and remove from oven when apples are pierced easily with a fork. Spoon juice over apples and serve warm.

1 cup teff flour 1 cup oat or rice flour 1 tsp. baking soda ½ tsp. cinnamon ¼ tsp. salt ¼ tsp. nutmeg 1 cup unsweetened applesauce 1 tbsp. safflower or sesame oil ½ cup brown rice syrup or fruit juice concentrate egg replacer to equal 1 egg (recipe under Baking Tips) 3–4 tbsp. apple butter 1 tsp. pure vanilla extract

Baking Powder Biscuits—Makes one dozen

)2

(c

1½ cups brown rice flour ½ cup tapioca flour 4 tsp. baking powder 1/8 tsp. salt 3 tbsp. safflower or sesame oil 1 cup applesauce, unsweetened

0

01

Combine the dry ingredients in a large bowl. Combine the wet ingredients in a small bowl and mix into the dry ingredients. Pour into oiled 9-inch square pan. Bake at 350 degrees for 30 minutes.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Preheat oven to 425 degrees. In a medium-large mixing bowl, stir together dry ingredients. Sprinkle oil on top and mix well with a pastry blender or fork, until consistency is crumbly. Mix in applesauce and stir until blended. Spoon heaping tablespoonfuls onto ungreased cookie sheet. With spoon, lightly shape into biscuit. Bake 15–18 minutes until slightly browned. Serve warm for best flavor, but may be lightly reheated in a microwave.

Asparagus Soup—Serves 4 Used with permission from “The Allergy Self Help Cookbook,” by Marjorie Hurt Jones, R.N. Rodale Press, Emmaus, Pa. 1 lb. asparagus, trimmed 2 medium leeks or 4 large shallots 1 tbsp. oil 2–3 cloves garlic, minced 2 cups water, vegetable, or chicken stock (or a combination) 1 tsp. dried dill weed pinch nutmeg

Banana Bread—Yields 14 slices

¼ cup walnuts, ground finely in blender 1¾ cups brown rice flour ½ cup arrowroot 2 tsp. baking soda ¼ tsp. salt ½ cup chopped walnuts 1½ cups ripe mashed banana ¼ cup safflower or sesame oil 6 tbsp. apple juice concentrate egg replacer to equal 2 eggs (recipe under Baking Tips) 1 tsp vanilla extract

e

in

ic

ed

Slice off the tips of the asparagus and reserve them. Cut the remaining stalks into 1” pieces. Slice the leeks in half lengthwise and wash under cold water to remove any sand. Slice into ¼“ pieces. Sauté the leeks or shallots in the oil over medium heat until soft. Add the garlic and sliced asparagus stalks. Cook, stirring, another minute or two. Add the water or stock and dill. Simmer 10–12 minutes. Remove from heat, allow to cool 5–10 minutes. Puree half the volume at a time. Return to pan, add the reserved asparagus tips and simmer 3–5 minutes or until tips are just barely tender. Add nutmeg. If soup is too thick, thin with additional water or stock.

Preheat oven to 350 degrees. Mix finely ground walnuts with flour, arrowroot, baking soda and salt in a large bowl. Stir in the chopped walnuts. In a separate bowl, mix together the banana, oil, apple juice, egg replacer, lemon and vanilla. Add to the flour mixture and stir until just moistened. Do not overmix. Pour into a greased 9” x 5” loaf pan and bake for 55–60 minutes or until cake tester inserted in middle comes out clean. Cool in pan for 10 minutes, then remove from pan and cool on wire rack.

Baked Apple—Serves 6 1/3 cup golden raisins 2 tbsp. apple juice 6 cooking apples, cored 1½ cups water ¼ cup frozen unsweetened apple juice concentrate 2 tsp. pure vanilla extract 1 tsp. cinnamon 1 tsp. arrowroot

804

Appendix

Basic Kasha—Serves 4–5

½ tsp. turmeric 1 cup uncooked long-grain brown rice

1 cup buckwheat groats 2 cups water, chicken or vegetable broth (or a combination)

In a 2-quart saucepan over low heat, sauté onions in oil until tender, about 5 minutes. Add the garlic and sauté 1 minute. Stir in turmeric, then rice. Add stock. Bring to a boil, cover and simmer 45 minutes over low heat, or until rice is tender and all liquid is absorbed. Do not stir. Spoon beans over rice.

Roast the dry buckwheat groats over medium heat in a dry skillet, stirring until the grains begin to smell toasty, about 2 minutes. Add the water or broth, cover and simmer for 20–30 minutes, until kasha is tender but not mushy. Pour off any excess liquid. Optional: add onion, garlic and herbs to the dish.

Breakfast Bars

Beans and Greens Soup—Serves 4–5

Add egg replacer (recipe under Baking Tips) to equal 2 eggs to Nutri-Ola (recipe below). Slowly add additional water to make a stiff batter. Follow directions for Nutri-Ola, but spread into an 8- or 9-inch square pan (ungreased) and bake at 350 degrees about 30 minutes. Cut into squares when done.

)2

(c

2 cups cooked white beans 2 tbsp. olive oil 2 medium cloves garlic, crushed 1 large onion, chopped 1 bay leaf 1 stalk celery, diced 2 medium carrots, diced 1 tsp. salt fresh black pepper 6 cups water, vegetable or chicken broth (or a combination) ½ lb. fresh chopped escarole, spinach, chard, or collards (or a combination)

01

Breakfast Rice Pudding—Serves 4

0

1 cup uncooked short grain brown rice 1¼ cups coconut milk 1¼ cups water ½ tsp. salt 1 tbsp. brown rice syrup 1 tsp. cinnamon chopped almonds or sunflower seeds or other nuts of choice or a mixture (optional)

lM na tio d. un rve r F se fo re te ts itu h st rig In All

In a 4–6 quart soup pot, sauté the onions and garlic in olive oil over low heat. When onions are soft, add bay leaf, celery, carrot, salt and pepper. Stir and sauté another 5 minutes. Add broth or water and cover. Simmer about 20 minutes. Add cooked beans and your choice of greens. Cover and continue to simmer, over very low heat, another 15–20 minutes. Serve immediately or refrigerate and reheat. Black Beans and Yellow Rice—Serves 4

Combine water and coconut milk in heavy pot; bring to boil, adding rice and salt. Simmer, covered (do NOT stir) for about 45 minutes or more, until liquid is mostly absorbed and rice is soft. Remove from heat and allow to cool for 15 minutes. Stir in brown rice syrup and cinnamon and top with nuts or seeds as desired. Brown Rice and Peas—Serves 4

ed

Black Beans 1 cup dry black beans, soaked overnight and drained 4 cups water 1 small onion, chopped 1 small carrot, chopped 2 cloves garlic, minced 1 bay leaf 1 tsp. cumin

e

in

ic

Add 1 cup of green peas (either fresh and lightly steamed or frozen and just defrosted baby peas) to 2 cups of cooked brown rice. Top with your favorite herbs and flax oil to taste. Cabbage Salad—Serves 4–6

1 small to medium head red cabbage, thinly sliced (or use half red and half green cabbage) 8 sliced radishes, and/or 1 grated carrot 3 green apples, diced 1 stalk celery, chopped ½ cup chopped walnuts or pecans (or mixture) dash garlic powder 2 tbsp. olive oil 2 tsp. vinegar 1 tsp. lemon juice

In a 3-quart saucepan, combine beans, water, onion, carrot, garlic, bay leaf, cumin, and pepper flakes. Bring to a boil over medium heat and simmer, uncovered, about 2½ hours, or until beans are tender and almost all liquid is absorbed. Discard bay leaf. (May be made up to 2 days ahead; reheat before serving.) Yellow Rice 2 cups chicken or vegetable stock 1 small onion, finely chopped 2 tsp. olive oil 1 clove garlic, minced

Mix all ingredients in a bowl and allow to rest and blend for an hour, stirring once or twice. Serve cold or at room temperature.

805

Textbook of Functional Medicine

Crispy Rice Squares—2 dozen

In a large mixing bowl, combine the agave nectar and oil. Beat on high speed until thoroughly blended. Add in the eggs, one at a time. Be sure to beat well between eggs. Add in the orange rind and vanilla and continue to blend together. Set aside.

1 tsp. cold pressed canola oil ½ cup brown rice syrup 2 tbsp. sesame tahini or almond butter 3 tsp. vanilla extract 2 cups crispy brown rice cereal 2 cups puffed rice 2 cups puffed millet or Perky’s Nutty Rice ½ cup pumpkin or sunflower seeds ½ cup currants or chopped dried apple or chopped dates

Meanwhile, preheat the oven to 350 degrees and spray a 9 x 9 square pan with a nonstick spray. Sift together the dry ingredients and add the nuts. Add some of the dry ingredients to the wet ingredients, a little at a time, blending well. Add in ¼ cup of the applesauce, blend, then add in more flour. Continue this process until you have added all of the ingredients. Pour the batter into the prepared pan and bake for 20–25 minutes, or until the gingerbread is done. Check for doneness by inserting a toothpick, or touching lightly on the center. Freezes well.

(c

Heat oil in a large pot; add rice syrup and tahini or almond butter. Stir until bubbly. Remove from heat and stir in vanilla. Add remaining ingredients and mix well with a wooden spoon. Press into an ungreased 13 x 9 pan and press mixture flat. Let mixture rest at room temperature or refrigerate. Cut into squares. Store in an airtight container.

)2

Guacamole—Makes 1½–2 cups Used with permission from “The Allergy Self Help Cookbook,” by Marjorie Hurt Jones, R.N. Rodale Press, Emmaus, Pa.

01

Fruity Spinach Salad—Serves 6–8

0

2–3 ripe avocados ¼ cup chopped onions ¼ tsp. vitamin C crystals 1 tbsp. water 1 small clove garlic, chopped

Dressing: 2 tbsp. sesame seeds 1 tbsp. poppy seeds 2 scallions, chopped ¼ cup flax seed oil ¼ cup safflower oil ¼ cup balsamic vinegar

lM na tio d. un rve r F se fo re te ts itu h st rig In All

1 lb. fresh spinach, washed, dried, torn into pieces 1 pint fresh organic strawberries or raspberries, washed ½ cup chopped walnuts or sliced almonds

Cut the avocados in half, remove the pits, then scoop the flesh into a blender or food processor. Add the onions, vitamin C crystals, water, and garlic. Process until smooth. Transfer to a small bowl. Cover and chill. Use within 2–3 days. To prevent darkening, coat top with a thin layer of oil. For a chunky version, mash the avocado with a fork and finely chop onions and garlic.

Cut berries in half and arrange over spinach in serving bowl. Combine dressing ingredients in blender or food processor and process until smooth. Just before serving, pour over salad and toss. Garnish with nuts.

Lentil Soup—Serves 4

ed

2 cloves garlic, minced 1 medium onion, chopped 2 large carrots, sliced or chopped 2 stalks celery, chopped 1½ cups red and/or green lentils, well rinsed 2 quarts water or broth pinch thyme or any herbs of your choice Salt to taste

e

in

ic

Gingerbread—9 squares Adapted with permission from “Gluten-Free, Sugar-Free Cooking” by Susan O’Brien, Da Capo Press, 2006. ½ cup pecans or walnuts, finely chopped ½ cup agave nectar (preferred) or fruit sweetener ¼ cup canola oil egg replacer to equal 2 eggs (see Baking Tips) 1 tsp vanilla 1½ cups brown rice flour ½ tsp salt 1 tsp baking powder 1 tsp baking soda 2 tsp ginger 1½ tsp cinnamon ¼ tsp nutmeg 1/8 tsp cloves ½ tsp orange rind 1 cup unsweetened applesauce

Combine first 6 ingredients and bring to boil. Add seasonings. Reduce heat to medium-low and simmer, partially covered, until lentils are soft. Add herbs and salt about 5–10 minutes before cooking is finished. Green lentils need about 45 minutes to 1 hour, while red lentils only need 20–30 minutes. Puree half of the soup in the blender if you prefer a creamy soup.

806

Appendix

Cut the avocado in half and remove the pit. Scoop out the flesh and place it in bowl of a food processor. Add the basil, lemon juice, garlic and pine nuts. Process for about 2 minutes—scrape the bowl as necessary. Transfer it to a small bowl and coat the surface with oil to prevent browning. Chill.

Meal in a Muffin—Makes one dozen Adapted with permission from “Wheat-free Sugar-Free Gourmet Cooking” by Susan O’Brien, Gig Harbor, WA, 2001 1 medium carrot, grated 1 large apple, grated ¼ cup canola oil ¼ cup unsweetened applesauce egg replacer to equal 2 eggs (recipe under Baking Tips) 1/3 cup Mystic Lake Dairy sweetener 2 tsp. vanilla ¼ cup garbanzo bean flour ½ cup brown rice flour ¼ tsp. cinnamon ½ tsp. baking powder ¼ tsp. ginger 1/8 tsp. nutmeg ¼ cup shredded unsweetened coconut ½ cup chopped dates

Nutri-Ola (basic recipe)—Serves 10 Adapted with permission from “Allergy Recipes,” by Sally Rockwell, Nutrition Survival Press, Seattle, Washington

)2

(c

2 cups arrowroot or millet flour or finely ground filberts, pecans, almonds, walnuts, or sesame seeds 1 cup filberts or walnuts, coarsely ground 1 cup whole sesame seeds or sunflower seeds (or a combination) 1 cup (combined) finely chopped dried apples, papaya, apricots, currants ½ cup fruit puree or frozen fruit concentrate ½ cup sesame or walnut or sunflower oil 2 tsp. pure vanilla or almond extract

0

01

Preheat oven to 275 degrees. Use a blender or food processor to grind nuts, grains, or seeds to desired consistency. Mix the nuts, seeds and/or grains in a large bowl. Mix with fruit and sweetener, oil and vanilla. Pour over the dry mixture and stir lightly. Spread mixture into a lightly oiled 15” x 10” x 1” baking pan. Bake for 1 hour, stirring every 15 minutes. Cool. Break into small pieces for cereal or large chunks for snacks.

Mochi Rice Waffles—Serves 4

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Preheat oven to 375 degrees. Mix together all wet ingredients and set aside. In a separate bowl, mix dry ingredients then mix both together. Lightly coat muffin tins with oil spray. Fill 3/4 full and bake 15–20 minutes or until toothpick comes out clean. Allow to cool on a rack.

Nutty Green Rice—Serves 4

Purchase 1 package of cinnamon-apple Mochi and defrost. Cut into quarters. Slice each quarter across to form 2 thinner squares. Place one square into preheated waffle iron and cook until done. Top with your choice of fruit or sautéed apples (recipe below).

1 cup brown basmati rice 2 cups water ¼ to ½ tsp salt ½ cup almonds 1 bunch parsley 1 clove garlic 1½ tbsp. lemon juice 1½ tbsp. olive oil ½ cucumber, diced pepper to taste

ed

Mock Mac’n Cheese—Servings depend on amounts of ingredients used

e

in

ic

Cook desired amount of brown rice pasta according to package instructions. Toss cooked pasta with olive oil and sprinkle with several tablespoons of nutritional yeast. The yeast gives the pasta a cheese-like taste.

Bring water to a boil, add rice and salt, stir and simmer, covered, for 45 minutes. Remove from heat and let sit for another 10 minutes; then remove cover and allow to cool. While rice is cooking, blend almonds, parsley, garlic, and oil in a food processor. When rice is cool, stir with nut mixture and add pepper to taste. Garnish with cucumber if desired.

Mock Pesto—Makes 1 cup Used with permission from “The Allergy Self Help Cookbook,” by Marjorie Hurt Jones, R.N. Rodale Press, Emmaus, Pa. 1 large ripe avocado 1 cup basil leaves ¼ tsp. lemon juice 1 garlic clove, minced or 1/8 tsp. garlic powder ¼ cup pine nuts ½ tsp. olive or flax oil

807

Textbook of Functional Medicine

Pickled Beets—Serves 4–6

Adapted and used with permission from “The Allergy Self Help Cookbook,” by Marjorie Hurt Jones, R.N., Rodale Press, Emmaus, Pa.

Adapted and used with permission from “The Allergy Self Help Cookbook,” by Marjorie Hurt Jones, R.N., Rodale Press, Emmaus, Pa.

½ cup cashews or other nuts ¾ cup water 3 tbsp. vinegar 2 tbsp. oil 1 tbsp. arrowroot 1 tbsp. brown rice syrup 1 tbsp. minced parsley 1 tbsp. snipped chives 1½ tsp. dry mustard

4 beets, cooked and skinned ¼ cup water 1 tbsp. brown rice syrup or fruit sweetener ¼ cup rice vinegar ¼ tsp. ground cinnamon pinch each of cloves and allspice Combine the water, sweetener, vinegar, cinnamon, cloves and allspice in a medium saucepan. Simmer for 2 minutes. Stir in the beets, and heat through. Serve hot or warm.

Grind the nuts to a fine powder in a blender. Add the water, blend 1 minute to make sure the nuts are fully ground. Add the vinegar, oil, arrowroot, sweetener, and seasonings. Blend until very smooth. Pour into a saucepan and cook a few minutes, until thick. Allow to cool, transfer to a glass jar. Store in the refrigerator.

Quinoa Salad—Serves 8–10

(c

Nutty Mayo—Makes 1¼ cups. Keeps well for 3 weeks

)2

1½ cups quinoa, rinsed several times 3 cups water, or chicken or vegetable broth (or a combination) 1 cup fresh or frozen peas (frozen baby peas should be just defrosted) chopped veggies, raw or lightly steamed (broccoli, asparagus, green beans, etc.) ½ cup chopped red onion 1 pint cherry tomatoes (optional) ½ cup chopped black olives (optional) 1/3 cup olive oil 2 tbsp. balsamic vinegar or lemon juice 1 or 2 crushed garlic cloves 2–4 tbsp. fresh dill, chopped (or 1 tbsp. dried dill) 2 tbsp. chopped fresh parsley salt and pepper to taste

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Oven-roasted Veggies—number of servings depends on amount of veggies used

Use any combination of the following vegetables, unpeeled, washed, and cut into bite-sized pieces: eggplant, small red potatoes, red onion, yellow or green summer squash, mushrooms, asparagus. Toss with crushed garlic cloves and olive oil and sprinkle with rosemary, oregano, tarragon, and basil to taste. Spread in roasting pan in single layers and roast approximately 20–25 minutes at 400 degrees until veggies are tender and slightly brown, stirring occasionally. The amount of time needed depends on the size of the veggie pieces. Salt and pepper to taste. Serve while warm, or use cold leftovers in salad.

Rinse quinoa well (quinoa tastes bitter if not well rinsed). Bring 3 cups water or broth to a boil. Add rinsed quinoa and bring back to boil. Simmer uncovered for about 15 minutes until liquid is well absorbed. Transfer to large bowl with a small amount of olive oil to prevent sticking, and allow to cool. Meantime, mix together remaining oil, vinegar or lemon juice, parsley, and garlic in a small bowl. Add veggies to quinoa and toss well with dressing mixture, dill, salt and pepper. Chill before serving.

ic

ed

Pear Honey—Makes 3 pints Used with permission from “The Allergy Self Help Cookbook,” by Marjorie Hurt Jones, R.N. Rodale Press, Emmaus, Pa.

e

in

15 very ripe pears ½ cup water ½ cup brown rice syrup or fruit juice sweetener

Rice Pancakes—Makes approximately 14 (4-inch) pancakes Peel, quarter and core the 15 pears. Place 12 of the pears in a stainless steel or enamel Dutch oven or 3 quart saucepan. Coarsely chop the remaining 3 pears. Place them and the water in a blender. Process until pureed. Pour into the pan with the pear quarters.

1 1/3 cups rice flour ½ cup oat or millet flour 2 tsp. baking powder ½ tsp. baking soda ¼ tsp. salt 1 tbsp. apple butter 1 tbsp. safflower or sesame oil egg replacer to equal 2 eggs (recipe under Baking Tips) 1½ cups almond, oat, or rice milk 1½ tbsp. white vinegar

Bring to a boil, then reduce the heat to a simmer. Stir in the sweetener. Cook until pears are tender, about 30 minutes. Purée the cooked fruit in batches using a blender or food processor. The purée should be about the consistency of honey. If too thin, return it to the pan and boil it down a bit. If too thick, dilute with a little juice. Pour into jars, and store in the refrigerator for up to 1 month.

808

Appendix

Mix the almond or rice milk with the vinegar and allow the mixture to stand for 5 minutes until curdles form. Mix dry ingredients together and set aside. In large mixing bowl, beat apple butter, oil, egg, and milk. Add dry mixture and stir gently. Be careful not to overmix. Serve with sautéed apples (recipe below).

Split Pea Soup—Serves 6 3 cups dry split peas, well rinsed 2 quarts water 1 tsp. salt 1 bay leaf ½ –1 tsp. dry mustard 2 onions, chopped fine 4 cloves garlic, minced 3 stalks celery, chopped 2 medium carrots, sliced salt and pepper to taste 3 tbsp. apple cider vinegar or rice vinegar

Rice Pasta Primavera—Serves 4 2 cups uncooked rice pasta (noodles, spaghetti, elbows) 1 large whole chicken breast, cut into thin strips (optional) broccoli florets, chopped carrot, and/or other favorite veggie, lightly steamed 3-4 scallions, chopped 2 cloves garlic, minced 1 tbsp. olive oil (more if needed) ¼ cup fresh basil, finely chopped ¼–½ cup coconut milk Cook rice pasta according to package directions. While pasta is cooking, heat oil in wok or heavy frying pan, and stir fry chicken strips (or tofu chunks), garlic, scallions, and basil for about 5 minutes; add remaining vegetables and coconut milk and continue to cook until veggies are soft and glisten. Add more coconut milk as needed. Remove from heat and spoon over drained rice pasta and garnish with black olives and extra olive oil, if desired.

)2

(c

Combine peas, water, salt, bay leaf, and mustard in 6-quart pot. Bring to boil, reduce heat and simmer, partially covered for about 20 minutes. Add vegetables and simmer for another 40 minutes, stirring occasionally. Add more water as needed. Add salt, pepper, and vinegar to taste.

01

0

Sweet Potato Delight—Serves 1–2 Adapted and used with permission from “The Allergy Self Help Cookbook,” by Marjorie Hurt Jones, R.N., Rodale Press, Emmaus, Pa.

2 apples, washed ½ tbsp. safflower oil or canola oil 2 tsp. cinnamon 2–3 tbsp. apple juice

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Sautéed Apples—Serves 2

2–4 tbsp. chopped nuts 1 ripe banana 1 medium sweet potato, cooked 1 tsp. oil 1 tbsp. fruit sweetener, molasses, or brown rice syrup (optional) In a large frying pan, dry roast the nuts over medium heat for a few minutes. Shake the pan often. Cut the banana in half lengthwise. Cut the cooked sweet potato into ½ " pieces. Add the oil to the pan. Push the nuts to the outer edges. Place the banana pieces, flat sides down, in the pan. Add the sweet potatoes. Cover and cook for 2 minutes. Uncover, and cook for 5 minutes, until everything is heated through and browned on one side. Add the sweetener before serving.

ed

Thinly slice apples and sauté in oil until softened. Add cinnamon and apple juice and simmer, stirring, uncovered for a few more minutes.

ic

Spiced Lentil Casserole—Serves 4

in

Vinaigrette Dressing—6 servings (approximately)

e

1½ cups lentils, rinsed well 2 tbsp. sesame oil 3 cloves garlic, crushed 1 stalk celery, chopped 1 large onion, chopped ½ tsp. salt 1 cup shredded, unsweetened coconut ½ tsp. cinnamon ½ tsp. powdered ginger ½ tsp. turmeric 2 large green apples, washed and diced

Note: Ingredient amounts in this recipe are approximate; use more or less of certain ingredients to adapt recipe to your personal taste. ¼ cup each flax and extra-virgin olive oils 3 tbsp. balsamic vinegar (preferred because it has the richest flavor) 2–3 tbsp. water 1 tsp. dry mustard 1–3 cloves fresh garlic (whole pieces for flavor or crushed for stronger taste) Salt and pepper to taste Oregano, basil, parsley, tarragon or any herbs of your choice, fresh or dried

Simmer lentils, covered, in 2½ cups water for 30–40 minutes, until tender. While they are cooking, in a wok or heavy skillet, sauté remaining ingredients, except apples, in oil until tender. Add water as necessary. Add apples and cook 10 more minutes covered. Combine with cooked lentils in a casserole dish.

Place vinegar, water, and mustard in a tightly capped jar, and shake well to thoroughly dissolve mustard. Add oil and remaining

809

Textbook of Functional Medicine

ingredients and shake well again. Refrigerate and shake well before using. Dressing will harden when cold; allow 5-10 minutes to re-liquify.

Egg Replacer (equals one egg) 1/3 cup water 1 tbsp. whole or ground flaxseed

Baking Tips Finely-ground nut meal is included in muffin recipes, in addition to chopped nuts, because it helps retain moisture and allows for a small amount of leavening.

Combine the water and flaxseed and allow to jell for about 5 minutes. This mixture will bind patties, meat loaves, cookies, and cakes as well as eggs do, but it will not leaven like eggs for souffles or sponge cakes. Increase amounts accordingly for additional egg replacement.

To grind soft nuts such as walnuts or pecans, use 1–2 tbsp. of the starch called for in the recipe and add to the grinding mixture to prevent clumping.

Corn Free Baking Powder 2 tsp. cream of tartar 2 tsp. arrowroot 1 tsp. baking soda

(c

The grinding may be done with a nut chopper, a small (very clean) coffee grinder, or by pulsing on a food processor. Particles should be fine enough to pass through a strainer. Grind only what you will need. If you are allergic to nuts, replace the amount of nut flour with an equal amount of another flour or starch called for in the recipe.

)2

Sift together to mix well. Store in an airtight container. Make small batches.

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 810

Appendix

Table 1. Typical Foods to Include and Exclude on an Elimination Diet Program Include

Exclude

Whole fruits, unsweetened, frozen or waterpacked, canned fruits and diluted juices

Oranges and orange juice

Dairy and dairy substitutes

Rice, oat, and nut milks such as almond milk and coconut milk

Dairy and eggs: milk, cheese, eggs, cottage cheese, cream, yogurt, butter, ice cream, frozen yogurt, non-dairy creamers

Grains and starch

Brown rice, oats, millet, quinoa, amaranth, teff, tapioca buckwheat, potato flour

Grains: corn and non-gluten grains: wheat, barley, spelt, kamut, rye, triticale

Animal protein

Fresh or water-packed fish, wild game, lamb, duck, organic chicken and turkey

Pork, beef/veal, sausage, cold cuts, canned meats, frankfurters, shellfish

Vegetable protein

)2

(c

Fruits

0

01

Split peas, lentils, and all dried beans other than soybeans

Soybean products (soy sauce, soybean oil in processed foods; tempeh, tofu, soy milk, soy yogurt, textured vegetable protein)

Sesame, pumpkin, and sunflower seeds, walnuts, hazelnuts, pecans, almonds, cashews, nut butters such as almond or tahini

Peanuts and peanut butter

Vegetables

All raw, steamed, sautéed, juiced or roasted vegetables

Corn, creamed vegetables

Oils

Cold-pressed olive, flax, walnut, safflower, grapeseed, sesame, almond, sunflower, canola, pumpkin, and coconut oils

Butter, margarine, shortening, processed oils, salad dressings, mayonnaise, and spreads

Drinks

Filtered or distilled water, non-caffeinated herbal teas, seltzer or mineral water

Alcohol, coffee and other caffeinated beverages, soda pop or soft drinks

Sweeteners

Brown rice syrup, agave nectar, stevia, fruit sweeteners, blackstrap molasses

Refined sugar, white/brown sugars, honey, maple syrup, high fructose corn syrup, evaporated cane juice, sucanat

Condiments

Vinegar, all spices, including salt, pepper, basil, carob, cinnamon, cumin, dill, garlic, ginger, mustard, oregano, parsley, rosemary, tarragon, thyme, turmeric

Chocolate, ketchup, relish, chutney, soy sauce, barbecue sauce, teriyaki, and other condiments

e

in

811

ic

Read Ingredient Labels Carefully! Things to watch for: Corn starch in baking powder and any processed foods. Corn syrup in beverages and processed foods. Vinegar in ketchup, mayonnaise and mustard is usually from wheat or corn. Breads advertised as gluten-free may contain spelt, kamut, rye. Many amaranth and millet flake cereals have corn. Many canned tunas contain textured vegetable protein, which is from soy. Look for low-salt versions which tend to be pure tuna, with no fillers. Multi-grain rice cakes may not be just rice. Purchase plain rice cakes.

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Nuts and seeds

Textbook of Functional Medicine

Table 2. Sample Shopping List for Use with an Elimination Diet Fruits Apples, applesauce Apricots (fresh) Bananas Blackberries Blueberries Cantaloupe Cherries Coconut Figs (fresh) Grapefruit Huckleberries Kiwi Kumquat Lemon, lime Loganberries Mangos Melons Mulberries Nectarines Papayas Peaches Pears Prunes Raspberries Strawberries All the above fruits can be consumed raw or juiced.

)2

(c

Onions Pak-Choi Parsley Potato Red leaf chicory Sea vegetables—seaweed, kelp Snow peas Spinach Squash Sweet potato & yams Swiss chard Tomato Watercress Zucchini All the above vegetables can be consumed raw, juiced, steamed, sautéed, or baked.

01 0

Beans All beans except soy Lentils—brown, green, red Split peas All the above beans can be dried or canned.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

in

ic

ed

Vegetables Artichoke Asparagus Avocado Bamboo shoots Beets & beet tops Bok choy Broccoflower Broccoli Brussels sprouts Cabbage Bell peppers Carrots Cauliflower Celery Chives Cucumber Dandelion greens Eggplant Endive Kale Kohlrabi Leeks Lettuce (red or green leaf; Chinese) Mushroom Okra

Nuts & Seeds Almonds Cashews Flax seeds Hazelnuts (Filberts) Pecans Pistachios Poppy seeds Pumpkin seeds Sesame seeds Sunflower seeds Walnuts All the above seeds can be consumed as butters and spreads (e.g., tahini). Non-Gluten Grains Amaranth Millet Oat Quinoa Rice—brown, white, wild Teff Buckwheat Vinegars Apple cider Balsamic Red wine Rice Tarragon Ume plum

812

Appendix

Herbs, Spices & Extracts Basil Black pepper Cinnamon Cumin Dandelion Dill Dry mustard Garlic Ginger Nutmeg Oregano Parsley Rosemary Salt-free herbal blends Sea salt Tarragon Thyme Turmeric Pure vanilla extract

Beverages Herbal tea (non-caffeinated) Mineral water Pure unsweetened fruit or vegetable juices Spring water Oils

)2

(c

Almond Flax seed Canola Grapeseed Olive Pumpkin Safflower Sesame Sunflower Walnut

01 0

Sweeteners Fruit sweetener (Mystic Lake Dairy, or Wax Orchards, or apple juice concentrate) Agave nectar Molasses, blackstrap only Rice syrup Stevia

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Cereals & Pasta Cream of rice Oats Puffed rice Puffed millet Quinoa flakes Rice pasta 100% buckwheat noodles Rice crackers and rice cakes

Condiments Mustard (made with apple cider vinegar) Nutritional yeast

e

in

ic

ed

Breads & Baking Arrowroot Baking soda Rice bran Gluten free breads Flours: rice, teff, quinoa, millet, tapioca, amaranth, garbanzo bean, potato, tapioca, oat, buckwheat Rice flour pancake mix Mochi

Flesh Foods Free-range chicken, turkey, duck Fresh ocean fish, e.g., Pacific salmon, halibut, haddock, cod, sole, pollock, tuna, mahi-mahi Lamb Water-packed canned tuna (watch for added protein from soy) Wild game Dairy Substitutes Almond milk Rice milk Coconut milk Oat milk

813

Textbook of Functional Medicine

Table 3. Sample Food Reintroduction Tracking Form Food Date or Day Time

Food

Digestion/ Bowel Function

Joint/ Muscle Aches

Headache Pressure

KidneyBladder Skin Function

Nasal or Chest Congestion

Energy Level

)2

(c 0

01 e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All Note: Please reintroduce only one new food at a time. Ingest it 2–3 times in the same day, and then assess your response over the next 48 hours. Wait two full days to see whether you have a reaction. You may insert different headings on this chart to correspond with whatever signs or symptoms you experience. Important indicators that must be charted include: digestion, bowel function, and energy level. If you require more space, use the back of this sheet and clearly mark the day, the food, and your symptoms. If you are unsure whether you had a reaction, retest the same food in the same manner (after the two-day waiting period).

814

Appendix

Cytochrome P450 Enzymes: Drug and Natural Product Substrates, Inhibitors, and Inducers

Cytochrome P450 1A2 Drug Substrate Riluzole Ropinirole Ropivacaine Tacrine: Cognex Theophylline—Theo-Dur Verapamil—Calan R-warfarin Zileuton—Zyflo Zolmitriptan—Zomig

)2

(c

0

01

Cabbage Ginkgo leaf Grapefruit skin Indole-3-carbinol Ipriflavone Nutmeg Mace Ipriflavone St. John’s Wort

Inhibitors Amiodarone Cimetidine Ciprofloxacin Citalopram Clarithromycin Diltiazem Enoxacin Erythromycin Acetaminophen Fluvoxamine Hops Isoniazid Ketoconazole Methoxsalen Mexiletine Nalidixic acid Norethindrone Norfloxacin Omeprazole Oral contraceptives Paroxetine Tacrine Ticlopidine Troleandomycin Zileuton

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Acetaminophen Amitriptyline—Elavil Caffeine Chlordiazepoxide Clomipramine—Anafranil Clopidogrel—Plavix Clozapine—Clozaril Cyclobenzaprine— Flexeril Desipramine—Norpramin Diazepam—Valium Estradiol—Estrace Flutamide Fluvoxamine—Luvox Haloperidol—Haldol Imipramine—Tofranil Levobupivacaine Mexiletine—Mexitil Mirtazapine—Remeron Naproxen Nortriptyline Olanzapine—Zyprexa Ondansetron—Zofran Pentazocine—Talwin Propafenone Propranolol—Inderal

Natural Substrate

815

Inducers Carbamazepine Charbroiled food Cruciferous vegetables Lansoprazole Omeprazole Phenobarbital Phenytoin Primidone Rosemary Rifampin Ritonavir Smoking St. John’s Wort

Textbook of Functional Medicine

Cytochrome P450 2C9 Drug Substrate Omeprazole Ondansetron—Zofran Phenytoin Piroxicam Rosiglitazone Sildenafil Sulfamethoxazole Tacrine—Cognex Tolbutamide Torsemide Valdecoxib Valsartan Verapamil— Calan Voriconazole S—Warfarin—Coumadin Zafirlukast Zileuton-Zyflo

Ipriflavone St. John’s Wort

)2

(c

0

01

Inhibitors

Inducers

Amiodarone Chloramphenicol Cimetidine Clopidogrel Cotrimoxazole Delavirdine Disulfiram Efavirenz Fenofibrate Fluconazole Fluorouracil Fluoxetine Fluvastatin Fluvoxamine Gemfibrozil Imatinib Isoniazid Itraconazole Ketoconazole Leflunomide Lovastatin Metronidazole Milk Thistle Modafinil Omeprazole Paroxetine Sertraline Sulfonamides Ticlopidine Voriconazole Zafirlukast

Aprepitant Carbamazepine Phenobarbital Primidone Rifampin Rifapentine

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Amitriptyline—Elavil Carvedilol Celecoxib Clomipramine—Anafranil Clopidogrel—Plavix Clozapine—Clozaril Desogestrel Diazepam—Valium Diclofenac Dronabinol Estradiol (Estrace) Fluoxetine—Prozac Flurbiprofen Fluvastatin—Lescol Formoterol Glimepiride Glipizide Glyburide Grepafloxacin—Raxar Ibuprofen Imipramine—Tofranil Indomethacin Irbesartan Losartan—Cozaar Mefenamic acid Meloxicam Mirtazapine—Remeron Montelukast Naproxen Nateglinide

Natural Substrate

816

Appendix

Cytochrome P450 2C19 Drug Substrate Phenytoin Progesterone Proguanil Propranolol—Inderal Rabeprazole Teniposide Thioridazine Tolbutamide Voriconazole R-warfarin

Inhibitors Citalopram Delavirdine Efavirenz Felbamate Fluconazole Fluoxetine Fluvastatin Fluvoxamine Indomethacin Isoniazid Ketoconazole Letrozole Modafinil Omeprazole Oxcarbazepine Paroxetine Sertraline Telmisartan Ticlopidine Topiramate Voriconazole

)2

(c 0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Amitriptyline—Elavil Carisoprodol Cilostazol Citalopram Clomipramine—Anafranil Cyclophosphamide Desipramine—Norpramin Diazepam—Valium Esomeprazole Formoterol Hexobarbital Imipramine—Tofranil Indomethacin Lansoprazole—Prevacid Mephobarbital Moclobemide Nelfinavir Nilutamide Omeprazole Pantoprazole Pentamidine

Natural Substrate

817

Inducers Carbamazepine Norethindrone Phenobarbital Phenytoin Prednisone Rifampin

Textbook of Functional Medicine

Cytochrome P450 2D6 Drug Substrate Meperidine Methadone Methamphetamine Methoxyamphetamine Metoprolol Mexiletine—Mexitil Mirtazapine—Remeron Morphine Nortriptyline Olanzapine Ondansetron— Zofran Oxycodone Paroxetine Perphenazine Pindolol Propafenone Propoxyphene Propranolol—Inderal Quetiapine Risperidone Thioridazine Tramadol Trazodone Venlafaxine

Ginkgo leaf Ginseng, Panax St. John’s Wort

)2

(c

0

01

Inhibitors

Inducers

Amiodarone Bupropion Celecoxib Chloroquine Chlorpheniramine Cimetidine Citalopram Clomipramine Cocaine Desipramine Diphenhydramine Fluoxetine Fluphenazine Halofantrine Haloperidol Hydroxychloroquine Imatinib Levomepromazine Methadone Moclobemide Norfluoxetine Paroxetine Perphenazine Propafenone Propoxyphene Quinacrine Quinidine Ranitidine Ritonavir Sertraline Terbinafine Thioridazine

Carbamazepine Ethanol Phenobarbital Phenytoin Primidone Rifampin Ritonavir St. John’s Wort

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Amitriptyline—Elavil Amphetamine Atomoxetine Bisoprolol Carvedilol Cevimeline Chlorpromazine Chlorpropamide Clomipramine—Anafranil Clozapine—Clozaril Codeine Cyclobenzaprine—Flexeril Desipramine—Norpramin Dexfenfluramine Dextromethorphan Dolasetron Donepezil—Aricept Doxepin Encainide Fenfluramine Fentanyl—Duragesic Flecainide Fluoxetine—Prozac Fluphenazine Fluvoxamine—Luvox Formoterol Galantamine Haloperidol—Haldol Hydrocodone Imipramine—Tofranil Lidocaine Maprotiline

Natural Substrate

818

Appendix

Cytochrome P450 3A4 Drug Substrate Dronabinol Dutasteride Efavirenz Ergotamine Erythromycin Esomeprazole Estrogens, contraceptives Ethinyl estradiol Ethosuximide Etonogestrel Etoposide Exemestane Felodipine Fentanyl—Duragesic Fexofenadine Finasteride Flutamide Fluticasone Fulvestrant Galantamine Haloperidol—Haldol Hydrocodone Hydrocortisone Ifosfamide Imatinib Imipramine—Tofranil Indinavir Isradipine Itraconazole Ketoconazole Lansoprazole—Prevacid Letrozole Levobupivacaine Lidocaine Lopinavir Loratadine Losartan—Cozaar Lovastatin Methadone Methylprednisolone Miconazole Midazolam Mifepristone Mirtazapine—Remeron Modafinil Mometasone Montelukast

)2

(c

0

01

American elder Bishop’s weed Bitter orange Cat's claw Chamomile DHEA Echinacea Elder root Garlic Ginkgo leaf extract Goldenseal Licorice Milk thistle Red clover Red yeast Saw palmetto St. John’s wort Valerian Wild cherry bark

Inhibitors Acitretin Amiodarone Amprenavir Aprepitant Cimetidine Ciprofloxacin Clarithromycin Cyclosporine Danazol Delavirdine Diltiazem Diethyldithiocarbamate Efavirenz Eleuthera Erythromycin Acetaminophen Fluconazole Fluoxetine Fluvoxamine Gestodene Grapefruit Indinavir Imatinib Isoniazid Itraconazole Ketoconazole Metronidazole Methylprednisone Miconazole Mifepristone Milk Thistle Nefazodone Nelfinavir Nicardipine Nifedipine Norethindrone Norfloxacin Norfluoxetine Oxiconazole Prednisone Quinine Ritonavir Roxithromycin Saquinavir Sertraline Synercid

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Alfentanil Almotriptan Alprazolam Amitriptyline—Elavil Amiodarone Amlodipine Amprenavir Aprepitant Atorvastatin Bepridil Bexarotene Bromocriptine Budesonide Buprenorphine Buspirone Busulfan Cannabinoids Caffeine Carbamazepine Cevimeline Chlorpheniramine Cilostazol Cisapride Citalopram Clarithromycin Clindamycin Clomipramine—Anafranil Clonazepam Clopidogrel—Plavix Cocaine Cyclobenzaprine—Flexeril Cyclophosphamide Cyclosporine Dapsone Delavirdine Desogestrel Dexamethasone Dextromethorphan Diazepam—Valium Dihydroergotamine Diltiazem Disopyramide Docetaxel Dofetilide Dolasetron Donepezil—Aricept Doxorubicin

Natural Substrate

819

Inducers Aminoglutethimide Acetaminophen Carbamazepine Dexamethasone Efavirenz Ethosuximide Garlic Glucocorticoids Glutethimide Griseofulvin Modafinil Nafcillin Nevirapine Oxcarbazepine Phenobarbital Phenytoin Primidone Rifabutin Rifampin Rifapentine St. John’s Wort

Textbook of Functional Medicine

Cytochrome P450 3A4 (Continued) Drug Substrate Salmeterol Saquinavir Sertraline Sibutramine Sildenafil Simvastatin Sirolimus Tacrolimus Tamoxifen Temazepam Testosterone Tiagabine Tolterodine Toremifene Tramadol Trazodone Triazolam Trimetrexate Valdecoxib Verapamil- Calan Vinblastine Vincristine Vinorelbine Voriconazole R-warfarin Zaleplon Zileuton-Zyflo Ziprasidone Zolpidem Zonisamide

Inhibitors

Inducers

Troleandomycin Verapamil Voriconazole Zafirlukast Zileuton

)2

(c

0

01 e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Nateglinide Nefazodone Nelfinavir Nevirapine Nicardipine Nifedipine Nimodipine Nisoldipine Nitrendipine Nortriptyline Norethindrone Omeprazole Ondansetron—Zofran Oral contraceptives Oxybutynin Paclitaxel Pantoprazole Pimozide Pioglitazone Prednisolone Prednisone Progesterone/Progestins Quetiapine Quinidine Quinine Rabeprazole Repaglinide Rifabutin Rifampin Ritonavir

Natural Substrate

820

Appendix

Detailed Review of Systems

General

Fever, weight loss, weight gain. Are you at the weight you want? How much time do you exercise per day _____, per week _____? Hours of sleep per night? Any problems with sleep?

Head

Headaches, migraine, trauma, vertigo, syncope, convulsive seizures.

Eyes

Visual loss or color blindness, diplopia, hemianopsia, trauma, inflammation, glasses (date of refraction). Cataracts, decreased vision or blindness at night.

Ears

Deafness, tinnitus, vertigo, discharge from the ears, pain, mastoiditis, operations. Sounds you have trouble hearing. Coryza, rhinitis, sinusitis, discharge, obstruction, epistaxis, polyps, deviation of septum, operations.

)2

Soreness of the mouth or tongue, gingivitis, change in taste, tooth pain, aphthous ulcers.

0

01

Mouth

(c

Nose

Sore throats, tonsillitis, voice changes, hoarseness, polyps, difficulty swallowing.

Neck

Swelling, suppurative lesions, enlargement of the lymph nodes, goiter, stiffness, limitation of motion.

Breasts

Development, lactation, trauma, lumps, pains, discharge from nipples, gynecomastia, changes in nipples, soreness, previous biopsies.

Respiratory

Pain, shortness of breath, wheezing dyspnea, nocturnal dyspnea, orthopnea, cough, sputum, hemoptysis, night sweats, pleurisy, bronchitis, tuberculosis (history of contacts), pneumonia, asthma, other respiratory infections—coccidioidomycosis, histoplasmosis exposures.

Cardiovascular

Palpitation, tachycardia, irregularities of rhythm, pain in the chest, exertional dyspnea, paroxysmal nocturnal dyspnea, orthopnea, cough, cyanosis, ascites, edema. Intermittent claudication, cold extremities, phlebitis, postural or permanent skin color changes. Hypertension rheumatic fever, chorea, syphilis, diphtheria. When you exercise how fast do you get your heart rate? _____% Maximal predicted heart rate (220 - age = _____). Wheezing with exercise. Problems walking up a hill. Do you get short of breath or have chest pain when vacuuming, raking, or shoveling snow or dirt?

Gastrointestinal

Appetite, anorexia, dysphagia, nausea, eructations, flatulence, abdominal pain or colic, vomiting, hematemesis, jaundice (pain, fever, intensity, duration, color of urine and stools), stools (color, frequency, consistency, odor, gas, cathartics), hemorrhoids—internal/external. Change in bowel habits.

Genitourinary

Color of urine, polyuria, oliguria, nocturia, dysuria, hematuria, pyuria, urinary retention, urinary frequency, incontinence, pain or colic, passage of stones or gravel. Menstrual history: Age of onset, frequency of periods, regularity, duration, amount of flow, leukorrhea, dysmenorrhea, date of last normal and preceding periods, date and character of menopause, postmenopausal bleeding. Pregnancies: Number, abortions, miscarriages, stillbirths, chronologic sequence, complications of pregnancy. Venereal history: Chancre, bubo, penile or vaginal discharge. Treatment of venereal diseases. Sexual history: Age of onset of sexual relations, single partner or number of partners, libido, ability to orgasm, erectile dysfunction, sexual preference, satisfaction. Fertility issues?

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Throat

821

Textbook of Functional Medicine

Nervous system

Disturbances of smell (1), visual disturbances (2,3,4,6); orofacial paresthesias and difficulty in chewing (5); facial weakness and taste disturbances (7); disturbances in hearing and equilibrium (8); difficulties in speech, swallowing and taste (9,10,12); limitation in motion of neck (11). Motor system: Paralysis, atrophy, involuntary movements, convulsions, gait, incoordination Sensory system: Pain, lightning pain, girdle pain, paresthesia, hypesthesia, anesthesia. Autonomic system: Control of urination and defecation, sweating, erythema, cyanosis, pallor, reaction to heat and cold.

Mental status

Describe reactions to and influence of parents, siblings, spouse, children, friends and associates, sexual adjustments, successes and failures, illnesses. Lability of mood, hallucinations, grandiose ideas, sleep disturbances. How is your memory—short term, long term? Any memory frustrations?

Skin

Color, pigmentation, temperature, moisture, eruptions, pruritus, scaling, bruising, bleeding. Hair: Color, texture, abnormal loss or growth, distribution. Nails: Color changes, brittleness, ridging, pitting, curvature or white spots.

(c

Enlargement, pain, suppuration, draining sinuses, location.

)2

Lymph nodes

Fractures, dislocations, sprains, arthritis, myositis, pain, swelling, stiffness, migratory distribution, degree of disability, muscular weakness, wasting, or atrophy. Night cramps.

Hematopoietic

Anemia (type, therapy, and response), lymphadenopathy, bleeding (spontaneous, traumatic, familial).

Endocrine

History of growth, body configuration and weight. Size of hands, feet, and head, especially changes during adulthood. Hair distribution, skin pigmentation, weakness, goiter, exophthalmos, dryness of skin and hair, intolerance to heat or cold, tremor. Polyphagia, polydipsia, polyuria, glycosuria. Secondary sex characteristics, impotence, sterility, treatment. Sun exposure/week.

Immunologic and allergy

Dermatitis, urticaria, angioneurotic edema, eczema, hay fever, vasomotor rhinitis, asthma, migraine, vernal conjunctivitis. Seasonal incidence of previous conditions. Known sensitivity to pollens, foods, danders, or drugs. Previous skin tests and their results. Results of tuberculin tests and others. Desensitization, vaccinations and immunizations. Lyme disease. Mold sensitivities. HIV exposures or concerns. Hepatitis exposures or concerns.

0

01

Bones, joints, muscles

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

in

ic

ed

Adapted from Degowin EL and Degowin RL. Bedside Diagnostic Examination. 3rd Edition. Macmillan Publishing Co.,1975, p. 24-26.

822

Appendix

Adult Toxin Exposure Questionnaire Considering the LAST 12 MONTHS, do you have regular exposure to anything in the lists below? Please check: (Y) Yes (N) No (?) Unknown (P) for exposure more than 12 months ago

Community Do you have regular exposure to:

N

?

P

Notes

)2

(c

Automobile exhaust

Y

Farm/Industrial/Power plant or lines

01

Radio tower

0

Hydro tower

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Landfill/Dump

Home and/or Work Environment Do you live in a: (Circle one) Do you work in: (Circle one)

Bathing/Showering water source: (Circle one)

Apartment Building

Mobile Home

House

Office Building

Factory

Well

Public Works

Bottled

Y

N

?

ed

Do you have regular exposure to:

House

P

Notes

ic e

in

Forced air heat Renovations (new carpets, add-ons, etc.) Basement cracks or dirt floor Damp basement or crawl space Wet windows or outside closet walls Water leaks (ceilings, walls, floors) Visible mold Old or cracking ceiling tiles Old or cracking vinyl linoleum flooring

823

Outdoors

Textbook of Functional Medicine

Do you have regular exposure to:

Y

N

?

P

Notes

Crumbling pipe insulation Crumbling wall or ceiling insulation Old or cracking paint Carpets or rugs Stagnant or stuffy air Gas or propane stove Coal or wood stove

(c

)2

Other gas appliance (water heater, furnace)

0

01 lM na tio d. un rve r F se fo re te ts itu h st rig In All

Hobby and Work Activities

Do you have regular exposure to: Contact with smokers Pesticides or herbicides Harsh chemicals (varnish, glue, gas, acid, etc.) Welding or soldering Metals (lead, mercury, etc.)

N

?

P

Notes

ed

Paints

Y

in

ic

Photo developing/Dark room

e

Airplane travel Cleaning chemicals

Diet Drinking/Cooking water source:

Well

Caffeine?

What kind:

Public Works

Bottled How much:

824

Filtered

Appendix

Do you regularly consume:

Y

N

?

P

Notes

Fish (fresh, frozen, canned, etc.) Artificial sweeteners (circle all that apply): NutraSweet, Equal, Aspartame, Splenda Alcohol • If yes, how much? • How often?

)2

(c

Animal products • How often? • What percentage of your animal product consumption is organic?

0

01

Do you wash your produce? • What percentage of your produce is organic?

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Deep fat fried foods

Sodas, juices, drinks containing high fructose corn syrup. If yes, how many per day? Do you have: Allergies

Y

N

?

P

N

?

P

Sensitivity to smells (gas, perfume, paint, etc.)

Artificial materials in the body (implants, pins, joints, etc.) Immunizations

Y

ic

ed

Have you ever:

e

in

Used tobacco Experimented with recreational drugs Led a high-stress lifestyle Experienced a stressful or traumatic event Been under anesthesia Had an illness during foreign travel Had an illness while camping or hiking Had food poisoning

825

Textbook of Functional Medicine

Dental Care Y

N

?

P

Notes

Do you currently have amalgam fillings or caps? • How many amalgam fillings do you have now? Have you removed or lost dental fillings or caps? Did you have fillings as a child? • How many fillings did you have? Have your wisdom teeth been removed? • At what age? • Any complications such as dry socket or abscesses?

(c

)2

Have you had any root canals? • How many and when were they placed?

01

0

Did your mother have dental fillings prior to giving birth to you? • During her pregnancy with you?

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Other:

Please list all PRESCRIPTION or OVER THE COUNTER medications you currently take on a regular basis, including birth control pills and allergy injections:

Name of medication

Dose (mg, ML, IU)

How often do you take it?

How long have you taken it?

If you have side effects, please specify

e

in

ic

ed Please list all VITAMINS/MINERALS, HERBS, or OTHER SUPPLEMENTS you currently take on a regular basis:

Name of supplement

Dose (mg, ML, IU)

How often do you take it?

826

How long have you taken it?

If you have side effects, please specify

Appendix

Adverse Reactions: Please list ANY medication, anesthetics, immunizations, herbs or supplements you have had to stop taking because of side effects or allergic reactions: Name of medication/ immunization

Type of side effects or allergic reaction that caused you to stop it

)2

(c 0

01 e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 827

Age

Year

Textbook of Functional Medicine

Child Toxin Exposure Questionnaire Considering the LAST 12 MONTHS, does your child have regular exposure to anything in the lists below? Please check: (Y) Yes (N) No (?) Unknown (P) for exposure more than 12 months ago

Community Does your child have regular exposure to:

N

?

P

Notes

Farm/Industrial/Power plant or lines

)2

(c

Automobile exhaust

Y

0

01

Radio tower

Hydro tower

Home and/or Work Environment Where does your child live? (Circle one) If he/she works, where? (Circle one) Bathing/Showering water source: (Circle one)

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Landfill/Dump

House

Apartment Building

Mobile Home

House

Office Building

Factory

Well

Public Works

Bottled

Y

N

?

P

ed

Does your child have regular exposure at home or work to:

Notes

ic e

in

Forced air heat Renovations (new carpets, add-ons, etc.) Basement cracks or dirt floor Damp basement or crawl space Wet windows or outside closet walls Water leaks (ceilings, walls, floors) Visible mold Old or cracking ceiling tiles Old or cracking vinyl linoleum flooring

828

Appendix

Does your child have regular exposure at home or work to:

Y

N

?

P

Notes

Crumbling pipe insulation Crumbling wall or ceiling insulation Old or cracking paint Carpets or rugs Stagnant or stuffy air Gas or propane stove Coal or wood stove

(c

)2

Other gas appliance (water heater, furnace)

0

01 lM na tio d. un rve r F se fo re te ts itu h st rig In All

Hobby and Work Activities

Does your child have regular exposure at home or work to: Contact with smokers Pesticides or herbicides

Y

N

?

P

Notes

Harsh chemicals (varnish, glue, gas, acid, etc.) Welding or soldering Metals (lead, mercury, etc.)

ed

Paints

in

ic

Photo developing/Dark room

e

Airplane travel Cleaning chemicals

829

Textbook of Functional Medicine

Diet Drinking/Cooking water source:

Well

Caffeine?

What kind:

Does your child regularly consume:

Public Works

Bottled How much:

Y

N

?

P

Notes

Fish (fresh, frozen, canned, etc.) Artificial sweeteners (circle all that apply): NutraSweet, Equal, Aspartame, Splenda

)2

(c

Alcohol • If yes, how much? • How often?

0

01

Animal products • How often? • What percentage of your animal product consumption is organic?

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Do you wash your produce? • What percentage of your produce is organic? Deep fat fried foods

Sodas, juices, drinks containing high fructose corn syrup. If yes, how many per day? Does your child have: Allergies

Y

N

?

P

N

?

P

ed

Sensitivity to smells (gas, perfume, paint, etc.)

in

ic

Artificial materials in the body (implants, pins, joints, etc.)

e

Immunizations Has your child ever:

Filtered

Y

Used tobacco Experimented with recreational drugs Led a high-stress lifestyle Experienced a stressful or traumatic event Been under anesthesia Had an illness during foreign travel

830

Appendix

Had an illness while camping or hiking Had food poisoning

Dental Care Y

N

?

P

Notes

Does your child currently have amalgam fillings or caps? • How many amalgam fillings are in place at this time? Has your child ever removed or lost dental fillings or caps?

(c

)2

Has your child had any wisdom teeth removed? • At what age? • Any complications such as dry socket or abscesses?

0

01

Does your child have any root canals?

lM na tio d. un rve r F se fo re te ts itu h st rig In All

How many and when were they placed?

Did the child’s mother have dental fillings prior to giving birth? • Did she have dental work done during her pregnancy? Other:

School Age of school building: Location of school building:

Rural

City

Suburban

N

?

P

e

in

Y

ic

ed

Does your child have regular exposure at school to: Automobile exhaust Farm/Industrial/Power plant or lines Radio tower Landfill/Dump Water tower Renovations (carpeting, ceiling tiles, rooms) Outdoor activities (recess, sports, etc.) Other:

831

Notes

Textbook of Functional Medicine

Please list all PRESCRIPTION or OVER THE COUNTER medications your child currently takes on a regular basis, including birth control pills and allergy injections:

Name of medication

Dose (mg, ML, IU)

How often does he/she take it?

How long has she/he taken it?

If he/she has side effects, please specify

(c

)2

Please list all VITAMINS/MINERALS, HERBS, or OTHER SUPPLEMENTS your child currently takes on a regular basis:

01

Dose (mg, ML, IU)

0

Name of supplement

How often does he/she take it?

How long has she/he taken it?

If he/she has side effects, please specify

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Adverse Reactions: Please list ANY medication, anesthetics, immunizations, herbs or supplements your child has had to stop taking because of side effects or allergic reactions:

Type of side effects or allergic reaction that caused your child to stop it

e

in

ic

ed

Name of medication/ immunization

832

Age

Year

Appendix

Health Benefits of Exercise

System

Increases

Cardiovascular

Insulin requirements

Exercise endurance Cognition Work tolerance VO2 max

Breathlessness

Bone retention Muscle mass Sleep Balance Muscle strength Coordination

Number of falls

Depression scores

Chronic disease risk Desire for alcohol, smoking

e

in

ic

Mobility, strength, endurance Overall longevity

Serum triglycerides Proportion of fat Body weight

ed

Overall health

Improves glucose tolerance Concentration of insulin receptors HDL cholesterol Increases Caloric expenditure Proportion of lean body mass Endorphins

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Skeletal

Serum triglycerides Heart rate CRP Incidence of cardiac arrest Coronary mortality Coronary artery occlusion Peripheral arteriolar resistance Blood pressure

0

Respiratory disease

01

Mood

)2

Hyperlipidemias Metabolic rate

HDL cholesterol Cardiac output Fibrinolytic activity in Response to venous occlusion Increases arteriolar diameter

(c

Endocrine Diabetes

Decreases

Recommended Reading: Boule NG, Kenny GP, Haddad E, et al. Meta-analysis of the effect of structured exercise training on cardiorespiratory fitness in Type 2 diabetes mellitus. Diabetologia. 2003 Aug;46(8):1071-1081. Castaneda C, Gordon PL, Parker RC, et al. Resistance training to reduce the malnutrition-inflammation complex syndrome of chronic kidney disease. Am J Kidney Dis. 2004 Apr;43(4):607-616. Craft LL, Perna FM. The benefits of exercise for the clinically depressed. Prim Care Companion J Clin Psychiatry. 2004;6(3):104-111. Karlsson M. Does exercise reduce the burden of fractures? Acta Orthop Scand. 2002 Dec;73(6):691-705. Nestle M. Exercise and Work Performance, Chapter 50, p. 271 in Nutrition in Clinical Practice. Jones Medical Publication. 1985. Okura T, Nakata Y, Tanaka K. Effects of exercise intensity on physical fitness and risk factors for coronary heart disease. Obes Res. 2003 Sep;11(9):1131-1139. Rochester CL. Exercise training in chronic obstructive pulmonary disease. J Rehabil Res Dev. 2003 Sep-Oct;40(5 Suppl 2):59-80. Sato Y, Nagasaki M, Nakai N, et al. Physical exercise improves glucose metabolism in lifestyle-related diseases. Exp Biol Med (Maywood). 2003 Nov;228(10):1208-1212. Seguin R, Nelson ME. The benefits of strength training for older adults. Am J Prev Med. 2003 Oct;25(3 Suppl 2):141-149.

833

Textbook of Functional Medicine

Internet-based Resources for the Healthcare Practitioner http://medicine.iupui.edu/flockhart/ This site provides a table that is designed as a hypothesis testing, teaching and reference tool for physicians and researchers interested in drug interactions that are the result of competition for, or effects on, the human cytochrome P450 system.

Harvard Department of Molecular and Cellular Biology http://mcb.harvard.edu/Biolinks.html Rosenthal Directory of Databases www.rosenthal.hs.columbia.edu/Databases.html This website provides a compilation of established sources in the U.S., Europe and Asia, designed to facilitate research by both professionals and the public in clinical, biomedical, review, meta-analytical or survey research. Many of the databases listed do charge a fee.

)2

(c

PDR net for physicians http://www.pdr.net/pdrnet/librarian/ Database containing 15 full text journals, PDR drug book, PDR drug interactions book. Medical news is also posted, and Medline can be accessed. Free to some health professionals.

01

MedWeb Plus http://medwebplus.com/about.html From the site: Our goal at MedWebPlus is to give users tools to quickly locate and assimilate good and reliable information covering the entire spectrum of healthcare.

0

MD consult http://www.mdconsult.com A library of 48 full text journals, 36 books, medical news, and Medline access. Subscription. Free 10-day trial for physicians.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Cancer Detection and Prevention Online http://www.cancerprev.org/ This is an International Society for Preventive Oncology (ISPO) website that offers access to current and past issues of Cancer Detection and Prevention journals. $225 annual subscription fee. Some free browsing.

Medscape http://www.medscape.com/px/splash Access to 62 full text journals, many non-journal periodicals and professional publications, Medline, online medical textbooks, and journal scanning to extract highlights from recent literature within chosen fields. Conference listings; direct CME offerings; news items.

ed

Pesticides, Metals, & Chemical http://vm.cfsan.fda.gov/~lrd/pestadd.html This is U.S. FDA/Center for Food Safety and Applied Nutrition (CFSAN) website provides information regarding pesticides, metals, and chemical contaminants in food(s).

e

in

ic

WebMD http://www.webmd.com Consumer-focused content. Medscape is their physician content site. This site provides access to a wide array of physician-focused and medical office Internet-based services.

BioMedNet http://www.biomednet.com/ This website provides information for biological and medical researchers. It offers access to a full-text library (over 170 biological and medical journals), and BioMedLink (evaluated and annotated database of internet resources for biological and medical researchers). Access to Medline reviews of 3500 websites. Free registration.

Databases, Research, and Scientific Resources Organizing Medical Networked Information (OMNI) http://omni.ac.uk/ OMNI offers free access to a searchable catalogue of Internet sites covering health and medicine. Merck Manual http://www.merck.com/mrkshared/mmanual/home.jsp This website provides access to the 17th edition of the Merck Manual.

834

Appendix

NIH Office of Dietary Supplements http://odp.od.nih.gov/ The International Bibliographic Information on Dietary Supplements (IBIDS) is a NIH website produced by the Office of Dietary Supplements (ODS). It offers a database of published, international, scientific literature on dietary supplements, including vitamins, minerals, and botanicals. Search can be limited to peerreviewed publications.

Medical Biochemistry Subject List http://web.indstate.edu/thcme/mwking/subjects.html This website offers details on specific biochemistry and medical subjects. Elsevier Science http://www.elsevier.nl/ This website provides access to purchasing of research publications and journals in the physical, life and social sciences.

Herb Research Foundation (HRF) http://www.herbs.org/ A nonprofit research and educational organization focusing on herbs and medicinal plants.

The Lancet http://www.thelancet.com/

(c

)2

British Medical Journal http://bmj.com/ All articles of BMJ are available for free online.

0

01

American Botanical Council's Herbal Information http://www.herbalgram.org/ This website provides information about herbs that have been compiled from a number of reputable scientific sources including the German Commission E Monographs, Botanical Safety Handbook, and numerous clinical trials that have been referenced in HerbalGram, their quarterly publication.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

NLM Clinical Trials Database http://clinicaltrials.gov Location, design, purpose, criteria and other information on NIH clinical trials. PubMed http://www.ncbi.nlm.nih.gov/PubMed/ National Library of Medicine; free access to Medline.

Healthfinder http://www.healthfinder.gov This website provides consumer health and human services information developed by the U.S. Department of Health and Human Services. It provides access to selected online publications, clearinghouses, databases, websites, and support and self-help groups.

ed

USDA Nutrient Database http://www.nal.usda.gov/fnic/cgi-bin/nut_search.pl This interface allows simple searches on the USDA Nutrient Database

ic

General Resources

in

NIH Consumer Health Information http://health.nih.gov/ This website provides access to consumer publication titles specific to certain conditions/diseases.

e

National Center for Complementary and Alternative Medicine (NCCAM) http://nccam.nih.gov This is a NIH website offering fairly comprehensive information regarding alternative therapies. Includes Consensus Reports, research, clinical trials, database links.

HealthGate http://www.healthgate.com/ This website provides patient and consumer information regarding drugs and vitamins, symptoms and medical tests, and general health. It also provides access to Medline. Provider of web-enabled technology and services for healthcare organizations, including hospitals.

835

Textbook of Functional Medicine

• www.alternative-therapies.com (Alternative Therapies in Health and Medicine) • www.bmj.com (British Medical Journals) • www.bruceames.org (researcher in aging and nutrition) • www.cdc.gov/exposurereport (Second National Report on Human Exposure to Environmental Chemicals) • www.celiac.com (resource for celiac disease and gluten-free diet) • www.cfsan.fda.gov/~dms/admehg3.html (EPA Mercury Fish Advisory) • www.cmbm.org (The Center for Mind Body Medicine) • www.consumerlab.com (Consumer Lab: Independent Assays of Supplements) • www.ehponline.org (Environmental Health Perspectives) • www.ewg.org (Environmental Working Group) • www.ewg.org/reports/bodyburden (Study of Body Burden of Toxins) • www.functionalmedicine.org (The Institute for Functional Medicine) • www.healthjourneys.com (resource for audio recordings to support mind body healing) • www.imconsortium.org (The Consortium of Academic Health Centers for Integrative Medicine or CAHCIM) • www.jama.com (Journal of the American Medical Association) • www.nap.edu/books/0309071402/html (Toxicological Effects of Methyl Mercury, 2000; National Academy of Sciences Press) • www.ncbi.nlm.nih.gov/entrez (National Library of Medicine—Pub Med) • www.nccam.nih.gov (National Center for Complementary and Alternative Medicine) • www.nejm.org (New England Journal of Medicine) • www.padmamedia.com (practical products to support an authentic life and the healing arts) • www.whccamp.hhs.gov (White House Commission on Complementary and Alternative Medicine Policy. Final Report, March 2002) • www.yourcancerrisk.harvard.edu (a risk assessment questionnaire)

Medherb http://medherb.com/ This website of Medical Herbalism, a quarterly journal of clinical herbalism. It provides links to medical information and to any resource relevant to medicinal herbs or herbalism practiced in clinical settings, plus sample articles on hundreds of herbs. The World Lecture Hall http://www.utexas.edu/world/lecture/ This website provides links to pages created by faculty worldwide who are using the web to deliver universitylevel academic courses in any language.

(c

)2

Food Allergy and Anaphylaxis Network (FAAN) http://www.foodallergy.org/ This website provides access to FAAN, a nonprofit organization established to increase public awareness about food allergy and anaphylaxis. It offers, among other things, a bimonthly newsletter, product alerts, and updates on food allergy.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Dr. Duke's Phytochemical and Ethnobotanical Databases http://www.ars-grin.gov/duke/ Database of phytochemical ingredients for herbs and spices.

e

in

ic

ed

http://www.essentialfats.com This website presents information about the role of essential fatty acids in health and disease. It includes discussions on fatty acid analysis, research results, new diagnostic and treatment approaches of fatty acids in such areas as lipid abnormalities and inflammatory bowel disease.

Other Useful Sites • http://commons.ucalgary.ca/mercury (Video on the toxic neurologic effects of mercury) • http://ods.od.nih.gov (Office of Dietary Supplements Database) • http://vm.cfsan.fda.gov/~frf/sea-mehg.html (EPA Report of Mercury Levels in Seafood) • www.ajcn.org (American Journal of Clinical Nutrition)

836

Appendix

• www.liposcience.com (nuclear medicine spectroscopy for the assessment of lipid particle size; assessing cardiovascular risk factors) • www.melisa.org (immunotoxicology of heavy metals) • www.metametrix.com (nutritional and metabolic testing) • www.prometheus-labs.com (testing for glutenrelated disease) • www.questdiagnostics.com (common conventional laboratory testing) • www.questest.com (self-testing) • www.spectracell.com (functional analysis of essential micronutrients) • www.yorkallergyusa.com (IgG food sensitivity testing)

Food Resources • www.vitalchoice.com (Vital Choice Seafood—wild salmon and other food products) • www.whfoods.org (World’s Healthiest Foods) • www.diamondorganics.com (source for home delivery of organic and healthful foods)

Supplement Companies and Distributors

)2

(c

(There are many to choose from; here are a few to get started with.) • www.biotics research.com • www.collegepharmacy.com • www.designsforhealth.com • www.douglaslabs.com • www.emersonecologics.com • www.integrativeinc.com • www.metabolicmaintenance.com • www.metagenics.com • www.nordicnaturals.com • www.protherainc.com • www.thorne.com • www.tidhealth.com • www.vitalnutrients.net • www.xymogen.com

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Laboratory Testing and Diagnostic Resources

e

in

ic

ed

• www.doctorsdata.com (testing for heavy metal toxicity and other nutritional and metabolic disorders) • www.enterolab.com (home stool gluten sensitivity testing) • www.geimatron.com (electron beam tomography scanning for evaluation of calcium scores of the heart to assess cardiovascular risk) • www.genovations.com (genetic testing for SNPs) • www.gsdl.com (testing for digestive, immune, nutritional, endocrine, and metabolic function) • www.igenex.com (specialized testing for detecting chronic infections such as Lyme Disease with PCR technology) • www.immunolabs.com (IgG food sensitivity testing) • www.immunoscienceslab.com (immunological and infectious diseases assessments)

837

Textbook of Functional Medicine

Medical Symptoms Questionnaire

Name: _____________________________________________________Date: _________________________ Rate each of the following symptoms based upon your typical health profile for:

 Past 30 days Past 48 hours

)2

(c

Point Scale 0 - Never or almost never have the symptom 1 - Occasionally have it, effect is not severe 2 - Occasionally have it, effect is severe 3 - Frequently have it, effect is not severe 4 - Frequently have it, effect is severe __________ Headaches __________ Faintness __________ Dizziness __________ Insomnia

Total __________

EYES

__________ Watery or itchy eyes __________ Swollen, reddened or sticky eyelids __________ Bags or dark circles under eyes __________ Blurred or tunnel vision (does not include near- or far-sightedness)

Total __________

EARS

__________ Itchy ears __________ Earaches, ear infections __________ Drainage from ear __________ Ringing in ears, hearing loss

Total __________

NOSE

__________ Stuffy nose __________ Sinus problems __________ Hay fever __________ Sneezing attacks __________ Excessive mucus formation

Total __________

MOUTH/THROAT

__________ Chronic coughing __________ Gagging, frequent need to clear throat __________ Sore throat, hoarseness, loss of voice __________ Swollen or discolored tongue, gums, lips __________ Canker sores

SKIN

__________ Acne __________ Hives, rashes, dry skin __________ Hair loss __________ Flushing, hot flashes __________ Excessive sweating

Total __________

HEART

__________ Irregular or skipped heartbeat __________ Rapid or pounding heartbeat __________ Chest pain

Total __________

0

01

HEAD

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

838

Total __________

Appendix

__________ Chest congestion __________ Asthma, bronchitis __________ Shortness of breath __________ Difficulty breathing

Total __________

DIGESTIVE TRACT

__________ Nausea, vomiting __________ Diarrhea __________ Constipation __________ Bloated feeling __________ Belching, passing gas __________ Heartburn __________ Intestinal/stomach pain

Total __________

JOINTS/MUSCLE

__________ Pain or aches in joints __________ Arthritis __________ Stiffness or limitation of movement __________ Pain or aches in muscles __________ Feeling of weakness or tiredness

Total __________

)2

(c

LUNGS

01

__________ Binge eating/drinking __________ Craving certain foods __________ Excessive weight __________ Compulsive eating __________ Water retention __________ Underweight

Total __________

ENERGY/ACTIVITY

__________ Fatigue, sluggishness __________ Apathy, lethargy __________ Hyperactivity __________ Restlessness

Total __________

MIND

__________ Poor memory __________ Confusion, poor comprehension __________ Poor concentration __________ Poor physical coordination __________ Difficulty in making decisions __________ Stuttering or stammering __________ Slurred speech __________ Learning disabilities

Total __________

EMOTIONS

__________ Mood swings __________ Anxiety, fear, nervousness __________ Anger, irritability, aggressiveness __________ Depression

OTHER

__________ Frequent illness __________ Frequent or urgent urination __________ Genital itch or discharge

0

WEIGHT

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Total __________

Total __________

GRAND TOTAL ____________________

839

Textbook of Functional Medicine

Life Stress Questionnaire Name _______________________________________________________________

Date ______________________________

During the past two years, have you had any of the following things happen to you? If so, simply circle one of the numbers following those items (and only those items that apply to you). Circle only one number after each event which has occurred in your life recently. LIFE EVENT

POINT VALUE Moderate

Great

10 10 10

15 15 15

20 20 20

10 10 10 15 15 20 20 20 25 25 25 25 25 25 25 25 30 30 30 35 35 35 40 40 45 45 45 45 55 50 50 55 55 65 80 __________ __________

15 15 20 20 20 25 25 25 30 30 30 30 30 30 30 30 35 35 35 40 40 40 45 45 50 50 50 50 60 60 60 65 65 76 100 __________ __________

20 20 30 25 25 30 30 30 35 35 35 35 35 35 35 40 40 40 45 45 45 50 50 55 55 55 55 65 70 70 75 75 85 120 __________ __________

__________

__________

Slight

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37

Change in social activities Change in sleeping habits Change in residence Change in work hours Change in church activities Tension at work Small children in the home Change in living conditions Outstanding personal achievement Problem teenager(s) in the home Trouble with in-laws Difficulties with peer group Son or daughter leaving home Change in responsibilities at work Taking over a major financial responsibility Foreclosure of mortgage or loan Change in relationship with spouse Change to different line of work Loss of a close friend Gain of a new family member Sex difficulties Pregnancy Change in health of family member Retirement Loss of job Change in quality of religious faith Marriage Personal injury or illness Loss of self-confidence Death of a close family member Injury to reputation Trouble with the law Marital separation Divorce Death of spouse Other (invalid in family; drug or alcohol problem, etc.) Other: ________________________________________________

)2

0

01

in

840

ic

Scoring System (1) Greater than 300, highly significant life stress (2) 200–300, significant life stress (3) 150–200, moderate life stress (4) Less than 150, low life stress

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All Total of three columns

__________

e

Change in social activities Change in sleeping habits Change in residence

(c

Example:

Appendix

Nutrient Deficiency Signs and Symptoms By Nutrient: Vitamin A Acne, dermatitis (dry, scaly skin), follicular hyperkeratosis

Eyes

Photophobia; poor twilight vision; loss of shiny, bright, moist appearance of eyes; xerosis of bulbar conjunctivas; loss of light reflex; decreased lacrimation; keratomalacia (corneal softening); corneal ulceration which may lead to extrusion of lens; Bitot's spots (frothy white or yellow spots under bulbar conjunctivas); conjunctival xerosis; corneal xerosis

Mouth

Gingivitis Enlarged tonsils in a child

01

Skin

)2

Throat

(c

Face

0

Dry skin (xerosis); rough, bumpy skin on back of arms; psoriasis; erythema early, vascularization, crusting, desquamation; increased pigmentation (even in black people), thickened, inelastic, fissured, especially in skin exposed to sun; becoming scaly, dry, atrophic in intertriginous areas, maceration and abrasion may occur; Casal's necklace in neckline exposed to sun; malar and supraorbital pigmentation; impaired wound healing

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Skeletal

Bone/joint pain

Vitamin B12

Yellow face

Eyes

Optic neuritis

Mouth

Angular stomatitis

Tongue

Geographic tongue; sore, reddened tongue; filiform papillary atrophy; glossitis

Skin

Hyperpigmentation; pallor, icterus; rough, bumpy skin on back of arm

Circulation

Anemia, megaloblastic

Nervous System

Ataxia, with loss of ankle knee reflexes; peripheral neuropathy; paresthesia; areflexia, extensor plantar responses, loss of position and vibratory sense, ataxia, paresthesia; psychotic behavior (dementia); wide-based gait

e

in

ic

ed

Face

Vitamin B6 Mouth

Angular stomatitis

Tongue

Sore, reddened tongue

Lips

Cheilosis, inflammation of the mucus membranes of the lips, loss of clear differentiation between mucocutaneous border

Skin

Seborrheic-like dermatitis; skin deterioration; rough, bumpy skin on back of arm

841

Textbook of Functional Medicine

Hands/Fingers/Fingernails

Tender lumps on finger end joints

Nervous system

Peripheral neuropathy; tremors, convulsions, behavioral disturbances; slow mentation, mental depression Riboflavin Circumcorneal capillary injection with penetration of corneal limbus; red and moist tissue at external angles of both eyes; angular blepharitis (or palpebritis); conjunctival xerosis

Mouth

Gums, periodontal problems; angular stomatitis; gingivitis

Tongue

Sore, reddened tongue; filiform papillary atrophy; glossitis

Lips

Cheilosis, inflammation of the mucus membranes of the lips, loss of clear differentiation between mucocutaneous border

Nose

)2

(c

Eyes

Decreased skin-hair-nail turgor; seborrheic-like dermatitis

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Skin

0

01

Nasolabial dyssebacea (exfoliation, inflammation, excessive oil production, fissuring of sebaceous glands, which are moist and red)

Niacin

Gingival tenderness; gingivitis; angular stomatitis

Tongue

Sore, reddened tongue; filiform papillary atrophy; glossitis; tongue fissuring; halitosis

Lips

Cheilosis, inflammation of the mucus membranes of the lips, loss of clear differentiation between mucocutaneous border

Skin

Dermatitis, hyperpigmentation; erythema early, vascularization, crusting, desquamation; increased pigmentation (even in black people), thickened, inelastic, fissured, especially in skin exposed to sun; becoming scaly, dry, atrophic in intertriginous areas, maceration and abrasion may occur; Casal's necklace in neckline exposed to sun; malar and supraorbital pigmentation; scrotum dermatitis, erythema, hyperpigmentation; pellagrous dermatosis

Hands/Fingers/Fingernails

Onycholysis

Gastrointestinal Tract

Diarrhea

Nervous System

Psychotic behavior (dementia); acute disorientation

e

in

ic

ed

Mouth

Thiamine Throat

Parotid enlargement

Muscular

Muscle pain; calf muscle tenderness, weakness

Cardiovascular

Tachycardia, cardiac enlargement, congestive heart failure (high-output type); palpitations, arrhythmia; cardiomegaly

Circulation

Intermittent claudication

842

Appendix

Nervous System

Ataxia, with loss of ankle knee reflexes; peripheral neuropathy; paresthesia; loss of proprioception; hyporeflexia, foot and wrist drop; hypesthesia; paresthesia; psychotic behavior (dementia); nystagmus; ophthalmoplegia; wide-based gait; peripheral edema; somatic wasting Niacinamide

Hands /Fingers/ Fingernails

Slightly swollen and painful PIP joints (osteoarthritis); painful, swollen MCP joints, as well as wrists and other joints (rheumatoid arthritis); tender lumps on fingers and joints Vitamin C Gums, periodontal problems; herpes; reddened gumline without margination; ecchymotic-like lesions; interdental gingival hypertrophy

Throat

Enlarged tonsils in a child

)2

Skin

(c

Mouth

0

01

Perifollicular petechiae that produce a "pink-halo" effect around coiled hair follicles, intradermal petechiae (purpura, ecchymoses due to capillary fragility), hemarthroses (cortical hemorrhages of bone visualizable on X-ray); impaired wound healing Corkscrew, "swan neck" deformity

Hands/Fingers/Fingernails

Splinter hemorrhages

Skeletal

Bone/joint pain; subperiosteal hematoma, epiphyseal enlargement (painful)

Muscular

Intramuscular hematoma

General

Easy bruising

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Hair

Vitamin D

Gums, periodontal problems

Hands/Fingers/Fingernails

Psoriatic nails

Skeletal

Epiphyseal enlargement (painless), beading of ribs ("rachitic rosary"), delayed fusion of fontanelles, craniotabes (abnormal softening of the skull bones), bowed legs, frontal or parietal bossing of skull, deformities of thorax (Harrison's sulcus, pigeon breast), osteomalacia, osteoporosis, rickets; bone/joint pain; bone tenderness

Muscular

Hypotonia; myofascial back pain; decreased grip strength

Cardiovascular

Hypertension

General

Tetany and muscle cramps

e

in

ic

ed

Mouth

Vitamin E Eyes

Retinal field defect

Circulation

Anemia, hemolytic

Nervous System

Ataxia, with loss of ankle knee reflexes; peripheral neuropathy

843

Textbook of Functional Medicine

Vitamin K Skin

Perifollicular petechiae that produce a "pink-halo" effect around coiled hair follicles, intradermal petechiae (purpura, ecchymoses due to capillary fragility), hemarthroses (cortical hemorrhages of bone visualizable on X-ray); intracutaneous hemorrhages, GI hemorrhage

Mouth

Ecchymotic-like lesions

Circulation

Prolonged clotting time

Cardiovascular

Palpitations, arrhythmia

General

Easy bruising

Tongue

)2

(c

Biotin

Sore, reddened tongue

01

Dry skin (xerosis); seborrheic-like dermatitis

Hair

Thin, sparse distribution; hair becomes fine, dull, dry, brittle, stiff, straight; becomes red in black people, then lighter in color; may be “bleached” in white people (“flag sign”); can be plucked easily and painlessly

Nervous System

Slow mentation, mental depression

0

Skin

lM na tio d. un rve r F se fo re te ts itu h st rig In All Copper

Hair

Menkes steely hair

Hands/Fingers/Fingernails

Fingernails that are ridging, brittle, easily broken, flattened, spoon-shaped, thin, lusterless, Beau's lines, Muehrcke's lines

Circulation

Anemia, microcytic hypochromic

ic

ed

Calcium Mottled enamel, fluorosis

Hands/Fingers/Fingernails

Fingernails that are weak, thin, bend easily, frequently crack and chip

Skeletal

Epiphyseal enlargement (painless), beading of ribs ("rachitic rosary"), delayed fusion of fontanelles, craniotabes (abnormal softening of the skull bones), bowed legs, frontal or parietal bossing of skull, deformities of thorax (Harrison's sulcus, pigeon breast), osteomalacia, osteoporosis, rickets

Cardiovascular

Hypertension; palpitations, arrhythmia

Nervous System

Paresthesias about the lips, tongue, fingers; carpopedal spasm

General

Tetany and muscle cramps

e

in

Teeth

844

Appendix

Folate/Folic Acid Eyes

Pale palpebral conjunctivas

Mouth

Gums, periodontal problems; aphthous stomatitis

Tongue

Geographic tongue; sore, reddened tongue; filiform papillary atrophy; glossitis

Skin

Hyperpigmentation; pallor, icterus

Circulation

Anemia, megaloblastic

Nervous System

Psychotic behavior (dementia)

Teeth

)2

(c

Fluoride Caries

0

01

Iodine

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Throat

Neck mass (goiter)

Nervous System

Hyporeflexia, foot and wrist drop, hypesthesia, paresthesia Iron

Pale tongue, cheeks, and conjunctives

Eyes

Pale palpebral conjunctivas

Mouth

Angular stomatitis

Tongue

Filiform papillary atrophy; glossitis

Skin

Pallor, icterus

Hands/Fingers/Fingernails

Fingernails that are ridging, brittle, easily broken, flattened, spoon-shaped, thin, lusterless, Beau's lines, Muehrcke's lines; onycholysis; pale nail beds

Circulation

Anemia microcytic hypochromic

Gastrointestinal Tract

Plummer Vinson syndrome

e

in

ic

ed

Face

Pyridoxine Eyes

Angular blepharitis (or palpebritis)

Tongue

Glossitis

Nose

Nasolabial seborrhea

Nervous System

Peripheral neuropathy, symmetrical sensory and motor deficits, especially in lower extremities; drug-resistant convulsions (infants); dementia, forgetfulness

845

Textbook of Functional Medicine

Selenium Face

Acne

Mouth

Cold sores

Cardiovascular

Cardiomegaly Zinc Acne; dermatitis (dry, scaly skin), follicular hyperkeratosis

Eyes

Photophobia; poor twilight vision; loss of shiny, bright, moist appearance of eyes; xerosis of bulbar conjunctivas; loss of light reflex; decreased lacrimation; keratomalacia (corneal softening); corneal ulceration which may lead to extrusion of lens; Bitot's spots (frothy white or yellow spots under bulbar conjunctivas) Angular stomatitis

0

01

Mouth

)2

(c

Face

Geographic tongue; hypogeusia (diminished taste acuity)

Throat

Enlarged tonsils in a child

Skin

Acne on back, chest, face, and shoulders; dry skin (xerosis); psoriasis; seborrheic-like dermatitis; erythema early, vascularization, crusting, desquamation; increased pigmentation (even in black people), thickened, inelastic, fissured, especially in skin exposed to sun; becoming scaly, dry, atrophic in intertriginous areas, maceration and abrasion may occur; Casal's necklace in neckline exposed to sun; malar and supraorbital pigmentation; impaired wound healing

Hair

Thin, sparse distribution; hair becomes fine, dull, dry, brittle, stiff, straight; becomes red in black people, then lighter in color; may be “bleached” in white people (“flag sign”); can be plucked easily and painlessly

Hands/Fingers/Fingernails

Cracks and splitting of skin on fingertips; fingernails that are weak, thin, bend easily, frequently crack and chip; white pitting (leukonychia); fingernails that are ridging, brittle, easily broken, flattened, spoon-shaped, thin, lusterless, Beau's lines, Muehrcke's lines; chronic paronychia; white spots on fingernails

Gastrointestinal Tract

Diarrhea

General

Somatic wasting

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Tongue

Essential Fatty Acids Face

Acne; dermatitis (dry, scaly skin), follicular hyperkeratosis

Eyes

Reduced visual acuity

Nose

Nasolabial seborrhea

Skin

Acne on back, chest, face, and shoulders (omega-3); dry skin (xerosis); rough, bumpy skin on back of arm; dermatitis; eczema; lackluster skin (omega-3); thick calluses (omega-3); impaired wound healing (omega-6); oily/combination skin (omega-3)

Hair

Dry hair, dandruff

846

Appendix

Hands/Fingers/Fingernails

Cracks and splitting of skin on fingertips; fingernails that are weak, thin, bend easily, frequently crack and chip

Nervous System

Paresthesia (omega-3); weakness, inability to walk (omega-3); neuropathy

General

Decreased memory and mental abilities, psychological disturbances; thirst, polydipsia, polyuria Protein

Face

Brown, patchy pigmentation of cheeks, parotid enlargement, and "moon face" (calorie)

Mouth

Reddened gumline without margination (energy)

Teeth

Malposition, hypoplastic line across upper primary incisors, becomes filled with yellow-brown pigment, caries then occurs and tooth may break off (calorie) Impaired wound healing (calorie)

)2

01

Hair

(c

Skin

0

Thin, sparse distribution (energy); dry, dull, depigmented; hair becomes fine, dull, dry, brittle, stiff, straight; becomes red in black people, then lighter in color; may be “bleached” in white people (“flag sign”); can be plucked easily and painlessly (calorie)

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Hands/Fingers/Fingernails

Transverse depigmentation; fingernails that are ridged, brittle, easily broken, flattened, spoonshaped, thin, lusterless, Beau's lines, Muehrcke's lines

Gastrointestinal Tract

Ascites; hepatomegaly

Muscular

Atrophic muscles; decreased grip strength

General

Peripheral edema, muscle wasting (calorie) Fat

Hepatomegaly

General

Reduced subcutaneous fat as evidenced by well-demarcated bony prominences and veins, loss of gluteal and perianal fat Coenzyme Q10

e

in

ic

ed

Gastrointestinal Tract

Mouth

Gums, periodontal problems

Cardiovascular

Tachycardia, cardiac enlargement, congestive heart failure (high-output type); palpitations, arrhythmia Lysine

Mouth

Herpes Flavonoids

Mouth

Herpes

847

Textbook of Functional Medicine

Phosphorus Teeth

Caries

Nervous System

Acute disorientation; circumoral and extremity paresthesias Nickel

Skin

Psoriasis Bromide

Skin

Psoriasis

(c )2

Dry, dull, sparse, depigmented

0

01

Hair

Manganese

Glucosamine Sulfate and Chondroitin

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Hands/Fingers/Fingernails

Slightly swollen and painful PIP joints (osteoarthritis) Eicosatetraenoic Acids

Hands/Fingers/Fingernails

Painful, swollen MCP joints, as well as wrists and other joints (rheumatoid arthritis) Cetyl Myristoleic Acid

Hands/Fingers/Fingernails

Painful, swollen MCP joints, as well as wrists and other joints (rheumatoid arthritis) Magnesium

Reactive airways

Muscular

Spasm

Cardiovascular

Hypertension; palpitations, arrhythmia

Nervous System

Tremor, convulsions, behavioral disturbances; carpopedal spasm

Gastrointestinal Tract

Ileus

Cardiovascular

Hypertension

General

Tetany and muscle cramps Linolenic Acid

Skin

Dry skin (xerosis); seborrheic-like dermatitis

848

e

Potassium

in

ic

ed

Respiratory

Appendix

Nutrient Deficiency Signs and Symptoms, continued Potential Association with Nutrient Deficiency/Insufficiency or Allergen:

By Physical Exam Finding: Face

Zinc Allergy (eliminate refined foods/sugars) Vitamin A Essential fatty acids Selenium

Pale tongue, cheeks, and conjunctivas

Anemia (iron deficient)

)2

(c

Acne

Protein-calorie

0

01

Brown, patchy pigmentation of cheeks, parotid enlargement, and “moon face”

Low stomach acid and pepsin production

Red face (rosacea)

Food allergy, yeast, skin mites allergy

Flushing Yellow face

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Reddened facial skin, especially on forehead and cheeks, often with scattered medium to large acne-like lumps (i.e., acne rosacea)

Allergy (e.g., red ears)

Vitamin B12

Dermatitis (dry, scaly skin), follicular hyperkeratosis

Essential fatty acids, vitamin A, zinc

Eyes

Dilated pupils

Allergy (especially milk) Vitamin A, zinc

Pale palpebral conjunctivas

Iron or folate

Circumcorneal capillary injection with penetration of corneal limbus

Riboflavin

Red and moist tissue at external angles of both eyes

Riboflavin

Angular blepharitis (or palpebritis)

Pyridoxine, riboflavin

Optic neuritis

Vitamin B12

Conjunctival xerosis

Vitamin A, riboflavin

Corneal xerosis

Vitamin A

Dark under-eye circles (allergic shiners)

Allergy (food or other)

e

in

ic

849

ed

Photophobia; poor twilight vision; loss of shiny, bright, moist appearance of eyes; xerosis of bulbar conjunctivas; loss of light reflex; decreased lacrimation; keratomalacia (corneal softening); corneal ulceration which may lead to extrusion of lens; Bitot's spots (frothy white or yellow spots under bulbar conjunctivas)

Textbook of Functional Medicine

Retinal field defect

Vitamin E

Reduced visual acuity

Essential fatty acids Mouth Food allergy(ies) Toothpaste with sodium lauryl sulfate can cause recurrences

Aphthous stomatitis

Folic acid

Cold sores

Selenium

Gums; periodontal problems

Coenzyme Q10, folate "mouthwash," vitamin C, riboflavin, vitamin D

Gingival tenderness

)2

(c

Canker sore (aphthous ulcer)

Angular stomatitis Interdental gingival hypertrophy Gingivitis

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Ecchymotic-like lesions

Lysine, vitamin C, flavonoids

0

Reddened gumline without margination

01

Herpes

Niacin

Vitamin C

Vitamins C and K, protein-energy

Riboflavin, niacin, other B vitamins, iron, zinc Vitamin C

Vitamin A, niacin, riboflavin

Tongue

Geographic tongue

in

ic

ed

Folate Vitamin B12 Zinc Genetic and unchangeable Niacin, folate, vitamins B12 and B6, biotin, riboflavin

Filiform papillary atrophy

Niacin, iron, folate, vitamin B12, riboflavin

Glossitis

Riboflavin, folic acid, pyridoxine, niacin, vitamin B12, iron

Hypogeusia (diminished taste acuity)

Zinc

Teeth indentations on tongue

Food allergy(ies)

Tongue fissuring

Niacin

Halitosis

Niacin

e

Sore, reddened tongue

850

Appendix

Lips Cheilosis, inflammation of the mucus membranes of the lips, loss of clear differentiation between mucocutaneous border

Riboflavin, vitamin B6, niacin

Teeth Caries

Fluoride, phosphorus

Mottled enamel, fluorosis

Fluoride (excessive), calcium

Malposition, hypoplastic line across upper primary incisors, becomes filled with yellow-brown pigment, caries then occurs and tooth may break off

Protein-calorie

Polyps in the nose

)2

(c

Nose Allergy (very likely salicylate sensitive)

01

0

Nasolabial dyssebacea (exfoliation, inflammation, excessive oil production, fissuring of sebaceous glands, which are moist and red)

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Nasolabial seborrhea

Riboflavin

Pyridoxine, essential fatty acids

Throat

Enlarged tonsils in a child

Swollen lymph nodes in neck Parotid enlargement

Food allergy(ies) Thiamin Iodine

Skin

e

in

ic

ed

Neck mass (goiter)

Food allergy(ies) Vitamin A Vitamin C Zinc

Acne (back, chest, face, shoulders)

High-dose vitamin A, zinc, omega-3 oils

Dry skin (xerosis)

Essential fatty acids, vitamin A, biotin, linolenic acid, zinc

Skin surface slightly yellow

Beta-carotene (excessive)

Rough, bumpy skin on back of arm

Vitamin A Essential fatty acids B vitamins Pancreatic enzymes to aid absorption of essential fatty acids, vitamin A, carotene

Psoriasis

Nickel, bromide, vitamin A, zinc

851

Textbook of Functional Medicine

Perifollicular petechiae that produce a "pink-halo" effect around coiled hair follicles, intradermal petechiae (purpura, ecchymoses due to capillary fragility), hemarthroses (cortical hemorrhages of bone visualizable on X-ray)

Vitamin C, vitamin K

Decreased skin-hair-nail turgor

Riboflavin

Dermatitis

Niacin, essential fatty acids

Seborrheic-like dermatitis

Riboflavin, vitamin B6, biotin, zinc, linoleic acid

Skin deterioration

Vitamin B6

Hyperpigmentation

Folate, vitamin B12, niacin

Intracutaneous hemorrhages, GI hemorrhage

Vitamin K

(c

Iron, folic acid, vitamin B12

)2

Pallor, icterus

Niacin, vitamin A, zinc

Scrotum dermatitis, erythema, hyperpigmentation

Niacin

Eczema

Allergy Fatty acids

0

01

Erythema early, vascularization, crusting, desquamation; increased pigmentation (even in black people), thickened, inelastic, fissured, especially in skin exposed to sun; becoming scaly, dry, atrophic in intertriginous areas, maceration and abrasion may occur; Casal's necklace in neckline exposed to sun; malar and supraorbital pigmentation

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Itching: anus, arms, ear canals, eyes, feet, hands, legs, nipples, nose, penis, roof of mouth, scalp, skin in general, throat

Allergy

Lackluster skin

Omega-3 oils

Thick calluses

Omega-3 oils; could also be vitamin A responsive; sometimes a weird expression of eczema

in

ic

ed

Bumps on back of upper arms

Omega-3 oils

Niacin

Impaired wound healing

Vitamin C, vitamin A, zinc, protein, omega-6 essential fatty acids

Oily skin (also what TV used to call combination skin)

Omega-3 oils

e

Pellagrous dermatosis

Hair Thinning hair on arms, legs, pubic area of older females

DHEA

Thin, sparse distribution

Protein-energy, biotin, zinc

Corkscrew, "swan neck" deformity

Vitamin C

Dry, dull, sparse, depigmented

Protein, manganese

852

Appendix

Hair becomes fine, dull, dry, brittle, stiff, straight; becomes red in black people, then lighter in color; may be “bleached” in white people (“flag sign”); can be plucked easily and painlessly

Protein-calorie, zinc, biotin

Menkes steely hair

Copper

Dry hair, dandruff

Essential fatty acids Hands/Fingers/Fingernails

Cracks and splitting of skin on fingertips

Zinc, essential fatty acids

Slightly swollen and painful PIP joints (osteoarthritis)

Glucosamine sulfate and chondroitin Niacinamide "Nightshade" vegetable allergies

(c

)2

Painful, swollen MCP joints, as well as wrists and other joints (rheumatoid arthritis)

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Tender lumps on finger end joints

Food allergy(ies) Niacinamide Eicosatetraenoic acids Cetyl myristoleic acid Niacinamide, vitamin B6

Fingernails that are weak, thin, bend easily, frequently crack and chip

Underfunctioning stomach (low acid, low pepsin) Essential fatty acid Calcium Zinc

Transverse depigmentation

Protein

White pitting (leukonychia) Psoriatic nails

Zinc

Vitamin D

Iron, copper, zinc, protein

Onycholysis

Iron, niacin

Chronic paronychia

Zinc

Splinter hemorrhages

Vitamin C

Pale nail beds

Iron

White spots on fingernails

Zinc

e

in

ic

ed

Fingernails that are ridging, brittle, easily broken, flattened, spoon-shaped, thin, lusterless, Beau's lines, Muehrcke's lines

Skeletal Epiphyseal enlargement (painless), beading of ribs ("rachitic rosary"), delayed fusion of fontanelles, craniotabes (abnormal softening of the skull bones), bowed legs, frontal or parietal bossing of skull, deformities of thorax (Harrison's sulcus, pigeon breast), osteomalacia, osteoporosis, rickets

Vitamin D, calcium

Bone/joint pain

Vitamin A, vitamin D, vitamin C

853

Textbook of Functional Medicine

Bone tenderness

Vitamin D

Subperiosteal hematoma, epiphyseal enlargement (painful)

Vitamin C Respiratory

Reactive airways

Magnesium Circulation Vitamin E

Anemia, microcytic hypochromic

Copper, iron

Anemia, megaloblastic

Folate, vitamin B12

Prolonged clotting time

Vitamin K

01

Intermittent claudication

)2

(c

Anemia, hemolytic

Thiamin

0 lM na tio d. un rve r F se fo re te ts itu h st rig In All Gastrointestinal Tract

Ascites Hepatomegaly Diarrhea Ileus Plummer Vinson syndrome

Protein

Protein, fat

Zinc, niacin, dysbiosis Potassium

Iron

Muscular

Vitamin D

ed

Hypotonia

Thiamin

Intramuscular hematoma

Vitamin C

Calf muscle tenderness, weakness

Thiamin

Atrophic muscles

Protein

Myofascial back pain

Vitamin D

Decreased grip strength

Protein, vitamin D

Spasm

Magnesium

e

in

854

ic

Muscle pain

Appendix

Cardiovascular Tachycardia, cardiac enlargement, congestive heart failure (high-output type)

Thiamine, coenzyme Q10

Hypertension

Calcium, potassium, magnesium, vitamin D

Palpitations, arrhythmia

Thiamine, magnesium, coenzyme Q10, vitamin K, calcium

Cardiomegaly

Selenium, thiamin Nervous System

Ataxia, with loss of ankle knee reflexes

(c

Thiamin, vitamin B6, vitamin E, vitamin B12

)2

Peripheral neuropathy

Thiamin, vitamin E, vitamin B12

Pyridoxine

0

01

Peripheral neuropathy, symmetrical sensory and motor deficits, especially in lower extremities; drug-resistant convulsions (infants); dementia, forgetfulness

Loss of proprioception

Thiamin, vitamin B12, omega-3 essential fatty acids

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Paresthesia

Thiamin

Hyporeflexia, foot and wrist drop, hypesthesia, paresthesia

Thiamin, iodine

Areflexia, extensor plantar responses, loss of position and vibratory sense, ataxia, paresthesia

Vitamin B12

Paresthesias about the lips, tongue, fingers

Calcium

Tremor, convulsions, behavioral disturbances

Magnesium, vitamin B6

Psychotic behavior (dementia)

Niacin, thiamin, vitamin B12, folate Phosphorus, niacin

ic

ed

Acute disorientation

Thiamin

Ophthalmoplegia

Thiamin

Wide-based gait

Thiamin, vitamin B12

Weakness, inability to walk

Omega-3 fatty acids

Carpopedal spasm

Calcium, magnesium

Circumoral and extremity paresthesias

Phosphorus

Slow mentation, mental depression

Biotin, vitamin B6

Neuropathy

Essential fatty acids

e

855

in

Nystagmus

Textbook of Functional Medicine

General Peripheral edema

Protein, thiamin

Muscle wasting

Protein, calorie

Somatic wasting

Thiamin, zinc

Reduced subcutaneous fat as evidenced by well-demarcated bony prominences and veins, loss of gluteal and perianal fat

Fat

Decreased memory and mental abilities, psychological disturbances

Essential fatty acids

Thirst, polydipsia, polyuria

Essential fatty acids

Allergy (food or other), often yeast, vitamin K, vitamin C

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Swollen ankles and feet

Allergy (food or other)

01

Easy bruising

Vitamin D, magnesium, calcium, potassium

)2

Red ears

(c

Tetany and muscle cramps

Allergy vs. the obvious cardiac/renal problems

e

in

ic

ed

856

Appendix

Three-Day Diet Diary etc. Record the amount of each food consumed using standard measurements as much as possible, such as 8 ounces, 1/2 cup, 1 teaspoon, etc. • Include any added items. For example: tea with 1 teaspoon sugar, potato with 2 teaspoons butter, etc. • Please record all beverages, including water. List them in the “Beverage” category.

Please complete this Three-Day Diet Diary for three consecutive days within a week before your scheduled visit. Please include one weekend day. • Record information as soon as possible after the food has been consumed. • Describe the food or beverage consumed e.g., milk—whole, 2%, or nonfat; toast—whole wheat, white, buttered; chicken—fried, baked, breaded,

)2

(c

Diet Diary

Name: _____________________________________________________________ Food

0

01

Time

Amount

Date: _________________________

Time

Beverage

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 857

Amount

Textbook of Functional Medicine

)2 (c

0 01

e in ic ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

858

Appendix

Glossary known antecedents, triggers, and mediators, and the salutogenic factors that promote health. Practitioners can use the matrix to help organize their thoughts and observations about the patient’s health and decide how to focus therapeutic and preventive strategies.

Antecedents: factors that predispose to acute or chronic illness. For a person who is ill, antecedents form the illness diathesis. From the perspective of prevention, they are risk factors. Examples of genetic antecedents include the breast cancer risk genes BRCA1 and BRCA2.

Core Clinical Imbalances: The foundational principles of how the human organism functions—and how its systems communicate and interact—are essential to the process of linking ideas about multifactorial causation with the perceptible effects we call disease or dysfunction. To assist clinicians in this process, functional medicine has identified and organized a set of core clinical imbalances that are linked to fundamental physiological processes. They serve to marry the mechanisms of disease with the manifestations and diagnoses of disease. Many common underlying pathways of disease are reflected in these clinical imbalances:

Biochemical individuality: the idea that each individual

)2

(c

has a unique physiological and biochemical composition, based upon the interactions of his or her individual genetic make-up with the environment—i.e., the continuous exposure to “inputs” (diet, experiences, beliefs, activity, toxins, medications, etc.) that influences our genes. It is this combination of factors that accounts for the endless variety of phenotypic responses seen every day by clinicians. The unique makeup of each individual requires personalized levels of nutrition and a lifestyle adapted to that individual’s needs in order to achieve optimal health. The consequences of not meeting the specific needs of the individual are expressed, over time, as degenerative disease.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Communication Imbalances • Endocrine • Neurotransmitter • Immune messengers • Cognition

Biomarker: a substance used as an indicator of a biological state. Such characteristics are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Cancer biomarkers include prostate specific antigen (PSA) and carcinoembryonic antigen (CEA).

ic

ed

Energy Imbalances • Energy regulation • Mitochondrial function

in

Defense and Repair Imbalances • Immune system • Inflammatory processes • Infection and microbiota

e

Biotransformation: the modification(s) of a chemical

compound made by an organism. Such compounds include, but are not limited to, nutrients, amino acids, toxins, heavy metals, or drugs in the body. Biotransformation also renders nonpolar compounds polar so that they are excreted, not reabsorbed in renal tubules.

Assimilation Imbalances • Digestion • Absorption • Microbiota/GI • Respiration

Functional medicine: a systems-based, science-driven approach to individualized medicine that focuses on uncovering the underlying causes of disease and dysfunction rather than on treatment of symptoms.

Structural Integrity Imbalances • From the subcellular membranes • To the musculoskeletal system

Functional Medicine Matrix: the graphic representation of the functional medicine approach, displaying the seven fundamental clinical imbalances, the patient’s

859

Textbook of Functional Medicine

be adaptive (e.g., fever) or pathological, depending on the context.

Biotransformation and Elimination Imbalances • Toxicity • Detoxification

Isoflavones: a class of polyphenolic, antioxidant, organic compounds, often naturally occurring, related to the isoflavonoids, many of which act as phytoestrogens in mammals. Some isoflavones and isoflavone-rich foods are purported to possess activity against cancer, including certain types of breast and prostate cancer. Isoflavones are produced almost exclusively by members of the Fabaceae/Leguminoseae (bean) family, such as soybeans.

Using this construct, it becomes much clearer that one disease/condition may have multiple causes (i.e., multiple clinical imbalances), just as one fundamental imbalance may be at the root of many seemingly disparate conditions Cytokines: immunoregulatory proteins (such as interleukin, tumor necrosis factor, and interferon). They may act locally or systemically and tend to have both immunomodulatory and other effects on cellular processes in the body. Cytokines have been used in the treatment of certain cancers.

)2

(c

Long latency disease: disease that becomes manifest at a time remote from the initial exposure to disease triggers, or diseases requiring continued exposure to triggers and mediators over an extended period of time to manifest frank pathology. Examples include heart disease, cancer, and osteoporosis.

01

0

Genomics: the study of the whole genome of organisms, including interactions between loci and alleles within the genome. Research on single genes does not fall into the definition of genomics unless the aim of this functional information analysis is to elucidate the gene’s effect on the entire genome network. Genomics may also be defined as the study of all the genes of a cell, or tissue, at the DNA (genotype), mRNA (transcriptome), or protein (proteome) levels.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Mediators: intermediaries that contribute to the continued manifestations of disease. Mediators do not “cause” disease; instead, they underlie the host response to triggers. Examples include biochemical factors (e.g., cytokines and leukotrienes) as well as psychosocial ones (e.g., reinforcement for staying ill).

Metabolomics (or metabonomics): “The study of metabolic responses to drugs, environmental changes and diseases. Metabonomics is an extension of genomics (concerned with DNA) and proteomics (concerned with proteins). Following on the heels of genomics and proteomics, metabonomics may lead to more efficient drug discovery and individualized patient treatment with drugs, among other things.” (From MedicineNet.com)

e

in

ic

ed

Glucosinolates: a class of organic compounds that contain sulfur and nitrogen and are derived from glucose and an amino acid. They occur as secondary metabolites of almost all plants of the order Brassicales. Glucosinolates have toxic effects in both humans and animals at high doses (mainly as goitrogens) but, at subtoxic doses, their hydrolytic and metabolic products may act as chemoprotective agents against chemicallyinduced carcinogens by blocking the initiation of tumors in a variety of tissues.

Nutrigenomics (or nutritional genomics): the study of how different foods may interact with specific genes to increase the risk of common chronic diseases such as type 2 diabetes, obesity, heart disease, stroke, and certain cancers. It can also be described as the study of the influence of genetic variation on nutrition by correlating gene expression or single-nucleotide polymorphisms with a nutrient's absorption, metabolism, elimination or biological effects. Nutrigenomics also seeks to provide a molecular understanding of how common chemicals in the diet affect health by altering the expression of genes and the structure of an individ-

Homeostasis and homeodynamics: The former term describes the tendency of living things to maintain physiological parameters within a narrow range usually considered “normal” in order to maintain optimal function. Under this definition, disease can be defined as a departure from the homeostatic state. The latter term describes the tendency of homeostatic set points to change throughout an organism’s lifespan, and thus describes how departures from a homeostatic norm can

860

Appendix

tions made to a particular set of proteins, produced by an organism or system. This will vary with time and distinct requirements, or stresses, that a cell or organism undergoes. As a result, proteomics is much more complicated than genomics: an organism's genome is more or less constant, while the proteome differs from cell to cell and from time to time.

ual's genome. The ultimate aim of nutrigenomics is to develop rational means to optimize nutrition, with respect to the subject's genotype. Organ reserve: The difference between the maximal function of a vital organ and the level of function required to maintain an individual’s daily life. In other words, it is the “reserve power” of a particular organ, above and beyond what is required in a healthy individual. It can also be thought of as the degrees of freedom available in the body organs to perform their functions and maintain health. Decline in the organ reserve occurs under stress, during sickness, and as we age.

(c

Single nucleotide polymorphism (SNP; pronounced snip): a DNA sequence variation occurring when a single nucleotide—A, T, C, or G—in the genome differs between members of a species or between paired chromosomes in an individual. Variations in the DNA sequences of humans can affect how humans develop diseases and respond to pathogens, chemicals, drugs, vaccines, and other agents. SNPs are also thought to be key factors in applying the concept of personalized medicine.

)2

Organ system diagnosis: In the allopathic medical model, it is common to give a collection of symptoms a name based on dysfunction of an organ system, then to cite the named disease as the cause of the symptoms the patient is experiencing. This bit of circular logic avoids any discussion of the systemic or underlying causes of dysfunction and also treats all people with “disease X” the same, despite the fact that two people with the same collection of symptoms may have completely different underlying physiological causes for the symptoms they display.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

The 5Rs: A mnemonic that contains a five step process for normalizing gastrointestinal function: 1. Remove – Removing the source of the imbalance (e.g., pathogens, allergic foods) is the critical first step

2. Replace – Next replace any factors that are missing (e.g., HCL, digestive enzymes)

Oxidation-reduction: paired chemical reactions that occur in balance with each other within the body of a healthy individual. These reactions involve the transfer of electrons (or the distribution of electron sharing) and thus require both a donor and acceptor. When this physiological parameter is out of balance, a net accumulation of donors or acceptors can lead to deleterious cellular oxidation phenomena (lipid peroxidation, free radical formation).

3. Reinoculate – Repopulate the gut with symbiotic bacteria (e.g., lactobacilli, bifidobacteria)

ed

4. Repair – Heal damaged gut membrane using, for example, glutamine, fiber, and butyrate

e

in

ic

5. Rebalance – Modify attitude, diet, and lifestyle of the patient to promote a healthier way of living Triggers: Triggers are discrete entities or events that provoke disease or its symptoms (e.g., microbes). Triggers are usually insufficient in and of themselves for disease formation, however, because the health of the host and the vigor of its response to a trigger are essential elements.

Precipitating event: similar to a trigger but, whereas a trigger only provokes illness as long as the person is exposed to it (or for a short while afterward), a precipitating event initiates a change in health status that persists long after the exposure ends.

Xenobiotics: chemicals which are found in an organism but which are not normally produced by or expected to be present in it. This may also include substances which are present in much higher concentrations than are usual. The term xenobiotics is very often used in the context of pollutants such as dioxins and

Proteomics: the large-scale study of proteins, particu-

larly their structures and functions and including how they're modified, when and where they're expressed, how they're involved in metabolic pathways, and how they interact with one another. The proteome is the entire complement of proteins, including the modifica-

861

Textbook of Functional Medicine

polychlorinated biphenyls and their effect on the biota, because xenobiotics are understood as substances foreign to an entire biological system, i.e. artificial substances, which did not exist in nature before their synthesis by humans. Exposure to several types of xenobiotics has been implicated in cancer risk.

Cytochromes P450 (CYP 450): a large and diverse group of enzymes, most of which function to catalyze the oxidation of organic substances. They are located either in the inner membrane of mitochondria or in the endoplasmic reticulum of cells. The substrates of CYP enzymes include metabolic intermediates such as lipids, steroidal hormones, and xenobiotic substances such as drugs.

Additional Terms Related to Cancer Active surveillance: Formerly called “watchful waiting,” active surveillance is a treatment option for patients with apparently slow-growing tumors in which no surgery, radiation, or chemotherapy is administered. Instead, the cancer is carefully monitored for signs of progression. If symptoms develop, or if tests indicate that the cancer is growing, treatment might be warranted. Commonly used in the treatment of prostate cancer.

Initiation: in carcinogenesis, the series of steps required for the transformation of healthy cells into malignant ones.

)2

(c

Integrative oncology: an approach to cancer that makes use of all available therapies to prevent and treat malignancy. It integrates conventional cancer therapies with science-based complementary and alternative cancer treatments, as well as therapies designed to lessen the side effects of chemotherapy and radiation.

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Angiogenesis: growth of new blood vessels. When cancer cells are dividing rapidly, they require more oxygen and nutrients than the surrounding tissue can provide. To solve this problem, the cells release angiogenesis factors that attract the growth of new blood vessels into the tumor. One avenue for cancer treatment involves administering anti-angiogenesis factors to disrupt this process.

Isothiocyanates: compounds that contain the functional group -N=C=S. Many natural isothiocyanates from plants (also known as mustard oils) are produced by enzymatic conversion of metabolites called glucosinolates. They have been shown to inhibit carcinogenesis and tumorigenesis and are therefore useful chemopreventive agents against the development and proliferation of cancers. In some cases, they can even induce apoptosis in cells that are resistant to some currently used chemotherapeutic drugs.

ed

Apoptosis: programmed cell death. As a normal part of growth and development, cells that are superfluous or that become damaged activate a cascade of intracellular processes leading to their own demise. In cancer cells, DNA damage may inactivate the apoptosis cascade, allowing mutated cells to survive and proliferate.

e

in

ic

Lifetime risk: the probability that an individual, over the course of a lifetime, will develop or die from cancer. In the US, men have slightly less than a 1 in 2 lifetime risk of developing cancer; for women, the risk is a little more than 1 in 3.

Cancer: a group of diseases characterized by uncontrolled growth and spread of abnormal cells, which, if not controlled, can result in death. Cancer is caused by both external factors (tobacco, infectious organisms, chemicals, and radiation) and internal factors (inherited mutations, hormones, immune conditions, and mutations that occur from metabolism), two or more of which may act together or in sequence to initiate or promote carcinogenesis. Ten or more years often pass between exposure to external factors and detectable cancer.

Progression: an increase in the size of a tumor or the spread of cancer in the body. Relative risk: a measure of the strength of the relationship between risk factors and a particular cancer. It compares the risk of developing cancer in persons with a certain exposure or trait to the risk in persons who do not have this characteristic. For example, male smokers are about 23 times more likely to develop lung cancer than nonsmokers, so their relative risk is 23. Most relative risks are not this large. For example, women who

862

Appendix

have a first-degree relative (mother, sister, or daughter) with a history of breast cancer have about twice the risk of developing breast cancer compared to women who do not have this family history. Survivorship: In cancer, survivorship covers the physical, psychosocial, and economic issues of cancer, from diagnosis until the end of life. It includes issues related to the ability to get health care and follow up treatment, late effects of treatment, second cancers, and quality of life.

)2

(c 0

01 e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 863

Textbook of Functional Medicine

)2 (c

0 01

e in ic ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

864

Index and depression, 229, 230 elevated, 228–30 and heart rate, 227 and hot flashes, 223, 227–28 insulin and balance of, 215 lowering of, 230 metabolism, 229 thyroid interactions, 229–30, 627 Adrenocorticotropin (ACTH), 142, 235, 582t, 608f ADRs. See Adverse drug reactions Advanced glycation end products (AGEs), 357, 405–6, 523 Adverse drug reactions (ADRs), 39, 69–70, 693–95 commonly identified drugs in, 70t, 694t, 695t, 789 race and, 694 Aerobic exercise, 130–33, 483–86. See also Exercise benefits of, 483–84 exercise program, 484–86 Aerobic oxidation of pyruvate, 185–88 Agent Orange, 147 AGEs. See Advanced glycation end products Aging, 18–19, 111–19. See also Degenerative diseases autoantibodies and, 593 chronic degenerative diseases of, 12, 368 decreases in androgens, 220, 238, 241 healthy aging, 18–19, 111–19 inflammation and, 85–86 mechanisms, 114–15 mitochondrial decay of, 394, 506 morbidity curve, 111–14 National Institute on Aging FICSIT trails, 135–36 neuroendocrine function and, 592–93 philosophy of treatment, 244–45 population aging, 113 resistance exercise and, 135–36 AID (aminoglycoside-induced deafness), 268t AIDS (acquired immune deficiency syndrome), 210, 615–17 clinical approaches to, 616–17 dementia, 617 highly active antiretroviral therapy (HAART), 616 Air, 8, 127–29 importance of assessing, 128 oxygen as limiting nutrient, 127–28 pollution, health effects of, 128–29 ALC. See Acetylcarnitine Alcohol bacteria-mediated production of, 568 and carcinogenesis, 355, 361 in diet, 358t, 598, 634 and oxidative stress, 362t and pancreatic secretions, 191 Alcoholism alcoholic liver disease, 567

NOTE: An f after a page number denotes a figure; a t denotes a table.

A

)2

(c

A NERD (mnemonic), 552–53 AA. See Arachidonic acid AAS. See Anabolic-androgenic steroids Abdominal fat, 245, 742t Absorption, 190–91, 330–32. See also Digestion and absorption, under Digestion imbalances associated with, 327–37, 435–44, 649 optimization of, 440–41 Accuracy, of laboratory tests, 707 Acetaldehyde, 568 Acetaminophen detoxification, 289, 289f Acetyl-CoA, 175, 185, 267 in acetylcholine production, 640 Acetylation, 280 Acetylation stimulating protein (ASP), 743 Acetylcarnitine (ALC), 114, 394, 640t supplementation for mitochondrial function, 362t Acetylcholine (ACH), 582t, 640 modulation of, 640t, 643 ACH. See Acetylcholine Acidic fibroblast growth factor (aFGF), 409 Aconitase, 270 Acquired immune deficiency syndrome. See AIDS Acrometagenic, 381–82 ACTH (adrenocorticotropin), 142, 235, 582t, 608f Action potential, 259–60 Acute myocardial infarction, 408–9 Adenosine, 643 Adenosine triphosphate. See ATP (adenosine triphosphate) ADHD, 639, 640t, 641–42, 768–785 (case) omega-3 fatty acid therapy, 87 Adhesion molecules, 306, 314, 587, 743 intercellular (ICAMs), 205, 582t, 587, 743 Adhesive capsulitis, 341 Adipocytes, 743 Adipokines, 743 Adiponectin, 179, 743 Adipose tissue AMPK in, 177 as endocrine organ, 743 Adrenal glands. See also Hypothalamic-pituitary-adrenal (HPA) axis adrenal exhaustion, 650 stress and, 604–5, 650 symptoms of adrenal imbalance, 357 Adrenaline, 12, 215, 223, 227–28 and anxiety, 228, 229, 624 and body type, 623 chronically elevated, 229 and cortisol, 229–30, 623 counterbalancing, 228–29

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 865

Textbook of Functional Medicine

NSAIDs, 70t, 311–13, 317 alternatives to, 414–17 Anti-inflammatory therapeutic interventions, 315, 414–17 Anti-rheumatic drugs, 314 Antibiotics, 55, 70t, 380t antibiotic-resistant bacteria, 385 residues in foods, 385, 647 Antibodies, 193–95 autoantibodies, 592, 599–600, 601 B-cells as source of, 210 role of, 195f Anticoagulants, 70f Anticonvulsants, 70f Antidepressants, 70t Antidiabetic agents, 70t Antiemetics, 70t Antigen-presenting cells (APCs), 209, 300–301, 565 Antihistamines, 70t Antioxidants, 10, 24, 113, 118, 119, 154, 155, 197, 259, 268, 270, 278, 281, 295, 322, 355, 359 Alzheimer’s disease and, 24, 118 as anti-inflammatory, 281 antioxidant capacity, 102 antioxidant enzymes, 270 antioxidant therapies, 271 biological response modifiers, 320 blood levels, 108 CoQ10, 113, 116, 259, 267, 268, 270, 503, 504 defenses (superoxide dismutase), 281 deficiency of, 357, 361 dietary, 259, 361 as dietary supplements, 635, 647 endogenous, 259 essential fatty acids (EFAs), 308, 361, 418–27, 468, 509–10 estrogen-like properties, 197 glutathione, 174–75, 292–93, 509, 586 herbal, 363t, 789 in HIV/AIDS treatment, 617 hyperglycemia and, 527–29 idebenone, 270 inflammation regulation, 356 and intercellular signaling, 586–87 lipoic acid, 114, 154, 394, 586–87 lowered in autism, 514t lycopene, 154 melatonin, 154, 582t, 640t metallothioneins and, 294 and mitochondrial function, 507–9 mitochondrial protection, 271 neuroprotective effects of, 270 nutritional support, 293 polyphenols and, 293 regulation of NFB, 322 in rosemary, 294 substrates optimizing, 271 support, 281 therapy, 322 vitamin C, 116, 154, 603 vitamins, 45 zinc, 374, 468, 521, 601, 646 Antiporter, 282–83, 282f Antipsychotics, 647 Anxiety, 226–27, 228, 230, 362t, 640t cortisol and, 229

)2

(c

chronic, 230–40 vitamin supplements and, 509 Aldosterone, 582t Aldrin, 149t Alexander, B. Jayne, 140, 790 Alkaptonuria, 10 Allergies. See Autoimmune diseases; Autoimmunity; Food allergies Allium sativa. See Garlic Allostasis, 138 Allostatic load, 138, 145–46, 670 Alosetron, 459 Alpha blockers, 744 Alpha lactalbumin (LAC), 642 -keto acid dehydrogenase, 586 -lipoic acid, 586–87, 622. See also lipoic acid supplementation for mitochondrial function, 362t ALS (amyotrophic lateral sclerosis), 271, 362t, 640, 644 Aluminum, 290, 549 Alzheimer’s disease, 71, 221, 236, 240, 258t, 269, 292, 300, 303, 315, 355, 371t, 394, 512, 514, 605, 644 acetylcholine in treatment of, 640, 643 antioxidants and, 24, 118 glutamate excess and, 640 and Herpes simplex, 585 NOS and, 262 and oxidative stress, 362t and stress (cortisol), 583 Ames, Bruce N., 12–13, 114, 355, 388, 508, 790 Amino acid neurotransmitters, 640 Amino acids insulinotropic, 126 needs during detoxification, 549 supplementation, 364t, 523, 617, 635 Aminoglycoside-induced deafness (AID), 268t Amiodarone (Cordarone), 647 Ammonia, 564–65 Amoxicillin, 70f, 380t AMP-activated protein kinase (AMPK), 175–77 AMPK (AMP-activated protein kinase), 175–77, 179 AMPKK, 174 Amygdala, 610 Amyotrophic lateral sclerosis (ALS), 271, 640, 644 Anabolic-androgenic steroids (AAS), 134–35, 237 Anaerobic catabolism of glucose, 183–85, 184f, 503 Anaphylaxis, 309 Anastrozole (Arimidex), 243 Androgens, 220. See also Male hormones; Testosterone age-related decrease in, 220, 238, 241 androgen receptor (AR), 235–36 androgenic vs. anabolic effects, 234 effects of, 235–38 Androstenedione, 220, 234, 235f, 631, 633 and DHEA, 240–41, 604–5, 611 Anemia, X-linked sideroblastic, 268 Angiotensin-converting enzyme inhibitors (ACEIs), 70t, 423, 744 Angiotensin-II, 741, 743 Angiotensin-receptor blockers (ARBs), 744 Angiotensinogen, 743 Ankylosing spondylitis (AS), 332, 441 Antecedents of illness, 80–81 Anti-inflammatory substances, 350t, 415–17. See also Inflammation antioxidants, 281 botanicals, 416–17 dietary omega-3 fatty acids, 420–27

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 866

Index

neuroendocrine function and, 101–3, 592 thyroid, 341, 599–600, 599–602, 645, 647, 649 Autoimmunity autism, 516 endocrinological influences, 411, 592, 624–25, 633 environmental/xenobiotic influences, 365, 411–12 inflammation and, 308, 314, 371t, 409–17 multiple manifestations of, 410–13, 750–767 endocrinological influences, 411 environmental/xenobiotic influences, 411–12 gastrointestinal and mucosal influences, 412–13, 435–36, 444– 45, 568 neurogenic influences, 413 nutritional influences, 413 psychoemotional influences, 410–11 triggers of, 368 Autonomic nervous system dysfunction, 497–98, 742t Autonomic signaling, 611 Awareness, 258 Azoreductases, 564 Azoospermic males, 238

)2

(c

APCs. See Antigen-presenting cells Apolipoproteins, 196 Apoptosis. See Cell death Applying Functional Medicine in Clinical Practice (AFMCP), 695 AR (androgen receptor), 236 Arachidonic acid (AA), 306, 312, 340, 413, 418–20, 507, 571, 582f, 642 and autism, 523 cascade, 420f and migraine, 42f ARBs (angiotensin-receptor blockers), 744 Arginine, 133–34, 167, 262, 289, 330, 357, 358t, 364t, 374, 612 Arimidex (anastrozole), 243 Aromatase, 231, 236 Arsenic, 290 Arthritis, 37, 58, 71, 81–82, 84–85, 103, 190t, 339, 371t, 380t, 412, 414, 448, 497, 589. See also Osteoarthritis; Rheumatoid arthritis fasting and, 561 psoriatic, 632 Artificial fats, 383 Artificial intelligence research, 41–43 Artificial sweeteners, 358t, 384–85 AS (ankylosing spondylitis), 332, 441 ASP (acetylation stimulating protein), 743 Aspartame, 384–85 Aspirin, 311–13 detoxification of, 290, 290f low-dose, 744 Asthma, 438, 463 fish oils and, 423–24 and oxidative stress, 362t Atenolol, 70t Atheromatous plaque, 406–7 Atherosclerosis, 60, 102, 126, 146, 203, 206, 211t, 246, 300, 303–4, 353, 405–8, 426, 588–89, 595, 741, 743 and DHEA, 240 Atopic syndrome/disease, 200, 299, 305–6, 312, 324, 326, 463 omega-3 fatty acid therapy, 87 ATP (adenosine triphosphate), 183–88, 699 in glycolysis, 183–84 mitochondria and, 265, 269, 507 structure of, 184f Attention deficit/hyperactivity disorder (ADHD), case presentation, 768–95 Autism, 445, 512–26, 640t blood brain barrier and, 516, 516t excitotoxic markers in, 518, 518f impaired cholinergics in, 518–19 impaired energetics in, 517–18, 518f lipofuscin in, 512–13, 513f melatonin deficiency and, 643 nutrients in treatment of, 519–23 oxidative stress in, 512–22, 514t future directions, 524–25 laboratory assessment of, 523–24 serotonin and, 639 Autoantibodies, 592, 593, 599–600, 601, 603 Autoimmune diseases. See also Rheumatoid arthritis and antigenic exposure, 305, 449 case presentation, 750–767 and elimination diet, 369, 463, 561 estrogen and, 231 and gluten sensitivity (or celiac disease), 60, 80, 319, 369, 370t hormones and, 230–32, 236 mechanisms, 231

01

B

0

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

B cells, 194, 210, 221, 422, 565 B-complex nutrients, 116, 219, 224, 357, 391–92. See also Vitamins Back pain, 496 Bacteria. See Microorganisms Bacterial infections, GI, 380t Bacteroides, 564 Baker, Sidney MacDonald, 10, 55, 696, 754 Balance. See Dynamic balance Balance exercises, 489–90 Basal body temperature, 645 Bayer, Friedrich, 311 Bayes inference, 42–44, 43f Benign prostate hypertrophy (BHP), 238–39, 243 Bennett, Peter, 554, 556, 790 Benzodiazepine-like compounds, 565 Beta-amyloid, 262 Beta-blockers, 70t, 744 Beta carotene, 154, 163, 365t, 508–9, 598 Beta-glucuronidase, 564 BFRs. See Brominated flame retardants BHA (butylated hydroxyanisole), 385 BHP (benign prostate hypertrophy), 238–39, 243 BHT (butylated hydroxytoluene), 385 Bicarbonate, 191 Bifidobacterium, 446, 447, 451, 467. See also Probiotics Bile, 332 Bioactivation, vs. bioinactivation, 277 Biochemical individuality, 6, 55–78 detoxification and, 70–71, 548–52 early life effects on, 73 environment in, 70–71 epigenetic effects, 73 future of, 74–75 history of, 64–66 knowledge base in, 63–75 nutrition and, 71–73 proteomics and metabolomics, 73–74 Biochemical mediators, 85–86 Bioenergetics, 8, 183–88 aerobic oxidation of pyruvate, 185–88, 186f energy from food, 187

867

Textbook of Functional Medicine

progesterone and, 219, 225 insulin and, 225–26 risk factors, 224–26, 227t, 361, 632 Breastfeeding, 151, 453 Broccoli, 154 “Broken Toe” case, 695, 696f, 699–700 Brominated flame retardants (BFRs), 148–49 Bronchial asthma, fish oils and, 423–24 Bronchodilators, 70t Butterfly effect, 308

in functional medicine, 501–12 glycogen, 187 glycolysis, 183–85, 184f Krebs cycle, 186, 186f oxidative phosphorylation, 186–87, 187f Biofilms, 332–33 Bioflavonoids, 154, 278, 296, 319, 372t Bioinactivation, vs. bioactivation, 277 Biological variation, 708 Biotin, 357, 358t, 364t, 377t, 388, 621, 739, 744t deficiency, 393 in insulin balance, 621 Biotransformation, 183–88, 277–81, 543–80. See also Detoxification; Detoxification/biotransformation imbalances bioinactivation vs. bioactivation, 277 clinical approaches to, 543–80 clinical implications of, 280–81 defined, 277 enzyme system interactions, 547f gut-liver axis, 562–72 imbalances, 275–98, 341–42 phase I and phase II reactions, 278–80, 279f, 281f importance of balancing, 281–82 Bipolar disease, 640, 640t Bismuth, 380t Bland, Jeffrey S., 5, 10, 11, 20, 111, 123, 127, 189, 501, 543, 581, 590, 790 Blood-brain barrier, 259, 314 in autism, 516, 516t hypothalamic components located outside, 610 injured by nitrite, 515 oxidative stress sensitivity, 516 BNDF (brain-derived neurotrophic factor), 642 Body-building effects of androgens, 236–37 Body weight, testosterone and, 237 Bombesin, 582t Bone effects of androgenic steroids on, 236, 237 health cortisol and, 145–46 estrogens and, 233 exercise and, 136–37 Bone marrow cells, vulnerability to radiation, 153–54 Borrelia burgdorferi, 85 Boswellia (Boswellia serrata), 417, 420, 634 Bradykinin, 204, 306 Brain in digestion, 327 effects of androgens on, 235–36, 237–38 and estrogens, 226–27 functional approaches in practice, 640–43 gut-brain axis, 334, 376t oxidative stress sensitivity, 516 second brain, 327 Brain-derived neurotrophic factor (BNDF), 642 Brassica family of vegetables, 95, 154, 218, 283, 293 and thyroid function, 595, 646–47 Breast cancer BRCA genes, 224, 227t cortisol and, 219, 226 glucose metabolism and, 225–26 hormones and, 224–26 estradiol and, 584 estrogen and, 224–25

C

)2

(c

C-reactive protein (CRP), 307, 408, 409, 411, 582t, 743 C3 (complement 3), 743 Cabbage, 154, 283 CAD. See Coronary artery disease Cadmium, 290, 549 Caffeine, 288–89, 571 Calbindin, 455, 644 Calcitonin, 455 Calcitonin gene-related peptide (CGRP), 455 Calcium channel blockers, 70t deficiency, 393–94 levels for postmenopausal women, 136–37 supplementation for mitochondrial function, 364t Calcium channel blockers (CCBs), 744 Calcium-D-glucarate, 635 Calor, 203, 299 Caloric restriction, 363, 553, 557 Calprotectin, 443, 448 Calretinin, 456 CAM (complementary and alternative medicine), 317 Cancer. See also Breast cancer; Colorectal cancer; Prostate hypertrophy insulin resistance and, 247 nutrients and, 116, 391t, 545–46 and oxidative stress, 362t risk, 392–93, 546 and detoxification, 546 and smoking, 71 Candida, 332, 333, 411, 449 case presentations, 750–785 albicans, 333 glutamine as a substrate for, 449 Cannon, Walter, 138, 318 Carbamazepine, 70f Carbohydrates, 176, 187, 190, 191, 196, 329, 348–52, 354, 355, 383, 386–87, 585, 618–20, 624, 633, 648 carbohydrate-rich foods, 568 complex, 615 cravings for, 378, 618, 624 excess, 176 glycemic load and, 357 high-carbohydrate diet, 181, 383, 549, 619–20 and LDL phenotype, 355 low-carbohydrate diet, 336, 571 meals, 359, 618 metabolism, 225, 608f and aerobic exercise, 131–32 nondigestible, 544 protein-carbohydrate complex, 582 proteins digested into, 190 refined, 49, 303, 315, 317, 351, 357, 358t, 383, 384, 615 therapeutic strategies, 360t, 376t

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 868

Index

585–88, 601 xenobiotics and dysfunction, 584–85, 601–2 neurotransmitters, 589–90 Cellular messaging: tissue sensitivity and intracellular response, 590– 609 adrenal function and stress, 604–5 evaluating growth hormone function, 605–7 GH replacement considerations, 606–7 GH supplementation, 607 stimulating GH release, 607 evaluating thyroid function, 593–604 alternatives to laboratory testing, 594 clinical effects of thyroid imbalance, 599 heterodimerization, 598 inflammatory cytokines and, 600–601 iodination of thyroxine and related processes, 595–96 laboratory thyroid screening, 594–95 managing HPT axis imbalances, 602–3 maternal thyroid dysfunction effects, 595 mitochondria and, 598–99 molecular biology of thyroid hormone action, 596 natural therapies for thyroid dysfunction, 603–4 resistance to thyroid hormone, 597–98 soy consumption and, 596–97 subclinical thyroid dysfunction, 593–94, 595 supplementation and, 603 thyroid autoantibodies, 599–600, 601 thyroid hormone antagonists, 597 TSH/TPO testing, 594, 597, 600 vitamin A and, 598 vitamin D and, 601 xenobiotics and, 601–2 HPA axis, 590–91 melatonin and menopausal female neuroendocrine system, 607–9 neuroendocrine mediators, assessing and balancing, 591–92 neuroendocrine system as indicator of cellular aging, 592–93 stress and adrenal function, 604–5 Central nervous system. See also Brain; Nervous system in digestion, 327–28 response to stress, 141–42, 142f Ceruloplasmin, 551 CFIDS, 369, 491 CFS. See Chronic fatigue syndrome CGRP (calcitonin gene-related peptide), 455 Challenge testing, 288 Change, 33–46, 722–28 continuing medical education and, 29–30 feedback and, 720–22 health promotion programs, 681–82 helping patients change behaviors, 670–71, 722–28 motivating patients, 719–20 stages of change model, 681 Transtheoretical Model (TTM) of, 723–28 decisional balance (Pros and Cons), 724 intra- and Internet expert system program, 727 processes of change, 724–25 self-efficacy, 724 staged-matched interventions, 725–27 stages of change, 723, 725f CHD. See Coronary heart disease Chemokines, 205 Chemotaxin, 743 Chemotherapy, antioxidants and, 635 Cheney, Paul, 510–11

)2

(c

types, 124–25 and yeast infections, 378 Carbohydrate types, 124–25 Carcinoma ionizing radiation and, 152–53 Cardiolipin, 266 Cardiovascular disease (CVD), 59–60, 729–49. See also Coronary heart disease (CHD) atherosclerosis and, 405–8 case presentation/extended discussion, 729–49 causation in, 351–54 cytokines and, 207t DHEA and, 240 diet and, 351–54 inflammation and, 203–12, 211t and oxidative stress, 362t prevention, 744 risk factors, 165, 426–27, 740, 741, 744 testosterone and, 237 Cardiovascular risks, screening before exercise, 483 Cardiovascular system benefits of aerobic exercise, 484 and immune system, 102 symptoms associated with food allergy/intolerance, 190t Carnitine, 503, 509, 512, 643, 699 Carnitine palmitoyl transferase-1 (CPT-1), 176, 187 Carnosic acid, 602–3 Carson, Rachel, 148 Case-based reasoning, 42 Case presentations, metabolic syndrome, 729–49, 750–767 Casein, 564 casein-free diet, 523 Catechins, 528 Catechol-O-methyltransferase (COMT), 224, 366, 632–33, 634 Catecholamines, 638–40 and body type, 623 Cat’s Claw (Uncaria spp), 416, 440 Causation in cardiovascular disease, 351–54 causality models, 36–39, 351–52 epidemiological association and, 241 randomized clinical trials and, 33 CCBs (calcium channel blockers), 744 CD. See Celiac disease CD8 cells, 209 CD40 ligand, 207t Celiac disease (CD), 60, 80, 319, 331, 568 Celiac sprue, 370t Cell adhesion molecules. See Adhesion molecules Cell death (apoptosis), 231, 265, 267, 270, 271 glutamate and, 640 mitochondria and, 506–7 programmed, 265 Cellular communication. See Cellular messaging Cellular insensitivity to insulin signaling, 98–99 Cellular interventions, 698–99, 700 Cellular membrane, and thyroid function, 649 Cellular messaging, 581–90 altered cellular communication and disease risk, 588–89 classes of intercellular communication agents, 582t environmental impact on, 583–88 chronic stress and dysfunction, 583–84, 600–601 inflammation and dysfunction, 585 nutrients and intercellular communication/gene expression,

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 869

Textbook of Functional Medicine

Coenzyme Q10 (CoQ10), 116, 267, 268, 270, 365t, 737t as conditionally essential nutrient, 509 hyperglycemia and, 528 mitochondrial protection from oxidative stress, 503, 504 supplementation for mitochondrial function, 362t Cognitive function, 258–59 androgens and, 235–36 decline/impairment, 246, 258, 258t, 640t DHEA and, 240 insulin imbalance and, 246 therapy, 676 Collagenases, 408 Colon. See Large intestine Colonoscopy, 443 Colony stimulating factor-1 (CSF-1), 743 Colorectal cancer (CRC), 445 Commensal microorganisms. See under Microorganisms Communication, doctor-patient, 715–16 Communications, intracellular and extracellular, 8, 171–82 cellular messaging, 581–90 intercellular communication agents, 582t intracellular environment: oxidative stress, 174–77, 174f metabolic syndrome, 177–79 signal transduction, 171–74, 172f Community, and stress, 674–76 Comorbidity, 18, 35 Complement 3 (C3), 743 Complementary and alternative medicine (CAM), 317 Complex I, 270–71 Comprehensive history-taking, 692–95, 693t Comprehensive physical exam, 695–98, 697t COMT (catechol-O-methyltransferase), 224, 362, 366, 632–33, 634 Concussion, case study, 146–47 Conflicts of interest, 56 Conjugated linoleic acid (CLA), 308, 510, 699 and insulin balance, 621–22 Constipation, 459–60 Contemplators, 726 Continuing medical education (CME), 3, 28–30 Contractions, 495 Coping skills, 139–40. See also Stress CoQ10 See Coenzyme Q10 (CoQ10) Cordarone (amiodarone), 647 Corn syrup, high fructose (HFCS), 383–84 Coronary artery disease (CAD) ALA and, 425–26 fish intake and, 424–25 omega-3 fatty acid therapy, 87 Coronary heart disease (CHD), 740. See also Cardiovascular disease (CVD) diet and, 353f and insulin imbalances, 245, 246–47 omega-3 fatty acid therapy, 87 risk of, 116 Corpus callosum, 610 Corpus luteum, 219 Corticosteroids, 70f, 70f, 192t, 235, 409, 419, 422–23, 608f, 624, 694t, 736t Corticosterone, 235 Corticotropin-releasing factor (CRF), 230, 234, 235 L-tryptophan and, 642 Corticotropin-releasing hormone (CRH), 85, 144, 146 as a neurotransmitter, 612 and ACTH production, 235

)2

(c

Chlamydia pneumoniae, 210, 585 Chlordane, 149t Chlorophyll, 545 Cholesterol, 158, 168, 198, 234–35, 255–56, 267, 329, 332 benefits of aerobic exercise, 484 cholesterol emboli syndrome, 210–11 cholesterol-lowering foods, 325 elevated, 595 HDL-cholesterol, 168, 226, 237, 245–46, 618, 737t to HDL ratio, 383 hypercholesterolemia, 156, 240, 255, 325 LDL-cholesterol, 156, 168, 482, 595, 737t and male sex hormone synthesis, 235f precursors, 315 serum, 315 synthesis, 181, 267 VLDL-cholesterol, 619 Chondroitin sulfate, 415 Chromium, in insulin balance, 621 Chronic alcoholism, 230–40 Chronic Care Model, 17–18 Chronic constipation, 458 Chronic degenerative diseases, 292 Chronic disease, 56–58 Chronic Care Model, 17–18 degenerative diseases of aging, 12 diet and, 350–51 exercise and, 137 GALT and immunity and, 369 immune imbalance/inflammation and, 85–86, 299–300 lifestyle changes and, 113 management of, 15–18 Chronic fatigue syndrome (CFS), 51–52, 510–11 and oxidative stress, 362t Chronic progressive external ophthalmoplegia (CPEO), 260t, 268t Chronic stress. See under Stress Chrysin, 547 Chyme, 191 Cigarette smoke/smoking, 71, 288, 363t, 395, 619 Cilansetron, 459 Cimetidine, 286 Cinnamon, 622 Circulation, 8, 196–97 Cirrhosis, liver, 564 CLA. See Conjugated linoleic acid Cline, John, 147, 790–91 Clinical/core imbalances, 9–11 Clinical decision-making, 36–44 artificial intelligence and ways of thinking, 41–44 Bayes inference, 42–44, 43f case-based reasoning, 42 critical thinking in, 40–41 fuzzy logic, 42 integrating spirituality into, 678–80 neural networks, 42 rules-based systems, 42 Clinical intervention. See Intervention, clinical Clinical trial, 50 Clinician training, 27–31 Clostridium, 564 Cloves (eugenol), 420 CME (continuing medical education), 3, 28–30 CoA. See Acetyl-CoA Cobalamin, 361

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 870

Index

Cystic fibrosis omega-3 fatty acid therapy, 87 and pancreatic secretions, 191 Cytochrome c, 267 Cytochrome P450, 195–96, 269 in detoxification, 195–96, 279–80, 284–86 enzymes and genetic polymorphism, 284–86 genetic polymorphisms and, 694 mind-spirit research and, 166 substrates/inhibitors/inducers, 815–820 in testosterone synthesis, 234–35 Cytochromes, 60–70 Cytokines, 205, 206–8, 207t. See also Tumor necrosis factor in atherosclerosis, 406–7 in autism, 514 in autoimmune diseases, 231 in cardiovascular inflammation, 207t and HPA axis, 142, 613–14 in inflammation, 207t, 303, 306–10 inflammatory, and thyroid function, 600–601 monoclonal antibodies against, 314–15 polymorphisms, 225 proinflammatory, 231, 271, 302, 307, 309 in stress, 141 suppression of release of, 142 Th1/Th2, 305, 441, 448, 565, 601

)2

(c

action in the HPA axis, 611–13 behavior and, 613 in HIV/AIDS treatment, 616 interaction cascade, 608f in PCOD/PCOS, 614 and stress, 139, 142, 584 Cortisol, 341, 582t and anxiety, 229 blood sugar and, 229 and body type, 623 and breast cancer, 219 breast cancer and, 226 in depressed males, 238 depression and, 85 diurnal rhythm, 166, 248, 251 elevated, 142, 229 and HPA axis, 142 inhibits bone formation, 145–46 in stress, 139, 229, 583–84, 650 in women, 160 excretion, 248 as hormonal nutrient regulatory system, 190 hydroxycortisol, 289 hypercortisolism, 90 as inflammation mediator, 307 insufficiency in inflammatory/rheumatic disorders, 341 insulin and balance of, 215 norepinephrine-cortisol ratio, 146 nuclear receptors for, 174 thyroid interactions, 645 Cosgrove, Daniel, 234, 791 Cost of diabetes, 19–20 of healthcare, 16–17 COX (cyclooxygenase), 418–20, 699 inhibitors, 8, 312–13, 341, 419–20 receptors, 440 CPEO (chronic progressive external ophthalmoplegia), 260t, 268t CPT-1. See Carnitine palmitoyl transferase-1 CRC (colorectal cancer), 445 Creatine, supplementation for mitochondrial function, 362t CREB, 641, 642 CRF. See Corticotropin-releasing factor CRH. See Corticotropin-releasing hormone Crinnion, Walter J., 554, 791 Critical thinking, 40–41 Crohn’s disease, 85, 314, 330, 331–32, 422 gut flora and, 464 intestinal immune system and, 565 Cromolyn, 569 CRP (C-reactive protein), 408, 409, 411, 582t in thyroid disorders, 601 Cruciferous vegetables, 361, 366, 367t, 440, 634, 646 Cryptosporidium spp., 379t CSF-1 (colony stimulating factor-1), 743 CT scans, 698 Cultural norms, 676 Curcumin. See Turmeric CVD. See Cardiovascular disease Cybernetics, 318 Cyclooxygenase. See COX CYP, single nucleotide polymorphisms, 631, 632–33, 694 Cysteine, 523, 550, 572 Cysteinyl LTs (CysLT), 423–24

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All D

e

in

ic

ed

DAG. See 1,2-Diacylglycerol Dairy products, 438, 450–51, 634 Darland, Gary, 171, 183, 791 2,4-D, 147 DDT, 149t, 385 Death leading cause of in hospitals, 56 and stress, 673–74 Decision-making. See Clinical decision-making Decisional balance (pros and cons), 724 Defense systems of the body, 191–96, 204–6, 329–30 Degenerative diseases, 11, 12, 65, 94, 118, 247, 292, 343, 348, 368, 373, 388, 389. See also Aging; Neurodegenerative disorders Degrees of freedom, 127 Dementias, 258, 258t, 640t Dendritic cells, 301, 565 Depression, 85–86, 228–29, 230, 362t Beck Depression Inventory (BDI), 238 neurotransmitter imbalances and treatment of, 641–42 serotonin and, 639, 640t, 641–42 testosterone and, 238 DES (diethylstilbestrol), 385 Detoxification, 195–96, 543–80. See also Biotransformation; Detoxification/biotransformation imbalances A NERD (mnemonic), 552–53 balancing phase I and phase II, 281–82 and biochemical individuality, 70–71 capacity, 366t clinical approaches to, 543–80 clinical implications of, 280–81 clinical perspective on, 290–94 defined, 275–77 diet and, 365–67 disclaimer concerning procedures, 553–54 discovery of, 276 enzymes, 195–96, 282–83, 284–85

871

Textbook of Functional Medicine

and oxidative stress, 362t and pancreatic secretions, 191 refined carbohydrates/sugars and, 384 type 1, 85, 445 type 2, 19, 125, 177–78, 245–46 AMPK activation in, 179 antidiabetic agents, 70t diabetic polyneuropathy, 587 high-carbohydrate diets and, 619 nutrient protection and, 116 treatment for, 744 1,2-Diacylglycerol (DAG), 173 Diagnosis in functional medicine, 9, 10, 39–40 organ system, 8 patient-centered, 10 Diarrhea, 459 Dieldrin, 149t Diet, 8, 123–27, 190–91. See also Dietary supplements; Nutrients; Nutrition and aging population, 18–20 beneficial dietary habits, 350t caloric restriction, 363, 553, 557 carbohydrate types and, 124–25 changing, 681–82 and chronic diseases, 16, 351–54 clinical nutrition, 349–50, 387–88 detoxification and, 365–67, 553 diet-gene interactions, 354–55 dietary assessment, 703–6 dietary choices, 348–49 digestive function and, 373–82 disease components, 383–84 elimination diet, 375, 438–39, 450–51, 703–6, 711f patient handouts for, 800–14 for estrogen metabolism disorders, 633–35 and genetic risk, 126 gluten-free, 523, 600 glycemia, insulinemia, and food proteins, 126 glycemic index, 125 high carbohydrate, 181, 383, 549, 619-20 hypoallergenic, 600 lifestyle and, 350–51, 376t low-carbohydrate , 336, 571 low-GI dietary plan, 620 Mediterranean-style, 124, 351 micronutrient insufficiency, 388–95 and nutrients, 123–24, 347–88 and nutrition, 347–88 oligoantigenic, 375, 438, 463, 557, 561, 562, 704 optimal fat intake, 427 optimal function and, 356–82 dietary influences on function, 373–81 hormonal balance, 357–62 oxidative stress/mitochondrial function/energy metabolism, 362–65 in prevention and treatment, 19–20 risk in, 383–86 standard American diet (SAD), 340, 364 3-Day Diet Record, 693, 857 whole grains and insulin sensitivity, 125 Dietary reference intakes (DRIs) of nutrients, 60 Dietary supplements, 363t, 562, 634–35 for detoxification, 367t

)2

(c

effect of xenobiotics on, 584 enzyme system interactions, 547f factors influencing, 283t fasting and, 548–49, 557–61 contraindications to, 561 genetic and environmental influences on, 543–54 genetic variability and, 544–45 gut-liver axis, 562–72 home-based, 556–62 fasting, 557–61 fasting contraindications, 561 oligoantigenic diet, 561 sauna/hydrotherapy, 561–62 seven day plan, 558–60 supplements, 562 inhibitors of, 284t intestine, role of, 282–83 lifestyle, 552–53 liver detoxification pathways, 278f markers, 698 metallothioneins and, 285 modulators/influencers of, 545–48 and musculoskeletal pain, 341–42 phase I, 218, 276, 278–80, 279f, 545–46 phase II, 218–19, 224, 276, 280, 281f, 545–46 plant compounds influencing, 293t, 545 regulation of, 283–87 age, gender, and disease influences, 285, 285–86 enzymes and genetic polymorphism, 284–87 induction activities, 283 inhibition activities, 283–84, 284t medication effects, 286–87 systemic in-office, 554–56 systems, 275–77 Detoxification/biotransformation imbalances, 275–98, 341–42. See also Biotransformation; Detoxification clinical perspective on, 290–94 functional assessment of phases I and II and toxic load, 287–90 challenge testing, 288 probe substances, 288–90, 289f testing for toxic element presence, 290 importance of balancing Phases I and II, 281–82 regulation of detoxification, 283–87 supporting detoxification systems, 292–93, 548–53, 556–72 and thyroid function, 648 Devil’s Claw (Harpagophytum procumbens), 416 DGLA (dihomogamma-linoleic acid), 418, 419, 421, 523 DHA (docosahexaenoic acid), 86, 308, 420f, 422–23, 468 functions of, 509, 602 and intercellular signaling, 586 in treatment of inflammation, 341 DHEA (dihydroepiandrosterone), 231, 234, 240–41, 308, 604–5 and androstenedione, 240–41, 604–5, 611 in hypopituitary conditions, 604–5 insufficiency in inflammatory/rheumatic disorders, 341 in intercellular communication, 582t not an androgen, 240–41 replacement, 605 in testosterone therapy, 242–43 DHT. See Dihydrotestosterone Diabetes, 176. See also Insulin resistance diabetic gastroparesis, 458 mitochondrial dysfunction and, 174, 510 noninsulin dependent, 24, 132, 176

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 872

Index

questions to ask, 717–19 rapport, 713–14, 716–17 Dolor, 203, 299 Dong quai, 635 Dopamine, 582t, 608f, 638–39, 643 hyperdopaminergic states, 642–43 hypodopaminergic states, 642 imbalances, treatment of ADHD and depression, 641–42 modulation of, 640t Dorsal root ganglion, 458 Down syndrome, and thyroid abnormalities, 599, 600, 601 Downstream medicine, 22–23 Dreser, Heinrich, 311 DRIs (dietary reference intakes) of nutrients, 60 Drucker, Peter, 3, 4 Drug reactions. See Adverse drug reactions Drug resistance, 197, 385 Drugs, top-selling, 789 Dubos, René, 356 Dynamic balance, 6, 8 Dysgraphia, case presentation, 768–85 Dyslipidemia, 59, 744 Dysmenorrhea, omega-3 fatty acid therapy, 87

)2

(c

fiber, 376t herbal, 363t, 789 for inflammation, 372t for metabolic syndrome, 744t mineral, 239 noted in patient history, 693 vitamins, 394, 509 Diethylstilbestrol (DES), 385 Dieting, and metabolic rate, 647 Digestion, 189–97 digestion and absorption, 190–91, 330–32, 435–44 clinical treatment for, 438–44 complex interactions, 436 elimination diet, 438–39 enzymatic function, 436–37 function and dysfunction in, 435–37 laboratory testing for, 442–43 small intestinal phase, 437 symptoms, 436 digestive enzymes, 191, 328, 436–37, 465–66 function, 373–83 GI mucosal barrier, 191–92, 192f gut-brain axis, 334, 376t imbalances associated with, 327–37 clinical implications of, 333–34 digestive function, 373–81 and thyroid function, 649 protection and defense systems, 191–95 structures of digestive system, 327–30 symptoms and diseases associated with, 190t Digoxin, 70t Dihomogamma-linoleic acid (DGLA), 418, 419, 421, 523 Dihydroepiandrosterone. See DHEA Dihydrotestosterone (DHT), 236, 238–39, 243 Diltiazem, 70t Dimer-captosuccinic acid (DMSA), 555 Dioxins, 149t, 189 Diphosphatidylglycerol, 266 Disease. See also Chronic disease antecedents, triggers, and mediators, 79–91 long-latency disease, 61–62 mechanisms of, functional medicine approach to, 691, 701 prevention, 15–16 health promotion programs, 681–82 Diuretics, 70t, 744 DMARDs, 314 DMSA (dimer-captosuccinic acid), 555 DNA, 67t damage, 388–94 ionizing radiation and, 153–54 methylation, 361, 634 mitochondrial, 266, 267–68, 504–5, 592 noncoding regions of, 68f structure, 20 undermethylated, 304 Doctor-patient relationships, 713–22. See also Patient-centered care communication, 715–16 emotional states, 714–15 feedback, 720–22 helping patients change, 670–71, 722–28 matching, 717 motivation, 719–20 pacing, 717 presuppositions, 714, 722

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

E

e

in

ic

ed

EAE (experimental autoimmune encephalomyelitis), 262 EBM. See Evidence-based medicine EC. See Enterochromaffin (EC) cells Eckhardt, Robert, 74–75 Economic burden, 16–17 Education, in stress assessment, 675 EFAs. See Essential fatty acids EGF (epidermal growth factor), 225 Eichengrun, Arthür, 311 Eicosanoids, 198, 279, 308, 418–19 Eicosapentaenoic acid. See EPA EKG (electrocardiogram), 127 Electrocardiogram (EKG), 127 Electrolytes, 70t Electromagnetic fields, 154–55 Electromagnetic therapies, 155 Electron transport, 186–87, 187f Elimination diet, 375, 438–39, 450–51, 703–6, 711f patient handouts for, 800–14 Elimination of waste, 8, 197–99 Encephalopathy, 291–92 Endocrine benefits of aerobic exercise, 484 Endocytic receptors, 302 Endometriosis, 232–33, 637–38 Endorphins, 582t Endotoxin, 204, 205, 566 Endrin, 149t Energy, 183–88. See also Bioenergetics; Oxidation-reduction imbalances from food, 187, 190–91 metabolism, 362–65 mitochondria and, 502–4 from oxidation, 259–60, 265–66, 502–4 production imbalances, 342 requirements of nervous system, 258–59 ENS. See Enteric nervous system Entamoeba histolytica, 379t Enteric nervous system (ENS), 327–28, 331, 453–62 neuronal detection of intraluminal conditions, 453 neuropathies of, 334

873

Textbook of Functional Medicine

Esophagogastroduodenoscopy (EGD), 443 Essential fatty acids (EFAs), 308, 361, 418–27, 468. See also EPA (eicosapentaenoic acid); Omega-3 fatty acids definitions and pathways, 418–20 dietary sources and AA cascade, 310f influence on intercellular communication, 585–86, 586f mitochondrial function and, 509–10 and neurotransmitter imbalances, 640t optimal fat intake, 427 PUFAs, eicosanoids, prostanoids, isoprostanes, and resolvins, 418– 19 supplementation, 523 and thyroid function, 602–3 in treatment of insulin resistance, 620 Estradiol, 174, 174f, 608f in osteoporosis treatment, 233 role in men, 235 in testosterone therapy, 243, 244 Estriol, 630–31 Estrogens, 174, 174f, 215–19, 360t, 608f adrenaline and anxiety, 228 anxiety and, 226–27, 228, 230 and bone health, 233 brain and, 226–30 and breast cancer, 224–26 conjugated equine estrogens (CEEs), 217 depression and, 228–29, 230 detoxification of, 218–19, 223, 584 diet and, 359–62, 633–35 estradiol, 174, 174f, 235, 243, 244, 608f estriol, 630–31 Estrogen Responsive Genes Database (ERGD), 218 glucuronidation of, 219 and heart disease, 226 hormone therapy, 230 hot flashes and, 226–28 in intercellular communication, 582t life cycle of, 216–19 metabolism diet and, 359–62 phase I detoxification, 218 phase II detoxification, 218–19 methylation, 219, 223 receptors, 217–18 replacement therapy (ERT), 50, 628–29 response elements (EREs), 217–18 role in men, 239–40 selective estrogen enzyme modulators (SEEMs), 223 selective estrogen receptor modulators (SERMs), 231 sulfation, 218–19, 223 sulfation of, 219 thyroid interactions, 229–30 xenoestrogens, 230, 231, 361 Eugenol (cloves), 420 Euthyroid sick syndrome, 596, 598 Evans, Joel M., 635, 791–92 Evans, William J., 129, 792 Evidence design, 35 model, 33–46 right kind of, 44 Evidence-based medicine (EBM), 33–39, 50–54 limitations of, 35–36 paradigm shift for, 38–39

)2

(c

reflexes mediated independently of CNS, 455–56 serotonin antagonizing receptors can slow motility, 459–60 postsynaptic receptors, 459, 459f presynaptic receptors, 457–58, 457f receptor activity stimulates submucosal IPANs, 456–57, 457f receptors involved in gut-to-brain signaling, 458–59 SERT-mediated uptake terminates responses to, 454–56 storage, 454 SERT expression is decreased in bowel inflammation and IBS, 460– 62 similarities to the CNS, 453 Enterochromaffin (EC) cells, 454, 454f, 456f Enterocytes, 455, 455f Enterohepatic circulation, 332 Environment and aging population, 18–20 and biochemical individuality, 70–73 impact on cellular messaging, 583–84 interface with genetics, 20–21 physical, in stress assessment, 675–76 Environmental inputs, 6–8, 7f, 123–63 air and water, 127–29 in autoimmunity, 411–12 case presentation, 735 clinical approaches to, 347–403, 543–54 detoxification, 543–54 diet and nutrition, 123–27, 347–88 DNA and mitochondrial damage, 388–95 in utero, 601 micronutrient insufficiency, 388–95 microorganisms, 150–53 physical exercise, 129–37 psycho-social factors, 137–40 radiation, 153–55 structural imbalances, 339–40 trauma, 140–47 xenobiotics, 147–50 Environmental Sensitivity Adult Toxin Exposure Questionnaire, 823–27 Child Toxin Exposure Questionnaire, 828–32 Enzyme basics, 175 Enzyme function testing, 442 Eosinophil protein X (EPX), 443 EPA (eicosapentaenoic acid), 86, 308, 361, 418–19, 420–25, 468 amount in plasma phospholipids, 87 and depression, 86 and intercellular signaling, 586 and thyroid function, 602 in treatment of inflammation, 341 and tumor inhibition, 586 Epidermal growth factor (EGF), 225 Epigenetic effects, 73 Epilepsy glutamate excess and, 640, 640t MERRF (myoclonic epilepsy, ragged red fibers), 260t, 267–68, 268t prevention of, 258 Erectile dysfunction, 238 EREs (estrogen response elements), 217–18 ERGD (Estrogen Responsive Genes Database), 218 ERT (estrogen replacement therapy). See under Estrogens Erythromycin, 70f Erythropoiesis, 234 Escherichia coli, 411, 446, 564

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 874

Index

endometriosis, 232–33, 637–38 environmental and nutritional balance of, 223–24 estrogen life cycle, 216–19 estrogen receptors, 217–18 estrogen response elements (EREs), 217–18 fibroids, 233, 635–37 gynecological syndromes, 232–33 hormone imbalances, 360t hot flashes and, 226–28 melatonin and, 607–9 menopause/perimenopause, 622–35 model of medical care, 215–16 modulation of hormonal balance, 221, 223–24 osteoporosis, 233 postmenopausal hormones, 220 progesterone, 219–20 risk factors, 360t sex hormone binding globulin (SHBG), 217, 222–23 testosterone, 220, 222–23 therapeutic strategies, 360t Ferril, William B., 644, 792 Fertility, hypogonadism and, 238 FFM. See Fat-free mass Fiber, dietary, 125, 198–99, 348, 350t, 361, 387, 544, 565, 634, 635 and detoxification, 548, 549 and estrogen metabolism, 361 and insulin balance, 620 suggestions for increasing, 376t Fibroblast growth factor, acidic (aFGF), 409 Fibroids, 233, 635–37 Fibromyalgia, 446, 495, 497t exercise program for, 491 and lactic acidosis, 503 and oxidative stress, 362t Fibrosis, 144 FICSIT trials, 135–36 Fight or flight response, 583 Finances, and stress, 672–73 Fish oils, 419–22, 468. See also EPA (eicosapentaenoic acid) in autism treatment, 523 and cardiac risk factors, 426–27 and coronary artery disease, 424–25 in treatment of inflammation, 341 Fitness. See Exercise Fitzgerald, Kara, 750, 768 Flavonoids, 293t, 361, 528, 545 Flaxseed oil, 420 Fleming, Andrew, 55 Fluor (excessive secretion), 299 Fluoride, 647 Fluoxetine, 70t Folate, 36, 37, 43, 60, 62, 72, 354, 355, 360t, 361, 389, 390–91, 744 deficiency states, 37, 55, 59, 72, 362, 641–42 low, 393 and methylation, 72 methylenetetrahydrofolate, 60, 72, 116, 355 serum, 75 Folic acid, 571, 635, 640t, 641–42 Folinic acid, 522 Follicle-associated epithelia (FAE), 329–30 Follicle stimulating hormone (FSH), 235, 238, 607, 608f in PCOD/PCOS, 614–15 Food energy from, 187, 190–91

)2

(c

Excitotoxicity, 260–62, 271, 506–7 in autism, 517–18, 518f Excretion, fecal vs. urinary, 198–99 Exercise, 8, 129–37, 481–93 aerobic, 130–33, 483–86 balance exercises, 489–90 benefits of, 483–84, 833 bone health and, 136–37 in chronic disease treatment, 137 compliance with exercise program, 491–92, 681–82 exercise history, 481–82 exercise risks/risk assessment, 482–83 for insulin resistance, 619 patients with neurodegenerative disorders, 489–90 patients with orthopedic conditions, 488 patients with special conditions, 490–91 in prevention and treatment, 19–20 protein requirements and, 134–35 resistance, 133–34, 135–36 strength training, 133–37, 486–88 structural imbalances and, 481–93 and thyroid function, 647 and weight loss, 132–33 Exorphins, 564 Experimental autoimmune encephalomyelitis (EAE), 262 Explanatory models, 36–39

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All

F

e

in

ic

ed

Facilitation, spinal, 144–45 FAE (follicle-associated epithelia), 329–30 Farnesyl protein transferase, 586 Fas, 209 Fasting, 548–49, 557–61 contraindications, 561 Fat. See also Essential fatty acids; Fatty acids; Obesity abdominal, 245, 742t absorption test, 442 adipose tissue as endocrine, 743 dietary, 355, 357, 585, 634 and cell signaling, 585–86, 586f digestion of, 437 dyslipidemia, 59, 744 fake fats, 383 hypertriglyceridemia, 237, 509 trans-fats, 349, 351, 352–53, 354t, 383 Fat-free mass (FFM), 132–33 Fatigue, 340, 362t, 363, 594 chronic fatigue syndrome, 51–52, 510–11 Fatty acids. See also Essential fatty acids and depression, 86 free (FFAs), 245–46, 422 influence on intercellular communication, 585–86, 586f mitochondrial function and, 509–10 oxidation, 187, 187f polyunsaturated (PUFAs), 418, 620 supplementation, 523 trans-fatty acids, 353, 356, 368, 383 Fecal excretion, 198–99 Feedback, in doctor-patient relationships, 720–22 Female hormones, 215–34, 359–62. See also Estrogens; Menopause autoimmune diseases and, 230–32 breast cancer and, 224–26 crosstalk of hormones, 221–23, 225 depression, anxiety and hormone therapy, 230

875

Textbook of Functional Medicine

vs. complementary and alternative medicine, 317 web-like interconnections of, 100f, 669–70, 691, 691f web tool, 691, 692f, 695 Furosemide, 70t Fuzzy logic, 42

genetically engineered, 386 as medicine, 619–20 reintroduction of excluded foods, 705–6 as trigger for allergy/sensitivity, 438 Food additives, 384–86 Food allergies, 189–90, 331–32, 369 digestive enzymes in treatment of, 465–66 and GALT, 450 and mucosal immune system, 450–51 symptoms and diseases associated with, 190t, 463–65, 464t testing, 443 Food pyramids, 693 Foreignness, immune response and, 304 Forskolin, 293t 4R program for GI complaints, 462–68 reinoculate, 467 remove, 463–65 repair, 467–68 replace, 465–67 Frataxin, 269–70 FRDA (Friedrich’s ataxia), 268, 269–70 Free fatty acids (FFAs), 245–46, 422, 743 Free radicals, 362t. See also ROS (radical/reactive oxygen species) melatonin and, 154 production elevated in autism, 514–16 production, glutamate excitotoxicity and, 261–62 and stress in the nervous system, 259–62, 270, 271 targets, 260t theory of aging, 114–15 Friedrich’s ataxia (FRDA), 268, 269 Fries hypothesis, 112, 113–14 Fructose, high fructose corn syrup, 383–84 FSH. See Follicle stimulating hormone Fumigants, 385 Functional medicine. See also Patient-centered care AFMCP course, 695 assessment and therapeutic strategy, 703–12 clinical decision-making in, 39–44 continuing medical education and, 3, 28–30 core questions, 349–50 decisions on intervention, 669–70 defined, 5–6, 10, 669–70 evidence-based medicine and, 33–39 evidence model, changing, 33–46 history of, 10–13 intervention opportunities in, 691f, 698–99, 700–701, 709–11 introduction to, 5–10 laboratory testing in, 706–8 matrix, 347, 691, 692f, 695, 733, 739 mentoring in, 29–30 model, 27–31 comprehensive care in, 692–701 comprehensive history-taking, 692–95, 693t comprehensive physical exam, 695–98, 697t referrals in, 700–701 need for, 3–4, 15–25 and nutrition, 356–57 origins of, 318 principles of, 6, 11 process of, 318–19 as science-based, 49–54 selecting effective treatments, 698–701 teaching of, 27–31 vision/mission statement of IFM, 3–4

G

)2

(c

G-protein coupled receptors (GPRCs), 172–73, 172f GABA, 565, 640 modulation of, 640t receptors, 219 reduced in autism, 515 Gabapentin, 228 Gall bladder, 332 Galland, Leo, 10, 79, 792 Gallstones, 191 GALT (gut-associated lymphoid tissue), 193–94, 329–30, 369, 374 food allergies and, 450–51 gut pathology associated with deregulation of, 441 immune function of, 449, 565 interactions of, 449 Peyer’s patches, 449 and thyroid function, 599–600 Gamma-aminobutyric acid (GABA), 565 receptors reduced in autism, 515 Gamma interferon, 207t Gamma linoleic acid (GLA), 374, 419 Garlic (Allium sativa), 372t, 420, 545, 547, 744 selenium enriched, 296 Garrod, Archibald, 11 Gastric acid, 436–37 Gastric analysis, 442 Gastrin, 328 Gastroesophageal reflux disease (GERD), 371t, 445, 733 Gastrointestinal tract, 102–3. See also Digestion; Motility, GI tract abnormalities in autism, 515t, 517, 517t autoimmunity and, 412–13 diseases, 445 food allergy/intolerance symptoms, 189–90, 190t function, 563–64 testing for, 381t, 442–44 gut-brain axis, 334, 376t gut-liver axis, 562–72 diseases/syndromes associated with, 565–68 promoting health in, 568–72 healing nutrients for, 381t identifying and treating bacterial infections, 380t imbalances associated with, 327–37, 373–81, 435–79 balance of flora, GALT, and mucosal integrity, 444–53 clinical implications of, 333–34 digestion and absorption, 435–44 enteric nervous system, 453–62 4R program, 462–68 treatment of, 437–44, 438–42 and immune system, 102–3, 190 inflammation measurements, 443 inhalation and, 193 laboratory assessment of, 570 and liver, 100–103 microorganisms in, 151–52, 196, 377t, 445–48 bacterial infections, 380t balance of, 444–53 critical functions of, 446 and digestion/absorption imbalances, 191, 441, 444–45

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 876

Index

managing glucose/insulin balance, 618–22 metabolism, 175–76. See also Insulin breast cancer and, 225–26 storage form (glycogen), 187 Glucose intolerance, 237, 246, 744 Glucose transporter (GLUT4), 175–76, 178, 621 Glucuronidation, 219, 280, 292, 546–48 GLUT4, 175–76, 178, 621 Glutamate, 582t, 640 disease states associated with, 640, 640t excitotoxicity, 260–62 modulation of, 640t Glutamine, 364, 374, 381t, 440, 449, 468, 518, 549, 569, 710 glutamine-free parenteral nourishment, 569 Glutamine synthetase, 518, 518f, 525t Glutathione (GSH), 174–75, 180, 196, 200, 224, 249, 250, 259, 272, 276, 278, 280–81, 284–85, 289–94, 307, 364–66, 547f deficiency, 293–94 hepatic, 361 in liver function assessment, 572 and mitochondrial function, 362t reactions, 292–93, 509, 586 reduced in autism, 515, 517, 522 synthesis of, 364 Glutathione peroxidase, 174–75, 517, 524, 528 Glutathione S-transferase (GST), 224, 284, 291, 293, 355, 361, 366, 544 gene, 71 Gluten, 348–49, 369–70. See also Celiac disease contamination of oat products, 125–26 gluten-free diet, 523 for thyroid autoantibodies, 600 and malabsorption, 569–70 partial digestion of, 564 Glycemia, 125–26 hyperglycemia, 7f, 245–46, 405, 526–28, 527–28, 608f, 614, 735, 741 hypoglycemia, 357, 359, 362t, 376t, 491, 561, 606, 611, 618t, 670 Glycemic control, 526–29 Glycemic index, 125 Glycemic load, 350t and sex hormones, 361 Glycogen, 187 Glycolysis, 183–85, 184f, 503 GM (genetically engineered) foods, 386 GnRH. See Gonadotropin-releasing hormone Goitrogens, 596–97, 603, 645–46 Gonadotropin-releasing hormone (GnRH), 234–35, 237, 608f agonist therapy, 637 in PCOD/PCOS, 614 GPRCs. See G-protein coupled receptors Grade seed extract, 372t Granulocytes, 204–6 Granuloma, 205 Graves’ disease, 647 Green tea, 367t, 372t, 419, 440, 622, 635, 744t Growth hormone (GH), 222, 235, 605–7, 608f bovine (BGH), 385 function, 605–6 replacement, 606–7 stimulating release of, 607 supplementation, 607 Growth hormone releasing hormone (GHRH), 608f GSH. See Glutathione GST. See Glutathione S-transferase

)2

(c

and food allergies, 451 and glucuronidation of estrogens, 219 imbalances in, 198, 446–47 and immune response, 305 reinoculation with, 467 small intestine bacterial overgrowth (SIBO/SBBO), 198, 380t, 446, 570 and toxicity, 564 mucosal barrier, 191–92, 192f integrity of, 448–49 neurologic symptoms and, 102–3 parasitic infections, 379t permeability, 192, 331–32, 562–63 changes, 448–49, 566, 569 factors associated with, 192t leaky gut (LG), 440 testing, 443 status, 340 testing, 381t, 442–44 therapeutic strategies for, 376t, 437–44 yeast infections, 378t, 750–785 (cases) Gene expression, 67t. See also Genetics; Genomics; Polymorphisms, genetic dogma of, 65, 65f influence of nutrients on, 585–88 interventions, 699, 700 post-translational, 354–55 Gene terminology, 67t Genetically engineered (GM) foods, 386 Genetics. See also Gene expression; Genomics; Polymorphisms, genetic and detoxification, 543–54 genetic inheritance, 694 genetic uniqueness, 55–78, 548–52 genetic variability, 544 genetotrophic diseases, 12 genotype, 67t, 115–17 mitochondrial, 266 Genistein, 597 Genitourinary system, food allergy/intolerance and, 190t Genomics, 13, 20–23. See also Nutrigenomics genome defined, 67 genomic stability, 114–15 and hormone balance, 631–33 Human Genome Project, 21–22, 66–70 and proteomics, 21–22 GERD (gastroesophageal reflux disease), 371t, 445, 733 Gerhardt, Charles, 311 Gershon, Michael D., 327, 445, 453, 792 GH. See Growth hormone Ghrelin, 177 GHRH (growth hormone releasing hormone), 608f Giardia lamblia, 379t Gilbert’s syndrome, 291 Ginger (Zingiber officinale), 372t, 417 Ginkgo biloba, 154, 372t, 545, 617 Ginseng, 154, 372t Gleevec, 173 Gliadin, 303 Glucagon, 582t Glucosamine, 372t, 415 Glucosamine SO4, 635 Glucose, 187. See also Glycemia; Insulin anaerobic catabolism of (glycolysis), 183–85, 184f hypoglycemia, and hot flashes, 228

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 877

Textbook of Functional Medicine

High fructose corn syrup (HFCS), 348, 350t, 383–84 Highly active antiretroviral therapy (HAART), 616 Hillenbrand, Laura, 51–52 Hippocampus, 610, 614, 640 cortisol toxic to, 145 Hippocrates, 311 Histamine, 204, 306 History of functional medicine, 10–13 patient-centered, 623–24 patient history, 10–11, 79–86, 689–702 comprehensive, 689–90, 692–95, 693t integrating, 83–86 patients with trauma, 142–47 understanding, questions to ask, 717–19 HIV/AIDS, 615–17 HLA antigens, 441, 448 4-HNE (4-hydroxynonenal), 523 HOCl. See Hypochlorous acid Hoffer, Abram, 12 Hoffman, Felix, 311 Holmes, Oliver Wendell, 55 Homeodynamic flexibility (“degrees of freedom”), 127 Homeodynamics, 93–95, 318–19 Homeostasis, 93–96, 306, 318–19 definition of, 171 HPA axis and, 614 Homocysteine, 60, 72–73, 116, 180, 197, 219, 303, 361, 598, 643, 706, 737t and estrogen methylation, 219, 571 hyperhomocysteinemia, 59 serum, testing for, 219 HOPE questionnaire, 167 Hormonal imbalances, 215–56, 341, 359–62, 581–668. See also Female hormones; Hormones; Insulin; Male hormones cellular messaging, 581–90 classes of intercellular communication agents, 582t female hormones, 215–34, 360t cross-talk of hormones, 221–23, 225 insulin insensitivity, 245–48 male hormones, 234–45 symptoms in women, 360t and thyroid function, 648 Hormone sensitive lipase (HSL), 177 Hormones. See also Hormonal imbalances; specific hormones; Thyroid and autoimmune diseases, 230–32 balance to imbalance, 220–21 bioavailable fraction of, 637 hormonal balance, dietary influences on, 357–62 hormone replacement DHEA, 605 estrogen replacement therapy, 50, 628–29 growth hormone, 606–7 progesterone, 629 testosterone replacement, 236, 238, 242–44, 631 for thyroid conditions, 593–94 hormone therapy, 230 master hormones, 357 residues in foods, 647 sex hormones, 359–62 testing hormonal function, 361–62 Hot flashes, 226–28 Houston, Mark C., 729, 793 HPA. See Hypothalamic-pituitary-adrenal (HPA)axis

Gut-associated lymphoid tissue. See GALT Gut-brain axis, 327, 334, 376t Gut-liver axis, 562–72 diseases/syndromes associated with, 565–68 promoting health in, 568–72

H

)2

(c

H2 blockers, 286 HAART (highly active antiretroviral therapy), 616 Haemophilus influenzae, 411 Hair analysis, 552 Hamer, Dean, 167 Hanaway, Patrick, 150, 444, 792–93 Harman, Denham, 114 Harpagophytum procumbens (Devil’s Claw), 416 Hashimoto’s thyroiditis, 445, 647 Hays, Bethany, 215, 622, 793 HCB, 149t HCl, produced by stomach, 328, 436–37, 465–66 HDL-cholesterol, 168, 226, 237, 245–46, 618, 737t HDL (high density lipoproteins), 98, 208, 212, 237, 246, 302, 354, 359t, 384, 482, 484, 599, 619, 733, 734, 737t. See also Lipoproteins cholesterol to HDL ratio, 383 triglycerides to HDL ratio, 619 HE (hepatic encephalopathy), 564–65 Headache, 362t. See also Migraine headaches manipulation for, 496–97 Healing relationship/partnership, 713–28 Health, 669–84 continuum of health and health care, 6–8, 7f derivation of, 107 fundamental processes in, 8–9 goal of, 107–8 impact of spirituality/religion on, 676–80 origins of illness, 115–17 as positive vitality, 6, 107–10 promotion, 681–82 quality of life, 108–9 Healthy eating pyramid, 693 Heaney, Robert, 61–62, 508 Heart disease. See also Cardiovascular disease; Coronary heart disease acute myocardial infarction, 408–9 hormones and, 226, 237 Heat shock proteins, 225, 226, 304, 641 Heavy metals, 288, 290, 440, 549–52 chelation treatment, 366, 555 sources of exposure, 367t and thyroid function, 647 Hedaya, Robert J., 669, 793 Helicobacter pylori, 84, 191, 380t, 411 chronic, 585 prevention, 447 Heme synthesis, 393 Hemochromatosis-linked gene (HFE), 71–72 Hepatic encephalopathy (HE), 564–65 Hepatic metabolism, impaired, 564–65 Heptachlor, 149t Herbal antioxidants, 363t Herbal supplements, top-selling, 789 Herbicides, 385 Hereditary spastic paraplegias, 270 Herpes simplex virus, 585 HFCS. See High fructose corn syrup HFE (hemochromatosis-linked gene), 71–72

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 878

Index

Hypothalamic-pituitary-thyroid-adrenal (HPTA) axis, 609 Hypothalamic-pituitary-thyroid (HPT) axis, 594–95 managing imbalances in, 602–3, 603–4 Hypothalamus. See also specific hypothalamic axes AMPK in, 177 blood brain barrier and, 610 female neuroendocrine system and, 608f and limbic system, 610–11 master neurohormone production, 610, 611 median eminence (ME), 610 organum vasculosum of the lamina terminalis (OVLT), 610, 613 posterior pituitary gland (hypophysis), 610 response to stress, 142, 142f

HPT. See Hypothalamic-pituitary-thyroid (HPT) axis HPTA (hypothalamic-pituitary-thyroid-adrenal axis), 609 HSD. See 17-Hydroxysteroid dehydrogenase HSL. See Hormone sensitive lipase Human genome Human Genome Project, 21–22 single nucleotide polymorphisms in, 66–70 Human paraoxonase (PON1) gene, 71 Huntington’s disease, 271 Huperzine, 640t, 643 Hydrochloric acid, gastric, 328, 436–37, 465–66 Hydrochlorothiazide, 70t Hydrotherapy, 561–62 Hydroxy urea, 11–12 17-Hydroxysteroid dehydrogenase (HSD), 222 5-Hydroxytryptamine (5-HT). See Serotonin Hygiene hypothesis, 151, 448 Hyman, Mark A., 55, 347, 750, 768, 793–94 Hypercholesterolemia, 156, 240, 255, 325 Hyperdopaminergic states, 642–43 Hyperglycemia, 7f, 245–46, 405, 526–28, 608f, 614, 735, 741 antioxidants and, 527–28 Hyperinsulinemia, 98, 99, 245, 246, 247, 298, 299, 357, 359, 622 compensatory, 239 decrease, 246 glucose metabolism and breast cancer, 225 Hypersensitivity reactions, 43, 84, 306, 446, 450, 458, 461, 463, 704 delayed, 301, 310 with food, 295 visceral hypersensitivity, 458, 460 Hypersensitization of sensory nerve fibers, 306 Hypertension, 58, 60, 81, 90, 98, 101, 109, 126, 130, 139, 237, 247, 317, 384, 741, 742t, 743 arterial, 196 borderline, 196 essential, 247 essential fatty acids in, 419 induced, 248 insulin resistance and, 247, 741 low testosterone and, 237 treatment of, 744 Hyperthyroidism, 138, 147 Hypertriglyceridemia, 237, 307, 426, 509, 618 primary, 308 Hypoallergenic diet, 600 Hypochlorhydria, 191 Hypochlorous acid (HOCl), 204 Hypodopaminergic states, 642 Hypoglycemia, 357, 359, 362t, 376t, 491, 561, 606, 611, 618t, 670 and hot flashes, 228, 359 reactive, 704 Hypogonadism, male, 238, 239, 242 Hypothalamic-pituitary-adrenal (HPA) axis, 142, 145–46, 590–91, 610– 18 CRH and, 611–13 cytokines and, 142, 613–14 downregulated by cortisol, 142, 142f dysfunction, 357, 640 function of, 611–14 HIV/AIDS and, 615–17 hypothalamus and the limbic system, 610–11 overactivity in women, 230 polycystic ovary disease and, 614–15 stress and adrenal function, 604–5

I

)2

(c

IBD (inflammatory bowel disease). See under Inflammatory diseases IBS. See Irritable bowel syndrome Ibuprofen, 70t ICAMs. See Intercellular adhesion molecules Idebenone, 270 IELs (intra-epithelial lymphocytes), 449 IGFs. See Insulin-like growth factors IgGs, 205, 463, 750–767 Illness as a stress, 673 absence of good research on, 554 origins of, 115–17 Imatinib mesylate (Gleevec), 173 Imbalances, major types of, 9–11. See also specific types of imbalances clinical/core, 9–11 detoxification/biotransformational, 275–98, 648 digestive, absorptive, and microbiological, 327–37, 649 gastrointestinal, 435–79 hormonal, 215–56, 581–668, 648 immune, 299–326, 341, 405–33, 649 neuroendocrine, 581–668 neurological, 257–63 neurotransmitter, 341, 565, 640–44, 648 oxidation-reduction, 265–73, 648 structural, 339–44, 481–500, 649 Imipramine HCl, 70t Immune imbalances, 299–326, 341, 405–33, 649 acquired/adaptive immune responses and inflammation, 306–10 counter-regulatory control mechanisms, 307–8 endogenous inflammatory mediators and their effects, 306–7 loss of regulatory control, 308–10 autoimmunity and inflammation, 409–17 endocrinological influences, 411 environmental/xenobiotic influences, 411–12 gastrointestinal and mucosal influences, 412–13 multiple manifestations of, 410–13 neurogenic influences, 413 nutritional influences, 413 psychoemotional influences, 410–11 cellular and molecular biology of, 300–305 and chronic disease, 299–300 clinical approaches to, 305–33, 435–79 acute myocardial infarction, 408–9 atherosclerosis, 405–8 balance of flora, GALT, and mucosal integrity, 444–53 digestion and absorption, 435–44 enteric nervous system, 453–62 4R program, 462–68 danger signals in immune activation, 304–6

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 879

Textbook of Functional Medicine

cardinal features of, 203, 299 cardiovascular diseases involving, 211t causes of, 368 cellular and molecular biology of, 300–305 and cellular communication dysfunction, 585 chronic, 301, 302–3, 308–10, 368 interventions for, 315 and chronic disease, 85–86, 299–300 clinical approaches to, 305–33 counter-regulatory control mechanisms, 307–8 cytokines, 206–8, 207t diet and, 368–72 digestion/absorption disorders and, 439–40 drug-disease model of, 310–16 endogenous inflammatory mediators and their effects, 306–7 essential fatty acids and, 420–27 functional medicine applied to, 317–20 gut-brain axis and, 334 immune imbalances and, 229–326, 306–10, 341, 371t inflammatory response, 299, 309–10, 584 local, 306–7 lymphocytes and, 209–10 major causes of, 371t management of, 372t and metabolic syndrome, 741 NFB-mediated gene activation, 303 NSAIDs and, 70t, 311–13, 311–16, 317, 341 alternatives to, 414–17 and pancreatic secretions, 191 phagocytes and, 204–6 proinflammatory state, 207–8, 212, 230–31, 233, 248, 303–4, 322, 340–43, 742t, 743 proinflammatory cytokines, 231, 271, 302, 307, 309 systemic, 306–7 testing for, 368 therapeutic interventions for, 414–17 Boswellia, 417, 420 botanical anti-inflammatories, 416–17, 420 Cat’s Claw, 416, 440 Devil’s Claw, 416 dietary omega-3 fatty acids, 420–27 ginger, 417 glucosamine and chondroitin sulfate, 415 manual therapies, 414–15 niacinamide, 415 nutritional supplementation, 415–16 proteolytic enzymes, 415–16 willow bark, 311, 416–17 thyroid function and, 649 treating symptoms rather than causes, 314–15 triggers of, 301–2, 304–5, 319 vasculature and, 203–4 Inflammatory diseases. See also Rheumatoid arthritis acute myocardial infarction, 408–9 atherosclerosis, 405–8 inflammatory bowel disease (IBD), 152–53, 331–32, 445 essential fatty acids and, 87, 422 probiotic treatment for, 447 zinc deficiency in, 468 inflammatory enteric neuropathy, 334 Inflexibility, 495 Infliximab, 314 Inhalants, 193 Inositol triphosphate (IP3), 173–74

)2

(c

disease responses to, 306–10 drug-disease model of inflammation, 310–16 functional medicine applied to, 317–20 stress and, 650 and thyroid function, 649 Immune response. See also Immune imbalances; Immune system acquired (helper T cells), 209, 300–301 antigen-presenting cells (APCs), 209, 300–301, 565 B cells, 210 cellular and molecular biology of, 300–305 cellular (cytotoxic T cells), 209, 306 and chronic inflammation, 301, 302–3 danger signals and, 304–5 delayed reactions, 306 gut-liver axis and, 565–68 innate, 206, 300–301, 306 innate receptors, 302–3 intracellular signaling pathways/gene products, 302 loss of tolerance, 305 lymphocytes as mediators of, 209–10 microorganisms and, 305, 448 NFB-mediated gene activation, 303 oral tolerance, 152, 319, 441, 441f, 449–50 Th1/Th2 imbalance, 305, 441–48 triggers of, 301–2, 304–5, 319 Immune system, 101–3, 193–95. See also Immune imbalances; Immune response and cardiovascular system, 102 and gastrointestinal tract, 101–2, 193–94 gut-associated lymphoid tissue (See GALT) healthy and balanced, 300–301 immune-boosting mushrooms, 372t inflammation and, 203–6 innate, 206 interaction with nervous system, 590, 590f modulation of hormonal balance, 221 mucosa-associated lymphoid tissue (MALT), 194 mucosal, 449–53 symptoms associated with food allergy/intolerance, 190t systemic, 194–95, 195f Immunity. See Immune response Immunoglobulins, 205–6, 310, 451 IgG, 205, 463 Immunosuppressants, 341 Indapamide, 744 Individual susceptibility, 115–17 Individuality. See Biochemical individuality Indole-3-carbinol, 293t, 361 Infections bacterial, identifying and treating, 380t inflammation and, 204–5, 412–13 occult, 412–13 Infertility, 238 Inflammation, 203–12, 299–326, 409–17 acute response, 306–7 anaphylaxis, self-amplifying cascades, and butterfly effect, 309 autoimmunity and, 409–17 endocrinological influences, 411 environmental/xenobiotic influences, 411–12 gastrointestinal and mucosal influences, 412–13 multiple manifestations of, 410–13 neurogenic influences, 413 nutritional influences, 413 psychoemotional influences, 410–11

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 880

Index

interleukin-18, 233 Internet-based resources, 834–37 Intersystemic integration, 142, 142f Intervention, clinical cellular/metabolic, 698–99, 700 for chronic inflammation, 315, 414–17 decisions on, 669–70 for insulin resistance, 619–22 mind-body, 680–82 nutritional, 22 opportunities in functional medicine, 691, 691f, 698–99, 700–701, 709–11 organ system, 698, 700 pharmaceutical, 52–53 risk factors and, 682 for stress, 671–74 subcellular/gene expression, 699, 700 subcellular/mitochondrial, 699, 700 whole body, 698, 700 Interventions based on TTM (stage-matched), 725–27 Intestinal permeability, 191–92, 334. See also Leaky gut changes, 448–49 factors associated with, 192t testing, 443 Intestine. See also Gastrointestinal tract; Motility, GI tract; Small intestine promoting health in, 568–72 role in detoxification, 282–83, 565 role in immune responses, 565 Intolerance, food, 190t. See also Food allergies Intra-epithelial lymphocytes (IELs), 449 Intracellular environment, 174–77 Intrinsic primary afferent neurons (IPANs), 455–57, 456f Iodination of thyroxine, 595–96, 602 Iodine, 602, 645–46 dietary sources of, 646 excess, 646 Iodothyronine iodinase dysfunction, 645 Ionizing radiation, 153–54, 363t, 367t, 647 IP3. See Inositol triphosphate IPANs (intrinsic primary afferent neurons), 455–57, 456f Iron, 512 deficiency, 549 and oxidative stress, 362t Irritable bowel syndrome (IBS), 445, 447, 463 antagonizing serotonin receptors slows motility, 459–60 constipation and, 459–60 mucosal SERT expression decreased in, 460–62 pain of, 458 Rome II criteria, 446 Isoflavones, 361, 635 cooking and bioavailability, 646 genistein, 597 from soy, 596–97 Isoniazid, 70f Isoprostanes, 344, 365t, 418–19, 419, 507, 512, 523, 528 Isothiocyanate, 174, 355

)2

(c

Inotropic agent/pressor, 70t Insomnia, 341 Institute for Functional Medicine AFMCP course, 695 CME accreditation, 3 vision and mission of, 3–4 website, 695 Insulin, 21, 70t, 72, 104, 131, 215, 221, 582t. See also Diabetes; Hyperinsulinemia; Insulin resistance; Metabolic syndrome actions of, 98–99, 133–34, 158–59, 176, 225, 245, 743, 743f balance, 245 and blood pressure, 104 and body type, 623 breast cancer and, 225–26 case presentations, 729–767 exercise and, 132, 133–34 as hormonal nutrient regulatory system, 190 insensitivity, 98, 245–48 insulinemia, 126, 156 insulinotropic amino acids, 126 interaction with trophic hormones, 215 managing insulin/glucose balance, 618–22 mitochondrial dysfunction and, 510 neuroprotective effect, 156 pancreatic islet secretion of, 159 pathway, 77 and PCOD/PCOS, 98, 614–15 receptor, 172, 178, 225 secretory response, 98–99, 125–26, 133–34, 158–59, 245 sensitivity, 99, 124, 178–79, 240 decreased, 99 modulating, 95 whole grains and, 125 signaling, cellular insensitivity to, 98–99 signaling pathway, 178f treatment, 247 Insulin-like growth factors (IGFs), 133, 156, 225, 227t, 235, 608f, 614 as hormonal nutrient regulatory systems, 190 Insulin resistance, 24, 59–60, 98, 99f, 245–48, 357–59, 618–22. See also Metabolic syndrome adiponectin and, 179 case presentations, 729–767 chronic, 743 clinical and laboratory diagnosis, 618–19, 742t clinical intervention, 619–22 exercise, smoking and obesity, 619 food as medicine, 619–20 nutritional modulation, 619 selected nutrients/phytonutrients, 620–22 laboratory testing for, 359t prevalence of, 384 symptoms of, 359, 741 therapeutic strategies for, 358t, 619–22, 744 Intercellular adhesion molecules (ICAMs), 205, 582t, 587, 743 Intercellular communication. See Cellular messaging Interferon gamma, 85, 207t, 208, 231, 233, 308, 582t Interleukins, 61, 205, 207–8, 307, 582t ILI-B, 743 interleukin-1, 207–8, 207t, 633 interleukin-2, 209, 600 interleukin-6, 208, 210, 633, 743 interleukin-10, 207t, 565 interleukin-12, 233 interleukin-17, 207t

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All J

James, Mary, 562, 794 Jenner, Edward, 55 Job stress, 672 Jones, David, 3, 5, 10, 15, 18, 27, 55, 111, 275, 543, 581, 590, 689, 794

881

Textbook of Functional Medicine

K

Lieber, Charles, 509 Life expectancy, 112–13 Life span, 112–13 Life Stress Questionnaire, 693, 840 Lifestyle, 194, 196, 199, 218, 233–34, 255, 283, 288, 317, 320 aging population and, 18–20 changes, 237, 242, 248, 311, 315, 320, 358t diet and, 325, 341, 350–51, 376t high adrenaline, 228–29 Limbic system, 142f, 610–11 Lipid metabolism (dyslipidemia), 744 Lipo-oxygenases, 310 Lipofuscin, 512–13, 513f Lipoic acid (LA), 114, 154, 394, 586–87 -lipoic acid, 362t, 586–87, 622 as conditionally essential nutrient, 509 hyperglycemia and, 527 Lipopolysaccharide, 566 Lipoprotein lipase, 743 Lipoproteins analysis, 734f HDL (high density lipoproteins), 98, 208, 212, 237, 246, 302, 354, 359t, 384, 482, 484, 599, 619, 733, 734, 737t LDLs (low density lipoproteins), 71, 212, 226, 302, 306, 359, 383, 484, 528, 596, 606, 622, 730, 733, 734, 737t, 738, 741, 742t, 743 VLDLs (very low density lipoproteins), 246, 359t, 730t, 733, 734, 737t, 738, 742t Lisinopril, 70t Liska, DeAnn, 49, 63, 97, 163, 189, 275, 795 Lithium, 647 Liver, 100–103 alcoholic liver disease, 567 AMPK in, 176–77 cirrhosis, 564 detoxification by, 195–96, 278–80, 278f gut-liver axis, 562–72 hepatic CYP2E1, 568 impaired hepatic metabolism, 564–65 laboratory assessment of function, 571–72 non-alcoholic fatty liver disease (NAFLD), 567 non-alcoholic steatohepatitis (NASH), 445, 567–68 organ reserve, 332 role of, 563, 565–66 support for, 570–71 Lombard, Jay, 638, 795 Long-latency disease, 61–62 Longevity, limits of, 113 Low-density lipoproteins. See LDLs LPS, 566, 567–68 LTs. See Leukotrienes Lukaczer, Dan, 97, 245, 462, 526, 618, 703, 795 Lumpkin, Michael D., 610, 795–96 Lung cancer, 71 Luteinizing hormone (LH), 234, 235, 238 and female menopause, 607, 608f in PCOD/PCOS, 614–15 Luteolin, 547 LV (left ventricular) hypertrophy and dysfunction, 146 Lycopene, 154 Lymph, 329 Lymphatics, 141 Lymphocytes, 194–95, 209–10 lymphocytic responses, 195f Lymphokines, 206–8

Kainic acid, 512 Kandel, Eric, 138 Kearns-Sayre syndrome (KSS), 260t, 268, 268t Kidney detoxification by, 195 renal disease, 422–23 renal insufficiency, 744 waste elimination by, 198–99 Klebsiella, 441, 448, 565 Kraut, Carl, 311 Krebs cycle, 186, 186f KSS (Kearns-Sayre syndrome), 260t, 268t Kuhn, Thomas, 55 Kupffer cells, 566, 567–68

L

)2

(c

L-arginine. See Arginine LA. See Lipoic acid Laboratory testing, 706–8. See also Testing assessing performance of, 707–8 non-analytical factors in, 708 LAC (alpha lactalbumin), 642 Alpha lactalbumin (LAC), 642 Lactate, 503 Lactobacillus, 446, 447, 467 L. acidophilus, 196, 198, 467 L. casei, 467 L. rhamnosus, 451 reinoculation with, 467 Lactulose, 446, 565 Lamb, Joseph L., 93, 794 Lampe, Johanna, 546 Large intestine, 329, 332. See also Gastrointestinal tract colonoscopy, 443 colorectal cancer (CRC), 445 motility in, 460 LDL-cholesterol, 156, 168, 482, 595, 737t LDLs (low density lipoproteins), 71, 212, 226, 302, 306, 359, 383, 484, 528, 596, 606, 622, 730, 733, 734, 737t, 738, 741, 742t, 743. See also Lipoproteins particle size, 383, 426 phenotype, 355 receptor, 406 and thyroid dysfunction, 595 Lead, 290, 549 Leaky gut (LG), 192, 200, 330, 334, 440. See also Intestinal permeability Leber’s hereditary optic neuropathy (LHON), 260t, 267, 268t, 269 Left ventricular (LV) hypertrophy and dysfunction, 146 Leigh’s syndrome, 268, 268t, 269 Leiomyoma. See Fibroids Leptin, 177, 237, 582t, 743 Lerman, Robert H., 418, 794 Leukocytes, 204, 306 Leukotrienes (LTs), 204, 306–7, 309–10, 324, 418, 420, 423–24, 438, 582t, 585 Lewy body disorders, 258t Leydig cells, 234–35, 235f Leyton, Edward (Ted), 713, 794 LG. See Leaky gut LH. See Luteinizing hormone LHON. See Leber’s hereditary optic neuropathy Libby, Peter, 203, 405, 794–95 Licorice, 372t

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 882

Index

McMakin, Carolyn, 153, 796 MCP-1, 205, 207t, 208, 406, 743 ME (median eminence), 610 Mechanisms of disease, 691, 701 Meclizine HCl, 70t Median eminence (ME), 610 Mediators of illness, 10, 40, 79-87, 82t, 100, 103, 108-9, 203-6, 209, 211t psychosocial, 85, 140 Medical Symptoms Questionnaire, 693, 838–39 Medline Subject Headings (MESH), 84 Medroxyprogesterone acetate (MPA), 222, 226 MELAS, 260t, 267, 268t Melatonin, 42, 154, 155, 163, 166–68, 419, 516, 524, 582t, 590, 640t as antioxidant, 154 and biological clock, 609, 642–43 deficiency, 643 as dopamine inhibitor, 643 in female menopause, 607–9, 608f free radicals and, 154 oncostatic properties, 155 Memory, long-term, 610 Menopause, 622–35 bone health and, 136–37 calcium levels for postmenopausal women, 136–37 clinical approach, 622–33 assessing body type, 622–23 balancing hormones, 628–31 laboratory evaluation, 625–26 patient-centered history, 623–24 physical examination, 624–25 prescribing hormones, 626–28 dietary modifications for, 633–35 estradiol levels and breast cancer, 584 evaluate downstream metabolites of hormones prescribed, 627–28 female homeostat, 609f genomics and hormone balance, 631–33 hormone administration/replacement, 226, 230 after oophorectomy, 629–30 estriol, 630–31 estrogen, 628–29 progesterone, 629 testosterone, 631 hot flashes, 226–28 melatonin and, 607–9, 608f neuroendocrine system and, 607–9, 608f postmenopausal hormones, 220 symptoms/therapeutic strategies, 360t Mental/emotional system, food allergy/intolerance and, 190t Mentoring, 29–30 Meperidine, 270 Mercury, 290, 385–86, 549, 550 MERRF (myoclonic epilepsy, ragged red fibers), 260t, 267–68, 268t MESH (Medline Subject Headings), 84 Messaging. See Cellular messaging Metabolic syndrome, 117, 177–79, 245, 348–49, 614 case presentations/extended discussion, 729–767 criteria for diagnosis, 741t, 742t definitions, 741, 742t exercise program for, 491 low testosterone and, 237 mechanisms of action, 741 prevention and treatment, 743–44 Metabolism. See also Thyroid basal body temperature, 645

interferon gamma, 207t, 208, 582t Lyon, Michael, 275, 543, 796

M

)2

(c

M cells, 329–30, 565 M-CSF. See Macrophage-colony-stimulating factor Macrophage-colony-stimulating factor (M-CSF), 206, 207t Macrophage inflammatory protein-1 (MIP-1), 743 Macrophage/monocyte chemoattractant protein-1 (MCP-1), 205, 207t, 208, 406, 743 Macrophage scavenger receptors, 302–3 Macrophage-stimulating protein (MSP), 232 receptor (RON), 232 Macrophages, 205–6 Kupffer cells, 566, 567–68 Macroscopic distortion, case study, 146–47 Magnesium in autism treatment, 520 as glutamate antagonist, 643 in insulin balance, 621 and migraine headache, 39–40, 44 stress depletion of, 650 supplementation for mitochondrial function, 364t Maimonides, 299, 318 Major histocompatibility complex (MHC), 209, 301 Male hormones, 234–45, 359–62 androgenic vs. anabolic effects, 234 approach to the patient concerning, 241–42 deficiencies in, 241–42 effects of androgens, 235–38 bone effects, 237 brain and cognitive effects, 235–36 cardiovascular disease, 237 depression and, 238 hypogonadism and fertility, 238 muscle and body-building effects, 236–37 perception and, 237–38 feedback modulation of production, 235 role of estrogen in men, 239–40 synthesis, 234–35, 235f testosterone and its derivates, 238–41 testosterone therapy, 242–44 Malitol, 385 Malondialdehyde (MDA), 523 MALT (mucosa-associated lymphoid tissue), 194 Manan-binding protein (MBP), 307 Manipulation therapy, 341, 342, 493–99 structural changes at micro level, 493–94 Mannitol-lactulose test, 443 MAPK. See Mitogen activated protein kinase MAPKKK (MAPK kinase kinase), 173 Marital problems, 671–72 Massage therapy, 193, 341, 342, 343, 367t, 415, 495, 498 Mast cells, 206, 569–70 Mastication, 327–28 Matching behaviors, 717 Maternally inherited Leigh’s syndrome (MILS), 268, 268t Maternally inherited myopathy with cardiomyopathy, 260t Matrix metalloproteinases (MMPs), 232, 407 MAU (microalbuminuria), 740, 741, 742t MBP (mannan-binding protein), 307 McCully, Kilmer, 55–56 McEwen, Bruce, 138 McGinnis, Woody R., 512, 796

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 883

Textbook of Functional Medicine

magnesium concentration and, 271, 643 omega-3 fatty acid therapy, 87 prevention of, 258 treatment of, 39–40, 42f, 44, 640t Migration inhibitory factor (MIF), 232 MILS (maternally inherited Leigh’s syndrome), 268t Mind and spirit, 165–68, 669–84. See also Spirituality interconnection of, 6, 340–41, 690 interventions in clinical practice, 680–82 research on spirituality and health, 165–68, 677–78 as single interactive unit, 677 and thyroid function, 649–50 Minerals and hyperglycemia, 528 toxic metals and, 549–50 Minimal hepatic encephalopathy (MHE), 564–65 MIP-1 (macrophage inflammatory protein-1), 743 Mirex, 149t Mission statement, IFM, 3 Mitochondria cell death and, 506–7 damage of, 388–95, 394, 510–11, 648, 699 diet and, 362–65 DNA in, 266, 267–69, 504–5, 592 dysfunction, testing for, 365t electron transport and, 186–87, 187f, 502–4 energy production and, 502–4 functions, 265–66, 266t clinical conditions associated with, 510–11 and functional medicine, 501–12 nutrients and, 507–10 supplements to enhance, 364t interventions, 699, 700 in liver, 567 mitochondria-related disorders/pathologies, 260t, 267–68, 268t, 362t mitochondrial genetics, 266 oxidative decay and aging, 388, 506 in oxidative phosphorylation, 186–87, 187f oxidative stress and, 505–7 structure of, 266–67 and thyroid hormone activity, 598–99 Mitogen activated protein kinase (MAPK), 173, 173f, 743, 743f integration of CPCR with, 173f MAPKKK, 173 Mitogens, 173 MMPs. See Matrix metalloproteinases Modifiable factors, 15 MODS (multiple organ dysfunction syndrome), 566 Monoamine oxidase B (MAO-B), 270–71 Monocyte/macrophage chemoattractant protein-1 (MCP-1), 205, 207t, 208, 406, 743 Monokines, 207–8 Monoterpenoids, 293t Mood, DHEA and, 240 Morbidity curve, 111–14 Mortality, 112 rectangularization of, 113 signature, 112 Motility, GI tract, 328–29, 436, 455, 456, 458, 459–61, 584, 585, 649 cholesterol and, 329 dysmotility, 329, 334, 436, 569 gastric, 328 vagus nerve and, 328

)2

(c

defined, 215 energy from, 362–65 metabolic interventions, 698–99, 700 metabolic rate, dieting and, 647 phase III metabolism, 282f regulation of, 175 Metabolomics, 73–74 Metalloproteinases matrix (MMPs), 232 tissue inhibitor, 232 Metallothioneins (MT), 285, 549, 550 Metals. See also Detoxification heavy, 288, 290, 440, 549–52 chelation, 555 sources of exposure, 367t and thyroid function, 647 laboratory assessment of toxic exposure, 552 toxic, 290, 549–52 Metchnikoff, Elie, 204 Metformin, 744 Methylation, 72–73, 219, 223, 278f, 280, 353, 359, 360t, 543, 641, 698 cofactors, 361, 366 of estrogens, 219, 223, 224, 584 and homocysteine, 571 undermethylated DNA, 304, 390–91, 504 Methylenetetrahydrofolate. See Folate Methylenetetrahydrofolate reductase. See MTHFR Metoprolol, 70t MHC (major histocompatibility complex), 209 MHE (minimal hepatic encephalopathy), 564–65 Microalbuminuria (MAU), 740, 741, 742t Microbiology testing, 442–43 Micronutrients insufficiency of, 72, 388–95 proper balance of, 190 Microorganisms, 8, 150–53 altered balance in human environment, 152–53 antibiotic-resistant, 385 bacteria-mediated production of alcohol, 568 biofilms, 332–33 colonization of gastrointestinal flora, 152 commensal in the gut, 151, 196, 329, 332–33 balance of, 444–53 critical functions of, 446 and digestion/absorption imbalances, 191, 441, 444–45 diseases connected with, 464 and glucuronidation of estrogens, 219 health of, 453 reinoculation with, 467 role of, 377t and toxicity, 564 GI bacterial infections, 380t imbalances associated with, 327–37, 441, 444–45, 649 and immune response, 305, 448 microbiology testing, 442–43 production of alcohol mediated by, 568 small intestine bacterial overgrowth (SIBO/SBBO), 198, 380t, 446, 570 Microvilli, 448, 569 MIF. See Migration inhibitory factor Migraine headaches childhood, 438 food allergy/intolerance and, 190t glutamate excess and, 640

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 884

Index

N-acetylcysteine (NAC), 293, 298, 303, 523, 587 supplementation for mitochondrial function, 362t NAFLD (non-alcoholic fatty liver disease), 567 NAPQ1, 289–90 Naproxen, 70t NARP (neuropathy, ataxia, retinitis pigmentosa), 260t, 268t NASH (non-alcoholic steatohepatitis), 445, 567–68 Nash, Ogden, 150 NaSO4, 635 Natalizumab, 314–15 Natriuretic peptides, 582t NEC (necrotizing enterocolitis), 447 Neck pain, 496 Necrotizing enterocolitis (NEC), 447 Need for functional medicine, 3–4, 15–25 Neopterin, 523 Nernst equation, 186 Nervous system. See also Neurological imbalances blood-brain barrier, 259 energy requirements, 258–59 free radical stress, 259–62 function and structure, 258–59 interaction with immune system, 590, 590f oxidative dependence, 259–62 response to stress, 141–42 unique features, 259t NETA decrease sulfatase, 222 Neural networks, 42 Neurodegenerative disorders, 94, 258t, 269-71. See also Aging; Degenerative diseases balance training for, 481, 489–90 glutamate excess and, 640, 640t and homocysteine, 643 and inflammation, 308, 368, 371t mitochondrial disfunction in, 269–71 and nitric oxide, 262 and oxidative stress, 419, 501, 507 protection from antioxidants, 362 role of exercise, 130 and stress, 583 and toxic influences, 365-6 traditional, 258, 258t and trans fatty acids, 383, 768–85 Neuroendocrine system, 82, 85–6, 154, 341, 352, 411, 444, 546, 593, 674 assessing and balancing mediators in, 591–92 changing view of, 591–92 female, in menopause, 607–9, 609f imbalances in, 581–668 cellular messaging and, 581–90 as indicator of cellular aging, 592–93 neuroendocrine-immune system, 125-6, 142, 669-70 Neurologic systems, 100–103 Neurological imbalances, 257–63 energy requirements of nervous system, 258–59 episodic neurological disorders, 271 free radical stress, 259–62 function and structure of nervous system, 258–59 neurological assessment, 257–58 neurological vulnerability, 259–62 oxidative stress, 259–62 traditional assessment, 257–58 Neuropathy diabetic, 177, 527, 587, 622 enteric, 334

)2

(c

Motivating patients, 719–20 Motor neuron diseases, 258t, 271 Mouth, in digestive process, 327–28 MPA. See Medroxyprogesterone acetate MPTP, 270–71, 639 model, 262, 270–71 MRI scans, 238, 638, 698 MRNAs, 66f, 67t and cellular phenotype, 22 MSG, 385 MSP. See Macrophage-stimulating protein MT (metallothioneins), 285 MTHFR (methylenetetrahydrofolate reductase), 60, 116, 335 polymorphism, 72, 224, 632, 634 SNP, 72–73, 72f Mucosa-associated lymphoid tissue (MALT), 194 Mucosal barrier, 191–92, 192f. See also Intestinal permeability; Leaky gut integrity of, 448–49 Mucosal glycoprotein, 411 Mucosal immune system, 449–53 food allergies, 450–51 immunologic cross-talk, 449 oral tolerance, 449–50 prebiotic treatment, 452 probiotic treatment, 451–52 stool analysis, 451 Multi-drug resistant genes (MDRs), 197 Multiple chemical sensitivities (MCS) exercise program for, 491 and oxidative stress, 362t Multiple organ dysfunction syndrome (MODS), 566 Multiple sclerosis, 60, 90, 194, 252, 257, 258, 305, 362t, 412, 450, 514, 601, 640 experimental drug treatments for, 314–15 experimental model of (EAE), 262 glutamate excess and, 640 nitric oxide synthetase and, 262 omega-3 fatty acid therapy, 87 and oxidative stress, 362t prevention of, 258 Multiple symptoms, 709–11 Multivitamins, 394 Murad, Ferid, 588 Muscle AMPK in, 175–76 body-building effects of androgens, 236–37 effects of androgenic steroids on, 236–37 Musculoskeletal conditions, 339–44 manipulation for, 496–97 screening before exercise, 483 Musculoskeletal system, 103 structural imbalances, 339–44 symptoms associated with food allergy/intolerance, 190t Mushrooms, immune-boosting, 372t Musnick, David, 481, 796 Mutation, 67t of mitochondrial DNA, 267–68 Myasthenia gravis, 592 Mycin, 41, 41t Myelin disorders, 269, 314. See also Multiple sclerosis Myoclonic epilepsy, ragged red fibers (MERRF), 260t, 267–68, 268t Myopathy, maternally inherited, with cardiomyopathy, 260t

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

N

885

Textbook of Functional Medicine

NSAIDs, 70t, 311–13, 317, 341 alternatives to, 414–17 Nuclear hormone receptor superfamily, 173–74 Nurse, Paul, 73 NutraSweet®, 384 Nutrients, 8, 59–61. See also Diet; Nutrition; specific nutrients and aging, 114–17 dietary reference intakes (DRIs), 60 and gene expression and intercellular communication, 585–88 general advice, 350t micronutrients insufficiency of, 72, 388–95, 841–56 proper balance of, 190 and mitochondrial function, 507–10 nutrition intervention, 22 phytonutrients, 94–95, 124, 190–91, 242, 330, 340, 361, 372t, 510, 545 role beyond deficiency diseases, 59–60 role in preventing genetotrophic diseases, 12 role of, 12, 59–61 in treatment of insulin resistance, 620–22 Nutrigenomics, 21–22, 59, 62–63, 348, 354–55 Nutrition. See also Diet; Nutrients autoimmunity and, 413 biochemical individuality and, 71–73, 115–16 clinical, 349–50 diet and, 347–88 general nutritional advice, 350t and hormonal balance, 223–24 undernutrition, 116, 362t, 841–56 Nuts, 348, 350t, 356, 376t

)2

(c

and gluten, 438 inflammatory, 410 NARP (neuropathy, ataxia, retinitis pigmentosa), 260t, 268t optic, 260, 267, 268t, 510 peripheral, 258, 412, 526, 788t sensory, 269 Neuropeptides, 82, 141, 228, 358–59, 564 Neurotoxicants, 102. See also Toxicants Neurotransmitters, 589–90, 638–44. See also specific neurotransmitters about, 638 acetylcholine (ACH), 640 amino acid neurotransmitters, 640 catecholamines, 638–40 dopamine, 638–39 serotonin, 639–40 complexity of action/interaction, 643–44 corticotropin-releasing hormone as, 612 functional brain approaches in practice, 640–43 imbalances of, 341, 565 modulating in neuropsychiatric conditions, 640–44, 640t magnesium and, 643 omega-3 fatty acids and, 642 tryptophan, 642 NFB, 175, 208, 212, 232, 307, 315, 321–22, 582t, 586–87 activation, 86, 180, 207, 302, 322 antioxidant regulation of, 322 functions of, 303 inhibition/inactivation of, 86, 303, 321–22, 361 -mediated gene activation, 303, 699 protein family, 303 redox sensitivity, 180 upregulation of, 302, 317 NHL (non-Hodgkin’s lymphoma), 148 Niacin. See Vitamin B3 Niacinamide, 372t, 415 Nickel, 290 Nitrates, 385 Nitric oxide (NO), 197, 201, 205, 218, 251, 261–62, 374, 449, 513, 514t, 589 in autism, 514–16, 517, 582t deficiency, 741 and disease risks, 588–89 estrogen and, 226 free radical metabolism and, 261, 514–16 in inflammation, 205 as intercellular communication agent, 582t, 588–89 Nitric oxide synthetase (NOS), 81, 197, 261–62, 307, 426 in disease models, 262, 520 inhibitor (7-nitosindazole), 262 Nitrite, 515–16, 523 NMDA receptors, 260–61, 269, 582t, 640 blockers of, 262, 643 potentiation by omega-3 fatty acids, 642 NO. See Nitric oxide Nociceptors, 141–42 Non-alcoholic fatty liver disease (NAFLD), 567 Non-alcoholic steatohepatitis (NASH), 445, 567–68 Non-Hodgkin’s lymphoma (NHL), 148 Nonionizing radiation, 154–55 Noradrenaline, 228 Norepinephrine, 142 norepinephrine-cortisol ratio, 146 Nortriptyline HCl, 70t NOS. See Nitric oxide synthetase

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All O

e

in

ic

ed

Oat products, gluten contamination of, 125–26 Obesity, 225–26, 349, 740, 741 abdominal, 742t effects on insulin/glucose balance, 619 exercise program for, 491 and hormone levels, 239, 242, 614, 740 and liver damage, 567 negative health effects of, 85 and PCOS, 225 refined carbohydrates/sugars and, 384 Occult infections, 412–13 Occupation, in stress assessment, 675 Olestra, 383 Oligoantigenic diet, 375, 438, 463, 557, 561, 562, 704. See also Elimination diet Oligospermia, 238 Omega-3 fatty acids, 86, 87, 124, 197, 319, 350t, 389, 394, 413, 446, 509. See also Essential fatty acids anti-inflammatory effects of, 420–27 consuming, 197 consumption, 86 consumption of, 352, 354 deficiency, 642 and depression, 85–86 dietary sources of, 420f as dietary supplement, 634 effects, 426 fatty acid rich, 349 in HIV/AIDS treatment, 617 and inflammation, 368 insufficiency of, 413

886

Index

P

lowered, 90 and neurotransmitters/neuroprotection, 642 omega-6 acid linoleic, 413 oxidized, 324 and PPARs, 355 therapy with, 86–87 total, 124 Oncogenes, 173 Onion (quercetin), 372t, 420, 528, 545, 547, 570 Oophorectomy, replacing hormones after, 629–30 Optimal outcomes, 34f Oral tolerance, 152, 319, 441, 441f, 449–50 Organ reserve, 6, 111–19 liver, 332 Organ system diagnosis, 8 Organ system function underlying mechanisms (the interconnected web), 99–104 gastrointestinal tract and immune system, 101–2 gastrointestinal tract and liver, 100–101 Organ system interventions, 698, 700 Organic toxicants, 551–52 Organochlorine compounds, 601 Organophosphate pesticides, 147–48 Organum vasculosum of the lamina terminalis (OVLT), 610, 613 Origins of illness, 80–81 Osler, William, 79, 691 Osteoarthritis, 85, 108, 308, 342–44, 561, 710, 730 of the knee, 242 and oxidative stress, 362t of temporomandibular joint, 161 Osteoporosis, 233 prevention, exercise program for, 490–91 OTC remedies, 373 Ovary, hormone actions, 608f Over-the-counter remedies, 373 OVLT (organum vasculosum of the lamina terminalis), 610, 613 Oxidation and cancer risk, 392–93 as energy source, 259–60, 265–66 Oxidation-reduction imbalances, 265–73, 342 episodic neurological disorders, 271 mitochondrial functions, 265–66, 266t mitochondrial genetics, 266 mitochondrial structure, 266–67 mitochondropathies, 267–68, 268t neurodegenerative disorders, 269–71 oxidative stress, 268–69 and thyroid function, 648 Oxidative phosphorylation, 186–87, 187f Oxidative stress, 174–77, 268–69, 501–41 autism and, 512–26 creation of, in biotransformation, 281 diet and, 362–65 in functional medicine, 501–12 glycemic control and, 526–29 laboratory assessment of, 523–24 mitochondria and, 505–7 in the nervous system, 259–62 neuroprostanes, 419 symptoms/associated conditions/contributing factors, 362t testing for, 365t therapeutic and protective, 363t Oxygen, as a limiting nutrient, 127–28 Oxytocin, 582t

)2

(c

PAI-1. See Plasminogen activator inhibitor 1 Palsy, progressive supranuclear, 258t PAMPs (pathogen-associated molecular patterns), 301–2, 307 Pancreas, 191, 436 beta cells, protection of, 528 pancreatic enzymes, 436–37 Pancreatitis, 191, 291–92 PANDAS syndrome, 304 PANs (primary afferent nociceptors), 141–42 Pantothenic acid, 468 supplementation for mitochondrial function, 364t Paradigm change, 58–60 Paraplegias, hereditary spastic, 270 Parasitic infections, 379t Parasympathetic nerves, 453 Paraventricular nucleus (PVN), 611 Parkinson’s disease, 58, 71, 102, 105, 189, 199, 223, 257, 258t, 269–73, 276, 279, 292, 300, 362t, 371t, 385, 489, 507, 522, 605, 635 chronic, 272 idiopathic, 258, 489 and oxidative stress, 362t Parkinsonism, 259 symptoms, 270 Pathogen-associated molecular patterns. See PAMPs Patient-centered care, 6, 51–53, 79–91, 316–17 doctor-patient relationships, 713–22 patient’s story/clinician’s thinking, 689–702 Patient history. See under History Patient-oriented evidence that matters (POEMs), 29 Pattern-recognition receptors (PRRs), 448 Pauling, Linus, 11–12, 21, 59 PCBs. See Polychlorinated biphenyls PCOD. See Polycystic ovary syndrome PCOS. See Polycystic ovary syndrome Pearson’s syndrome (PS), 260t, 268t Penicillin, 55 PEPI trials, 222 Pepsin, 328 Pepsinogen, 328 Perimenopause. See Menopause Peripheral nervous system, response to stress, 141–42 Peripheral neuropathies, 258, 258t Peripheral vascular disease, omega-3 fatty acid therapy, 87 Peristaltic reflex, 453 Permeability. See Intestinal permeability Peroxidation (of nervous tissue), 259 Peroxisome proliferator-activated receptors. See PPARs Peroxisome proliferators (PPs), 621, 743 Peroxisomes, 509 Peroxynitrite, 262, 269, 293, 502, 515 Persistent organic pollutants (POPs), 147–49, 149t dietary sources of, 149t health effects of, 148–50 Personalization of care, 39 Personalized medicine, 23, 115 Pert, Candace, 590 Pesticides, 189, 288, 385, 647 PET scans, 638, 639, 698 Peyer’s patches, 449, 565 Phagocytes, 204–6, 329 Pharmaceutical industry, NSAIDs and the development of, 311–16 Pharmaceutical intervention treatment, 52–53 Pharmaceutical marketing, 56

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 887

Textbook of Functional Medicine

Portal system, 329 Post-traumatic stress disorder (PTSD), 146, 166 Postmenopausal hormones, 220 Postmenopausal women. See Menopause Potassium, 70t PPARs (peroxisome proliferator-activated receptors), 178–79, 307–8 agonists, 510 antagonists, 421, 602 in atherosclerosis treatment, 408 in insulin balance, 621–22, 743 mitochondrial function and, 509, 510 and thyroid function, 586 PPIs (proton pump inhibitors), 328 PPs (peroxisome proliferators), 621 Prebiotics, 374, 447 reinoculation with, 467 treatment with, 452 use of, 377t Precision, of laboratory tests, 707 Prednisone, 70f Pregnancy, 219, 231 hypothyroidism in, 595 Premenstrual syndrome (PMS), 228–29 dietary modifications for, 633–35 symptoms, 360t Prevention of disease, 15–16 PRH, 608f Primary afferent nociceptors (PANs), 141–42 PRL. See Prolactin Probes for drug metabolizing enzymes, 288–90, 289f Probiotics, 332, 333–34, 361, 447 as dietary supplement, 635 and estrogen metabolism, 361 and food allergies, 451 reinoculation with, 467 treatment with, 451–52, 569 use of, 377t Prochaska, James O., 722, 797 Prochaska, Janice M., 722, 797 Progesterone, 219–20, 221, 608f and cancer risk, 219, 226 receptors, 220 replacement, 629 vs. progestins, 221–22 Progestins as mitogenic, 225 vs. progesterone, 221–22 Programmed cellular demise, 265 Progressive resistance training (PRT), 133 Proinflammatory cytokines, 231, 271, 302, 307, 309 Proinflammatory state, 207–8, 212, 230–31, 233, 248, 303–4, 322, 340, 340–43, 742t, 743 Prolactin (PRL), 235, 238, 608f Prolactin producing pituitary microadenomas, 235 Pros and Cons, 724 Prostacyclins (PGIs), 418–19 Prostaglandins (PGs), 418, 565, 582t, 743 in endometriosis, 637, 638 proinflammatory, 312 Prostanoids, 418–19 Prostate differentiation, 238 Prostate hypertrophy, benign (BHP), 238–39, 243 Protection and defense, 8, 191–96 GI mucosal barrier, 191–92

)2

(c

Pharmacogenomics, 69–70 Pharmacologic treatment, 8–9 Phase III metabolism, 282f Phases I and II. See under Detoxification Phenome, 22 Phenotype, 22, 67t, 115–17 Phenylketonuria, 10 Phenytoin, 70f, 647 Phosphatidylinositol 3-kinase (PI3-K), 743, 743f Phosphatidylinositol-4,5 bisphosphate (PIP2), 173 Phospholipase A2 (PLA2), 419, 512 Physical environment, in stress assessment, 675–76 Physical exam, comprehensive, 695–98, 697t Physical exercise. See Exercise Physical fitness. See Exercise Physiological processes, 8–10 core clinical imbalances, 9–10 web-like interconnections of, 6 Phytonutrients, 94–95, 124, 190–91, 242, 330, 340, 372t, 510 in detoxification, 545 and estrogen metabolism, 361 PI3-K (phosphatidylinositol 3-kinase), 743, 743f Pick’s dementia, 258t Piezoelectricity, 103 Pinocytosis, 331 PIP2 (phosphatidylinositol-4,5 bisphosphate), 173 Piroxicam, 70t Pituitary gland. See also Hypothalamic-pituitary-adrenal (HPA) axis anterior pituitary hormones, 142f, 608f dysfunction, 645 hormones, 235 hypopituitary conditions, DHEA and, 604–5 posterior (hypophysis), 610 prolactin producing pituitary microadenomas, 235 Pizzorno, Joseph E., Jr., 39, 796 Pizzorno, Lara, 57, 644, 797 PKA. See Protein kinase A Placebo group, 33 lack of, 317 Plasminogen activator inhibitor 1 (PAI-1), 205, 237, 743 PMS. See Premenstrual syndrome POEMs (patient-oriented evidence that matters), 29 Political empowerment, and stress, 676 Polybrominated diphenyl ethers (PBDEs), 148–50 Polychlorinated biphenyls (PCBs), 149t, 385, 551, 553, 601–2 Polycystic ovary disease (PCOD). See Polycystic ovary syndrome (PCOS) Polycystic ovary syndrome (PCOS) clinical approaches to, 615 and HPA axis, 614–15 with hyperinsulinemia, 247 insulin resistance and, 98, 245, 247 obesity and, 225 Polymorphisms, genetic, 13, 67t, 71–72, 166, 355, 694 cytokines, 225 definitions, 67t of detoxifying enzymes, 284–85 enzymatic, 699 heat shock proteins, 225 of metallothioneins, 285 of MTHFR, 72, 224, 355, 632, 634 single nucleotide polymorphisms, 20–21, 60, 61, 66–73, 67t, 126 Polyunsaturated fatty acids (PUFAs), 418, 620 POMC, 608f POPs. See Persistent organic pollutants

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 888

Index

and thyroid function, 647 Radical oxygen species. See ROS RAGEs, 302–3 Randomized controlled trial (RCT), 33–36, 50–51 comorbid conditions and, 35 limitations of, 33–36, 37, 56 Rapport, 713–14, 716–17 Rasagiline, 270–71 Ray, Oakley, 139–40 RCT. See Randomized controlled trial RDAs (recommended daily allowances), 388 Reactive oxygen species. See ROS Receptor tyrosine kinases (RTKs), 172, 172f Recommended daily allowances (RDAs), 388 Redox state, 174, 174f Referrals, 700–701 Reinforcement, 725 Reintroduction of excluded foods, 705–6. See also Elimination diet Reiter’s syndrome, 332 Relative risk (RR), 219 Releasing factors, 608f, 610–11 Religion, impact on health, 676–80. See also Spirituality Renal disease, fish oils and, 422–23 Renal insufficiency, 744 Replication, 8 Research base, 33–39 Resistance exercise, 135–36 progressive resistance training (PRT), 133 Resistin, 743 Resolvins, 419 Respiration, oxidative requirements of nervous system, 258, 259–62 Respiratory system, food allergy/intolerance and, 190t Resveratrol, 420 Retinoic acid, 598, 603 Review of essential elements, 691 Review of systems, 690, 693, 821–22 Rhabdomyolyses, 503–4 Rheumatoid arthritis (RA), 231, 308, 313, 314, 317, 332, 339, 341, 342, 445 fish oils and, 421–22 and gut flora, 464 neuroendocrine function in, 592 omega-3 fatty acid therapy, 87 and oxidative stress, 362t Riboflavin See Vitamin B2 Rifampin, 70f, 647 Right hemisphere/right brain effects, 667 Risk factors altered cellular communication and, 588–89 breast cancer, 224–26, 227t, 361, 632 cancer, 71, 392–93, 546 cardiac, fish oils and, 426–27 cardiovascular disease, omega-3 fatty acids and, 426–27 clinical intervention and, 682 coronary heart disease, 246 diet and, 126, 383–86 female hormones, 360t nitric oxide and, 588–89 Risk, relative (RR), 219 Risks/risk assessment for physical exercise, 482–83 Rome criteria for IBS, 446 ROS (radical/reactive oxygen species), 281, 303, 362t, 363, 364, 743 Rosemary, as dietary supplement, 634 Rountree, Robert, 299, 797–98

)2

(c

immune system, 193–95 inhalation and the GI tract, 193 skin as a barrier, 193 Protein kinase A (PKA), 173 Proteins adequate dietary, 292 food, 126 metabolism and exercise, 133–34 requirements and exercise, 134–35 Proteinuria, 744 Proteolytic enzymes, 415–16 Proteomics, 73–74 and genomics, 21–22 Proteus, 565 P. mirabilis, 448 Prothrombotic state, 742t Proton pump inhibitors (PPIs), 328 Protozoa, 465 PRRs (pattern-recognition receptors), 448 PS (Pearson’s syndrome), 260t, 268t PSA, 243–44 Psoriasis, 314, 423 Psoriatic arthritis, 632, 750–767 Psychiatry, modulating neurotransmitter imbalances in, 640–44, 640t Psycho-social factors, 8, 85, 137–40, 669 psychosocial mediators, 85 in stress, 138–40, 670–71 Psychoneuroimmunology, 12, 590, 590f PTSD (post-traumatic stress disorder), 146 PUFAs (polyunsaturated fatty acids), 418, 620 Pulmonary risks, screening before exercise, 483 Pulsed wave tissue Doppler imaging (PWTDI), 594 Purpose statement, 3 Pus, 206 PVN (paraventricular nucleus ), 611 PWTDI (pulsed wave tissue Doppler imaging), 594 Pyramids, food, 693 Pyridoxine. See Vitamin B6 Pyruvate aerobic oxidation of, 185–88, 186f in anaerobic glycolysis, 503

0

01

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

ic

Q

e

in

Quality of life, 108–9 Quercetin (onion), 372t, 420, 528, 545, 547, 570 Questionnaires Adult Toxin Exposure Questionnaire, 823–27 Child Toxin Exposure Questionnaire, 828–32 HOPE Questionnaire, 167 Life Stress Questionnaire, 693, 840 Medical Symptoms Questionnaire, 693, 838–39 Quinn, Sheila, 3, 5, 15, 18, 27, 111, 797 Quinone reductase (QR), 546 Quinones, 218

R RA. See Rheumatoid arthritis Race, and adverse drug reactions, 694 Radiation, 8, 153–55 electromagnetic therapies, 155 ionizing, 153–54, 363t, 367t, 647 nonionizing, 154–55 protectant from, 154 therapy, antioxidants and, 635

889

Textbook of Functional Medicine

Serum amyloid A (SAAO), 582t SES (socioeconomic status), 674–76 Sex hormone binding globulin (SHBG), 217, 219, 222–23, 247 in endometriosis, 637–38 in evaluating hormone replacement, 628 reduced by testosterone, 631 single nucleotide polymorphisms and, 633 Sex hormones, 359–62 SH. See Subclinical hypothyroidism Shapiro, Virginia, 709, 798 SHBG. See Sex hormone binding globulin Shippen, Eugene, 239 Short-chain fatty acids (SCFAs), 152, 196, 329, 331 Shy-Drager syndrome, 258t SIBO/SBBO (small intestine bacterial overgrowth), 198, 380t, 446, 570 Signal transduction, 171–74, 172f Signaling. See Cellular messaging Silent Spring, 148 Silymarin, 548, 634 Simplesse, 383 Single nucleotide polymorphisms (SNPs), 20–21, 60, 61, 66–73 adverse drug reactions and, 69–70 in assessing toxic exposure, 551 definitions, 67t function and, 68–69 and hormone metabolism/production, 631–33 219G toT polymorphism, 126 Skin as a barrier, 193 dark skin, 393–94 symptoms associated with, 190t SLE. See Systemic lupus erythematosus Sleep, 642–43, 650 melatonin regulation of, 582t, 609, 642–43 stress and, 673 Small intestine. See also Gastrointestinal tract; Intestine bacterial overgrowth (SIBO/SBBO), 198, 380t, 446, 570 in digestive process, 328, 332, 437 ileal brake, 332 motility, 328–29 pancreatic enzymes in, 437 Smallpox vaccination, 55 Smoke/smoking, 71, 288, 363t, 395, 619 SNPs. See Single nucleotide polymorphisms Social Readjustment Rating Scale, 138 Social support networks, 676 Socioeconomic status (SES) patient’s perception of, 675 and stress, 674–76 SOD. See Superoxide dismutase Somatostatin, 456, 582t, 608f, 647 Somatovisceral activation/dysfunction, 498, 498f Somatovisceral reflexes, 145 Sorbitol, 385 Soy products, 361, 425, 634 effects on thyroid function, 596–97 Specificity, of laboratory tests, 708 SPECT scans, 639, 698 Spinal manipulation, 414–15 Spirituality, 165–68, 669–70. See also Mind and spirit defining, 676 evidence on health effects of, 165–68, 677–78 impact on health, 676–80 integrating in clinical practice, 678–80

RR. See Relative risk RTKs. See Receptor tyrosine kinases Rubor, 203, 299 Rules-based systems, 42 Rutin, 372t

S

)2

(c

S-adenosylmethionine (SAM), 72, 281t, 570 SAAO (serum amyloid A), 582t Saccharomyces boulardii, 447, 467 SAD (seasonal affective disorder), 595 SAD (standard American diet), 340, 364 Salicylates, 311–16 Salix spp. (willow bark), 311, 416–17 SAM (SS-adenosylmethionine), 72, 635 Santayana, George, 671 Sapolsky, Robert, 138, 139 Sarcopenia, 381–82 Sauna therapy, 561–62 SBBO. See SIBO/SBBO SCA (short-chain fatty acids), 196 Scavenger receptors, 302–3 Schiltz, Barb, 703, 798 Schizophrenia, 12, 332, 640 dopamine and, 640t, 643 melatonin deficiency and, 643 omega-3 fatty acid therapy, 87 vitamin A deficiency and, 642 Science base for functional medicine, 49–54 Seasonal affective disorder (SAD), 595 Second brain, 327 SEEMs (selective estrogen enzyme modulators), 223 Selective estrogen enzyme modulators (SEEMs), 223 Selective estrogen receptor modulators (SERMs), 231 Selective serotonin reuptake inhibitors, 70t Selenium, 116, 278, 296, 549, 647 in autism treatment, 521–22 dietary sources of, 646 hyperglycemia and, 528 and thyroid function, 603, 646, 647 Self-amplifying cascades, 308 Selye, Hans, 12, 138, 219, 583, 670 Semmelweis, Ignaz, 55 Sensitivity, of laboratory tests, 707–8 Septicemia, 205 SERMS (selective estrogen receptor modulators), 231 Serotonin (5-HT), 582t, 639–40, 644 agonists, 458 brain, 642 imbalances, treatment of ADHD and depression, 641–42 modulation of, 640t receptors activity stimulates submucosal IPANs, 456–57, 457f antagonizing can slow motility, 459–60 involved in gut-to-brain signaling, 458–59 postsynaptic, 459, 459f presynaptic, 457–58, 457f reuptake, 454–56 inhibitors, 70t, 228 storage, 454 L-tryptophan and, 642 SERT expression and bowel inflammation/IBS, 460–62 SERT-mediated uptake and serotonin responses, 454–56

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 890

Index

aerobic exercise, 483–86 exercise calendar, compliance with, 491–92 exercise history, 481–82 exercise risks/risk assessment, 482–83 patients with neurodegenerative disorders, 489–90 patients with orthopedic conditions, 488 patients with special conditions, 490–91 strength training, 486–88 structural interconnections, 342 and thyroid function, 649 Subcellular interventions, 699, 700 Subclinical hypothyroidism (SH), 593–94, 601 Substance P, 456 Sudak, Nancy, 107, 709, 798 Sugar dietary, 634 refined, 384 Sulfation of estrogen, 219 Sulfites, 385 Sulfotransferase (SULT) enzymes, 219 Sulfur dietary, 292 sulfation of estrogens, 218–19, 223, 225 sulfation pathway, 572 SULT (sulfotransferase) enzymes, 219 Sult, Thomas, 327, 435, 798 Sumatriptan, and migraine headache, 39–40 Superoxide, 174, 262, 515 Superoxide dismutase (SOD), 226, 259, 270 Supplements. See Dietary supplements Susceptibility, individual, 115–17, 548–49 Sweeteners, artificial, 358t, 384–85 Sympathetic nervous system (SNS), 142 Symptoms Medical Symptoms Questionnaire, 693, 838–39 multiple, 709–11 treating, instead of underlying dysfunction, 314–18 Syndrome X. See Metabolic syndrome Systemic immune system, 194–95, 195f Systemic lupus erythematosus (SLE), 231, 252, 304, 308, 370, 592, 605 Systems biology approach, iii-iv, 22, 216, 318 Systems, review of, 690, 821–22 Szent-Györgyi, Albert, 55, 132, 142, 299

)2

(c

mind-body interventions, 680–82 interconnection of mind and spirit, 6, 340–41 relevance to healthcare providers, 676–77 Spondyloarthropathies, 464 SS-adenosylmethionine (SAM), 72, 635 SSRIs, 228, 286 Stage-matched interventions, 725–27 Staphylococcus aureus, 210 StAR protein, 234, 235 Statins, 59, 183, 188, 267, 315, 324–25, 503–4, 744 STEPed Care, 37–38 Stimulus-response model, 315–16 Stomach, 328. See also Gastrointestinal tract gastric motility, 328 Helicobacter pylori and, 84, 191, 380t, 411, 585 ulcers, 380t Stone, Michael, 689, 798 Stool analysis, 451 Strength training, 133–37, 486–88 orthopedic conditions and, 488 Stress, 12, 138–40, 669–84 adrenal function and, 604–5 chronic and cellular messaging dysfunction, 583–84 and thyroid function, 649–50 vs. acute, 138, 670–71 clinical interventions in, 671–74 community and, 674–76 defined, 670–71 and digestive system function, 376 health effects of, 138–39, 583–84 historical emergence of, 138–40 Holms and Rahe Social Readjustment Rating Scale, 138 individual response to, 139–40, 166 Life Stress Questionnaire, 693, 840 oxidative, 174–77 practical clinical approach to, 669–84 psychosocial factors in, 671–74 PTSD, 146, 166 socioeconomic status and, 674–76 stress-induced diseases, 584 testosterone and, 237 and thyroid function, 600–601, 649–50 Stroke, 267, 643 insulin resistance and, 247 NOS and, 262 prevention of, 116, 258 stroke-like episodes in MELAS, 260t, 267 Structural imbalances, 339–44, 339f, 481–500 clinical approaches to, 481–500 common pathway of pathophysiology, 494, 498, 498f conditions associated with, 495–96 detoxification, 341–42 environmental inputs, 339–40 functional assessment, 496 gastrointestinal status, 340 hormones and neurotransmitters, 341 immune/inflammatory imbalances, 341 macro level structural changes, 494 manipulation therapy, 493–99 micro level structural changes, 493–94 mind/spirit/emotions/community, 340–41 oxidative stress and energy production, 342 physical fitness and exercise, 481–93

0

01

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All T

e

T. See Testosterone T cell growth factor, 209 T cells, 142, 252, 306, 406–7, 448, 565 cytolytic/cytotoxic, 209, 306, 407 helper, 209, 300–301, 407 norepinephrine and, 142 TNF- production by, 233, 252 T2, 598 T3, 595, 599, 601, 645. See also T4 (thyroxine) conversion of T4 to, 599, 602, 604, 645, 646, 647, 650 depression and, 595 in euthyroid sick syndrome, 598 foods rich in nutrients for T3 binding, 646 free, 594 inflammation and, 600 low T3 syndrome, 603 and mitochondrial function, 598–99 nuclear receptors, 598, 599 reverse-T3-to-T3, 599, 601, 645, 647

891

Textbook of Functional Medicine

hypogonadism and fertility, 238 muscle and body-building effects, 236–37 perception and, 237–38 feedback modulation of production, 235 insufficiency in inflammatory/rheumatic disorders, 341 in intercellular communication, 582t receptors, 235 replacement, 236, 238, 242–44, 631 role of estrogen in men, 239–40 synthesis of, 234–35, 235f therapy, 238, 242–44 in women, 220, 222–23 Tests. See Testing Th cells, 221 Th1/Th2 imbalance, 305, 441, 448 and autoimmunity, 194, 221, 369 Thalamus, 611 Theophylline, 70t Therapeutic plan, developing and implementing, 690–702 Thiamine, supplementation for mitochondrial function, 362t Thiamine tetrahydrofurfuryl disulfide (TTFD), 523 Thiazide, 744 Thiazolidinediones, 744 Thiobarbituric reactive substance (TBARS), 512, 514 Thiopurine S-methyltransferase (TPMT) protein, 69 Thomas, Lewis, 49 3-Day Diet Record, 693, 857 Thromboxanes (TXs), 418, 582t Thymidine phosphorylase, 268 Thyroglobulin, 595–96 Thyroid, 644–50. See also T2; T3; T4 (thyroxine); Thyroid peroxidase (TPO); Thyroid stimulating hormone; Thyroid stimulating hormone (TSH) autoimmune diseases, 341, 603 detoxification/biotransformation imbalances and, 648 digestive/absorptive/microbiological imbalances and, 649 environmental inputs, 645–48 diet and nutrients, 645–47 exercise, 647 goitrogens, 645–46 medications, 647 trauma (surgery/radiation), 647 xenobiotics, 647 euthyroid sick syndrome, 596, 598 evaluating thyroid function, 593–604 alternatives to laboratory testing, 594 basal body temperature, 645 clinical effects of thyroid imbalance, 599 heterodimerization, 598 inflammatory cytokines and, 600–601 iodination of thyroxine and related processes, 595–96 laboratory thyroid screening, 594–95, 644–45 managing HPT axis imbalances, 602–3 maternal thyroid dysfunction effects, 595 mitochondria and, 598–99 molecular biology of thyroid hormone action, 596 natural therapies for thyroid dysfunction, 603–4 resistance to thyroid hormone, 597–98 soy consumption and, 596–97 subclinical thyroid dysfunction, 593–94, 595 supplementation and, 603 thyroid autoantibodies, 599–600 thyroid hormone antagonists, 597 TSH/TPO testing, 594, 597

)2

(c

stimulation of male hormone production, 235 stress and, 595 typical serum values, 644 T4 (thyroxine), 594–600, 645 conversion to T3, 599, 602, 604, 645, 646, 647, 650 depression and, 595 in euthyroid sick syndrome, 598 foods rich in nutrients for, 646 foods rich in nutrients for T4 to T3 conversion, 646 free, 594 metabolism of, 596 and mitochondrial function, 603 precursors for, 602, 604 production, 597 receptor binding, 602, 604 typical serum values, 644 Tai Chi, 135–36 Tartrazine, 385 Tatum, John M., 137, 798–99 Taurine, hyperglycemia and, 528 TBARS (thiobarbituric reactive substance), 512, 514 TCI (Temperament and Character Inventory), 167 Teaching functional medicine, 27–31 Tegaserod, 458 Temperament and Character Inventory (TCI), 167 Temporomandibular joint, osteoarthritis of, 161 Terpenoids, 545 Testing accuracy of, 707 assessing performance of, 707–8 challenge testing, 288 colonoscopy, 443 for digestion/absorption disorders, 442–43 enzyme function testing, 442 esophagogastroduodenoscopy (EGD), 443 fat absorption test, 442 food allergy, 443 gastric analysis, 442 for GI tract function, 381t, 442–44 for gut inflammation, 443 for inflammation, 368 for insulin resistance, 359t intestinal permeability, 443 laboratory testing in functional medicine, 706–9 microbiology, 442–43 non-analytical factors in, 708 for oxidative stress, 365t precision of, 707 sensitivity of, 707–8 specificity of, 708 for toxic element presence, 290 visualization of the mucosa, 443 Testosterone (T), 234–45. See also Androgens; Male hormones aging-related decrease in, 220, 238, 241 approach to the patient concerning, 241–42 deficiencies in, 241–42 derivates of, 238–41 DHEA, 240–41, 243 dihydrotestosterone (DHT), 236, 238–39, 243 effects of, 235–38 bone effects, 237 brain and cognitive effects, 235–36 cardiovascular disease and, 237 depression and, 238

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 892

Index

toxic metals, 290, 549–52 TP (true positive), 44 TPMT (thiopurine S-methyltransferase) protein, 69 TPO (thyroid peroxidase), 575, 594, 595, 596–97 Trace elements, and intercellular communication, 587–88 Training of clinicians, 27–31 Trans-fats, 349, 351, 352–53, 354t, 383 Trans-fatty acids, 353, 356, 368, 383 Transcription, 67t Transforming growth factor-, 565 Translation, 67t Transport and circulation, 8, 196–97 Transtheoretical Model (TTM) of behavior change, 723–28 Trauma, 8, 140–47, 647 case studies, 146–47 immune response and, 304 input to the CNS, 141–42, 142f long-term consequences of unresolved, 144–46 patient history in, 142–44 post-traumatic stress disorder (PTSD), 146 response to, 140–42 supporting patient health, 146 Treatment planning, 86–87 TRH, 608f Tricyclic antidepressants, 70t Triggers of illness, 81–85 Triglycerides to HDL ratio, 619 True positive (TP), 44 L-Tryptophan, 642 TSH. See Thyroid stimulating hormone TTFD (thiamine tetrahydrofurfuryl disulfide), 523 TTM (Transtheoretical Model of behavior change), 723–28 Tuberculosis, 205 Tumor necrosis factor (TNF), 205, 207–9, 207t, 231–33, 322, 582t action on adipocytes, 743 essential fatty acids and, 420–23 inflammation and, 352 monoclonal antibodies against, 314 TNF-, 101, 132, 177, 208, 225, 231, 300, 303, 307–9 blocker, 314 deprivation, 173 polymorphisms, 225 production by T cells, 233, 252 receptor, 308, 314 Tumor (swelling), 203, 299 Turmeric (curcumin), 293t, 361, 372t, 420, 440, 647 219G toT polymorphism, 126 TXA, 421, 424, 426 TXs (thromboxanes), 418, 582t Tyrosine kinase receptor, 172, 172f

)2

(c

vitamin A and, 598 vitamin D and, 601 xenobiotics and, 601–2, 647 Hashimoto’s thyroiditis, 445, 647 hormonal/neurotransmitter imbalances and, 648 hyperthyroidism, 138, 147 hypothyroidism, 593–95, 647 immune/inflammatory imbalances and, 649 interactions with estrogens, 229–30 mind and spirit and, 649–50 mitochondropathy and, 648 nutritional supplementation and, 646–47 oxidation/reduction imbalances and, 648 structural imbalances (cellular membrane) and, 649 subclinical hypothyroidism (SH), 593–94, 601 symptoms of imbalances, 593 Thyroid peroxidase (TPO), 575, 593, 594, 595, 596–97 Thyroid stimulating hormone (TSH), 582t, 586, 608f, 644–45 in euthyroid sick syndrome, 598 excess iodine and, 646 in HIV/AIDS treatment, 616–17 in hypothyroidism, 593–95 inflammation and, 600 stress and, 644–45 testing, 238, 594, 597, 600 typical serum values, 644 Thyroxine (T4), 594–600, 645 conversion to T3, 599, 602, 604, 645, 646, 647, 650 depression and, 595 diet and, 646 in euthyroid sick syndrome, 598 foods rich in nutrients for, 646 foods rich in nutrients for T4 to T3 conversion, 646 metabolism of, 596 precursors, 602, 604 production, 597 receptor binding, 602, 604 typical serum values, 644 Tight junctions, 331, 562 TIMPs (tissue inhibitor metalloproteinases), 232 Tissue inhibitor metalloproteinases (TIMPs), 232 Tissue sensitivity and intracellular response, 590–609 TLRs. See Toll-like receptors TNF. See Tumor necrosis factor Tobacco/smoke, 288 Toll-like receptors (TLRs), 206, 302 down-regulation of, 308 inhibition of, 304 response to microorganisms, 449 TOTE model, 316 Toxaphene, 149t Toxic exposure history, 551 Toxic load assessment, 287–90, 366t, 555–56 Toxicants, 77, 100–102, 193, 195–96, 197, 200, 286–87, 341 naturally occurring, 89 neurotoxicants, 102 Toxicogenomics, 551 Toxins, 189, 192, 365. See also Biotransformation; Detoxification; Xenobiotics bacterial endotoxin, 204, 205, 566 clinical presentations for, 291–92 laboratory assessment of, 551–52 organic, 551–52 oxidative stress and, 517

0

01

e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All U

UDP-glucuronosyltransferase (UGT), 633 UGT (UDP-glucuronosyltransferase), 633 Ulcerative colitis, 467, 565 Uncaria spp (Cat’s Claw), 416, 440 Uncertainty, 43, 44 Undernutrition, 116 and oxidative stress, 362t signs of, by nutrient, 841–88 signs of, by physical exam finding, 849–56 Upstream medicine, 22–23

V

893

Textbook of Functional Medicine

high-dose vitamin therapy, 355 and hyperglycemia, 527–28 and mitochondrial function, 507–9 multivitamins, 350t, 360t, 394 soluble, 585 VLA-4. See Very late antigen-4 VLDL-cholesterol, 619 VLDLs (very low density lipoproteins), 246, 359t, 730t, 733, 734, 737t, 738, 742t

Vagus nerve, 458 and GI motility, 328 Vanadium, in insulin balance, 621 Variation biological, 708 genetic, 544 Vascular cell adhesion molecule-1 (VCAM-1), 205 Vascular endothelial factors, in metabolic syndrome, 741 Vascular endothelial growth factor (VEGF), 409 Vasculature changes associated with structural imbalances, 495 inflammation and, 203–4 insulin actions on, 743 peripheral vascular disease, omega-3 fatty acid therapy, 87 Vasoactive intestinal peptide, 582t Vasopressin, 582t Vasquez, Alex, 99, 339, 409, 799 VCAMs, 205, 582t VDRs (vitamin D receptors), 633 Vegetables, 350t. See also specific vegetables Brassica family of, 95, 154, 218, 283, 293 cruciferous, 361, 366, 367t, 440, 634, 646 Vegetarian food pyramid, 693 VEGF (vascular endothelial growth factor), 409 Verapamil, 70t Vertigo, 495–96 Very late antigen-4 (VLA-4), 205 Very low-density lipoproteins. See VLDLs Virchow, Rudolph, 203–4 Viscerosomatic reflexes, 145 Vision statement, IFM, 3 Vitamin A, 270, 278, 292, 363t, 365t, 374, 524 deficiency, 598, 642 and hypodopaminergic states, 640t, 642 and intercellular communication, 587–88 sources of, 598, 646 and thyroid function, 598, 602, 646 Vitamin B2 (riboflavin), 571, 646, 699 supplementation for mitochondrial function, 364t Vitamin B3 (niacin), 507, 646, 744, 787 Vitamin B6 (pyridoxine), 391, 571, 744 in anxiety/seizure treatment, 640t in autism treatment, 519–20 dietary sources of, 646 Vitamin B12, 388, 389, 391, 571 in autism treatment, 522 Vitamin C, 116, 154, 363t, 364, 392, 524, 526, 552, 603 dietary sources of, 646 and thyroid function, 646, 647 Vitamin D, 60, 360t, 363t, 393–94, 603, 635, 750–767 autoantibody production and, 601 deficiency, 356 musculoskeletal pain and, 340–41 receptors (VDRs), 633 and thyroid function, 598 Vitamin E, 116, 154, 357, 358t, 360t, 365t, 392, 420, 508, 524, 526, 552 dietary sources of, 646 as dietary supplement, 635 and thyroid function, 603, 646, 647 Vitamins, 349, 353, 355, 387–89, 527–28, 570 B-complex, 116, 219, 224, 357, 359, 363t, 391–92, 507, 524, 547f deficiencies, 59, 389, 507, 642 degradation, 464 and health, 699

W

)2

(c

Warfarin, 69–70, 70t Waste elimination, 8, 197–99 Water, 8, 127–29 importance of assessing, 128 as limiting nutrient, 127–28 pollution, health effects of, 128–29 Web-like interconnections, 6, 97–99, 99f, 100f, 691 alterations and, 669–70 HPA axis and, 614 Weight loss, 132–33, 351 Whole body interventions, 698, 700 Whole grains, 125, 350t, 376t Wickes, David, 493, 799 Wild-type, 67t Willett, Walter, 23, 73, 116, 352, 353t, 693 Williams, Roger, 12, 65 Willner, Catherine, 257, 265, 799 Willow bark (Salis spp.), 311, 416–17 Wilson’s disease, 270, 645 Wolff-Parkinson-White syndrome, 510

0

01

lM na tio d. un rve r F se fo re te ts itu h st rig In All X

e

in

ic

ed

X-rays, 363t, 647, 698. See also Radiation Xanthine oxidase (X0), 514 Xenobiotics, 8, 147–50 in autoimmunity, 411–12 and cellular communication dysfunction, 584–85 detoxification/biotransformation of, 195–96, 277–82, 279f dietary sources of, 149t in disease processes, 276–77 exposure to, 277–78 health effects of, 148–50 and hormonal function, 223–24, 601–2 lipophilic, 555–56 pesticides, 189 and thyroid function, 601–2, 647 toxic load, 287–88 xenoestrogens, 230, 231, 361 Xylitol, 385

Y Yates, J. E., 93 Yeast alcohol production and, 568 infections, 378t, 750–785 (cases) syndrome, 465

Z Zinc, 363t, 374, 468, 601 in autism treatment, 520–21 deficiency, 224, 468, 520, 550, 646 dietary sources of, 646 functions of, 521, 646

894

Index

hyperglycemia and, 528 supplementation for mitochondrial function, 362t supplements, 239 in thyroid function/disorders, 601, 603, 646 Zingiber officinale (ginger), 372t, 417

)2

(c 0

01 e

in

ic

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All 895

Textbook of Functional Medicine

)2 (c

0 01

e in ic ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

896

01

)2

(c

21st century medicine: 0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

A New Model for Medical Education and Practice

ed e

in ic Institute for Functional Medicine David S. Jones, MD Laurie Hofmann, MPH Sheila Quinn

01

)2

(c 0 ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All e

in ic ©2010 The Institute for Functional Medicine 4411 Pt Fosdick Dr NW, Ste 305 Gig Harbor, WA 98335

21st century medicine: A New Model for Medical Education and Practice

(c

Table of Contents

01

)2

Page No.

0

Preface............................................................................................ iii

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Foreword....................................................................................... vii Executive Summary....................................................................... xi Chapter 1 Introduction............................................................... 1 Chapter 2 The Changing Medical Environment........................ 9 Chapter 3 Emerging Models..................................................... 23

ed

Chapter 4 The Clinician’s Dilemma......................................... 43

e

in ic

Chapter 5 F  unctional Medicine: A 21st Century Model of Patient Care and Medical Education ................. 61 References..................................................................................... 80 About The Institute for Functional Medicine............................... 88 Appendix Table of Contents....................................................... A1

21st Century Medicine | i

01 )2 (c

0

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e in ic

| 21st Century Medicine

ii

21st century medicine: A New Model for Medical Education and Practice

Preface ________________________________________ Beginning a Journey of Discovery

01

)2

(c

The document you are about to read emerged from a systematic process of inquiry and intentionality about some of the most critical issues in health care today. While there are many vital structural factors to be addressed elsewhere (reimbursement practices, insurance coverage, electronic medical records, the medical home concept), our attention and expertise are here focused on the content and process of care. The path we followed to conceive of, research, and write this white paper on 21st century medicine can be traced back to 2006, when the Fountainhead Foundation approved a grant to The Institute for Functional Medicine to establish and manage a scholarship program for medical schools and residency programs to send selected faculty, students, and residents to learn about functional medicine. Over a two-year period, 57 scholarships were awarded, representing 27 medical schools and 6 residency programs. The impact and opportunities that have grown out of this seed funding have been significant, immediate, and wide-ranging across academic medicine, clinical programs, fellowships, and residency programs.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

ed

Our interviews, meetings, and follow-up discussions with scholarship recipients and their colleagues underscored the fact that IFM needed to provide a rationale and methodology for facilitating a more systematic and widespread introduction of functional medicine into these diverse institutions and programs. It is very arduous to modify both the process and content of medical education. There must be a compelling reason and a clear path toward the goal. Our journey therefore, involved documenting the urgent need for a major shift in medical education, and then describing a model of care that can be adapted to the teaching needs of medical (and other health professions) schools and residency programs. In so doing, we provide both the justification for, and a description of, the change that must occur to equip clinicians to adapt successfully to the health care demands of the 21st century.

e

in ic

21st Century Medicine | iii

21st century medicine: A New Model for Medical Education and Practice

We looked first at relevant major themes in health care today: the epidemic of chronic disease; the evolution of evidence-based medicine; the poor performance of the acute-care model in a chronic care environment; the emergence of new paradigms such as systems biology, integrative medicine, and personalized care; and the lack of consensus on how to address these issues in a systematic way. This journey took us deep into the literature of costs vs. performance, science vs. art, research vs. clinical practice, and the many ideas about how to consolidate the gains of the 20th century without losing flexibility or constraining the promise of new information and new models of care for the future.

01

)2

(c

With this background in place, we began to explore how all of this looks and feels to the individual clinician who is immersed in the daily demands of clinical practice. This, of course, is where the rubber meets the road. We found that not only have we failed to materially assist most primary care practitioners in understanding how to make better use of evidence, or in translating new tools and ideas into their clinical practice, but we have left clinical medicine poorly equipped to address two critical elements: (1) managing the uncertainty that is inherent in clinical practice, and (2) creating a healing partnership with their patients. We found that clinicians are no longer taught how to integrate the science and the art of medicine—indeed, the art of medicine has all but disappeared as a subject of teaching. From the evidence-based medicine perspective, all you really need to do is gather data, focus the data toward securing the diagnosis, and then research the evidence about the best molecule (Rx) or procedure to treat that diagnosis. Doctors trained in the EBM, acute-care model have become technicians. Converging pressures have reinforced this model by forcing doctors to focus their office visits more and more narrowly, and to deliver care in less and less time (often for less and less money).

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

ed

If this model worked, we wouldn’t have had grounds for writing this paper. Unfortunately, the model has failed spectacularly to help stem the rising tide of chronic disease. Fortunately, however, there is plenty of evidence that this is not the only way forward. Physicians and other practitioners can be taught to shift into a personalized, systems-medicine approach that is much better adapted to the complex demands of chronic disease. They can learn to gather and analyze patient data differently. They can twist the kaleidoscope and apply critical thinking to the use of evidence. And they can create healing partnerships that allow both patients and practitioners to achieve insight and then to evaluate that insight in the light of knowledge and experience.

e

in ic

Reintegrating the Science and Art of Medicine There are always two deeply powered processes at work in any life-changing endeavor. Human beings require both denotative and connotative information for mastery—that is, we need both data and intuition, science and art. Brain scientists have made great progress in illuminating the deep creative processes by which our “minds” make use of the “matter” of our brains.”1,2,3,4,5,6 Clinicians, particularly, need to bring to the therapeutic encounter the unique qualities of both right- and left-brain function that have been emerging from brain science research. In the last decade, wider use of functional imaging technology has delivered a much clearer picture of coordinated brain function—why and how it occurs. It is now possible to weave together the integrated functionality of the two sides of the brain in a way that can inform our understanding about a comprehensive patient care model that respects and integrates both the science and the art of medicine.

iv

| 21st Century Medicine

PREFACE

The Institute for Functional Medicine (IFM) has developed a model of comprehensive care and primary prevention for complex, chronic illness that is grounded in both the science (the Functional Medicine Matrix Model) and the art (the healing partnership in the therapeutic encounter) of clinical medicine. We call this model functional medicine, and we have taught it for many years. It is not a separate discipline or specialty—it is an approach to clinical care that is both comprehensive and patient-centered. It can be taught to and practiced by any health practitioner who has a background in the basic medical sciences and clinical practice, and it can adapt quickly and easily to emerging evidence. It can also provide a common language and shared principles, organizing tools, and analytic process to support and facilitate integrated health care.

)2

(c

Continuing the Journey

01

We find ourselves at the beginning of the 21st century faced with a healthcare system in disarray on many levels. We must reassemble the disparate pieces of this baffling puzzle into a new and more coherent pattern (a new operating system). The intention of this document is to establish the need for a new model of care, and to make conscious, transparent, and usable the functional medicine model and our methods of teaching. We will show how this integrated model can better meet the needs of a population afflicted with steadily increasing rates of chronic disease. We believe that these changes will also help physicians establish a more satisfying basis for clinical practice.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

The diligent work and thinking of 20th century clinicians and scientists have brought us to this moment with many tools and key concepts, including:  the art and science of clinical medicine

 systems biology and personalized, systems medicine  prospective health care

 integrative medicine

e

 nutrigenomics, pharmacogenomics, proteomics, metabolomics

in ic

 the chronic-care model and the chronic-care team

ed

 patient-centered health care

 evidence-based medicine (EBM)  right and left brain functionality and the healing partnership  the science and practice of creating insight as part of the therapeutic encounter  the process of managing the uncertainty inherent in the clinical encounter

21st Century Medicine | v

21st century medicine: A New Model for Medical Education and Practice

We will explore all of these topics in the following pages, and we will address the challenge of synthesizing a model of health care for the 21st century that cogently integrates the best components of both established and emerging knowledge and practices. We will describe a model for therapeutic relationships that enhances the emergence of a healing partnership, that engages all parts of the brain, and that strengthens the bodies, minds, and spirits of both physicians and patients as they share the path toward improved health.

01

)2

(c

Our heartfelt thanks to the Bitzer Family and the Fountainhead Foundation for the ongoing support that has made this project possible.

0 lM na tio d. un rve r F se fo re te ts itu h st rig In All

David S. Jones, MD President, The Institute for Functional Medicine

Laurie Hofmann, MPH Executive Director, The Institute for Functional Medicine Sheila Quinn Consulting Author and Editor

ed e

in ic

vi

| 21st Century Medicine

21st century medicine: A New Model for Medical Education and Practice

Foreword ________________________________________ )2

(c

21st Century Medicine: A Gift to Our Patients and Our Students

01

As we see our healthcare system falling to pieces in front of us, we must ask some key questions. What is wrong with our views of health, disease, and the provision of care? Why does something that costs so much yield so little for so many? How can we best bring the science and art of medicine to our communities for the greatest good?

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Framing this discussion are two very different hypotheses:

1 Advances in medical science and technology will solve all of our personal and global health needs. 2 Natural healing techniques are safer and more effective than drugs and surgery.

Between these two points of view, both idealistic persuasions but starry eyed, is a reality about the future of medicine. This vision is well articulated in the monograph, “21st Century Medicine: A New Model for Medical Education and Practice,” by David Jones, Laurie Hofmann, and Sheila Quinn.

ed

e

in ic

The field of functional medicine offers educators, clinicians, and researchers a scientifically valid semantic and conceptual bridge between the benefits of hard sciences, clinical medicine, and integrative practices. Evolving sciences such as genomics, pharmacogenomics, and nutrigenomics offer innovative and promising medical treatments. At the same time, the common sense application of prevention, wellness promotion, improved lifestyle, diet, the use of botanicals and nutritional supplements, mind-body therapies, and other complementary and integrative approaches can be blended with these sciences through the Functional Medicine Matrix Model approach.

This synergy can not only improve our health as individuals and communities, but can close the maw of the gluttonous economic pit that excessive application of medical technology with its “Fix me; I’m broken” paradigm provides to us. Indeed, much of the resistance to changing medicine to a more integrative approach has been rooted in the absence of a common language encompassing what doctors learn to speak during medical school, or in other types of healthcare training programs, and the varied landscapes of complementary and integrative theories and practices.

21st Century Medicine | vii

21st century medicine: A New Model for Medical Education and Practice

This new model, as discussed in the monograph, offers cutting-edge systems biology, synthesized with whole-person medicine. This is the best of both worlds. No longer is the patient seen purely through the lens of a dysfunctional organ system, a disease, or a syndrome. By evaluating a matrix of root causes in the diagnostic and therapeutic process, we open our eyes to a different altitude as well as latitude of thinking about complex and chronic disease states. We can look further “upstream” to understand the physiology and pathophysiology and not simply treat the end stage manifestations of that altered physiology.

)2

(c

The Institute for Functional Medicine (IFM) is contributing to the development of medical school curricula to introduce this higher level of reasoning and assessment. IFM has supported a number of academic initiatives to expand the view of the patient from linear cause and effect, symptom and diagnosis, to a broader, real-life phenomenological perspective.

01

Traversing the view of function, health, and disease from the molecular and genomic to the psychosocial, cultural, and behavioral has always been a breathtaking stretch of mind and consciousness. Bringing this into medical training is particularly challenging even though it offers the opportunity to both respect our students as persons and adult learners, and to meld their interest in science with their desire to heal. It is a way to create a reciprocal languaging that provides bridges between learners and their patients as well as with their colleagues. This language, embedded with the various functional medicine constructs, expands our ability to communicate and to contextualize our own and our students’ understanding of the underlying science of medicine with the art of healing.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Since our work involves training medical students and residents for practice, we have given much thought, as have the authors of this monograph, to the future of medicine. To conclude we offer some comments we think mirror the authors’ vision in both spirit and values.

ed

The doctor of the future will be an integrative healer whose practice differs in many ways from that of today’s typical physician. The doctor of the future will provide care that is patient-centered and comprehensive (body, mind, and spirit), care that is both high-tech (using genomic prediction tools, systems biology, and functional medicine, for example) and high-touch. Care will focus more extensively on preventing disease and injury. The practice of the future will be provided by smoothly working teams that will include primary care physicians, complementary and alternative health practitioners, health coaches, and wellness mentors, as well as medical specialists, allied health and nursing practitioners. Putting the patient in the driver’s seat allows representatives from any number of disciplines to serve as navigator through the healthcare system, helping people sort through conflicting data as well as the many difficult choices they must make during their lives in times of both wellness and illness. Tomorrow’s physicians will consistently assess new evidence, to ensure that their practices meet the highest standards of quality and patient outcomes.

e

in ic

To a great degree, the body has the capacity to heal itself; this concept, in some ways, opposes the mechanical model in which doctors act as fixers. One goal of future practitioners will be to guide and empower patients toward self-healing. Consonant with this approach will be use of prevention and health promotion, the full range of natural treatments, use of the safest and least expensive interventions first, and also the mobilizing of community and social support for healthy living. This vision of the future doctor does not reflect a purely in-the-clinic model. Future clinicians, if they are to be integrative healers, need to be out where people are and to participate in social and environmental policy change.

viii

| 21st Century Medicine

FOREWORD

As both medicine and medical education evolve in this century, as health care and healthcare reform take shape, we believe that the concepts developed in this monograph will lead the way in thinking and practical application. Integrative Medicine is defined as the practice of medicine that reaffirms the importance of the relationship between practitioner and patient, focuses on the whole person, is informed by evidence, and makes use of all appropriate therapeutic approaches, healthcare professionals and disciplines to achieve optimal health and healing.1 As such, this model of care partners closely with the approach taken in functional medicine to bring the best of our thinking and practice to the bedside and to the community. The Functional Medicine Matrix Model, as elucidated in this paper, is an essential architecture for the kind of medicine of the future we see both as imminent and necessary.

(c

01

)2

Victor S. Sierpina, MD Chair of the Consortium of Academic Health Centers for Integrative Medicine Galveston, Texas

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Adam Perlman, MD, MPH Vice Chair of the Consortium of Academic Health Centers for Integrative Medicine Newark, New Jersey

ed e

in ic

1

Consortium of Academic Health Centers for Integrative Medicine definition of Integrative Medicine. http://www.imconsortium.org

21st Century Medicine | ix

01 )2 (c

0

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e in ic

| 21st Century Medicine

x

21st century medicine: A New Model for Medical Education and Practice

Executive Summary ________________________________________ )2

(c 01

In early 2009, an extraordinary degree of public attention was focused on healthcare reform. In Washington, DC, two hearings were held before the Senate Committee on Health, Education, Labor and Pensions, and the Institute of Medicine of the National Academy of Sciences hosted a Summit on Integrative Medicine and the Health of the Public. In New York City, a major conference on Integrative Health Care was held. The January/February 2009 issue of Health Affairs was devoted entirely to The Crisis in Chronic Disease. Why?

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

ed

We know with certainty now that rapidly rising rates of complex, chronic disease are creating an unsustainable burden on the national economy in both direct (e.g., treatment) and indirect (e.g., lost productivity) costs.7 The $1.3 trillion estimated to be the cost of chronic disease today may well grow to $4.2 trillion within 15 years.8 Health professionals struggle every day to cope with the increase in suffering and disability that accompanies this modern epidemic. At a time when many other urgent pressures on the national economy command our attention, we absolutely must sustain our focus on the system-wide changes in health care that will be required in the years ahead if the most severe consequences of this epidemic are to be avoided.

e

in ic

A careful examination of the evidence on both performance and costs in American health care convincingly demonstrates the urgent need for this transformation. We have been taught to believe that we have the best health care in the world, but the facts do not support such an assessment. We spend about twice as much per capita as other industrialized countries and yet we rank shockingly low on most parameters of health.9 Many diverse influences are responsible for the current state of the public’s health (see Figure 1).10, 11, 12 It is not enough, however, to demonstrate, as many experts have done, that the majority of today’s chronic diseases could be prevented or ameliorated by changes in lifestyle,13 and then suggest that patient responsibility and self-care can take care of the problem. We must also ask what contributes to such unhealthy lifestyles and how can we best equip clinicians to serve the

21st Century Medicine | xi

21st century medicine: A New Model for Medical Education and Practice

01

)2

(c

patients who are living every day under those pressures. It is critical that we understand how great a proportion of environment and lifestyle is influenced by conditions beyond the control of individual patients—not only the genetic vulnerability one is born with, but increases in environmental toxicity, the homogenization and denaturing of the food supply, the influence of sedentary technology on jobs, education, and entertainment, the powerlessness and despair of poverty, the debility produced by chronic stress, and the fragmentation of family and community life that leads to isolation and a lessened sense of purpose and meaning. These are all complex problems that took many decades to create and that will require a long-term national effort and effective leadership in public policy to alter. We recognize—and emphasize—that not only must we change healthcare and medical education (the primary focus of this paper), but over the next decades we must also change the practices and priorities of our political, social, and economic structures to achieve fundamental change in the public’s health.

0 Se (yo lif de un est nta g a yle ry nd s old ) Chronic stress

Chronic Disease Epidemic

l ta en nm ty ro ici

vi x En to lM na tio d. un rve r F se fo re te ts itu h st rig In All

Nutrition (food supply, dietary habits)

Fragmented families, communities

ed In do (? or l vit ivi D) ng

e

in ic

rty d ve re Po insu Un

Aging Aging population population

Figure 1: Major Influences Contributing to the Epidemic of Chronic Disease

In order to change our future, however, we must thoroughly understand our past. Therefore, after presenting an overview of the paper (Chapter 1), we focus first on exploring the dominant influences that have helped to shape the current crisis in health care (Chapter 2). Next, we present and discuss the most prominent models that have been proposed for the future (Chapter 3). The implications of these issues

xii

| 21st Century Medicine

EXECUTIVE SUMMARY

for the practicing clinician are then analyzed (Chapter 4). And last, a preferred model for 21st century medicine is presented (Chapter 5). It is important to recognize that even if patients do everything it is possible for individuals to do for their own health (an idealized state that is highly unlikely to be realized), we still have tens of millions of people with multiple chronic diseases, and well over 100 million with at least one,14 and both figures are on the upswing. All of these people need more effective therapeutic services, and everyone needs more effective disease prevention and wellness promotion strategies in order to cope with the pervasive environmental influences that make achieving health such a challenge.

01

)2

(c

The transformation of 21st century medicine from the prevailing acute-care model to a far more effective chronic-disease model will succeed only if we attack the underlying drivers of the epidemic—the complex, lifelong interactions among lifestyle, environment, and genetics—and if we engage the entire healthcare system in a concerted effort to implement a unified, flexible approach that can readily adapt to shifting needs and emerging evidence. The central purpose of this paper is to demonstrate that such changes are urgently needed and achievable.

0

In order to accomplish such an ambitious goal, several key objectives must be achieved. As discussed in the succeeding pages, these include:

lM na tio d. un rve r F se fo re te ts itu h st rig In All

1. A shared understanding of the powerful, primary influence of lifestyle and environment upon genetic vulnerability in the initiation and progression of chronic disease must be matched with a therapeutic tool kit that reverses the trajectory toward disease and disability, promotes health, and empowers patients as full partners in the lifelong pursuit of wellness. 2. A more balanced perspective on the appropriate uses of both evidence and insight must be integrated with broad-based clinical skills to establish the foundation for healing partnerships between practitioners and patients.

ed

3. A common set of principles, concepts, and practices that can be used by all health professionals must be taught and applied in clinical practice so that well-trained integrated healthcare teams can be deployed appropriately.

in ic

e

4. A model that incorporates all these elements must pervade education, clinical practice, and research in both private and public arenas. In this paper, we propose that functional medicine exemplifies the systems-oriented, personalized medicine that is needed to transform clinical practice, education, and research. The functional medicine model of comprehensive care and primary prevention for complex, chronic illnesses is grounded in both science (the Functional Medicine Matrix Model; evidence about common underlying mechanisms and pathways of disease; evidence about effective approaches to the environmental and lifestyle sources of disease) and art (the healing partnership and the search for insight in the therapeutic encounter). Many years of developing, writing about, and teaching this model to thousands of clinicians in both private practice and academic medicine have demonstrated that functional medicine can enable us to reshape health care for the demands of the 21st century. Using this approach, a healing partnership between doctor and patient can flourish, new and useful insights can be achieved, and a broad array of assessment and therapeutic tools can be utilized by integrated healthcare teams.

21st Century Medicine | xiii

01 )2 (c

0

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e in ic

21st century medicine: A New Model for Medical Education and Practice

Chapter 1 _______________________________________ 01

Opportunity

)2

(c

Introduction

0

If done right, the development of a health care system that focuses on personalized health planning will be every bit as transformational as the coupling of science to medicine was in the early 20th century.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

—Ralph Snyderman, MD, and R. Sanders Williams, MD15

ed

Throughout the medical system, the heartbeat of impending change has been heard with increasing intensity since the turn of the century. Concepts such as prospective health care, personalized medicine, systems biology, nutritional genomics, integrative medicine, the chronic-care model, and others represent diverse aspects of the impetus to devise a substantively different way of approaching health care in the 21st century. The shift in prevalence from acute to chronic disease16, 17 and a growing recognition of the inherent limitations and consequences of shaping medicine primarily around an acute-care model18 are among the most powerful forces that are driving change. The context of uncertainty that pervades the realm of clinical care19 demands a comprehensive and flexible model that can integrate evidence relevant to the individual without forcing physicians and other practitioners to manage complex, chronic disease using an acute-care model that is ill-suited to the task. Transformation is imminent—the opportunity is now.

e

in ic

The “next next transformation” will change the paradigm to focus on health—positively defined and measured as something other than the “absence of disease”; conceived as an integrated function of biology, environment, and behavior; and measured as a product of physical, mental, social, and spiritual variables. —Michael Johns, MD, and Kenneth Brigham, MD20

As we come to the close of the first decade of the 21st century, the opportunity to influence the strategic decisions that will redirect medical education and practice for the foreseeable future will encounter many challenges. Philosophies of health and disease, exciting new models of delivery and management of care, practitioner diversity and interrelationships, emerging perspectives on science

21st Century Medicine | 1

21st century medicine: A New Model for Medical Education and Practice

and evidence, and the teaching of analytical thinking and clinical reasoning are all under pressure to evolve. Resistance to change and eagerness for it exist simultaneously within all established systems; both perspectives represent important issues that must be addressed successfully to ensure that changes are purposeful, practical, and effective. Educational programs and leaders will be called upon to set the pace of change, identify the best models, integrate those models into existing curriculums, and advocate for widespread adoption.

01

)2

(c

We can facilitate this process by taking into account the substantial common ground that already exists among many of the leading innovative paradigms, even when they are not directly comparable in intent or in practical applications. Congruent elements can be identified, extracted, and synthesized to inform a comprehensive new model that will be compatible with both established and emerging approaches to health education and practice. In addition, there are important principles and practices that can provide a solid foundation for synthesizing these congruent elements into a workable new model.

0

Visualizing and implementing a fresh approach to health and disease will require collaborative efforts and systems that work to the benefit of patients and practitioners alike. In this paper, we will describe how certain key forces and concepts are critical components of a dedicated effort to achieve productive and lasting improvements in our healthcare system. We will demonstrate how the common themes in these overlapping paradigms represent fertile terrain for synthesizing a comprehensive new model. We will identify elements that must be added to the common themes to create an effective model for teaching and practice. And we will describe that new model and advance suggestions about how to strengthen and implement it. The ideas are (metaphorically) bursting out of the literature, essential tools are being developed, and the pivotal technologies are rapidly advancing—the moment is ripe with promise.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Purpose

ed

Our overarching purpose in writing this paper is to illuminate a path toward health and vitality for patients—not an easy or straightforward task in a world of increasing complexity and epidemic levels of chronic disease (Chapter 2). The intention of this document is to establish the need for a new model of care and to make conscious, transparent, and usable the functional medicine model. We offer to academic medicine leaders, practicing physicians, and other health professionals a model that we believe will substantially improve management of disease risk and assessment—as well as treatment for the millions of patients who already suffer from complex, chronic disease—using personalized, systemsoriented, cost-effective approaches. Blending the foundational principles and practices of functional medicine with the substantial common ground that already exists in emerging models clarifies a more comprehensive and effective model of teaching and practice for medical schools, residency programs, and eventually other health professions schools. Such an ambitious goal will succeed only if the plans rest upon a solid foundation that resonates strongly with leaders and early adopters in medical education and the health professions. Strategic objectives and effective tools to guide action steps appropriately will be required. The need for change and the matching of solutions to problems must be clear and persuasive. This paper will analyze emerging trends and needs and address the power of this synthesized model to shape those trends and meet critical needs in order to help improve the education and effectiveness of healthcare practitioners and offer their patients a better path toward lifelong health.

e

in ic

2

| 21st Century Medicine

INTRODUCTION

Emerging Models

(c

From among the creative and fascinating new paradigms, we will address six that have emerged as leaders and already claim many adherents. They share a great deal of common ground that is critical to a synthesized, comprehensive model for 21st century medicine. Each of these new models, while incomplete in itself, contains elements that help to ensure compatibility and integration into an overarching approach. These will be discussed in much greater detail in Chapter 3, but here we introduce the key concepts of each model. (There are other models of note, of course, including the Future of Family Medicine project and the Medical Home project; information on both of these is provided in the Appendix. In the body of this paper, however, we have narrowed our discussion to the models that appear to have the greatest potential impact on the actual content of care, rather than the structure of care.)

01

)2

A graphic representation of some of the common themes and key concepts in these six models can be seen in Figure 2.

0

Applies knowledge of genetic individuality to improve diagnostics and therapeutics; pharmacogenomics

rly by de ed M Un orm l Inf na tio d. un rve r F se fo re te ts itu h st rig In All

Personalized Medicine

Pr os pe Mu ct ive ltid isc He Pa ipl alt tie i nt s nary h Ca Pe t e e lf-m am rso re n a b a n a Sy l a s i z e g ste ed dc em Inf me are en orm ms b d t i i e c olo Sy d i n ste by e gy evi mwi d e de nc e ch an ge

Genetic vulnerabilities

Environmental influences

Patient self-management Prepared, proactive practice team; informed activated patient; decision support; clinical information systems; delivery system design; patient self-management

System-wide change Informed by EBM guidelines

Prediction, prevention, personalization, participation; pharmacogenomics

NEEDED:

Synthesized Model for Teaching and Practice with Common language, principles Practical tools

e

Multidisciplinary team-based care

GOAL:

Comprehensive 21st Century Medicine

in ic

Chronic Care Model

Informed by evidence

ed

Prediction, prevention, personalization, participation; pharmacogenomics

y og iol sB ary lin em p i st isc ine Sy dic ltid e s Mu dm sm i n lize e ha c na nc me rso de Pe evi ing

Reduce adverse drug effects amd interactions

Integrative Medicine Multidisciplinary

Practitioner-patient relationship Evidence-based Medicine Best: “green medicine”; clarifies mechanisms and actions

Diverse approaches Whole person focus

Worst: rigidity; focus on drug solutions; failure to use adaptive unconscious in the context of uncertainty; failure to match RCT outcomes to individual patients

Informed by evidence

Adopts best of CAM; collaboration with CAM providers; importance of mind/body

Applies most current research on therapeutics and diagnostics to patient care

Figure 2: Common Themes and Key Concepts Among Emerging Models in Medical Education and Clinical Practice

21st Century Medicine | 3

21st century medicine: A New Model for Medical Education and Practice

1. Personalized medicine

01

)2

(c

Personalized medicine is often rather narrowly defined to comprise primarily the development of genetic tests to identify risk factors for adverse or unpredictable drug effects and to identify individuals who are most appropriate for certain kinds of drug therapies or diagnostic procedures.21, 22 This kind of assessment should certainly help to improve the matching of drugs and diagnostics to individual patients and, as a result, may also help to reduce death, disability, and costs associated with individual differences in the biotransformation of drugs and other substances.23 However, under the rubric of personalized medicine lie many other complex issues relevant to biochemical, physiological, genetic, and environmental individuality that must also be attended to if we hope to reverse the modern epidemic of chronic disease and assist patients toward healthier lives. This broader model of personalized care has already become an explicit component of systems biology and prospective health care, and it is implicit in the chronic-care model and integrative medicine as well. Personalized medicine is critical to the future of health care.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

2. Prospective health care

A bold new model for 21st century medicine called prospective health care was proposed in 2003 by Snyderman and Williams.24 Pilot projects have been initiated and are being tested now at Duke University. In a 2006 article,25 Snyderman and Langheier described their rationale in terms completely consistent with the focus of functional medicine for the past two decades:

ed

Chronic diseases develop as a consequence of an individual’s baseline susceptibility coupled with their exposure to environmental factors. These may trigger initiating events, leading to the accumulation of pathological changes and the onset and progression of chronic disease. Today, most health-care expenditure is focused on the later stages of this process, long after the development of many underlying pathological changes. Until recently, it could be argued that the focus on treating disease was justified because the ability to predict, track, and prevent its onset was not technically feasible. This is no longer the case, and the emerging sciences of genomics, proteomics, metabolomics, medical technologies and informatics are revolutionizing the capability to predict events and enable intervention before damage occurs. Personalized risk prediction and strategic health-care planning will facilitate a new form of care, which we have called “prospective health care.”

e

in ic



4

Including the same four elements as systems biology (prediction, prevention, personalization, and participation), prospective health care offers a much broader perspective, describing structural and procedural transformations that must also occur in reimbursement, research, risk management assessment, record keeping, and the delivery of care.26 The thrust of these changes is “toward managing disease risk and providing personalized care for chronic and acute disease.”27

| 21st Century Medicine

INTRODUCTION

3. Chronic-care model

The full chronic-care model (CCM), first conceived in 1993, was formally presented in a 2001 publication by Wagner et al.28 Since that time, it has undergone serious study, implementation, and revision to accommodate experiences in clinical settings and findings from research. Emerging evidence has shown fairly conclusively that patient outcomes in a variety of chronic conditions can be improved whenever substantive progress is made on integrating the elements of this model into clinical practice. Core elements include:  Productive interactions between informed, activated patients and prepared practice teams  Effective patient self-management strategies

(c

01

)2

 Delivery system redesign (team approach; multidisciplinary, planned interventions instead of acute, reactive interventions; use of case managers; regular follow-up)

0

 Decision support (integration of evidence-based guidelines into the flow of clinical practice so that information to support clinical decision making is readily available)

lM na tio d. un rve r F se fo re te ts itu h st rig In All

 Clinical information system (the use of a database and other resources that bring timely, relevant information to both physicians and patients)  Community resources and policies

CCM has in common with prospective health care a strong emphasis on redesigning the systems that support and shape clinical practice. Both have explicit emphases on a team approach to chronic care, the necessity of patient self-management, and the urgent need to involve community resources and attract the attention of policymakers.

4. Evidence-based medicine

ed

Evidence-based medicine (EBM) is “the conscientious, explicit, and judicious use of current best evidence in making decisions about the care of individual patients. The practice of EBM means integrating individual clinical expertise with the best available external clinical evidence from systematic research.”i



We include EBM in the analysis of emerging models because of its growing influence on clinical practice and medical education. Although it is not, in and of itself, a type of medical education or clinical practice, at its best it can provide practitioners and healthcare delivery organizations with more current and focused decision support through the integration of relevant research findings into clinical decision making. Although EBM is intended to reduce uncertainty and improve the consistent use of best practices in patient care, experimental designs have not yet caught up with the complexity of chronic disease, the multiple needs and diverse presentations of patients in the clinical setting, and the multifactorial interventions that are required to address such diversity and

e

in ic



Used with permission of the Centre for Evidence-based Medicine. A more expanded definition of Evidence-based medicine is included in the Appendix.

i

21st Century Medicine | 5

21st century medicine: A New Model for Medical Education and Practice

complexity.29 EBM cannot replace analytical thinking, clinical reasoning, and clinical experience,30 although sometimes it is presented as doing just that. Improperly applied, EBM can place patients in serious jeopardy.31 Ideally, it can be used to increase practitioner effectiveness if its strengths are appropriately utilized and its limitations are clear: “The methods of EBM do not supply ‘correct’ answers but rather information that can improve clinical judgment.”32 Ultimately, the appropriate use of EBM relies on a more precise definition of what constitutes relevance and best evidence for each individual patient encounter. 5. Systems biology The Institute for Systems Biology in Seattle, Washington, identifies four factors that comprise its field: prediction, prevention, personalization, and participation. Although elsewhere systems biology is not defined quite so broadly, it is useful to consider it through this wide-angle lens, for it makes readily apparent the interconnections with integrative medicine, prospective health care, and personalized medicine that open the door to a synthesized model. Systems biology as currently pursued focuses primarily, as does personalized medicine, on genetic mechanisms in drug responses, but given a broad vision—and the will and funding to execute on that vision—it could become the scientific engine driving clinical medicine toward the model we are proposing. A more detailed description from the Institute for Systems Biology’s Web site is provided in the Appendix.

01

)2

(c



0



lM na tio d. un rve r F se fo re te ts itu h st rig In All

6. Integrative medicine

ed

In the years since 1999, when eight academic medical institutions first met to discuss the emerging field of integrative medicine, active participation among academic medical centers has grown dramatically. Now more than 45 institutions are members of the Consortium of Academic Health Centers for Integrative Medicine (CAHCIM), comprising many of the finest medical schools in the country, with several having endowed centers or foundations to support expanded development in the field. Their collective mission is:

e

in ic

…to help transform medicine and health care through rigorous scientific studies, new models of clinical care, and innovative educational programs that integrate biomedicine, the complexity of human beings, the intrinsic nature of healing and the rich diversity of therapeutic systems.33



Their definition of integrative medicine is: …the practice of medicine that reaffirms the importance of the relationship between practitioner and patient, focuses on the whole person, is informed by evidence, and makes use of all appropriate therapeutic approaches, healthcare professionals and disciplines to achieve optimal health and healing.

See list of CAHCIM members in the Appendix.

ii

6

| 21st Century Medicine

INTRODUCTION



Several elements of integrative medicine are highly relevant to the model proposed in this paper:  The openness to new diagnostic and therapeutic strategies (e.g., nutrients, botanicals, mindbody interventions, acupuncture) and to cooperation with health professionals from other disciplines signals an important readiness to develop a fully integrated healthcare model—one in which the patient is the central focus and all practitioners have in common certain critical elements of language, philosophy, and clinical practice.  The commitment to adopt innovative approaches in education is essential to the transformation of medicine.

01

)2

(c

 The emphasis on the value of practitioner-patient relationships and the focus on the whole person will play a significant role in the medicine of the future. These values—formerly so intrinsic a part of medicine that they went almost unnoticed—are receiving renewed attention now that their disappearance from much of medical care has become apparent. They are absolutely vital components of a transformed approach to health care.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Summary

ed

In this white paper, we will establish the need for a new model of education and care; we will address forces that may represent obstacles to change; and we will explore the key concepts and elements already present in science and medicine that are ripe for synthesis into a new, more comprehensive model. Our goal is to make improvement in medical education programs and clinical practice feasible—not in an abstract or ideal sense, but in the real world with all its resistance to change and discomfort with emerging concepts. To that end, funding has already been secured for the development of a pilot project for adapting the model to medical education. Before being finalized, each phase of the project will be reviewed by a small group of leaders within academic medicine who are interested in achieving a major shift in medical education, so that we tailor our recommendations to the audience with as close a fit as possible. IFM is pleased to announce that the roll-out of the first academic medicine project is scheduled for the first half of 2011. Our aim is nothing short of inspiring system-wide change—the transformation of medicine is imminent, it is urgently needed, and it is entirely possible.

e

in ic

21st Century Medicine | 7

01 )2 (c

0

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e in ic

21st century medicine: A New Model for Medical Education and Practice

Chapter 2 _______________________________________ 01

Background

)2

(c

The Changing Medical Environment

0

There are, literally, innumerable facts and statistics available with which to describe and analyze health and health care. Any discussion must of necessity be based on a selected subset of the data and, thus, subject to the bias of the authors. We have, for example, omitted such critical issues as the reimbursement structure, governmental regulatory influences, health disparities, environmental degradation, and the uses of technology—all topics on which reams of important material have been written. Our goal here is not to cover everything that is either problematic or of value within the medical environment, but to concentrate our thinking on well-established data that help to illuminate an overarching problem—that we are losing the battle against chronic disease and that fundamental change will be required to improve our performance.

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Global and economic issues

e

in ic

The healthcare system is influenced by increasingly complex and varied issues. Although many of these are beyond the scope of this paper, we would be remiss if we did not at least acknowledge their importance:

 The growing ethnic diversity of the U.S. population poses challenges of communication, varied beliefs and preferences about treatment, and the adverse impact of the standard American diet (SAD) on genetically vulnerable populations. [An excellent overview of emerging global health issues that are brought to the U.S. by immigrant populations can be found in the July/August 2008 issue of Health Affairs, which focuses on India and China. These articles demonstrate unequivocally that health issues in the developing countries parallel those of the developed world, as affluence, sedentary lives, and fragmentation of communities increase while food quality and diversity decrease.]

21st Century Medicine | 9

21st century medicine: A New Model for Medical Education and Practice

 The transmissibility of new diseases (e.g., avian flu) between species and across the world’s continents poses a special challenge to both acute and chronic care.34  Economic shifts that are strongly affected by global markets could have profound effects on the U.S. model of healthcare financing, an issue that has been under considerable scrutiny for many years already. Increasingly, the evidence identifies our patchwork approach to reimbursement as a considerable barrier to equitable and effective care.35  Importation and transportation of foods, prescription drugs, botanicals, and nutraceuticals among countries with widely differing quality control and environmental standards will affect virtually every citizen over time.

01

)2

(c

While we focus in this paper on models for clinical practice and medical education, we should keep the above issues in mind, because they will continue to influence both the healthcare system and individual health.

0

The pharmaceutical and acute-care models

lM na tio d. un rve r F se fo re te ts itu h st rig In All

The acute-care model is characterized by rapid differential diagnosis aimed at prescribing a drug (or procedure) that will ameliorate the patient’s presenting symptoms and avert the immediate threat.36 It minimizes the involvement of the patient, who functions as a mostly passive recipient of the procedure or prescription.37 It is not a model that reimburses the practitioner for looking into why the patient became ill, or whether she/he will be back many times for ramifications of the same underlying problem.38 Instead, it prioritizes quick solutions to the most pressing problems. It is, of course, absolutely essential in emergency and hospital-based care, but difficulties arise when this model is applied to ongoing, community-based care, a process that accelerated under the managed-care movement (which turned

20th Century Medicine

ed in ic

cs, bioti Anti n relief, pai ncer, n, ca eptio rac cont urgical s s nce adva

e

te Acu ns ctio infe

ma Trau

Acute-care m urg

tical and s

Pharmaceu Poo r hyg public sani iene, tatio n Igno abo rance ut g erm s

odel rs ical answe

Dan g wo erous con rking ditio ns End e pove mic rty

Pha rma c prof eutica l its Surg ery prof Man its age d ca Drug r e adve rtisi ng

Figure 3: Forces Narrowing the Focus of 20th Century Medicine 10

| 21st Century Medicine

the changing medical environment

out to be far more about managing costs than managing care) and the direct-to-patient advertising of drugs. With hindsight, it seems as though everything has been pushing the system toward this narrowed focus, regardless of fit (Figure 3).

01

)2

(c

The advances achieved by drugs in curing acute infections and managing some of the most threatening diseases mankind has faced were dramatic in the last century. The extended romance with pharmaceutical medicine, which first blossomed in the early 1930s when penicillin began to cure previously intractable infectious diseases, has now dominated medicine and medical education for more than seven decades. From depression to diabetes, from heart disease to asthma, the search for therapeutic compounds that can be patented as drugs continues unabated. The accompanying financial incentives have attracted (and perhaps distracted, see Sidebar) some of the best minds and most influential leaders in research and medical education, including those engaged in the development of systems biology and personalized medicine, both of which are primarily focused on pharmacogenomics at this time (see Chapter 3 and the Appendix for more information on these models).

Research Bias: The Pharmaceutical Hegemony in Funding and Focus

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Opportunities lost are perhaps the greatest concern in the dominance of the pharmaceutical research model. Too often, the search for drugs that will pay off for investors and executives of pharmaceutical companies determines the research agenda. Rather than being driven by patient needs, public health priorities, or scientific curiosity about mechanisms and pathways, the profit motive is the driver of the research agenda,39 and the gains to science and health are collateral outcomes, not central purposes. Lest we think this is trivial, consider that 70% of the money for clinical drug trials in the U.S. comes from the pharmaceutical industry.40

Costs and Performance in the Battle for Health

ed

e

in ic

It is discouraging to note that among the vast array of peerreviewed medical research reports published every year, there is so little that addresses whether the overall health of the population shows an adequate positive response to current medical treatment. Thousands upon thousands of studies compare one drug to another without ever acknowledging that Americans are far less healthy—at far greater cost—than their counterparts in the rest of the industrialized world. The reduction in deaths from, for example, heart disease is emphasized,45 while the fact that we have failed to prevent CVD—even while reducing, through drugs, the prevalence of CVD risk factors such as hypertension and high cholesterol46— is too often ignored. In fact, we must turn primarily to philanthropic or governmental agencies for data and analyses that reveal the scope of the failure. “The Milken Institute recently estimated that the most common chronic diseases cost the economy more than $1 trillion annually, mostly from lost

“Scientifically, a neutral or negative trial is as valuable as a positive one, although commercially this is clearly not the case.”41 Unless all results are available to the scientific community, the evidence record about those drugs that are investigated can be significantly skewed by the absence of negative or neutral findings. The value to academic researchers (and their institutions) of bringing in large clinical trials with drug company funding may be very significant; promotions, recognition, and supplemental income provide a triple-threat incentive that is virtually impossible to ignore when considering research priorities.42, 43

Many studies have shown a bias toward positive results when the research was funded by the drugs’ manufacturers.44

21st Century Medicine | 11

21st century medicine: A New Model for Medical Education and Practice

worker productivity, which could balloon to nearly $6 trillion by the middle of the century.”47 If nothing else, that estimate alone should galvanize us to action! The broad education in science and clinical arts that physicians experience today is expressed in clinical practice through a constricting and linear process that is primarily aimed at naming a drug of choice for the patient at hand.48 Unfortunately, 50 years of such practices have failed to stem the rising tide of chronic diseases among both young and old,49 while related problems have emerged to cause great concern:

01

)2

(c

 The cost of care is unmanageably high and rising,50 driven by the high costs of hospitalization51 and drugs,52, 53 but also fueled by increasing prevalence of complex, chronic disease at all ages of the population.54, 55 It is estimated, for example, that more than half of all Americans suffer from one or more chronic diseases,56 and that the 8 million Medicare beneficiaries who have five or more chronic conditions accounted for over two-thirds of the program’s $302 billion in spending in 2004.57

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

The Milken Institute report, An Unhealthy America (October 2007), provides the following food for thought: To quantify the potential savings from healthier lifestyles and plausible but modest advances in treatment, we compared a “business-as-usual” baseline scenario with an optimistic scenario that assumes reasonable improvements in health-related behavior and treatment. The major changes contemplated here are weight control combined with improved nutrition, exercise, further reductions in smoking, more aggressive early disease detection, slightly faster adoption of improved therapies, and less-invasive treatments….

ed

Across the seven diseases, the optimistic scenario would cut treatment (direct) costs in 2023 by $217 billion…. And the cumulative avoidable treatment costs from now through 2023 would total a whopping $1.6 trillion. Note that this would be a gift that keeps on giving, saving hundreds of billions annually in the years beyond 2023.

in ic

e

All told, our analysis implies that modest reductions in avoidable factors—unhealthy behavior, environmental risks, and the failure to make modest gains in early detection and innovative treatment—will lead to 40 million fewer cases of illness and a gain of over $1 trillion annually in labor supply and efficiency by 2023. Compared to the costs we project under the business-as-usual scenario, this represents a 27 percent reduction in total economic impact.

 Table 1 displays the bookends of health: rankings on infant mortality and life expectancy. The U.S. makes a very poor showing on both, particularly for a country whose citizens have been taught to believe they have the best health care in the world. The U.S. spends twice the median per-capita costs calculated by the Organization for Economic Cooperation and Development (OECD),58 has extraordinarily poor outcomes for such a massive investment,59 and does not even provide coverage for all its citizens (an estimated 47 million currently uninsured60; 75 million under- and uninsured combined61).

12

| 21st Century Medicine

the changing medical environment

Table 1. Infant Mortality and Life Expectancy Rankings of the United States

Ranking Country

Country

01

)2

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Japan Switzerland Sweden Australia Canada Italy France Spain Norway Israel Greece Austria New Zealand Germany United Kingdom Finland United States Denmark Cyprus

Ranking 1 2 3/4 3/4 5 6/7 6/7 8 9 10 11 12 13/14 13/14 15 16 17/18/19 17/18/19 17/18/19

e

in ic

1. Infant deaths per 1,000 live births. 2. Life expectancy at birth, in years, both sexes. Source: U.S. Census Bureau, International Database. From: http://www.infoplease.com/ipa/A0004393.html Information Please® Database, © 2007 Pearson Education, Inc. All rights reserved.

Life Expectancy2 81.4 80.6 80.6 80.6 80.3 79.9 79.9 79.8 79.7 79.6 79.4 79.2 79.0 79.0 78.7 78.7 78.0 78.0 78.0

ed

Sweden Japan Finland Norway Czech Republic Germany France Spain Switzerland Austria Denmark Australia Canada Portugal United Kingdom Ireland Greece Italy New Zealand Korea, South United States

(c

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Infant Mortality1 2.8 3.2 3.5 3.6 3.9 4.1 4.2 4.3 4.3 4.5 4.5 4.6 4.6 4.9 5.0 5.2 5.3 5.7 5.7 6.1 6.4

 The “quick fix” mentality that drug dependence has fostered in patients creates an unhealthy cycle that drives further drug dependence. Sensible and distinguished voices calling for major long-term investments in helping people establish healthy behaviors and in ensuring a healthy planet have heretofore been mostly ignored in the struggle for attention and funding. And yet, with only a few exceptions, the development of chronic disease is predominantly influenced by multiple interactions between genes and environment experienced over many years; neither factor alone is enough—the genes must be plunged into an adverse environment to express disease and they must be rescued from such environments to restore health (not just suppress symptoms): ➢➢ Walter Willett: “For most diseases contributing importantly to mortality in Western populations, epidemiologists have long known that nongenetic factors have high attributable risks, often at least 80 or 90%, even when the specific etiologic factors are not clear.”62

21st Century Medicine | 13

21st century medicine: A New Model for Medical Education and Practice

➢➢ Kenneth Thorpe: “Health behavior such as overconsumption of food, lack of exercise, smoking, and stress accounts for 40% to 50% of morbidity and mortality.”63 ➢➢ Robert Heaney: “Discerning the full role of nutrition in long-latency, multifactorial disorders is probably the principal challenge facing nutritional science today. The first component of this challenge is to recognize that inadequate intakes of specific nutrients may produce more than one disease, may produce diseases by more than one mechanism, and may require several years for the consequent morbidity to be sufficiently evident to be clinically recognizable as ‘disease.’”64

01

)2

(c

 Drug-resistance phenomena,65 adverse drug reactions,66 and adverse interactions between drugs and foods,67 drugs and botanicals,68 and drugs and other drugs69 now affect millions of lives each year and are a cause of death in unprecedented numbers.70 Rates of visits to provide care for adverse drug reactions increased by one-third between 2001 and 2004.71

0

On a deeper level, the drug paradigm—and the most rigid part of the evidence-based movement that supports it—may adversely affect clinical judgment. To minimize time spent with patients, physicians are forced to focus on prescribing the “right” drug. Very often, however, the evidence about the “right” drug rests on studies that do not reflect a real patient population as seen in clinical practice72; multiple comorbidities, for example, are usually excluded from RCTs.73, 74 Until very recently, nearly all clinical trials failed to account for variations in individual biochemistry and physiology, as well.75, 76

lM na tio d. un rve r F se fo re te ts itu h st rig In All

ed

This shift toward rapid prescribing results in a de-emphasis on establishing therapeutic relationships and exploring the patient’s story. Time pressures applied by reimbursement entities make it very difficult to do the analytical thinking that develops broad pattern-recognition abilities. Immensely valuable clinical skills for managing complex, chronic disease and multiple comorbidities are thus being sidelined; as that happens, fears about innovation and creativity surface, a retreat to dogma and linearity becomes apparent, and the idea that the job of medicine is to find the right drug(s) for the most parsimonious diagnosis preoccupies mainstream thought. Such forces separate the physician from many analytical and inferential skills that are likely to be extremely useful in the search for common underlying pathways of chronic disease and for new approaches designed to intervene where such disease actually originates—in the patient’s unique mix of biochemistry, genetics, and environment.

e

in ic

The focus on drugs could be considered both cause and effect of the dominance of the acute-care model that has come to characterize medicine today. As the challenges of infectious disease and trauma gave ground to advances in drugs and surgery, startling successes strengthened the belief that modern medicine would eventually conquer most diseases with those tools, a perspective that only intensified as the profits to be made from drugs and surgery became a magnet for both individuals and institutions. Few scientists or physicians in the 1950s and 60s foresaw a moment when the challenge of chronic disease would swamp the healthcare system and prove resistant to the miracles of 20th century medicine.

14

| 21st Century Medicine

the changing medical environment

01

)2

(c

Now, however, in the 21st century, we are fully aware that complex, lifelong interactions between our genes and environmental degradation,77 unhealthy diets78 (fueled by changes in both eating habits and food supply79), stress,80, 81, 82 sedentary lives,83 and social fragmentation of families and communities84 have surged to the forefront as interwoven causes of chronic disease that are not amenable to treatment with an acute-care model. (Figure 4 depicts the pressures that are forcing a broader process of clinical thinking and care.) With an aging population, these effects are present through many more years of life and thus become impressive cost drivers (see, for example, the Medicare data in Figure 5). The system must expand to address these interconnected trends. Broad-based pattern-recognition and communications skills will be needed to prevent, treat, and reverse the declining function associated with these pervasive influences. We must transform our system of health care through new models for medical education, acute and chronic disease management, research, health insurance, and fiscal responsibility.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

21st Century Medicine

ges le Chan y t s e f i L Em calo pty ries Fast food O abun verdanc e

Lack supp of ort Stres Spiri s tu Com ality mun ity

Popu la leve tion l: Agin g, Dive Glob rsity aliza tion

Chronic care model Prevention Lifestyle modification Patient education and empowerment

zed Personali and integrative medicine

Figure 4: Forces Expanding the Focus of 21st Century Medicine

are Chronic-cnd model a risk ent managem

e

ve Prospectie medicin s m and syste biology

in ic

Nutraceuticals Botanicals n Meditatio

ed

Genetics Nutrigenomics

Lac exer k of ci Sede se ntary ho workme/ lives

Envi ronm leve ental Pest l: icide s Toxi c Wa st Urba nizat e ion

21st Century Medicine | 15

21st century medicine: A New Model for Medical Education and Practice

0 Chronic Conditions 1% of Medicare Spending

1 Chronic Condition 3% of Medicare Spending 2+ Chronic Conditions 6% of Medicare Spending 3+ Chronic Conditions 10% of Medicare Spending

01

)2

(c

4+ Chronic Conditions 12% of Medicare Spending

0

5+ Chronic Conditions 68% of Medicare Spending

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Figure 5: Medicare Spending as a Function of Number of Chronic Conditions Data from Chronic Conditions: Making the Case for Ongoing Care. Johns Hopkins University and The Robert Wood Johnson Foundation: Partnership for Solutions, September 2004.

ed

The seemingly intractable poor performance of American medicine on a wide range of health measures85, 86 forces us to pose some critical questions:

e

in ic

 Does the investment in a paradigm that identifies drugs as the treatment of choice across a broad array of diagnoses still produce the same returns on investment that were achieved in earlier decades?  Is a system that seeks to reduce doctor-patient face time to the fewest possible minutes, and that measures effectiveness by how little time and money are spent, going to enable us to address population-wide health needs in the century ahead?  Does the acute-care model respond appropriately to the needs of patients already suffering from complex, chronic disease and multiple comorbidities, as well as to the exigency of preventing those diseases for currently healthy people and future generations? We suggest that not only is the evidence persuasive that the answer to those questions is “no,” but that the continued almost exclusive reliance on pharmaceutical answers to an epidemic of complex, chronic disease may constitute an unintended rejection of some practices critical to improving our response to today’s urgent problems.

16

| 21st Century Medicine

the changing medical environment

Changing Patterns: From Acute to Chronic Disease The changes in mortality and morbidity in the United States over the last century have been described as a shift from an age of “pestilence and famine” to an age of “degenerative and man-made diseases.”87 In other words, infections and undernutrition as relatively straightforward causes of illness and (often early) death have been overwhelmingly superseded by chronic, degenerative conditions caused by multiple, complex influences. In addition to the discovery and development of antibiotics, the great achievements of the public health system88—vaccinations; safety in municipal water and sewage systems, foods, medicine, workplace, highways and motor vehicles; prenatal and pediatric care; reduction in smoking—were among the most critical factors in making this shift, particularly in the first half of the 20th century.

(c

01

)2

Medicine’s focus on the development of a sophisticated and multifaceted pharmaceutical war chest to cope with infectious disease achieved many notable successes. Unfortunately, infectious disease still has an uncomfortable persistence—a way of breaking out in a different guise just when it was thought to be under control—witness the emergence of AIDS, the ability of bacteria and viruses to become resistant to drug treatments, and the ever-evolving influenza virus, to name a few examples. There is no question, however, that pneumonia, influenza, tuberculosis, and diarrhea/enteritis (the leading causes of death in the United States in the early 1900s) have been replaced by heart disease, cancer, and cerebrovascular disease at the top of the mortality list.89

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

The tremendous advantage of this shift is that we can live much longer with chronic than acute diseases.iii Cardiovascular disease (CVD), for example, is the biggest killer,iv even though three of its four primary risk factors (hypertension, hypercholesteremia, smoking) have been significantly reduced.90 Unfortunately, the fourth, diabetes, has increased.91 Pharmaceutical and surgical interventions have evolved to address both secondary prevention and symptom management. The upshot of this massive, long-term effort is that people with CVD are living longer and the incidence of death from this disease has substantially decreased.92

ed

e

in ic

We could stop there and declare victory, but that would be tragically shortsighted. Although we have reduced the mortality associated with many serious chronic diseases, the prevalence of, for example, cancer, diabetes, asthma, and heart disease—and the conditions that precede and perpetuate them—has grown, rather than diminished. Rising disease prevalence is complex, of course, composed of at least three primary factors: “…a rise in the population prevalence of disease, changes in clinical thresholds (and awareness) for treating and diagnosing disease, and new technologies that allow physicians to treat additional patients with a particular medical condition. A rise in total disease prevalence (both diagnosed and undiagnosed) is associated with changing population risk factors such as obesity. For instance, among adults ages 20–74, obesity prevalence increased from 14.5% (1976–1980) to 30.4% 20 years later (1999–2000). During the same period, total diabetes prevalence, which is clinically linked to obesity, increased 53%, and diagnosed (treated) diabetes prevalence increased 43%.”93 iii

In the last century, overall life expectancy has risen from 51 to 79.4 years for women and from 48 to 73.9 years for men. Source: Chapter on Human Health, EPA Report on the Environment, 2003. Available at http://www.epa.gov/roe/roe/html/roeHealthSt.htm.

iv

“According to the NCHS, if all forms of major CVD were eliminated, life expectancy would rise by almost seven years. If all forms of cancer were eliminated, the gain would be three years.” Heart Disease and Stroke Statistics—2008 Update, American Heart Association. Cited source: U.S. Decennial Life Tables for 1989-91, Volume 1, No. 4. Eliminating Certain Causes of Death, 1989-91. NCHS, September 1999.

21st Century Medicine | 17

21st century medicine: A New Model for Medical Education and Practice

The Role of Obesity in Chronic Disease

01

)2

(c

Focusing on the role of obesity in chronic disease could pay untold dividends. “[O]ne of the most heritable of human traits,”94 obesity is also profoundly influenced by lifestyle and environment.95 It fuels (and can be exacerbated by) chronic diseases with high morbidity as well as mortality— cancer, diabetes (now projected to touch 30-40% of all Americans during their lifetimes), heart disease, and depression. As an outcome of the rise in diabetes and other obesity-driven diseases, Olshansky et al. made the shocking projection in 2005 that “… the steady rise in life expectancy during the past two centuries may soon come to an end.”96 In other words, if current trends continue unchecked, future generations will have shorter and less healthy lives than the adults of today.

e

| 21st Century Medicine

 Overall health-related quality of life (HRQOL) has gone down as chronic disease rates have risen. The Mortality and Morbidity Weekly Report Surveillance Summaries reported that “during 1993-2001, the mean number of physically unhealthy days, mentally unhealthy days, overall unhealthy days, and activity limitation days was higher after 1997 than before 1997. …Adults increasingly rated their health as fair or poor and decreasingly rated it as excellent or very good.”106

in ic

18

 Depression is strongly associated with chronic disease; it has become one of the world’s most common conditions and results in severely decreased quality of life and increased direct and indirect costs.105

ed

»» Adults: “Two-thirds of adults in the United States today are obese or overweight.”98 “…the prevalence of diagnosed type 2 diabetes mellitus continued to increase concurrently with increases in obesity.”99

We also know with greater certainty that longer life without vitality and health imposes a considerable burden in addition to the costs of treatment:

lM na tio d. un rve r F se fo re te ts itu h st rig In All

»» Elderly: “Obese seventy-yearolds will live about as long as those of normal weight but will spend more than $39,000 more on health care. Moreover, they will enjoy fewer disability-free life years and experience higher rates of diabetes, hypertension, and heart disease.”97

0

The urgency of this situation is underscored in many compelling— and poignant—scientific papers that highlight some of the profound effects of the obesity epidemic on all age groups:

The current (and growing) dominance of chronic and degenerative diseases in the population is accompanied by many grave problems in addition to shortened life expectancy for today’s children: increasing disability over time, lowered quality of life, and far greater costs—both for direct treatment and as a result of important factors such as lowered productivity, reduced income due to early disability, and the cost of supporting disabled people in society for many years. As discussed above, the cost of simply treating—with all the tools and expertise at our command—the current epidemic of chronic disease threatens to either bankrupt us or to displace resources needed for other urgent priorities such as education, infrastructure, social security, defense, research, and countless other vital activities.

 Prolonged stress is exerted on families that provide care for disabled elders. “An estimated 16 million Americans—more people than live in all of New England—find themselves ‘sandwiched’ between two generations, struggling to raise their kids while caring for an aging loved one. That number is about to explode: In 25 years, there will be 60 million Americans between the ages of 66 and 84, many of them needing full- or part-time care.”107

the changing medical environment

»» Adolescents: “…extrapolation from current data suggests that adolescent overweight will increase rates of CHD among future young and middle-aged adults, resulting in substantial morbidity and mortality … more than 100,000 excess cases of CHD attributable to the increased obesity.”100

 Creativity and innovation are lost to underemployment or unemployment and the shrinking work force must support an increasingly disabled aging population for many more years.

»» Children: Type 2 diabetes, previously almost unheard of in children, “…has become common among the pediatric age population, accounting for ~40% of all diabetes diagnosed.”101

01

)2

(c

We can and should feel grateful that the threat of acute disease decreased so substantially over the last century and, concomitantly, that our life expectancy increased dramatically. We must also recognize, however, the urgent need to redirect some of our healthcare dollars, energy, expertise, and time toward stopping and ultimately reversing the spread of chronic disease. While it is certainly true that we all must die of something, and conquering acute disease made space for chronic diseases to rise to the top of the mortality charts, we cannot allow our much longer lives to be increasingly haunted by unprecedented rates of chronic disease and its accompanying disability, depression, and sharply rising costs. Instead of spending all our resources on managing symptoms and secondary prevention, we must turn our attention to causal factors. We know with steadily increasing confidence and knowledge that the primary driver of chronic disease is the interaction among genes, activities of daily living (lifestyle), and the environment. Describing a model that folds that very general awareness into actual clinical practice, enabling physicians to acquire effective skills and tools for addressing the unique pattern of each individual patient’s life and health, is the ultimate goal of this paper.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Environment / Lifestyle Energy imbalance Excess calories Sedentary lives

Little/no exercise

Inefficient metabolism Low energy

Psychosocial

Stress Sleep deficit Loneliness

ed

Nutrigenomics / Primary Prevention

A (highly simplified) model of the multiple, complex influences that create obesity and associated chronic diseases:

e

in ic

Diet/Nutrition

High-fat, high-sugar foods High fructose corn syrup Empty calories Low fiber

Environment

Pharmacogenomics

Hormonal changes Respiratory diseases

Obesity

 inflammation

Hypertension Diabetes

Arthritis Depression

Heart Disease

If we concentrate our resources at the bottom of the diagram, on pharmacogenomics, we have already lost the battle; chronic disease is already entrenched and the costs of treating it will only rise.

21st Century Medicine | 19

21st century medicine: A New Model for Medical Education and Practice

The Role of Obesity in Chronic Disease, continued

Improving the Response to Chronic Disease Chronic disease is now the principal cause of disability and use of health services and consumes 78% of health expenditures. (p. 1057 in the publication cited) [D]eveloping a different way to practice medicine for chronic disease is at the heart of any solution to the problem. (p. 2975, a reply to letters generated by the cited publication) —Halstead Holman, MD, JAMA, 2004108

01

)2

(c

It is important to note, however, that there is no precise, predictive formula. One person’s obesity is not identical in cause, signs and symptoms, or secondary outcomes to another’s, and thus both treatment and prevention must be individualized to accommodate the genetics, lifestyle, and environment of each patient. Any model for managing chronic disease that does not address all of these components will fall short in comprehensiveness and effectiveness. In a 2008 publication in Circulation,102 the American Heart Association described a comprehensive populationbased approach to preventing obesity, including the following key strategies (among others):

| 21st Century Medicine

e

20

The three arenas in which fundamental change is required in order to improve both prevention and treatment of chronic disease are medical education, clinical care (which is conditioned by medical education), and consumer/patient behavior. This paper focuses primarily on clinical care.

in ic

Often in medicine the marshaling of substantial and focused resources to fight a public health problem waits upon the research agenda. While there are many questions yet to be answered about how and why obesity develops and how and why it is such a risk factor for other serious diseases, it is a long and expensive process to test and verify strategies for prevention and treatment.103 We cannot afford

—Mark Chassin, MD, MPH; IOM National Roundtable on Health Care Quality, JAMA, 1998109

ed

»» Use of an ecological model that “includes multiple layers of influences on eating and physical activity across multiple societal sectors”

lM na tio d. un rve r F se fo re te ts itu h st rig In All

»» Differentiating environmental and policy approaches from clinicallybased interventions

0

»» Prevention at the population level, with emphasis on key risk subgroups

The burden of harm conveyed by the collective impact of all of our health care quality problems is staggering. It requires the urgent attention of all the stakeholders: the health care professions, health care policymakers, consumer advocates and purchasers of care. The challenge is to bring the full potential benefit of effective health care to all Americans while avoiding unneeded and harmful interventions and eliminating preventable complications of care. Meeting this challenge demands a readiness to think in radically new ways about how to deliver health care services and how to assess and improve their quality. Our present efforts resemble a team of engineers trying to break the sound barrier by tinkering with a Model T Ford. We need a new vehicle or perhaps, many new vehicles. The only unacceptable alternative is not to change.

Medical education The Institute of Medicine report, Crossing the Quality Chasm, in the chapter on “Preparing the Workforce” (p. 213) observes: “Despite changes that have been made, the fundamental approach to medical education has not changed since 1910.”110 The report also addresses some of the factors that make changing medical education very difficult. However, it does not directly address the imperative to integrate creative and innovative approaches to chronic disease into the process. Medical education must teach physicians to quickly and skillfully differentiate situations requiring an acute-care intervention from those presenting the very different challenge of complex, chronic disease. Once that

the changing medical environment

differentiation is achieved, then physicians must be given new tools, information, and skills with which to address the common comorbidities and complexities of chronic disease. Key concepts that underlie and will facilitate these fundamental changes are presented in Chapters 4 and 5 of this paper.

Clinical care

01

)2

(c

Changes in the roles of both patients and clinicians are critical to transforming our healthcare system. Chapter 4 addresses “The Clinician’s Dilemma”: how to practice in such a way that both the continuing advances of science and the essential art of medicine are integrated seamlessly into clinical practice, neither overshadowing the other. Clinicians must improve their capacity to incorporate important emerging evidence into a personalized, systems-oriented model of care, within the context of a strong healing partnership with patients. Chapter 5 presents the functional medicine model and methods that facilitate this evolution as well as an approach to establishing and strengthening the healing relationship. Two cases that exemplify the process are presented in the chapter, and two more cases, organized in a detailed and comprehensive functional medicine model, are presented at the end of the Appendix.

that delay; there are far too many lives at stake. Dr. Richard Horton, editor-in-chief of The Lancet, addressed this issue in an editorial titled, “The Precautionary Principle”:

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

We must act on facts, and on the most accurate interpretation of them, using the best scientific information. That does not mean we must sit back until we have 100% evidence about everything. Where the state of the health of the people is at stake, the risks can be so high and the cost of corrective action so great, that prevention is better than cure. We must analyze the possible benefits and cost of action and inaction. Where there are significant risks of damage to the public health, we should be prepared to take action to diminish those risks even when the scientific knowledge is not conclusive, if the balance of likely costs and benefits justifies it.104

Consumer (Patient) needs and preferences

ed

e

in ic

The growth and sustained energy of consumer interest in alternative and complementary medicine over the last quarter century is one indicator of the desire patients have for a different kind of healthcare system. Although not addressed directly in this paper, healthcare consumers must be assisted to take a lifelong interest in the forces that push each of us toward health or disease. As difficult as it is for physicians and other health practitioners to alter their mode of practice, that’s how difficult it is for patients to alter their mode of living to maximize the prospects of health and minimize the risks of disease. These changes represent a major undertaking and we will not be successful unless both consumers and providers of health care commit to a long-term, sustained effort.

We must act in concert with emerging research, being willing and able to adapt as new information becomes available. That is why we need a model of care that is comprehensive, yet flexible; science-based but not rigidly bound to an imperfect and incomplete evidence base; personalized and holistic. That model will be presented and discussed in Chapters 4 and 5.

21st Century Medicine | 21

01 )2 (c

0

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e in ic

| 21st Century Medicine

22

21st century medicine: A New Model for Medical Education and Practice

Chapter 3 ________________________________________ )2

(c

Emerging Models

01

Personalized Medicine

0

If it were not for the great variability among individuals, medicine might as well be a science, not an art.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

—Sir William Osler, 1892

What is it?

ed

Personalized medicine can be described as the effort to define and strengthen the art of individualizing health care by integrating the interpretation of patient data (medical history, family history, signs, and symptoms) with emerging “–omic” technologies—nutritional genomics,v pharmacogenomics,vi proteomics,vii and metabolomics.viii,111 Developing these strategies is critical to enabling physicians to match individual patients to the best diet, environment, nutraceuticals, and pharmaceuticals for their genetic make-up—a process that will eventually revolutionize medicine. Such a comprehensive individual fingerprint is still many

e

in ic

“Nutritional genomics or, as commonly used, nutrigenomics: The study of how different foods may interact with specific genes to increase the risk of common chronic diseases such as type 2 diabetes, obesity, heart disease, stroke and certain cancers. Nutrigenomics also seeks to provide a molecular understanding of how common chemicals in the diet affect health by altering the expression of genes and the structure of an individual’s genome. The premise underlying nutrigenomics is that the influence of diet on health depends on an individual’s genetic makeup. (From MedicineNet.com)

v

“…pharmacogenomics includes identifying candidate genes and polymorphisms, correlation of polymorphisms with therapies, prediction of drug response and clinical outcomes, reduction in adverse events, and selection and dosing of drugs based on genotype.” (Issa, 2007)

vi

“Proteomics: The study of the proteome, the complete set of proteins produced by a species, using the technologies of large-scale protein separation and identification. The term proteomics was coined in 1994 by Marc Wilkins who defined it as “the study of proteins, how they’re modified, when and where they’re expressed, how they’re involved in metabolic pathways and how they interact with one another.” (From MedicineNet.com)

vii

“Metabolomics/Metabonomics: The study of metabolic responses to drugs, environmental changes and diseases. Metabonomics is an extension of genomics (concerned with DNA) and proteomics (concerned with proteins). Following on the heels of genomics and proteomics, metabonomics may lead to more efficient drug discovery and individualized patient treatment with drugs, among other things. (From MedicineNet.com)

viii

21st Century Medicine | 23

21st century medicine: A New Model for Medical Education and Practice

Integrating Pharmacogenomic Testing in Clinical Practice

years away from being feasible, in research or clinical practice. It is not too early, however, to begin learning about it and applying key concepts and early data to patient care in incremental steps as the evidence base advances.

)2

(c

McKinnon et al.115 describe a general process for developing pharmacogenomics tests that can be used in clinical practice. Each of these steps represents a point at which poor outcomes may completely stall the development of an affordable and effective clinical test:

01

1. Identify circumstances in which knowledge of inter-individual variation in drug response is likely to improve clinical (or financial) outcomes

4. Propose model of how genotyping would guide clinical practice

e

7. Implement testing in a staged manner

in ic

6. Educate stakeholders on appropriate use

ed

5. Collect data on cost effectiveness of new pharmacogenomic profile vs. current practice

lM na tio d. un rve r F se fo re te ts itu h st rig In All

3. Determine reproducibility across ethnic populations

0

2. Find a significant genotypephenotype association

To date, the research underlying personalized medicine has concentrated mostly on pharmacogenomics. The knowledge that “a relatively large number of patients treated for cancer, infectious disease, psychiatric illnesses, respiratory diseases and cardiovascular conditions are not responding to the drugs they are given”112 has been one of the key drivers of the field. The process of developing new drugs specifically designed for personalized applications involves many phases: identification and screening of candidate genes; detection and description of various polymorphisms that affect drug response (e.g., slow or rapid metabolizers); the correlation of each polymorphism with possible therapeutic targets; and the evaluation of clinical outcomes with large enough study sizes to create confidence in the efficacy of the new strategy. All of these steps must occur before selection of a drug and specification of therapeutic dosage can be based on genotype.113 Once the drug development process is complete, the transformation of research-based data into a new tool for clinical practice must await a cost-effective screening test for patients (a process that involves many challenging and timeconsuming phases—see Sidebar), delineation of which patients should be screened and at what stage in their care, and longterm follow-up to check for possible adverse effects of therapy. The identification of drugs already in the pharmacopeia that have inter-individual variability in dosing, efficacy, and/or side effects that would make them amenable to a pharmacogenomics approach will also be a lengthy and expensive process, as there are thousands of drugs that could be tested for such personalized applications. Screening tests to detect various polymorphisms must also be developed and they must be cost effective if they are to be utilized routinely in clinical care. Pharmacodiagnostic tests that enable clinicians to quickly and cost effectively identify patients who are at risk for adverse drug responses “must possess high sensitivity and specificity with regards to their predictive performance.”114 A couple of examples will indicate the incalculable potential— and the complexity and costliness—of pharmacogenomics as a clinical strategy:

24

| 21st Century Medicine

EMERGING MODELS

01

)2

(c

 New drug development: Herceptin® (trastuzumab) is a monoclonal antibody developed to treat breast cancer that over-expresses HER2 (human epidermal growth factor receptor 2). This characteristic “is associated with an aggressive phenotype, high recurrence rate and reduced survival”116 and it affects approximately 25-30% of breast cancer patients.117 Before a drug could even be conceptualized, the HER2 protein had to be detected and reliably identified, and many breast cancers had to be analyzed to discover the proportion with overexpressed HER2. Then, the search for a drug targeted to this trait could begin. Ultimately, trastuzumab was developed, tested, and validated in research trials as an effective treatment for breast cancers that over-express HER2; its ability to work with other chemotherapeutic agents was also assessed. Two cost-effective screening tests were developed and are now available—immunohistochemistry (IHC—appropriate as a general screening tool for all breast cancer) and fluorescence in situ hybridization (FISH—used as further screening for patients with 2+ and 3+ IHC scores).118 And “…five recent adjuvant breast cancer trials have demonstrated an astonishing and highly reproducible benefit in halving the recurrence rate and reducing mortality in patients with this phenotype.”119

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

ed

 Existing drug specifications: Warfarin, an effective anticoagulant in use for many decades, has “a narrow therapeutic range because of both genetic and environmental factors,”120 and has been under-prescribed because of “historically high rates of drugassociated adverse events.”121 Understanding these factors sufficiently well to alter dosing appropriately would enable this cost-effective drug to be used more widely. Studies assessing the role of patient demographics and known variants in CYP2C9 alleles and VKORC1 genotypes have been performed, and therapeutic response to warfarin is now known to vary among Jewish (both Ashkenazi and Sephardic origins), African American, and Asian patients.122, 123, 124 In 2005, “the U.S. FDA Clinical Pharmacology Sub-Committee (CPSC) of the Advisory Committee for Pharmaceutical Science voted to re-label the dosing of warfarin to take into consideration the new information.”125 It is not known how many patients already on warfarin have undergone testing to re-evaluate their dosage since the prescribing recommendations were changed. However, at least one study has determined that “prospective application of a multivariate CYP2C9 gene-based warfarin dosing model is feasible,”126 and another reported that “a quantitative dosing algorithm incorporating genotypes for 2C9 and VKORC1 could substantially improve initial warfarin dose-selection and reduce related complications.”127

e

in ic

The incorporation of nutrigenomics (the effect of diet on gene expression), nutrigenetics (effect of genetics on response to diet, foods, or nutrients), proteomics, and metabolomics into the personalized medicine model has moved much more slowly,128, 129 perhaps simply as a reflection of the marked dominance of drug treatments that characterizes our healthcare system and shapes the funding priorities (see Sidebar in Chapter 2). However, much that is learned in pharmacogenomics will drive the knowledge base in these related fields as well because the underlying principle is common to all: individual genetic variations affect our physiological and biochemical response to virtually everything we are exposed to. This represents a fundamental alteration in our understanding of health and disease. The knowledge of how to identify and manage these individual differences is acutely needed for lifelong prevention of chronic disease. It won’t be enough to say “Eat more vegetables and less fat and sugar.” We will need to be able to individualize

21st Century Medicine | 25

21st century medicine: A New Model for Medical Education and Practice

healthy diets, add targeted nutraceuticals, prescribe specific exercise programs, advise stress reduction efforts, plan to avoid certain pollutants, all based on individual genetic variations. Ultimately, personalized medicine will not be fully realized until all the influences, effects, and interactions are researched and described in such a way that practitioners are able to bring them to bear on an individual patient’s health and on lifelong prevention of chronic disease.

Strengths and weaknesses

01

)2

(c

The ultimate promise of personalized medicine is its potential to uncover “the causes of the causes” of disease.130 From the unlocking of the human genome to the development of proteomics (wherein we begin to understand how the proteins made by genes behave131), scientists can now demonstrate how individualized both health and disease really are. It’s a powerful and exciting model that is already beginning to affect both research and clinical practice. Its strength is the rapidly developing science (all the –omics) that opens new vistas and new possibilities for dramatically increasing the effectiveness of individualized prevention and treatment strategies.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

On the other hand, the many challenges of transferring this model to clinical practice are daunting; they include:  The “clinical complexity of genomic-based diagnostics and treatment.”132 A recent NIH report phrases the complexity question clearly: “An enormous scientific challenge now presents itself: What are the best ways to understand, prevent, and treat common, chronic diseases like heart disease, cancer, addiction, and mental illness when it is apparent that they are the result of interactions between individuals—in all their biological complexity—and their ever-changing physical, behavioral, and societal environments?”133  Excessive cost134

e

 The need for new information technology138

in ic

 Ethical concerns137

ed

 Regulatory issues135, 136

At the level of patient care, additional complex challenges arise that may take decades to resolve:  Devising accurate and cost-effective genomic and/or proteomic screening tools  Identifying biomarkers that will indicate whether/when an active adverse process is in play for specific conditions in a given patient  Testing and validating diagnostic tools across many populations  Selecting appropriate patients for screening and demonstrating the usefulness of screening in improving patient outcomes through long-term clinical trials  Convincing third-party payers to reimburse for screening tests (likely to happen only when the results from long-term trials demonstrate cost-effectiveness)  Interpreting individual patient screening reports appropriately  Devising and validating effective interventions based on individual screening results

26

| 21st Century Medicine

EMERGING MODELS

Common ground with other emerging models As shown in Figure 2 (Chapter 1), personalized medicine shares many features with other emerging models: the emphasis on discovering individual patients’ genetic vulnerabilities, the vision of individualized diagnostics and treatment, and the reliance on a powerful (and still emerging) scientific evidence base. It also shares with other models the absence of a clear and practical method of integrating emerging information into medical education and practice. Nor does it address structural and multidisciplinary issues in clinical practice that are part of the chronic-care model and integrative medicine.

(c

Role in a synthesized, comprehensive model of 21st century medicine

01

)2

Despite the rapidly evolving research base, therefore, personalized medicine does not (yet) have a robust, consistent architecture for clinical applications, nor does it describe a clear pathway toward achieving that goal. Research designs are still in development, and research findings do not specify how personalized medicine may (or may not) contribute to a new model of care for chronic disease. Even when a gene mutation, or SNP, can be identified, we may still be “six degrees of separation removed from the functional aspects of the disease,”139 because gene analysis does not tell us which protein and protein pathways are affected and what the aberrant protein is doing. “Proteins are actually the drug targets; analysis of genes and gene expression just gives an indication of whether or not the proteins may be present.”140 The same can be said of the effects of diet, environmental toxins, psychosocial influences, and many other lifestyle and environmental factors on gene expression and protein function. For these reasons, it is difficult to plan for the integration of this model into medical education in a systematic way in the near future.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

ed

It will be necessary, therefore, to ensure that whatever transformative model is used, it will allow clinicians to integrate new and useful information from personalized medicine as and when it becomes available, and will also empower them to respond effectively now to the urgent need for improved prevention and management of complex, chronic disease. Perhaps the single most valuable portion of the personalized medicine model at the moment is the transparency it brings to the concept of patient individuality. The evidence clearly reveals that each patient is a unique individual—one whose gene expression patterns are constantly in flux and whose complex and ever-changing response to treatment, environment, and lifestyle will challenge physicians to listen differently, see differently, and respond differently than taught by the linear model of acute care.

e

in ic

21st Century Medicine | 27

21st century medicine: A New Model for Medical Education and Practice

Prospective Medicine “The ability to identify those individuals most at risk for developing chronic diseases and to provide a customized means to prevent or slow that progression are emerging competencies and provide the foundation for prospective care.” —Ralph Snyderman, MD and R. Sanders Williams, MD 141

What is it?

01

)2

(c

A relatively new concept introduced in 2003, prospective medicine is a descriptive rather than a prescriptive term, encompassing “personalized, predictive, preventive, and participatory medicine.”142 Snyderman argues persuasively that a comprehensive system of care would address not only new technologies (e.g., identification of biomarkers, use of electronic and personalized health records), but also delivery systems, reimbursement mechanisms, and the needs of a variety of stakeholders (government, consumers, employers, insurers, and academic medicine). Prospective medicine does not claim to stake out new scientific or clinical territory; instead, it focuses on creating an innovative synthesis of technologies and models—particularly personalized medicine (the “-omics”) and systems biology—in order to “determine the risk for individuals to develop specific diseases, detect the disease’s earliest onset, and prevent or intervene early enough to provide maximum benefit. Each individual would have a personalized health plan to accomplish this.”143

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Strengths and weaknesses

ed

A very compelling element of prospective medicine is the call for fundamental change in clinical practice— from treating people only when they are sick enough to visit the doctor’s office to prospectively examining individual risks and developing comprehensive preventive strategies based on the best available evidence at the time. This would, indeed, revolutionize medicine; not only would it shift the focus of primary care, but it would establish a serious partnership between patient and clinician aimed at lifelong health. Snyderman emphasizes the need for clinical medicine and the emerging genomic models to integrate their respective knowledge and skills to create the best outcomes for patients. He discusses some diagnostic and risk-assessment tools that are already available, such as the following examples:

in ic

e

 Know Your Number®, a program that “uses … synthesis modeling to quantify an individual’s risk of developing chronic, preventable, obesity-related diseases such as diabetes, chronic obstructive pulmonary disease, and heart disease. In addition, KYN calculates what modifiable factors are contributing to that risk so that individuals can take steps to improve their overall risk profile.”144 Although Know Your Number is not available directly to consumers, other similar programs are. One example is Navigenics Health Compass,145 offering “A scan of your whole genome, carried out by a government-certified laboratory, that captures data on 1.8 million of your genetic risk markers.” For $2500, individuals can obtain an analysis of their “genetic predisposition for a variety of common health conditions, and the information, support and guidance to know what steps you can take to prevent, detect or diagnose them early.” For $250 per year, they will have a subscription that entitles them to regular updates.  Biomarkers can be assessed through an analysis of 250 serum proteins ($3400). According to the company’s Web site: “Biophysical250 … measures 250 different biomarkers that may indicate the presence of diseases and conditions often before symptoms appear. Unlike standard physicals

28

| 21st Century Medicine

EMERGING MODELS

that measure only up to 40 biomarkers, Biophysical250 simultaneously assesses hundreds of biomarkers used by 12 different medical specialties.”146  Two gene-expression assays that predict recurrence of breast cancer in patients with stage I or II node-negative breast cancer. These tests can be used to individualize follow-up treatment by helping to determine “the need for systemic adjuvant therapy in such patients.”147 Also compelling is the call to involve a broad range of stakeholders to “work together to develop innovative applications of new technologies and appropriate delivery models.”148 It is certainly true that reimbursement strategies and academic training practices will have to evolve to encompass such a broadbased new model of care, and retraining existing practitioners must become a high priority.

01

)2

(c

What’s missing? Like the other emerging models we are discussing, prospective medicine does not provide a clear road map for integrating these new technologies into clinical practice. Precisely how, one wonders, will the 500,000+ MDs and DOs already in practice be retrained? How will academic medicine evolve? How many patients can spend $2500-$3500 on laboratory tests to assess risk biomarkers? How much new and expensive testing is actually necessary compared to how much risk is already clear when a comprehensive history is taken and a thorough examination including (mostly) standard laboratory tests is performed? And what, exactly, will change in clinical practice once expanded information is in hand from these new technologies? Will doctors still be in the same position they are in today—suggesting better diet, losing weight, and reducing stress without knowing how to help their patients make all of that happen?

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

The big missing piece in prospective medicine (at least as described thus far in the literature) lies in the absence of a clear, practical, and systematic method for altering clinical practice. Recognizing that the interactions between doctor and patient and between patients and their lifestyle-environment exposures and choices are where real change happens, Johns and Brigham,149 offer this commentary on a postprospective medicine world:

ed

This “next next transformation” will identify “healthy” biologic processes (i.e., homeostatic) and provide tools for measuring early deviations from health (“unhealth”) that are not necessarily disease specific but that predict dire outcomes and warrant health-focused interventions. For example, many chronic diseases (diabetes, atherosclerosis, autoimmune diseases) share inflammation as a common mechanism. Characterizing an individual inflammatory phenotype may be a potent health predictor. And inflammatory responses to stress can be modified by behavior. Such health-focused treatment is the logical step beyond the “next transformation” that Snyderman and Yoediono advocate.

e

in ic

Common ground with other emerging models Prospective medicine urges the integration of the developing sciences of personalized medicine and systems biology with the skills and knowledge of clinicians, and describes recommendations for revisions in reimbursement mechanisms and medical education that will be required in order to implement a comprehensive new system of care. It clearly relies on the emerging evidence base, but not to the exclusion of other important information. It does not specifically address the chronic-care model, nor issues of integrated care or integrative medicine; neither diagnostic approaches nor treatment strategies appear to include a multidisciplinary model of care.

21st Century Medicine | 29

21st century medicine: A New Model for Medical Education and Practice

Crossing the Quality Chasm

Role in a synthesized, comprehensive model of 21st century medicine

The Institute of Medicine’s report, Crossing the Quality Chasm,151 comments extensively on the unmet needs of those with chronic conditions:

Because prospective medicine relies on personalized medicine and systems biology for the science of risk-assessment, many of its strengths and its limitations are found in those two models. It is, however, more comprehensive in sweep than either of them, incorporating not only technologies such as electronic health records but also acknowledging the need for simultaneous reform of the reimbursement structure and the training of future physicians. Thus, it is an important step forward, but it still lacks a robust, consistent architecture for clinical applications.

01

)2

(c

»» Page 4: “… there remains a dearth of clinical programs with the infrastructure required to provide the full complement of services needed by people with heart disease, diabetes, asthma, and other common chronic conditions (Wagner et al., 1996). The fact that more than 40% of people with chronic conditions have more than one such condition argues strongly for more sophisticated mechanisms to communicate and coordinate care (The Robert Wood Johnson Foundation, 1996).”

| 21st Century Medicine

e

30

in ic

»» Page 89: “Common chronic conditions should serve as a starting point for the restructuring of health care delivery because, as noted in Chapter 1, chronic conditions are

The chronic-care model (CCM) is briefly outlined in Chapter 1 and fairly thoroughly described in the Appendix, where extensive material from the Improving Chronic Care Web site is included. The primary focus of this model is to include “…the essential elements of a healthcare system that encourage high-quality chronic disease care…. the community, the health system, selfmanagement support, delivery system design, decision support and clinical information systems. Evidence-based change concepts under each element, in combination, foster productive interactions between informed patients who take an active part in their care and providers with resources and expertise.”150 The CCM is a response to powerful evidence that patients with chronic conditions often do not obtain the care they need, and that the healthcare system is not currently structured to facilitate such care (see Sidebar).

ed

»» Page 29: “Thus the American health care system does not have well-organized programs to provide the full complement of services needed by people with such chronic conditions as heart disease, cancer, diabetes, and asthma.”

What is it?

lM na tio d. un rve r F se fo re te ts itu h st rig In All

»» Page 28: “In a population increasingly afflicted by chronic conditions, the health care delivery system is poorly organized to provide care to those with such conditions.”

0

»» Page 9: “Care for the chronically ill needs to be a collaborative, multidisciplinary process.”

Chronic-Care Model

Strengths and weaknesses The chronic-care model has the advantage of having been around for more than a decade; it has undergone considerable testing and revision. Implementation trials have indicated that, when enough of the model can be implemented, compliance with current algorithms and guidelines can be improved for conditions such as diabetes,152, 153 depression,154 and tobacco cessation.155 The CCM is a structure-of-care (or processof-care) more than a content-of-care model; it describes a

EMERGING MODELS

01

)2

(c

multidisciplinary, multi-stakeholder approach to delivering care that will improve both patient and practitioner compliance with current evidence-based best practices. For this reason, integrating new technologies, such as those emerging from personalized medicine, are not explicitly addressed; one might assume that as those tools make their way into clinical guidelines and algorithms, they will become part of the CCM as well. However important improving the structure of care may be—and we certainly agree that it is important—the care thus provided will still be limited to the current medical model, which does not address individualizing care, lifelong primary prevention, or reversal of chronic disease, and which is primarily pharmaceutical in nature. We could imagine implementing, for example, personalized medicine using the chronic-care model, but no mechanism for achieving that is described. In fact, just implementing the full CCM itself is a very difficult proposition that encounters many barriers (e.g., no consensus on the value of the changes, limited change management skills within organizations, too many competing priorities, and failure to engage the commitment of physicians).156 The Academic Chronic Care Collaborative, representing 22 academic medical centers, has reported some initial promising outcomes from their experiences with implementing aspects of the CCM.157 It is worth noting that these institutions were committed to providing effective leadership and resources for the change process. The Agency for Healthcare Research and Quality provides an extensive Toolkit for Implementing the Chronic Care Model in an Academic Environment.158

now the leading cause of illness, disability, and death in the United States, affecting almost half of the population and accounting for the majority of health care resources used (Hoffman et al., 1996).”

0

»» Page 94: “Four chronic conditions (cardiovascular disease, cancer, chronic obstructive pulmonary disease, and diabetes) account for almost three-quarters of all deaths in the United States (Centers for Disease Control and Prevention, 1999).”

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

in ic

The CCM shares with integrative medicine an emphasis on a multidisciplinary care model, the use of evidence-based best practices, and engagement of the patient in self-care. It does not address biochemical and physiological individuality, any of the emerging genomic technologies, or the influence of underlying mechanisms of disease. It shares with prospective health care a focus on structural, system-wide change, although the two models emphasize different aspects of structural change.

ed

Common ground with other emerging models

»» Page 211: “The ability to plan care and practice effectively using multidisciplinary teams takes on increasing importance as the proportion of the population with chronic conditions grows, requiring the provision of a mix of services over time and across settings…. A changing relationship between clinicians and their patients also calls for new skills in communication and support for patient self-management, especially for patients with chronic conditions. Collaborative management requires collaboration between clinicians and patients in defining problems, setting goals, and planning care; training and support in self-management; and continuous follow-up (Von Korff et al., 1997). Patients with chronic conditions who are provided with knowledge and skills for self-management have been shown to experience improvements in health status and reduced hospitalizations (Lorig et al., 1999). Clinicians need to have skills to train

21st Century Medicine | 31

21st century medicine: A New Model for Medical Education and Practice

Role in a synthesized, comprehensive model of 21st century medicine

Crossing the Quality Chasm, continued patients in techniques of good selfmanagement.”

The CCM advances our knowledge of how to improve the structure or process of care for chronic disease using standard approaches, but it does not advance our ability to select more effective strategies for actually improving both treatment and prevention. Still lacking is a robust, consistent architecture for selecting the most effective clinical applications for each unique patient.

»» Page 237: “Patients with chronic conditions, for which certain routine examinations and tests are crucial in order to prevent complications, do not all get the care they need.”

(c

Note: Citations included in the above quotations are available in the Institute of Medicine report, but are not provided here.

01

)2

Evidence-based Medicine (EBM) What is it?

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

EBM is a tool for improving clinical practice. Its stated goal is to ensure that clinical decision making is grounded in the best available evidence. Despite its many limitations, it wields a great deal of power over medical training, clinical practice, and—increasingly—reimbursement decisions and legal determinations.159, 160 We include it in our discussion of emerging models because of its multifaceted influences on patient care. Although it is beyond the scope of this paper to explore EBM in depth, it is critical to the future of health care to understand its strengths and weaknesses. To that end, we provide a brief description of this evolving paradigm.

ed

Since the late 1970s, various efforts have been made to systematize the use of research findings in clinical decision making.161 Rather than expecting each practitioner to establish and maintain a constant surveillance over a rapidly expanding evidence base, and to know which studies should generate the highest level of confidence, specific guidelines have been proposed concerning the interpretation of evidence that influences clinical decision making. There have been many definitions and ratings of what constitutes poor, good, and best evidence, but in the early 1990s, the term evidence-based medicine appeared for the first time,162, 163 reflecting an increasing consensus that a more standardized approach to the use of medical evidence was on the way. Early efforts sought explicitly to reduce “…the emphasis on unsystematic clinical experience and pathophysiological rationale” while promoting “the examination of evidence from clinical research.”164

e

in ic

32

| 21st Century Medicine

EMERGING MODELS

A hierarchy of evidence reliability was proposed, with meta-analyses and systematic reviews at the top and personal communications at the bottom (see Figure 6). Over the years, this hierarchy has been revised and adapted many times for a number of reasons:  It did not identify a mechanism for decreasing or increasing an assessment of value based upon, for example, study size, adequacy of blinding, bias, directness of the evidence, and other factors.165

(c

 It failed to accommodate many important criteria for translating evidence into clinical practice—for example, the degree to which outcomes being tested were important to patients, whether results were consistent with past studies, and whether confidence intervals were overly broad.166

01

)2

 It inappropriately identified systematic reviews and meta-analyses as evidence (they are, rather, interpretations of the evidence and should be produced, at least in part, based on EBM principles).167, 168

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

 It did not differentiate between quality of evidence and strength of recommendations. “High quality evidence doesn’t necessarily imply strong recommendations, and strong recommendations can arise from low quality evidence.”169 One example of a subsequent adaptation is provided in Figure 7, where we can see that other useful criteria were added to the model, altering the earlier and more simplistic assessment of evidence usefulness.170

ed

The basic concepts have continued to evolve. “In 2000, the Evidence-Based Medicine Working Group presented the second fundamental principle of EBM (the hierarchy of evidence being the first): Whatever the evidence, value and preference judgments are implicit in every clinical decision. A key implication of this second principle is that clinical decisions, recommendations, and practice guidelines must not only attend to the best available evidence, but also to the values and preferences of the informed patient.”171

e

in ic

A major advance over the use of any hierarchy, however complex, has been the development of the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Figure 8 shows a partial representation of this system; in practice, it has other important elements as well. The GRADE system describes a very sophisticated, multi-level evaluation of evidence; its purpose is to strengthen recommendations for clinical practice and to increase confidence in those recommendations. Because of its complexity, however, it is not intended for use by individual clinicians, who generally have neither the time nor the expertise to implement it. It is aimed primarily at researchers and clinical guideline developers, who have not heretofore used a consistent and uniform methodology that is transparent to all potential users.172 GRADE software is now available for free at the GRADE Working Group’s Web site,173 making it even more likely that its use will continue to expand.

21st Century Medicine | 33

21st century medicine: A New Model for Medical Education and Practice

1. A Systematic reviews; meta-analyses B RCTs C Experimental designs 2. A Cohort control studies B Case control studies

(c

3.

A B C D E

Personal communication

01

)2

4.

Consensus conference Expert opinion Observational study Other types of study (e.g., interview-based) Quasi-experimental, qualitative design

0

Figure 6: Hierarchy of Evidence (Sackett)

lM na tio d. un rve r F se fo re te ts itu h st rig In All



Effectiveness

Excellent Good

Appropriateness

Systematic reviews Multi-center studies RCTs Observational studies

Descriptive studies Case studies Expert opinion Studies with poor methodology

Expert opinion Case studies Studies with poor methodology

Figure 7: Hierarchy of Evidence (Evans)

34

| 21st Century Medicine

e

Poor

in ic

Uncontrolled trials; dramatic results Before and after studies Non-randomized CTs

Systematic reviews Multi-center studies RCTs Observational studies Interpretive studies Descriptive studies Action research Before and after studies Focus groups Expert opinion Case studies Studies with poor methodology

ed

Fair

Systematic reviews Multi-center studies RCTs Observational studies Interpretive studies Descriptive studies Focus groups

Feasibility

EMERGING MODELS

High Low Very Low (+1) (+2) (+1) (+1)

01

)2

(c

A. Criteria for Assigning Level of Evidence Type of Evidence Randomized trial Obsvervational study Any other type of research evidence Increase level if: Strong association Very strong association Evidence of a dose-response gradient Plausible confounders reduce observed effect Decrease level if: Serious or very serious limitations in quality Important inconsistency Some or major uncertainty about directness Imprecise or sparse data* High probability or reporting bias

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

(-1) or (-2) (-1) (-1) or (-2) (-1) (-1)

B. Definitions for levels of evidence

High Further research is not likely to change our confidence in the effect estimate Moderate Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate Low Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate

Very Low Any estimate of effect is uncertain

ed

e

in ic

*Few outcome events or observations or wide confident limits around an effect estimate

Figure 8: Overview of the GRADE System for Evaluating Evidence (Bagshaw)

Over the years, a number of studies have verified that teaching EBM will, in fact, significantly increase the degree to which practitioners apply it.174 Training is more successful if it is both experiential and didactic.175, 176, 177 Unfortunately, there are very few studies available as yet that tell us whether EBM improves overall patient health over a period of years.

Strengths and weaknesses There can be little doubt that a thoughtful evaluation of evidence is an indispensable factor in delivering high-quality health care. The emergence of formal assessment processes reflects a desire to establish greater clarity and confidence about the reliability of evidence. Even a casual user of Medline or PubMed

21st Century Medicine | 35

21st century medicine: A New Model for Medical Education and Practice

quickly becomes aware of the overwhelming quantity of published research available today; it is a daunting prospect to identify the best or most relevant papers among hundreds or thousands that may be available on a particular topic. For example, a PubMed search for the phrase evidence-based medicine in titles and abstracts returns nearly 5000 entries encompassing dozens of journals! There are, of course, tools for narrowing a search term or process, but it is still inordinately time consuming to obtain, read, evaluate, and then compare even a few individual research papers on a specific subject. Such a process, even if an EBM hierarchy is used, is also subject to a great deal of individual bias. Thus, any tool that provides significant and reliable assistance in such an endeavor is welcome, and that is one of the primary rationales for the development of clinical guidelines.ix

01

)2

(c

As the use of EBM has become increasingly widespread, its limitations and weaknesses have also become more apparent. Paramount among the problems is that EBM reflects an acute-care model: it most often assumes that the goal of care is a single diagnosis followed by a hierarchy of (primarily) singleagent treatments. Although GRADE has made an admirable attempt to compensate for many EBM weaknesses, these fundamental goals remain the gold standard. Therefore, EBM fails at the same point where the research itself fails—in its inability to account for unique patient geno/phenotypes, multiple comorbidities, and personalized approaches to care that include multiple interventions for complex, chronic disease. Such multifaceted interventions may include dietary, nutraceutical, pharmaceutical and/ or surgical recommendations, as well as many options from the natural medicine world (e.g., botanical medicine, acupuncture and oriental medicine, body/mind practices).

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

EBM and any guidelines derived from applying an EBM model to the evidence are, of course, only as good as the underlying research, which presents several problems:  Not only is the research agenda disproportionately driven by the pharmaceutical industry, but it is tainted by the failure to publish negative or neutral results and by industry bias (see Chapter 2).

ed

 Much of generally accepted medical practice has not been systematically evaluated. For example: “Of around 2500 treatments covered [in BMJ Clinical Evidence] 13% are rated as beneficial, 23% likely to be beneficial, 8% as trade off between benefits and harms, 6% unlikely to be beneficial, 4% likely to be ineffective or harmful, and 46%, the largest proportion, as unknown effectiveness [italics added].”178

e

in ic

 Individuals studied in RCTs do not reflect the patient population seen most often in primary care; confidence in the transferability of the data is thereby reduced.179  “Randomized trials, especially if evaluating complex interventions or with strict inclusion/ exclusion criteria, often only provide data in a clinical context that does not exist outside the trial itself and have limited power to detect harm…. Systematic reviews require vigilant interpretation and should not necessarily be considered as high level evidence due to issues related to … incomplete reporting and the inclusion of evidence from trials of poor quality…. Meta-analyses are not primary evidence; they are statistically assisted interpretations of

ix

Clinical guidelines are “systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances”—Institute of Medicine, 1990. “They define the role of specific diagnostic and treatment modalities in the diagnosis and management of patients. The statements contain recommendations that are based on evidence from a rigorous systematic review and synthesis of the published medical literature”— http://www.nhlbi.nih.gov/ guidelines/about.htm.

36

| 21st Century Medicine

EMERGING MODELS

primary evidence. They have been shown to contradict confirmatory trials, especially when such meta-analyses are based upon small, low quality studies.”180  “Even the most promising findings of basic research take a long time to translate into clinical experimentation, and adoption in clinical practice is rare.”181 Evidence-based guidelines of genomic applications are even more rare, and thus are unavailable to practitioners who rely on EBM processes to update their clinical practices.182

Common ground with other emerging models

01

)2

(c

EBM is, to differing degrees, part of all the other models described in this paper. Since EBM focuses primarily on mechanisms for translating research findings into clinical applications, it is less useful for those aspects of personalized medicine and systems biology that concentrate on the basic research itself. Also, as noted above, integrating personalized assessment and treatment with EBM models is not yet feasible on a systematic basis. It will be extremely interesting to see whether this can be done.

0 lM na tio d. un rve r F se fo re te ts itu h st rig In All

Role in a synthesized, comprehensive model of 21st century medicine In our opinion, the role of EBM is strongest in acute-care situations, where the physician or healthcare team must focus on short-term and fairly narrowly defined issues. When we consider its role in outpatient primary care for complex, chronic disease, however, it is more difficult to make an overall determination of usefulness. Certainly there are situations where EBM and the clinical guidelines that flow out of it are extremely useful. In general, however, it seems easier to see the problems (described above) than it is to detect the benefits. Nonetheless, there is great benefit to researchers, practitioners, and patients in improving our ability to objectively and systematically evaluate data and determine clinical usefulness. Overall, this is perhaps the most important role that EBM will play over time.

in ic

What is it?

ed

Systems Biology

e

Although there is not yet a universally recognized definition of systems biology, the National Institute of General Medical Services (NIGMS) at NIH provides the following explanation: “A field that seeks to study the relationships and interactions between various parts of a biological system (metabolic pathways, organelles, cells, and organisms) and to integrate this information to understand how biological systems function.”183 The Molecular Systems Biology Blog on Systems & Synthetic Biology poses—and provides some possible answers to—the question of why it appears to be difficult to come up with a concise and generally applicable definition: “One of the reasons might be that every definition has to respect a delicate balance between ‘the yin and the yang’ of the discipline: the integration of experimental and computational approaches; the balance between genome-wide systematical approaches and smaller-scale quantitative studies; top-down versus bottom-up strategies to solve systems architecture and functional properties.” The blog hypothesizes that, “despite the diversity in opinions and views, there might be two main aspects that are conserved across these definitions: a) a system-level approach attempts to consider all the components

21st Century Medicine | 37

21st century medicine: A New Model for Medical Education and Practice

of a system; b) the properties and interactions of the components are linked with functions performed by the intact system via a computational model.”184

01

)2

(c

We would add to the NIGMS definition that it is also vital to understand how the human system interacts with the environment, as well as how all the components act and interact. We see systems biology as a broad term for the basic science underlying the personalized medicine revolution (described above). While the fields of personalized, prospective, and integrative medicine all recognize (to varying degrees) the importance of nutritional genomics, pharmacogenomics, metabolomics, and proteomics to the future of health care, most of the scientific research has been generated by systems biologists (whether or not they identify with that term or any of the many definitions proposed). Thus far, although systems biology claims virtually the same broad territory as personalized medicine, it actually focuses almost exclusively on pharmacogenomics—in the Willie Sutton idiom, “That’s where the money is.” Attention to the applicability of those findings to patient care (i.e., the gene-environment interaction that creates the phenotype) is what connects systems biology to personalized medicine.

0 lM na tio d. un rve r F se fo re te ts itu h st rig In All

Strengths and weaknesses

Identifying the nature and effects of the myriad interactions that occur where human biology is exposed to the environment is almost unimaginably complex. Yet that effort is critical to a better understanding of the multifactorial nature of disease development. We know that “the causes of most chronic diseases will require an understanding of both the genetic and environmental contribution to their etiology…. The most critical issue is how to relate exposure-disease association studies to pathways and mechanisms…. Scientists will need tools with the capacity to monitor the global expression of thousands of genes, proteins and metabolites simultaneously…. Even when all the highly relevant genes and their interactions with specific environmental components have been identified, it will still be difficult to relate the influence of an individual’s genotype to their disease phenotype due to the added complexity of gene-gene interactions, post-translational processing, and protein-protein interactions.”185

ed

e

in ic

Because of the magnitude and complexity of the challenge, “Systems biology research should create an interactive inter-disciplinary scientific culture. For progress to occur, experts in engineering, physics, mathematics, and computer science must join biochemists, cell biologists, and physiologists in the effort to figure out how to obtain the required data and develop the sophisticated computational approaches that will be needed to make viable predictions.”186 This is a long-term prospect, of course, although early studies have shown some highly beneficial outcomes of genomic medicine187 (a plausible term for applying the findings of systems biology to patient care). Many of the same obstacles discussed earlier in this chapter vis-à-vis personalized medicine and pharmacogenomics188 are inherently shared by systems biology. In addition to barriers of cost, complexity, equipment, ethics, and education, “the evidence and importance of most pharmacogenomics associations are not sufficient to overcome the barriers to clinical implementation…. It is likely that complementary technologies, such as metabonomics, will be able to compensate for some limitations of genotypephenotype association.”189

38

| 21st Century Medicine

EMERGING MODELS

Common ground with other emerging models Systems biology seeks to elucidate the biological underpinnings of disease risk and apply that knowledge within a personalized, predictive, prospective, and participatory model of patient care. The science of systems biology clearly underlines the congruent goals of personalized medicine, prospective medicine, and—to a lesser extent—integrative medicine. It is not entirely congruent with evidence-based medicine, because it has not yet generated a large number of clinical trials. In fact, systems biology somewhat reverses the direction of EBM described above, in that it takes us back to a more “pathophysiological rationale” of disease and treatment. Eventually, research models will be devised to test the effectiveness and reliability of patient care based on diagnostic tests and therapeutic recommendations derived from systems biology.

(c

01

)2

Role in a synthesized, comprehensive model of 21st century medicine

0

Systems biology illuminates the science that will support a new model of health care—one that is based on an intimate understanding of complex human systems interacting with complex environments and unique genetic inheritances.190 In order to achieve its greatest potential, it must broaden its scope far beyond pharmacogenomics, which represents a very small portion of what we need to know about preventing and treating complex, chronic disease.

What is it?

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Integrative Medicine

ed

“Integrative medicine can be defined as an approach to the practice of medicine that makes use of the best available evidence taking into account the whole person (body, mind, and spirit), including all aspects of lifestyle. It emphasizes the therapeutic relationship and makes use of both conventional and complementary/alternative approaches.”191 The field is now nearly 10 years old and it is the only one of the emerging models discussed in this paper to explicitly encompass the integration of therapeutics that, until recently, were the sole purview of complementary and alternative medicinex (CAM). A number of forces are responsible for the emergence of this new discipline:

e

in ic

 The initial driver was undoubtedly the burgeoning interest in and demand for CAM displayed by consumers over many years. As reported in the Annals of Internal Medicine in 2001, “Use of CAM therapies by a large proportion of the study sample is the result of a secular trend that began at least a half century ago. This trend suggests a continuing demand for CAM therapies that will affect health care delivery for the foreseeable future.”192  The establishment of the NIH National Center for Complementary and Alternative Medicine (NCCAM) provided research funding to investigate CAM therapies. As research into CAM therapies revealed many effective natural (nonpharmaceutical, nonsurgical) approaches to

A widely used definition of CAM therapies from the Osher Institute at Harvard: “clinical services not routinely used within conventional care, such as chiropractic, acupuncture, massage therapy, homeopathy, meditation, music therapy, therapeutic touch, yoga, Reiki, and advice involving herbal products and other dietary supplements.”

x

21st Century Medicine | 39

21st century medicine: A New Model for Medical Education and Practice

a wide variety of diseases and conditions, it was thought desirable for physicians to understand CAM in much greater depth193 and to devise a pathway for validated approaches to be brought into the standard “medicine chest.”194

Meditation and Brain Science

01

)2

(c

 Integrative medicine might also be characterized as a response to the increasing depersonalization of health care that came with the rise of HMOs, greater use of technology, decreasing time spent in the outpatient visit, and the insertion of third-party payers into the doctor-patient relationship.196

Integrative medicine curriculums now commonly describe a fairly comprehensive set of core competencies that include dietary interventions, nutraceuticals, botanical medicines, body-mind practices (see, for example, Sidebar on meditation), energy medicine (e.g., acupuncture), and manual medicine (e.g., massage, chiropractic).197, 198 The balance of didactic knowledge (for the purpose of providing better-informed advice and referrals to patients) vs. practical skills (for actually integrating clinical applications) varies from program to program.

e

in ic

| 21st Century Medicine

lM na tio d. un rve r F se fo re te ts itu h st rig In All

40

0

MBCT [mindfulness-based cognitive therapy] was more effective than m-ADM [maintenance antidepressant medication] in reducing residual depressive

 The philanthropic funding of centers and departments of integrative medicine within the academic medicine community (e.g., University of Arizona, Harvard, Vanderbilt, Duke; also see list in the Appendix of members of the Consortium of Academic Health Centers for Integrative Medicine) brought high-level attention to the educational element: “Integration of CAM with conventional health care requires educational venues that prepare conventionally trained caregivers with a sufficient knowledge base for assessing beneficial and detrimental interactions between CAM and conventional care approaches; development of criteria for making informed referrals to CAM practitioners; and enhanced research capacity.”195

ed

Meditation may be one of the best studied body-mind modalities. The effects of meditation on the brain have been studied using sophisticated functional MRI (fMRI) and electroencephalographic (EEG) techniques. Not only have researchers detected significant differences in brain activity between experienced meditators and nonmeditators (or inexperienced meditators), but there also may be detectable differences resulting from the particular type of meditation studied.199 Although more substantial differences can be found with long-term meditators, even a short training period of eight weeks “produces demonstrable effects on brain and immune function.”200 Some findings suggest that “the resting state of the brain may be altered by longterm meditative practice,” and that “attention and affective processes…are flexible skills that can be trained.”201 The practical implications of such findings, if replicated on a large scale, could be considerable. One report concluded that “it is plausible from our results that meditation may strengthen the ability to inhibit cognitive and emotional mental processes such as rumination that can lead to or exacerbate stress, anxiety, or depression.”202 A subsequent study to test this hypothesis returned startling results203:

Strengths and weaknesses Integrative medicine is an important step toward a functionally integrated healthcare system that includes all appropriately credentialed practitioners. Not only does it provide an avenue for validated CAM therapies to be more widely used, but it supports

EMERGING MODELS

the interdisciplinary team concept in both educational and clinical settings. It allows patients greater freedom of choice in both therapies and providers, and it encourages dialogue among all health practitioners.

symptoms and psychiatric comorbidity and in improving quality of life in the physical and psychological domains. There was no difference in average annual cost between the two groups. Rates of ADM usage in the MBCT group was [sic] significantly reduced, and 46 patients (75%) completely discontinued their ADM. For patients treated with ADM, MBCT may provide an alternative approach for relapse prevention.

01

)2

(c

There is a danger that integrative medicine physicians will extend their practices beyond the scope of their education. Completing a program in integrative medicine does not turn an MD or a DO into a trained chiropractor, acupuncturist, naturopathic physician, or other such practitioner. It is important that those who wish to fully practice an alternative discipline seek comprehensive training from accredited institutions, just as those who wish to practice as medical doctors must do.

0

Common ground with other emerging models

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Integrated medicine uses evidence-based medicine to select the practices to integrate. It is multidisciplinary and oriented toward whole-person health care. It is the only one of the models to explicitly integrate alternative practitioners and approaches, to emphasize the importance of the practitionerpatient relationship, and to bring body-mind issues to the fore. Other than EBM, it is the only one that already has a significant foothold within academic medicine.

Role in a synthesized, comprehensive model of 21st century medicine

ed e

in ic

Integrative medicine provides great leadership in demonstrating the importance of a more integrated healthcare system and in creating academic models to educate practitioners in this new approach. It could benefit from a greater emphasis on genomic medicine, perhaps by incorporating some of the principles or recommendations of personalized or prospective medicine.

21st Century Medicine | 41

01 )2 (c

0

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e in ic

| 21st Century Medicine

42

21st century medicine: A New Model for Medical Education and Practice

Chapter 4 ________________________________________ 01

)2

(c

The Clinician’s Dilemma

0

[W]hat we observe is not nature itself, but nature exposed to our method of questioning. Natural science, does not simply describe and explain nature; it is part of the interplay between nature and ourselves.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

—Werner Heisenberg, Physics and Philosophy, 1958

ed

We have spent, to this point, a great deal of time and effort exploring both the challenge of 21st century medicine—to first halt and then reverse the epidemic of chronic disease—and some of the most prominent among many proposed solutions. We hope we have achieved a shared recognition that our current tools and approaches are not sufficient to the task, and that changes in the practice of medicine are necessary and imminent. At the same time, we cannot ignore the challenge of making these conclusions relevant to the individual practice of medicine. For, ultimately, most health care is delivered one patient and one practitioner at a time. In this chapter, we explore the clinician’s dilemma: how to practice in such a way that both the continuing advances of science and the essential art of medicine are integrated seamlessly into clinical practice, neither overshadowing the other. It won’t matter how intelligent and persuasive the arguments for change may be if we cannot convert them into practical approaches that can be taught to and adopted by individual clinicians.

e

in ic

This paper is not intended as an exploration of the actual clinical interventions that comprise functional medicine nor of the extensive science that underlies them. For that purpose, we refer the reader to the books, monographs, and courses available through The Institute for Functional Medicine (IFM).xi In these final two chapters, we address clinical practice at a different level, presenting the foundational concepts and principles that we believe should shape the coming changes in health care.

A complete list of IFM publications and courses can be found at www.functionalmedicine.org.

xi

21st Century Medicine | 43

21st century medicine: A New Model for Medical Education and Practice

The Central Hub of 21st Century Medicine The primary principle around which 21st century medicine—functional medicine—will revolve is personalized, systems medicine. Grouping people into categories based on organ system diseases, and then prescribing as though all people with a given diagnosis were inherently alike, is beginning to give way to a model that recognizes each patient’s genetic and environmental uniqueness. Clinicians must develop the knowledge and skills to deliver individually tailored care. They must be able (and willing) to incorporate the science of systems biology, the emerging discipline of personalized care, and a much broader array of assessment, therapeutic, and preventive strategies into a new therapeutic relationship.

01

)2

(c

Each human emerges from a mold that has but one model.xii Uniqueness continues to develop throughout life as a result of myriad influences. Family, school, work, community, diet, exercise, stress, and environmental toxicity all communicate information from outside the organism to the epigenetic translational structures that are married to nuclear DNA and that create powerful downstream effects on the genome, proteome, and metabolome. This phenomenon of biochemical uniqueness was recognized, researched, and documented in the 20th century, and is the foundation from which many key constructs have evolved, including systems biology and systems medicine, prospective health care, patient-centered health care, nutrigenomics, pharmacogenomics, proteomics, and metabolomics/metabonomics (see Chapter 3).

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Decision Making in the Face of Uncertainty

ed

From this chaotic, nonlinear interplay of complex factors, involving the integration of both genetics and context of living, emerges the haunting reality that all care is provided in a context of uncertainty. This is the shadow side of modern clinical medicine and it poses a daunting conundrum—how do you structure and systematize the assessment and treatment of patients when each is the product of a multitude of unique genetic and environmental influences and interactions? Kathryn Montgomery in her scholarly book, How Doctors Think, directly addresses this challenging issue:

e

in ic

Complexity and uncertainty are built into the physician’s effort to understand the particular in light of general rules…. The obstacle they encounter is the radical uncertainty of clinical practice: not just the incompleteness of medical knowledge but, more important, the imprecision of the application of even the most solid-seeming fact to a particular patient.204

What elevates the importance (and the stress) of clinical care over the work of, for instance, engineers, lawyers, accountants, and other nonclinical professionals is its continuous involvement in matters of life and death. The cost of failure is so high—death, when life might have been possible; illness, when health might have been attainable. The daily unconscious concern of every clinician is the weight of this cumulative decision making—inherently uncertain and lacking full (or sometimes even adequate) information to inform the clinical picture. Dr. Jerome Groopman in his provocative book with the same title, How Doctors Think, addressed this issue from his clinical perspective:

The potential for human cloning might be considered the exception to this rule. However, exact replication from a clone donor cannot duplicate the pre and post epigenetic imprinting that skews the exactness of a clone.

xii

44

| 21st Century Medicine

THE CLINICIAN’S DILEMMA

Uncertainty creeps into medical practice through every pore. Whether a physician is defining a disease, making a diagnosis, selecting a procedure, observing outcomes, assessing probabilities, assigning preferences, or putting it all together, he is walking on very slippery terrain. It is difficult for non-physicians, and for many physicians, to appreciate how complex these tasks are, how poorly we understand them, and how easy it is for honest people to come to different conclusions.205

)2

(c

Personalized, systems medicine serves to inform us about the enormity of the uncertainty. The message is clear: there is no one-size-fits-all solution to resolve any specific diagnosis. The limitations of clinical algorithms and evidence-based medicine can now be more clearly discerned. We can no longer allow them to skew our understanding of the larger picture, however difficult it may be to look at unflinchingly. We are at a crossroads where only honesty about the limitations of strategies that seek to avoid or ignore uncertainty will suffice.

01

For the great enemy of truth is very often not the lie—deliberate, contrived, and dishonest—but the myth—persistent, persuasive, and unrealistic. Too often we hold fast to the clichés of our forbears. We subject all facts to a prefabricated set of interpretations. We enjoy the comfort of opinion without the discomfort of thought.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

—John F. Kennedy, Yale Commencement, 1962

Medicine has attempted historically, through a number of shifts in perspective, to provide greater certainty to both practicing clinicians and patients, a patently valuable goal. Setting aside traditional methods of instilling confidence—oracles or shamans, for example—science has been a very important tool for reducing uncertainty.

ed

Twentieth century medicine completed a great philosophical and practical transformation into the organ system model of disease and diagnosis. This provided an evolving and reassuring sense of control and certainty as a result of ever-increasing specialization (often described as knowing more and more about less and less) as well as myriad fascinating scientific breakthroughs in understanding the nature of life, health, and disease. From early x-rays through the sophisticated imaging processes in use today, through ever more complex and detailed biochemical pathways, we have explored the silos of mammalian organ systems taxonomy. Objective facts accreted in uncountable numbers during the 1900s, describing human anatomy, physiology, and mechanisms of dysfunction from the cellular level to the specific organs themselves. The medical specialties (e.g., cardiology, neurology, nephrology) emerged and grew strong from these historic breakthroughs.

e

in ic

Near the end of the 20th century, however, the reality of the web-like, chaotic, nonlinear and complex nature of life (and health)—exposed by advances in the systems-oriented life sciences—began to erode this reassuring sense of certainty. Twenty-first century medicine has now come face-to-face with the practical implications of uncertainty—a problem that flummoxed many mid-20th century physicists (including the great Albert Einstein, who ultimately rejected what is now an accepted principle) when they first confronted Heisenberg’s articulation of the principle of uncertainty in physics. Fortunately, once the seriousness of this issue is consciously acknowledged, management strategies can be developed. First, however, we have to stop denying the presence and power of uncertainty in medicine. Research by brain scientists using advanced imaging and electronic technologies and analytic techniques equips the clinician with important knowledge for facing squarely the daunting task of assessing and treating each patient as

21st Century Medicine | 45

21st century medicine: A New Model for Medical Education and Practice

a unique individual, shaped by innumerable complex interactions between genetics and the cumulative influences of daily life.

01

)2

(c

The rest of this chapter will discuss these findings and will describe why the context of uncertainty in medicine requires a change in our view of evidence and the therapeutic relationship, and a considerable expansion in the clinical tool kit of the practitioner. The increasingly technical (and increasingly brief) clinical encounter that has characterized the last few decades in medicine can be transformed into a healing partnership through the appropriate integration of relevant evidence from clinical trials, the knowledge gained from breakthroughs in brain science and systems biology, and an expanded clinical armamentarium. Within this complex relational system can be found effective strategies for individualized assessment and treatment, taking into account the uncertainty generated by the complex genetic and environmental uniqueness of each patient—we can, in fact, begin the practice of personalized, systems medicine today.206, 207

0

Evidence-based Medicine in the Clinical Setting: Uses and Limitations

lM na tio d. un rve r F se fo re te ts itu h st rig In All

The scientific method disciplines the creative process of human inquiry. In the applied biological sciences (e.g., clinical medicine) prior to World War II, evaluation of emerging therapeutics was mainly the purview of recognized leaders in the medical profession, based primarily on their clinical experience and reputations, and without the rigor of systematic controls or external standards.208 To improve the quality of evidence and render a more accurate judgment with less personal bias, postwar researchers developed the randomized controlled trial (RCT) protocol. The major characteristics of this method include blinded assessment (of subjects, investigators, or both), often in the presence of a placebo control; random assignment to comparable groups; and inferential statistics as a surrogate for establishing causation.209

ed

The reliance on the expert gave way to reliance on results from RCTs. Clinicians could no longer reduce uncertainty by following the lead of a confident expert, but they increasingly appreciated the power of the double-blind, randomized, placebo-controlled clinical trial—a step up in certitude.210, 211 Putting aside, for the moment, the many problems inherent in the RCT model, not the least of which is the bias introduced by the influence of big Pharma,212, 213, 214, 215 let’s briefly explore EBM—the offspring of the RCT model— as understood and used by clinicians to reduce uncertainty.

e

in ic

Proponents of the RCT as the gold standard for unbiased research results have fostered its preeminence in the applied medical fields, both in primary and specialty care. They have argued for and developed algorithms for grading recommendations based on a research quality scale that ranks methodologies in descending order of accepted best evidence:216, 217  Systematic reviews and meta-analyses of RCT studies  RCTs  Nonrandomized intervention studies  Nonexperimental studies  Expert opinion

46

| 21st Century Medicine

THE CLINICIAN’S DILEMMA

Amid the early excitement generated by this new schema, certain assumptions were posited as foundational: A new paradigm for medical practice is emerging. Evidence-based medicine de-emphasizes intuition, unsystematic clinical experience, and pathophysiologic rationale as sufficient grounds for clinical decision making and stresses the examination of evidence from clinical research. Evidence-based medicine requires new skills of the physician including efficient literature searching and the application of formal rules of evidence evaluating the clinical literature.218 [Italics added.] —Evidence-based Medicine Working Group, JAMA, 1992

The application of EBM in the clinical setting is described as following this general scenario:219, 220

)2

(c

 Select specific clinical questions from the patient’s problem(s)

01

 Search the literature or databases for relevant clinical information

0

 Appraise the evidence for:

lM na tio d. un rve r F se fo re te ts itu h st rig In All

➢➢ validity against the hierarchy of evidence as described above, and ➢➢ usefulness to the patient and practice

 Implement useful findings in everyday practice

Arguments in favor of EBM infusion into both medical education and clinical practice are based on the following facts and inferences:221, 222  Available new evidence can and should lead to major changes in patient care  Practicing physicians often fail to obtain available newer relevant evidence  Medical knowledge and clinical performance deteriorate over time without the leavening of newer evidence influencing clinical decisions

ed

e

in ic

 Traditional continuing medical education (CME) alone is inefficient and generally does not improve clinical performance without significant follow-up and evaluation measures  The discipline of using evidence-based medicine can keep clinicians up-to-date In a cogent paper in The Lancet in 1999, van Weel and Knottnerus responded to the proddings of many eminent medical thought leaders to move ahead quickly and comprehensively with the integration of EBM into the clinical setting by pointing out the many difficulties of using this schema to manage the care of individual patients with complex, chronic illness:223  EBM tends to concentrate on research methodology and reduces clinical practice to the technical implementation of research findings. In a more colloquial view, it is the tail wagging the dog. Rather than using clinical judgment to guide the choice of relevant evidence, EBM is structured with a hierarchy of evidence as the driver of clinical judgment.

21st Century Medicine | 47

21st century medicine: A New Model for Medical Education and Practice

 The structure of RCT methodology assumes the consequences of individual variability in response to treatment will “wash out” if the subject pool is large enough and the statistical analyses sophisticated enough. While this may be true for populations, it seriously limits the applicability of the research in primary care, where therapy is delivered one unique patient at a time.  Co-morbid conditions are the usual justified reason for the exclusion of many patients from RCTs, so the very patients most in need of usable evidence (e.g., those with complex, chronic conditions) are often not in the cohorts of patients being studied, making the findings from the research trials very limited in their applicability.

01

)2

(c

 In primary care, treatment usually involves several interventions, sometimes delivered concurrently and sometimes sequentially. Unfortunately, combinations of evidence-based interventions do not sum to a treatment plan that is evidence-based. Interactions between single interventions may increase or decrease their efficacy (even under ideal trial conditions), when blended into a comprehensive plan. Adverse interactions among treatments may, and often do, occur.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

 Clinical research does not focus on the overall outcome of composite interventions because of the complexity of such studies and the absence of well-developed tools for studying such whole systems approaches.  Drug interventions have been studied more extensively than nonpharmacological interventions, in part due to the technical and methodological difficulties in the design of RCTs for nondrug interventions (and, in part, because of the nonpatentable nature of most lifestyle interventions). This situation creates a significant problem in primary care, where the use of educational, dietary, and lifestyle interventions is attractive because of their resonance with the principle of “maximum effect using minimum resources.”

ed

In marked contrast to the assertions of the EBM Working Group cited earlier, van Weel and Knottnerus suggest that the driving force behind EBM should be a coherent system of fundamental research in pathophysiology and the humanities, combined with careful clinical observations, on which systematic (RCT-based) evidence of effectiveness is superimposed. Existing clinical practice should be supported or, if erroneous, corrected on the basis of this coherent system. They go on to propose that “two complementary approaches are needed to strengthen the evidence base of nonpharmacological interventions and complex multifaceted strategies. First, the generic characteristics of complex interventions must be acknowledged as essential for its evaluation. Second, a methodology to allow the assessment of complex effects should be further developed.”

e

in ic

Dr. David Mant in his seminal 1999 paper, “Can randomized trials inform clinical decisions about individual patients?” takes a slightly different tack in exploring the irony that the RCT combines strength of concept for the population being studied with weakness of specific application to the individual patient:224

48

| 21st Century Medicine

THE CLINICIAN’S DILEMMA

The paradox of the clinical trial is that it is the best way to assess whether an intervention works, but is arguably the worst way to assess who will benefit from it…. However, the nub of the argument for me is that randomized controlled trials are primarily about medical interventions and not patients. In clinical trials, patients are randomized to allow a comparison of intervention efficacy unbiased by the individuality of patient. This methodological approach provides society with powerful protection against witch-doctoring, and helps us eliminate the inefficiencies in the provision of medical care described by Cochrane. But the methodological minimization of information on effectiveness in relation to the individual patient leaves an evidence gap for clinicians. [Italics added.]

01

)2

(c

Dr. Alan Feinstein, from the Department of Medicine at Yale University, echoes similar reservations in his article, “Problems in the evidence of evidence-based medicine.”225 Larry Culpepper and Thomas Gilbert, in their Lancet commentary, “Evidence and ethics,” focus on this same difficulty in the primary-care arena.226 Although the debate has continued over the past decade, these reasoned arguments have been heard less frequently as the push toward EBM has gained momentum. However, the problems described above have not been solved. Rather, with the advent of personalized medicine and systems biology, it is even more clear that the reductionist simplicity of the RCT frequently does not work to address the significant questions now facing 21st century practitioners in their struggle to cope with the epidemic of complex, chronic disease.227, 228, 229, 230, 231

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

ed

We can now begin to understand why the effect of research findings on clinical practice has been weaker than the early proponents of EBM postulated. The first problem that has impeded the successful application of EBM to patient care is the complex nature of the translation of research studies to the individual patient’s unique clinical problem(s)—what Larry Weed called knowledge coupling.232, 233 John Hampton, Professor of Cardiology, University Hospital, Nottingham, England, in a review titled “Evidence-based medicine, opinion-based medicine, and real-world medicine,” reasons: “Clinical trials will tell us what treatments are effective, but not necessarily which patients should receive them…Treatment must always be tailored to the individual patient.”234 (We would add to that statement that RCTs can only tell us what treatments are effective from among those studied. The decision about what to investigate introduces so much bias into the evidence base that it would be difficult to overstate its impact.)

in ic

e

Added to this methodological conundrum are the real-world exigencies of daily clinical practice that make it virtually impossible to acquire, collate, and filter all relevant evidence prior to direct application to the unique needs of the patient. Imagine a clinic where, after each therapeutic encounter—involving both appropriate history taking and physical examination procedures—a problem list is developed and then carefully subjected to a medical literature search and analysis. The pace of clinical practice will not tolerate the inertia of such a process,235 even to improve the care of patients who may be in desperate need of new interventions based on emerging evidence. A second major issue is even more complex. If medical care were as simple as making a diagnosis and then prescribing an appropriate pharmacologic agent (or agents), then the EBM system, as presently configured and applied, might work—but only if appropriate Problem Oriented Evidence that Matters (POEMs) xiii, 236 were available for each medical problem (and disregarding, for the moment, that To assist the practicing physician’s effective inclusion of new evidence into daily practice, both government-sponsored and commercially affiliated organizations have moved EBM forward with a collation of filtered studies called: Problem Oriented Evidence that Matters (POEMs). Most POEMs and most studies in the Cochrane Collection are research trials of pharmacologic therapeutic interventions. It is now possible to search these specific databases, or self-developed relevant databases that review groups of studies that directly link research findings with specific clinical problems.

xiii

21st Century Medicine | 49

21st century medicine: A New Model for Medical Education and Practice

most chronic disease is complicated by multiple comorbidities that are rarely addressed by POEMs). Unfortunately, the “better living through chemistry” dream that fueled half a century of research has not, in fact, created a healthier population (see Chapter 2).237 Although many acute medical problems do appear to respond consistently as envisioned by the EBM model, more than 70% of health problems presenting to clinicians today are both chronic and complex238 (Chapter 2), and they require a different approach. “Treating only known biological components of disease minimizes the ability of the practitioner to tailor therapeutic interventions to individual patients.”239

01

)2

(c

Despite these sobering facts, physician education, training, and reimbursement, as well as research designs for clinical studies that physicians depend upon for effective decision making, continue to be focused primarily on an acute-care model that emphasizes pharmacologic solutions for complex, chronic problems, leaving the discerning clinician without the evidence and tools needed for addressing their patients’ complex needs.

0

It’s not enough, of course, for us to understand what’s wrong. We must also seek better solutions for these urgent problems, regardless of the difficulty of the task and the elusiveness of the answers. The RCT tool was developed during a specific period in our medical history and worked well to differentiate the traditionalists, who claimed that clinical experience trumped bench science, from the scientists, who perceived the value in systematic inquiry. Major strides in treatment have occurred in the intervening 50 to 60 years as a result of the shift toward the use of RCT methodology. But we are now at another nodal decision point, unique to our cultural and medical evolution. We need more sophisticated tools to shed light on the nature of the web-like interweaving of mechanisms at work in complex, chronic illness.240, 241, 242 While alternate study designs and statistical methodologies are being developed for analyzing complex data sets,243, 244, 245 we must return the practice of EBM to its original mission of using evidence to inform clinical experience and to expand the understanding of basic mechanisms of health and disease.246, 247 This will help to reverse the decade-long plunge toward “... reducing clinical practice to the technical implementation of research findings.”248, 249

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

in ic

In sum, we are now facing another major transition in how we perceive and utilize evidence in clinical medicine. Thomas Kuhn offers this insightful analysis:

e

When defects in an existing paradigm accumulate to the extent that the paradigm is no longer tenable, the paradigm is challenged and replaced by a new way of looking at the world. Medical practice is changing, and the change, which involves using the medical literature more effectively in guiding medical practice, is profound enough that it can appropriately be called a paradigm shift.250

A Science-Using Profession Given the serious limitations of applying the EBM model in clinical practice, we must ask two questions central to the future of medicine:  How do we develop an effective therapeutic relationship based upon (1) efficacious, reproducible, and personalized clinical applications that are solidly anchored in science, (2) emerging knowledge about the multifactorial causes of chronic disease, and (3) an expanded awareness of the nature of clinical/critical thinking?

50

| 21st Century Medicine

THE CLINICIAN’S DILEMMA

 How do we transition from an EBM-based, guideline-driven, prescriptive clinical practice to an individualized, patient-centered approach that captures both the science and the art of medicine?

01

)2

(c

First, we must recognize that most clinicians, by professional training and inclination, are not scientists. Clinical medicine is a science-using profession. It is true that diagnosis and treatment have become intensely science-using activities, but these activities have a distinctly different process and endpoint than those of the professional scientist.251 “Physicians start from the demands of the patient’s condition and not from the demand for generalizable knowledge, and their goal is just as particular: to treat the patient’s illness, not to test the therapy.”252 The evidence needs of clinical medicine are also distinctly different. The focus on application and usefulness centers on how the evidence informs the assessment and treatment process for each individual patient, given that patient’s unique genetic propensities and unique environmental influences.

0

At a number of points in this paper, we have documented how most clinical evidence based on RCTs informs about cohorts of patients with similar signs and symptoms (the basis of diagnosis and diagnostic groups), but not does not necessarily provide decision support for an individual patient. The primary responsibility of the attending clinician is to ferret out meaningful evidence for each patient, knowing that unique genomic specificities may predispose that patient to unanticipated results. From this perspective, evidence often serves to qualify insight, but when applied in a simplistic or statistically linear way, can create unintended mischief.253 From this perspective, every maneuver, either further assessment or therapeutic intervention, becomes a clinical probe that must be assessed in partnership with the client as the shared journey of investigation and healing proceeds.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

ed

Dr. Sackett, founder and advocate for EBM, was quite clear about this in the early development of EBM: “Evidence based medicine is the conscientious, explicit, and judicious use of current best evidence in making decisions about the care of individual patients. The practice of evidence based medicine means integrating individual clinical expertise with the best available external clinical evidence from systematic research…. Good doctors use both individual clinical expertise and the best available external evidence and neither alone is enough.”254 [Italics added.]

in ic

e

The combining of these elements can be viewed as a Venn diagram, where the best outcomes occur when all three elements are represented (Figure 9).

Research Evidence

Optimal Outcomes

Clinical Practice

The Patient’s Story

Figure 9: Optimal Outcomes: Applying Evidence-based Medicine to the Real World 21st Century Medicine | 51

21st century medicine: A New Model for Medical Education and Practice

Another Perspective on the Biomedical Model

01

)2

(c

The complexity of the developing explanatory models has been serially addressed in the Annals of Family Medicine, a peer-reviewed medical journal “dedicated to advancing knowledge essential to understanding and improving health and primary care,” including the development of methodology and theory for addressing this conundrum. In the article, “The biopsychosocial model 25 years later: Principles, practice, and scientific inquiry,”255 the authors critique the limitations of the conventional biomedical model and the research methodologies that evolve from this model and preview the evolving model of complexity and causality and the nested model of structural causality:

David Deutsch, in The Fabric of Reality, describes the need for a next step in using the science of underlying pathophysiological mechanisms of disease in the clinical setting of medicine:

The real question now facing every discerning, informed clinician263 is how to bring relevant, graded, emerging scientific evidence to the complex list of problems made unique by the patient’s genetic susceptibilities and potentialities that, in turn, communicate constantly with the ever-changing environment within which the patient lives. No RCT can inform, in a specific way, the appropriate clinical roadmap for assessment and planning for therapeutic interventions in this complex environment.264 Clinicians must use science; it is a powerful tool. But they should be in charge of how and when to use it, not dominated and intimidated by it.

ed

e

in ic

| 21st Century Medicine

lM na tio d. un rve r F se fo re te ts itu h st rig In All

52

0

Few morbid conditions could be interpreted as being of the nature “one microbe, one illness”; rather, there are usually multiple interacting causes and contributing factors. Thus, obesity leads to both diabetes and arthritis; both obesity and arthritis limit exercise capacity, adversely affecting blood pressure and cholesterol levels; and all of the above, except perhaps arthritis, contribute to both stroke and coronary artery disease. Some effects (depression after a heart attack or stroke) can then become causal (greater likelihood of a second similar event)….These observations set the stage for models of circular causality that describe how a series of feedback loops sustain a specific pattern of behavior over time.256, 257, 258 Complexity science is an attempt to understand these complex recursive and emergent properties of systems259, 260 and to find interrelated proximal causes that might be changed with the right set of interventions.261

The science of medicine is perhaps the most frequently cited case of increasing specialization seeming to follow inevitably from increasing knowledge, as new cures and better treatments for more diseases are discovered. But as medical and biochemical research comes up with deeper explanations of disease processes (and healthy processes) in the body, understanding is also on the increase. More general concepts are replacing more specific ones as common, underlying molecular mechanisms are found for dissimilar diseases in different parts of the body. Once a disease can be understood as fitting into a general framework, the role of the specialist diminishes.... Physicians… can look up such facts as are known. But [more importantly] they may be able to apply a general theory to work out the required treatment, and expect it to be effective even if it has never been used before.262

THE CLINICIAN’S DILEMMA

The Heuristics that Guide Doctors’ Thinking

(c

We believe it is fair to say that the fear of uncertainty has led us to narrow our field of vision far too soon. “Science has not one method, but many. These include observation in the natural world, experimentation in the laboratory, mathematical proof, computer simulation with real data, analysis of surveys and demographical statistics, and thought experiments for the great geniuses, such as Galileo and Einstein. In the social sciences, a climate of anxious identification with a sub-discipline goes hand in hand with methodological rituals … methodological uniformity and discipline-oriented research are two sides of the same coin....” A shift is needed to “free us from the straightjacket of methodological rituals, allowing us to consider and choose proper methodologies for the problem at hand and to verify a result obtained with one method by using other methods.”265

01

)2

Has broad-based and open-minded scientific inquiry been skewed by EBM and its hierarchy of evidence codification and ranking?266, 267, 268, 269, 270, 271 Is the hegemony of EBM in contemporary medicine, as exemplified by Drs. Montori and Guyatt,272 closing the door on the reintegration of the science and art of medicine?xiv We need to ask what we have surrendered by de-emphasizing “unsystematic clinical experience and pathophysiologic rationale.” What is the irreplaceable loss in patient outcomes with the dismissing of experience, intuition, and wisdom? What must we do to develop skills and methodologies appropriate to clinical decision making in a context of uncertainty?

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

ed

There is a robust literature that explores the actual methodologies used by clinicians who must make decisions when time and information are limited and the outcome is uncertain. It is clear from brain research that there is an important difference between the human brain and other features of the universe. The brain is a complicated, nonlinear, living system capable of self-organization. The brain does not respond to incoming stimuli in a direct, reflex-like action but continuously changes, constructing its own neural activity patterns in order to adapt to and synchronize with external stimuli. Genetic makeup and continuous stimuli from the environment are the only factors that create individual differences; the twin magnets of chaos and self-organization shape the constant interplay of those factors. The human mind is highly capable of dual processing; in fact, the continuous and virtually seamless integration of reason to test intuition and of intuition to generate the creative thinking that fuels rational inquiry is what advances insight and knowledge.

e

in ic

We usually represent problems in a linear fashion despite the convincing evidence that this type of modeling is not appropriate or adequate for studying the nervous system or human behavior.273, 274 This naturally leads to some interesting conclusions about the interrelationship of brain and mind when faced with decision making in a sea of uncertainty.275, 276, 277, 278, 279 The mind is an adaptive toolbox with genetically, culturally, and individually created and transmitted rules of thumb. These rules of thumb are called heuristics and are foundational to daily function, intuition, or inspiration.280 The study of judgment under uncertainty is the study of heuristics. The human species’ response to uncertainty is to rely upon experience, coupled with knowledge, data, and applied wisdom through processes such as heuristics and insight.

xiv

In their 2008 review of the progress in EBM, VM Montori and GH Guyatt reiterate a basic principle of EBM cited earlier in this chapter: “Evidence-based medicine de-emphasizes intuition, unsystematic clinical experience, and pathophysiologic rationale (italics added) as sufficient grounds for clinical decision making and stresses the examination of evidence from clinical research,” ignoring the significant push back from the international scientific and clinical community regarding the hobbling effects of EBM on both research and translational medicine.

21st Century Medicine | 53

21st century medicine: A New Model for Medical Education and Practice

Heuristics and “rules of thumb” are synonymous terms. It is important to distinguish between heuristic and analytic thinking. For instance, heuristic thinking is indispensable for discovering a mathematical proof, whereas analytic thinking is necessary for checking the steps of the proof.281 A limited number of simplifying heuristics rather than more formal and extensive algorithmic processing is the rule.282 The classic example of a heuristic that most people have experienced is the “rule of thumb” (gaze heuristic) used for catching a ball, as illustrated in Figure 10.

01

)2

(c 0 lM na tio d. un rve r F se fo re te ts itu h st rig In All

Figure 10: How to Catch a Fly Ball: Players rely on unconscious rules of thumb. When a ball comes in high, a player fixates his gaze on the ball, starts running, and adjusts his speed so that the angle of the gaze remains constant. From page 22 of the essay Rationality for Mortals, originally published in Blackwell Handbook of Judgement and Decision Making. Copyright Oxford University Press/UK Blackwell, 2004.

ed

The angle of gaze is the angle between the eye and the ball, relative to the ground. For years, brain scientists assumed that a complex process of computations was required for tasks like catching a ball. The artificial intelligence (AI) groups attempted to duplicate these tasks with robotic technologies. However, research by the ‘heuristics’ groups showed a very different process at work.283 It turns out that a player who uses the gaze rule does not need to measure wind, air resistance, spin, or the other complex, causal variables. “All the relevant facts are contained in one variable: the angle of gaze. Note that a player using the gaze heuristic is not able to compute the point at which the ball will land. Yet the heuristic leads the player to the landing point...most fielders are blithely unaware of the gaze heuristic, despite it simplicity. Once the rationale underlying an intuitive feeling is made conscious, however, it can be taught.”284

e

in ic

Elwyn et al., in their well reasoned paper, “Decision analysis in patient care,”285 demonstrate the efficacy and comprehensiveness of this methodology. Naylor summarizes in his editorial comments on their paper (published in the Lancet): The process of individualized decision analysis might best be viewed as a way of enhancing communication with patients, rather than as a “black box” from which directives emerge. But if that is the ultimate aim, it seems more useful to develop simple decision aids aimed at helping patients and doctors share information and work through tough choices in the clinical setting. To that end, Elwyn and colleagues call on clinicians and patients to communicate better while embracing fast and frugal rules of thumb [heuristics]. In so doing they have arguably drawn their

54

| 21st Century Medicine

THE CLINICIAN’S DILEMMA

readers full circle—from clinical art to bedside science and back again. It is ironic, moreover, that the best lessons in fast and frugal rules of thumb may well come from understanding the cognitive processes of those master clinicians who consistently make superb decisions without obvious recourse to the canon of evidence-based medicine.286 [Italics added.]

If we are to develop both a clinical methodology and a curriculum that will approximate the best characteristics of successful clinicians, we must compare what is usually done with what could be done. A very pertinent example of how we might transform medical care affects the primary heuristic of contemporary medicine—the patient history and physical exam reporting structure (the H&P heuristic)— that dominates all communication among healthcare practitioners today. We will then compare it to the new heuristic developed by IFM to achieve a more comprehensive communication tool.

(c

01

)2

Every healthcare provider recognizes this formal construct for medical information and communication. It both describes and dictates the process of the patient visit. The story that emerges from a clinical encounter is typically organized around the following elements:

0 lM na tio d. un rve r F se fo re te ts itu h st rig In All

From Patient Encounter to the Diagnosis: The Conventional Medical Heuristic

ed

• Chief Complaint (CC)* • History of Present Illness (HPI)* • Past Medical History (PMH)* • Review of Organ Systems (ROS)* • Medication and Supplement History* • Dietary History* • Social, Lifestyle, Exercise History** • Physical Examination (PE)* • Laboratory and Imaging Evaluations* • Assessment and Diagnosis* •T  reatment Interventions (usually pharmaceutical and/or procedure -based)*

e

in ic

* = STANDARD PRACTICE ** = EXPANDED MODEL It is not always recognized that this construct facilitates the “fast and frugal processing” needed to efficiently collect, collate, and use patient information. The conventional H&P heuristic propels all information headlong toward the diagnosis, with the intention of identifying and prescribing the pharmaceutical or procedural therapy associated with that diagnosis. Each individual diagnosis is viewed as a distinct entity unto itself—often investigated during separate office calls and/or by different practitioners. There is no place in the conventional H&P heuristic to tie together multiple diagnoses into a consistent and coherent patient narrative. There is no identification of the antecedent conditions that may predispose the patient to the triggering of dysfunctional adaptive responses, nor of the mediators that may perpetuate the dysfunction. Thus, patients filtered through this conventional heuristic never have a chance

21st Century Medicine | 55

21st century medicine: A New Model for Medical Education and Practice

to be fully heard and understood in the context of their whole life experience. Instead, their stories are reduced to a series of diagnoses, treated by different specialists, often in isolation from one another. The H&P heuristic was shaped by, and thus reinforces, the organ-system model of disease, with its distinct and separate information silos, rather than a systems-medicine perspective that encourages the search for common underlying mechanisms of, and pathways to, disease. IFM’s functional medicine heuristic (FM heuristic) expands upon the same basic structure we are all familiar with, but organizes the information to integrate the patient’s genetic and developmental susceptibilities (antecedents), historical triggers, and ongoing mediators of disease. Thus, the patient’s story emerges with greater detail, a broader context, and a different focus and ultimate goal:

(c

)2

The Functional Medicine Heuristic

01

• Chief Complaint (CC) • History of Present Illness (HPI) • Past Medical History (PMH) — Explore antecedents, triggers, and mediators of CC, HPI, and PMH • Review of Organ Systems (ROS) — Genetic predispositions? • Medication and Supplement History • Dietary History • Social, Lifestyle, Exercise History • Physical Examination (PE) • Laboratory and Imaging Evaluations: — Immune/inflammatory imbalance — Energy imbalance/mitochondrial dysfunction — Digestive/absorptive and microbiological imbalance — Detoxification/biotransformation/excretory imbalance — Imbalance in structural, boundary, and membrane integrity — Hormonal and neurostransmitter imbalances — Imbalance in mind - body - spirit integration • Initial Assessment: — Enter data on Matrix form; look for common themes — Review underlying mechanisms of disease — Recapitulate patient’s story — Organ system-based diagnosis — Functional medicine assessment: underlying mechanisms of disease; genetic and environmental influences • Treatment Plan: — Individualized — Dietary, lifestyle, environmental — Nutritional, botanical, psychosocial, energetic, spiritual — May include pharmaceuticals and/or procedures

0

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

in ic

56

| 21st Century Medicine

THE CLINICIAN’S DILEMMA

As can be seen in the FM heuristic, the diagnosis is one factor among many that help the clinician and patient explore why and how a condition was triggered and why and how the dysfunction is being mediated. From a disciplined filtering of the patient information through the Functional Medicine Matrix Model (see Chapter 5), patterns emerge that illuminate both the underlying causes of dysfunction as well as plausible (and multiple) points of leverage where individualized treatment can create improved function. The potential interventions reflect a broader array of health vectors than just pharmaceutical and procedural interventions because the FM heuristic elicits a pattern that helps the clinician and patient identify where lifestyle and environmental interventions can be applied.

01

)2

(c

Because clinical reasoning is very often grounded in heuristics (simplified models that guide evaluation and treatment at an unconscious level of awareness), we argue that to change the outcome, we must change the model. The ability to utilize heuristics when time and information are limited and outcomes are uncertain is a very special cognitive trait—an evolutionary breakthrough in adaptive cognition. To understand and refine clinical reasoning and clinical practice—to ultimately improve outcomes—a deeper understanding of these adaptive skills must be understood and consciously applied.

0 lM na tio d. un rve r F se fo re te ts itu h st rig In All

Insight

If we are to develop an effective model for the healing partnership, we must also explore the research that illuminates the emergence of insight as a reproducible phenomenon.xv Brain research has illuminated very different functions of the left and right brain that explicate the objective neural correlates of a brain that produces insight. Among the most important features of this emerging view of brain function are the following:

ed

 Solving computational questions is primarily a left-brain function. Asking a computational question triggers left-brain activity at the expense of right-brain function. (This has tremendous relevance to the interactions between doctor and patient. When a patient is interrupted with a computational question in the midst of an attempt to describe a pattern of dysfunction, the patient’s own opportunity for insight may be lost.)

in ic

e

 If the left hemisphere excels at denotation—storing the primary meaning of a word— the right hemisphere deals with connotation, everything that gets left out of a dictionary definition, such as the emotional charge in a sentence or a metaphor. Language is so complex that the brain has to process it in two different ways at the same time. As humans, we need to see both the forest and the trees. The right hemisphere is what helps you see the forest.287, 288  Much of the research into the adaptive unconscious (aka unconscious cognition) suggests that pattern recognition capacity resides in the right brain, but is not specifically localized.289, 290 Solving questions requiring insight generates activity that starts in the prefrontal cortex and eventually extends throughout the cortex and deeper structures,

xv

“What is insight? The term ‘insight’ is used to designate the clear and sudden understanding of how to solve a problem. Insight is thought to arise when a solver breaks free of unwarranted assumptions, or forms novel, task-related connections between existing concepts or skills.” (Bowden EM. New approaches to demystifying insight. TRENDS in Cognitive Sciences. 2005;9(7):322-28.)

21st Century Medicine | 57

21st century medicine: A New Model for Medical Education and Practice

searching for possible experiential information that contributes to the emergence of a pattern. It is the appearance of that pattern that sparks the “aha” or “Eureka!” experience in the connotative language centers of the right brain. In brief, left-brain function helps us with the denotative, computational, linear functions of life and thought, whereas the right brain provides the connotative shadings that give depth and character and color to meaning. Right-brain function is the source of pattern recognition and moments of insight.

01

)2

(c

The researchers in this field have produced a robust and credible body of research about pattern recognition from experiments that delineate and substantiate the functions of unconscious cognition (the adaptive unconscious) that shape moments and expressions of insight.291, 292, 293 Reproducible patterns of brain activity correlate with the experience of insight.294 The prefrontal cortex does not simply function as an aggregator of information. Instead, like the conductor of an orchestra, brain wave activity and energy expenditure are coordinated as if instructed by the prefrontal cortex maestro, waving its baton and directing the players.

0

This is known as top-down processing, since the prefrontal cortex (the top of the brain) is directly modulating the activity of other areas. Studies show that cells in the right hemisphere are more broadly tuned than cells in the left hemisphere, with longer branches and more dendritic spines. As a consequence, neurons in the right hemisphere are collecting information from a larger area of cortical space. They are less precise but better connected. When the brain is searching for an insight, these are the cells that are most likely to produce it. A small fold of tissue on the surface of the right hemisphere, the anterior superior temporal gyrus (aSTG), becomes unusually active in the second before the insight. The activation is described as sudden and intense, a surge of electricity leading to a rush of blood.295, 296

lM na tio d. un rve r F se fo re te ts itu h st rig In All

ed

One of the unusual aspects of insight is not the revelation itself but what happens afterward. The adult brain is an infinite library of associations, a cacophony of competing ideas, and yet, as soon as the right association appears, we know. The new thought, which is represented by that rush of gamma waves in the right hemisphere, immediately grabs our attention. As soon as the insight happens, it seems so obvious. People can’t believe they didn’t see it before.297, 298, 299

in ic

e

Insight researchers call the “aha” experience the moment of categorical insight. This moment of epiphany registers as a new pattern of neural activity in the prefrontal cortex. The brain cells have been altered by the breakthrough. An insight is a restructuring of information—it’s seeing the same old thing in a completely new way. Once that restructuring occurs, you never go back.300

Insight and the Healing Partnership “While it’s commonly assumed that the best way to solve a difficult problem is to focus, minimize distractions, and pay attention only to the relevant details, this clenched state of mind may inhibit the sort of creative connections that lead to sudden breakthroughs. We suppress the very type of brain activity that we should be encouraging. Jonathan Schooler has recently demonstrated that making people focus on the details of a visual scene, as opposed to the big picture, can significantly disrupt the insight process. ‘It doesn’t take much to shift the brain into left-hemisphere mode,’ he said.”301 We can extrapolate that, as clinicians, although we don’t ignore evidence, when we want insight about a patient’s condition, we are clearly better off not turning to left-brain analysis of the most recent RCTs. And, when we want the patient’s insight, we must learn to elicit the patient’s story (pattern) and really listen to it.

58

| 21st Century Medicine

THE CLINICIAN’S DILEMMA

Research focused on the typical, clinical therapeutic encounter has noted that clinicians interrupt the patient’s flow of conversation within the first 12 to 18 seconds (or less) of the patient’s response to a question.302, 303 This reproducible phenomenon in the conventional clinical setting makes sense if you compare the heuristic for contemporary medicine to the functional medicine heuristic. The heuristic of conventional medicine (rule of thumb) achieves the stated goal in an expeditious manner: clinicians use it to identify the primary organ system domain of the presenting problem and then focus on the differential diagnosis within that domain, marching resolutely to the final diagnosis. This is a computational process, without need for a partnership that can produce insight into the underlying causes and mechanisms of the medical problem.

01

)2

(c

The functional medicine heuristic, on the other hand, requires a carefully nurtured and protected partnership between the clinician and the patient to illuminate the underlying mechanisms of the patient’s illness(es). The FM heuristic requires an iterative, cooperative process that yields a more complete narrative story. From a thorough investigation of the antecedents, triggers and mediators of the patient’s condition, emerge information and insights that can help to shape a deeper and more comprehensive therapeutic response.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Summary

ed

We have devoted this chapter to achieving a better understanding of an urgent problem facing clinicians today: how to combine both science and art, evidence and insight, into an individualized, patient-centered approach to complex, chronic disease. We do not claim to have the (sole or definitive) answer. But we do offer a new focus for both education and practice that can be described and substantiated, taught and practiced. We have presented findings that suggest that the management of uncertainty—the inherent context of clinical medicine—requires a change in the therapeutic relationship on the part of both clinician and patient and a change in how we view and use evidence. The technical therapeutic encounter that has characterized a great deal of patient care for the last few decades must be transformed into a healing partnership through appropriate applications of scientific understanding, evidence from clinical trials, and a new understanding of brain function.

in ic

e

The Institute for Functional Medicine’s model of comprehensive care and primary prevention for complex, chronic illnesses (described further in Chapter 5) is grounded in both science (the Functional Medicine Matrix Model; evidence about common underlying mechanisms and pathways of disease; evidence about effective approaches to the environmental and lifestyle sources of disease) and art (the healing partnership and the search for insight in the therapeutic encounter). These two cornerstones of clinical medicine must be integrated into our teaching and practice in order to achieve what we owe to our patients and ourselves—a more effective response to the epidemic of chronic disease. We assert that this can be done.

21st Century Medicine | 59

01 )2 (c

0

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e in ic

| 21st Century Medicine

60

21st century medicine: A New Model for Medical Education and Practice

Chapter 5 ________________________________________ 01

)2

(c

Functional Medicine: A 21st Century Model of Patient Care and Medical Education

0 lM na tio d. un rve r F se fo re te ts itu h st rig In All

It is much more important to know what sort of a patient has a disease than what sort of a disease a patient has. The good physician treats the disease; the great physician treats the patient who has the disease. —William Osler

Treat the patient, not the diagnosis.

—The Institute for Functional Medicine

ed

In this chapter, we will review the basic principles, constructs, and methodology of functional medicine. It is not the purpose of this paper to recapitulate the range and depth and science of functional medicine; books and monographs covering that material in great detail are already available for the interested clinician and for use in health professions schools. Our purpose in the first part of this chapter is to describe how functional medicine is organized to deliver personalized, systems medicine and, as such, is equipped to respond to the challenge of treating complex, chronic disease more effectively. In the second part of the chapter, we will discuss how clinicians can be helped to re-integrate the art and science of medicine to create a healing partnership.

e

in ic

Part I: What is Functional Medicine? Functional medicine conceptualizes health and illness as part of a continuum in which all components of the human biological system interact dynamically with the environment. These interactions produce patterns that change over time in individuals. To manage the complexity inherent in this approach, functional medicine has adopted practical models for obtaining and evaluating clinical information that leads to individualized, patient-centered therapies.

21st Century Medicine | 61

21st century medicine: A New Model for Medical Education and Practice

Functional medicine encompasses a dynamic approach to assessing, preventing, and treating complex, chronic disease. It helps clinicians identify and ameliorate dysfunctions in the physiology and biochemistry of the human body as a primary method of improving patient health. In this model of practice, we emphasize that chronic disease is almost always preceded by a period of declining function in one or more of the body’s systems. Returning patients to health requires reversing (or substantially improving) the specific dysfunctions that have contributed to the disease state. Those dysfunctions are, for each of us, the result of lifelong interactions among our environment, our lifestyle, and our genetic predispositions. Each patient, therefore, represents a unique, complex, and interwoven set of influences on intrinsic functionality that have set the stage for the development of disease or the maintenance of health.

01

)2

(c

Historically, the word “functional” has been used somewhat pejoratively in medicine. It has implied a disability associated with either a geriatric or psychiatric problem. We suggest, however, that this is a very limited definition of an extremely useful word. Medicine has not really produced an efficient method for identifying and assessing changes in basic physiological processes that produce symptoms of increasing duration, intensity, and frequency, even though we know that such alterations in function often represent the first signs of conditions that, at a later stage, become pathophysiologically definable diseases. If we broaden the use of functional to encompass this view, functional medicine becomes the science and art of detecting and reversing alterations in function that clearly move a patient toward chronic disease over the course of a lifetime. Thus, with functional medicine, we begin to define a model of patient care that seeks to identify underlying chronic dysfunctions associated with altered physiological processes and to maximize functionality at all levels of body, mind, and spirit.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

ed

One way to conceptualize where functional medicine falls in the continuum of health and health care is to examine the functional medicine “tree.” In its approach to complex, chronic disease, functional medicine encompasses the whole domain represented by the graphic shown in Figure 11, but first addresses the patient’s core clinical imbalances, fundamental physiological processes, environmental inputs, and genetic predispositions. Diagnosis, of course, is part of the functional medicine model, but the emphasis is on understanding and improving the functional core of the human being as the starting point for intervention.

e

in ic

62

| 21st Century Medicine

FUNCTIONAL MEDICINE

Cardiology Pulmonary Endocrinology

Urology/Nephrology Hepatology

Gastroenterology

Allergy

Neurology Organ System Diagnosis

01

)2

(c

Signs and Symptoms

0

Fundamental Clinical Imbalances

lM na tio d. un rve r F se fo re te ts itu h st rig In All

• Hormonal and Neurotransmitter Imbalances • Redox Imbalance + Oxidative Stress + Mitochondropathy • Detox/Biotransformation/Excretory Imbalance • Immune imbalance • Inflammatory Imbalance • Digestive/Absorptive and Microbiological Imbalance • Structural Integrity Imbalance

Fundamental Physiological Imbalances 1. Communication 4. Elimination of Waste • outside the cell 5. Protection/Defense • inside the cell 6. Transport/Circulation 2. Bioenergetic/Energy Transformation 3. Replication/Repair/Maintenance/ Structural Integrity

ed

Psycho-social

Physical Exercise Trauma

Diet Nutrients Air/Water

e

Experiences, Attitudes, Beliefs

in ic

Mind and Spirit Genetic Disposition

Xenobiotics Micro-organisms Radiation

Environmental Inputs Figure 11: The Continuum of Health and Health Care

21st Century Medicine | 63

21st century medicine: A New Model for Medical Education and Practice

Functional medicine clinicians focus on restoring balance to the dysfunctional systems by strengthening the fundamental physiological processes that underlie them, and by adjusting the environmental and lifestyle inputs that nurture or impair them. This approach leads to therapies that focus on restoring health and function, rather than simply controlling signs and symptoms.

Principles Seven basic principles characterize the functional medicine paradigm:  Acknowledging the biochemical individuality of each human being, based on the concepts of genetic and environmental uniqueness

)2

(c

 Incorporating a patient-centered rather than a disease-centered approach to treatment

01

 Seeking a dynamic balance among the internal and external factors in a patient’s body, mind, and spirit

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

 Addressing the web-like interconnections of internal physiological factors  Identifying health as a positive vitality—not merely the absence of disease—and emphasizing those factors that encourage a vigorous physiology  Promoting organ reserve as a means of enhancing the health span, not just the life span, of each patient  Functional medicine is a science-using profession

Environmental Inputs

ed

At the base of the medicine tree graphic are found the building blocks of life, as well as the primary influences on them. When we talk about influencing gene expression, we are interested in the interaction between environment in the broadest sense and any genetic predispositions with which a person may have been born—including the epi genome.xvi Many environmental factors that affect genetic expression are (or appear to be) a matter of choice (such as diet and exercise); others are very difficult for the individual patient to alter or escape (air and water quality, toxic exposures); and still others may be the result of unavoidable accidents (trauma, exposure to harmful microorganisms in the food supply). Some factors that may appear modifiable are heavily influenced by the patient’s economic status—if you are poor, for example, it may be impossible to choose more healthful food, decrease stress in the workplace and at home, or take the time to exercise and rest properly. Existing health status is also a powerful influence on the patient’s ability to alter environmental input. If you have chronic pain, exercise may be extremely difficult; if you are depressed, self-activation is a huge challenge.

e

in ic

xvi

Epigenetics—the study of how environmental factors can affect gene expression without altering the actual DNA sequence, and how these changes can be inherited through generations.

64

| 21st Century Medicine

FUNCTIONAL MEDICINE

The influence of these inputs on the human organism is indisputable and they are often powerful agents in the battle for health. Ignoring them in favor of the quick fix of writing a prescription means the cause of the underlying dysfunction may be obscured, but is usually not eliminated. In general terms, the environmental inputs listed below should be considered when working to reverse dysfunction or disease and restore health:  Diet (type and quantity of food, food preparation, calories, fats, proteins, carbohydrates)  Nutrients (both dietary and supplemental)  Air  Water

(c

)2

 Microorganisms (and the general condition of the soil in which food is grown)

0

 Trauma

01

 Physical exercise

lM na tio d. un rve r F se fo re te ts itu h st rig In All

 Psychosocial and spiritual factors (including family, work, community, economic status, stress, and belief systems)  Xenobiotics  Radiation

Fundamental Physiological Processes

e

• outside the cell

in ic

1. Communication

ed

There are certain physiological processes that are necessary to life. These are the “upstream” processes that can go awry and create “downstream” dysfunctions that eventually become disease entities. Functional medicine requires that clinicians consider these in evaluating patients, so that intervention can occur at the most fundamental level possible. They are:

• inside the cell 2. Bioenergetics/Energy Transformation 3. Replication/Repair/Maintenance/Structural Integrity 4. Elimination of Waste 5. Protection/Defense 6. Transport/Circulation Although these fundamental physiological processes are usually taught in the first two years of medical training, where they are appropriately presented as the foundation of modern, scientific patient care, subsequent training in the clinical sciences often fails to fully integrate knowledge of the functional mechanisms of disease with therapeutics and prevention, emphasizing instead teaching/learning based

21st Century Medicine | 65

21st century medicine: A New Model for Medical Education and Practice

on organ system diagnosis.304 Focusing predominantly on organ system diagnosis without examining the underlying physiology that produced the patient’s signs, symptoms, and disease often leads to managing patient care by matching diagnosis to pharmacology. The job of the healthcare provider then becomes a technical exercise in finding the drug or procedure that best fits the diagnosis (not necessarily the patient), leading to a significant curtailment of critical thinking pathways: “Medicine, it seems, has little regard for a complete description of how a myriad of pathways result in any clinical state.”305

01

)2

(c

Even more important, pharmacologic treatments are often prescribed without careful consideration of their physiological effects across all organ systems and physiological processes (and genetic variations).306 Pharmaceutical companies have exploited this weakness. Did you ever see a drug ad that urged the practitioner to carefully consider the impact of all other drugs being taken by the patient before prescribing a new one? The marketing of drugs to specific specialty niches, and the use of sound bite sales pitches that suggest discrete effects, skews healthcare thinking toward this narrow, linear logic, as notably exemplified by the COX-2 inhibitor drugs that were so wildly successful on their introduction, only to be subsequently withdrawn or substantially narrowed in use due to collateral damage.307, 308

0 lM na tio d. un rve r F se fo re te ts itu h st rig In All

Core Clinical Imbalances

The functional medicine approach to assessment, both before and after diagnosis, charts a course using different navigational assumptions. Every health condition instigates a quest for information centered on understanding when and how the specific biological system(s) under examination spun out of control to begin manifesting dysfunction and/or disease. Analyzing all the elements of the patient’s story, the signs and symptoms, and the laboratory assessment through a matrix focused on functionality requires analytic thinking and a willingness on the part of the clinician to reflect deeply on underlying biochemistry and physiology. The foundational principles of how the human organism functions—and how its systems communicate and interact—are essential to the process of linking ideas about multifactorial causation with the perceptible effects we call disease or dysfunction.

ed

To assist clinicians in this process, functional medicine has adapted and organized a set of core clinical imbalances that function as the intellectual bridge between the rich basic science literature concerning physiological mechanisms of disease (first two years of medical training) and the clinical studies, clinical experience, and clinical diagnoses of the second two years of medical training. The core clinical imbalances serve to marry the mechanisms of disease with the manifestations and diagnoses of disease. Many common underlying pathways of disease are reflected in a few basic clinical imbalances:

e

in ic

 Immune/inflammatory imbalance  Energy imbalance/mitochondrial dysfunction  Digestive/absorptive and microbiological imbalance  Detoxification/biotransformation/excretory imbalance  Imbalance in structural, boundary, and membrane integrity  Hormonal and neurotransmitter imbalances  Imbalance in mind-body-spirit integration

66

| 21st Century Medicine

FUNCTIONAL MEDICINE

Using this construct, it becomes much clearer that one disease/condition may have multiple causes (i.e., multiple clinical imbalances), just as one fundamental imbalance may be at the root of many seemingly One Condition – Many Imbalances disparate conditions (see Figure 12). Inflammation

Hormones

Genetics & Epigenetics

Diet & Exercise

Mood Disorders

Diet & Exercise

Mood Disorders

One Condition – Many Imbalances

Inflammation

Hormones

Genetics & Epigenetics Obesity

Obesity

01

)2

(c

One Imbalance – Many Conditions Inflammation

0

One Imbalance – Many Conditions

lM na tio d. un rve r F se fo re te ts itu h st rig In All Inflammation Arthritis

Heart Disease

Depression

Cancer

Heart Disease

Figure 12: Core Clinical Imbalances—Multiple Influences Depression Arthritis Cancer

Diabetes

Diabetes

The most important precept to remember about functional medicine is that restoring balance—in the patient’s environmental inputs and in the body’s fundamental physiological processes—is the key to restoring health.

Constructing the Model

ed

Combining the principles, environmental inputs, fundamental physiological processes, and core clinical imbalances creates a new information-gathering-and-sorting architecture for clinical practice. This new model includes an explicit emphasis on principles and mechanisms that weld meaning and mechanistic explanations to the diagnosis and deepen the clinician’s understanding of the often overlapping ways things go wrong. Any methodology for constructing a coherent story and an effective therapeutic plan in the context of complex, chronic illness must be flexible and adaptive. Like an accordion file that can compress and expand upon demand, the amount and kind of data needed will necessarily change in accordance with the patient’s situation and the clinician’s time and ability to piece together the underlying threads of dysfunction. There are many pathways to illness; therefore, the accordion file must expand to incorporate a much larger database of relevant information. For example, the Chief Complaint, History of Present Illness, and Past Medical History sections must expand to include a thorough investigation of antecedents, triggers, and mediators. Personalized medical care without this expanded investigation will fall short.

e

in ic

Distilling the data from the expanded history, physical exam, and laboratory into a narrative story line that includes antecedents, triggers, and mediators can be challenging. Key to developing a thorough narrative

21st Century Medicine | 67

21st century medicine: A New Model for Medical Education and Practice

is organizing the story according to the seven common underlying mechanisms that influence health (the core clinical imbalances), as shown on the Functional Medicine Matrix Model™ form (see Figure 13). Oxidative/Reductive Homeodynamics

Immune Surveillance & Inflammatory Process

Digestion & Absorption

Detoxification & Biotransformation

Hormone & Neurotransmitter Regulation

The Patient’s Story Retold

Antecedents

Psychological & Spiritual Equilibrium

Triggering Events

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Nutrition Status

0

Structural & Membrane Integrity

01

)2

(c

(Predisposing)

(Activation)

Exercise

Sleep

Beliefs & Self Care

Relationships

ed

Date:______ Name:_________________ Age __________ Sex____ Diagnoses:__________________________________________

e

Figure 13: The Functional Medicine Matrix Model™ Form

in ic

©2008 The Institute for Functional Medicine

The matrix form helps organize and prioritize information, and also clarifies the level of present understanding, thus illuminating where further investigation is needed. For example, indicators of inflammation on the matrix might lead the clinician to request tests for specific inflammatory markers (such as hsCRP, interleukin levels, and/or homocysteine). Essential fatty acid levels, methylation pathway abnormalities, and organic acid metabolites help determine adequacy of dietary and nutrient intakes. Markers of detoxification (glucuronidation and sulfation, cytochrome P450 enzyme heterogeneity) can determine functional capacity for molecular biotransformation. Neurotransmitters and their metabolites (vanilmandelate, homo vanillate, 5-hydroxyindoleacetate, quinolinate) and hormone cascades (gonadal and adrenal) have obvious utility in exploring messenger molecule balance. CT scans, MRIs, or plain x-rays extend our view of the patient’s structural dysfunctions. The use of bone scans, DEXA scans, or bone resorption markers309, 310 can be useful in further exploring the web-like interactions of the matrix.

68

| 21st Century Medicine

FUNCTIONAL MEDICINE

Newer, useful technologies such as functional MRIs, SPECT or PET scans offer more comprehensive assessment of metabolic function within organ systems. It is the process of completing a comprehensive history and physical and then charting these findings on the matrix that best directs the choice of laboratory work and successful treatment. A completed matrix form facilitates the review of common pathways, mechanisms, and mediators of disease, and helps clinicians select points of leverage for treatment strategies. However, even with the matrix as an aid to synthesizing and prioritizing information, it can be very useful to consider the impact of each variable at five different levels: 1. Whole body (the “macro” level)

(c

2. Organ system

)2

3. Metabolic or cellular

01

4. Subcellular/mitochondrial

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

5. Subcellular/gene expression

Therapies should be chosen for their potential impact on the most central imbalances of the particular patient. Evaluating interventions that are available at each of the five levels can help to identify a reasonably comprehensive set of options from which to choose. The following lists incorporate only a few examples of various types of interventions within these five different levels.

ed

1. Whole body interventions: Because the human organism is a complex adaptive system, with countless points of access, interventions at one level will affect points of activity in other areas as well. For example, improving the patient’s sleep will beneficially influence the immune response, melatonin levels, T cell lymphocyte levels, and will help to decrease oxidative stress. Exercise reduces stress, improves insulin sensitivity, and improves detoxification. Reducing stress (and/or improving stress management) can reduce cortisol levels, improve sleep, improve emotional well being, and reduce the risk of heart disease. Changing the diet can have myriad effects on health, from reducing inflammation to reversing coronary artery disease.

e

in ic

2. Organ system interventions: These interventions are used more frequently in the acute presentation of illness. Examples include splinting; draining lesions; repairing lacerations; reducing fractures, pneumothoraxes, hernias or obstructions; or removing a stone to reestablish whole organ function. There are many interventions that improve organ function. For example, bronchodilators improve air exchange, thereby decreasing hypoxia, reducing oxidative stress, and improving metabolic function and oxygenation in a patient with reactive airway disease.

21st Century Medicine | 69

21st century medicine: A New Model for Medical Education and Practice

)2

(c

3. Metabolic or cellular interventions: Cellular health can be addressed by insuring the adequacy of macronutrients, essential amino acids, vitamins, and cofactor minerals in the diet (or, if necessary, from supplementation). An individual’s metabolic enzyme polymorphisms can profoundly affect his or her nutrient requirements. For example, adding conjugated linoleic acid (CLA) to the diet can alter the PPAR system, affect body weight, and modulate the inflammatory response.311, 312, 313 However, in a person who is diabetic or insulin resistant, adding CLA may induce hyperinsulinemia, which is detrimental.314, 315 Altering the types and proportions of carbohydrates in the diet may increase insulin sensitivity, reduce insulin secretion, and fundamentally alter metabolism in the insulin-resistant patient. Supporting liver detoxification pathways with supplemental glycine and N-acetylcysteine improves the endogenous production of adequate glutathione, an essential antioxidant in the central nervous system and GI tract.

01

4. Subcellular/mitochondrial interventions: There are many examples of mitochondrial nutrient support interventions.316, 317 Inadequate iron intake causes oxidants to leak from mitochondria, damaging mitochondrial function and mitochondrial DNA. Making sure there is sufficient iron helps alleviate this problem. Inadequate zinc intake (found in >10% of the U.S. population) causes oxidation and DNA damage in human cells.318 Insuring the adequacy of antioxidants and cofactors for the at-risk individual must be considered in each part of the matrix. Carnitine, for example, is required as a carrier for the transport of fatty acids from the cytosol into the mitochondria, improving the efficiency of beta oxidation of fatty acids and resultant ATP production. In patients who have lost significant weight, carnitine undernutrition can result in fatty acids undergoing omega oxidation, a far less efficient form of metabolism.319 Patients with low carnitine may also respond to riboflavin supplementation. 320

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

ed

5. Subcellular/gene expression interventions: Many compounds interact at the gene level to alter cellular response, thereby affecting health and healing. Any intervention that alters NFκB entering the nucleus, binding to DNA, and activating genes that encode inflammatory modulators such as IL-6 (and thus CRP), cyclooxygenase 2, IL-1, lipoxygenase, inducible nitric oxide synthase, TNF-α, or a number of adhesion molecules will impact many disease conditions.321, 322 There are many ways to alter the environmental triggers for NFκB, including lowering oxidative stress, altering emotional stress, and consuming adequate phytonutrients, antioxidants, alpha-lipoic acid, EPA, DHA, and GLA.323 Adequate vitamin A allows the appropriate interaction of vitamin A-retinoic acid with over 370 genes.324 Vitamin D in its most active form intercalates with a retinol protein and the DNA exon and modulates many aspects of metabolism including cell division in both healthy and cancerous breast, colon, prostate, and skin tissue.325 Vitamin D has key roles in controlling inflammation, calcium homeostasis, bone metabolism, cardiovascular and endocrine physiology, and healing.326

e

in ic

Experience using this model, along with improved pattern-recognition skills, will often lessen the need for extensive laboratory assessments. There will always be, however, certain clinical conundrums that simply cannot be assessed without objective data and, for most patients, there may be an irreducible minimum of laboratory assessments required to accumulate information. For example, in the clinical workup of autistic spectrum disorders in children, heavy metal exposure and toxicity may play an important role. Heavy metal body burden cannot be sensibly assessed without laboratory studies. Another example is

70

| 21st Century Medicine

FUNCTIONAL MEDICINE

in the context of the progressive, ongoing workup. When clinical acumen and educated steps in both assessments and therapeutic trials do not yield expected improvement, lab testing often provides rewarding information when focused on the unexpected outcomes in the progressive workup. This is frequently the context for focused genomic testing. In most initial workups, lab and imaging technologies can be reserved for those complex cases where the initial interventions prove insufficient to the task of functional explication.

01

)2

(c

Even using the functional medicine model that has been reviewed here, no single practitioner—and no single discipline—can cover all the viable therapeutic options. Interventions will differ by training, licensure, specialty focus, and even by beliefs and ethnic heritage. However, all healthcare disciplines (and all medical specialties) can—to the degree allowed by their training and licensure—use a functional medicine approach, including integrating the matrix as a basic template for organizing and coupling knowledge and data. So, functional medicine can provide a common language and a unified model to facilitate integrated care. Regardless of what discipline the primary care provider has been trained in, developing a network of capable, collaborative clinicians with whom to co-manage challenging patients and to whom referrals can be made for therapies outside the primary clinician’s own expertise will enrich patient care and strengthen the clinician-patient relationship.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Part II: The Healing Partnership— A Synthesis of the Art and Science of Medical Practice We form partnerships to achieve an objective. For example, a business partnership forms to engage in commercial transactions for financial gain; a marriage partnership forms to build a caring, supportive home-centered environment. A healing partnership forms to heal the patient through the integrated application of both the art of medicine (insight driven) and the science of medicine (evidence driven). An effective partnership requires that trust and rapport be established. Patients must feel comfortable telling their stories and revealing intimate information and significant events.

ed

The characteristics of a therapeutic encounter are fundamentally different from a healing partnership, and each emerges from specific emphases in training. In the therapeutic encounter, the relationship forms to assess and treat a medical problem using (usually) an organ system structure, a differential diagnosis process, and a treatment toolbox focused on pharmacology and medical procedures. The therapeutic encounter pares down the information flow between physician and patient to the minimum needed to identify the organ system domain of most probable dysfunction, followed by a sorting system search (the differential diagnosis heuristic). The purpose of this relationship is to arrive at the most probable diagnosis as quickly as possible and select an intervention based on probable efficacy. The relationship is a left brain-guided conversation controlled by the clinician, steeped in Bayesian statistics (EBM), and characterized by algorithmic processing and statistical thinking.327, 328

e

in ic

The functional medicine healing partnership forms with a related but broader purpose: to help the patient heal by identifying the underlying mechanisms and influences that initiated and continue to mediate the patient’s illness(es). This type of relationship emphasizes a shared responsibility for both identifying the causes of the patient’s condition and achieving insight about enduring solutions. The healing partnership is critical to the delivery of personalized, systems medicine, and to manage the uncertainty (choices under risk)

21st Century Medicine | 71

21st century medicine: A New Model for Medical Education and Practice

inherent in clinical practice. Here, in the healing partnership, we find the appropriate utilization and integration of left-brain and right-brain functions. Germane to this discussion, Dr. Jerome Groopman—quoted previously in Chapter 4—states: So a thinking doctor returns to language: “Tell me the story again as if I’d never heard it—what you felt, how it happened, when it happened.”329

In language, we have the fullest expression of the integration of left- and right-brain function. Language is so complex that the brain has to process it in different ways simultaneously—both denotatively and connotatively. For complexity and nuance to emerge in language, we need the left brain to see the trees, the right brain to help us see and understand the forest.330, 331

01

)2

(c

To grasp the profound importance of the healing partnership to the creation of a system of medicine adequate to the demands of the 21st century, we need to briefly address the nature of healing and its role in the therapeutic relationship. We have noted an emerging body of research in this area.332, 333, 334 As Louise Acheson, MD, MS, Associate Editor for the Annals of Family Practice, articulated recently in that journal335:

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

It is challenging to research this ineffable process called healing…. Hsu and colleagues asked focus groups of nurses, physicians, medical assistants, and randomly selected patients to define healing and describe what facilitates or impedes it.336 The groups arrived at surprisingly convergent definitions: “Healing is a dynamic process of recovering from a trauma or illness by working toward realistic goals, restoring function, and regaining a personal sense of balance and peace.” They heard from diverse participants that “healing is a journey” and “relationships are essential to healing.”

ed

In the 20th century, contemporary medicine, traditionally considered a healing profession, evolved away from the role of healer of the sick to that of curing disease through modern science. Research into this transition reveals that healing was/is associated with themes of wholeness, narrative, and spirituality. Professionals and patients alike report healing as an intensely personal, subjective experience involving a reconciliation of meaning for an individual and a perception of wholeness. The biomedical model as currently configured no longer encompasses these traditional characteristics for practitioners. Healing in a holistic sense has faded from medical attention and is rarely discussed in biomedical research reports. Contemporary medicine considers the wholeness of healing to be beyond its orthodoxy—the domain of the nonscientific and nonmedical.337

e

in ic

Research into the role of healing in the medical environment has recently generated some thoughtful and robust investigations. John Scott and his co-investigators’ research into the healing relationship found very similar descriptions to those of Hsu’s group, mentioned above. The participants in the study338 articulated aspects of the healing partnership as: 1. Valuing and creating a nonjudgmental emotional bond 2. Appreciating power and consciously managing clinician power in ways that would most benefit the patient 3. Abiding and displaying a commitment to caring for patients over time

72

| 21st Century Medicine

FUNCTIONAL MEDICINE

Three relational outcomes result from these processes: trust, hope, and a sense of being known. Clinician competencies that facilitate these processes are self-confidence, emotional self-management, mindfulness, and knowledge.339 In this rich soil, the healing partnership flourishes. The starting point for creating a healing partnership is the patient’s experience: People, not diseases, can heal. The integration of brain science research discussed in Chapter 4—to frame and apply right- and left-brain functions to create a mindful, insightful context—enhances the healing partnership during the therapeutic encounter. Mindful integration of brain function is at the heart of a healing partnership. Some of the basic steps for establishing a healing partnership include:

01

)2

(c

1. Allow patients to express, without interruption,xvii their story about why they have come to see you. (This is an elaboration of the Chief Complaint and Present Illness.) The manner in which the patient frames the initial complaints often presages later insight into the root causes. Any interruption in this early stage of narrative moves the patient back into left-brain processing and away from insight.340

0

2. After focusing on the main complaint, encourage the patient’s narrative regarding their present illness(es). Clarifications can be elicited by further open-ended questioning (e.g., “tell me more about that”; “what else do you think might be going on?”). During this portion of the interview, there is a switching back and forth between right- and left-brain functions.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

• During this conversation, signs and symptoms of the present illness are distributed by the practitioner into the Functional Medicine Matrix Model form, according to the functional medicine heuristic sorting system described in Chapter 4. • The parsing is determined by an assessment of probable underlying causes—based on the robust research evidence base about common underlying mechanisms of disease—and ongoing mediators of the disease.

ed

3. Next, convey to the patient in the simplest terms possible that to achieve lasting solutions to the problem(s) for which he/she has come seeking help, a few fundamental questions must be asked and answered in order to understand the problem in the context of the patient’s personal life. This framing of the interview process moves the endeavor from a left-brain compilation to a narrative that encourages insight—based on complex pattern recognition— about the root causes of the problem.

e

in ic

4. Explaining the structure of the next step helps the patient participate in a journey of exploration about their illness—and their search for health. At this stage, partial control is handed over to the patient with the statement: “Without your help, we cannot understand your medical problem in the depth and breadth you deserve.” Leo Galland, MD originally articulated the structure for the patient’s part of the investigation in his antecedents/triggers/mediators schema (ATM model).341 (An excerpt from his outstanding chapter on this topic in the Textbook of Functional Medicine is included in the Appendix.)

xvii

Research focused on the therapeutic encounter has repeatedly found that clinicians interrupt the patient’s flow of conversation within the first 18 seconds or less, often denying the patient an opportunity to finish. (Beckman DB, et al. The effect of physician behavior on the collection of data. Ann Intern Med. 1984;101:692-96.)

21st Century Medicine | 73

21st century medicine: A New Model for Medical Education and Practice

a) For determining antecedent conditions, the following questions are very useful: • When was the present problem not a problem? When were you free of this problem? • What were the circumstances surrounding the appearance of the problem? • Have similar problems appeared in family members? b) For triggers, the following question is critical:

)2

(c

• What conditions, activities, or events seemed to initiate the problem? (Microbes and stressful personal events are examples, but illustrate quite different categories of triggers. Triggers by themselves are usually insufficient for disease formation, so triggers must be viewed within the context of the antecedent conditions.)

01

c) Mediators of the problem are influences that help perpetuate it.

0

• There can be specific mediators of diseases in the patient’s activities, lifestyle, and environment. Many diverse factors can affect the host’s response to stressors.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

• Any of the core clinical imbalances, discussed above and shown on the Functional Medicine Matrix Model, can transform what might have been a temporary change in homeostasis into a chronic allostatic condition. It helps at this juncture to emphasize again that the following issues are elemental in forming a healing partnership:  Only the patient can inform the partnership about the conditions that provided the soil from which the problem(s) under examination emerge(s). The patient literally owns the keys to the joint deliberation that can provide insight about the process of achieving a healing outcome.

ed

 The professional brings experience, wisdom, tools, and techniques that can be applied to the journey of healing. The professional also works to create the context for a healing insight to emerge.

in ic

e

 The patient’s information, input, mindful pursuit of insight, and engagement become “the horse before the cart.” The cart carries the clinician—the person who guides the journey using evidence, experience, and judgment, and who contributes the potential for expert insight. The crux of the healing partnership is an equal investment of focus by both clinician and patient. They work together to identify the right places to apply leverage for change. Patients must commit to engage both their left-brain skills and their right-brain function to inform and guide the exploration to the next steps in assessment, therapy, understanding, and insight. Clinicians must also engage both the left-brain computational skills and the right-brain pattern-recognition functions that, when used together, can generate insight about the patient’s story.

74

| 21st Century Medicine

FUNCTIONAL MEDICINE

Two patient case studies (presented below by Dr. Jones) provide a glimpse into a functional medicine practice and the healing partnership that is necessary for success. The Appendix contains a form developed by IFM faculty for enhancing the pattern-recognition process in ulcerative colitis, and two additional cases with a comprehensive, detailed presentation of the use of the Matrix. Patient #1: Kikuchi syndrome in an 18 year old female—insight from the healing partnership

01

)2

(c

Lila was an 18-year-old female transitioning from high school to college, who during the intervening summer experienced rapid onset of unexplained fever, profound fatigue, and lymphadenitis, especially pronounced in the cervical region. Her extended family included physicians, one who lived locally and led the initial investigation. The differential included lymphoma; because of the seriousness of this possible diagnosis, a biopsy of the enlarged cervical lymph nodes was completed expeditiously. Fortunately, the biopsy was more consistent with Kikuchi syndrome than lymphoma. The pathology of Kikuchi is a histocytic necrotizing lymphadenitis. Her ANA was positive at 1:320, speckled. Kikuchi syndrome is presumed to be an immune response of T cells and histiocytes to an infectious agent, probably viral. At this point, I was asked to consult with the patient and her parents.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

ed

The patient was articulate, intelligent (she had been accepted to Harvard), and appeared recovered from the acute phase of her illness. Her father and mother were both present during the consultation. Lila was asked to narrate her story. During the telling of her story, I sorted her symptoms and signs using the FM Heuristic (Chapter 4) and the Functional Medicine Matrix Model (discussed above). At the end of recounting of her story, I explained to her and her parents the functional medicine sorting system, postulating that what we now knew from the history, lab results, and the biopsy was that Lila’s immune system had probably been activated by a triggering agent (e.g., microbe, toxicant). I explained that our job now required forming a partnership, using Lila’s and her parents’ experiences through this episode of illness and my experience with immunemediated illnesses to build a hypothetical story together.

e

in ic

I further explained that we would need to consider the conditions in Lila’s family and “habits of living” history that could be antecedent to her illness. I explained that we would then move to the possible triggers in her recent past that might be causal or correlative in the acute expression of her illness. I explained that once an acceptable model emerged from our joint inquiry into the antecedents and triggers of her present illness, we would evaluate the possible probes that might elicit further information or generate treatment plans. They agreed to work together with me using this partnering model. They were not aware of any exceptional family history of autoimmune or other immune dys-regulatory illnesses. The family’s lifestyle, including eating and exercise habits, was laudable. We next addressed the issues of triggers. We knew from reading research sources on Kikuchi syndrome that the most common cause of the lymphadenitis associated with the syndrome was a microbe trigger. The parents were hopeful that we could perform lab analyses for a host of potential viral agents. Lila interrupted her parents at this point to advocate for quite a different possible cause.

21st Century Medicine | 75

21st century medicine: A New Model for Medical Education and Practice

Lila recounted that she had been seen in the regional dermatologic referral center for her worsening acne vulgaris. The treatment recommended by the consulting dermatologist was a sulfa-containing antibiotic. Before coming for consultation in my clinic, Lila had posited to her dermatologist and her primary care physician that her lymphadenitis was an adverse drug reaction. She and her parents had been told that the severity of her illness, if caused by a drug reaction, would necessarily be accompanied by a rash; she, however, was absent a rash. She had been advised to continue her antibiotic. Her parents retreated from this inquiry in the face of the authoritative disclaimer by both the specialist and the family doctor.

01

)2

(c

However, Lila did not retreat from her insight. We discussed her intuition (insight) and her reasoning. On the basis of her hypothesis, we jointly finalized a plan that included abstinence from her antibiotic. I advised against a planned back-packing trip to Mexico because of possible toxicant exposures in that environment that might confound her clinical story. We chose to call this a therapeutic probe with my added advice regarding follow-up. (We planned a low allergy diet and detoxification program IF the simple step of removing the triggering agent proved to be an insufficient intervention.)

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

That evening, I received an email from Lila with the following graph of her illness:

Kikuchi/Sulfa Timeline

Began 6/16

10pm 7/12

2pm 7/21

ed

10.00 8.00 6.00 4.00 2.00 0.00

7/7

6/30

7/7

Bumps appear 6/21 KEY:

e

6/23

in ic

6/16

7/14

7/21

7/28

Initiation of taking sulfa drug Single re-initiation of sulfa drug Stopped taking sulfa drug

Outcome: Lila has been asymptomatic following continued abstinence from the sulfacontaining antibiotic. She has started her first semester at Harvard. The student health center physician became very interested in her story and has provided regular follow up, including lab. Her ANA titer has slowly returned to normal. No further interventions have been required. She has sought non-pharmacologic treatment interventions for her acne.

76

| 21st Century Medicine

FUNCTIONAL MEDICINE

Patient #2: Ulcerative Colitis in a 45 year old female— providing a context for insight

01

)2

(c

The next case illustrates the use of this same model: the pursuit of an antecedent and/or initial trigger for illness (these categories often overlap considerably)—that is, we looked for causes underneath the surface explanations for her condition. This 45-year-old female presented at my office for IBS and diverticulitis with a recent history of hemicolectomy for infectious colitis. The patient’s primary residual postsurgical complaints were diffuse abdominal pain and loose stooling alternating with constipation. The review of her present illness revealed a history since her mid-twenties of “gut problems” (her words), including intermittent loose stools with alternating constipation. She had also over the years become intolerant of a plethora of foods. As a result, she had received thorough work-ups for food allergies and intolerances and was trying to follow a rather patchwork diet plan in response to these previous lab evaluations. She had received imaging and endoscopic procedures. However, she had not had follow-up colonoscopy since her surgery. We discussed the need to do follow-up endoscopy to evaluate her present symptoms (to rule out possible post-surgical adhesions complicating stool passage).

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

The conversation soon shifted into the ATM (antecedents, triggers, and mediators) portion of the investigation. After describing the joint responsibilities for a deeper understanding (insight) regarding her GI maladies, we moved to the questions regarding antecedents for her condition. She denied any family history of similar GI illnesses in her siblings. I then asked the question: “When was the present problem not a problem? That is, when were you free of the problem and what were the circumstances of the problem’s first appearance?”

ed

At this point, our conversation stopped. She looked a bit flummoxed and asked to consider the question further and more fully answer it when she next returned. At her next appointment, she returned to the question, stating that she wanted to share an experience that preceded her first episode of GI irritability. She said that she had not shared this story with any physician before in the context of the clinical workups for her GI problems. She then told the following story:

e

in ic

I left home at an early age to escape my father. He sexually abused me and my sisters. There did not seem to be any way to stop him; my mother seemed powerless, even when she walked into an abusive episode. In desperation, I left my sisters and my family, married and moved away. My mother called me one afternoon, years after my leaving home. By that time I was a mother myself, having married and started my own family. My mother was quite upset and related that one of my sisters had arrived at her door, confronting her with the accusation of my father’s sexual abuse of her in childhood and the lack of protection by our mother. My mother was adamant in her denial of knowledge of such wrongdoing by my father (my father had died in the intervening years since my leaving home). I was silent for a moment on the phone with my mother. I then made a choice to placate my mother; I responded to her distress with a lie: “Mother, you know how my sister is; she is so hysterical.”

21st Century Medicine | 77

21st century medicine: A New Model for Medical Education and Practice

My response seemed to settle my mother down. However, now that you have asked, this was the beginning of my gut problems. I stuffed that lie about our childhood with our father deep down into my gut and my gut has not been normal since.

(c

Outcome: My patient’s therapy for her GI problems has been guided by both this insight regarding the origins of her illness as well as by my professional expertise in the area of both mind-body connections and GI physiology. Her therapeutic interventions focused on the 4R functional medicine approach to GI dysfunctions342 and EMDR psychotherapeutic modalities developed for PTSD343 (an approach that has emerged from work with returning GIs from the Gulf War and the Afghanistan and Iraq conflicts). She now reports no further problems referable to her GI tract.

01

)2

Our healing partnership helped elicit the insights that focused our attention on a fundamental issue that was critical to her healing. Without the supportive, mindful context that encouraged her insight to emerge, we would not have had the comprehensive patient story that was necessary for resolution of her problems. In this journey together, both left-brain computation (clinical and scientific evidence about the importance of the 4R GI dysfunction program and EMDR therapy in the context of PTSD) and right-brain functionality (a context for insight) were necessary.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

As described in Chapter 4, insight researchers call this “aha” experience the moment of categorical insight. The epiphany registers as a new pattern of neural activity in the prefrontal cortex. The brain cells have been altered by the breakthrough. An insight is a restructuring of information—it’s seeing something in a completely new way. Once that restructuring occurs, you never go back.344

Summary

ed

At The Institute for Functional Medicine (IFM) we believe that functional medicine exemplifies a systemsoriented, personalized medicine that recognizes the common underlying mechanisms of complex and chronic diseases that cut across multiple organ systems to shape a patient’s trajectory toward health or disease. IFM’s model of comprehensive care and primary prevention for complex, chronic illnesses is grounded in both science (the Functional Medicine Matrix Model; evidence about common underlying mechanisms and pathways of disease; evidence about effective approaches to the environmental and lifestyle sources of disease) and art (the healing partnership and the search for insight in the therapeutic encounter). We have shown how this approach offers both a conceptual model and pragmatic tools that help to integrate the best of emerging models in both conventional and integrative medicine. When practiced with an explicit emphasis on the importance of pattern-recognition and heuristic competencies inherent to right-brain function, a healing partnership can flourish, insight can be achieved, and a broad array of assessment and therapeutic tools can be utilized. We can produce a mindful medical practice paradigm shift that can encompass the uniqueness of each person, deriving probabilities that are clinically meaningful.

e

in ic

78

| 21st Century Medicine

FUNCTIONAL MEDICINE

As articulated in Gerd Gigerenzer’s thoughtful book, Rationality for Mortals: How People Cope with Uncertainty, heuristic processing (right brain) and statistical thinking (left brain) are “complementary mental tools, not mutually exclusive strategies; our minds need both.”345 Through this uniting of competencies, we can incorporate the strengths of both science and art to craft an effective, personalized, and integrative approach to patient care. Without both elements steadily at work, we will find it exceptionally difficult to address successfully the epidemic of chronic disease that is the challenge of 21st century medicine.

What’s Ahead?

01

)2

(c

Over the past few years, 33 medical schools and graduate nutrition programs plus 13 medical residency programs have sent attendees for training with IFM. These faculty, residents, fellows, and students have returned to their home institutions as strong advocates for functional medicine. They have helped to guide us toward key decision makers and have coached us on useful strategies. Thanks to these relationships, significant progress has been made to introduce functional medicine into medical schools and residency programs. Early funding has been secured and strategies, timelines, delivery formats (grand rounds, guest lectures, Webinars, print/online course materials), faculty training, and other issues are now being worked out.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Several elective courses in functional medicine have already been offered or are in the planning stages. As we bring the current discussion to a close, we’d like to reiterate that the ultimate goal of this entire project is to inspire system-wide change. We look forward to a transformation in health professions education and clinical practice that will help us conquer the 21st century challenge of chronic disease with as much efficacy as the 20th century brought to acute care. The change is imminent, it is urgently needed, and it is entirely possible.

ed e

in ic 21st Century Medicine | 79

21st century medicine: A New Model for Medical Education and Practice

References

Swen JJ, Huizinga TW, Gelderblom H, et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Medicine. August 2007 | Volume 4 | Issue 8 | e209. 25 Snyderman R, Williams RS. Prospective medicine: The next health care transformation. Acad Med. 2003;78:1079-84. 26 Snyderman R, Langheier J. Prospective health care: the second transformation of medicine. Genome Biol. 2006;7(2):104.1-104.8. 27 Syderman R, Yoediono Z. Prospective health care and the role of academic medicine: Lead, follow, or get out of the way. Acad Med. 2008;83(8):707-714. 28 Johns MME, Brigham KL. Transforming health care through prospective medicine: The first step. Acad Med. 2008;83(8):706. 29 Wagner EH, Austin BT, Davis C, et al. Improving chronic illness care: translating evidence into action. Health Affairs. 2001;20(6):64-78. 30 Mutch DM, Wahli W, Williamson G. Nutrigenomics and nutrigenetics: the emerging faces of nutrition. FASEB J. 2005;19:160216. 31 Montgomery K. How Doctors Think: Clinical Judgment and the Practice of Medicine. Oxford University Press: New York, NY, 2006. Ch. 2. 32 Groopman J. How Doctors Think. Houghton Mifflin: New York, 2007-2008. Pp. 236-239. 33 Montgomery K. How Doctors Think: Clinical Judgment and the Practice of Medicine. Oxford University Press: New York, NY, 2006. P. 90. 34 http://www.imconsortium.org/ 35 Racaniello VR. Emerging infectious disease. J Clin Investigation, 2004;113(6):796-8. 36 Johns MME, Brigham KL. Transforming health care through prospective medicine: The first step. Acad Med. 2008;83(8):706. 37 Ely JW, Osheroff JA, Gorman PN, et al. A taxonomy of generic clinical questions: classification study. BMJ. 2000;321:429-32. 38 Holman H. Chronic disease—The need for a new clinical education. JAMA. 2004;292(9):1057-1059. 39 American College of Physicians. The Impending Collapse of Primary Care Medicine and its Implications for the State of the Nation’s Health Care: A Report from the American College of Physicians. January 30, 2006. 40 Overholt A. Health and the profit motive. FastCompany.com. Accessed at http://www.fastcompany.com/node/46025/print. 41 Bodenheimer T. Uneasy alliance. Clinical investigators and the pharmaceutical industry. N Engl J Med. 2000;342(20):1539-44. 42 Freemantle N. Stocken D. The commercialization of clinical research: who pays the piper, calls the tune? Fam Pract. 2004;21:335-6. 43 Angell M. Is academic medicine for sale? N Engl J Med. 2000;342(20):1516-18. 44 Ross LF, Norton JW, Young SA, et al. Is academic medicine for sale? Letters responding to Angell’s editorial of that title. N Engl J Med. 2000;343(7):508-10. 45 Bodenheimer T. Uneasy alliance. Clinical investigators and the pharmaceutical industry. N Engl J Med. 2000;342(20):1539-44. 46 Kramarow E, Lubitz j, Lentzner H, Gorina Y. Trends in the health of older Americans, 1970-2005. Health Affairs. 2007;25(5):1417-25. 47 Gregg EW, Cheng YJ, Cadwell BL, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA. 2005;293(15):1868-74Gregg EW, Cheng YJ, Cadwell BL, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA. 2005;293(15):1868-74. 48 _____The high cost of health care (editorial). The New York Times, November 25, 2007. Accessed at http://www.nytimes. com/2007/11/25/opinion/25sun1.html. 49 Ely JW, Osheroff JA, Gorman PN, et al. A taxonomy of generic clinical questions: classification study. BMJ. 2000;321:429-32. 24

Walter Freeman How Brains Make Up Their Minds. 2000. Columbia University Press. 2 Peter Dayan, L. F. Abbott. Theoretical Neuroscience: Computational and Mathematical Modeling of Neural Systems. The MIT Press; 2005. 3 Roland Baddeley (Editor), Peter Hancock (Editor), Peter Földiák (Editor). Information Theory and the Brain. Cambridge University Press. 2008. 4 Eric R. Kandel In Search of Memory: The Emergence of a New Science of Mind, W. W. Norton; 2007. 5 Roberto Cabeza (Editor), Alan Kingstone (Editor). Handbook of Functional Neuroimaging of Cognition The MIT Press; 2 edition, 2006. 6 Henry P. Stapp. Mindful Universe: Quantum Mechanics and the Participating Observer (The Frontiers Collection) Springer; 1 edition 2007. 7 Chronic Disease and Health Promotion. Centers for Disease Control, November 2008. Accessed at http://www.cdc.gov/NCCdphp/ overview.htm. 8 http://www.ted.com/index.php/talks/jill_bolte_taylor_s_powerful_ stroke_of_insight.html (1/1/09) 9 Bodenheimer T, Chen E, Bennett H. Confronting the growing burden of chronic disease: can the U.S. health care workforce do the job? Health Affairs. 2009;28(1):64-74. 10 Voelker R. US health care system earns poor marks. JAMA. 2008;300(24):2843-4. 11 O’Toole TE, Conklin DJ, Bhatnagar A. Environmental risk factors for heart disease. Rev Environ Health. 2008;23(3):167-202. 12 Pan SY, DesMeules M. Energy intake, physical activity, energy balance, and cancer: epidemiologic evidence. Methods Mol Biol. 2009;472:191-215. 13 Egger G, Dixon J. Should obesity be the main game? Or do we need an environmental makeover to combat the inflammatory and chronic disease epidemics? Obes Rev. 2009;10(2):237-49. 14 Goetzel RZ. Do prevention or treatment services save money? The wrong debate. Health Affairs. 2009;28(1):37-41. 15 Bodenheimer T, Chen E, Bennett H. Confronting the growing burden of chronic disease: can the U.S. health care workforce do the job? Health Affairs. 2009;28(1):64-74. 16 Snyderman R, Williams RS. Prospective medicine: The next health care transformation. Acad Med. 2003;78:1079-84. 17 Partnership for Solutions. Chronic Conditions: Making the Case for Ongoing Care. A Project of Johns Hopkins University and The Robert Wood Johnson Foundation. September 2004. Available at http://www. partnershipforsolutions.org/DMS/files/chronicbook2004.pdf. 18 American College of Physicians. The impending collapse of primary care medicine and its implications for the state of the nation’s health care. A report from the American College of Physicians, January 30, 2006. Available at http://www.acponline.org/advocacy/events/ state_of_healthcare/statehc06_1.pdf. 19 Thorpe KE. The rise in health care spending and what to do about it. Health Aff. 2005;24(6):1436-45. 20 Groopman J. How Doctors Think. Houghton Mifflin: New York, 2007-2008. Pp. 151-155. 21 Johns MME, Brigham KL. Transforming health care through prospective medicine: The first step. Acad Med. 2008;83(8):706. 22 McKinnon RA, Ward MB, Sorich MJ. A critical analysis of barriers to the clinical implementation of pharmacogenomics. Ther Clin Risk Manag. 2007;3(5):751-9. 23 Issa AM. Personalized medicine and the practice of medicine in the 21st century. McGill J Med. 2007 10(1):53-57. 1

01

)2

(c

0

e

in ic

| 21st Century Medicine

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

80

REFERENCES

Thorpe KE, Florence CS, Howard H, Joski.P. The rising prevalence of treated disease: effects on private health insurance spending. Health Affairs, Web exclusive, June 27, 2005. 51 _____The high cost of health care (editorial). The New York Times, November 25, 2007. Accessed at http://www.nytimes. com/2007/11/25/opinion/25sun1.html. 52 Strunk BC, Ginsburg PB, Gabel JR. Tracking health care costs: hospital care surpasses drugs as they key cost driver. Health Affairs, Web exclusive, September 26, 2001. 53 Lichtenberg FR. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Affairs. 2001;20(5):241-51. 54 Appleby J. Prices for some drugs skyrocket. USA Today, August 7, 2008. Accessed at http://www.usatoday.com/money/industries/ health/drugs/2008-08-07-costlydrugs_N.htm. 55 Thorpe KE, Florence CS, Joski.P. Which medical conditions account for the rise in health care spending? Health Affairs, Web exclusive, August 25, 2004. 56 Thorpe KE, Florence CS, Howard H, Joski.P. The rising prevalence of treated disease: effects on private health insurance spending. Health Affairs, Web exclusive, June 27, 2005. 57 DeVol R, Bedroussian A. An Unhealthy America: The Economic Burden of Chronic Disease. The Milken Institute, October 2007. 58 Dr. Gerard Anderson, Partnership for Solutions, “Medicare and Medicaid Are Programs for People with Chronic Illness … But Do Not Know It,” presentation to General Accounting Office, February 5, 2004; Partnership for Solutions, Chronic Conditions: Making the Case for Ongoing Care, December 2002; Medicare spending data from U.S. Department of Health and Human Services. 59 Bureau of Labor Education, University of Maine. The U.S. Health Care System: Best in the world, or just the most expensive? Summer, 2001. 60 The Commonwealth Fund Commission on a High Performance Health System. Why Not the Best? Results from the national scorecard on U.S. health system performance, July 2008. 61 Morrissey S, Curfman GD, Drazen JM. Health of the nation— coverage for all Americans. N Engl J Med. 2008;259(8);855-6. 62 The Commonwealth Fund Commission on a High Performance Health System. Why Not the Best? Results from the national scorecard on U.S. health system performance, July 2008. 63 Willett WC. Balancing life-style and genomics research for disease prevention. Science. 2002; 296:695-97. 64 Thorpe KE, Florence CS, Howard H, Joski.P. The rising prevalence of treated disease: effects on private health insurance spending. Health Affairs, Web exclusive, June 27, 2005. 65 Heaney RP. Long-latency deficiency disease: insights from calcium and vitamin D. Am J Clin Nutr 2003;78:912–9. 66 Racaniello VR. Emerging infectious disease. J Clin Investigation, 2004;113(6):796-8 67 Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5. 68 Sørensen JM. Herb-drug, food-drug, nutrient-drug, and drug-drug interactions: mechanisms involved and their medical implications. J Altern Complement Med. 2002 Jun;8(3):293-308. 69 Huang CF, Lin SS, Liao PH, et al. The Immunopharmaceutical effects and mechanisms of herb medicine. Cell Mol Immunol. 2008;5(1):23-31. 70 Sørensen JM. Herb-drug, food-drug, nutrient-drug, and drug-drug interactions: mechanisms involved and their medical implications. J Altern Complement Med. 2002 Jun;8(3):293-308. 71 Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5. 50

01

)2

(c

0

The Commonwealth Fund Commission on a High Performance Health System. Why Not the Best? Results from the national scorecard on U.S. health system performance, July 2008. 73 Zetin M, Hoepner CT, Bjornson L. Rational antidepressant selection: Applying evidence-based medicine to complex real-world patients. Psychopharmacol Bull. 2006;39:38-104. 74 Hordijk-Trion M, Lenzen M, Wijns W, Peter de Jaegere P, et al. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. Eur Heart J. 2006;27:671-8. 75 Mengis C, Aebi S, Tobler A, Dahler W, Fey MF. Assessment of differences in patient populations selected for or excluded from participation in phase III acute myelogenous leukemia trials. J Clin Oncology. 2003;21(21):3933-9. 76 Hedaya R, Quinn S. Depression: Advancing the Treatment Paradigm. The Institute for Functional Medicine; Gig Harbor, WA: 2008. 77 Jones DS. Changing the evidence model. Chapter 5 in Textbook of Functional Medicine (DS Jones, ed). The Institute for Functional Medicine; Gig Harbor, WA: 2005. 78 Ramos RG, Olden K. Gene-environment interactions in the development of complex disease phenotypes. Int J Environ Res Public Health. 2008;5(1):4-11. 79 Lakdawalla DN, Goldman DP, Shang B. The health and cost consequences of obesity among the future elderly. Health Affairs, September 26, 2005 (Web exclusive). 80 Kumanyika SK, Obarzanek E, Stettler N, Bell R, et al. Populationbased prevention of obesity. The need for comprehensive promotion of healthful eating, physical activity, and energy balance. Circulation. 2008;118:428-64. 81 Kivimäki M, Virtanen M, Elovainio M, Kouvonen A, Väänänen A, Vahtera J. Work stress in the etiology of coronary heart disease--a meta-analysis. Scand J Work Environ Health. 2006 Dec;32(6):431-42. 82 Gareau MG, Silva MA, Perdue MH. Pathophysiological mechanisms of stress-induced intestinal damage. Curr Mol Med. 2008 Jun;8(4):27481. 83 Logan JG, Barksdale DJ. Allostasis and allostatic load: expanding the discourse on stress and cardiovascular disease. J Clin Nurs. 2008 Apr;17(7B):201-8. 84 Lakdawalla DN, Goldman DP, Shang B. The health and cost consequences of obesity among the future elderly. Health Affairs, September 26, 2005 (Web exclusive). 85 Hedaya RJ. Stress, spirituality, poverty and community—effects on health. Chapter 33 in Jones DS (Ed), Textbook of Functional Medicine. The Institute for Functional Medicine, Gig Harbor, WA: 2005. 86 The Commonwealth Fund Commission on a High Performance Health System. Why Not the Best? Results from the national scorecard on U.S. health system performance, July 2008. 87 Bureau of Labor Education, University of Maine. The U.S. Health Care System: Best in the world, or just the most expensive? Summer, 2001. 88 Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA. 1999;281(1):61-6. 89 Ten great public health achievements—United States, 1900-1999. Morbidity and Mortality Weekly Report, April 2, 1999;48(12). 90 Centers for Disease Control. Leading causes of death, 1900-1998. Accessed at http://www.cdc.gov/nchs/data/dvs/lead1900_98.pdf. 91 Gregg EW, Cheng YJ, Cadwell BL, Imperatore G, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA. 2005;293(15):1868-74. 72

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

in ic

21st Century Medicine | 81

21st century medicine: A New Model for Medical Education and Practice

Gregg EW, Cheng YJ, Cadwell BL, Imperatore G, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA. 2005;293(15):1868-74. 93 Kramarow E, Lubitz J, Lentzner H, Gorina Y. Trends in the health of older Americans, 1970-2005. Health Affairs. 2007;26(5):1417-25. 94 Thorpe KE, Florence CS, Howard H, Joski.P. The rising prevalence of treated disease: effects on private health insurance spending. Health Affairs, Web exclusive, June 27, 2005. 95 Froguel P, Blakemore AI. The power of the extreme in elucidating obesity. N Engl J Med. 2008;359(9):891-3. 96 Lakdawalla DN, Goldman DP, Shang B. The health and cost consequences of obesity among the future elderly. Health Affairs, September 26, 2005 (Web exclusive). 97 Olshansky SJ, Passaro DJ, Hershow RC, Layden J, et al. A potential decline in life expectancy in the United States in the 21st century. NEJM. 2005;352(11):1138-45. 98 Lakdawalla DN, Goldman DP, Shang B. The health and cost consequences of obesity among the future elderly. Health Affairs, September 26, 2005 (Web exclusive). 99 Olshansky SJ, Passaro DJ, Hershow RC, Layden J, et al. A potential decline in life expectancy in the United States in the 21st century. NEJM. 2005;352(11):1138-45. 100 Kumanyika SK, Obarzanek E, Stettler N, Bell R, et al. Populationbased prevention of obesity. The need for comprehensive promotion of healthful eating, physical activity, and energy balance. Circulation. 2008;118:428-64. 101 Bibbins-Domingo K, Coxson P, Pletcher MJ, et al. Adolescent overweight and future adult coronary heart disease. N Engl J Med. 2007;357(23):2371-9. 102 Caballero B, Wang Y. Commentary: Obesity and mortality—light at the end but still a long tunnel. Int J Epidemiol. 2006;35:21-22. 103 Kumanyika SK, Obarzanek E, Stettler N, Bell R, et al. Populationbased prevention of obesity. The need for comprehensive promotion of healthful eating, physical activity, and energy balance. Circulation. 2008;118:428-64. 104 Prentice RL, Willett WC, Greenwald P, et al. Nutrition and physical activity and chronic disease prevention: research strategies and recommendations. J Natl Canc Inst. 2004;96(17):1276-87. 105 Horton R. Commentary: The new new public health of risk and radical engagement. Lancet. 1998;352(9124):251-52. 106 Hedaya R, Quinn S. Depression: Advancing the Treatment Paradigm. A Functional Medicine Monograph. The Institute for Functional Medicine: Gig Harbor, WA, 2008. 107 Zahran HS, Kobau R, Moriarty DG, Zack MM, et al. HealthRelated Quality of Life Surveillance—United States, 1993-2002. MMWR Surveillance Summaries. October 28, 2005;54(SS04);1-35. Accessed at http://www.cdc.gov/mmwr/preview/mmwrhtml/ ss5404a1.htm. 108 CBS Evening News. The Sandwich Generation. May 8, 2006. 109 Holman H. Chronic disease—The need for a new clinical education. JAMA. 2004;292(9):1057-1059. 110 Chassin MR, Galvin RW. The urgent need to improve health care quality. Institute of Medicine National Roundtable on Health Care Quality. JAMA. 1998;280(11);1000-05. 111 Institute of Medicine Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. National Academy Press: Washington, DC, 2001. 112 Issa AM. Personalized medicine and the practice of medicine in the 21st century. McGill J Med. 2007 10(1):53-57. 113 Jorgensen JT. From blockbuster medicine to personalized medicine. Personalized Med. 2008;5(1):55-63. 114 Issa AM. Personalized medicine and the practice of medicine in the 21st century. McGill J Med. 2007 10(1):53-57. 92

01

)2

(c

0

e

| 21st Century Medicine

in ic

82

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

115 Jorgensen JT. From blockbuster medicine to personalized medicine. Personalized Med. 2008;5(1):55-63. 116 Dinh P, de Azambuja E, Cardoso F, Piccart-Gebhart MJ. Facts and controversies in the use of trastuzumab in the adjuvant setting. Nat Clin Pract Oncol. 2008 Sep 9. [Epub ahead of print] 117 Issa AM. Personalized medicine and the practice of medicine in the 21st century. McGill J Med. 2007 10(1):53-57. 118 Dendukuri N, Khetani K, McIsaac M, Brophy J. Testing for HER2positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ. 2007;176(10):1429-34. 119 Dinh P, de Azambuja E, Cardoso F, Piccart-Gebhart MJ. Facts and controversies in the use of trastuzumab in the adjuvant setting. Nat Clin Pract Oncol. 2008 Sep 9. [Epub ahead of print] 120 Scott SA, Edelmann L, Kornreich R, Desnick RJ. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet. 2008 Feb;82(2):495500. Epub 2008 Jan 17. 121 Caldwell MD, Awad T, Johnson JA, Gage BF, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008 Apr 15;111(8):410612. Epub 2008 Feb 4. 122 Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH. Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics. 2007 Nov;8(11):1535-44. 123 Tham LS, Goh BC, Nafziger A, Guo JY, Wang LZ, Soong R, Lee SC. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther. 2006 Oct;80(4):346-55. 124 Scott SA, Edelmann L, Kornreich R, Desnick RJ. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet. 2008 Feb;82(2):495500. Epub 2008 Jan 17. 125 Issa AM. Personalized medicine and the practice of medicine in the 21st century. McGill J Med. 2007 10(1):53-57 McKinnon RA, Ward MB, Sorich MJ. A critical analysis of barriers to the clinical implementation of pharmacogenomics. Ther Clin Risk Manag 2007;3(5):751-9. 126 Hillman MA, Wilke RA, Yale SH, et al. A prospective randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res. 2005;3(3);137-45. 127 Carlquist JF, Horne BD, Muhlestein JB, Lappe DL, et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis. 2006;22(3):191-7. 128 Ghosh D, Skinner MA, Laing WA. Pharmacogenomics and nutrigenomics: synergies and differences. Eur J Clin Nutr. 2007;61:567-74. 129 Subbiah MT. Nutrigenetics and nutraceuticals: the next wave riding on personalized medicine. Trans Res. 2007;149:55-61. 130 Mabry PL. Olster DH, Morgan GD, Abrams DB. Interdisciplinarity and systems science to improve population health. A view from the NIH Office of Behavioral and Social Sciences Research. Am J Prev Med. 2008:35(2S). 131 Culliton BJ. Nanomedicine—The power of proteins: A conversation with Lance Liotta and Emanual Petricoin. Health Aff. 2008;27(4):w310-w314. Published online June 17, 2008. 132 Phillips KA, Liang SY, Van Bebber S; Canpers Research Group. Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value. Curr Opin Mol Ther. 2008;10(3):260-6. 133 Mabry PL. Olster DH, Morgan GD, Abrams DB. Interdisciplinarity and systems science to improve population health. A view from the NIH Office of Behavioral and Social Sciences Research. Am J Prev Med. 2008:35(2S).

REFERENCES

01

)2

(c

134 Benner SA, Hoshika S, Sukeda M, et al. Synthetic biology for improved personalized medicine. Nucleic Acids Symp. 2008. Series No. 52;243-4. 135 Richmond TD. The current status and future potential of personalized diagnostics: Streamlining a customized process. Biotechnol Annu Rev. 2008;14:411-22. 136 de Leon J. Pharmacogenomics: The promise of personalized medicine for CNS disorders. Neuropsychopharmacology. 2008;Sep 17. [Epub ahead of print] 137 McKinnon RA, Ward MB, Sorich MJ. A critical analysis of barriers to the clinical implementation of pharmacogenomics. Ther Clin Risk Manag 2007;3(5):751-9. 138 Issa AM. Personalized medicine and the practice of medicine in the 21st century. McGill J Med. 2007 10(1):53-57. 139 Culliton BJ. Nanomedicine—The power of proteins: A conversation with Lance Liotta and Emanual Petricoin. Health Aff. 2008;27(4):w310-w314. Published online June 17, 2008. 140 Culliton BJ. Nanomedicine—The power of proteins: A conversation with Lance Liotta and Emanual Petricoin. Health Aff. 2008;27(4):w310-w314. Published online June 17, 2008. 141 Snyderman R, Williams RS. Prospective medicine: The next health care transformation. Acad Med. 2003;78:1079-84. 142 Snyderman R, Yoediono Z. Prospective health care and the role of academic medicine: lead, follow, or get out of the way. Acad Med. 2008;83(8):707-14. 143 Snyderman R, Williams RS. Prospective medicine: The next health care transformation. Acad Med. 2003;78:1079-84. 144 Predictive model focuses on morbidity. New program quantifies risk in terms that get attention. Disease Management Advisor. 2007;13(8): August. Accessed October 22, 2008 at http://www.knowyournumber. com/pdf/DMA_2099.pdf. 145 Information accessed October 22, 2008 at: http://www.navigenics. com/healthcompass/Overview/;jsessionid=0AC087B7DEFA99327D0 3E99696D603DD.129781-prodappl. 146 Information accessed October 22, 2008 at: http://www. biophysicalcorp.com/assessments/know-more.aspx. 147 Dobbe E, Gurney K, Kiekow S, et al. Gene-expression assays: new tools to individualized treatment of early stage breast cancer. Am J Health Syst Pharm. 2008;65:23-8. 148 Snyderman R, Williams RS. Prospective medicine: The next health care transformation. Acad Med. 2003;78:1079-84. 149 Johns MM, Brigham KL. Transforming health care through prospective medicine: The first step. Acad Med. 2008;83(8):706. 150 Information accessed October 23, 2008 at: http://www. improvingchroniccare.org/index.php?p=Model_Elements&s=18. 151 Institute of Medicine Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. National Academy Press: Washington, DC, 2001. 152 Nutting PA, Dickinson WP, Dickinson LM, et al. use of chronic-care model elements is associated with higher-quality care for diabetes. Ann Fam Med. 2007;5:14-20. 153 Dipiero A, Dorr DA, Kelso C, Bowen JL. Integrating systematic chronic care for diabetes into an academic general internal medicine resident-faculty practice. J Gen Intern Med. 2008; August 28. [Epub ahead of print] 154 Henke RM, Chou AF, Chanin JC, et al. Physician attitude toward depression care interventions: Implication for implementation of quality improvement initiatives. Implementation Science. 2008;3:40-9. 155 Hung DY, Shelley DR. Multilevel analysis of the chronic-care model and 5A services for treating tobacco use in urban primary care clinics. Health Serv Res. 2008; September 8. [Epub ahead of print] 156 Hroscikoski MC, Solberg LI, Sperl-Hillen JM, et al. Challenges of change: A qualitative study of chronic-care model implementation. Ann Fam Med. 2006;4;317-26.

157 Baxley EG, Stanek M. The AAMC Academic Chronic Care Collaborative: Family medicine’s participation and lessons learned. Ann Fam Med. 2007;5(2):183-4. 158 www.ahrq.gov/populations/chroniccaremodel/chronicintro.htm 159 Beltran DJ and Lubow HW and Driedger AA. Letters and response to “Why is evidence-based medicine the legal standard of practice?” Medscape J Med. 2008;10(1 and 3). 160 Hurwitz B. How does evidence based guidance influence determinations of medical negligence? BMJ. 2004;329:1024-8.

0

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

161 GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ. 2004; 328(7454):1490-7. 162 Evidence-based Medicine Working Group. Evidence-based medicine: A new approach to teaching the practice of medicine. JAMA 1992;68:2420-5. 163 Sackett DL, Rosenberg WM. The need for evidence-based medicine. J Royal Soc Med. 1995;88:620-4. 164 Guyatt G, Cook D, Hanes B. Evidence based medicine has come a long way. BMJ. 2004;329:990-1. 165 Guyatt GH, Oxman AD, Vist GE, et al. GRADE: What is “quality of evidence” and why is it important to clinicians? BMJ. 2008; 336(7651):995-8. 166 Guyatt GH, Oxman AD, Vist GE, et al. GRADE: What is “quality of evidence” and why is it important to clinicians? BMJ. 2008; 336(7651):995-8. 167 Guyatt GH, Oxman AD, Vist GE, et al. GRADE: What is “quality of evidence” and why is it important to clinicians? BMJ. 2008; 336(7651):995-8. 168 Bagshaw SM, Bellomo R. The need to reform our assessment of evidence from clinical trials: A commentary. Philos Ethics Humanit Med. 2008;3:23-33. 169 Guyatt GH, Oxman AD, Vist GE. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336: 170 Evans D. Hierarchy of evidence: a framework for ranking evidence evaluating healthcare interventions. J Clin Nurs. 2003; 12: 77–84. 171 Montori VM, Guyatt GH. Progress in evidence-based medicine. JAMA. 2008;300(15):1814-6. 172 Schunemann AH, Oxman AD, Brozek J. GRADE: grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336:1106-10. 173 http://www.gradeworkinggroup.org/toolbox/index.htm 174 Del Mar C, Glasziou P, Mayer D. Teaching evidence based medicine. BMJ. 2004;329:989-90. 175 Straus S, Jones G. What has evidence based medicine done for us? BMJ. 2004;329:987-988. 176 Lockwood DN, Armstrong M. Grant AD. Integrating evidence based medicine into routine clinical practice: seven years’ experience at the Hospital for Tropical Diseases, London. BMJ. 2004;329:1020-3. 177 Coomarasamy A, Khan KS. What is the evidence that postgraduate teaching in evidence based medicine changes anything? A systematic review. BMJ. 2004;329:1017-21. 178 http://clinicalevidence.bmj.com/ceweb/about/knowledge.jsp 179 Cleophas TJ, Zwinderman AH. Clinical trials are often false positive: a review of simple methods to control the problem. Curr Clin Pharmacol. 2006;1(1):1-4. 180 Bagshaw SM, Bellomo R. The need to reform our assessment of evidence from clinical trials: A commentary. Philos Ethics Humanit Med. 2008;3:23-33. 181 Contopoulos-Ioannidis DG, Ntzani E, Ioannidis JP. Translation of highly promising basic science research into clinical applications. Am J Med. 2003;114(6):477-84.

e

in ic

21st Century Medicine | 83

21st century medicine: A New Model for Medical Education and Practice

01

)2

(c

182 Khoury MJ, Gwinn M, Yoon PW, et al. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med. 2007;9(10):665-74. 183 http://publications.nigms.nih.gov/thenewgenetics/glossary.html#S. Accessed October 27, 2008. 184 http://blog-msb.embo.org/blog/2007/07/what_is_systems_ biology_3.html. Accessed October 27, 2008. 185 Ramos RG, Olden K. Gene-environment interactions in the development of complex disease phenotypes. Int J Environ Res Public Health. 2008;5(1):4-11. 186 http://www.systemsbiology.org/Systems_Biology_in_Depth/ Premise_of_Systems_Biology. Accessed October 27, 2008. 187 Scheuner MT, Sieverding P, Shekelle PG. Delivery of genomic medicine for common chronic adult diseases. A systematic review. JAMA. 2008;299(11):1320-34. 188 Swen JJ, Huizinga TW, Gelderblom H, et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Medicine. 2007;4(8):e209-e210. 189 McKinnon RA, Ward MB, Sorich MJ. A critical analysis of barriers to the clinical implementation of pharmacogenomics. Ther Clin Risk Manage. 2007;3(5):751-9. 190 Auffray C, Chen Z, Hood L. Review: Systems medicine: the future of medical genomics and healthcare. Genome Medicine. 2009; 1:2:111. 191 Kligler B, Maizes V, Schachter S, et al. Core competencies in integrative medicine for medical school curricula: A proposal. Acad Med. 2004;79:521-31. 192 Kessler RC, Davis RB, Foster DF, et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Int Med. 2001;135:262-8. 193 Konefal J. The challenge of educating physicians about complementary and alternative medicine. Acad Med. 2002;77:847-50. 194 Kligler B, Maizes V, Schachter S, et al. Core competencies in integrative medicine for medical school curricula: A proposal. Acad Med. 2004;79:521-31. 195 Gaylord SA, Mann JD. Rationales for CAM education in health professions training programs. Acad Med. 2007;82(10):927-33. 196 Kligler B, Maizes V, Schachter S, et al. Core competencies in integrative medicine for medical school curricula: A proposal. Acad Med. 2004;79:521-31. 197 University of Texas Medical Branch at Galveston, Family Medicine Residency Program, Complementary and Integrative Medicine Curriculum, 2003-04. 198 Drisko J. University of Kansas Medical Center Program in Integrative Medicine Fellowship Curriculum August 2008-July 2009. 199 Lutz A, Slagter HA, Dunne JD, Davidson RJ. Attention regulation and monitoring in meditation. Trends Cogn Sci. 2008;12(4):163-9. 200 Davidson RJ, Kabat-Zinn J, Schumacher J, et al. Alterations in brain and immune function produced by mindfulness meditation. Psychosom Med. 2003;65:564-70. 201 Lutz A. Long-term meditators self-induce high-amplitude gamma synchrony during mental practice. PNAS. 2004;101(46):16369-73. 202 Brefczynski-Lewis JA, Lutz A, Schaefer HS, Levinson DB, Davidson RJ. Neural correlates of attentional expertise in long-term meditation practitioners. PNAS. 2007;104(27):11483-88. 203 Kuyken W, Byford S, Taylor RS, et al. Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. J Consulting Clin Psych. 2008;Vol 76(6):966-978. 204 Kathryn Montgomery. How Doctors Think. Oxford Univ Press. 2006. 205 Jerome Groopman. How Doctors Think, pgs 51-52. 206 Sieberts SK. Schadt EE. Moving toward a system genetics view of disease. Mamm Genome. 2007; 18:389-401.

0

e

| 21st Century Medicine

in ic

84

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

207 Holman H. Chronic disease—The need for a new clinical education. JAMA. 2004;292(9):1057-1059. 208 Marks HM. The progress of experiment: science and therapeutic reform in the United States, 1900-1990. Cambridge: Cambridge University Press, 1995. 209 Kaptchuk TJ. Intentional ignorance: a history of blind assessment in medicine. Bull Hist Med. 1998;72(3):389-433. 210 Genuis, SK, Genuis SJ. Exploring the continuum: medical information to effective clinical practice. Paper I: the translation of knowledge into clinical practice. Journal of Evaluation in Clinical Practice. 2006. 12 (1): 49–62. 211 Bagshaw, SM & Bellomo, R. The need to reform our assessment of evidence from clinical trials: A commentary. Philosophy, Ethics, and Humanities in Medicine 2008, 3:23. 212 Genuis, SJ, Genuis SK. Exploring the continuum: medical information to effective clinical practice. Paper II. Towards aetiologycentred clinical practice. Journal of Evaluation in Clinical Practice. 12 (1):63–75. 213 Gardiner Harris. Research Center Tied to Drug Company. New York Times. November 25, 2008. 214 DeAngelis CD. The Influence of Money on Medical Science. JAMA, Published online August 7, 2006. 215 Nieto A, et al. Adverse Effects of Inhaled Corticosteroids in Funded and Nonfunded Studies. Arch Intern Med. 2007;167(19):2047-2053. 216 Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323:334-36. 217 Guyatt GH, Sinclair J, Cook, DJ, Glasziou P. Users’ guides to the medical literature: XVI. How to use a treatment recommendation. JAMA. 1999;281(19):1836-43. 218 Evidence-based medicine. A new approach to teaching the practice of medicine. Evidence-Based Medicine Working Group. JAMA. 1992;268(17):2420-25. 219 Geyman JP. Evidence-based medicine in primary care: an overview. J Am Board Fam Pract. 1998;11:46-56. 220 Rosenberg W, Donald A. Evidence based medicine: an approach to clinical problem-solving. BMJ. 1995;310:1122-26. 221 Sackett DL. Evidence-based medicine: how to practice and teach EBM. New York: Churchill Livington, 1997:2-16. 222 Davidoff F, et. al. Evidence based medicine. BMJ. 1995; 310:108586. 223 Weel CV, Knottnerus JA. Evidence-based interventions and comprehensive treatment. Lancet. 1999;353:916-18. 224 Mant D. Can randomized trials inform clinical decisions about individual patients? Lancet. 1999;353:743-46. 225 Feinstein AR, Horwitz RI. Problems in the “evidence” of “evidencebased medicine.” Am J Med. 1997;103:529-35. 226 Culpepper L, Gilbert TT. Evidence and ethics. Lancet. 1999;353:829-31. 227 Auffray C, Chen Z, Hood L. Review: Systems medicine: the future of medical genomics and healthcare. Genome Medicine. 2009; 1:2:111. 228 Ramos RG, Olden K. Gene-Environment Interactions in the Development of Complex Disease Phenotypes. Int J Environ Res Public Health. 2008;5(1):4-11. 229 Bell IR, Koithan M. Models for the study of whole systems. Integr Cancer Ther. 2006 5(4):293-307. 230 Bagshaw, SM & Bellomo, R. The need to reform our assessment of evidence from clinical trials: A commentary. Philosophy, Ethics, and Humanities in Medicine 2008, 3:23. 231 Katerndahl,, Crabtree,.B Creating Innovative Research Designs: The 10-Year Methodological Think Tank Case Study. Annals of Family Medicine.2006; 4 (5):443. 232 Weed LL, Zimny NJ. The problem-oriented system, problemknowledge coupling, and clinical decision making. Phys Ther. 1989;69(7):565-8.

REFERENCES

01

)2

(c

233 Weed LL. Medical Records, Medical Education, and Patient Care. The Problem-Oriented Record as a Basic Tool. Chicago: Year Book Medical Publisher, Inc.: 1970. 234 Hampton JR. Evidence-based medicine, opinion-based medicine, and real-world medicine. Perspect Biol Med. 2002;45(4):549-68. 235 Grahame-Smith D. Evidence based medicine: Socratic dissent. BMJ. 1995;310:1126-27. 236 Definition of POEMs published in tips from other journals. Am Fam Physician. 2005;71(1):153. 237 A DuPont advertising slogan. 1939. http://heritage.dupont.com/ touchpoints/tp_1939/depth.shtml 238 http://www.cdc.gov/pcd/issues/2004/apr/04_0006.htm 239 Starfield B. Threads and Yarns: Weaving the Tapestry of Comorbidity. Ann Fam Med 2006;4:101. 240 Cerutti A, Sinorini MG. Non-linear algorithms for processing biological signals. Comput Methods Programs Biomed. 1996; 51:5173. 241 Smart A, Martin P, Parker M. Tailored medicine: whom will it fit? Bioethics. 2004; 18:322-42. 242 Bell IR, Koithan M. Models for the study of whole systems. Integr Cancer Ther. 2006 5(4):293-307. 243 Bland, J. Alternative therapies—a moving target. Altern Ther Health Med. 2005;11(2):2-4. 244 Bagshaw, SM & Bellomo, R. The need to reform our assessment of evidence from clinical trials: A commentary. Philosophy, Ethics, and Humanities in Medicine 2008, 3:23. 245 Auffray C, Chen Z, Hood L. Review: Systems medicine: the future of medical genomics and healthcare. Genome Medicine. 2009; 1:2:111. 246 Evidence-based medicine. A new approach to teaching the practice of medicine. Evidence-Based Medicine Working Group. JAMA. 1992;268(17):2420-25. 247 Sackett, DL. Evidence based medicine: what it is and what it isn’t. BMJ. 1996;312:71-72. 248 Weel CV, Knottnerus JA. Evidence-based interventions and comprehensive treatment. Lancet. 1999;353:916-18. 249 Greenhalgh T, et. al. Learning in Practice. BMJ. 2003;326:142-45. 250 Kuhn TS. The Structure of Scientific Revolutions. Chicago, Ill: University of Chicago Press; 1970. 251 Dornhurst AC. Information Overload: Why Medical Education Needs a Shake-up. Lancet 1981. 2:513-14. 252 Montgomery K. How Doctors Think: Clinical Judgment and the Practice of Medicine. Oxford University Press: New York, NY, 2006. P. 31-33. 253 Jerome Groopman. How Doctors Think. Houghton Mifflin. NY, NY 2007, Chapter 10. 254 Sackett, DL. BMJ. 1996; 312:71-72. 255 Borrell-Carrio F, et al. The biopsychosocial model 25 years later: Principles, practice, and scientific inquiry. Ann Fam Med. 2004; 2(6):576-82. 256 Mackie JL. Causes and conditions. Amer Philosoph Q. 1965;2:24564. 257 Mackie JL. The Cement of the Universe. A Study of Causation. Oxford UK: Oxford University Press; 1974. 258 Bateson G. Steps to an Ecology of Mind: A Revolutionary Approach to Man’s Understanding of Himself. New York, NY: Ballantine Books; 1972. 259 Fraser SW, Greenhalgh T. Coping with complexity: educating for capability. BMJ. 2001;323:799-803. 260 Miller WL, Crabtree BF, McDaniel R, Stange KC. Understanding change in primary care practice using complexity theory. J Fam Pract. 1998; 46:369-76.

0

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

261 Borrell-Carrio F, et al. The biopsychosocial model 25 years later: Principles, practice, and scientific inquiry. Ann Fam Med. 2004; 2(6):576-82. 262 David Deutsch. The Fabric of Reality. New York, NY: Penguin Press; 1997:16. 263 Little P, et al. Preferences of patients for patient centred approach to consultation in primary care: observational study. BMJ. 2001;322:1-7. 264 Mant D. Can randomized trials inform clinical decisions about individual patients? Lancet. 1999;353:743-46. 265 Gigerenzer G. Rationality for Mortals: How People Cope with Uncertainty. Oxford University Press, 2008. pg.vi. 266 Bagshaw, SM & Bellomo, R. The need to reform our assessment of evidence from clinical trials: A commentary. Philosophy, Ethics, and Humanities in Medicine 2008, 3:23. 267 Grossman J, Mackenzie FJ. The Randomized Controlled Trial: gold standard, or merely standard? Perspectives in Biology and Medicine, 2005. 48 (4):516–34. 268 Paul Glasziou, Jan Vandenbroucke, Iain Chalmers Assessing the quality of research BMJ 2004. 328; (3):39-41. 269 Mercer S, et al. Study Designs for Effectiveness and Translation Research: Identifying Trade-offs. Am J Prev Med 2007;33(2):139-154. 270 Genuis J. Diagnosis: contemporary medical hubris; Rx: a tincture of humility. Journal of Evaluation in Clinical Practice. 2005.12; (1): 24–30. 271 Miles A., Grey J.E., Polychronis A., Price N. & Melchiorri C. Developments in the evidence-based health care debate. Journal of Evaluation in Clinical Practice. 2004. 10:129–142. 272 Montori VM, Guyatt GH. Progress in Evidence Based Medicine. JAMA. 2008;300:1814-16. 273 Walter Freeman How Brains Make Up Their Minds. 2000. Columbia University Press. 274 Yuri Kuzyk’s review of Walter Freeman’s book: How Brains Make Up Their Minds, on Amazon.com. 275 Peter Dayan, L. F. Abbott. Theoretical Neuroscience: Computational and Mathematical Modeling of Neural Systems. The MIT Press; 2005. 276 Roland Baddeley (Editor), Peter Hancock (Editor), Peter Földiák (Editor). Information Theory and the Brain. Cambridge University Press. 2008. 277 Eric R. Kandel In Search of Memory: The Emergence of a New Science of Mind, W. W. Norton; 2007, 278 Roberto Cabeza (Editor), Alan Kingstone (Editor).Handbook of Functional Neuroimaging of Cognition The MIT Press; 2 edition, 2006. 279 Henry P. Stapp. Mindful Universe: Quantum Mechanics and the Participating Observer (The Frontiers Collection) Springer; 1 edition 2007. 280 Gerd Gigerenzer. Gut Feelings. Penguin Books. London, 2007. 281 Gerd Gigerenzer. Rationality for Mortals. Oxford U Press. Oxford, 2008. 282 Thomas Gilovich, et al. Heuristics & Biases. Cambridge University Press. 2002. 283 See previous three endnotes. 284 Gerd Gigerenzer. Gut Feelings. Penguin Books. London, 2007, pg 10-11. 285 Elwyn G, et al. Decision analysis in patient care: Review. Lancet. 2001; 358: 571–74. 286 Naylor, C. Clinical decisions: From art to science and back again. The Lancet. 2001. 358:523-24. 287 Fiore, S. and Schooler, J. Right hemisphere contributions to creative problem solving: Converging evidence for divergent thinking. In Right Hemisphere Language Comprehension: Perspectives from Cognitive Neuroscience (Beeman, M. and Chiarello, C., eds), pp. 255–284, Erlbaum Pub. Philadelphia, PA, 1998.

e

in ic

21st Century Medicine | 85

21st century medicine: A New Model for Medical Education and Practice

01

)2

(c

288 Seger, C.A. et al. FMRI evidence for right hemisphere involvement in processing unusual semantic relationships. Neuropsychology. 2000;14, 361–369. 289 Bowden EM. New approaches to demystifying insight. TRENDS in Cognitive Sciences 2005;9(7):322-28. 290 Jung-Beeman, M. et al. Neural activity observed in people solving verbal problems with insight. PLOS Biol. 2004; 2, 500–510. 291 Chronicle, E.P. et al. What makes an insight problem? The roles of heuristics, goal conception, and solution recoding in knowledge-lean problems. J. Exp. Psychol. Learn. Mem. Cogn. 2004; 30, 14–27. 292 Luo, J. and Niki, K. Function of hippocampus in ‘insight’ of problem solving. Hippocampus 2003; 13, 316–323 293 Siegler, R. Unconscious insights. Curr. Dir. Psychol. Sci. 2000; 9, 79–83. 294 Bowden EM. New approaches to demystifying insight. TRENDS in Cognitive Sciences 2005;9(7):322-28. 295 Bowden, E.M. and Jung-Beeman, M. Getting the right idea: semantic activation in the right hemisphere may help solve insight problems. Psychol. Sci. 1998; 6, 435–440. 296 John Kounios J, et al. The origins of insight in resting-state brain activity Neuropsychologia. 2008; 46:281–291. 297 Jonah Lehrer. The Annals of Science: The Eureka Hunt. The New Yorker, July 28, 2008: pgs 40-45. 298 Jung-Beeman, M. et al. Neural activity observed in people solving verbal problems with insight. PLOS Biol. 2004; 2, 500–510. 299 Smith, R. W., & Kounios, J.. Sudden insight: All-or-none processing revealed by speed-accuracy decomposition. Journal of Experimental Psychology: Learning, Memory, and Cognition. 1996;22: 1443–1462. 300 Jonah Lehrer. The Annals of Science: The Eureka Hunt. The New Yorker, July 28, 2008: pgs 40-45. 301 Jonah Lehrer. The Annals of Science: The Eureka Hunt. The New Yorker, July 28, 2008: pgs 40-45. 302 Rhoades DR, McFarland KF, Finch WH, Johnson AO. Speaking and interruptions during primary care office visits. Fam Med. 2001 Jul-Aug;33(7):528-32. 303 Beckman DB, et al. The effect of physician behavior on the collection of data. Ann Intern Med. 1984;101:692-96. 304 Magid CS. Developing tolerance for ambiguity. JAMA. 2001;285(1):88. 305 Rees J. Complex disease and the new clinical sciences. Science. 2002; 296:698-701. 306 Radford T. Top scientist warns of “sickness” in US health system. BMJ. 2003;326:416. 307 Vioxx: lessons for Health Canada and the FDA. CMAJ. 2005;172(11):5. 308 Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. The Lancet. 2004;364:202129. 309 Yu SL, Ho LM, Lim BC, Sim ML. Urinary deoxypyridinoline is a useful biochemical bone marker for the management of postmenopausal osteoporosis. Ann Acad Med Singapore. 1998;27(4):527-29. 310 Palomba S, Orio F, Colao A, et al. Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87(4):1502-1508. 311 Moya-Camarena SY, Vanden Heuvel JP, Blanchard SG, et al. Conjugated linoleic acid is a potent naturally occurring ligand and activator of PPARa. J Lipid Res. 1999;40:1426-33. 312 Gaullier JM, Halse J, Hoye K, et al. Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans. Am J Clin Nutr. 2004;79:1118-25. 313 O’Shea M, Bassaganya-Riera J, Mohede IC. Immunomodulatory properties of conjugated linoleic acid. Am J Clin Nutr. 2004:79(S):1199S-206S.

314 Malloney F, Yeow TP, Mullen A, et al. Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 DM. Am J Clin Nutr. 2004;80(4):887-95. 315 Riserus U, Vessby B, Arner P, Zethelius B. Supplementation with CLA induces hyperproinsulinaemia in obese men: close association with impaired insulin sensitivity. Diabetalogia. 2004;47(6):1016-19. 316 Ames, BN. The metabolic tune-up: metabolic harmony and disease prevention. J Nutr. 2003;133:1544S-48S. 317 Ames BN, et al. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased Km): relevance to genetic disease and polymorphisms. Am J Clin Nutr. 2002;75(4):616-58. 318 Ames BN, et al. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased Km): relevance to genetic disease and polymorphisms. Am J Clin Nutr. 2002;75(4):616-58. 319 Bralley JA, Lord RS: Laboratory Evaluations in Molecular Medicine. 2001. In Organic Acids, Chapter 6, p. 181.

0

e

| 21st Century Medicine

in ic

86

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

320 Bralley JA, Lord RS: Laboratory Evaluations in Molecular Medicine. 2001. In Organic Acids, Chapter 6, p. 181. 321 Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kB pathway in the treatment of inflammation and cancer. J Clin Invest. 2001;107(2):135-42. 322 Tak PP, Firestein GS. NF-kB: a key role in inflammatory disease. J Clin Invest. 2001;107(1):7-11. 323 Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kB pathway in the treatment of inflammation and cancer. J Clin Invest. 2001;107(2):135-42. 324 Balmer JE, Blomhoff R. Gene expression regulation by retinoic acid. J Lipid Res. 2002;43:1773-808. 325 Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular diseases. Am J Clin Nutr. 2004;80(6 Suppl):1678S-88S. 326 Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular diseases. Am J Clin Nutr. 2004;80(6 Suppl):1678S-88S. 327 Brown MM, et al. Evidence-Based to Value-Based Medicine. AMA Press. USA. 2005: pp 3-5. 328 Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB. Evidence-Based Medicine: How to Practice and Teach EBM. New York: Churchill Livingstone; 2000. 329 Jerome Groopman. How Doctors Think. Houghton Mifflin. NY, NY 2007. 330 Fiore, S. and Schooler, J. Right hemisphere contributions to creative problem solving: Converging evidence for divergent thinking. In Right Hemisphere Language Comprehension: Perspectives from Cognitive Neuroscience (Beeman, M. and Chiarello, C., eds), pp. 255–284, Erlbaum Pub. Philadelphia, PA, 1998. 331 Seger, C.A. et al. FMRI evidence for right hemisphere involvement in processing unusual semantic relationships. Neuropsychology. 2000;14, 361–369. 332 Scott JG, et al. Understanding Healing Relationships in Primary Care. Ann Fam Med. 2008;6(4):315-22. 333 Miller WL, et al. Research guidelines for assessing the impact of healing relationships in clinical medicine. Altern Ther Health Med. 2003;9(3)(Suppl):A80-A95. 334 Jackson C. Healing ourselves, healing other: first in a series. Holist Nurs Pract. 2004;18(2):67-81 335 Acheson L. Community Care, Healing, Annals Fam Med. 2008;6:290. 336 Hsu C, et al. Healing in Primary Care: A Vision Shared by Patients, Physicians, Nurses, and Clinical Staff. Ann Fam Med. 2008;6(4):30714.

REFERENCES

01

)2

(c

337 Egnew TR. The Meaning of Healing: Transcending Suffering. Ann Fam Med. 2005;3(3):255-62. 338 Scott JG, et al. Understanding Healing Relationships in Primary Care. Ann Fam Med. 2008;6(4):315-22. 339 Scott JG, et al. Understanding Healing Relationships in Primary Care. Ann Fam Med. 2008;6(4):315-22. 340 Jonah Lehrer. The Annals of Science: The Eureka Hunt. The New Yorker, July 28, 2008: pgs 40-45. 341 Galland L. “Person-Centered Diagnosis,” in Power Healing. New York: Random House, 1997, pp 52-97. 342 Lukaczer D. The 4R Program. In Ch. 28, Clinical Approaches to Gastrointestinal Imbalance. The Textbook of Functional Medicine. Gig Harbor, WA: The Institute for Functional Medicine, 2005. 343 Silver SM, Rogers S, Russell M. Eye movement desensitization and reprocessing (EMDR) in the treatment of war veterans. J Clin Psychol. 2008;64(8):947-57. 344 Jonah Lehrer. The Annals of Science: The Eureka Hunt. The New Yorker, July 28, 2008: pgs 40-45. 345 Gerd Gigerenzer. Rationality for Mortals: How people cope with Uncertainty. Oxford: Oxford University Press: 2008. pg v.

0 ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All e

in ic 21st Century Medicine | 87

21st century medicine: A New Model for Medical Education and Practice

About the Institute for Functional Medicine

)2

(c

The Institute for Functional Medicine (IFM) is a nonprofit, tax-exempt 501(c)3 educational organization that educates physicians and other healthcare practitioners in improving the assessment and management of complex, chronic disease through the use of functional medicine. The Institute’s mission is threefold: to develop the functional medicine knowledge base as a bridge between research (both emerging and established) and clinical practice; to educate physicians and other healthcare providers in the basic science and clinical applications of functional medicine; and to communicate with policy makers, practitioners, educators, researchers, and the public to disseminate the functional medicine knowledge base more widely. IFM has developed a model of comprehensive care and primary prevention for complex, chronic illness that is grounded in both the science (the Functional Medicine Matrix Model) and the art (the healing partnership in the therapeutic encounter) of clinical medicine that is now being implemented by functional medicine practitioners around the world.

01

The Institute for Functional Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. IFM offers educational publications and programs designed to raise the bar on clinicians’ standard of care. Programs such as IFM’s Functional Medicine Certification Program and Applying Functional Medicine in Clinical Practice (AFMCP) provide comprehensive clinical training for the assessment, treatment, prevention, and management of patients with complex, chronic disease. Other programs include IFM’s Advanced Practice Modules, online Webinars, and the annual International Symposia on functional medicine. The Institute publishes textbooks, monographs, and other educational materials available for CME credits and offers clinicians a Forum for the shared exploration of emerging research and clinical applications to improve patient care and outcomes. Detailed information about the Institute, its educational activities, and membership can be found at www.functionalmedicine.org.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

ed

Author David S. Jones, MD is the President of The Institute for Functional Medicine. He has practiced as a family physician with emphasis in functional and integrative medicine for over 25 years. He is a recognized expert in the areas of nutrition, lifestyle changes for optimal health, and managed care, as well as the daily professional functions consistent with the modern specialty of family practice. He is the Editor-in-Chief of the Textbook of Functional Medicine. Laurie Hofmann, MPH, is IFM’s Executive Director and an advisor and consultant to several public healthcare and health education initiatives across the country. Sheila Quinn is consulting author and editor of 21st Century Medicine: A New Model for Medical Education and Practice and has contributed to many other IFM publications including the Textbook of Functional Medicine.

e

in ic

For information on obtaining additional copies of 21st Century Medicine or to join us in IFM’s vision and mission as a functional medicine practitioner, member, advocate, or sponsor, we invite you to visit our Web site, www.functionalmedicine.org, call us at 800-228-0622, or write us at [email protected]. To contact the authors of 21st Century Medicine or to submit comments or questions on this publication, please write to David S. Jones, MD at [email protected].

88

| 21st Century Medicine

21st century medicine: A New Model for Medical Education and Practice

)2

(c

Appendix

01

Table of Contents

0

Page No.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Recommendations from the Future of Family Medicine Project.............................................................. A2 Joint Principles of the Patient-Centered Medical Home............. A5 List of Members of the Consortium of Academic Health Centers for Integrative Medicine..................................... A8 Institute for Systems Biology...................................................... A11

ed

Definition of Evidence-Based Medicine.................................... A14

in ic

Information about the Chronic Care Model............................. A18

e Excerpts from Chapter 8, Textbook of Functional Medicine... A25 Pattern Recognition Form—Ulcerative Colitis......................... A28 Functional Medicine Cases: Psoriatic Arthritis................................................................. A36 Attention Deficit Hyperactivity Disorder (ADHD)............. A57 Kara N. Fitzgerald, ND; Mark Hyman, MD

21st Century Medicine | A1

21st century medicine: A New Model for Medical Education and Practice

Recommendations from the Future of Family Medicine Project (http://www.futurefamilymed.org/x24878.html) New Model of Family Medicine

01

)2

(c

Family medicine will redesign the work and workplaces of family physicians. This redesign will foster a New Model of Care based on the concept of a relationship-centered personal medical home, which serves as the focal point through which all individuals — regardless of age, gender, race, ethnicity, or socioeconomic status participate in health care. In this new medical home, patients receive a basket of services of acute, chronic, and preventive medical care services that are accessible, accountable, comprehensive, integrated, patient-centered, safe, scientifically valid, and satisfying to both patients and their physicians. This New Model will include technologies that enhance diagnosis and treatment for a large portion of problems that people bring to their family physicians. Business plans and reimbursement models will be developed to enable the reengineered practices of family physicians to thrive as personal medical homes, and resources will be developed to help patients make informed decisions about choosing a personal medical home. A financially self-sustaining national resource will be implemented to provide practices with ongoing support in transitioning to the New Model of Family Medicine.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Communications

ed

A unified communications strategy will be developed to promote an awareness and understanding of the New Model of Family Medicine and the concept of a Personal Medical Home. As part of this strategy, a new symbol for family physicians will be created, and consistent terminology will be established for the specialty, (“family medicine” rather than “family practice” and “family physician” rather than “family practitioner”). In addition, a system will be developed to communicate and implement best practices within family medicine.

e

in ic

Electronic Health Records Electronic health records that support the New Model of family medicine will be implemented. The electronic health record will enhance and integrate communication, diagnosis and treatment, measurement of processes and results, analysis of the effects of co-morbidity, recording and coding elements of whole-person care, and promoting ongoing, healing relationships between family physicians and their patients.

Family Medicine Education Family medicine will oversee the training of family physicians who are committed to excellence, steeped in the core values of the discipline, expert in providing family medicine’s basket of services within the New Model of Family Medicine, skilled at adapting to varying patient and community needs, and prepared to

A2

| 21st Century Medicine

APPENDIX

embrace new evidence-based technologies. Family medicine education will continue to include training in maternity care, the care of hospitalized patients, community and population health, and culturally effective and proficient care. Innovation in family medicine residency programs will be supported by the Residency Review Committee for Family Practice through 5-10 years of curricular flexibility to permit active experimentation and ongoing critical evaluation of competency-based education, expanded training programs and other strategies to prepare graduates for the New Model. In preparation for this process, every family medicine residency will implement electronic health records by 2006.

Life-Long Learning

01

)2

(c

The discipline of family medicine will develop a comprehensive, life-long learning program. This program will provide the tools for each family physician to create a continuous personal, professional, and clinical practice assessment and improvement plan that supports a succession of career stages. This personalized learning and professional development will include self-assessment and learning modules directed at individual physicians and group practices that incorporate science-based knowledge into educational interventions that foster improved patient outcomes. Family medicine residency programs and departments will incorporate continuing professional development into their curricula and will initiate and model the support process for life-long learning and maintenance of certification.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Enhancing the Science of Family Medicine

ed

Participation in the generation of new knowledge will be integral to the activities of all family physicians and will be incorporated into family medicine training. Practice-based research will be integrated into the values, structures and processes of family medicine practices. Departments of family medicine will engage in highly collaborative research that produces new knowledge about the origins of disease and illness, how health is gained and lost, and how the provision of care can be improved. A national entity should be established to lead and fund research on the health and health care of whole people. Funding for the Agency for Healthcare Research and Quality should be increased to at least $1 billion per year.

e

in ic

Quality of Care Close working partnerships will be developed between academic family medicine, community-based family physicians and other partners in order to address the quality goals specified in the IOM’s Quality Chasm report. Family physicians and their practice partners will have support systems to measure and report regularly their performance on the 6 IOM aims of quality health care (safe, timely, effective, equitable, patient-centered, and efficient). Family med residency programs will track and report regularly the performance of their residents during their training on the 6 IOM quality measures and will modify their training programs as necessary to improve performance.

21st Century Medicine | A3

21st century medicine: A New Model for Medical Education and Practice

Role of Family Medicine in Academic Health Centers Departments of family medicine will individually and collectively analyze their position within the academic health center setting and will take steps to enhance their contribution to the advancement and rejuvenation of the AHC to meet the needs of the American people. A summit of policymakers and family medicine leaders in academia and private practice will be convened to review the role of and make recommendations on the future of family medicine in academia.

Promoting a Sufficient Family Medicine Workforce

01

)2

(c

A comprehensive Family Medicine Career Development Program and other strategies will be implemented to recruit and train a culturally diverse family physician workforce that meets the needs of the evolving US population for integrated health care for whole people, families and communities. Departments of family medicine will continue to develop, implement, disseminate and evaluate best practices in expanding student interest in the specialty.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Leadership and Advocacy

ed

Recommendation #10 from the Future of Family Medicine Report concerned Leadership and Advocacy. The Strategic Initiative calls for: A Leadership Center for Family Medicine and Primary Care will be established which will develop strategies to promote family physicians and other primary care physicians as health policy and research leaders in their communities, in government, and in other influential groups. In their capacity as leaders, family physicians will convene leaders to identify and develop implementation strategies for several major policy initiatives, including assuring that every American has access to basic health care services. Family physicians will partner with others at the local, state and national levels to engage patients, clinicians and payers in advocating for a redesigned system of integrated, personalized, equitable and sustainable health care.

e

in ic

A4

| 21st Century Medicine

APPENDIX

Joint Principles of the Patient-Centered Medical Home February 2007

American Academy of Family Physicians (AAFP) American Academy of Pediatrics (AAP) American College of Physicians (ACP) American Osteopathic Association (AOA)

(c

Introduction

01

)2

The Patient-Centered Medical Home (PC-MH) is an approach to providing comprehensive primary care for children, youth and adults. The PC-MH is a health care setting that facilitates partnerships between individual patients, and their personal physicians, and when appropriate, the patient’s family. The AAP, AAFP, ACP, and AOA, representing approximately 333,000 physicians, have developed the following joint principles to describe the characteristics of the PC-MH.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Principles

Personal physician – each patient has an ongoing relationship with a personal physician trained to provide first contact, continuous and comprehensive care. Physician directed medical practice – the personal physician leads a team of individuals at the practice level who collectively take responsibility for the ongoing care of patients.

ed

Whole person orientation – the personal physician is responsible for providing for all the patient’s health care needs or taking responsibility for appropriately arranging care with other qualified professionals. This includes care for all stages of life; acute care; chronic care; preventive services; and end of life care.

in ic

e

Care is coordinated and/or integrated across all elements of the complex health care system (e.g., subspecialty care, hospitals, home health agencies, nursing homes) and the patient’s community (e.g., family, public and private community-based services). Care is facilitated by registries, information technology, health information exchange and other means to assure that patients get the indicated care when and where they need and want it in a culturally and linguistically appropriate manner. Quality and safety are hallmarks of the medical home:  Practices advocate for their patients to support the attainment of optimal, patient-centered outcomes that are defined by a care planning process driven by a compassionate, robust partnership between physicians, patients, and the patient’s family.  Evidence-based medicine and clinical decision-support tools guide decision making  Physicians in the practice accept accountability for continuous quality improvement through voluntary engagement in performance measurement and improvement.

21st Century Medicine | A5

21st century medicine: A New Model for Medical Education and Practice

 Patients actively participate in decision-making and feedback is sought to ensure patients’ expectations are being met  Information technology is utilized appropriately to support optimal patient care, performance measurement, patient education, and enhanced communication  Practices go through a voluntary recognition process by an appropriate non-governmental entity to demonstrate that they have the capabilities to provide patient centered services consistent with the medical home model.  Patients and families participate in quality improvement activities at the practice level.

)2

(c

Enhanced access to care is available through systems such as open scheduling, expanded hours and new options for communication between patients, their personal physician, and practice staff.

01

Payment appropriately recognizes the added value provided to patients who have a patient-centered medical home. The payment structure should be based on the following framework:

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

 It should reflect the value of physician and non-physician staff patient-centered care management work that falls outside of the face-to-face visit.  It should pay for services associated with coordination of care both within a given practice and between consultants, ancillary providers, and community resources.  It should support adoption and use of health information technology for quality improvement;  It should support provision of enhanced communication access such as secure e-mail and telephone consultation;  It should recognize the value of physician work associated with remote monitoring of clinical data using technology.

ed

e

in ic

 It should allow for separate fee-for-service payments for face-to-face visits. (Payments for care management services that fall outside of the face-to-face visit, as described above, should not result in a reduction in the payments for face-to-face visits).  It should recognize case mix differences in the patient population being treated within the practice.  It should allow physicians to share in savings from reduced hospitalizations associated with physician-guided care management in the office setting.  It should allow for additional payments for achieving measurable and continuous quality improvements.

A6

| 21st Century Medicine

APPENDIX

Background of the Medical Home Concept The American Academy of Pediatrics (AAP) introduced the medical home concept in 1967, initially referring to a central location for archiving a child’s medical record. In its 2002 policy statement, the AAP expanded the medical home concept to include these operational characteristics: accessible, continuous, comprehensive, family-centered, coordinated, compassionate, and culturally effective care. The American Academy of Family Physicians (AAFP) and the American College of Physicians (ACP) have since developed their own models for improving patient care called the “medical home” (AAFP, 2004) or “advanced medical home” (ACP, 2006).

)2

(c

For More Information:

01

American Academy of Family Physicians (http://www.futurefamilymed.org)

0 ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All e

in ic 21st Century Medicine | A7

21st century medicine: A New Model for Medical Education and Practice

List of Members of the Consortium of Academic Health Centers for Integrative Medicine (cahcim) United States

Hawaii

Arizona

University of Hawaii-Manoa John A. Burns School of Medicine Department of Complementary and Alternative Medicine www.jabsom.hawaii.edu/jabsom

University of Arizona Program in Integrative Medicine www.integrativemedicine.arizona.edu California

(c

01

)2

Stanford University Stanford Center for Integrative Medicine http://www.stanfordhospital.com/ clinicsmedServices/ clinics/complementaryMedicine/default

Illinois

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Northwestern University Feinberg School of Medicine Northwestern Memorial Physician’s Group Center for Integrative Medicine www.nmpg.com

University of California, Irvine Susan Samueli Center for Integrative Medicine www.sscim.uci.edu University of California, Los Angeles Collaborative Centers for Integrative Medicine www.uclamindbody.org University of California, San Diego Center for Integrative Medicine

Connecticut University of Connecticut School of Medicine www.uchc.edu Yale University Integrative Medicine @ Yale cam.yale.edu Integrative Medicine Center at Griffin Hospital www.imc-griffin.org

A8

| 21st Century Medicine

Maryland

e

University of Colorado at Denver School of Medicine The Center for Integrative Medicine www.uch.edu/integrativemed

University of Kansas Program in Integrative Medicine http://integrativemed.kumc.edu/

in ic

Colorado

Kansas

ed

University of California, San Francisco Osher Center for Integrative Medicine www.osher.ucsf.edu

University of Chicago Pritzker School of  Medicine NorthShore University HealthSystem www.northshore.org/integrative University of Illinois at Chicago School of  Medicine chicago.medicine.uic.edu

Johns Hopkins University School of Medicine Center for Complementary and Alternative Medicine www.hopkinsmedicine.org/cam University of Maryland Center for Integrative Medicine www.compmed.umm.edu Massachusetts Boston University School of Medicine Program in Integrative Cross Cultural Care www.bumc.bu.edu Harvard Medical School Osher Institute www.osher.hms.harvard.edu

APPENDIX

University of Massachusetts Center for Mindfulness www.umassmed.edu/cfm/index.aspx

University of North Carolina at Chapel Hill Program on Integrative Medicine pim.med.unc.edu

Michigan

Wake Forest University School of Medicine Program for Holistic & Integrative Medicine http://www1.wfubmc.edu/phim/

University of Michigan Integrative Medicine www.med.umich.edu/umim Minnesota

01

)2

(c

Mayo Clinic Complementary and Integrative Medicine Program www.mayoclinic.org/general-internal-medicinerst/cimc.html Research http://mayoresearch.mayo.edu/mayo/research/ cimp/

0

University of Medicine and Dentistry of New Jersey Institute for Complementary & Alternative Medicine www.umdnj.edu/icam New Mexico

University of Cincinnati College of Medicine Oregon Oregon Health and Science University Women’s Primary Care and Integrative Medicine, Center for Women’s Health www.ohsu.edu/cam www.ohsuwomenshealth.com/services/doctors/ integrative.html

lM na tio d. un rve r F se fo re te ts itu h st rig In All

University of Minnesota Center for Spirituality and Healing www.csh.umn.edu New Jersey

Ohio The Ohio State University Center for Integrative Medicine www.medicalcenter.osu.edu/go/integrative

Pennsylvania

Thomas Jefferson University Jefferson Myrna Brind Center of Integrative Medicine jeffline.jefferson.edu/jmbcim www.jeffersonhospital.org/cim

ed

University of Pennsylvania CAM at Penn www.med.upenn.edu/penncam

New York

University of Pittsburgh Center for Integrative Medicine http://integrativemedicine.upmc.com

Columbia University Richard and Hinda Rosenthal Center for Complementary & Alternative Medicine www.rosenthal.hs.columbia.edu North Carolina Duke University Duke Integrative Medicine www.dukeintegrativemedicine.org

e

Albert Einstein College of Medicine of Yeshiva University Continuum Center for Health and Healing www.healthandhealingny.org

in ic

University of New Mexico Health Science Center hsc.unm.edu/som/cfl

Tennessee Vanderbilt University Vanderbilt Center for Integrative Health www.vcih.org Texas University of Texas Medical Branch UTMB Integrative Health Care http://cam.utmb.edu/

21st Century Medicine | A9

21st century medicine: A New Model for Medical Education and Practice

Vermont

Canada

University of Vermont College of Medicine Program in Integrative Medicine www.med.uvm.edu/integrativemedicine

Alberta

Washington University of Washington UW Integrative Health Program www.uwcam.org

University of Calgary

Washington, DC

01

)2

(c

George Washington University Center for Integrative Medicine www.integrativemedicinedc.com

0

Georgetown University School of Medicine http://www8.georgetown.edu/departments/ physiology/cam/index.html http://som.georgetown.edu/

Canadian Institute of Natural & Integrative Medicine www.cinim.org Ontario McMaster University Family Practice Centre of Integrative Health and Healing www.fpcihh.com

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Wisconsin

University of Alberta Complementary and Alternative Research and Education (CARE) www.care.ualberta.ca/

University of Wisconsin-Madison UW Integrative Medicine Program www.uwhealth.org/integrativemed www.fammed.wisc.edu/integrative

Quebec Laval University Integrated Approach in Prevention www.cours.fmed.ulaval.ca/modules/ approche-integree/accueil

ed e

in ic

A10

| 21st Century Medicine

APPENDIX

Institute for Systems Biology, Seattle, WA From their website and used with their permission: http://www.systemsbiology.org/Intro_ to_ISB_and_Systems_Biology/Predictive_Preventive_Personalized_and_Participatory The goal of systems biology is to fundamentally transform the practice of medicine, and ISB researchers have taken the leadership role in catalyzing this transformation. We are developing tools and techniques, and pursuing research that will usher in a new era of predictive, preventive, and personalized medicine.

01

)2

(c

Today’s medicine is reactive: we wait until someone is sick before administering treatment. Medicine of the future will be predictive and preventive, examining the unique biology of an individual to assess their probability of developing various diseases and then designing appropriate treatments, even before the onset of a disease. Today’s medicine is also myopic: we use only a few measurements to diagnose disease and are generally unable to make fine distinctions between individuals or between subtle variations of the same disease. Medicine of the future will use more sophisticated measurements, as well as more measurements overall, thereby yielding accurate health assessments for truly personalized treatments.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

ed

Improved personal measurements and personalized treatments are the keys to improving health care. Diseases arise from either genetic abnormalities, detrimental environmental factors (poor diet, infectious organisms, or toxins), or a combination of these. We know certain genetic patterns can make a person unusually susceptible to factors in their environment. We also know certain defective genes will increase the probability of an individual having certain health problems. For example, a woman with a single copy of the mutant breast cancer 1 gene (BRCA-1) has a 70 percent chance of developing breast cancer by the time she’s 60 years old. Unfortunately, today there is no practical way for each of us to determine our genetic makeup and, more important, to understand the likely health consequences. However, in the future individuals will be able to easily obtain such information, and then work closely with their health practitioner to develop a predictive, preventive and personalized health-care program.

e

in ic

Prediction. The technologies and tools of systems biology will provide medical practitioners with two exciting sources of health-related diagnostic data: By examining an individual’s complete genetic makeup, a physician will be able to generate comprehensive predictions about the patient’s health prospects. And by examining protein markers which naturally occur in an individual’s blood, a physician will be able to accurately determine a person’s health status, including both the current effects of any abnormal genes and the current reactions to any environmental toxins or infectious pathogens. Prevention. The new approach to medicine, based on each individual’s genetic makeup, will help us determine the probability of an individual contracting certain diseases, as well as reveal how an individual may respond to various treatments, thereby providing guidance for developing customized therapeutic drugs. Thus another use of the technologies and tools of systems biology will be to develop preventive treatments for individuals, based on their potential health problems, as indicated by their genetic makeup and current blood- protein markers.

21st Century Medicine | A11

21st century medicine: A New Model for Medical Education and Practice

The goal of this new approach to medicine will be to use the most fundamental health-related information—an individual’s genetic makeup plus current health status (as identified by blood protein markers)—to prescribe appropriate preventive drugs. For example, given your genetic makeup, you may have a 40% chance of developing breast cancer by age 50, but if you start taking a certain drug at age 35, that chance could drop to 5% at age 50.

)2

(c

In fact, scientists at ISB are currently involved in several research programs involving blood diagnosis of complex diseases, including type I diabetes, breast cancer, and prostate cancer. Cancer is the second leading cause of death in the United States, with prostate cancer accounting for one third of all cancer cases among men, and breast cancer accounting for approximately half of all cancer cases among women. ISB scientists are currently researching protein markers which occur in blood to better identify the onset, metastatic potential, and probable course of these cancers in individuals, with the eventual goal of developing more effective treatments.

01

The common theme running through all of this research and its application to medicine—the predictive and preventive potential of systems biology—is personalization. On average, each human differs from another by less than one percent of their genetic makeup. But these genetic differences give rise to our physical differences, including our potential predisposition to various diseases. So the ability to examine each individual’s unique genetic makeup and thereby customize our approaches to medical treatment is at the heart of this new era of predictive, preventive, personalized medicine.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

As a result of this personalization, medicine will become participatory. Patients will actively participate in personal choices about illness and well–being. Participatory medicine will require the development of powerful new approaches for securely handling enormous amounts of personal information and for educating both patients and their physicians. —————————————————————————————————————————— http://www.systemsbiology.org/Systems_Biology_in_Depth/Premise_of_Systems_Biology

ed in ic

e

The true test of a good system model is successful prediction of the system’s behavior under targeted alterations (genetic or environmental perturbations) of experimental conditions. But the very properties that make biological systems interesting and worthwhile to study their emergent properties, robustness, stability, modularity and adaptability to change, also make their behavior hard to predict at the molecular level. Confounding factors include functional redundancy (i.e., a given process might be accomplished by several different molecular mechanisms), and the stochasticity of cell populations (what is measured, e.g., gene expression, could be an average of a wide range of discrete responses among individual cells). Systems biologists approach this conundrum by adopting the following principles: 1. Global approaches should be taken to data collection and analyses. Ideally, high-throughput platforms are used to collect accurate measurements under multiple sets of well-defined experimental conditions. Technologies for performing quantitative, multi parameter measurements on a single sample need to be developed. To add value to the analyses of data

A12

| 21st Century Medicine

APPENDIX

obtained from multiplex technologies such as chips and panels of gene deletion mutants or RNAi gene knockouts, global approaches will incorporate relevant findings from curated databases and the published literature. 2. Information derived from diverse data types should be integrated. Systems biology derives power from the leveraging of pre-existing biochemical and cell biology knowledge with the various interaction network models inferred from the global datasets. Even though each source of data type might be sparse, noisy, or contain systematic errors, a meaningful pattern among the diverse data might become apparent and further analysis made possible if the network models are integrated.

01

)2

(c

3. Mathematical and statistical modeling is essential to the quantitative analysis of a system’s properties. Based on a working model and relevant assumptions, computer simulations are used to probe the probable effects of perturbations on a system’s components and interactions in the interest of making predictions that can be validated by the collection of more data. Thus, there is a tight integration of computer modeling with experimental design.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

4. Biology should drive technology which, in turn, makes better biology possible. Invention of novel or more sophisticated data collection, analysis and modeling tools is motivated by the need to solve a real-world biological problem. As a paradigm case, the Human Genome Project forced the development of high-throughput DNA sequencing methodologies. The need to perform multiparameter measurements on single cells is currently driving the invention of microfluidic/nanotechnology devices.

ed

5. Systems biology research should create an interactive inter-disciplinary scientific culture. For progress to occur, experts in engineering, physics, mathematics, and computer science must join biochemists, cell biologists, and physiologists in the effort to figure out how to obtain the required data and develop the sophisticated computational approaches that will be needed to make viable predictions. For scientists who have been trained primarily in one of these disciplines, doing systems biology research involves stepping outside one’s comfort zone to learn new concepts and methodologies. Systems biology-focused institutions accept that crossdisciplinary training from the get-go is the best way for new investigators to embrace the field.

e

in ic

6. The results of research should be freely disseminated. The Human Genome Project has revealed the enormous benefit that derives from the public release of data to the community of researchers. While not as easy to work with as genomic sequence, available microarray datasets, yeast two-hybrid analyses, collections of gene knockout strains and the like have accelerated progress in systems biology research. Similarly, computational biology is facilitated by the sharing of open-source software.

21st Century Medicine | A13

21st century medicine: A New Model for Medical Education and Practice

Definition of Evidence-Based Medicine Extracted from the Centre for Evidence-Based Medicine website; used by permission http://www.cebm.net/index.aspx?o=1014

What is EBM? This article is based on an editorial from the British Medical Journal on 13th January 1996 (BMJ 1996; 312: 71-2)

)2

(c

Brief definition:

01

Evidence-based medicine is the conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients. The practice of evidence-based medicine means integrating individual clinical expertise with the best available external clinical evidence from systematic research.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Expanded definition:

ed

Evidence-Based Medicine, whose philosophical origins extend back to mid-19th century Paris and earlier, remains a hot topic for clinicians, public health practitioners, purchasers, planners, and the public. There are now frequent workshops in how to practice and teach it (one sponsored by this journal will be held in London on April 24th); undergraduate [1] and post-graduate training programmes [2] are incorporating it [3] (or pondering how to do so); British centres for evidence-based practice have been established or planned in adult medicine, child health, surgery, pathology, pharmacotherapy, nursing, general practice, and dentistry; the Cochrane Collaboration and the York Centre for Review and Dissemination in York are providing systematic reviews of the effects of health care; new evidence-based practice journals are being launched; and it has become a common topic in the lay media. But enthusiasm has been mixed with some negative reaction [4-6]. Criticism has ranged from evidence-based medicine being old-hat to it being a dangerous innovation, perpetrated by the arrogant to serve cost-cutters and suppress clinical freedom. As evidence-based medicine continues to evolve and adapt, now is a useful time to refine the discussion of what it is and what it is not.

e

in ic

Evidence-based medicine is the conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients. The practice of evidence-based medicine means integrating individual clinical expertise with the best available external clinical evidence from systematic research. By individual clinical expertise we mean the proficiency and judgement that individual clinicians acquire through clinical experience and clinical practice. Increased expertise is reflected in many ways, but especially in more effective and efficient diagnosis and in the more thoughtful identification and compassionate use of individual patients’ predicaments, rights, and preferences in making clinical decisions about their care. By best available external clinical evidence we mean clinically relevant research, often from the basic sciences of medicine, but especially from patient centred clinical research into the accuracy and precision of diagnostic tests (including the clinical examination), the power of prognostic

A14

| 21st Century Medicine

APPENDIX

markers, and the efficacy and safety of therapeutic, rehabilitative, and preventive regimens. External clinical evidence both invalidates previously accepted diagnostic tests and treatments and replaces them with new ones that are more powerful, more accurate, more efficacious, and safer. Good doctors use both individual clinical expertise and the best available external evidence, and neither alone is enough. Without clinical expertise, practice risks becoming tyrannised by evidence, for even excellent external evidence may be inapplicable to or inappropriate for an individual patient. Without current best evidence, practice risks becoming rapidly out of date, to the detriment of patients.

01

)2

(c

This description of what evidence-based medicine is helps clarify what evidence-based medicine is not. Evidence-based medicine is neither old-hat nor impossible to practice. The argument that everyone already is doing it falls before evidence of striking variations in both the integration of patient values into our clinical behaviour [7] and in the rates with which clinicians provide interventions to their patients [8]. The difficulties that clinicians face in keeping abreast of all the medical advances reported in primary journals are obvious from a comparison of the time required for reading (for general medicine, enough to examine 19 articles per day, 365 days per year [9]) with the time available (well under an hour per week by British medical consultants, even on self-reports [10]).

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

The argument that evidence-based medicine can be conducted only from ivory towers and armchairs is refuted by audits in the front lines of clinical care where at least some inpatient clinical teams in general medicine [11], psychiatry (JR Geddes, et al, Royal College of Psychiatrists winter meeting, January 1996), and surgery (P McCulloch, personal communication) have provided evidence-based care to the vast majority of their patients. Such studies show that busy clinicians who devote their scarce reading time to selective, efficient, patient-driven searching, appraisal and incorporation of the best available evidence can practice evidence-based medicine.

ed

Evidence-based medicine is not “cook-book” medicine. Because it requires a bottom-up approach that integrates the best external evidence with individual clinical expertise and patient-choice, it cannot result in slavish, cook-book approaches to individual patient care. External clinical evidence can inform, but can never replace, individual clinical expertise, and it is this expertise that decides whether the external evidence applies to the individual patient at all and, if so, how it should be integrated into a clinical decision. Similarly, any external guideline must be integrated with individual clinical expertise in deciding whether and how it matches the patient’s clinical state, predicament, and preferences, and thus whether it should be applied. Clinicians who fear top-down cook-books will find the advocates of evidence-based medicine joining them at the barricades.

e

in ic

Evidence-based medicine is not cost-cutting medicine. Some fear that evidence-based medicine will be hijacked by purchasers and managers to cut the costs of health care. This would not only be a misuse of evidence-based medicine but suggests a fundamental misunderstanding of its financial consequences. Doctors practising evidence-based medicine will identify and apply the most efficacious interventions to maximise the quality and quantity of life for individual patients; this may raise rather than lower the cost of their care.

21st Century Medicine | A15

21st century medicine: A New Model for Medical Education and Practice

01

)2

(c

Evidence-based medicine is not restricted to randomised trials and meta-analyses. It involves tracking down the best external evidence with which to answer our clinical questions. To find out about the accuracy of a diagnostic test, we need to find proper cross-sectional studies of patients clinically suspected of harbouring the relevant disorder, not a randomised trial. For a question about prognosis, we need proper follow-up studies of patients assembled at a uniform, early point in the clinical course of their disease. And sometimes the evidence we need will come from the basic sciences such as genetics or immunology. It is when asking questions about therapy that we should try to avoid the non-experimental approaches, since these routinely lead to false-positive conclusions about efficacy. Because the randomised trial, and especially the systematic review of several randomised trials, is so much more likely to inform us and so much less likely to mislead us, it has become the “gold standard” for judging whether a treatment does more good than harm. However, some questions about therapy do not require randomised trials (successful interventions for otherwise fatal conditions) or cannot wait for the trials to be conducted. And if no randomised trial has been carried out for our patient’s predicament, we follow the trail to the next best external evidence and work from there.

0

Authors:

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Despite its ancient origins, evidence-based medicine remains a relatively young discipline whose positive impacts are just beginning to be validated [12, 13], and it will continue to evolve. This evolution will be enhanced as several undergraduate, post-graduate, and continuing medical education programmes adopt and adapt it to their learners’ needs. These programmes, and their evaluation, will provide further information and understanding about what evidence-based medicine is, and what it is not.

David L. Sackett, Professor, NHS Research and Development Centre for Evidence-Based Medicine, Oxford.

ed

William M. C. Rosenberg, Clinical Tutor in Medicine, Nuffield Department of Clinical Medicine, Oxford.

in ic

e

J. A. Muir Gray, Director of Research and Development, Anglia and Oxford Regional Health Auhtority, Milton Keynes R. Brian Haynes, Professor of Medicine and Clinical Epidemiology, McMaster University Hamilton, Canada W. Scott Richardson, Rochester, USA

A16

| 21st Century Medicine

APPENDIX

References: 1. British Medical Association: Report of the working party on medical education. London: British Medical Association, 1995. 2. Standing Committee on Postgraduate Medical and Dental Education: Creating a better learning environment in hospitals: 1.Teaching hospital doctors and dentists to teach. London: SCOPME, 1994. 3. General Medical Council: Education Committee Report. London: General Medical Council, 1994.

(c

4. Grahame-Smith D: Evidence-based medicine: Socratic dissent. BMJ 1995;310:1126-7.

)2

5. Evidence-based medicine, in its place (editorial). Lancet 1995;346:785.

01

6. Correspondence. Evidence-Based Medicine. Lancet 1995;346:1171-2.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

7. Weatherall DJ: The inhumanity of medicine. BMJ 1994;308:1671-2. 8. House of Commons Health Committee. Priority setting in the NHS: purchasing. First report sessions 1994-95. London: HMSO, 1995, (HC 134-1.) 9. Davidoff F, Haynes B, Sackett D, Smith R: Evidence-based medicine; a new journal to help doctors identify the information they need. BMJ 1995;310:1085-6. 10. Sackett DL: Surveys of self-reported reading times of consultants in Oxford, Birmingham, Milton-Keynes, Bristol, Leicester, and Glasgow, 1995. In Rosenberg WMC, Richardson WS, Haynes RB, Sackett DL. Evidence-Based Medicine. London: Churchill -Livingstone (in press). 11. Ellis J, Mulligan I, Rowe J, Sackett DL: Inpatient general medicine is evidence based. Lancet 1995;346:407-10.

ed

12. Bennett RJ, Sackett DL, Haynes RB, Neufeld VR: A controlled trial of teaching critical appraisal of the clinical literature to medical students. JAMA 1987;257:2451-4.

in ic

e

13. Shin JH, Haynes RB, Johnston ME: Effect of problem-based, self-directed undergraduate education on life-long learning. Can Med Assoc J 1993;148:969-76.

21st Century Medicine | A17

21st century medicine: A New Model for Medical Education and Practice

Information about the Chronic Care Model from www.improvingchroniccare.org With the exception of the Chronic Care Model image, all materials and text found on our Web site may be freely used and disseminated. No official permission is needed from ICIC. Certain tools, developed by ICIC, have a copyright attached in order for us to retain the right to distribute and make revisions to the work.

01

)2

(c

Reprint permission is required for use of the Chronic Care Model image. Copyright is held by the American College of Physicians (ACP), which publishes the Annals of Internal Medicine journal. The CCM image first appeared in its current format in the Effective Clinical Practice article Chronic Disease Management: What Will It Take To Improve Care for Chronic Illness? published in August/September of 1998. Used with permission.

0

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All e

in ic Promoting effective change in provider groups to support evidence-based clinical and quality improvement across a wide variety of health care settings. There are many definitions of “chronic condition,” some more expansive than others. We characterize it as any condition that requires ongoing adjustments by the affected person and interactions with the health care system. 133 million people, or almost half of all Americans, live with a chronic condition. 1 That number is projected to increase by more than one percent per year by 2030, resulting in an estimated chronically ill population of 171 million. Almost half of all people with chronic illness have multiple conditions. As a result, many managed care and integrated delivery systems have taken a great interest in correcting the many deficiencies in current

A18

| 21st Century Medicine

APPENDIX

management of diseases such as diabetes, heart disease, depression, asthma and others. 2, 3, 4 Those deficiencies include:  Rushed practitioners not following established practice guidelines  Lack of care coordination  Lack of active follow-up to ensure the best outcomes  Patients inadequately trained to manage their illnesses

01

)2

(c

Overcoming these deficiencies will require nothing less than a transformation of health care, from a system that is essentially reactive - responding mainly when a person is sick - to one that is proactive and focused on keeping a person as healthy as possible. (5, 6, 7) To speed the transition, Improving Chronic Illness Care created the Chronic Care Model, which summarizes the basic elements for improving care in health systems at the community, organization, practice and patient levels.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Model Elements

The Chronic Care Model (CCM) identifies the essential elements of a health care system that encourage highquality chronic disease care. These elements are the community, the health system, self-management support, delivery system design, decision support and clinical information systems. Evidence-based change concepts under each element, in combination, foster productive interactions between informed patients who take an active part in their care and providers with resources and expertise. The Model can be applied to a variety of chronic illnesses, health care settings and target populations. The bottom line is healthier patients, more satisfied providers, and cost savings.

ed in ic

Development of the Chronic Care Model

e

The staff at the MacColl Institute for Healthcare Innovation developed the CCM by drawing on available literature about promising strategies for chronic illness management, and organizing that literature in a new more accessible way. The Model was further refined during a nine-month planning project supported by The Robert Wood Johnson Foundation, and revised based on input from a large panel of national experts. It was then used to collect data and analyze innovative programs recommended by experts. RWJF funded the MacColl Institute to test the Model nationally across varied health care settings, creating the national program, “Improving Chronic Illness Care” (ICIC).

Refinements to the Chronic Care Model In 2003, ICIC and a small group of experts updated the CCM to reflect advances in the field of chronic care both from the research literature and from the scores of health care systems that implemented the Model in their improvement efforts. We list more specific concepts under each of the six elements. Based on more

21st Century Medicine | A19

21st century medicine: A New Model for Medical Education and Practice

recent evidence, five new themes were incorporated into the CCM:  Patient Safety (in Health System);  Cultural competency (in Delivery System Design);  Care coordination (in Health System and Clinical Information Systems)  Community policies (in Community Resources and Policies); and  Case management (in Delivery System Design).

0

Health System

01

)2

(c

The Model element pages have been redesigned to reflect these updates. Each page describes the overall strategy for each element, and the health system change concepts necessary to achieve improvement in that component. The refinements have been emphasized in bold typeface for ready identification.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Create a culture, organization and mechanisms that promote safe, high quality care  Visibly support improvement at all levels of the organization, beginning with the senior leader  Promote effective improvement strategies aimed at comprehensive system change  Encourage open and systematic handling of errors and quality problems to improve care  Provide incentives based on quality of care

 Develop agreements that facilitate care coordination within and across organizations

ed

A system seeking to improve chronic illness care must be motivated and prepared for change throughout the organization. Senior leadership must identify care improvement as important work, and translate it into clear improvement goals and policies that are addressed through application of effective improvement strategies, including use of incentives, that encourage comprehensive system change. Effective organizations try to prevent errors and care problems by reporting and studying mistakes and making appropriate changes to their systems. Breakdowns in communication and care coordination can be prevented through agreements that facilitate communication and data-sharing as patients navigate across settings and providers.

e

in ic

Delivery System Design Assure the delivery of effective, efficient clinical care and self-management support  Define roles and distribute tasks among team members

A20

| 21st Century Medicine

APPENDIX

 Use planned interactions to support evidence-based care  Provide clinical case management services for complex patients  Ensure regular follow-up by the care team  Give care that patients understand and that fits with their cultural background

01

)2

(c

Improving the health of people with chronic illness requires transforming a system that is essentially reactive - responding mainly when a person is sick - to one that is proactive and focused on keeping a person as healthy as possible. That requires not only determining what care is needed, but spelling out roles and tasks for ensuring the patient gets care using structured, planned interactions. And it requires making follow-up a part of standard procedure, so patients aren’t left on their own once they leave the doctor’s office. 5,6,7 More complex patients may need more intensive management (care or case management) for a period of time to optimize clinic care and self-management. Health literacy and cultural sensitivity are two important emerging concepts in health care. Providers are increasingly being called upon to respond effectively to the diverse cultural and linguistic needs of patients.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Decision Support

Promote clinical care that is consistent with scientific evidence and patient preferences  Embed evidence-based guidelines into daily clinical practice

 Share evidence-based guidelines and information with patients to encourage their participation  Use proven provider education methods

 Integrate specialist expertise and primary care

ed

Treatment decisions need to be based on explicit, proven guidelines supported by clinical research. Guidelines should also be discussed with patients, so they can understand the principles behind their care. Those who make treatment decisions need ongoing training to stay up-to-date on the latest evidence, using new models of provider education that improve upon traditional continuing medical education. To change practice, guidelines must be integrated through timely reminders, feedback, standing orders and other methods that increase their visibility at the time that clinical decisions are made. The involvement of supportive specialists in the primary care of more complex patients is an important educational modality.

e

in ic

Clinical Information Systems Organize patient and population data to facilitate efficient and effective care  Provide timely reminders for providers and patients

21st Century Medicine | A21

21st century medicine: A New Model for Medical Education and Practice

 Identify relevant subpopulations for proactive care  Facilitate individual patient care planning  Share information with patients and providers to coordinate care  Monitor performance of practice team and care system

01

)2

(c

Effective chronic illness care is virtually impossible without information systems that assure ready access to key data on individual patients as well as populations of patients. 11, 12 A comprehensive clinical information system can enhance the care of individual patients by providing timely reminders for needed services, with the summarized data helping to track and plan care. At the practice population level, an information system can identify groups of patients needing additional care as well as facilitate performance monitoring and quality improvement efforts.

0

Self-Management Support

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Empower and prepare patients to manage their health and health care  Emphasize the patient’s central role in managing their health

 Use effective self-management support strategies that include assessment, goal-setting, action planning, problem-solving and follow-up  Organize internal and community resources to provide ongoing self-management support to patients All patients with chronic illness make decisions and engage in behaviors that affect their health (selfmanagement). Disease control and outcomes depend to a significant degree on the effectiveness of selfmanagement.

ed

Effective self-management support means more than telling patients what to do. It means acknowledging the patients’ central role in their care, one that fosters a sense of responsibility for their own health. It includes the use of proven programs that provide basic information, emotional support, and strategies for living with chronic illness. Self-management support can’t begin and end with a class. Using a collaborative approach, providers and patients work together to define problems, set priorities, establish goals, create treatment plans and solve problems along the way.9

e

in ic

The Community Mobilize community resources to meet needs of patients  Encourage patients to participate in effective community programs

A22

| 21st Century Medicine

APPENDIX

 Form partnerships with community organizations to support and develop interventions that fill gaps in needed services  Advocate for policies to improve patient care By looking outside of itself, the health care system can enhance care for its patients and avoid duplicating effort. Community programs can support or expand a health system’s care for chronically ill patients, but systems often don’t make the most of such resources. A health system might form a partnership with a local senior center that provides exercise classes as an option for elderly patients. State departments of health and other agencies often have a wealth of helpful material available for the asking - wallet cards with tips for controlling diabetes, for example. National patient organizations such as the American Diabetes Association can help by promoting self-help strategies.

(c

01

)2

Local and state health policies, insurance benefits, civil rights laws for persons with disabilities, and other health-related regulations also play a critical role in chronic illness care. Advocacy by medical organizations on behalf of their patients can make a difference.

0 lM na tio d. un rve r F se fo re te ts itu h st rig In All

Footnotes

Partnership for Solutions: Johns Hopkins University, Baltimore, MD for the Robert Wood Johnson Foundation (September 2004 Update). “Chronic Conditions: Making the Case for Ongoing Care”

2.

D.H. Stockwell, S. Madhavan, H. Cohen, G. Gibson and M.H. Alderman, “The determinants of hypertension awareness, treatment, and control in an insured population”, American Journal of Public Health 84 (1994): 1768-1774

3.

S.J. Kenny et al., “Survey of physician practice behaviors related to diabetes mellitus in the U.S.: Physician adherence to consensus recommendations”, Diabetes Care 16 (1993): 15071510

4.

J.M. Perrin, Homer CJ, Berwick DM, Woolf AD, Freeman JL, Wennberg JE. “Variations in rates of hospitalization of children in three urban communities”, New England Journal of Medicine 320: 1183-1187

5.

E.H. Wagner, B.T. Austin and M. Von Korff, “Improving outcomes in chronic illness”, Managed Care Quarterly 4 (1996): (2) 12-25

6.

E.H. Wagner, B.T. Austin and M. Von Korff, “Organizing care for patients with chronic illness”, Milbank Quarterly 74 (1996): 511-544

7.

E. Calkins, C. Boult, E.H. Wagner and J. Pacala, “New Ways to Care for Older People: Building Systems Based on Evidence”, New York: Springer; (1999)

8.

D.K. McCulloch, M.J. Price, M. Hindmarsh and E.H. Wagner, “A population-based approach

ed

1.

e

in ic

21st Century Medicine | A23

21st century medicine: A New Model for Medical Education and Practice

to diabetes management in a primary care setting: early results and lessons learned”, Effective Clinical Practice (1998):12-22 9.

M. Von Korff, J. Gruman, J.K. Schaefer, S.J. Curry and E.H. Wagner, “Collaborative management of chronic illness”, Annals of Internal Medicine 127 (1997): 1097-1102

10. W. Katon, M. Von Korff, E. Lin, E. Walker, G.E. Simon, T. Bush, P. Robinson and J. Russo, “Collaborative management to achieve treatment guidelines”, Journal of the American Medical Association 273 (1995): 1026-1031 11. M.R. Greenlick, “The emergence of population-based medicine”, HMO Practice 9 (1995): 120-122

)2

(c

12. E.H. Wagner, “Population-based management of diabetes care,” Patient Education and Counseling 16 (1995): 225-230

01

13. E.H. Wagner, C. Davis, J. Schaefer, M. Von Korff, B. Austin, “A survey of leading chronic disease management programs: are they consistent with the literature?”, Managed Care Quarterly 7 (1999): (3) 56-66

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

14. Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. “Impact of Recent Increase in Incidence on Future Diabetes Burden, U.S., 2005-2050”. Diabetes Care, 2006, 29 (9), 2114-2116

ed e

in ic

A24

| 21st Century Medicine

APPENDIX

Excerpts from Patient-Centered Care: Antecedents, Triggers, and Mediators Chapter 8, Textbook of Functional Medicine By Leo Galland, MD

01

)2

(c

The goal of person-centered diagnosis is to enable healers to develop individualized treatment plans that are based upon an understanding of the physiological, environmental, and psychosocial contexts within which each person’s illnesses or dysfunctions occur…. you must start by eliciting all of the patient’s concerns. In actively listening to the patient’s story, you attempt to discover the antecedents, triggers and mediators that underlie symptoms, signs, illness behaviors, and demonstrable pathology. Functional medicine is based upon treatment that is collaborative, flexible, and focused on the control or reversal of each person’s individual antecedents, triggers and mediators, rather than the treatment of disease entities.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

It is the functional medicine practitioner’s job to know not just the ailments or their diagnoses, but the physical and social environment in which sickness occurs, the dietary habits of the person who is sick (present diet and pre-illness diet), his beliefs about the illness, the impact of illness on social and psychological function, factors that aggravate or ameliorate symptoms, and factors that predispose to illness or facilitate recovery. This information is necessary for establishing a functional treatment plan. What modern science has taught us about the genesis of disease can be represented by three words: triggers, mediators, and antecedents. Triggers are discrete entities or events that provoke disease or its symptoms. Microbes are an example. The greatest scientific discovery of the 19th century was the microbial etiology of the major epidemic diseases. Triggers are usually insufficient in and of themselves for disease formation, however. Host response is an essential component.

ed

Identifying the biochemical mediators that underlie host responses was the most productive field of biomedical research during the second half of the 20th century. Mediators, as the word implies, do not “cause” disease. They are intermediaries that contribute to the manifestations of disease. Antecedents are factors that predispose to acute or chronic illness. For a person who is ill, they form the illness diathesis. From the perspective of prevention, they are risk factors. Knowledge of antecedents has provided a rational structure for the organization of preventive medicine and public health.

e

in ic

Medical genomics seeks to better understand disease by identifying the phenotypic expression of disease-related genes and their products. The application of genomic science to clinical medicine requires the integration of antecedents (genes and the factors controlling their expression) with mediators (the downstream products of gene activation). Mediators, triggers, and antecedents are not only key biomedical concepts, they are also important psychosocial concepts. In person-centered diagnosis, the mediators, triggers, and antecedents for each person’s illness form the focus of clinical investigation.

21st Century Medicine | A25

21st century medicine: A New Model for Medical Education and Practice

Antecedents and the Origins of Illness Understanding the antecedents of illness helps the physician understand the unique characteristics of each patient as they relate to his or her current health status. Antecedents may be thought of as congenital or developmental. The most important congenital factor is gender: women and men differ markedly in susceptibility to many disorders. The most important developmental factor is age; what ails children is rarely the same as what ails the elderly. Beyond these obvious factors lies a diversity as complex as the genetic differences and separate life experiences that distinguish one person from another.

Triggers and the Provocation of Illness

(c

01

)2

A trigger is anything that initiates an acute illness or the emergence of symptoms. The distinction between a trigger and a precipitating event is relative, not absolute; the distinction helps organize the patient’s story. As a general rule, triggers only provoke illness as long as the person is exposed to them (or for a short while afterward), whereas a precipitating event initiates a change in health status that persists long after the exposure ends.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

ed

Common triggers include physical or psychic trauma, microbes, drugs, allergens, foods (or even the act of eating or drinking), environmental toxins, temperature change, stressful life events, adverse social interactions, and powerful memories. For some conditions, the trigger is such an essential part of our concept of the disease that the two cannot be separated; the disease is either named after the trigger (e.g., “Strep throat”) or the absence of the trigger negates the diagnosis (e.g., concussion cannot occur without head trauma). For chronic ailments like asthma, arthritis, or migraine headaches, multiple interacting triggers may be present. All triggers, however, exert their effects through the activation of host-derived mediators. In closed-head trauma, for example, activation of NMDA receptors, induction of nitric oxide synthase (iNOS), and liberation of free intra-neuronal calcium determine the late effects. Intravenous magnesium at the time of trauma attenuates severity by altering the mediator response.1,2 Sensitivity to different triggers often varies among persons with similar ailments. A prime task of the functional practitioner is to help patients identify important triggers for their ailments and develop strategies for eliminating them or diminishing their virulence.

e

in ic

Mediators and the Formation of Illness A mediator is anything that produces symptoms, damage to tissues of the body, or the types of behaviors associated with being sick. Mediators vary in form and substance. They may be biochemical (like prostanoids and cytokines), ionic (like hydrogen ions), social (like reinforcement for staying ill), psychological (like fear), or cultural (like beliefs about the nature of illness). A list of common mediators is presented in Table 8.1. Illness in any single person usually involves multiple interacting mediators. Biochemical, psychosocial, and cultural mediators interact continuously in the formation of illness.

1

Cernak I, Savic VJ, Kotur J, et al. Characterization of plasma magnesium concentration and oxidative stress following graded traumatic brain injury in humans. J Neurotrauma. 2000;17(1):53-68. Vink R, Nimmo AJ, Cernak I. An overview of new and novel pharmacotherapies for use in traumatic brain injury. Clin Exp Pharmacol Physiol. 2001;28(11):919-921.

2

A26

| 21st Century Medicine

APPENDIX

Table 8.1 Common Illness Mediators Biochemical Hormones Neurotransmitters Neuropeptides Cytokines Free radicals Transcription factors

01

)2

(c

Subatomic Ions Electrons Electrical and magnetic fields

0

Cognitive/emotional Fear of pain or loss Feelings or personal beliefs about illness Poor self-esteem, low perceived self-efficacy Learned helplessness Lack of relevant health information

lM na tio d. un rve r F se fo re te ts itu h st rig In All

ed

Social/cultural Reinforcement for staying sick Behavioral conditioning Lack of resources due to social isolation or poverty The nature of the sick role and the doctor/patient relationship Sample Form used by Functional Medicine Practitioners to Enhance Pattern Recognition

e

in ic 21st Century Medicine | A27

21st century medicine: A New Model for Medical Education and Practice

Pattern Recognition: Ulcerative Colitis Immune Surveillance Practitioner’s Notes 1 n Breastfed How long? 2 n Vaccinated Adverse reactions? 3 n Skin rashes

9 10

11

15

A28

n Fatigue n Other:

| 21st Century Medicine

e

14

n Multiple infections n Non-specific increased mucus / allergic symptoms

in ic

13

n Neurological symptoms that developed slowly over the course of a day and then resolved after several weeks to months, clearing slowly n Change in vision n Coordination n Numbness n Cognitive problems n Family history of autoimmune disease

ed

12

n Migraines Triggered by foods ______ odors _______ n Cravings Fatigue after eating certain foods? n Illness, dysfunction after flu-like or GI flu illness

lM na tio d. un rve r F se fo re te ts itu h st rig In All

8

0

7

n Dry mouth, lack of salivation n Dry eyes

01

6

)2

5

(c

4

n Reaction to contact with significant redness (dermatographia)? n Joint swelling, redness

APPENDIX

Pattern Recognition: Ulcerative Colitis Inflammatory Process Practitioner’s Notes 1 n Swelling n Diffuse (edema) n Localized (angioedema, papules, uticaria) 2 n Erthema (hyperemia, rashes, erysipelas) 3 4

(c

5

n Heat n systemic (fever) n localized (warmth) n Pain (arthralgias, neuralgias, cramping)

12

n Other:

6

01

)2

11

n Irritation (pruritis, sneezing, etc.) n Loss of function n Associated with pain or scarring n Cognitive impairment (neurodegeneration) n Excessive mucus or fluid production (includes bronchospasm, diarrhea, etc.) n Inflammatory markers n Elevated CRP, ESR, WBC (microscopic or gross purulence) n thrombocytosis n fibrinogen n inflammatory cytokines (IL-1, IL-6, TNF alpha), n decreased complement split products, n homocysteine n lipoprotein A2 (PLAC) n calprotectin (fecal or serum) n Autoantibodies (ANA, RF) or elevated immunoglobulins (abnormal SPEP, tissue transglutaminase IgC, etc. n Elevated free radical markers (lipid peroxides, F2 isoprostanes, 8-OH-d-G) n Hypercoagulability

0

8

e

in ic

10

ed

9

lM na tio d. un rve r F se fo re te ts itu h st rig In All

7

21st Century Medicine | A29

21st century medicine: A New Model for Medical Education and Practice

Pattern Recognition: Ulcerative Colitis Digestion, Absorption, Barrier Integrity Practitioner’s Notes 1 n Symptoms that arise around eating 2

3 4 5

9 10

11

15

A30

| 21st Century Medicine

e

14

in ic

13

n Burping, belching, gurgling, rumbling n Diagnosed with reflux disease (GERD)? Medication________________ x day, week n Diagnosed with peptic ulcers Antacids________________ x day, week n Tend toward wither diarrhea (loos stools) or constipation? If so, which is more typical? Bowel mocements____________ x day, week n Stool consistency varies______________ If so, which is more typical? Bowel movements_________ x day / week n Ever sweat intensely after eating certain foods or after meals? n Camp, raft or spend time in wilderness areas and if so, do you drink stream water? n Live with pets? If so, have they had gastrointenstinal infections? n Other:

ed

12

lM na tio d. un rve r F se fo re te ts itu h st rig In All

8

0

7

01

6

)2

(c

n Chew your food thoroughly and east slowly or n East quickly or on the run n Problems with saliva, such as dry mouth or drooling? n Experience early satiety, fullness with small portions n Consistent discomfort after eating a typical meal n Frequent nauseas Triggered by:___________________________ n Gas or bloating

APPENDIX

Pattern Recognition: Ulcerative Colitis Detoxification and Biotransformation Practitioner’s Notes 1 n Smoke_____ how much x day / week______ n Exposed regularly to secondhand smoke 2 3 4

10

11

lM na tio d. un rve r F se fo re te ts itu h st rig In All

9

0

8

01

7

n Use of chemical preparations at work or as hobby n Breathe toxic elements in the air, fumes or other petrochemicals n Symptoms (fatigue, headaches, nausea) upon exposure to various chemicals (such as perfume, smoke, diesel or gas fumes, etc.) n Eat fish three times a week or more

)2

6

(c

5

n Mercury amalgam fillings n Live or work in a densely populated area or near an industrial plant n Use of pesticides, herbicides, insecticides in the n home or garden

n Prone to problems taking most medications (overly sensitive to most medication and experience numerous side effects) n React quickly to dental anesthetics n Require repeated administraiton of anesthetic n Numbness of one shot lasts a long time n Other:

ed e

in ic 21st Century Medicine | A31

21st century medicine: A New Model for Medical Education and Practice

Pattern Recognition: Ulcerative Colitis Oxidative/Reductive Practitioner’s Notes 1 n Smoke_____ how much x day / week______ Exposed regularly to secondhand smoke 2 n Has chronic inclammatory condition or an autoimmune disease 3 n Exercise intolerance 4

11

n Easily fatigued n Regularly feels ‘foggy headed’ or mentally fatigued for no apparent reason n Live or work in a densely populated area or near an industrial plant n Use of pesticides, herbicides, insecticides in the home or garden n Breathe toxic elements in the air, fumes or other petrochemicals n Unpleasant or worrisome symptoms at higher altitudes n Radiation exposure n extensive medical radiation n environmental exposure n Fly regularly

12

n Other:

5

10

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

9

0

8

01

7

)2

(c

6

e

in ic

A32

| 21st Century Medicine

APPENDIX

Pattern Recognition: Ulcerative Colitis Hormone, Neurotransmitter Regulation Practitioner’s Notes 1 n Sluggish and unable to get started n Agitated/anxious, difficulty slowing down, relax 2

n Difficulty falling asleep n Awaken frequently during the night x ________ Typical reason for waking up_____________

3

n n n n

4

n More likely to be calm in a crisis n Completely disheveled and agitated even in mildly stressful circumstances n Temperature intolerant: n More often colder than others n More often hotter than others n Variable sensitivity to temperature n Experience hot flashes n Heavy or irregular periods

01

)2

(c

Change in metabolism, in weight or energy levels Loss of stamina with weight gain Increased nervousness with weight loss, or A different combination of these problems

0

6 7

8

12

e

11

n Signs or insulin resistance/metabolic syndrome n Problems with mood or lability of emotional responses (rapid mood swings) n Emotionally stable n Emotionally labile n Other:

in ic

10

n Loss of libido n Erectile dysfunction n Inability to achieve orgasm n Memory loss or brain fog

ed

9

lM na tio d. un rve r F se fo re te ts itu h st rig In All

5

21st Century Medicine | A33

21st century medicine: A New Model for Medical Education and Practice

Pattern Recognition: Ulcerative Colitis Psychological and Spiritual Equilibrium Practitioner’s Notes 1 n Feeling stressed n Problems with acute or chronic stress n Sadness, depression, emotional lability, anxiety as n current symptoms or n in the past n Mood disorders (current or past diagnosis)

3

n Psychiatric diseases: thought disorders, character disorders, neuroses (as a current symptom as well as any history of). Symptoms as well as a formal diagnosis. n Addictions (food, alcohol, drugs, cigarettes)

7 8 9

10

14 15

A34

n Lack or social support n Other:

| 21st Century Medicine

e

13

n Caregiver for a disable, sick or elderly person n Feeling unhappiness with life situation (job, family. friends) n Loss or meaning, faith

in ic

12

n Chronic or serious illness or pain in patient, family or friend n Allergies to food/environment that create difficulties (serious issues avoiding allergens) in living n Grief, mourning, loss

ed

11

lM na tio d. un rve r F se fo re te ts itu h st rig In All

6

n Problems with body weight (over or under) or image: eating disorders n Self destructive behavior (defined by practitioner or patient) n History of trauma, abuse neglect

0

5

01

4

)2

(c

2

APPENDIX

Pattern Recognition: Ulcerative Colitis Structural Integrity Practitioner’s Notes 1 n Joint pain 2 3

4

n Pains impacted by repositioning the body (worse or better) n Postural abnormalities (head anterior to shoulders, swayback, tilted head, elevated shoulder, hip sway with gait, awkward gait) n Abnormal wear pattern of shoes

01

)2

6

(c

5

n Pain impacted by movement (better or worse) n Pains that diminish as the day progresses, returning the next AM n Pains that increase as the day progresses, minimized the next AM n Pains impacted by posture

0

8 9 10

lM na tio d. un rve r F se fo re te ts itu h st rig In All

7

n Abnormal (awkward) gait patterns n Stiffness in AM getting out of bed, relieved by a hot shower n Other:

ed e

in ic 21st Century Medicine | A35

21st century medicine: A New Model for Medical Education and Practice

Functional Medicine Case: Psoriatic Arthritis1 Kara N. Fitzgerald, ND, and Mark Hyman, MD

Functional Medicine and Autoimmune Disease

01

)2

(c

Autoimmune diseases collectively affect up to 23.5 million Americans.1 They are heterogeneous in pathology but relatively uniform in etiology. Classifying autoimmune diseases based on symptoms and pathology does not usually improve treatment decisions. Standard treatments include NSAIDs, steroids, anti-neoplastic agents, and tumor necrosis factor-alpha antagonists. These tools have significant risks and are often applied regardless of the diagnosis. Frequently, they are only modestly effective in relieving symptoms and limiting the advancing disease process. Despite the extensive categorization of autoimmune diseases into diagnoses such as lupus, rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, multiple sclerosis, nephritis, and scleroderma, the treatments are based on pathology, not etiology. The conventional approach to autoimmune disease seeks to answer the question of WHAT disease the patient has, not WHY the patient has the disease, suggesting only small variations in treatment.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Functional medicine considers the diagnosis, of course, but also seeks to answer the question WHY. The etiology of any disease may be different in people with the same diagnosis or pathology. Conversely, the etiology may be the same in patients with very different pathologies—for example, mercury toxicity is found in both multiple sclerosis and Crohn’s disease. Approaches to treatment, therefore, will vary when the upstream causes and downstream effects differ from patient to patient. Treating only the downstream effects (such as nutrient deficiencies or food sensitivities due to malabsorption and intestinal hyperpermeability) without treating the upstream causes (such as gluten sensitivity, gastrointestinal yeast, or mercury toxicity) will often result in treatment failure.

ed

Focusing on the patient’s individual etiology of autoimmune disease provides a personalized framework for diagnosis and treatment. There are 5 primary etiologic factors that affect gene expression and give rise to nearly all disease, including autoimmune disease: toxins, allergens, infections (or microbial imbalances), poor diet, and stress.

e

in ic

Findings and Assessment at Initial Visit History of Present Illness

At age 56, MP presented with a 4-year diagnosis of psoriatic arthritis that was progressively worsening despite aggressive medication therapy. He experienced severe pain, decreased range of motion, and swelling in his feet, ankles, knees, and hands. He walked with a limp. His left shoulder was also frequently painful. All symptoms were worse in the morning. He had been taking etodolac (Lodine®) and methotrexate for the past 3 years, and adalimumab (Humira®) for the past 6 months. The onset of psoriatic arthritis began with the development of pain and redness in his right great toe, for which he was treated unsuccessfully with antibiotics. Shortly thereafter, he developed psoriasis behind his knees, on his feet, and behind his ears. He had psoriatic nails for most of his life.

This case was assembled and edited by The Institute for Functional Medicine with the gracious support of Metametrix Clinical Laboratory and The UltraWellness Center.

1

A36

| 21st Century Medicine

APPENDIX

Just prior to receiving the diagnosis of psoriatic arthritis, he had a left knee arthroscopy that was negative for degenerative disease but positive for synovitis. He also developed a hemorrhagic Baker’s cyst, causing severe swelling and pain in his left foot and knee. MP also complained of esophageal reflux, a recent 15-pound weight gain, and intermittent depression.

Past Medical History Migraine headaches Disc protrusion with sciatica at L5-S1

Family Medical History

)2

(c

 MP’s mother is alive at age 82; she has been diagnosed with congestive heart failure, malnutrition, rheumatoid arthritis, depression, and schizophrenia.

01

 MP’s father died at age 62; he had cancer, obesity, and alcoholism.

0

 MP’s brothers have been diagnosed with cancer, inflammatory arthritis, inflammatory bowel disease, alcoholism, and depression.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

 His sisters have alcoholism, depression, and bipolar disorder.

 The maternal grandmother died at 80; she had been diagnosed with hypertension, diabetes and depression.  The paternal grandmother died at 70; she had heart disease, hypertension, obesity, and diabetes.  The paternal grandfather died at 80; he had heart disease, hypertension, obesity, and diabetes.  MP’s son has schizophrenia and his daughter has ADHD.

ed

Medications and Supplements

e

in ic

Etodolac (Lodine) 500 mg; 1 tab PO QD Methotrexate 2.5 mg; 6 tablets per week Adalimumab (Humira) 40 mg/0.8 mL; 1 SQ injection every other week Aspirin 81 mg; 1 tablet PO QD Zolpidem (Ambien®) prn Omega-3 EPA 1000 mg; 1 capsule PO QD Multivitamin and mineral; 1 tablet PO QD Past history of multiple courses of antibiotics

Social History MP leads a stressful life with a highly demanding job as a university professor and researcher. His schedule leaves little time for relaxation, although he does meditate daily. MP is married with 2 children, including one who has been diagnosed with schizophrenia and lives at home.

21st Century Medicine | A37

21st century medicine: A New Model for Medical Education and Practice

Nutrition, Exercise, and Environmental Exposures Usual Dietary Intake: Breakfast: oatmeal with low fat milk, brown sugar Lunch: tuna wrap or soup with cookies Dinner: fish or meat, vegetables, potato or pasta, occasional salad with commercial salad dressing Snacks: cookies or protein bars MP avoids chocolate and fatty foods. He eats out more than 5 times per week. He craves sweets and caffeine. MP consumes 3-4 cups of coffee and one diet soda per day (357-464 mg caffeine). MP drinks approximately 12 alcoholic beverages per week, including wine and the occasional scotch. MP reported that his liver enzymes have been elevated, and he has some concern about his drinking.

)2

(c

Exercise:

01

MP does not engage in exercise due to his long days, but is motivated to start.

Systems Review

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Many mercury amalgams Mold exposure

0

Environmental Exposures:

General: 15-pound weight gain HEENT: Sensitive to loud noises; dry eyes with crusty secretions; intolerant of cigarette smoke, perfumes, and auto exhaust; canker sores; esophageal reflux GI: Chronic constipation MSK: Tendonitis M/E: Intermittent depression, difficulty concentrating, irritability

| 21st Century Medicine

e

A38

in ic

Blood pressure 138/87 (LAS) Height 70.5" Weight 204 pounds Body mass index 28.85 Waist circumference 40" Hip circumference 43" Waist-hip ratio 0.9

ed

Significant Physical Exam Findings

APPENDIX

Initial Assessment and Laboratory Recommendations Organized According to the Functional Medicine Matrix Initial Clinical Assessment

Laboratory Tests Ordered

Immune Surveillance and Inflammatory Process Psoriatic arthritis Psoriasis Psoriatic nails Blepharitis Aphthous stomatitis

01

)2

(c

1. 2. 3. 4. 5. 6. 7. 8.

HLA DQ2 and DQ8 genotypes Celiac panel IgG food sensitivities Inflammatory/autoimmune panel with Iron Vitamin D Omega-3 and 6 fatty acids Lipid peroxides (oxidative stress marker) RBC magnesium

0

Hormone and Neurotransmitter Regulation 9. Comprehensive metabolic panel with fasting glucose & insulin, HgbA1C 10. Lipids 11. Saturated and monounsaturated fatty acids 12. Thyroid panel

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Depression Family history of heart disease, hypertension, psychiatric disorders, diabetes

Digestion and Absorption

Gastroesophageal reflux disease Chronic constipation Yeast overgrowth Migraines Family history IBD

13. DNA microbial stool analysis with chemistries *HLA DQ , IgG foods, celiac panel

14. Whole blood toxic metals 15. Urine toxic metals challenge test (with DMPS chelating agent)

e

in ic

Mercury toxicity (multiple amalgams)

ed

Detoxification and Biotransformation

Psychological and Spiritual Equilibrium High-stress work life Depression Family history of psychiatric illness

*Vitamin D, omega-3 and -6 fatty acids, thyroid panel

*Laboratory tests frequently pertain to multiple areas of imbalance, and therefore may be listed in more than one Matrix category.

21st Century Medicine | A39

21st century medicine: A New Model for Medical Education and Practice

Significant Laboratory Findings Organized According to the Functional Medicine Matrix Immune Surveillance and Inflammatory Process Test

Results

1. DQ Genotype

Allele Detected: HLA DQA1*0501

01

)2

(c

Psoriatic arthritis is associated with celiac disease and subclinical gluten enteropathy.2 HLA DQ is a heterodimer cell surface type protein found on antigen-presenting cells. There are 9 serotypes of DQ proteins. Approximately 90% of celiac patients express the DQ2 heterodimer serotype, and approximately 7% of patients express the DQ8. The DQ2 heterodimer is encoded by the DQA1*0501 and the DQB1*0201 alleles; DQ8 is encoded by the DQA1*0301 and the DQB1*0302 alleles. More than 3% of celiac patients present with half the DQ2 heterodimer. In one study looking at 1008 European celiac patients, 61 were identified who carried neither the DQ2 nor DQ8 heterodimers; 57 of these encoded half of the DQ2 heterodimer.3

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

MP’s test results demonstrated the presence of half the DQ2 heterodimer—specifically, the HLA DQA1*05 allele. Thus, celiac disease could not be ruled out based on this finding. HLA DQ susceptibility is carried by about 30-40% of the population, but only 1% manifest with frank celiac disease. Test 2. Celiac Disease Panel Immunoglobulin A

438 2800

H

1,079-2,733; 1,079-2,800

Palmitic acid Monounsaturated Fatty Acids:

01

)2

(c

0

Test 12. Thyroid Panel TSH T4, Free T3, Free

Reference Interval

2.39

HN

0.28-3.89 mIU/L

0.58

LN

0.58-1.64 ng/dL



LN

2.5-3.9 pg/mL

2.9

< 20

< 40 IU/mL

< 20

or = 3.5 is associated with an increased burden of coronary artery disease on cardiac catheterization. J Cardiometab Syndr. Winter 2006;1(1):13-15. 26. Diagnosis and management of the metabolic syndrome: an american heart association/national heart, lung, and blood institute scientific statement: executive summary. Crit Pathw Cardiol. Dec 2005;4(4):198-203. 27. Tam LS, Tomlinson B, Chu TT, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls--the role of inflammation. Rheumatology (Oxford). May 2008;47(5):718-723. 28. Attie AD, Krauss RM, Gray-Keller MP, et al. Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J Lipid Res. Nov 2002;43(11):1899-1907. 29. Wartofsky L, Dickey RA. The evidence for a narrower thyrotropin reference range is compelling. J Clin Endocrinol Metab. Sep 2005;90(9):54835488. 30. Waldman A, Gilhar A, Duek L, Berdicevsky I. Incidence of Candida in psoriasis--a study on the fungal flora of psoriatic patients. Mycoses. May 2001;44(3-4):77-81. 31. ATSDR. Public Health Statements: Mercury. www.atsdr.cdc.gov/phs/phs.asp?id=112&tid=24. Accessed 01-15-10.

0

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

in ic

A56

| 21st Century Medicine

APPENDIX

Functional Medicine Case: Attention Deficit Hyperactivity Disorder (ADHD)1 Kara N. Fitzgerald, ND, and Mark Hyman, MD

Findings and Assessment at Initial Visit History of Present Illness

01

)2

(c

LC, 12 years old, presented with attention deficit hyperactivity disorder (ADHD), dysgraphia, environmental allergies, asthma, insomnia, eczema, canker sores, migraine headaches, muscle cramps, stomach pain, nausea and diarrhea. He was first diagnosed with ADHD at age 5. He repeated kindergarten because of attention and behavioral difficulties. He began methylphenidate (Ritalin®) in first grade and continued to take it through fourth grade, although it did not change his behavior significantly. The drug was discontinued in fourth grade due to growth retardation. Off the medication, he gained weight but also increased his intake of junk food and deli meats.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

LC had never received a positive teacher’s report. Off the methylphenidate, he continued to be disruptive and unfocused. He excelled in math but had severe dysgraphia (Figure 1). (Dysgraphia is defined as illegible handwriting and spelling errors and is associated with ADHD.1) LC’s environmental allergy symptoms were sinus congestion, postnasal drip, sore throats, and hives, for which he took cetirizine (Zyrtec®). His mother had removed his bedroom carpet and installed hardwood floors, but there was minimal improvement in his symptoms after these changes. His mother noted that dairy worsened his sinus congestion and postnasal drip. LC usually developed full-blown sinusitis about twice a year, for which he was prescribed antibiotics.

ed

As a toddler, LC had developed asthma, hyperkeratosis pilaris, and eczema. For the asthma, LC was maintained on albuterol, levalbuterol (Xopenex®) and flunisolide (AeroBid®). The asthma caused difficulty with breathing at night, and therefore he did not sleep well. LC also suffered with cold-induced asthma attacks. His skin and anus were frequently itchy, and he got frequent canker sores in his mouth.

in ic

e

LC suffered from migraine headaches with hypersensitivity to light and sound, and had muscle cramps and spasms. For these complaints, he was given acetaminophen and ibuprofen. His stomach pain was treated with cimetidine. He also complained of nausea and had frequent bouts of diarrhea. Comment: In most realms of psychiatry all the physical problems covered in LC’s HPI are considered irrelevant in guiding diagnosis and therapy of brain disorders or ADHD. In looking at his case from a functional perspective, however, they are the most relevant findings in his history and provide clear treatment direction.

Past Medical History Birth and Infancy: LC was a healthy seven lb, 10 oz baby, but the vaginal delivery was difficult. He was treated for hyperbilirubinemia. LC was breastfed for 10 months, and then he was given soy formula due to a “sensitive stomach.” Gluten-containing grains were introduced before one year of age. He was prone to diaper rash, had sensitive skin, and received frequent antibiotics for otitis media as a toddler. This case was assembled and edited by The Institute for Functional Medicine with the gracious support of Metametrix Clinical Laboratory and The UltraWellness Center.

1

21st Century Medicine | A57

21st century medicine: A New Model for Medical Education and Practice

Comment: When introduced into the diet prior to the age of one, gluten-containing grains are associated with a statistically significant increase in the incidence of celiac disease in susceptible patients.2 Further, the use of soy formula in infants with a first degree relative with allergies may be associated with increased incidence of allergies, food intolerances and eczema.3 Early antibiotic use is also associated with increased incidence of atopic conditions, including asthma.4-7

Immunizations: LC received a full vaccine schedule, including annual influenza shots. Trauma: LC sustained a concussion at 5 years old, but the CAT scan was normal.

)2

(c

Family Medical History

01

LC’s mother had migraine headaches, sinusitis, and food allergies. His sister had environmental allergies. LC’s father was in good health.

0 Cetirizine (Zyrtec) Albuterol Levalbuterol Inhaler (Xopenex) Flunisolide (Nasarel) Cimetidine (Tagamet®) Acetaminophen Ibuprofen

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Medications

ed

Comment: This is an overwhelming pharmacopoeia for a 12-year-old boy, and his physical, mental, and behavioral symptoms still were not under control. Even the methylphenidate did not significantly help his school performance or behavior or “cure” his ADHD, although it did cause growth retardation, and was therefore discontinued. Side effects of his other medications may also have been involved in the pathogenesis of his complaints. For example, cimetidine has been associated with nutritional deficiencies and gastrointestinal bacterial overgrowth from gastric acid inhibition.8 Glutathione depletion results from acetaminophen use9; and intestinal permeability increases with use of nonsteroidal anti-inflammatory medications such as ibuprofen.10 Flunisolide has also been shown to inhibit growth in children.1

e

in ic

Nutrition and Environmental Exposures Usual Dietary Intake: Breakfast: eggs and bacon, cereals with soy milk, occasional fruit Lunch: deli meat sandwiches, cookies, peanut butter and crackers, carrots, and lemonade Dinner: pizza, pork or chicken, broccoli, green beans, and rice/pasta/potatoes LC had strong sugar and pasta cravings. He ate candy, cookies, or ice cream on a daily basis, although he felt better when he avoided dairy. Environmental Exposures: LC’s house had an unaddressed mold infestation. The type of mold was unknown. LC had no known drug allergies, but had numerous environmental allergies, including tree pollen and mold.

A58

| 21st Century Medicine

APPENDIX

Initial Assessment and Laboratory Recommendations Organized According to the Functional Medicine Matrix Initial Clinical Assessment

Laboratory Tests Ordered

Lifestyle Factors: Nutrient Imbalances 1. 2. 3. 4.

RBC essential minerals Serum vitamins A, E, & beta carotene Serum fatty acids Organic acid B vitamin markers

)2

(c

Nutrient-poor diet Muscle spasms Audio sensitivity Hyperkeratosis pilaris Anxiety ADHD

01

Immune Surveillance and Inflammatory Process

0

ADHD Asthma Allergies Headaches Hives Sinusitis Atopic dermatitis Aphthous stomatitis PMH: diaper rash, otitis media FMH: food and environmental allergies, migraine headaches, sinusitis

lM na tio d. un rve r F se fo re te ts itu h st rig In All

5. Vitamin D 6. IgG food sensitivities 7. Celiac panel

Digestion and Absorption

8. Complete blood count and metabolic panel (assesses yeast or parasite infection) 9. Organic acids microbial markers * IgG food sensitivities, celiac panel

ed

e

in ic

GERD IBS Pruritus ani > GI yeast infection Nausea Frequent antibiotic use ADHD

Detoxification and Biotransformation ADHD Food additives

10. 6-hour urine toxic metal challenge test with 250 mg DMPS (2,3-dimercapto-1-propanesulphonic acid) provocation

Hormone and Neurotransmitter Regulation ADHD Dysgraphia Insomnia Anxiety

11. Plasma amino acids 12. Urine neurotransmitter metabolites

*Laboratory tests frequently pertain to multiple areas of imbalance, and therefore may be listed in more than one Matrix category.

21st Century Medicine | A59

21st century medicine: A New Model for Medical Education and Practice

Significant Laboratory Findings Organized According to the Functional Medicine Matrix Lifestyle Factors: Nutritional Imbalances Results

Test

95% Reference Interval

1. Red Blood Cell Minerals 2.5

L

3.3-7.7 ppm

Magnesium

15

L

18-40 ppm

260

LN

257-500 ppb

22

LN

19-41ppb

1.7

LN

1.4-7.9 ppb

0

Chromium

01

Manganese

)2

Copper

(c

Zinc

lM na tio d. un rve r F se fo re te ts itu h st rig In All

LC was very low in zinc and magnesium; low-normal levels were reported for the rest of the minerals. These findings were not surprising given LC’s poor diet, GI inflammation, and cimetidine use. Zinc deficiency is implicated in asthma, atopic dermatitis, allergies, and ADHD.12-14 Magnesium deficiency is also implicated in headaches, insomnia, muscle cramps, and spasms.15 Copper and manganese are important cofactors in the antioxidant enzyme superoxide dismutase. Chromium as chromodulin may improve cellular glucose uptake by potentiating insulin receptor activity.16 Test 2. Serum Vitamins Vitamin E

7.2

LN

7.1-31.0

0.55

LN

0.41-1.5

37; 22-144

Eicosapentaenoic Acid (EPA)

100

>44; 19-362

Docosahexaenoic Acid (DHA)

60

>46; 31-112

Alpha Linolenic Acid (ALA)

Omega-6 fatty acids: Arachidonic Acid (AA)

785

H

330-630; 260-750

ed

e

in ic

Plasma free fatty acids (primarily palmitic acid) roughly approximate plasma triglyceride levels.17 The numerous high-normal saturated fatty acids indicated that, at 12 years old, LC probably had higher triglycerides as well, most likely caused by insulin-stimulated upregulation of liver fatty acid synthesis. Given LC’s high-sugar diet, early onset dysinsulinemia was not surprising. As discussed above, mild chromium deficiency could be another underlying factor contributing to dysinsulinemia. The elevated trans fatty acids (TFAs) were further evidence of LC’s poor food choices. TFAs are strongly implicated in metabolic syndrome and cardiovascular disease.18 Of the polyunsaturated omega fatty acids, the inflammatory eicosanoid precursor arachidonic acid (AA) was very elevated. It was found in much greater quantity than the anti-inflammatory omega-3 fatty acid eicosapentaenoic acid (EPA), creating a relative deficiency of EPA. AA is implicated in the pathogenesis of allergies and asthma,19,20 while EPA insufficiency and a low EPA/AA ratio are implicated in ADHD.21,22 Comment: Had LC continued with his presenting diet and lifestyle, the plasma fatty acid analysis reveals the likelihood for continued inflammatory conditions as an adult, including possibly heart disease, diabetes, and cancer. Addressing these findings early not only treated his initial complaints, but significantly reduced his risk for a future of ill health.

21st Century Medicine | A61

21st century medicine: A New Model for Medical Education and Practice

Test

Results ug/mg creatinine

80% and 95% Reference Intervals

Kynurenate

3.0

HN

≤2.9; ≤4.7

Xanthurenate

0.9

HN

≤0.90; ≤1.50

4. Urinary Organic Acids

01

)2

(c

When elevated, the organic acids above demonstrate a functional B6 insufficiency.23 A number of LC’s symptoms may have been attributable to insufficient B6, including ADHD, mood disturbances, and insomnia.24

0

Immune Surveillance and Inflammatory Process

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Test

Result

5. Serum Vitamin D 25 OH

24 ng/m

Reference Intervals

L

< 20 ng/mL: Insufficiency 20-40 ng/mL: Hypovitaminosis 40-100 ng/mL: Sufficiency > 100 ng/mL: Toxicity

Hypovitaminosis D likely played a role in LC’s imbalanced immune response, contributing to both his chronic infections and hypersensitivities. Low vitamin D has been implicated in asthma, general development problems, and mood disorders.25 Optimal serum vitamin D is now thought to be between 40-70 ng/mL; individuals with serious diseases should maintain levels between 55-70 ng/mL.26

ed in ic

Test

e

6. IgG (total) Reactive Foods* Bean, Kidney (+1)

Cheese (+1)

Milk, Cow’s (+4)

Mustard (+1)

Peanut (+4)

R. Seed (Canola) (+1)

Walnut (+1)

Yeast, Brewer’s (+2)

* Results range from 0 = no reaction to +5 = severe reaction.

ELISA testing for IgG response to 90 different foods demonstrated a strong positive reaction to dairy and peanuts, and mild positive reactions (+1 or +2) to six other foods, indicating intestinal hyperpermeability and GI inflammation.27-29 These sensitivities may be associated with the pathogenesis of atopic dermatitis, asthma, and ADHD.30-32

A62

| 21st Century Medicine

APPENDIX

Test

Result

7. IgG Antigliadin

17

95 % Reference Interval HN

0-19 units

LC’s IgG antigliadin antibodies were trending high at 17 units. Clinical experience warranted minimizing gluten intake. Digestion and Absorption

01

)2

(c

Test #8: Complete Blood Count and Metabolic Panel LC’s serum chemistries and complete blood count were within normal limits, although his lymphocyte count was higher than his neutrophil count. Clinical experience suggested that this finding, when combined with his history of antibiotic use and complaint of anal itching, probably indicated a fungal or viral infection.

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Test #9: Organic Acid Microbial Markers Surprisingly, LC’s organic acid microbial markers were within normal limits, ruling against significant GI dysbiosis, although he did demonstrate intestinal hyperpermeability with multiple food sensitivities, as discussed above in “Immune Surveillance and Inflammatory Process.”

Detoxification and Biotransformation Result ug/g creatinine

95% Reference Interval

ed

Test

17

H

≤5

e

Lead

in ic

10. Urine Toxic Metals (6-hour challenge test)

DMPS (2,3-dimercapto-1-propanesulfonic acid) provocation challenge demonstrated an elevated urine lead level in LC. While whole blood is considered the gold standard for identifying lead toxicity, urinary lead concentration has also been shown to increase with toxicity.33 Chelating agents have been shown to accelerate the urinary excretion of lead and therefore may be useful for revealing lead exposure. Lead exposure may produce cognitive deficits at levels commonly encountered in blood, and therefore numerous recommendations have been made to reduce safe threshold levels.34 Lead toxicity and environmental toxins such as household mold have been linked to cognitive and behavioral problems in children, including ADHD.35-38 Sources of lead include toys, paint, contaminated soil, lead plumbing, and glazed pottery.34 Since essential mineral deficiencies may allow for increased uptake of toxic metals,39 repletion prior to and during treatment of toxicity is important.

21st Century Medicine | A63

21st century medicine: A New Model for Medical Education and Practice

Hormonal and Neurotransmitter Regulation Test

Result

80% and 95% Reference Intervals

11. Plasma Amino Acids Tryptophan

36

LN

Test

Result ug/mg creatinine

>40; 26-62 80% and 95% Reference Intervals

5-Hydroxyindoleacetate

3.0

LN

3.2-16.7; 1.0-23.0

2.6

LN

2.7-14.0 1.2-39.0

01

)2

Homovanillate

(c

12. Urine Neurotransmitter Metabolites

0 lM na tio d. un rve r F se fo re te ts itu h st rig In All

The urinary neurotransmitter metabolites for dopamine and serotonin, homovanillate (HVA) and 5-hydroxyindoleacetate (5-HIAA), were low normal in LC, suggesting lower total body neurotransmitter turnover. Corroborative evidence for the risk of serotonin insufficiency was found with low plasma tryptophan, the amino acid precursor to serotonin. Furthermore, 2 important nutrients involved in dopamine and serotonin synthesis, B6 and magnesium, were both reported insufficient in LC (discussed above in “Lifestyle Factors: Nutritional Imbalances”). Genetic and metabolic research has linked imbalances of CNS dopamine and serotonin to ADHD with regard to uptake, synthesis, and breakdown, although there has not been a consistent pattern noted.40 Serotonin imbalance has also been implicated in insomnia41 and IBS.42

ed e

in ic

A64

| 21st Century Medicine

APPENDIX

Summary of Initial Assessments, Laboratory Findings, Treatments, and Treatment Rationale Organized According to the Functional Medicine Matrix Lifestyle Factors: Nutrient Imbalances Clinical Assessment and Diagnoses

Laboratory Results

Recommended Treatment

Treatment Rationale

• • • • • •

• Low RBC essential minerals • Low serum vitamins A, E, and beta carotene • Elevated plasma AA:EPA ratio • Low B6 (organic acid functional markers) • Elevated plasma saturated and trans fatty acids

• Zinc citrate 20 mg; 1 tab QD • Magnesium glycinate 120 mg; 2 caps QHS • Multivitamin/ mineral (MVM); 2 tabs QD

• MVM for general nutrient needs with extra zinc for immune dysfunction, diarrhea and allergies, and magnesium for muscle cramps, insomnia, anxiety, and auto sensitivity.

• EPA/DHA 6:1; 1 cap BID

• Anti-inflammatory omega-3 fatty acid used to minimize pro-inflammatory arachidonic acid cascade as seen clinically with asthma, allergies, dermatitis hyperkeratosis pilaris

01

)2

(c

Nutrient deficiencies Fatty acid imbalance Anxiety Muscle spasms Audio sensitivity Hyperkeratosis pilaris

0

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

• B6: evidence supports its use in ADHD, serotonin metabolism, and methylation/ sulfuration

e

in ic

• Pyridoxal 5’ phosphate (activated B6) 50 mg; 1 cap QD

• Dietary changes as noted in “Immune Surveillance and Inflammatory Process” below

21st Century Medicine | A65

21st century medicine: A New Model for Medical Education and Practice

Immune Surveillance and Inflammatory Process Laboratory Results

Recommended Treatment

Treatment Rationale

• Hypovitaminosis D • Multiple food sensitivities • Intestinal hyperpermeability • ADHD • Asthma • Allergies • Headache • Hives • Sinusitis • Atopic dermatitis • Aphthous stomatitis • PMH: diaper rash, otitis media • FMH: food and environmental allergies, migraine headaches, sinusitis

• Low serum vitamin D • Multiple + IgG food sensitivities • Elevated IgG antigliadin antibodies

• Vitamin D3 1000 U; 1 cap QD

• Serum vitamin D goal: 40-70 ng/mL

• Diet: Modified elimination diet based on test results. No dairy, peanuts, gluten, sugar, or trans fatty acids. Reduce saturated fat intake. Whole foods, minimally processed; organic diet. Organic dark chocolate is fine. (See also Nutritionist Comments below.)

• Dietary changes based on clinical history, IgG food sensitivities, antigliadin antibodies, intestinal hyperpermeability, fatty acid deficiency, and suspected fungal overgrowth

01

)2

(c

Clinical Assessment and Diagnoses

0

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

*Also supportive: zinc, magnesium, probiotics

e

in ic

A66

| 21st Century Medicine

APPENDIX

Digestion and Absorption Clinical Assessment and Diagnoses

Laboratory Results

Recommended Treatment

Treatment Rationale

Yeast overgrowth GERD IBS Pruritus ani Intestinal hyperpermeability • Nausea

• Elevated lymphocyte: neutrophil ratio

• Fluconazole 100 mg; 1 tab QD x 30 days

• Clinical and laboratory evidence for Candida overgrowth. Clinical experience suggests long-term fluconazole with dietary changes for best outcome

• Broad spectrum probiotics; 2 caps Q AM

• Probiotic therapy to support microbiota. Beneficial for treatment of intestinal hyperpermeability and immune hypersensitivity, food sensitivities, and IBS

• • • • •

01

)2

(c

* +IgG food sensitivities, IgG antigliadin antibodies

0

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

in ic 21st Century Medicine | A67

21st century medicine: A New Model for Medical Education and Practice

Detoxification and Biotransformation Laboratory Results

Recommended Treatment

Treatment Rationale

• Mild lead toxicity • ADHD • Food additives

• Elevated 6-hour urine lead after 250 mg DMPS (2,3-dimercapto-1propane-sulphonic acid) provocation

• After 2 months on treatment protocol: Start DMSA (dimercaptosuccinic acid) 100 mg, one twice a day, every other week for 3 days (such as MTW), then 11 days off. Do this for 6 months and then repeat the DMPS challenge test

• Oral chelation with DMSA is one of the main treatments for lead toxicity. Pulse dosing DMSA and concurrent detoxification and essential minerals supplementation will minimize adverse reactions. It is important to ensure normal kidney function and bowel movements and treat nutrient deficiencies first, particularly essential minerals, amino acid deficiencies, and impaired methylation

01

)2

(c

Clinical Assessment and Diagnoses

0

lM na tio d. un rve r F se fo re te ts itu h st rig In All

ed

• Dietary changes as noted in Immune Surveillance and Inflammatory Process (above)

| 21st Century Medicine

e

in ic

A68

APPENDIX

Hormone and Neurotransmitter Regulation Laboratory Results

Recommended Treatment

Treatment Rationale

• ADHD • Dysgraphia • Insomnia

• Low-normal plasma tryptophan • Low-normal urine HVA, 5HIAA

• 5HTP 50-100 mg QHS as needed for sleep

• 5HTP is a serotonin precursor. It will provide substrate for serotonin production while preserving tryptophan. CNS serotonin is methylated to produce melatonin. Increased serotonin may therefore help with insomnia

01

)2

(c

Clinical Assessment and Diagnoses

0 lM na tio d. un rve r F se fo re te ts itu h st rig In All

*Assessments, laboratory tests, and treatments frequently pertain to multiple areas of imbalance and may therefore be listed in more than one Matrix category.

Follow-up Visit at Two Months

ed

After starting his treatment, which included removing yeast and antigenic foods and adding the needed micronutrients and probiotics, LC’s mother stated that he was much less disruptive in the classroom. He was sleeping though the night. His headaches and runny nose improved. He hadn’t required cetirizine or flunisolide for some time. His asthma symptoms improved and were no longer triggered by cold. Light, sound, and smell sensitivities were reduced considerably. LC tolerated supplements and diet changes well, because he felt so much better when he followed the plan. No changes were made to LC’s treatment plan at his 2-month visit.

e

in ic

Follow-up Visit at Six Months

LC’s mother reported that he was free from his chronic symptoms for the first time in his life. His dysgraphia improved considerably (see Figures 1 and 2 for the pre- and post-treatment writing samples). He no longer required his medications, including antihistamines (cetirizine and cimetidine), bronchodilators, steroid inhaler, acetaminophen, and ibuprofen. His mood and behavior had stabilized, and his ability to focus improved greatly. His hyperactivity symptoms, including disruptiveness, irritability, and anxiety, were gone. His hives, asthma, runny nose and postnasal drip, anal itching, stomach aches, nausea, diarrhea, headaches, muscle cramps, and sensitivity to loud noises were all completely resolved. He slept soundly at night. He was doing well in school, academically and socially.

21st Century Medicine | A69

21st century medicine: A New Model for Medical Education and Practice

Just after his 6-month follow-up, LC’s mother wrote the following: We had a meeting at LC’s school this morning, where the teachers, school counselor, parents, and principal all get together to review “the plan” for kids with special educational needs (in LC’s case prompted by the ADHD diagnosis). This was the first time in his entire schooling history that everything seems to be going well. The input from his teachers was that he is “a different kid” than they saw in the first half of the year and that they’re amazed by the difference. The school nurse hasn’t seen him [in months] (and he used to be in her office several times a week). The school psychologist said his social skills are very good, age appropriate, and that she sees no problems at all. She also noted that LC seems very proud of himself and his new health and that he’s taking good ownership of all the changes in his diet. He even seems to be shrugging it off when the other kids at school tell him he’s an “alien” because he doesn’t drink soda.

Laboratory Tests:

01

)2

(c

This was just such a fantastic meeting and I wanted to pass along the good news and say Thank You!

0

Follow-up testing revealed normalization of the lymphocyte:neutrophil ratio and improvement in his nutritional status, including normalized levels of vitamin E and beta carotene, RBC minerals, and tryptophan. His saturated fatty acids and trans fatty acids were all within their normal ranges, reducing the concern for dysinsulinemia and confirming LC’s commitment to following dietary changes. He still required vitamins D and A. The dietary changes and supplement interventions reversed not only his presenting complaints, but radically improved the prognosis for his future health.

lM na tio d. un rve r F se fo re te ts itu h st rig In All

The RD/Nutritionist’s Comments:

ed

LC made remarkable changes, and he was very motivated to do so because he received the immediate feedback of improved health. Most notable, of course, was the resolution of the ADHD symptoms. LC’s changes did not come overnight. Indeed, his was a “top-down” change, with his mother making the first moves toward wellness in her life, and experiencing the fruits of good health herself, and then bringing along her family. Wellness of this nature is an ecological shift, like a pebble tossed in a pond that ripples slowly to those around us.

in ic

e

I had been working with LC’s mom for a long time before we saw LC. With his mom (as with most people), we started slowly. We did an initial clean-up of the worst (most problematic/toxic) foods in the house, and then removed one problem food per week from her diet. (Sometimes we would negotiate one food change a month. It’s important to move at the patient’s pace and ability to integrate change.) Generally, when a child needs to make major dietary changes, it does require the family’s buy-in. A significant move away from being unconscious about what we eat toward paying very close attention to where food comes from, what it’s made of, the toxin and nutrient content, and the macronutrient composition requires a powerful and intentional return to our roots, how we evolved to eat. We must also pay attention to how we feel after we eat, and notice the impact of food on our health and well-being. We need to have everyone on board in the family, even if only a little, when thinking about food from this perspective. The home front is the nutritional frontier!

A70

| 21st Century Medicine

APPENDIX

To succeed with such changes, the basics need to be addressed:  Where to shop/what to buy  How to avoid antigenic foods  How to replace the foods being eliminated from the diet with healthy alternatives  How to read and understand food labels  Identifying hidden food additives and antigens  “Natural” versus “organic”  Healthful, affordable foods

(c

)2

 Easy, quick recipe ideas

01

 Eating healthy on the go

0

 Eating well at restaurants

lM na tio d. un rve r F se fo re te ts itu h st rig In All

 Knowing the nutrient content of foods

 Relying on foods, rather than supplements, for long-term nutrient needs  Understanding the appropriate balance and quantity of food  Stress-free eating: rest and digest

 Resources for healthy eating: cookbooks, internet sites

The team approach to treatment in the case of LC was vital to his success. In addition to his medical doctor, he worked with me, a support RN, and of course his mother, father, and siblings. I am not sure we would have seen such a significant turnaround, as demonstrated by his writing specimens, without this approach to care.

e

in ic

 A completed Matrix form for LC is provided in Figure 3.

ed

Additional Forms

 A convenient case-at-a-glance summary for LC is provided in Figure 4.

21st Century Medicine | A71

21st century medicine: A New Model for Medical Education and Practice

01

)2

(c 0 ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All e

in ic Figure 1: LC’s Pre-treatment Writing Sample

A72

| 21st Century Medicine

APPENDIX

01

)2

(c 0 ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All e

in ic Figure 2: LC’s Post-treatment Writing Sample

21st Century Medicine | A73

21st century medicine: A New Model for Medical Education and Practice

Functional Medicine Matrix Model Patient: LC Age: 12 Sex: Male Chief Complaint: ADHD

Hormone & Neurotransmitter Regulation

Lifestyle Factors: Nutrient Imbalances Nutrient-poor diet Muscle spasms Audio sensitivity Hyperkeratosis pilaris Anxiety ADHD

(Predisposing)

Family history of migraines, sinusitis, food and environmental allergies Atopy Early introduction of potentially antigenic foods

SAD, sugar and pasta cravings. Candy, cookies, and ice cream daily. Congestion with dairy. Likes veggies.

Infectious and/or toxic exposures Early introduction (and chronic use) of antibotics Poor diet IBS NSAID use

Detoxification & Biotransformation ADHD Food additives

Triggering Events

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Nutrition Status

0

ADHD, asthma, headache Allergies, hives, sinusitis Atopic dermatitis Aphthous stomatitis PMH: Diaper rash, otitis media FMH: Allergies, sinusitis, headaches

01

)2

(c

Immune Surveillance & Inflammatory Process

ADHD Dysgraphia Insomnia Anxiety

The Patient’s Story Retold Antecedents

(Activation)

Digestion & Absorption

Exposure to environmental allergies and/or toxins Ingestion of antigenic foods

Exercise

Sleep

Minimal

Insomnia worsened by nightime asthma.

GERD IBS Pruritus ani Nausea Headache ADHA Frequent antibiotic use

Beliefs & Self-Care

Relationships

Wants to get better.

Supportive family and school.

ed in ic

©2010 The Institute for Functional Medicine

A74

| 21st Century Medicine

e

Figure 3: Completed Matrix Form for LC

APPENDIX

Case at a Glance: ADHD History of Present Illness LC presented at age 12 with attention deficit hyperactivity disorder (ADHD), dysgraphia, environmental allergies, asthma, insomnia, eczema, canker sores, migraine headaches, muscle cramps, stomach pain, nausea, and diarrhea. LC was first diagnosed with ADHD at age 5. He repeated kindergarten because of attention and behavioral difficulties. He began methylphenidate (Ritalin®) in 1st grade and continued to take it through 4th grade, although his behavior did not change significantly. The drug was discontinued in 4th grade due to growth retardation. Off the medication, he gained weight and increased his intake of junk food and deli meats. He continued to have trouble focusing in school and was still disruptive. He had never received a positive teacher report. He had severe dysgraphia, but excelled in math. His medications included: cetirizine (Zyrtec®), albuterol, levalbuterol inhaler (Xopenex®), flunisolide (Nasarel or AeroBid®), cimetidine (Tagamet®), acetaminophen, and ibuprofen. He liked pasta, sweets, and ice cream despite the fact that he felt better avoiding dairy.

(c Clinical Assessment

01

)2

Abbreviated Assessments, Laboratory Findings and Treatments Organized According to the Functional Medicine Matrix (Refer to full case presentation for details, including treatment rationale.) Laboratory results

Recommended Treatment

0

Lifestyle Factors: Nutrient Imbalances

lM na tio d. un rve r F se fo re te ts itu h st rig In All

Nutrient deficiencies Fatty acid imbalance Anxiety Muscle spasms Audio sensitivity Hyperkeratosis pilaris

Low essential minerals Low vitamins A, E, beta carotene Elevated AA:EPA ratio Low B6 (organic acid markers) Elevated saturated and trans fatty acids

Zinc citrate Magnesium glycinate Multivitamin/mineral EPA/DHA Pyridoxal 5’ phosphate Dietary changes as noted below

Immune Surveillance and Inflammatory Process Hypovitaminosis D Food sensitivities Intestinal hyperpermeability ADHD Asthma, allergies, headache, hives, sinusitis Atopic dermatitis Aphthous stomatitis

Low serum vitamin D Multiple + IgG food sensitivities Elevated IgG antigliadin antibodies

Fluconazole Broad spectrum probiotics

Detoxification and Biotransformation Mild lead toxicity ADHD Food additives

Elevated 6-hour urine lead after 250 mg DMPS (2,3-dimercapto-1-propane-sulphonic acid) provocation

e

in ic

Elevated lymphocyte:neutrophil ratio +IgG food sensitivities, IgG antigliadin antibodies

ed

Digestion and Absorption

Yeast overgrowth GERD, IBS, pruritus ani Nausea

Vitamin D3 Dietary changes: Modified elimination diet based on test results. No dairy, peanuts, gluten, sugar, or trans fatty acids. Reduce saturated fat intake. Whole foods, minimally processed, organic diet. (Nutritionist comments available in full case presentation.)

After 2 months on treatment protocol: Start DMSA (refer to full case presentation for details) Dietary changes as noted above

Hormone and Neurotransmitter Regulation ADHD, dysgraphia Insomnia

Low-normal plasma tryptophan Low-normal urine HVA, 5HIAA

6-Month Follow-up: LC’s mother reported that he was free from his chronic symptoms for the first time in his life. His dysgraphia improved dramatically (compare Figures 1 and 2 in full case presentation). He no longer required his medications, including antihistamines (cetirizine and cimetidine), bronchodilators, steroid inhaler, acetaminophen, and ibuprofen. His mood and behavior stabilized, and his ability to focus improved greatly. His hyperactivity symptoms, including disruptiveness, irritability, and anxiety, were gone. His hives, asthma, runny nose and postnasal drip, anal itching, stomachaches, nausea, diarrhea, headaches, muscle cramps, and sensitivity to loud noises were all completely resolved. He slept soundly at night. He was doing well in school, academically and socially (see mother’s comments in full case presentation). LC tolerated supplements and dietary changes well, because he felt so much better when he followed the plan.

Figure 4: LC Case-at-a-Glance

21st Century Medicine | A75

21st century medicine: A New Model for Medical Education and Practice

References

01

)2

(c

1. Adi-Japha E, Landau YE, Frenkel L, Teicher M, Gross-Tsur V, Shalev RS. ADHD and dysgraphia: underlying mechanisms. Cortex. Aug 2007;43(6):700-709. 2. Norris JM, Barriga K, Hoffenberg EJ, et al. Risk of celiac disease autoimmunity and timing of gluten introduction in the diet of infants at increased risk of disease. Jama. May 18 2005;293(19):2343-2351. 3. Osborn DA, Sinn J. Soy formula for prevention of allergy and food intolerance in infants. Cochrane Database Syst Rev. 2004(3):CD003741. 4. Kozyrskyj AL, Ernst P, Becker AB. Increased risk of childhood asthma from antibiotic use in early life. Chest. Jun 2007;131(6):1753-1759. 5. Farooqi IS, Hopkin JM. Early childhood infection and atopic disorder. Thorax. Nov 1998;53(11):927-932. 6. Shreiner A, Huffnagle GB, Noverr MC. The “Microflora Hypothesis” of allergic disease. Adv Exp Med Biol. 2008;635:113-134. 7. Wickens K, Pearce N, Crane J, Beasley R. Antibiotic use in early childhood and the development of asthma. Clin Exp Allergy. Jun 1999;29(6):766-771. 8. Evenepoel P. Alteration in digestion and absorption of nutrients during profound acid suppression. Best Pract Res Clin Gastroenterol. Jun 2001;15(3):539-551. 9. Kon K, Ikejima K, Okumura K, et al. Role of apoptosis in acetaminophen hepatotoxicity. J Gastroenterol Hepatol. Jun 2007;22 Suppl 1:S49-52. 10. Mielants H, Goemaere S, De Vos M, et al. Intestinal mucosal permeability in inflammatory rheumatic diseases. I. Role of antiinflammatory drugs. J Rheumatol. Mar 1991;18(3):389-393. 11. Sharek PJ, Bergman DA. Beclomethasone for asthma in children: effects on linear growth. Cochrane Database Syst Rev. 2000(2):CD001282. 12. Wintergerst ES, Maggini S, Hornig DH. Contribution of selected vitamins and trace elements to immune function. Ann Nutr Metab. 2007;51(4):301-323. 13. Arnold LE, DiSilvestro RA. Zinc in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. Aug 2005;15(4):619-627. 14. Yorbik O, Ozdag MF, Olgun A, Senol MG, Bek S, Akman S. Potential effects of zinc on information processing in boys with attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. Apr 1 2008;32(3):662-667. 15. Altura BM, Altura BT. Tension headaches and muscle tension: is there a role for magnesium? Med Hypotheses. Dec 2001;57(6):705-713. 16. Lord RS, Bralley JA. Laboratory Evaluations for Integrative and Functional Medicine. 2nd ed. Duluth, GA: Metametrix Institute; 2008:113114. 17. Lord RS, Bralley JA. Laboratory Evaluations for Integrative and Functional Medicine. 2nd ed. Duluth, GA: Metametrix Institute; 2008:278. 18. Mozaffarian D. Trans fatty acids - effects on systemic inflammation and endothelial function. Atheroscler Suppl. May 2006;7(2):29-32. 19. Serrano-Mollar A, Closa D. Arachidonic acid signaling in pathogenesis of allergy: therapeutic implications. Curr Drug Targets Inflamm Allergy. Apr 2005;4(2):151-155. 20. Wenzel SE. Arachidonic acid metabolites: mediators of inflammation in asthma. Pharmacotherapy. Jan-Feb 1997;17(1 Pt 2):3S-12S. 21. Matsudaira T. Attention deficit disorders--drugs or nutrition? Nutr Health. 2007;19(1-2):57-60. 22. Sorgi PJ, Hallowell EM, Hutchins HL, Sears B. Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder. Nutr J. 2007;6:16. 23. Council NRCUSCoDAFaNBNR. Human vitamin B6 requirements: proceedings of a workshop: Letterman Army. Washington, DC: National Academy of Sciences; 1976. 24. Mousain-Bosc M, Roche M, Polge A, Pradal-Prat D, Rapin J, Bali JP. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. I. Attention deficit hyperactivity disorders. Magnes Res. Mar 2006;19(1):46-52. 25. Holick MF. Vitamin D deficiency. N Engl J Med. Jul 19 2007;357(3):266-281. 26. Cannell JJ, Hollis BW. Use of vitamin D in clinical practice. Altern Med Rev. Mar 2008;13(1):6-20. 27. DeMeo MT, Mutlu EA, Keshavarzian A, Tobin MC. Intestinal permeation and gastrointestinal disease. J Clin Gastroenterol. Apr 2002;34(4):385-396. 28. Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut. Oct 2004;53(10):1459-1464. 29. Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science. Mar 25 2005;307(5717):1920-1925. 30. Del Giudice MM, Rocco A, Capristo C. Probiotics in the atopic march: highlights and new insights. Dig Liver Dis. Dec 2006;38 Suppl 2:S288290. 31. Newmark SC. ADHD and food sensitivity. Altern Ther Health Med. May-Jun 2002;8(3):18; author reply 18. 32. Schnoll R, Burshteyn D, Cea-Aravena J. Nutrition in the treatment of attention-deficit hyperactivity disorder: a neglected but important aspect. Appl Psychophysiol Biofeedback. Mar 2003;28(1):63-75. 33. Fitzgerald KN-D, C; Lord, RS. Laboratory Evaluations for Integrative and Functional Medicine. In: Lord RBJ, ed. Atlanta: Metametrix Institute; 2008. 34. Lord RS, Bralley JA. Laboratory Evaluations for Integrative and Functional Medicine. 2nd ed. Duluth, GA: Metametrix Institute; 2008:131. 35. Banerjee TD, Middleton F, Faraone SV. Environmental risk factors for attention-deficit hyperactivity disorder. Acta Paediatr. Sep 2007;96(9):1269-1274. 36. Braun JM, Kahn RS, Froehlich T, Auinger P, Lanphear BP. Exposures to environmental toxicants and attention deficit hyperactivity disorder in U.S. children. Environ Health Perspect. Dec 2006;114(12):1904-1909. 37. Kidd PM. Attention deficit/hyperactivity disorder (ADHD) in children: rationale for its integrative management. Altern Med Rev. Oct 2000;5(5):402-428. 38. Curtis LT, Patel K. Nutritional and environmental approaches to preventing and treating autism and attention deficit hyperactivity disorder

0

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e

in ic

A76

| 21st Century Medicine

APPENDIX

(ADHD): a review. J Altern Complement Med. Jan-Feb 2008;14(1):79-85. 39. Bressler JP, Olivi L, Cheong JH, Kim Y, Maerten A, Bannon D. Metal transporters in intestine and brain: their involvement in metalassociated neurotoxicities. Hum Exp Toxicol. Mar 2007;26(3):221-229. 40. Oades RD. Dopamine-serotonin interactions in attention-deficit hyperactivity disorder (ADHD). Prog Brain Res. 2008;172:543-565. 41. Bucci L. Migraine, insomnia, reactive depression due to brain serotonin deficiency. Br J Psychiatry. Jun 1988;152:867-868. 42. Sikander A, Rana SV, Prasad KK. Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clin Chim Acta. May 2009;403(1-2):47-55.

01

)2

(c 0 ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All e

in ic 21st Century Medicine | A77

01 )2 (c

0

ed

lM na tio d. un rve r F se fo re te ts itu h st rig In All

e in ic